
<html lang="en"     class="pb-page"  data-request-id="10620572-e8ad-42a1-a523-1b40810c61bb"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c01782;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2021.64.issue-3;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity" /></meta><meta name="dc.Creator" content="Xin-Hui  Zhang" /></meta><meta name="dc.Creator" content=" Qin-Ma" /></meta><meta name="dc.Creator" content="Hui-Pan  Wu" /></meta><meta name="dc.Creator" content="Mussa Yussuf  Khamis" /></meta><meta name="dc.Creator" content="Yi-Han  Li" /></meta><meta name="dc.Creator" content="Li-Ying  Ma" /></meta><meta name="dc.Creator" content="Hong-Min  Liu" /></meta><meta name="dc.Description" content="Histone deacetylases (HDACs) are essential for maintaining homeostasis by catalyzing histone deacetylation. Aberrant expression of HDACs is associated with various human diseases. Although HDAC inh..." /></meta><meta name="Description" content="Histone deacetylases (HDACs) are essential for maintaining homeostasis by catalyzing histone deacetylation. Aberrant expression of HDACs is associated with various human diseases. Although HDAC inh..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 1, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01782" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01782" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01782" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01782" /></link>
        
    
    

<title>A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01782" /></meta><meta property="og:title" content="A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0031.jpeg" /></meta><meta property="og:description" content="Histone deacetylases (HDACs) are essential for maintaining homeostasis by catalyzing histone deacetylation. Aberrant expression of HDACs is associated with various human diseases. Although HDAC inhibitors are used as effective chemotherapeutic agents in clinical practice, their applications remain limited due to associated side effects induced by weak isoform selectivity. HDAC6 displays unique structure and cellular localization as well as diverse substrates and exhibits a wider range of biological functions than other isoforms. HDAC6 inhibitors have been effectively used to treat cancers, neurodegenerative diseases, and autoimmune disorders without exerting significant toxic effects. Progress has been made in defining the crystal structures of HDAC6 catalytic domains which has influenced the structure-based drug design of HDAC6 inhibitors. This review summarizes recent literature on HDAC6 inhibitors with particular reference to structural specificity and functional diversity. It may provide up-to-date guidance for the development of HDAC6 inhibitors and perspectives for optimization of therapeutic applications." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01782"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01782">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01782&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01782&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01782&amp;href=/doi/10.1021/acs.jmedchem.0c01782" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 3</span><span class="cit-fg-pageRange">, 1362-1391</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/3" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01679" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01887" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Xin-Hui Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xin-Hui Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Key Laboratory of Technology Drug Preparation (Zhengzhou University), Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xin-Hui++Zhang">Xin-Hui Zhang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"> Qin-Ma</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name"> Qin-Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Key Laboratory of Technology Drug Preparation (Zhengzhou University), Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=+Qin-Ma"> Qin-Ma</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hui-Pan Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hui-Pan Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Key Laboratory of Technology Drug Preparation (Zhengzhou University), Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hui-Pan++Wu">Hui-Pan Wu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mussa Yussuf Khamis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mussa Yussuf Khamis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Key Laboratory of Technology Drug Preparation (Zhengzhou University), Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mussa+Yussuf++Khamis">Mussa Yussuf Khamis</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yi-Han Li</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yi-Han Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Key Laboratory of Technology Drug Preparation (Zhengzhou University), Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yi-Han++Li">Yi-Han Li</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Li-Ying Ma</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Li-Ying Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Key Laboratory of Technology Drug Preparation (Zhengzhou University), Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China</div><div class="loa-info-affiliations-info">China Meheco Topfond Pharmaceutical Co., Ltd., Zhumadian, 463000, PR China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#422f232e2b3b2b2c25023838376c2726376c212c"><span class="__cf_email__" data-cfemail="0c616d60657565626b4c76767922696879226f62">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Li-Ying++Ma">Li-Ying Ma</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7186-8259" title="Orcid link">http://orcid.org/0000-0002-7186-8259</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Hong-Min Liu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hong-Min Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Collaborative Innovation Center of New Drug Research and Safety Evaluation, Henan Province, Key Laboratory of Technology Drug Preparation (Zhengzhou University), Ministry of Education of China, Key Laboratory of Henan Province for Drug Quality and Evaluation; School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, PR China</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#fa96938f9297ba80808fd49f9e8fd49994"><span class="__cf_email__" data-cfemail="ddb1b4a8b5b09da7a7a8f3b8b9a8f3beb3">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hong-Min++Liu">Hong-Min Liu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6771-9421" title="Orcid link">http://orcid.org/0000-0001-6771-9421</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01782&amp;href=/doi/10.1021%2Facs.jmedchem.0c01782" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 3</span><span class="cit-pageRange">, 1362–1391</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 1, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 October 2020</li><li><span class="item_label"><b>Published</b> online</span>1 February 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 February 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01782" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01782</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1362%26pageCount%3D30%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DXin-Hui%2BZhang%252C%2B%2BQin-Ma%252C%2BHui-Pan%2BWu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D64%26issueNum%3D3%26contentID%3Dacs.jmedchem.0c01782%26title%3DA%2BReview%2Bof%2BProgress%2Bin%2BHistone%2BDeacetylase%2B6%2BInhibitors%2BResearch%253A%2BStructural%2BSpecificity%2Band%2BFunctional%2BDiversity%26numPages%3D30%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1391%26publicationDate%3DFebruary%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01782"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1743</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">5</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01782" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Xin-Hui&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;&quot;,&quot;last_name&quot;:&quot;Qin-Ma&quot;},{&quot;first_name&quot;:&quot;Hui-Pan&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Mussa&quot;,&quot;last_name&quot;:&quot;Yussuf Khamis&quot;},{&quot;first_name&quot;:&quot;Yi-Han&quot;,&quot;last_name&quot;:&quot;Li&quot;},{&quot;first_name&quot;:&quot;Li-Ying&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Hong-Min&quot;,&quot;last_name&quot;:&quot;Liu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;01&quot;,&quot;issue&quot;:&quot;3&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;1362-1391&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01782&quot;},&quot;abstract&quot;:&quot;Histone deacetylases (HDACs) are essential for maintaining homeostasis by catalyzing histone deacetylation. Aberrant expression of HDACs is associated with various human diseases. Although HDAC inhibitors are used as effective chemotherapeutic agents in clinical practice, their applications remain limited due to associated side effects induced by weak isoform selectivity. HDAC6 displays unique structure and cellular localization as well as diverse substrates and exhibits a wider range of biological functions than other isoforms. HDAC6 inhibitors have been effectively used to treat cancers, neurodegenerative diseases, and autoimmune disorders without exerting significant toxic effects. Progress has been made in defining the crystal structures of HDAC6 catalytic domains which has influenced the structure-based drug design of HDAC6 inhibitors. This review summarizes recent literature on HDAC6 inhibitors with particular reference to structural specificity and functional diversity. It may provide up-to-date guidan&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01782&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01782" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01782&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01782" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01782&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01782" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01782&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01782&amp;href=/doi/10.1021/acs.jmedchem.0c01782" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01782" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01782" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01782%26sid%3Dliteratum%253Aachs%26pmid%3D33523672%26genre%3Darticle%26aulast%3DZhang%26date%3D2021%26atitle%3DA%2BReview%2Bof%2BProgress%2Bin%2BHistone%2BDeacetylase%2B6%2BInhibitors%2BResearch%253A%2BStructural%2BSpecificity%2Band%2BFunctional%2BDiversity%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D3%26spage%3D1362%26epage%3D1391%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/3" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/jmcmar.2021.64.issue-3/20210211/jmcmar.2021.64.issue-3.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0031.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Histone deacetylases (HDACs) are essential for maintaining homeostasis by catalyzing histone deacetylation. Aberrant expression of HDACs is associated with various human diseases. Although HDAC inhibitors are used as effective chemotherapeutic agents in clinical practice, their applications remain limited due to associated side effects induced by weak isoform selectivity. HDAC6 displays unique structure and cellular localization as well as diverse substrates and exhibits a wider range of biological functions than other isoforms. HDAC6 inhibitors have been effectively used to treat cancers, neurodegenerative diseases, and autoimmune disorders without exerting significant toxic effects. Progress has been made in defining the crystal structures of HDAC6 catalytic domains which has influenced the structure-based drug design of HDAC6 inhibitors. This review summarizes recent literature on HDAC6 inhibitors with particular reference to structural specificity and functional diversity. It may provide up-to-date guidance for the development of HDAC6 inhibitors and perspectives for optimization of therapeutic applications.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43386" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43386" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Epigenetic regulation, a heritable change in gene function that culminates in a phenotypic change without altering DNA sequences,<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> plays an important role in cellular and molecular regulatory processes.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> It is associated with DNA methylation,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> histone modification,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> chromatin structural remodeling,<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and noncoding RNA regulation.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Among these, histone acetylation and deacetylation are widely occurring post-translational modification processes.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The lysine acetylation process, which is reversible, is catalyzed by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>a).<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> These maintain the balance between nuclear and cytoplasmic protein acetylation levels, which is crucial for cellular homeostasis.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Notably, dysregulation of HDACs, leading to the disruption of this balance, contributes to the development of several diseases.<a onclick="showRef(event, 'ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11">(9−11)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) The reversible lysine acetylation and deacetylation processes are catalyzed by HATs and HDACs, respectively. (b) Currently approved HDACis for cancer treatment in clinical practice (chidamide was approved in China) and their representative pharmacophore model: cap, linker, and zinc-binding group (ZBG).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To date, 18 HDAC isozymes have been identified and classified in mammals, based on sequence homology to yeast protein orthologues, into four classes: class I (HDAC1, 2, 3, 8), class IIa (HDAC4, 5, 7, 9), class IIb (HDAC 6, 10), and class IV (sole HDAC11) are Zn<sup>2+</sup>-dependent enzymes that adopt the arginase-deacetylase fold, whereas class III HDACs (sirtuins 1–7) are NAD<sup>+</sup>-dependent enzymes that adopt an unrelated fold.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> In fact, beyond the traditional definition of protein lysine deacetylases, HDAC members have been successively found showing different substrate preferences.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> For instance, HDAC 1/2/3 prefer to deacetylate histones and transcriptional regulators, while HDAC8 and HDAC11 preferentially hydrolyze nonacetyl acyllysine substrates. Particularly, HDAC10 is a polyamine deacetylase. More recently, Ganesan et al. creatively described a “solar system” of human HDACs to group them according to their in vitro substrate tolerance.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> On the other hand, HDAC inhibitors (HDACi) have been confirmed to be effective chemotherapeutic agents by altering the acetylated status of various cellular proteins, increasing the expression levels of p21 and other genes, and inhibiting the proliferation of tumor cells via the induction of cellular differentiation or apoptosis.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Currently, four HDACis, including vorinostat (SAHA, <b>1</b>), belinostat (<b>2</b>), panobinostat (<b>3</b>), and romidepsin (<b>5</b>), have been approved by FDA for the treatment of refractory or relapsed cutaneous and peripheral T cell lymphomas, or multiple myeloma (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b).<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Besides, chidamide (<b>4</b>) was another potent HDACi developed and approved in China for use in peripheral T cell lymphomas.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Unfortunately, most of these HDACis (romidepsin is a selective HDAC1/2 inhibitor) are lacking of isoform selectivity, thus leading to adverse side effects in clinical practice, such as cardiotoxicity, thrombocytopenia, and bleeding in the gastrointestinal tract.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> Therefore, interest is shifting toward the development of isoform-selective inhibitors,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> a process at which much effort is being directed.</div><div class="NLM_p">HDAC6 is the largest member of the HDAC family. HDAC6 contains 1 215 amino acid residues, two independent catalytic domains (CD1 and CD2, located at the N-terminal and the central region, respectively),<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and a zinc-finger ubiquitin-binding domain (ZnF-UBP) at its C-terminal, which mediates interaction with the ubiquitin proteasome and aggresome pathways to clear misfolded proteins (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Besides, nuclear export signaling (NES) enables HDAC6 to translocate to the cytoplasm and target nonhistone substrates located in the cytoplasm, such as α-tubulin,<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> protein tau,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> cortactin,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> heat shock protein (HSP90),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and peroxiredoxin.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Owing to its unique structure and substrate diversity, HDAC6 plays specific physiological roles in multiple cellular pathways, including cell movement, endocytosis, cell autophagy, apoptosis, and protein transport and degradation,<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> which are immediately responsible for a variety of human diseases, such as cancers, neurodegenerative diseases, and immunological disorders.<a onclick="showRef(event, 'ref26 ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28">(26−28)</a> More recently, a growing body of evidence indicates HDAC6 is a potential therapeutic target for Rett syndrome (RTT), inherited retinal disorders (IRDS), idiopathic pulmonary fibrosis (IPF), and Charcot-Marie-Tooth disease (CMT) in regard to human rare diseases.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a> During the past few decades, the role played by selective HDAC6 inhibitors as therapeutic agents has attracted a significant interest.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> At present, seven HDAC6 inhibitors have entered into clinical trails, either alone or in combination with other approved drugs, for the treatment of human diseases (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> Meanwhile, owing to the unique biological functions and inhibitors pharmacophore models, HDAC6 is increasingly emerging as an ideal target in multitargeted drug designs.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In recent years, HADC6 inhibitors have shown unique immunomodulatory properties, aiding for immunotherapy.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> Besides, the emerging proteolysis targeting chimera (PROTAC) technology based on HDAC6 inhibitors has shown significant advantages compared with conventional small-molecule HDAC6 inhibitors.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(37,38)</a> Excitingly, the X-ray crystallography of HDAC6 catalytic domains was disclosed in 2016 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>a), revealing two catalytic domains of HDAC6 exhibiting different substrate preferences, namely, CD2 exhibited much broader substrate specificity than CD1, which was primarily due to the mouth of the CD1 active site being constricted by K330 (the similar position in CD2 was occupied by L712) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>b), thus leading to the narrow catalytic specificity of HDAC6 CD1 for peptide substrates containing C-terminal acetyllysine residues.<a onclick="showRef(event, 'ref39 ref40 ref41'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41">(39−41)</a> More importantly, the comparison of crystal structures of HDAC6 CD2-inhibitor complexes revealed critical determinants of affinity and selectivity in the active site, which significantly boosted structure-based drug design (SBDD) of HDAC6 inhibitors.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> This perspective reviews the latest developments in the field of specific HDAC6 inhibitors by illustrating their key structural features contributing to enzyme-affinity and isoform-selectivity as well as diverse biological functions associated with the selective inhibition of HDAC6. This perspective may provide up-to-date structural information on the development of specific HDAC6 inhibitors and provide perspectives for optimization of therapeutic applications.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) The architecture of HDAC6 functional domains and cartoon representation of the CD1–CD2 crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G0J">5G0J</a>). The CD1 and CD2 domains are in cyan and dark red, respectively, while the interdomain linker is green. The catalytic pockets are indicated in red boxes.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> (b) Molecular surface of HDAC6 CD1 (upper blue one) and CD2 (lower gray one). Residues K330 and L712 differ between the catalytic domains, giving rise to different contours at the mouth of the active site. Reprinted with permission from ref <a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Specific HDAC6 Inhibitors Currently in Clinical Trails<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0030.gif" alt="" id="gr30" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">For combination trials, the other drugs involved are presented with “+”. The clinical trial is determined by the “ClinicalTrials.gov” NCT number.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">This clinical trail is identified by the “EU Clinical Trials Register” EudraCT number.</p></div></div><div></div></div><div class="NLM_p last">Owing to the special substrates catalytic mechanism of HDACs, the typical pharmacophore model of HDACis normally consists of three domains: cap, linker, and a zinc-binding group (ZBG) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>b).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> The isoform affinity and selectivity are generally dependent on the geometry of intermolecular interactions between these three parts with the active site.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Therefore, modifying the cap, varying the linker, or altering the ZBG are common strategies to improve selectivity.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Particularly, given the unique three-dimensional contour of the HDAC6 active site, the chemodiversity of HDAC6 inhibitors is preferentially manifest in the diverse array of capping groups, followed by somewhat conserved linkers and ZBGs.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> With this in mind, we classified HDAC6 inhibitors according to different ZBGs (hydroxamic acids or novel binding groups) and linkers (according to structural rigidity) and then summarized in detail the various capping groups.<a onclick="showRef(event, 'ref31 ref46'); return false;" href="javascript:void(0);" class="ref ref31 ref46">(31,46)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">2.  HDAC6 Inhibitors Bearing Hydroxamic Acid-Based ZBG</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40815" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40815" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Hydroxamic acid, known for its strong binding affinity to a wide spectrum of transition metal ions, plays an important role in coordination chemistry and chemical biology.<a onclick="showRef(event, 'ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref47 ref48">(47,48)</a> It has been used with siderophores, such as desferrioxamine B, to deal with iron-overload in transfusion-dependent patients.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Besides, hydroxamic acids chelate zinc ions in the active site of Zn(II)-containing metalloproteins, leading to the development of clinical candidates targeting matrix metalloproteinases.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> Marco et al. (2004) has described the crystal structure of a hydroxamic acid-based inhibitor which formed a complex with human HDAC8 protein. Coordination chemistry revealed the hydroxamic acid chelated the catalytic zinc ion of HDAC8 via a typical O, O′-bidentate process.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Before this, Pavletich et al. had reported this coordination model observed in the crystal structure of HDACi (trichostatin A (TSA) and SAHA) complexed with histone deacetylase-like protein (HDLP), an HDAC1 homologue from <i>Aquifex aeolicus</i>. The zinc-bound water molecule was replaced by hydroxamate hydroxyl, and chelation with zinc ion occurred in a bidentate fashion via hydroxamate hydroxyl and carbonyl oxygen (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>a).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Coordination model of trichostatin A (TSA) hydroxamic acid group bound with the Zn<sub>2</sub><sup>+</sup> ion of histone deacetylase-like protein (HDLP) exhibited a typical O,O′-bidentate fashion. (b) Representation of the bidentate (left) and monodentate (right) zinc-binding models observed in the coordination complex of HDAC6 with hydroxamate HDAC inhibitors. Reproduced with permission from <i>Proceedings of the National Academy of Sciences of the United States of America</i>, Porter, N. J.; Mahendran, A.; Breslow, R.; Christianson, D. W., Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors, 2017, 114, 13459−13464.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although most HDAC6 inhibitors contain this specific ZBG, the hydroxamic acid moiety may possess different zinc-binding modalities in the active site of HDAC6 due to its unique three-dimensional contour of the catalytic domains. In 2016, Christianson et al. discovered a novel hydroxamate-Zn<sup>2+</sup> coordination mode, in which the hydroxyl does not replace zinc-bound water.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> This unique monodentate binding model, the free energy of which was 0.5 kcal/mol higher than that of the bidentate model (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b, left), was more suitable for phenylhydroxamate inhibitors (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b, right), which are unable to bind deeply to the HDAC6 active site owing to the short and bulky linkers.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Based on the above findings, these HDAC6 inhibitors bearing hydroxamic acid-based ZBGs were divided into two broad categories according to the linker types (slender, flexible aliphatic linkers and rigid, bulky aromatic linkers), followed by a subclassification based on the features of the capping groups.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.1.  Inhibitors Containing Slender and Flexible Aliphatic Linkers</h3><div id="sec2_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6">2.1.1.  “Y”-Shaped Phenyl-Derived Capping Groups</h4><div class="NLM_p">Although some HDAC6 inhibitors have entered clinical trails, their chemical structures are not publicly available, except for ricolinostat (ACY-1215, <b>6</b>) and citarinostat (ACY-241, <b>7</b>) (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). It is worth nothing that both of these hydroxamic acid-based HDAC6 inhibitors employ a long and flexible aliphatic linker of six methylenes, which is similar to that of SAHA (<b>1</b>). Meanwhile, their aromatic capping groups all displayed “Y”-shaped geometry (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). They all displayed low nanomolar inhibition effect toward HDAC6, with more than 10-fold selectivity over other isoforms.<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a> Fortunately, the crystal structure of zebrafish HDAC6 CD2 in complex with ricolinostat was reported by Christianson et al. in 2017 (below).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The detailed information is summarized as follows:</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) The structure and HDAC inhibition data of ricolinostat (ACY-1215, <b>6</b>) are shown accordingly. (b) The X-ray crystal structure of zebrafish HDAC6 CD2 in complex with ACY-1215 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGL">5WGL</a>). Simulated annealing omit map (green, contoured at 2.5σ) for ACY-1215 bound to HDAC6 (monomer A). Two conformations for the capping group are shown with different shades of purple, the darker of which indicates the sole conformation observed in monomer B. The Zn<sub>2</sub><sup>+</sup> ion is shown as a large gray sphere, and water molecules are shown as smaller red spheres. Metal coordination and hydrogen bond interactions are indicated by solid and dashed black lines, respectively. The snapshot displayed the hydroxamate moiety of ACY-1215 coordinated to Zn<sub>2</sub><sup>+</sup> ion in an typical O,O′-bidentate fashion. Reproduced with permission from <i>Proceedings of the National Academy of Sciences of the United States of America</i>, Porter, N. J.; Mahendran, A.; Breslow, R.; Christianson, D. W., Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors, 2017, 114, 13459−13464.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ricolinostat (ACY-1215, <b>6</b>), is an orally bioavailable and selective HDAC6 inhibitor with a potent IC<sub>50</sub> value of 4.7 nM (more than 10-fold selectivity over HDAC1/2/3) (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>a)<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> and has entered phase 1/2 clinical trials as a monotherapy or in combination for the treatment of relapsed or relapsed and refractory multiple myeloma (MM) and other diseases (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). The X-ray crystal structure determination of zebrafish HDAC6 CD2 in complex with ricolinostat revealed that the hydroxamate moiety coordinated to Zn<sub>2</sub><sup>+</sup> ion in typical O,O′-bidentate fashion, forming a canonical five-membered chelate complex of Zn<sub>2</sub><sup>+</sup> ion with N–O<sup>–</sup> and C═O groups (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> In addition, the side chain of H573 served as a hydrogen bond donor to the N–O<sup>–</sup> group, while H574 accepted a hydrogen bond from the hydroxamate NH group. The side chain of Y745 formed a hydrogen bond with the hydroxamate C═O group. Other residues, including D612, D705, and H614 coordinated with Zn<sub>2</sub><sup>+</sup> ion directly. Besides, in one monomer, the amide C═O group of the “Y”-shaped capping group established a water-mediated hydrogen bond with S531 on the L1 loop, which is determined to be a unique residue located at the mouth of the HDAC6 CD2 active site, that can be used to design specific HDAC6 inhibitors whose capping groups can target this residue that is absent in other isozymes.<a onclick="showRef(event, 'ref42 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref42 ref43 ref44">(42−44)</a> Meanwhile, the aminopyrimidinyl ring nitrogen also formed a water-mediated hydrogen bond with D460 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>b). However, there was no obvious intermolecular interactions between two terminal phenyls and the HDAC6 CD2 active site, which might be explained by the fact that enzyme–inhibitor association appeared to be driven primarily by steric complementarity between the capping groups and the three-dimensional contours of the L1 and L2 pockets in the active site of HDAC6.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><div class="NLM_p">A wealth of novel biological functions of ricolinostat caused by the selective inhibition of HDAC6 was continually reported in recent years. It could induce apoptosis in esophageal squamous cell carcinoma (ESCC) by activating the extracellular-signal-regulated kinase (ERK) pathway,<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> and inhibit glioma cell growth by blocking the MKK7/JNK/c-Jun signaling pathway.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> In addition, it displayed synergistic antitumor potency with different chemotherapy drugs, such as the bromodomain inhibitor, JQ1, for nonsmall cell lung cancer (NSCLC)<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> and small cell lung cancer (SCLC),<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> oxaliplatin for colorectal cancer (CRC),<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> carfilzomib for BRAF-mutated CRC,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> PAX for recurrent ovarian cancer,<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> and gemcitabine for pancreatic cancer.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Moreover, ricolinostat slowed cyst growth in polycystic kidney disease<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> and polycystic liver disease.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Ricolinostat treatment exerted protective effects against acute liver failure<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> and chemotherapy-associated cognitive impairment and brain damage in mice.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> Other uses, e.g., as a treatment for axonal Charcot-Marie-Tooth disease,<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> anti-inflammatory,<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> and inhibition of vascular endothelial growth factor (VEGF) expression in osteoarthritis,<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> were also determined recently.</div><div class="NLM_p">A second generation analogue citarinostat (ACY-241, <b>7</b>) displays slightly higher HDAC6 (IC<sub>50</sub> = 2.6 nM) inhibition and isoform selectivity than ricolinostat,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> which may be attributed to the electron-withdrawing chloro substitution at one of the phenyl ring (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> It is also orally administered and primarily used for MM therapy, either alone or in combination, in phase I clinical trials (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Danhof et al. claimed it upregulated CD38 levels in MM cells and could be used in combination with the anti-CD38 antibody, daratumumab, to treat MM.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Citarinostat could target antitumor T cells and enhance antimelanoma immunity.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> In addition, it is used synergistically with immunomodulatory drugs, such as Alpha-Enolase inhibitor,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> pomalidomide,<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> and anti-PDL1 antibody,<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> to enhance anti-MM immunity and improve patients outcomes in MM. Treatment comprising a combination of citarinostat and paclitaxel showed potent antiproliferative effects and in vivo growth inhibition of solid tumor cells.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Also, cotargeting of HDAC6 and JAK2/signal transducer and activator of transcription 3 (STAT3) using a combination of citarinostat and momelotinib was shown to be promising therapy for malignant lymphoma (ML).<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures and HDAC inhibition data of citarinostat (ACY-241, <b>7</b>) and WT161(<b>8</b>) are shown accordingly (upper). Molecular dynamic (MD) simulations display the interaction diagram for WT161 bound to HDAC6 (lower). Reproduced with permission from <i>Proceedings of the National Academy of Sciences of the United States of America</i>, Hideshima, T.; Qi, J.; Paranal, R. M.; Tang, W.; Greenberg, E.; West, N.; Colling, M. E.; Estiu, G.; Mazitschek, R.; Perry, J. A.; Ohguchi, H.; Cottini, F.; Mimura, N.; Gorgun, G.; Tai, Y. T.; Richardson, P. G.; Carrasco, R. D.; Wiest, O.; Schreiber, S. L.; Anderson, K. C.; Bradner, J. E., Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma, 2016, 113, 13162−13167.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">WT161 (<b>8</b>) is another second-generation HDAC6 inhibitor with excellent inhibitory activity against HDAC6 (IC<sub>50</sub> = 0.4 nM) and high selectivity over other isoforms (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Molecular dynamic (MD) simulations revealed that WT161 displayed good shape complementarity to HDAC6 surface via the “Y”-shaped lipophilic capping group. The cap region positioned in the hydrophobic pocket in HDAC6 consisting of residues Phe200, Phe201, and Leu270 and formed a cation−π interaction between the top of the linker and Arg194 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). However, these key interactions were not observed when binding to HDAC2/3, indicating the structural basis for the selective inhibition of HDAC6 by WT161.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Besides, Bradner et al. found WT161 could dose-dependently increase the Ac-α-tubulin levels at low micromolar concentrations (0.1–3 μM), without the effect on histone H3K9 acetylation, thus leading to a reversible accumulation of acetylated α-tubulin (Ac-α-tubulin) in MM cell lines quickly (≈ 2 h). Potent cytotoxicity of WT161 to MM cells was also observed, with IC<sub>50</sub> values ranging from 1.5 to 4.7 μM. Moreover, WT161 was able to enhance the cytotoxicity in MM cells induced by proteasome inhibitors, including bortezomib (BTZ) and carfilzomib (CFZ), via the activation of cell-stress signaling (JNK, stress-activated protein kinase). Further in vivo tests indicated WT161 had a reasonable half-life in mice (1.4 h) and combined with BTZ displayed much stronger anti-MM activity than that used alone, suggesting the simultaneous inhibition of the proteasome and aggresome by BTZ and WT161, respectively, had potential for the treatment of MM, especially for BTZ-resistant MM.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> Intriguingly, Anderson et al. described WT161 downregulated the growth factor receptors expression in breast cancer cells, irrespective of the inhibition of HDAC6, and synergistically augmented BTZ-induced cytotoxicity in BTZ-resistant breast cancer cells.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a></div></div><div id="sec2_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i7" class="anchor-spacer"></div><h4 class="article-section__title" id="_i7">2.1.2.  Linear Phenyl-Derived Capping Groups</h4><div class="NLM_p">CAY10603 (<b>9</b>) bearing a linear phenylisoxazole-derived capping group was synthesized via nitrile oxide cycloaddition chemistry.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> It showed a high level of potency against HDAC6 (IC<sub>50</sub> = 0.002 nM, >200-fold selectivity over other HDACs) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) and excellent cytotoxicity toward pancreatic cancer cells with an IC<sub>50</sub> value of 0.1 μM. Structure–activity relationship (SAR) studies revealed interaction between the lipophilic cap region of CAY10603 and the surface the HDAC6 active site was essential for the selective inhibition. In particular, replacement of amine-protecting Boc group by acetyl would lead to significant loss of activity. Docking analysis with a homology model of HDAC6 revealed the Boc group might interact with His499 to position the cap residue on the surface of the HDAC6 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Moreover, recent binding free energy calculations indicated CAY10603 had high affinity toward HDAC6 CD2.<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a> In recent years, CAY10603 has been evidenced to be a promising lead in the development of therapeutic agents for cancer and other diseases. Xie et al. has studied its superior cytotoxicity and apoptosis-inducing effect on HDAC6-overexpressed lung adenocarcinoma (LADC) cells. In addition, CAY10603 synergistically enhanced gefitinib-induced epidermal growth factor receptor (EGFR)-related apoptosis in LADC.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Fu et al. has reported that CAY10603 increased α-tubulin acetylation in lung tissues and blocked NF-κB activation by inhibiting IκB phosphorylation, leading to the alleviation of lipopolysaccharide (LPS)-induced acute lung inflammation.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> Moreover, CAY10603 was involved in regulating the NF-κB and NLRP3 inflammasome pathways in high glucose (HG)-stimulated human retinal pigment epithelium cells, which in turn inhibited HG-induced oxidative stress and inflammation, indicating its potential for treating diabetic retinopathy.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> Anti-Burkitt lymphoma (BL) activity of CAY10603 was first investigated by the Fan group. It may induce caspase-dependent apoptosis, leading to cell cycle arrest via the suppression of cyclin-dependent kinase (CDK)-cyclin complex formation in BL cells. Moreover, it synergistically enhanced the potency of vp-16, a chemotherapeutic agent for BL.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Besides, the inhibition of HDAC6 by CAY10603 promoted degradation of mitogen-activated protein kinase (MAPK) kinase 7 and suppression of JNK/c-Jun in glioma cells, resulting in the inhibition of cell growth and invasion.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures and HDAC inhibition data of CAY10603 (left). CAY10603 docked into the binding site of HDAC6 homology model (right). Reprinted with permission from ref <a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a>. Copyright 2008, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A452 (<b>10</b>) was initially identified as a λ-lactam based HDAC6 inhibitor by Han et al., in 2011 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Previously, the authors had reported a class of δ-lactam based HDAC inhibitors.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> However, structural optimization revealed the smaller λ-lactam core was more suitable for the narrow hydrophobic tunnel of the HDAC6 catalytic pocket.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Recently, Kwon et al. claimed the suppression effect of A452 on the viability of diverse tumor cells was independent of p53. The induction of apoptosis was triggered by regulating apoptosis-associated cellular markers causing DNA damage as well as via the inhibition of protein kinase B and ERK activation of the p38 pathway. In addition, its selective inhibition of HDAC6 blocked migration and invasion in human CRC cells. Notably, it was able to upregulate programmed death-ligand 1 (PD-L1) by activating the STAT3 in CRC cells.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Meanwhile, A452 combined with irinotecan displayed an even better apoptosis-inducing effect than either drug alone in CRC cells. Moreover, it was synergetic toward alteration of apoptosis-associated cellular markers, induction of DNA damage, and inhibition of cell invasion, suggesting selective inhibition of HDAC6 may promote the potency of specific antitumor drugs in CRC cells.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Besides, when used in combination, A452 was able to overcome the resistance of MM to immunomodulatory drugs.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a></div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structure, HDAC inhibition data, and key SARs of HDAC6 inhibitors bearing linear phenyl-derived capping groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>11</b> carried a thiazole-containing alkyl linker, selectively inhibited HDAC6, with an IC<sub>50</sub> value of 199 nM, and specifically upregulated tubulin acetylation levels without affecting histone H3 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Docking analysis demonstrated a close van der Waals interaction between the thiazole group and channel residues of HDAC6. Additionally, it could improve the survival rate of sepsis mice by downregulating the expression of LPS-induced pro-inflammatory cytokines, TNF-α and IL-6.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Jung et al. had attempted further optimization of <b>11</b> via SAR studies and docking analysis.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> The results showed the total aliphatic linker length and capping group rigidification were vital for increasing HDAC6 selectivity, and the preferred molecule <b>12</b> displayed selective potency toward HDAC6 (IC<sub>50</sub> = 42 nM), with 126-fold over HDAC1 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). In-depth docking analysis indicated, in addition to the size of the aliphatic linker, the electron substitution effect of the aryl-capped group, and its rigidity, all played important roles in improving the selectivity of HDAC6.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></div></div><div id="sec2_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">2.1.3.  Old Drug-Based Capping Groups</h4><div class="NLM_p">During the past few decades, multitargeted drug design, wherein a single molecule interacts with multiple targets, has emerged as an innovative strategy that may be used to discover drugs which display synergistic effects when combined with other drug targets, resulting in better therapeutic efficacy and minimal side effects, such as dose limiting toxicity, drug resistance, and adverse drug–drug interactions.<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(93,94)</a> On the other hand, the active site cleft of HDAC6 is wider than other isoforms, which allows comfortable bindings of inhibitors having bulky and hydrophobic capping groups.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> In addition, the role played by capping groups in HDAC6 inhibition is, to some extent, slightly weaker than that of ZBGs and linkers, which tends to be more important in selectivity.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Inspired by this, medicinal chemists took advantage of molecular hybridization strategy to develop multitargeted HDAC6 inhibitors by introducing old drug scaffolds as capping groups. Besides, the long aliphatic linkers were always used to connect ZBGs with the caps, thus leading to old drug-based capping groups retaining the original target potency. Herein, we summarized some representative HDAC6 inhibitors developed by aforementioned molecular hybridization approaches, which displayed additional potency against other proteins or targets.</div><div id="sec2_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i9" class="anchor-spacer"></div><h5 class="article-section__title" id="_i9">2.1.3.1.  HSP90 Inhibitor-Derived Capping Groups</h5><div class="NLM_p">HSP90 is a cell-generated molecular chaperone involved in a variety of cellular functions by regulating the folding and/or localization of large multiprotein complexes and client proteins. Moreover, HSP90 enables mutant oncoproteins to avoid misfolding and degradation and allows malignant transformation, which plays an important role in tumorigenesis.<a onclick="showRef(event, 'ref95 ref96'); return false;" href="javascript:void(0);" class="ref ref95 ref96">(95,96)</a> On the other hand, HDAC6 is able to regulate the degradation of misfolded proteins by targeting HSP90 (a famous substrate of HDAC6), which process is essential for efficient oncogenic cell transformation.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">HSP90 inhibitors have been identified as potential cancer therapeutics.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> Besides, 4-isopropyl resorcinol fragment has been a key pharmacophore in second-generation HSP90 inhibitors design, such as luminespib (<b>13</b>), onalespib (<b>14</b>), and ganetespib (<b>15</b>) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a).<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> Thus, Liou et al. designed and synthesized a series of novel, dual HDAC6/HSP90 inhibitors by introducing a 4-isopropyl resorcinol fragment via molecular hybridization strategy.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> SAR studies revealed a linker of 5 or 6 methylenes was the most favored for HDAC6 inhibition and selectivity, namely, compound <b>16a</b> or <b>16b</b>, respectively. Particularly, compound <b>16b</b> exhibited stronger dual inhibition of HDAC6 and HSP90 with IC<sub>50</sub> values of 1.15 nM and 46.3 nM, respectively, and displayed a selectivity that was more than 110-fold higher than HDAC1/3/8 (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a). Besides, it could significantly upregulate the levels of Ac-α-tubulin at low submicromolar concentrations, without an effect on Ac-histone-H3. Further, it induced the degradation of multiple HSP90 client proteins, concentration- or time-dependently, resulting in comparable cytotoxicity against tested cell lines including A549, HCT 116, HL-60, and H1975, with GC<sub>50</sub> values ranging from 0.91 to 1.61 μM.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (a) Structure and HDAC inhibition of compounds <b>16</b> and <b>17</b> bearing HSP90 inhibitors-derived capping groups. (b) Isoform structural differences lead to HDAC6 selectivity of <b>17</b>. The docked pose of <b>17</b> (yellow) in HDA6 (blue) are superimposed with HDAC1 (green) and HDAC3 (purple) (up). The surface model of <b>17</b> docked in HDAC6 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU">5EDU</a>), HDAC1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ICN">5ICN</a>), and HDAC3 ((PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69">4A69</a>). A specific pocket for the capping group is observed in HDAC6 (lower). Reprinted with permission from <i>European Journal of Medicinal Chemistry</i> (ref <a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a>). Copyright 2020, Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Further studies have explored the possibility of developing more potent dual HDAC6/HSP90 inhibitors as anticancer agents for the treatment of NSCLC. Thus, the 4-isopropyl resorcinol fragment was retained, while the indoline moiety was replaced by isoindoline as the core skeleton, which was condensed with the resorcinol ring to form a critical pharmacophore shared by all target compounds.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> A representative compound <b>17</b> had a long alkyl linker of eight methylenes and exerted a potent enzymatic inhibitory effect against HDAC6 (IC<sub>50</sub> = 4.32 nM) and HSP90 (IC<sub>50</sub> = 46.8 nM) (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>a). Moreover, it exhibited stronger isoform selectivity than compound <b>16</b>, and docking studies demonstrated the 4-isopropyl resorcinol of <b>17</b> capping group formed hydrogen bonds with S564, F566, and I569 of HDAC6 CD2, and this area constituted a binding pocket absent from HDAC1 or HDAC3, thus leading to excellent HDAC6 selectivity (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>b). In addition, <b>17</b> exhibited higher growth inhibition of lung A549 cells (GI<sub>50</sub> = 0.76 μM) and lung EGFR-resistance H1975 cells (GI<sub>50</sub> = 0.52 μM) as well as potent tumor growth inhibition in an EGFR-resistance NSCLC H1975 xenograft model when used alone or in combination with afatinib. Besides, IFN-γ-mediated upregulation of the reduced PD-L1 in H1975 lung cancer cells was reversed by <b>17</b>, suggesting it might disrupt immunosuppressive ability of tumor microenvironment.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Together, these studies provided promising leads for the development of dual HDAC6/HSP90 inhibitors as therapeutic agents against lung cancer.</div></div><div id="sec2_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i10" class="anchor-spacer"></div><h5 class="article-section__title" id="_i10">2.1.3.2.  Janus Kinases (JAKs) Inhibitor-Derived Capping Groups</h5><div class="NLM_p">As acknowledged nonreceptor tyrosine kinases, the JAK family, consisting of JAK1, JAK2, JAK3, and TYK2, transduces cytokine-mediated signals via the JAK-signal transducer and activator of the transcription (JAK-STAT) pathway that is involved in many important biological processes, such as cell proliferation, differentiation, apoptosis, and immune regulation.<a onclick="showRef(event, 'ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref101 ref102">(101,102)</a> JAK inhibitors are used to selectively inhibit JAKs and block the JAK-STAT pathway to treat blood disorders, cancer, rheumatoid arthritis, and atopic dermatitis.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a></div><div class="NLM_p">Dymock et al. has aimed at the development of dual inhibitors of JAKs and HDACs over the past few years.<a onclick="showRef(event, 'ref104 ref105 ref106'); return false;" href="javascript:void(0);" class="ref ref104 ref105 ref106">(104−106)</a> A common approach was pharmacophores fusion through a molecular hybridization strategy. Of these, compound <b>19</b> was produced as a hybrid of SAHA (<b>1</b>) and pacritinib (<b>18</b>, a highly potent JAK2 inhibitor that they reported previously) (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref104 ref107'); return false;" href="javascript:void(0);" class="ref ref104 ref107">(104,107)</a> Since the pyrolidine side chain of pacritinib only serves to increase the aqueous solubility of the compound,<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Dymock et al. had replaced this less important pharmacophore with a hydroxamic acid group containing a long alkyl linker, thereby maintaining JAK2 inhibition as well as HDAC potency. As expected, <b>19</b> exhibited single-digit nanomolar potency toward both JAK2 and HDAC6 as well as high selectivity over other isoforms. Docking analysis of <b>19</b> bound to a homology model of HDAC6 revealed the hydroxamate moiety could bind deeply with HDAC6 catalytic Zn<sub>2</sub><sup>+</sup> ion in a bidentate manner, and the large macrocyclic capping group fully occupied the surface of HDAC6 active pocket. Meanwhile, a unique pocket of the HDAC6 entrance formed by P748 and L749 (marked by a red box in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>) was not present in HDAC1, resulting in the macrocycle of <b>19</b> that could not interact well with HDAC1. In addition, the hydroxamic acid linker was positioned in the solvent exposed channel of JAK2 modeling as previously hypothesized (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). <b>19</b> showed broad antiproliferative activity against both solid and hematological cell lines (IC<sub>50</sub> values varied in single-digit micromolar levels) via dual inhibition of the JAK-STAT and HDAC pathways.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Sturcture and HDAC inhibition of HDAC6 inhibitors bearing JAK inhibitor-derived capping groups. Docking models displayed the <b>19</b> bound to HDAC6 homology model (derived from the crystal structure of HDAC4, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQW">2VQW</a>), HDAC1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>), and JAK2 <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2B7A">2B7A</a>). A pocket unique to HDAC6 was formed by P748 and L749, marked by a red box. The hydroxamic acid linker of <b>19</b> is positioned in the solvent exposed channel of JAK2, marked by a orange box. Reprinted with permission from ref <a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a>. Copyright 2016, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Aiding by the same pharmacophores fusion strategy, they subsequently explored a novel serious of dual HDAC/JAK2 inhibitors on the basis of ruxolitinib (<b>20</b>, the first clinically applied selective JAK1/2 inhibitor).<a onclick="showRef(event, 'ref105 ref108'); return false;" href="javascript:void(0);" class="ref ref105 ref108">(105,108)</a> Herein, the key pyrazole substituted pyrrolopyrimidine of ruxolitinib was introduced as the capping groups, and the preferred compound <b>21</b> exhibited decent dual inhibition against JAK2 (IC<sub>50</sub> = 0.041 nM) and HDAC6 (IC<sub>50</sub> = 0.25 nM) and a selectivity which was 300-fold higher than that for HDAC1 (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). Docking studies revealed the pyrazole substituent was a very influential turning point for HDAC6 potency and selectivity. Moreover, <b>21</b> displayed excellent antiproliferative activity toward several solid tumor cell lines (IC<sub>50</sub> = 4.1–7.7 μM).<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></div><div class="NLM_p last">Next, they reported another class of dual JAK2/HDAC inhibitors by merging the pharmacophores of XL019 (<b>22</b>, a selective JAK2 inhibitor, IC<sub>50</sub> = 2.2 nM) and SAHA (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).<a onclick="showRef(event, 'ref106 ref109'); return false;" href="javascript:void(0);" class="ref ref106 ref109">(106,109)</a> Two series of compounds were designed and synthesized by varying the linkage sites of the hydroxamate-bearing alkyl chain attached to the XL019 core backbone, and the final SAR studies have illustrated the possibility to improve HDAC6 selectivity, while retaining the potent JAK2 activity. Among these, compounds <b>23</b> and <b>24</b> stood out due to low nanomolar inhibition of JAK2 and HDAC6 (<b>23</b>, JAK2 IC<sub>50</sub> = 0.9 nM, HDAC6 IC<sub>50</sub> = 0.1 nM; <b>24</b>, JAK2 IC<sub>50</sub> = 3.1 nM, HDAC6 IC<sub>50</sub> = 1.2 nM) and good selectivity over HDAC1. Meanwhile, <b>24</b> showed a 16–25-fold selectivity against other JAK members including JAK1, JAK3, and TYK2. In addition, these compounds showed submicromolar potency against both solid and hematological tumor cell lines without toxicity toward normal cells.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div></div><div id="sec2_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i11" class="anchor-spacer"></div><h5 class="article-section__title" id="_i11">2.1.3.3.  Other Protein Inhibitors-Derived Capping Groups</h5><div class="NLM_p">DNA topoisomerases (Topo) play an important role in resolving topological challenges associated with replication, transcription, and recombination and are involved in chromatin remodeling by introducing temporary single-strand (topoisomerase I, Topo I) or double-strand (topoisomerase II, Topo II) breaks in DNA.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> Topo inhibitors target DNA–enzyme complexes, leading to errors in DNA synthesis and inducing apoptosis of cancer cells. In addition, combinations of HDACi and Topo inhibitors may synergistically promote anticancer potency due to the fact that HDACi relax chromatin DNA, allowing Topo inhibitors to interact with DNA targets.<a onclick="showRef(event, 'ref111 ref112'); return false;" href="javascript:void(0);" class="ref ref111 ref112">(111,112)</a> Iida et al. had developed a new class of nucleoside-based selective Topo II inhibitors, represented by compound <b>25</b> (IC<sub>50</sub> = 19.1 μM),<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> which enabled them to design novel dual HDAC-Topo II inhibitors by merging SAHA (<b>1</b>) with the nucleoside scaffolds (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Of these, compound <b>26</b> was found to be a strong inhibitor of HDAC6 with IC<sub>50</sub> values of 44 nM (<b>26a</b>, alpha-nucleoside) and 51 nM (<b>26b</b>, beta-nucleoside), which were 20- and 15-fold more selective over HDAC1, respectively (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). In particular, <b>26b</b> exhibited potent cytotoxicity toward MCF-7, HCT-116, and DU-145 cells lines (IC<sub>50</sub> = 3.24–3.98 μM). Additionally, DNA decatenation assay indicated <b>26</b> retained Topo II inhibitory activity.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a></div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures and HDAC inhibition of HDAC6 inhibitors bearing Topo II (<b>26</b>), ER (<b>28</b>), Bcl-2 (<b>30</b>), and BD2 (<b>32</b>) inhibitor-derived capping groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The estrogen receptor (ER), a ligand-modulated transcription factor, is involved in many physiological and pathological activities and plays an essential role in the progression of breast cancer.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Compound <b>28</b> is a dual-targeted ER and HDAC6 inhibitor,<a onclick="showRef(event, 'ref116 ref117'); return false;" href="javascript:void(0);" class="ref ref116 ref117">(116,117)</a> which is a hybrid of an ER antagonist oxabicycloheptene sulfonate (OBHS, <b>27</b><a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a>) and SAHA (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). <b>28</b> showed high ER binding affinity and excellent ERα antagonistic activity. Besides, it exhibited high potency against DU-145 cells (IC<sub>50</sub> = 8.57 μM), attributed to the potent inhibition of HDAC6.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Huang et al. has reported treatment of gastric cancer (GC) cells with <b>28</b> at low micromolar concentrations could cause cell cycle arrest at the G2/M phase and induce early stage apoptosis by activating the intrinsic apoptotic pathway. Moreover, it suppressed the migration of GC cells and inhibited angiogenesis by reducing the levels of intracellular VEGF and hypoxia inducible factor 1α (HIF-1α).<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></div><div class="NLM_p">Venetoclax (ABT-199, <b>29</b>) was the first oral drug approved for the treatment of chronic lymphocytic leukemia targeting the BCL-2 protein.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Zheng et al. had developed a class of dual-targeted Bcl-2 and HDAC inhibitors suitable for treating multiple myeloma (MM) based on ABT-199.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> Representative compounds <b>30a</b>, <b>30b</b>, and <b>30c</b>, with the linker lengths of 5, 6, and 7 methylenes, respectively, showed highly selective HDAC6 potency (IC<sub>50</sub> = 28, 28, and 19 nM, respectively). Also, they exhibited strong binding affinities toward Bcl-2 (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). Moreover, they exhibited excellent growth inhibition effects on the MM cell line RPMI-8226, with IC<sub>50</sub> values ranging from 0.2 to 0.3 μM.<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a></div><div class="NLM_p last">ABBV-744 (<b>31</b>) is a highly potent and selective inhibitor of the BD2 domain of BET family members.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> With the help of the pharmacophore fusion strategy, Hu et al. developed a novel series of dual HDAC/BRD4 inhibitors by introducing the key backbone of ABBV-744 as a capping group (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>).<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> Among them, compound <b>32</b> was determined as a dual HDAC6/BRD4 (BD2) inhibitor, with high potency toward HDAC6 (IC<sub>50</sub> = 17.2 nM, >10-fold selectivity over HDAC1), and selective inhibition to BD2 domain of BRD4 similar to ABBV-744 (IC<sub>50</sub> = 1.2 nM, >300-fold selectivity over BD1). Meanwhile, <b>32</b> exhibited high cytotoxicity against the human acute meylogenous leukemia cell line, MV-4-11 (IC<sub>50</sub> = 0.3 μM), comparable to ABBV-744 (IC<sub>50</sub> = 0.26 μM).<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">2.2.  Inhibitors Containing Bulky and Rigid Aromatic Linkers</h3><div id="sec2_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i13" class="anchor-spacer"></div><h4 class="article-section__title" id="_i13">2.2.1.  Phenyl-Based Linker</h4><div id="sec2_2_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i14" class="anchor-spacer"></div><h5 class="article-section__title" id="_i14">2.2.1.1.  HPOB and HPB</h5><div class="NLM_p">HPOB (<b>33</b>) is a specific HDAC6 inhibitor (IC<sub>50</sub> = 56 nM) with a bulky and rigid phenyl-based linker, which was first reported by Marks et al. in 2013.<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> It showed more than 30-fold selectivity for HDAC6 over other isoforms (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>a). Noteworthily, the X-ray crystal structure of HPOB complexed with zebrafish HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EF7">5EF7</a>) first disclosed the unique monodentate Zn<sub>2</sub><sup>+</sup> coordination model related to phenylhydroxamate HDAC6 inhibitor (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>b; <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>a).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In other words, only the OH group of the HPOB hydroxamate moiety coordinated with Zn<sub>2</sub><sup>+</sup> directly, whereas the C═O group formed hydrogen with Zn<sub>2</sub><sup>+</sup>-bound water molecule. Besides, the short phenyl linker of HPOB spatially limited the closer binding of hydroxamic group with Zn<sub>2</sub><sup>+</sup> ion in the active site, which might also prevent the capping group from interacting well with the L1 loop, an interaction that seemed to be more essential for binding to HDAC1/2/3 than to HDAC6, thus leading to the high selectivity of HPOB for HDAC6. In addition, the phenyl linker formed double π stacking interaction with F583 and F643 (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>a).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> HPOB could reduce corticosterone-triggered damage in rat adrenal pheochromocytoma cells by blockading mitochondrial GR translocation and the intrinsic apoptosis pathway.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> A recent study revealed that HPOB was able to inhibit cellular melanin synthesis in B16-F10 murine melanoma cells without causing significant cytotoxicity.<a onclick="showRef(event, 'ref125'); return false;" href="javascript:void(0);" class="ref ref125">(125)</a> Besides, it served as a potential neuroprotectant in mouse models by reducing photo thrombotic stroke (PTS)-induced infarction volume and cell apoptosis and restoring motor behavior.<a onclick="showRef(event, 'ref126'); return false;" href="javascript:void(0);" class="ref ref126">(126)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (a) Structure and HDAC inhibition of HPOB (<b>33</b>) and crystal structure of the HPOB–HDAC6 CD2 complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EF7">5EF7</a>). (b) Structure and HDAC inhibition of HPB (<b>34</b>) and crystal structure of the HPB–HDAC6 CD2 complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEM">5EEM</a>). Reproduced with permission from <i>Proceedings of the National Academy of Sciences of the United States of America</i>, Porter, N. J.; Mahendran, A.; Breslow, R.; Christianson, D. W., Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors, 2017, 114, 13459−13464.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Despite its structural resemblance to HPOB, HPB (<b>34</b>) bearing a peptoid capping group showed higher potency toward HDAC6 (IC<sub>50</sub> = 25 nM).<a onclick="showRef(event, 'ref127'); return false;" href="javascript:void(0);" class="ref ref127">(127)</a> Meanwhile, the crystal structure of the HPB-zebrafish HDAC6 CD2 complex displayed additional intermolecular interactions distinct from that of HPOB. In particular, the energetically preferred trans-conformation allowed the hydroxyl group of the peptoid capping group to form a water-mediated hydrogen bond with S531 on the L2 loop, which was confirmed to be a key interaction to the HDAC6 active site that confers isoform affinity and selectivity (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>b).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div></div><div id="sec2_2_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i15" class="anchor-spacer"></div><h5 class="article-section__title" id="_i15">2.2.1.2.  Nexturastat A and Its Derivatives</h5><div class="NLM_p">Nexturastat A (NextA, <b>35</b>) has a slightly different structure from HPOB and HPB in that it contains a urea-benzyl capping group (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), which affects the geometry and orientation of NextA binding with the active site, resulting in an effective potency for HDAC6 (IC<sub>50</sub> = 5 nM, more than 190-fold higher selectivity than other HDACs).<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> Matthias et al. had disclosed HADC6 had a wider open basin (∼14 Å), a region that was occupied by the bulkiness of residues in other HDACs. Also, the height of the rim between the wide HDAC6 basin and the acetylated lysine binding channel was lower than others. Notably, NextA could tolerate these specific isoform-specific steric constraints well aided by its rigid structure and 90° angle between the phenyl linker and the urea-benzyl capping group, thus leading to NextA high selectivity for HDAC6.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> In B16 murine melanoma cells, NextA increased tubulin acetylation in a dose-dependent manner, without affecting histone H3 acetylation.<a onclick="showRef(event, 'ref128'); return false;" href="javascript:void(0);" class="ref ref128">(128)</a> The latest research suggested it may be used in combination with a photothermal therapy agent within nanoparticles for melanoma therapy.<a onclick="showRef(event, 'ref129'); return false;" href="javascript:void(0);" class="ref ref129">(129)</a> Moreover, it enhanced anti-PD-1 immune check-point blockade therapy in mice bearing melanoma cells (15 mg/kg).<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Besides, NextA could inhibited tumor growth in MM xenograft models.<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structure and HDAC inhibition of NextA and its derivatives. (a) Compound <b>36</b> docked into HDAC6 CD2 (PBD code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G0I">5G0I</a>) and an additional hydrogen bonding interaction was observed between indazole NH group and the carbonyl group of Ala641. Reprinted with permission from ref <a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a>. Copyright 2017, American Chemical Society. (b) Crystal structure of Suprastat–HDAC6 CD2 complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TCY">6TCY</a>). Newly introduced polar/ionic contacts between the aminomethyl and hydroxylbutyl groups of Suprastat and D460 and N530, respectively. (c) Molecular dynamics (MD) simulations showed H-bonding interaction between Suprastat and S531. Reprinted with permission from ref <a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a>. Copyright 2020, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Kozikowski et al. had attempted to increase hydrogen bond interactions with an HDAC6 active site cleft by introducing hydrophilic substituents at the capping domain of NextA.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> The preferred molecule <b>36</b> containing an indazole ring showed higher HDAC6 potency (IC<sub>50</sub> = 1.6 nM) and maintained selectivity over HDAC1 compared with NextA. As expected, docking analysis indicated the NH group of the indazole ring engaged additional hydrogen bonding with the carbonyl group of Ala641 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>a).</div><div class="NLM_p last">With the same aim to increase hydrogen bonding interactions between the capping group of NextA and the HDAC6 pocket in addition to providing hydrophobic interactions, Kozikowski et al. expanded on their previous works to develop Suprastat (<b>37</b>) as a novel specific HDAC6 inhibitor, with improved HDAC6 potency (IC<sub>50</sub> = 0.4 nM) compared with NextA and superior isoform selectivity, by introducing the aminomethyl and hydroxyl (similar to HPOB) groups into the capping group of NextA (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> The crystal structure of Suprastat complexed with zebrafish HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TCY">6TCY</a>) and molecular dynamics (MD) simulations confirmed the added aminomethyl and hydroxyl groups could form direct or water molecule-mediated hydrogen bonding with pocket residues D460, N530, and S531 (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>b,c), which were essential for the regulation of HDAC6 deacetylase function and were absent in other HDACs.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Owing to the excellent HDAC6 potency, Suprastat was able to selectively upregulate the Ac-α-tubulin levels in melanoma cells without cytotoxicity. Meanwhile, Suprastat displayed good metabolic stability, which was attributed to the newly introduced polar groups that confer improved lipophilic ligand efficiency and decreased plasma protein binding features. In addition, Suprastat (25 mg/kg) in combination with anti-PD1 immune checkpoint blockade therapy (15 mg/kg) potentiated antitumor immunity in melanoma models.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></div></div><div id="sec2_2_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i16" class="anchor-spacer"></div><h5 class="article-section__title" id="_i16">2.2.1.3.  Tubastatin A and Its Derivatives</h5><div class="NLM_p">Tubastatin A (TubA, <b>38</b>) bearing a tetrahydro-γ-carboline-derived capping group is a typical phenylhydroxamate HDAC6 inhibitor (IC<sub>50</sub> = 15 nM) rationally designed by Kozikowski et al. 10 years ago, with superior selectivity for HDAC6 over HDAC8 (57-fold) and other isozymes (1000-fold) (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).<a onclick="showRef(event, 'ref134'); return false;" href="javascript:void(0);" class="ref ref134">(134)</a> More recently, they disclosed the molecular basis of its affinity and selectivity with HDAC6 through X-ray crystallography (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>a).<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> Due to the bulky and short linker, TubA was not able to bind deeply into the active site of HDAC6 CD2 and engaged in a monodentate Zn<sub>2</sub><sup>+</sup> coordination model similar to previously reported binding fashions of related phenylhydroxamate HDAC6 inhibitors (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>b).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> In addition, the phenyl of the linker nestled in the hydrophobic tunnel composed of F583 and F643, forming a π–π stacking interaction (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>a). The indole portion of the carboline-based capping group was located against the hydrophobic patch of the L1-loop pocket of HDAC6 delineated by residues F583, H463, P464, and L712 (colored blue in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>c). Besides, the methylpiperidine motif positioned in a solvent-rich environment, engaging in limited van der Waals interaction with F643 and L712 (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>a,c).<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a> TubA increased α-tubulin acetylation, attenuated LPS-induced inflammatory effects<a onclick="showRef(event, 'ref136'); return false;" href="javascript:void(0);" class="ref ref136">(136)</a> and exerted protective effects on mouse doxorubicin-induced cardiomyopathy models (50 mg/kg),<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> cisplatin-induced acute kidney injury,<a onclick="showRef(event, 'ref138'); return false;" href="javascript:void(0);" class="ref ref138">(138)</a> as well as cecal ligation and puncture-induced lethal sepsis.<a onclick="showRef(event, 'ref139'); return false;" href="javascript:void(0);" class="ref ref139">(139)</a> In addition, it displayed potency against various neurological disease animal models,<a onclick="showRef(event, 'ref135 ref140'); return false;" href="javascript:void(0);" class="ref ref135 ref140">(135,140)</a> retinal disorder,<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> hypertension,<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a> encephalitis virus,<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> esophageal squamous carcinoma,<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> and glioblastoma.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> Interestingly, a recent study claimed that TubA was a potent HDAC10 inhibitor, which was contradicted by the findings of Kozikowski’s study.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> A possible reason was the difference between the types of assays used, namely, probe displacement assays vs enzymatic assays, respectively.<a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Sturcture and HDAC inhibition of TubA, and X-ray crystal structure of TubA complexed with HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6THV">6THV</a>). (a) Detailed view of the residues delineating the active site and the substrate tunnel: the catalytic Zn<sub>2</sub><sup>+</sup> ion and water molecules are shown as orange and red spheres, respectively. (b) Detailed view of monodentate binding model. (c) Interactions between the carboline-based capping group and the “L1-loop pocket” of HDAC6 established by H463, P464, F583, and L712 side chains (colored blue). The surface of HDAC6 is shown in a semitransparent surface representation. Reprinted with permission from ref <a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a>. Copyright 2020, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Based on structural optimization, Mahboobi et al. had developed a class of TubA derivatives bearing a tetrahydro-β-carboline-derived capping groups.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a> Among, Marbostat-100 (<b>39</b>) including (<i>R</i>)- and (<i>S</i>)-isomers displayed superior potency toward HDAC6 (<i>K</i><sub>i</sub> = 0.7 nM, more than 500-fold over HDAC1). SAR studies revealed substitutions of the aromatic moiety of capping group were tolerated on the enzymatic level (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). Docking analysis of Marbostat-100 with HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGK">5WGK</a>) showed there was no difference between two enantiomers with regard to the hydroxamic acid-ZBG and benzyl linker. Besides, the bulky capping groups of both enantiomers comfortably occupied the extended hydrophobic surface region (colored brown, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>, upper right), and formed van der Waals contacts with the surface residues. Notably, both isomers increased tubulin acetylation without exerting an effect on histone acetylation. Moreover, Marbostat-100 exerted anti-inflammatory effects on mouse collagen-induced arthritis models (30 mg/kg) with significant reduction of clinical arthritis scores of about 25% and histological scores of about 50%, without obvious changes in main safety-related blood parameters, suggesting Marbostat-100 deserved further clinical evaluation.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures and HDAC inhibition of TubA derivatives. (<i>R</i>)-Marbostat-100 (gray) and (<i>S</i>)-Marbostat-100 (yellow) docked into HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WEK">5WEK</a>). The binding site is represented by the lipophilic potential mapped onto a MOLCAD Connolly surface (hydrophobic areas, brown; polar areas, green and blue). Reprinted with permission from ref <a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a>. Copyright 2020, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>40</b> was another TubA derivative derived from the optimization of the rigid tetrahydro-β-carboline capping group.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a> It displayed highly selective inhibition capabilities against HDAC6 (IC<sub>50</sub> = 3.73 nM), with more than 200-fold selectivity over other isoforms, especially for HDAC10 (>10 000-fold). SAR studies revealed the piperazine-2,5-dione moiety was more potent as the extended pharmacophore than the imidazolidine-2,4-dione moiety. Meanwhile, the introduction of an additional methyl into tetrahydro-β-carboline scaffold reduced the selectivity for HDAC6, e.g., the selectivity index of HDAC1/6 decreased from 2265 (<b>40</b>) to 586 (<b>41</b>) (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). In addition, <b>40</b> could specifically and rapidly induce intracellular tubulin hyperacetylation at a concentration of 50 nM, which was superior to TubA. These findings indicate modification of the rigid capping group of TubA may be considered as an effective strategy for highly potent HDAC6 inhibitors design.<a onclick="showRef(event, 'ref148'); return false;" href="javascript:void(0);" class="ref ref148">(148)</a></div></div><div id="sec2_2_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i17" class="anchor-spacer"></div><h5 class="article-section__title" id="_i17">2.2.1.4.  Bifurcated Capping Groups</h5><div class="NLM_p">Compared with the structures of HPOB (<b>33</b>), NextA (<b>35</b>), and TubA (<b>38</b>), RTS-V5 (<b>42</b>) and NR-160 (<b>43</b>) employ much more bulky and extended caps, also called bifurcated capping groups, which cannot only make interactions in the L1 pocket (D460–P484) but also another shallow pocket defined by the L2 loop and nearby residues G640–N645 (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>a).<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> RTS-V5 (<b>42</b>) is a first-in-class dual HDAC-proteasome inhibitor, reported by Hansen et al. in 2018.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> X-ray crystallography further disclosed the interactions between bifurcated capping group and L1, L2 loop, except for the typical monodentate Zn<sub>2</sub><sup>+</sup> coordination and π–π stacking interaction with F583 and F643 related to phenylhydroxamate inhibitors. The para-substituted amide NH group interacted with S531 on the L2 loop by a hydrogen bond, and the carbonyl group of the neopentylamide moiety formed a hydrogen bond with H463 in the L1 loop. In addition, the amide group extending to the L2 loop connected with N530 through a water molecule-mediated hydrogen bond (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>b).<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> RTS-V5 showed submicromolar IC<sub>50</sub> values against both HDAC6 and chymotrypsin-like proteasome. Besides, it exhibited potent cytotoxicity against the B-cell precursor acute lymphoblastic leukemia cell line SEM (IC<sub>50</sub> = 0.89 μM). Considerably greater anticancer activities were observed when MM cells and refractory primary patient-derived leukemia cells were treated with RTS-V5.<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a></div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. (a) Structure of the HDAC6 CD2 complex with RTS-V5 bearing a bifurcated capping group (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CW8">6CW8</a>). Molecular surface of the active site illustrates the L1 and L2 pockets.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> (b) The structure and HDAC inhibition of RTS-V5 and crystal structure with HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CW8">6CW8</a>).<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> (c) The structure and HDAC inhibition of NR-160 and crystal structure with HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PYE">6PYE</a>). Reproduced with permission from refs <a onclick="showRef(event, 'ref43 ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref43 ref149 ref150">(43,149,and150)</a>. Copyright 2020, 2018, 2020, American Chemical Society, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">NR-160 (<b>43</b>) exerted a selectivity of more than 170-fold for HDAC6 (IC<sub>50</sub> = 30 nM) over that for HDAC1.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> X-ray crystal structure of NR-160 complexed with zebrafish HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PYE">6PYE</a>) revealed the bifurcated capping group branch out from the central benzylamine linker and interacted with pockets defined by the L1 and L2 loops (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>c). The CF<sub>3</sub> group sitting in the L1 loop accepted a hydrogen bond from a nearby water molecule, which in turn accepted a hydrogen bond from R605. Distinct from RTS-V5 (<b>42</b>), the capping group located in the L2 loop did not make any interactions with so-called HDAC6 “gatekeeper” residue S531; however, two water-mediated hydrogen bonds of the tetrazole moiety with the backbone NH group of F643 and side chain of H614 were observed (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>c). Thus, the impressive HDAC6 selectivity of NR-160 might be more due to the fully steric complementarity of the bifurcated capping group with L1 and L2 loops. Notably, NR-160 was able to synergistically enhance anticancer activity of BTZ, epirubicin, and daunorubicin, even if showing weak cytotoxicity against leukemia cell lines when used alone.<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a></div></div><div id="sec2_2_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i18" class="anchor-spacer"></div><h5 class="article-section__title" id="_i18">2.2.1.5.  Heterocyclic Ketone-Derived Capping Groups</h5><div class="NLM_p">Ma et al. developed a class of phenylhydroxamate HDACi bearing a benzisothiazolone-based capping group based on the structure of ebselen.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Among, compound <b>44</b> exerted potent and selective inhibitory activity against HDAC6 (IC<sub>50</sub> = 3 nM, >80-fold selectivity over HDAC1/2/3) (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>). It promoted α-tubulin hyperacetylation remarkably and inhibited cell growth in multiple tumor cell lines at low micromolar concentrations.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> Li et al. developed compound <b>45</b> as a multitarget ligand by fusing the pharmacophores of ebselen and phenylhydroxamate HDAC6 inhibitors directly. In addition to selective inhibition of HDAC6 (IC<sub>50</sub> = 37 nM), it displayed a good scavenging effect on hydrogen peroxide and free oxygen radicals as well as excellent glutathione peroxidase-like ability.<a onclick="showRef(event, 'ref152'); return false;" href="javascript:void(0);" class="ref ref152">(152)</a> Compound <b>46</b> employing a thiazolidinedione-based capping group showed a selective HDAC6 potency (IC<sub>50</sub> = 21 nM) that was 18-fold higher than that for HDAC1. It was able to increase the acetylation level of α-tubulin in a dose-dependent manner, thereby reversing cell morphology changes induced by methamphetamine in human neuroblastoma SH-SY5Y cells.<a onclick="showRef(event, 'ref153'); return false;" href="javascript:void(0);" class="ref ref153">(153)</a></div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structure and HDAC inhibition of HDAC6 inhibitors bearing heterocyclic ketone-derived capping groups. Docking model displayed lead compound <b>47</b> docked into HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU">5EDU</a>). Pocket analysis of HDAC6 was performed using <i>AlphaSpace</i>, and hydrophobic regions were colored, respectively. Reproduced with permission from ref <a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>48</b> bearing an 2,4-imidazolinedione-derived capping group was prepared based on an interesting SBDD strategy.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a> By docking the lead compound <b>47</b> into HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU">5EDU</a>), Fang et al. found the rational embellishment of 2,4-imidazolinedione scaffold would help the capping group to fully occupy the hydrophobic pocket comprising L1 loop pockets 1, 2, and 3 as well as newly defined 4 and 5 pockets by <i>AlphaSpace</i> (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>), thus resulting in improved binding affinity to HDAC6. SAR studies revealed the phenyl and substituted benzyl modifications on the cap region showed better HDAC6 activity. <b>48a</b>, <b>48b</b>, and <b>48c</b> displayed superior inhibition effects. In particular, <b>48b</b> exhibited the best HDAC6 potency with an IC<sub>50</sub> value of 4.4 nM, which was more than 50-fold higher over HDAC1/2/3. It could upregulate Ac-α-tubulin levels without significant effect on the acetylation of histone H3. In addition, <b>48b</b> displayed excellent cytotoxicity to HL-60 cells (IC<sub>50</sub> = 0.25 μM) by inducing caspase 3-associated apoptosis.<a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a></div><div class="NLM_p">Considering the fact that HDAC and phosphodiesterase 9 (PDE9) are important targets in the treatment of Alzheimer’s Disease (AD), Oyarzabal et al. developed a series of dual inhibitors targeting HDAC and PDE9 by introducing the key pharmacophores of reported PDE9 inhibitors as capping groups.<a onclick="showRef(event, 'ref155'); return false;" href="javascript:void(0);" class="ref ref155">(155)</a> Among, compound <b>49</b> was described as a dual HDAC6/PDE9 inhibitor, showing more than 100-fold selectivity for not only PDE9 over phosphodiesterase 5 (PDE5) but also HDAC6 over HDAC1/2 (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). Moreover, it showed balanced activity between the induction of cyclic AMP response element-binding protein (CREB) phosphorylation, acetylation, and cytotoxicity. In addition, <b>49</b> served as a tool molecule for evaluating the pharmacological functions of PDE9 and HDAC6 in AD due to its acceptable absorption, distribution, metabolism, and excretion (ADME) profiles and brain permeability. Compound <b>50</b>, typified by a quinazolin-4-one-derived capping group, was one of dual HDAC/PI3K inhibitors developed by Grewal et al. via a pharmacophore fusion strategy.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> It showed highly selective potency toward PI3Kγ, δ, and HDAC6, and the affinity between which was confirmed via a cellular thermal shift assay in MV411, an acute myeloid leukemia (AML) cell line. Meanwhile, it displayed potent cytotoxicity against several solid and blood cancer cells, which may be attributed to necrosis-associated cell death induced by <b>50</b>. Good microsomal stability and the in vivo pharmacokinetics (PK) profile indicated further research on antitumor activity of <b>50</b> may be justified. Campiani et al. developed a series of quinolone-capped HDAC6 inhibitors.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a> SAR studies revealed compound <b>51a</b> and <b>51b</b>, with modifications of phenyl and pyridine, respectively, at the C-4 position of a quinolone-based capping group, displayed the optimal HDAC6 potency, showing low nanomolar IC<sub>50</sub> values and good selectivity over HDAC1 (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). Meanwhile, both compounds shared the same flexible and protonatable diethylaminomethylbenzyl moiety, which was able to establish a salt bridge and a polar contact with a HDAC6 pocket that was helpful for improving binding affinity with HDAC6. <b>51a</b> induced apoptosis-triggered cell death in colon cancer cells at low micromolar concentrations. Besides, <b>51b</b> was proven to be less prone to Lossen’s rearrangement to generate a toxic isocyanate derivative, which was associated with hydroxamate-induced genotoxicity and mutagenicity.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structure and HDAC inhibition of HDAC6 inhibitors bearing heterocyclic ketone-derived capping groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>52</b> was one of the novel 2,5-diketopiperazine derivatives reported by Zhu et al.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> It showed strong inhibition against HDAC6 (IC<sub>50</sub> = 0.73 nM) and high selectivity ranging from 144- to 10 941-fold over other HDACs (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>), which was consistent with its capacity to dose-dependently increase α-tubulin acetylation rather than histone acetylation. Moreover, docking analysis revealed the indolyl NH moiety of <b>52</b> capping group binding with the HDAC6 pocket via water molecule-mediated hydrogen bonding interaction.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> Chern et al. has previously described <b>53</b>, a novel quinazolin-2,4-dione-based N-hydroxybenzamide derivative and potent HDAC6 inhibitor (IC<sub>50</sub> = 4 nM, <i>K</i><sub>i</sub> = 1.58 nM) useful for treating NSCLC.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> It showed a selectivity which was 2700-fold higher than that of HDAC1 and induced α-tubulin hyperacetylation without affecting histone acetylation in the lung carcinoma cell line, LL2. Additionally, <b>53</b> in combination with PAX improved anticancer activity by attenuating PAX-induced PD-L1 expression. Moreover, it is administered orally and enhanced antitumor activity of PAX (10 mg/kg) in a xenograft syngeneic NSCLS mouse model (20 mg/kg)<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> and suppressed autophagy and induced antitumor immunity in glioblastoma cells, thereby facilitating HDAC6 degradation and enhancing anticancer activity.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a> JW-1 (<b>54</b>), which contains a naphthalimide skeleton, was identified as a novel HDAC6 inhibitor with a fluorescence imaging function.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> It specifically induced α-tubulin hyperacetylation via highly selective enzymatic inhibition (1080-fold over HDAC1) (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>). In addition, it displayed good photophysical properties and cell-based fluorescence microscopy imaging, indicating it was localized in the cytoplasm rather than the nucleus, substantiating reports which indicated HDAC6 was primarily located in the cytoplasm. Thus, <b>54</b> may be used as a potential imaging tool as well as a therapeutic agent for the visual treatment of HDAC6-related disease.</div></div><div id="sec2_2_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i19" class="anchor-spacer"></div><h5 class="article-section__title" id="_i19">2.2.1.6.  Benzo Heterocyclic-Derived Capping Groups</h5><div class="NLM_p">Jope et al. developed a tetrahydroquinoline-based HDAC6 inhibitor, named SW-100 (<b>55</b>) (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>), in order to provide a strong rationale for pursuing HDAC6-based therapies for the treatment of the rare disease fragile X syndrome (FXS).<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> SW-100 displayed highly potent HDAC6 inhibition (IC<sub>50</sub> = 2.3 nM, with at least 1000-fold selectivity over other HDACs) and dose-dependently increased the levels of α-tubulin acetylation in HEK293 cells, with no efficacy on histone acetylation. Further docking analysis of SW-100 with HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G0I">5G0I</a>) revealed the hydroxamate moiety coordinated with Zn<sub>2</sub><sup>+</sup> ion in an expected monodentate fashion that was reinforced by hydrogen bonding with residues G582, Y745, and H614. The phenyl linker was sandwiched between P583 and P643, engaging in π–π stacking interactions. Besides, an additional interaction between the Cl atom of the capping group and N645 was observed. (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>). Surface views of SW-100 and TubA (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>b,c) in HDAC6 indicated their caps showed different orientation to the rim region of the HDAC6 pocket, suggesting capping groups increase the potency of inhibitors by interacting with different residues that defined the wide rim area of HDAC6. In comparison to TubA, SW-100 had a higher lipophilicity but lower p<i>K</i><sub>a</sub> value and thus an acceptable brain/plasma ratio, which was an important property for the central nervous system (CNS) disorder therapeutics. Moreover, SW-100 could recover impaired acetylated α-tubulin levels in the hippocampus of <i>Fmr1</i><sup>–/–</sup> mice, resulting in improved learning and memory impairments in mouse FXS models.<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a> Recently, SW-100 was found to be an effective treatment for CMT disease, attributed to its ability to improve motor and sensory dysfunction.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a></div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. (a) Binding interactions of SW-100 (orange) within HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G0I">5G0I</a>). (b) Surface pose of SW-100 (orange) within HDAC6 CD2. (c) Surface pose of TubA (cyan) within HDAC6 CD2. Hydrophobic interaction areas are colored yellow, and polar are colored green. Reprinted with permission from ref <a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Liou et al. reported a class of bicyclic arylamino or heteroarylamino HDAC6 inhibitors useful for treating MM, and the key SAR studies are shown in <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> Of these, compound <b>56</b>, which involves a quinoline capping group, displayed impressive preference against HDAC6 (IC<sub>50</sub> = 0.29 nM), which was 4 000–43 000-fold more selective over other isoforms, and showed potent growth inhibition of MM cells without any obvious toxicity. Moreover, <b>56</b>, either alone or in combination with BTZ (1 mg/kg), exhibited remarkable in vivo antitumor activity in human multiple myeloma RPMI 8226 xenograft with tumor growth inhibition factor (%TGI) of 86.2%.<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> Later, studies illustrated that <b>56</b> exerted a neuroprotective effect and improved learning and memory impairments by decreasing tau phosphorylation and aggregation in mouse AD models.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> In addition, it induced cortactin acetylation, facilitated aurora-A degradation, and inhibited the cofilin-F-actin pathway, thereby suppressing the metastasis of triple-negative breast cancer cells.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Structure and HDAC inhibition of HDAC6 inhibitors bearing benzo heterocyclic-derived capping groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To confirm the hypothesis that treatment using a combination of HDAC and amyloid-β (Aβ) exerted a synergistic effect on AD, Huang et al. developed a series of multitarget HDAC, Aβ-aggregation, and acetylcholine esterase (AChE) inhibitors by fusing the scaffold of phenylhydroxamic acids and acridine (a fragment which was always used for the design of anti-AD agents).<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Among these, compound <b>57</b> exhibited selective inhibitory activity against HDAC6 (IC<sub>50</sub> = 25 nM) (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>) and effectively inhibited Aβ-aggregation and AChE. In mouse hippocampus cells, they facilitated the growth of neurites without obvious neurotoxicity. In addition, <b>57</b> showed good microsome stability and modest blood-brain barrier (BBB) permeability.</div><div class="NLM_p">Based on pharmacophore fusion strategy, Bracher et al. developed a novel class of phenylhydroxamate-based HDAC6 inhibitors employing phenothiazine-derived capping groups.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a> As a lead compound, <b>58</b> displayed quite potent HDAC6 potency (IC<sub>50</sub> = 22 nM) (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>). Excitingly, the introduction of N atoms into the phenothiazine core resulted in a more superior potency and selectivity of inhibitors toward HDAC6. The optimal compound <b>59</b> exhibited single-digit nanomolar inhibition of HDAC6, with an IC<sub>50</sub> value of 5 nM, which was more than 530-fold more selective over HDAC1/8. In addition, <b>59</b> displayed modest in vitro antitumor activity, with less toxicity to nonmalignant cells. Interestingly, <b>59</b> was able to affect immune checkpoints and proteasome-dependent degradation, suggesting its potential for combination therapies with anticancer agents.<a onclick="showRef(event, 'ref169'); return false;" href="javascript:void(0);" class="ref ref169">(169)</a></div><div class="NLM_p">Compound <b>60</b> is an imidazo[1,2-<i>a</i>]pyridine-capped HDAC6 inhibitor, with an IC<sub>50</sub> value of 58 nM and 38-fold higher selectivity over HDAC1.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> Crystal structure of <b>60</b> complex with zebrafish HDAC6 CD2 (2.50 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CGP">6CGP</a>) showed the monodentate hydroxamate-Zn<sub>2</sub><sup>+</sup> coordination mode and π–π interactions with F583 and F643 (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>). Intriguingly, the capping group spread at the mouth of the active site, the pendant propyl was oriented toward residue P464 of the L1 loop, and the aromatic ring was accordingly oriented in the opposite direction toward F643 of the L2 loop, which was somewhat similar to the binding models of aforesaid bifurcated capping groups. In addition, a poor hydrogen bond was observed between the protonated N atom of the imidazo moiety and residue R798, which was thought to influence the binding conformation of <b>60</b> with HDAC6 (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>).<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Structure and HDAC inhibition of compound <b>60</b>, and X-ray crystal structure of the <b>60</b> complex with zebrafish HDAC6 CD2 (2.50 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CGP">6CGP</a>). Reprinted with permission from ref <a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a>. Copyright 2018, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Brogi et al. reported a novel series of selective HDAC6 inhibitors containing a N1-substituted spiroindoline core as the capping groups.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> The optimal compound, <b>61</b>, showed 95-fold selectivity for HDAC6 over HDAC1 (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>) as well as excellent upregulation of tubulin acetylation. It induced cell death at low micromolar concentrations in acute promyelocytic leukemia NB4 cells. Additionally, it suppressed the migration of neuroblastoma SH-SY5Y cells and did not induce obvious toxicity in mouse fibroblast NIH3T3 cells.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Through strategically overturning of the linker and ZBG group of <b>61</b> from the indoline N atom to the piperidine N, a novel hit compound <b>62</b> was produced, showing potential HDAC6 potency (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>).<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> The X-ray crystal structure of the <b>62</b>–HDAC6 CD2 complex (zebrafish, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V7A">6V7A</a>) revealed the piperidine ring adopted a chair conformation, and its N atom formed a water molecule-mediated hydrogen bond with residue R798, thus leading to the spiroindoline-based capping group oriented toward the L2 loop pocket, which was very rare, because the capping groups of most HDAC6 inhibitors tended to bind in the L1 loop pocket of the active site. In addition, a “wet” hydrogen bonded interface comprising three water molecules was helpful for <b>62</b> to interact with residues and increase the affinity (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). Subsequent structural optimization of <b>62</b> was focused on enlarging the capping group and modulating the linker portion. Compound <b>63</b> containing an insertion of carbamate functionality showed selectivity in potency toward HDAC6 over HDAC1 by docking models (<a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). Besides, the extended phenyl group of indoline moiety built a cation-π stacking with R673. Compound <b>63</b> displayed improved potency and selectivity in comparison to <b>61</b> and <b>62</b>. However, <b>63</b> showed low activity in cell-based assays and might be attributed to the weak stability of the inserted carbamate moiety.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a></div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. HDAC6 inhibitors employing spiroindoline-derived capping groups. (a) X-ray crystal structure of the <b>62</b> complex with zebrafish HDAC6 CD2 complex (2.09 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V7A">6V7A</a>). (b) Dock pose of <b>63</b> into human HDAC1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>). (c) Dock pose of <b>63</b> into human HDAC6 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU">5EDU</a>). Reprinted with permission from ref <a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a>. Copyright 2020, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20">2.2.2.  Five-Membered Heteroaryl-Based Linkers</h4><div class="NLM_p">As an important class of pharmacophores, five-membered heteroaromatic moieties were widely used in drug designs to improve the efficacy and in vivo pharmacokinetic profiles of compounds,<a onclick="showRef(event, 'ref173 ref174'); return false;" href="javascript:void(0);" class="ref ref173 ref174">(173,174)</a> including those of HDAC6 inhibitors. However, minimal effort was made to develop five-membered heteroaromatics as linkers directly connected to hydroxamate-based ZBG. On the other hand, the angle of the rigid linker can be modified by the use of five-membered heteroaromatic moieties (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) and may result in novel conformations and binding models with the HDAC6 active site.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a></div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Angle of the rigid five-membered heteroaryl-based linkers to ZBG differ from that of phenyl-based linkers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For the first time, Jung et al. performed detailed SAR studies on HDAC6 inhibitors involving three different heterocycles, oxazole, thiazole, and oxadiazole, that were attached to the hydroxamate moiety.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> Work begun with a virtual screening, by which compound <b>64</b> (IC<sub>50</sub> = 300 nM) employing a thiazole-based linker was determined as a potential lead for the next optimization (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>). SAR studies revealed that oxazole-containing inhibitors showed the best potency and selectivity toward HDAC6. Among, compound <b>65</b> exerted more than 240-fold selectivity for HDAC6 over HDAC1/8, with an IC<sub>50</sub> value of 59 nM. Meanwhile, a halogen or another phenyl ring substituted at the C4-position of the cap-functioned phenyl moiety was in favor for HDAC6 potency and selectivity. In contrast, substitution at the C2- or C3-position had a diminishing effect. In addition, molecular modeling and docking analysis demonstrated the thiazole-containing inhibitor (<b>66</b>) adopted slightly different orientation, due to the bulkiness of its sulfur atom, compared with <b>65</b>, thereby leading to reduced interactions of capping group with nearby residues (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>a), conferring its weak activity and selectivity toward HDAC6.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> More recently, Christianson et al. disclosed the crystal structure of <b>65</b>-HDAC6 CD2 complex (zebrafish, 1.75 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q0Z">6Q0Z</a>).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> It revealed the hydroxamate group of <b>65</b> chelated with Zn<sub>2</sub><sup>+</sup> ion in a bidentate coordination geometry, which was similar to the binding model of Ricolinostat (ACY-1215, <b>6</b>) (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>b). Additionally, the oxazole ring had favorable offset aromatic π–π interactions with F583 and F643. However, the bromophenyl-based capping group was oriented toward the solvent exposed region and did not interact well with either the L1 or L2 loop pocket, attributed to the geometry and orientation of the five-membered oxazole moiety (<a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>b). While, the oxazole ring and the bromophenyl moiety were in resonance with each other owing to within 14° of planarity and binded as a nearly rigid unit.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. HDAC6 inhibitors employing five-membered heteroaryl-based linkers. (a) Molecular surface of the HDAC6 binding pocket. The orientations of two docked inhibitors, <b>65</b> (cyan) and <b>66</b> (orange), are shown. Reproduced with permission from ref <a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a>. Copyright 2016, American Chemical Society. (b) Polder omit map of the zebrafish HDAC6 CD2–<b>65</b> complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q0Z">6Q0Z</a>). Reprinted with permission from ref <a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a>. Copyright 2020, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Intriguingly, follow-up studies indicated thiophene-containing compound <b>68</b> was a selective low-nanomolar HDAC6 inhibitor derived from the optimization of <b>67</b>, whose phenyl linker was replaced by a thiophene ring.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> In fact, the original compound <b>67</b> showed high potency toward HDAC6 (IC<sub>50</sub> = 15.6 nM) whereas a modest selectivity over HDAC1/8 (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>). After modification, the angle of the rigid linker changed from 180° to 156°, which further influenced the binding models of inhibitor with HDAC6 justified by docking analysis.<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> As a result, <b>68</b> displayed enhanced potency and selectivity significantly (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>).</div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Structures and HDAC inhibition of HDAC6 inhibitors bearing thiophene-containing linkers, which were obtained based on linker replacement strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Likewise, compound <b>70</b>, which shares a similar thiophene-containing linker with <b>68</b>, was derived from compound <b>69</b> through a linker replacement strategy.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> It was identified as a dual-targeted PDE5 and HDAC6 inhibitor, with high potency and excellent isoform selectivity (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>). SAR studies highlighted the role played by the thiophene ring in enhancing HDAC6 potency and selectivity, especially better than furan moiety. Besides, the replacement of methylene linker with the keto portion had a negative effect. In addition, as a sildenafil-based analogue, <b>70</b> decreased human amyloid precursor protein levels and phosphorylated tau protein (pTau) in Tg2576 neurons. It also showed a good pharmacokinetic profile, with an increase in the level of functional response characteristics observed in the hippocampus of mice after the administration of a 40 mg/kg dose.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a></div><div class="NLM_p">As a famous five-membered heterocyclic pharmacophore, isoxazole is suitable for multiple noncovalent interactions, including hydrogen bonding and π–π stacking, and is being widely used in drug development.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a> Compound <b>71</b>, which contains a special isoxazole-based linker, has been reported in Kozikowski’s earlier studies (<a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>).<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> Although it showed high potency and selectivity for HDAC6 over class I HDACs and HDAC10, it was nontoxic to pancreatic cancer cells, suggesting inhibition of HDAC6 alone did not favor antitumor activity; however, it might be more valuable in reactivation of the immune system through control of the expression levels of PD-L1.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> Subsequent studies demonstrated the isoxazole-3-hydroxamate-based compound SS-208 (<b>72</b>) showed broader inhibitory activity against HDAC isoforms than <b>71</b>, while retaining good selectivity for HDAC6.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> The crystal structure of SS-208 complex with zebrafish HDAC6 CD2 (1.15 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEM">5EEM</a>), in particular, revealed the coordination between the hydroxamate moiety and Zn<sub>2</sub><sup>+</sup> ion was bidentate (similar to that of <b>65</b>), which was different from the general monodentate binding models adopted by phenylhydroxamate-based inhibitors. As expected, the isoxazole ring and adjacent ethyl part of the linker nested in the hydrophobic channel established by residues F583, F643, and L712, engaging in van der Waals interactions. The C═O group of the amide moiety was able to interact with S531 by hydrogen bonding interaction directly, while the NH group must be with the help of two water molecules to establish interactions with H614. Besides, the dichlorophenyl ring-based capping group was oriented toward the L1 loop pocket and delineated by residues H463, P464, F583, and L712 (colored blue in <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>). For ADMET profiling, SS-208 showed no significant inhibition in the hERG assay and was metabolically stable with acceptable half-lives (22 and 135 min in mouse and human hepatocytes, respectively). In addition, SS-208 could efficiently decrease the IL-6-mediated Y705 phosphorylation of STAT3 and reduce PD-L1 expression at the mRNA levels in melanoma cells, even if having a weak cytotoxicity. Besides, it exhibited a strong in vivo antitumor activity in murine SM1 syngeneic melanoma models by enhancing immune-related antitumor activity involving increased infiltration of CD8+ and NK+ T cells and an enhanced ratio of M1 and M2 macrophages in the tumor microenvironment.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a></div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structures and HDAC inhibition of HDAC6 inhibitors bearing isoxazole-containing linkers. Crystal structure of <b>72</b> complex with zebrafish HDAC CD2 (1.15 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEM">5EEM</a>). (a) Detailed view of the substrate tunnel of HDAC6 in the complex with <b>72</b>. (b) Interactions between the dichlorophenyl-based capping group of <b>72</b> and the “L1-loop pocket” formed by side chains of H463, P464, F583, and L712 (colored blue). Reprinted with permission from ref <a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21">2.2.3.  Alkenyl-Based Linkers</h4><div class="NLM_p">As shown in <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>, the approved HDACs inhibitors belinostat (<b>2</b>) and panobinostat (<b>3</b>) share a same alkenyl hydroxamic acid moiety, whose structural rigidity is intermediate between that of the flexible aliphatic linkers and the rigid phenyl ring related to phenylhydroxamate inhibitors.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> In fact, selective HDAC6 inhibitors containing a somewhat rigid alkenyl hydroxamic acid moiety were rarely reported, let alone cocrystal structures with HDAC6. More recently, Christianson et al. disclosed the crystal structures of resminostat (<b>73</b>), a HDAC1/3/6 inhibitor bearing a 3-vinylpyrrole-based linker (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>), complexed with zebrafish HDAC6 CD1 (1.58 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UOB">6UOB</a>)<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and CD2 (2.30 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PZR">6PZR</a>).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> It was observed that the hydroxamate moiety coordinated to Zn<sub>2</sub><sup>+</sup> in a bidentate manner with both CDs, which might be explained by that the alkenyl-containing hydroxamic acid portion was long enough to be able to bind more closely to the Zn<sub>2</sub><sup>+</sup> ion compared to the phenylhydroxamate moiety. In addition, the insertion of alkenyl affected the π systems of the hydroxamate and the 3-vinylpyrrole moiety of <b>73</b> that was favorable for offset aromatic π–π interactions with F583 and F643 in CD2.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Structures and HDAC inhibition of HDAC6 inhibitors bearing alkenyl-based linkers. Crystal structures of resminostat (<b>73</b>), a HDAC1/3/6 inhibitor, complexed with zebrafish HDAC6 CD1 (1.58 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UOB">6UOB</a>) (a)<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and CD2 (2.30 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PZR">6PZR</a>) (b).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Reprinted with permission from refs <a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and <a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a>. Copyright 2019 and 2020, American Chemical Society, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">For the first time, Sheng et al. demonstrated a novel combination therapy for leukemia and invasive fungal infections via dual JAK2/HDAC inhibitors which was obtained based on the molecular hybridization strategy.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> The optimal compound, <b>74</b>, displayed a potent and selective inhibition effect on JAK2 and HDAC6 (<a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>). Moreover, it exerted potent cytotoxic effect on AML cells and synergistic efficacy with fluconazole when used as a treatment against resistant <i>C. albicans</i> infections. In addition, it exhibited potent antitumor activity against mouse AML models (5 mg/kg) and synergized with fluconazole to prolong the survival of mice infected with resistant <i>C. albicans</i>.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> Compound <b>75</b> contained a bulky <i>N</i>-hydroxy-2-quinolineacrylamide skeleton and displayed a high selectivity for HDAC6 which was in excess of 380-fold over HDAC8.<a onclick="showRef(event, 'ref182'); return false;" href="javascript:void(0);" class="ref ref182">(182)</a> In addition, it potently inhibited the growth of A549 and HCT116 cells at low micromolar concentrations, with GI50 values of 3.2 μM and 1.82 μM, respectively.</div></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">3.  HDAC6 Inhibitors Bearing Novel ZBGs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35687" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35687" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As stated above, hydroxamic acid-based ZBGs occupy a dominant position among the newly developed HDAC6 inhibitors due to remarkable zinc-chelating capability. However, hydroxamate-associated genotoxicity and mutagenicity, which derived from the Lossen rearrangement that yields a active electrophilic isocyanate (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>a), still limited the widespread application of corresponding HDAC6 inhibitors in the treatment of human diseases.<a onclick="showRef(event, 'ref158 ref183'); return false;" href="javascript:void(0);" class="ref ref158 ref183">(158,183)</a> To avoid such side effects, biochemists are searching for novel ZBGs that may be used for the synthesis of HDAC6 inhibitors.</div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structures and HDAC inhibition of HDAC6 inhibitors bearing mercaptoacetamide-based ZBG. (a) The mechanism for the Lossen rearrangement as potentially catalyzed by the Zn<sup>2+</sup> ion in the HDAC active site. (b) Crystal structure of <b>76</b> complexed with zebrafish HDAC6 CD2 (1.85 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MR5">6MR5</a>). (c) Schematic representation of active site interactions for <b>76</b> bound to HDAC6 CD2. Reprinted with permission from ref <a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a>. Copyright 2018, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Kozikowski et al. had reported a novel series of inhibitors bearing mercaptoacetamide-based ZBGs for CNS disorders.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> Compared with hydroxamate, mercaptoacetamide showed good pharmacological effects and druglike properties and was unlikely to cause mutagenicity.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> In their study, compounds <b>76</b> and <b>77</b>, containing indole and quinoline capping groups, respectively, showed high potency toward HDAC6 (IC<sub>50</sub> = 11, 2.8 nM) and excellent selectivity over HDAC1 (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>). Notably, dichlorine substituents were able to increase the lipophilicity of compounds, thus increasing the brain accessibility. Besides, they dose-dependently increased acetylated tubulin levels in the human embryonic kidney cell line, HEK 293. By contrast, <b>77</b> could significantly induce tubulin acetylation at a concentration of 10 μM, due to its better HDAC6 potency than <b>76</b>. Upregulation of tubulin acetylation was observed in the mouse cortex following treatment with the disulfide prodrugs of <b>76</b> and <b>77</b>.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> Soon thereafter, they reported the X-ray crystal structure of the complex between <b>76</b> and zebrafish HDAC6 CD2 (1.85 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MR5">6MR5</a>), revealing the mercaptoacetamide portion, in effect, functionally mimic the metal coordination and hydrogen bonding interactions related to the hydroxamate group in the active site of HDAC6 (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>b,c).<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> In detail, the thiol group of <b>76</b> was ionized to the negatively charged thiolate state and coordinated with Zn<sub>2</sub><sup>+</sup> such that the overall metal coordination geometry was a slightly distorted tetrahedral. Meanwhile, the positively charged side chain of H573 donated a hydrogen bond to the thiolate group to reinforce the coordination. In addition, the C═O moiety of the amide accepted a hydrogen bond from the phenolic hydroxyl group of Y745, and the NH group donated a hydrogen bond to the neutral imidazole of H574 (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>b,c), which was similarly required for the binding of hydroxamate inhibitors employing bidentate Zn<sub>2</sub><sup>+</sup> coordination geometry, such as ricolinostat (<b>6</b>), shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>. As Kozikowski et al. said, “Since both metal coordination and hydrogen bond interactions are required to activate the scissile amide group for hydrolysis, the amide group of the mercaptoacetamide is rendered chemically inert through its binding geometry in the HDAC6 active site”.<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a></div><div class="NLM_p">Rastelli et al. had developed compound <b>78</b> containing a unique 5-(trifluoromethyl)-1,2,4-oxadiazole ZBG as a dual HDAC6/HSP90 inhibitor (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>).<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> It showed comparable inhibitory activity against these two targets and induced α-tubulin hyperacetylation without impacting histone H3. Docking analysis revealed the trifluoromethyloxadiazolyl moiety bound with the Zn<sub>2</sub><sup>+</sup> ion in a conformation similar to what was observed in Nolan et al.’s previous study, revealing a fluorine atom and oxygen of trifluoromethyloxadiazolyl moiety were involved in zinc-binding via weak electrostatic interactions rather than direct coordination, which was attributed to the longer interaction distance than typical zinc interaction distances of ∼2.0 Å seen in hydroxamates (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>).<a onclick="showRef(event, 'ref186'); return false;" href="javascript:void(0);" class="ref ref186">(186)</a> Likewise, compounds <b>79</b> and <b>80</b>, bearing difluoromethyl and trifluoromethyl substituted 1,3,4-oxadiazole moieties, respectively, might employ similar binding models with Zn<sub>2</sub><sup>+</sup> ion in the HDAC6 active site.<a onclick="showRef(event, 'ref187'); return false;" href="javascript:void(0);" class="ref ref187">(187)</a> By contrast, difluoromethyl-based <b>79</b> exhibited higher selective inhibition against HDAC6 than <b>80</b> (IC<sub>50</sub> = 14 nM, 7142-fold selective over HDAC1) (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>).</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Structures and HDAC inhibition of HDAC6 inhibitors bearing trifluoromethyloxadiazolyl-based ZBGs. Predicted docking poses of <b>78</b> in HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU">5EDU</a>).<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> Reproduced with permission from ref <a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a>. Copyright 2020, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">4.  Selective HDAC6 Inhibitor-Derived PROTACs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30354" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30354" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Distinct from the inhibition of proteins, targeted protein degradation (TPD), characterized by heterobifunctional small molecules or proteolysis targeting chimeras (PROTACs), has been identified as an effective approach to remove diverse overexpressed disease-causing proteins by activating the ubiquitination-proteasome system (UPS) in cells.<a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a> Conventional small-molecule inhibitors often require sufficiently large doses, long half-lives, and high affinities to overcome efficacy limitations imposed by single-target inhibition. However, this inevitably leads to corresponding side effects, including toxicity to normal cells, off-target effects, and drug resistance problems. By contrast, the emerging PROTAC technology is redefining small-molecule drugs, due to a number of advantages, including low dosage/toxicity, ability to overcome drug resistance caused by mutations or overexpression of target proteins, independence from affinity, and the ability to clear accumulated protein.<a onclick="showRef(event, 'ref189 ref190'); return false;" href="javascript:void(0);" class="ref ref189 ref190">(189,190)</a></div><div class="NLM_p">For the first time, Tang et al. had attempted to use PROTAC technology to synthesize a class of HDAC6 degraders by conjugating selective HDAC6 inhibitor WT161 (<b>8</b>) with a thalidomide (a well-known E3 ubiquitin ligase ligand) analogue (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Among these, compound <b>81</b> selectively degraded HDAC6 over HDAC1, HDAC2, and HDAC4 at 5 μM concentration, thus resulting in the upregulation of Ac-α-tubulin level. Further studies indicated both cereblon (CRBN) E3 ubiquitin ligase and UPS were involved in the TPD process of <b>81</b>.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Compound <b>82</b> is another potent HDAC6 degrader utilizing Nexturastat A(<b>35</b>) as the ligand of a protein of interest (POI) for PROTAC (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>).<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a> Compared with CRBN-based <b>81</b>, <b>82</b> targeted Von Hippel–Lindau (VHL) E3 ubiquitin ligase and thus had a longer linker and could effectively dose-dependently degrade HDAC6 in MM1S cells with a DC<sub>50</sub> value of 7.1 nM and <i>D</i><sub>max</sub> value of 90% by ELISA. In addition to MM1S cells, <b>82</b> showed broad generality for the degradation of HDAC6 in other human cell lines including HEK293T, U87MG, A549, and MCF-7, suggesting that <b>82</b> may serve as a potential chemical probe to explore the biological regulatory pathways in which HDAC6 plays a role.</div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Selective HDAC6 inhibitors-derived PROTACs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">5.  Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_86040" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_86040" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Typical HDACs inhibitors consist of three domains: cap, linker, and ZBG, together conferring the enzyme-affinity and isoform-selectivity. Optimizations of these three domains are considered to be common strategies that may be used to improve selectivity.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> HDAC6, which is a well-known member of the HDAC family, has a unique structure basis<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and abundant substrate types.<a onclick="showRef(event, 'ref20 ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref20 ref22 ref23 ref24">(20,22−24)</a> X-ray crystallography reveals the catalytic domains of HADC6 has a wider open basin (∼14 Å), a region that was occupied by the bulkiness of residues in other HDACs, which allows comfortable bindings of inhibitors having bulky and hydrophobic capping groups.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Also, the height of the rim between the wide HDAC6 basin and the acetylated lysine binding channel was lower than others, suggesting the bulky and rigid linker may be favorable for improving HDAC6 selectivity.<a onclick="showRef(event, 'ref40 ref44'); return false;" href="javascript:void(0);" class="ref ref40 ref44">(40,44)</a> In addition, hydroxamic acids have been widely used as a ZBG group when designing selective HDAC6 inhibitors, due to its strong coordination ability.<a onclick="showRef(event, 'ref11 ref192'); return false;" href="javascript:void(0);" class="ref ref11 ref192">(11,192)</a> The crystal structures of hydroxamic acid-based inhibitors complexed with HDAC6 catalytic domains, especially CD2, indicated inhibitors with long and flexible aliphatic linkers showed a bidentate zinc-binding model, while inhibitors with bulky and rigid aromatic linkers favored the monodentate model, although there is little difference between the binding free energies of the two modes.<a onclick="showRef(event, 'ref39 ref42'); return false;" href="javascript:void(0);" class="ref ref39 ref42">(39,42)</a> In addition, the electrostatic or π–π stacking interactions between the linkers and the shallow hydrophobic catalytic channel are essential for HDAC6 affinity. In particular, the chemodiversity of HDAC6 inhibitors is preferentially manifest in the diverse array of capping groups, followed by somewhat conserved linkers and ZBGs.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Interestingly, people like to utilize the skeleton of old drugs as the capping groups when designing HDAC6 inhibitors bearing long aliphatic linkers, which might attribute to the flexible alkyl chain being favored for the steric complementarity between the capping groups and the three-dimensional contours of the L1 and L2 loop pockets of the HDAC6 active site.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> In contrast, phenylhydroxamates displayed much more tolerance to different capping groups, along with the hydroxamate moiety binding with Zn<sub>2</sub><sup>+</sup> in monodentate coordination, and the aromatic ring formed double π stacking interactions with P583 and P643. On the other hand, the direct or water-mediated hydrogen bonding interactions between capping groups and S531, a “gatekeeper” residue of HDAC6 CD2 that is absent in other isozymes, are vital for isoform selectivity.<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> Moreover, the embellishment of capping groups should consider how to increase hydrogen bond interactions with the HDAC6 active site cleft in addition to hydrophobic interactions.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> In brief, much progress has been made in the development of hydroxamic acid-based HDAC6 inhibitors. Nevertheless, in recent years, novel ZBGs have been developed giving due consideration to genotoxicity and mutagenicity,<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> and those such as mercaptoacetamide,<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> and trifluoromethyl oxadiazole<a onclick="showRef(event, 'ref185 ref187'); return false;" href="javascript:void(0);" class="ref ref185 ref187">(185,187)</a> show promising affinity and selectivity for HDAC6 and warrant further exploration.</div><div class="NLM_p">In recent years, HDAC6 inhibitors, either as a form of monotherapy or as combination therapy with other approved drugs, has attracted interest.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> In addition to highly potent HDAC6 inhibition and selectivity, in vivo biological data of some inhibitors have supported their promising therapeutic applications (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Particularly, HDAC6 inhibitors, used alone or in combination with immune checkpoint blockades, displayed unique immunomodulatory properties, aiding for immunotherapy.<a onclick="showRef(event, 'ref130 ref133 ref169 ref180'); return false;" href="javascript:void(0);" class="ref ref130 ref133 ref169 ref180">(130,133,169,180)</a> Drug combination with other agents, such as BTZ,<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> gefitinib,<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> afatinib,<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> and PAX,<a onclick="showRef(event, 'ref61 ref127'); return false;" href="javascript:void(0);" class="ref ref61 ref127">(61,127)</a> are able to overcome drug resistance and synergistically enhance the therapeutic effects on various diseases. In particular, drug combinations based on ricolinostat (ACY-1215, <b>6</b>) and citarinostat (ACY-241, <b>7</b>) have entered phase I/II clinical trials (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref69 ref75'); return false;" href="javascript:void(0);" class="ref ref69 ref75">(69,75)</a> However, combination strategies are always limited by adverse drug–drug interactions, thus that dual-target inhibitors based on HDAC6 were developed to address this issue. It is undeniable that multitarget inhibitors could produce synergistic effects on different drug targets via a single molecule, thereby achieving better therapeutic efficacy while minimizing side effects, such as dose limiting toxicity, drug resistance, and adverse drug–drug interactions.<a onclick="showRef(event, 'ref93 ref94'); return false;" href="javascript:void(0);" class="ref ref93 ref94">(93,94)</a> In fact, there have been several dual inhibitors in clinical trials that target HDACs and other proteins, including EGFR,<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a> PI3Kα,<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> and lysine specific demethylase 1 (LSD1).<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a> However, they all lack isoform selectivity for HDAC isoforms. HDAC6 has particular structure and diverse substrates and serves as an ideal target based on which dual-target inhibitors can be designed. Compounds exerting dual inhibitory effects on HDAC6 and other proteins, such as HSP90,<a onclick="showRef(event, 'ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref99 ref100">(99,100)</a> JAKs,<a onclick="showRef(event, 'ref104 ref105 ref106'); return false;" href="javascript:void(0);" class="ref ref104 ref105 ref106">(104−106)</a> Topo II,<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> ER,<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> and Bcl-2,<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> are primarily designed using molecular hybridization and pharmacophore fusion strategies, exhibiting excellent efficacy as treatments for cancers and other diseases as well as promising in vivo PK properties. Nevertheless, further studies are warranted to improve the HDAC6 selectivity of dual-target inhibitors to enhance the efficacy of targeted therapy, reduce side effects, and adaptation to clinical applications. Likewise, the process of designing HDAC6 degraders based on PROTAC technology is in its formative stages and faces many challenges. To enhance its clinical applicability, properties such as PK, pharmacodynamics (PD), bioavailability, delivery methods, and other druglike characteristics need further improvement.<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Representative HDAC6 Inhibitors with Their In Vivo Biological Data<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center" char=".">cmpd</th><th class="colsep0 rowsep0" align="center" char=".">HDAC6 IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">HDAC1/6 index</th><th class="colsep0 rowsep0" align="center">HDAC2/6 index</th><th class="colsep0 rowsep0" align="center">HDAC3/6 index</th><th class="colsep0 rowsep0" align="center">HDAC8/6 index</th><th class="colsep0 rowsep0" align="center">in vivo model</th><th class="colsep0 rowsep0" align="center">activity</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>8</b></td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">20</td><td class="colsep0 rowsep0" align="left">38</td><td class="colsep0 rowsep0" align="left">129</td><td class="colsep0 rowsep0" align="left">3575</td><td class="colsep0 rowsep0" align="left">human MM cell xenograft model, + BTZ</td><td class="colsep0 rowsep0" align="left">enhance anti-MM activity of BTZ<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>17</b></td><td class="colsep0 rowsep0" align="char" char=".">4.32</td><td class="colsep0 rowsep0" align="char" char=".">434</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="left">303</td><td class="colsep0 rowsep0" align="left">861</td><td class="colsep0 rowsep0" align="left">EGFR-resistance NSCLC H1975 xenograft, + afatinib</td><td class="colsep0 rowsep0" align="left">tumor growth inhibition<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>33</b></td><td class="colsep0 rowsep0" align="char" char=".">56</td><td class="colsep0 rowsep0" align="char" char=".">51</td><td class="colsep0 rowsep0" align="left">78</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="left">mouse brain</td><td class="colsep0 rowsep0" align="left">neuroprotection<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>35</b></td><td class="colsep0 rowsep0" align="char" char=".">5.02</td><td class="colsep0 rowsep0" align="char" char=".">601</td><td class="colsep0 rowsep0" align="left">1378</td><td class="colsep0 rowsep0" align="left">1330</td><td class="colsep0 rowsep0" align="left">190</td><td class="colsep0 rowsep0" align="left">melanoma xenograft model, + anti-PD-1 IMiD</td><td class="colsep0 rowsep0" align="left">enhance anti-PD-1 IMiD therapy<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>37</b></td><td class="colsep0 rowsep0" align="char" char=".">0.4</td><td class="colsep0 rowsep0" align="char" char=".">292</td><td class="colsep0 rowsep0" align="left">440</td><td class="colsep0 rowsep0" align="left">880</td><td class="colsep0 rowsep0" align="left">1245</td><td class="colsep0 rowsep0" align="left">melanoma xenograft model, + anti-PD1 IMiD</td><td class="colsep0 rowsep0" align="left">enhance anti-PD1 IMiD therapy<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>38</b></td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">1093</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="left">57</td><td class="colsep0 rowsep0" align="left">doxorubicin-induced cardiomyopathy mouse</td><td class="colsep0 rowsep0" align="left">cardioprotective effects<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>39</b></td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">511</td><td class="colsep0 rowsep0" align="left">1105</td><td class="colsep0 rowsep0" align="left">437</td><td class="colsep0 rowsep0" align="left">247</td><td class="colsep0 rowsep0" align="left">collagen-induced arthritis mouse</td><td class="colsep0 rowsep0" align="left">anti-inflammatory<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>53</b></td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char=".">2790</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="left">77</td><td class="colsep0 rowsep0" align="left">syngeneic NSCLS xenograft model, + PAX</td><td class="colsep0 rowsep0" align="left">enhanced antitumor activity of PAX<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>55</b></td><td class="colsep0 rowsep0" align="char" char=".">2.3</td><td class="colsep0 rowsep0" align="char" char=".">2273</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">1617</td><td class="colsep0 rowsep0" align="left">FXS mouse</td><td class="colsep0 rowsep0" align="left">improve learning and memory<a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="char" char="."><b>56</b></td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">0.29</td><td class="colsep0 rowsep0" rowspan="2" align="char" char=".">>10000</td><td class="colsep0 rowsep0" rowspan="2" align="left">>10000</td><td class="colsep0 rowsep0" rowspan="2" align="left">>10000</td><td class="colsep0 rowsep0" rowspan="2" align="left">4103</td><td class="colsep0 rowsep0" align="left">human MM RPMI 8226 xenograft model</td><td class="colsep0 rowsep0" align="left">enhance tumor suppression<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AD mouse</td><td class="colsep0 rowsep0" align="left">improve learning and memory<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>57</b></td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">13</td><td class="colsep0 rowsep0" align="left">62</td><td class="colsep0 rowsep0" align="left">48</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="left">mice hippocampus</td><td class="colsep0 rowsep0" align="left">promote neurite outgrowth<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>70</b></td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="left">248</td><td class="colsep0 rowsep0" align="left">140</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="left">AD mouse</td><td class="colsep0 rowsep0" align="left">increase functional response of hippocampus<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="char" char="."><b>72</b></td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">115</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="left">–</td><td class="colsep0 rowsep0" align="left">102</td><td class="colsep0 rowsep0" align="left">SM1 syngeneic melanoma model</td><td class="colsep0 rowsep0" align="left">enhance immune-related antitumor activity<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">–, not determined.</p></div></div></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">6.  Perspective</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02405" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02405" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Following resolution of the crystal structure of HDAC6, more efficient and selective HDAC6 inhibitors will inevitably be developed via computer-aided drug design and SBDD strategies. Thus, more attention should be directed toward improving the druglike properties of selective HDAC6 inhibitors, such as drug delivery and in vivo bioavailability as well as PK and PD characteristics, in order to enhance suitability for clinical application. It is anticipated that future progress of studies pertaining to HDAC6 inhibitors will occur in several fronts including combination therapies, dual mechanism agents and PROTACs, and immunotherapy, and expectedly more therapeutic optimization of HDAC6 inhibitors will take place in readiness for clinical applications involving treatment of human diseases.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01782" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71036" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71036" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li-Ying Ma</span> - <span class="hlFld-Affiliation affiliation">Collaborative
Innovation Center of New Drug Research and Safety Evaluation, Henan
Province, Key Laboratory of Technology Drug Preparation (Zhengzhou
University), Ministry of Education of China, Key Laboratory of Henan
Province for Drug Quality and Evaluation; School of Pharmaceutical
Sciences, Zhengzhou University, Zhengzhou 450001, PR China</span>; 
    <span class="hlFld-Affiliation affiliation">China
Meheco Topfond Pharmaceutical Co., Ltd., Zhumadian, 463000, PR China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7186-8259" title="Orcid link">http://orcid.org/0000-0002-7186-8259</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#d0bdb1bcb9a9b9beb790aaaaa5feb5b4a5feb3be"><span class="__cf_email__" data-cfemail="3e535f5257475750597e44444b105b5a4b105d50">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong-Min Liu</span> - <span class="hlFld-Affiliation affiliation">Collaborative
Innovation Center of New Drug Research and Safety Evaluation, Henan
Province, Key Laboratory of Technology Drug Preparation (Zhengzhou
University), Ministry of Education of China, Key Laboratory of Henan
Province for Drug Quality and Evaluation; School of Pharmaceutical
Sciences, Zhengzhou University, Zhengzhou 450001, PR China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6771-9421" title="Orcid link">http://orcid.org/0000-0001-6771-9421</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c7abaeb2afaa87bdbdb2e9a2a3b2e9a4a9"><span class="__cf_email__" data-cfemail="b1ddd8c4d9dcf1cbcbc49fd4d5c49fd2df">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xin-Hui Zhang</span> - <span class="hlFld-Affiliation affiliation">Collaborative
Innovation Center of New Drug Research and Safety Evaluation, Henan
Province, Key Laboratory of Technology Drug Preparation (Zhengzhou
University), Ministry of Education of China, Key Laboratory of Henan
Province for Drug Quality and Evaluation; School of Pharmaceutical
Sciences, Zhengzhou University, Zhengzhou 450001, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong"> Qin-Ma</span> - <span class="hlFld-Affiliation affiliation">Collaborative
Innovation Center of New Drug Research and Safety Evaluation, Henan
Province, Key Laboratory of Technology Drug Preparation (Zhengzhou
University), Ministry of Education of China, Key Laboratory of Henan
Province for Drug Quality and Evaluation; School of Pharmaceutical
Sciences, Zhengzhou University, Zhengzhou 450001, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hui-Pan Wu</span> - <span class="hlFld-Affiliation affiliation">Collaborative
Innovation Center of New Drug Research and Safety Evaluation, Henan
Province, Key Laboratory of Technology Drug Preparation (Zhengzhou
University), Ministry of Education of China, Key Laboratory of Henan
Province for Drug Quality and Evaluation; School of Pharmaceutical
Sciences, Zhengzhou University, Zhengzhou 450001, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mussa Yussuf Khamis</span> - <span class="hlFld-Affiliation affiliation">Collaborative
Innovation Center of New Drug Research and Safety Evaluation, Henan
Province, Key Laboratory of Technology Drug Preparation (Zhengzhou
University), Ministry of Education of China, Key Laboratory of Henan
Province for Drug Quality and Evaluation; School of Pharmaceutical
Sciences, Zhengzhou University, Zhengzhou 450001, PR China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi-Han Li</span> - <span class="hlFld-Affiliation affiliation">Collaborative
Innovation Center of New Drug Research and Safety Evaluation, Henan
Province, Key Laboratory of Technology Drug Preparation (Zhengzhou
University), Ministry of Education of China, Key Laboratory of Henan
Province for Drug Quality and Evaluation; School of Pharmaceutical
Sciences, Zhengzhou University, Zhengzhou 450001, PR China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The senior authors Y.M. and H.-M.L. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78860" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78860" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Xin-Hui Zhang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=BIO-d7e3624-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Xin-Hui Zhang</b> obtained his B.S. degree in Pharmaceutical Science from Zhengzhou University in 2013 and began his M.S. in Pharmacy at Zhengzhou University in 2015 under the supervision of Professor Hong-Min Liu. He is currently engaged in his fourth year Ph.D. studies in Medicinal Chemistry at Zhengzhou University under the supervision of Professor Hong-Min Liu. He now works on the design, synthesis, and biological evaluation of novel small-molecule epigenetic inhibitors.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Qin-Ma</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=BIO-d7e3629-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Qin-Ma</b> obtained her B.S. degree in Pharmacy at Zhengzhou University in 2018. She is currently studying for a Master’s degree in Pharmacy at Zhengzhou University under the direction of Associate Professor Li-Ying Ma. She now works on the design, synthesis, and biological evaluation of novel HDAC6 inhibitors.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Hui-Pan Wu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=BIO-d7e3634-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hui-Pan Wu</b> obtained her B.S. degree in Pharmacy at Xinxiang Medical University in 2019. She is currently studying for a Master’s degree in Medicinal Chemistry at Zhengzhou University under the direction of Professor Hong-Min Liu. She now works on the design, synthesis, and biological evaluation of novel HDAC6 inhibitors.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Mussa Yussuf Khamis</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=BIO-d7e3639-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Mussa Yussuf Khamis</b> obtained his B.S. degree in Process Engineering and Chemicals at the University of Science and Technology of Oran in 2018. He is currently studying for a Master’s degree in Medicinal Chemistry at Zhengzhou University under the direction of Professor Hong-Min Liu. He now works on the design, synthesis, and biological evaluation of novel HDAC6 inhibitors.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Yi-Han Li</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=BIO-d7e3644-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Yi-Han Li</b> obtained her B.S. degree in Pharmacy at Mudanjiang Medical University in 2019. She is currently studying for a Master’s degree in Medicinal Chemistry at Zhengzhou University under the direction of Associate Professor Li-Ying Ma. She now works on the design, synthesis, and biological evaluation of novel HDAC6 inhibitors.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Li-Ying Ma</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=BIO-d7e3649-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Li-Ying Ma</b> got his B.S. degree in Pharmaceutical Science from Yanbian University in 2007 and his Ph.D. in Medicinal Chemistry from Zhengzhou University in 2015 under the supervision of Professor Hong-Min Liu. He is currently an Associate Professor in the School of Pharmaceutical Sciences at Zhengzhou University. His current research interest resides in the identification of epigenetic targeted drugs and their biological study.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Hong-Min Liu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=BIO-d7e3654-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hong-Min Liu</b> received his M.S. in Pharmaceutical Science from Department of Pharmaceutical Sciences, Kanazawa University, Japan, and his Ph.D. from the Division of Life Sciences, Department of Bioactive and Related Substances Chemistry, Kanazawa University, Japan. He was appointed as a Professor in 1995 and has been the Dean of Key Lab of Advanced Drug Preparation Technologies, Ministry of Education of China, at Zhengzhou University since 2005. His work focuses on epigenetic targeted drug discovery.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68727" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68727" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation of China (Project Nos. 81430085 and 81773562 for Hong-Min Liu and Project No. 81703328 for Li-Ying Ma), the National Key Research Program (Grant Nos. 2018YFE0195100 and 2016YFA0501800 for Hong-Min Liu, China), the Scientific Program of Henan Province (Grant No. 182102310070 for Li-Ying Ma, China), and the China Postdoctoral Science Foundation (Grant No. 2020M672249 for Li-Ying Ma).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AChE</td><td class="NLM_def"><p class="first last">acetylcholine esterase</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s Disease</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">ALL</td><td class="NLM_def"><p class="first last">acute lymphoblastic leukemia</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">BTZ</td><td class="NLM_def"><p class="first last">bortezomib</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CRC</td><td class="NLM_def"><p class="first last">colorectal cancer</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular-signal-regulated kinase</p></td></tr><tr><td class="NLM_term">FXS</td><td class="NLM_def"><p class="first last">fragile X syndrome</p></td></tr><tr><td class="NLM_term">GC</td><td class="NLM_def"><p class="first last">gastric cancer</p></td></tr><tr><td class="NLM_term">HDACi</td><td class="NLM_def"><p class="first last">HDAC inhibitor</p></td></tr><tr><td class="NLM_term">HG</td><td class="NLM_def"><p class="first last">high glucose</p></td></tr><tr><td class="NLM_term">HSP90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term">JAKs</td><td class="NLM_def"><p class="first last">the Janus kinases</p></td></tr><tr><td class="NLM_term">LADC</td><td class="NLM_def"><p class="first last">lung adenocarcinoma</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">ML</td><td class="NLM_def"><p class="first last">malignant lymphoma</p></td></tr><tr><td class="NLM_term">MM</td><td class="NLM_def"><p class="first last">multiple myeloma</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">PAX</td><td class="NLM_def"><p class="first last">paclitaxel</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamics</p></td></tr><tr><td class="NLM_term">PDE5</td><td class="NLM_def"><p class="first last">phosphodiesterase 5</p></td></tr><tr><td class="NLM_term">PDE9</td><td class="NLM_def"><p class="first last">phosphodiesterase 9</p></td></tr><tr><td class="NLM_term">PD-L1</td><td class="NLM_def"><p class="first last">programmed death-ligand 1</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">PROTAC</td><td class="NLM_def"><p class="first last">proteolysis targeting chimera</p></td></tr><tr><td class="NLM_term">SAHA</td><td class="NLM_def"><p class="first last">vorinostat</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure-based drug design</p></td></tr><tr><td class="NLM_term">SCLC</td><td class="NLM_def"><p class="first last">small cell lung cancer</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">STAT3</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription 3</p></td></tr><tr><td class="NLM_term">Topo I</td><td class="NLM_def"><p class="first last">topoisomerase I</p></td></tr><tr><td class="NLM_term">Topo II</td><td class="NLM_def"><p class="first last">topoisomerase II</p></td></tr><tr><td class="NLM_term">Topo</td><td class="NLM_def"><p class="first last">DNA topoisomerases</p></td></tr><tr><td class="NLM_term">TPD</td><td class="NLM_def"><p class="first last">targeted protein degradation</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03411" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03411" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 196 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bird, A.</span></span> <span> </span><span class="NLM_article-title">Perceptions of epigenetics</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>447</i></span>,  <span class="NLM_fpage">396</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1038/nature05913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fnature05913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=17522671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsFOgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2007&pages=396-398&author=A.+Bird&title=Perceptions+of+epigenetics&doi=10.1038%2Fnature05913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Perceptions of epigenetics</span></div><div class="casAuthors">Bird, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue">7143</span>),
    <span class="NLM_cas:pages">396-398</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Geneticists study the gene; however, for epigeneticists, there is no obvious 'epigene'.  Nevertheless, during the past year, more than 2,500 articles, numerous scientific meetings and a new journal were devoted to the subject of epigenetics.  It encompasses some of the most exciting contemporary biol. and is portrayed by the popular press as a revolutionary new science - an antidote to the idea that we are hard-wired by our genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouKz8gQlpQmrVg90H21EOLACvtfcHk0ljVZWYPfcOqjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsFOgsrk%253D&md5=c1e6a0f02ee7a50f2befdc19b9df4489</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnature05913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05913%26sid%3Dliteratum%253Aachs%26aulast%3DBird%26aufirst%3DA.%26atitle%3DPerceptions%2520of%2520epigenetics%26jtitle%3DNature%26date%3D2007%26volume%3D447%26spage%3D396%26epage%3D398%26doi%3D10.1038%2Fnature05913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. S.</span></span> <span> </span><span class="NLM_article-title">Reversing the ‘irreversible’</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>450</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1038/450357a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2F450357a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=18004369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlajs7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2007&pages=357-359&author=R.+S.+Jones&title=Reversing+the+%E2%80%98irreversible%E2%80%99&doi=10.1038%2F450357a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Reversing the 'irreversible'</span></div><div class="casAuthors">Jones, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">7168</span>),
    <span class="NLM_cas:pages">357, 359</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">"Do not speak-unless it improves on silence" is generally wise advice, and is even vital for a subset of essential genes.  New studies describe how, when appropriate, the silence of these genes is broken.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0akFH73x-F7Vg90H21EOLACvtfcHk0ljVZWYPfcOqjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlajs7zP&md5=9c399b3e0d25bd9383cdbc59ae2bed2b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F450357a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F450357a%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DR.%2BS.%26atitle%3DReversing%2520the%2520%25E2%2580%2598irreversible%25E2%2580%2599%26jtitle%3DNature%26date%3D2007%26volume%3D450%26spage%3D357%26epage%3D359%26doi%3D10.1038%2F450357a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Law, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, S. E.</span></span> <span> </span><span class="NLM_article-title">Dynamic DNA Methylation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>323</i></span>,  <span class="NLM_fpage">1568</span>– <span class="NLM_lpage">1569</span>, <span class="refDoi"> DOI: 10.1126/science.1172782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1126%2Fscience.1172782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=19299607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvVSntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2009&pages=1568-1569&author=J.+A.+Lawauthor=S.+E.+Jacobsen&title=Dynamic+DNA+Methylation&doi=10.1126%2Fscience.1172782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic DNA Methylation</span></div><div class="casAuthors">Law, Julie A.; Jacobsen, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">5921</span>),
    <span class="NLM_cas:pages">1568-1569</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The methylation of DNA during plant development is a much more dynamic process than previously assumed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe8eERMvq7t7Vg90H21EOLACvtfcHk0ljVZWYPfcOqjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvVSntbo%253D&md5=9b1a650b9ea40d450905d39b5ba4b99b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1172782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1172782%26sid%3Dliteratum%253Aachs%26aulast%3DLaw%26aufirst%3DJ.%2BA.%26aulast%3DJacobsen%26aufirst%3DS.%2BE.%26atitle%3DDynamic%2520DNA%2520Methylation%26jtitle%3DScience%26date%3D2009%26volume%3D323%26spage%3D1568%26epage%3D1569%26doi%3D10.1126%2Fscience.1172782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kouzarides, T.</span></span> <span> </span><span class="NLM_article-title">Chromatin modifications and their function</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.cell.2007.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=17320507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis12ju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2007&pages=693-705&author=T.+Kouzarides&title=Chromatin+modifications+and+their+function&doi=10.1016%2Fj.cell.2007.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Chromatin modifications and their function</span></div><div class="casAuthors">Kouzarides, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">693-705</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The surface of nucleosomes is studded with a multiplicity of modifications.  At least eight different classes have been characterized to date and many different sites have been identified for each class.  Operationally, modifications function either by disrupting chromatin contacts or by affecting the recruitment of nonhistone proteins to chromatin.  Their presence on histones can dictate the higher-order chromatin structure in which DNA is packaged and can orchestrate the ordered recruitment of enzyme complexes to manipulate DNA.  In this way, histone modifications have the potential to influence many fundamental biol. processes, some of which may be epigenetically inherited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAH9AX2dGicbVg90H21EOLACvtfcHk0lgPjN2wtq-EJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis12ju7Y%253D&md5=c5995fe68fd9473f4268d59c01d3b9de</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DKouzarides%26aufirst%3DT.%26atitle%3DChromatin%2520modifications%2520and%2520their%2520function%26jtitle%3DCell%26date%3D2007%26volume%3D128%26spage%3D693%26epage%3D705%26doi%3D10.1016%2Fj.cell.2007.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, E.</span></span> <span> </span><span class="NLM_article-title">Epigenetics: a landscape takes shape</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">638</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.cell.2007.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=17320500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis12ju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2007&pages=635-638&author=A.+D.+Goldbergauthor=C.+D.+Allisauthor=E.+Bernstein&title=Epigenetics%3A+a+landscape+takes+shape&doi=10.1016%2Fj.cell.2007.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetics: a landscape takes shape</span></div><div class="casAuthors">Goldberg, Aaron D.; Allis, C. David; Bernstein, Emily</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">635-638</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Epigenetics has recently evolved from a collection of diverse phenomena to a defined and far-reaching field of study.  In this Essay, we examine the epistemol. of epigenetics, provide a brief overview of underlying mol. mechanisms, and suggest future challenges for the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgnXp5dGbNGbVg90H21EOLACvtfcHk0lgPjN2wtq-EJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis12ju74%253D&md5=ba84473b843a82b90a33bba8adb167eb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DA.%2BD.%26aulast%3DAllis%26aufirst%3DC.%2BD.%26aulast%3DBernstein%26aufirst%3DE.%26atitle%3DEpigenetics%253A%2520a%2520landscape%2520takes%2520shape%26jtitle%3DCell%26date%3D2007%26volume%3D128%26spage%3D635%26epage%3D638%26doi%3D10.1016%2Fj.cell.2007.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kugou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, K.</span></span> <span> </span><span class="NLM_article-title">Stepwise chromatin remodelling by a cascade of transcription initiation of non-coding RNAs</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>456</i></span>,  <span class="NLM_fpage">130</span>, <span class="refDoi"> DOI: 10.1038/nature07348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fnature07348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=18820678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCjt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=456&publication_year=2008&pages=130&author=K.+Hirotaauthor=T.+Miyoshiauthor=K.+Kugouauthor=C.+S.+Hoffmanauthor=T.+Shibataauthor=K.+Ohta&title=Stepwise+chromatin+remodelling+by+a+cascade+of+transcription+initiation+of+non-coding+RNAs&doi=10.1038%2Fnature07348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Stepwise chromatin remodelling by a cascade of transcription initiation of non-coding RNAs</span></div><div class="casAuthors">Hirota, Kouji; Miyoshi, Tomoichiro; Kugou, Kazuto; Hoffman, Charles S.; Shibata, Takehiko; Ohta, Kunihiro</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">456</span>
        (<span class="NLM_cas:issue">7218</span>),
    <span class="NLM_cas:pages">130-134</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Recent transcriptome analyses using high-d. tiling arrays and data from large-scale analyses of full-length complementary DNA libraries by the FANTOM3 consortium demonstrate that many transcripts are non-coding RNAs (ncRNAs).  These transcriptome analyses indicate that many of the non-coding regions, previously thought to be functionally inert, are actually transcriptionally active regions with various features.  Furthermore, most relatively large (∼several kilobases) polyadenylated mRNA transcripts are transcribed from regions harboring little coding potential.  However, the function of such ncRNAs is mostly unknown and has been a matter of debate.  Here the authors show that RNA polymerase II (RNAPII) transcription of ncRNAs is required for chromatin remodelling at the fission yeast Schizosaccharomyces pombe fbp1+ locus during transcriptional activation.  The chromatin at fbp1+ is progressively converted to an open configuration, as several species of ncRNAs are transcribed through fbp1+.  This is coupled with the translocation of RNAPII through the region upstream of the eventual fbp1+ transcriptional start site.  Insertion of a transcription terminator into this upstream region abolishes both the cascade of transcription of ncRNAs and the progressive chromatin alteration.  These results demonstrate that transcription through the promoter region is required to make DNA sequences accessible to transcriptional activators and to RNAPII.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo77Z6NGnfNgLVg90H21EOLACvtfcHk0lgPjN2wtq-EJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCjt7%252FM&md5=498cb1b8314bd97c4bdc276f7b6639f6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature07348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07348%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DK.%26aulast%3DMiyoshi%26aufirst%3DT.%26aulast%3DKugou%26aufirst%3DK.%26aulast%3DHoffman%26aufirst%3DC.%2BS.%26aulast%3DShibata%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DK.%26atitle%3DStepwise%2520chromatin%2520remodelling%2520by%2520a%2520cascade%2520of%2520transcription%2520initiation%2520of%2520non-coding%2520RNAs%26jtitle%3DNature%26date%3D2008%26volume%3D456%26spage%3D130%26doi%3D10.1038%2Fnature07348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, K. L.</span></span> <span> </span><span class="NLM_article-title">Regulation of cellular metabolism by protein lysine acetylation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">1000</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1126/science.1179689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1126%2Fscience.1179689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=20167786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVSjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2010&pages=1000-1004&author=S.+Zhaoauthor=W.+Xuauthor=W.+Jiangauthor=W.+Yuauthor=Y.+Linauthor=T.+Zhangauthor=J.+Yaoauthor=L.+Zhouauthor=Y.+Zengauthor=H.+Liauthor=Y.+Liauthor=J.+Shiauthor=W.+Anauthor=S.+M.+Hancockauthor=F.+Heauthor=L.+Qinauthor=J.+Chinauthor=P.+Yangauthor=X.+Chenauthor=Q.+Leiauthor=Y.+Xiongauthor=K.+L.+Guan&title=Regulation+of+cellular+metabolism+by+protein+lysine+acetylation&doi=10.1126%2Fscience.1179689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of cellular metabolism by protein lysine acetylation</span></div><div class="casAuthors">Zhao, Shimin; Xu, Wei; Jiang, Wenqing; Yu, Wei; Lin, Yan; Zhang, Tengfei; Yao, Jun; Zhou, Li; Zeng, Yaxue; Li, Hong; Li, Yixue; Shi, Jiong; An, Wenlin; Hancock, Susan M.; He, Fuchu; Qin, Lunxiu; Chin, Jason; Yang, Pengyuan; Chen, Xian; Lei, Qunying; Xiong, Yue; Guan, Kun-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">5968</span>),
    <span class="NLM_cas:pages">1000-1004</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Protein Lys acetylation has emerged as a key post-translational modification in cellular regulation, in particular through the modification of histones and nuclear transcription regulators.  Here, the authors show that acetylation of Lys residues is a prevalent modification in enzymes that catalyze intermediate metab.  Virtually every enzyme in glycolysis, gluconeogenesis, the tricarboxylic acid (TCA) cycle, the urea cycle, fatty acid metab., and glycogen metab. was found to be acetylated in human liver tissue.  The concn. of metabolic fuels, such as glucose, amino acids, and fatty acids, influenced the acetylation status of metabolic enzymes.  Acetylation activated enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in fatty acid oxidn. and malate dehydrogenase in the TCA cycle, inhibited argininosuccinate lyase in the urea cycle, and destabilized phosphoenolpyruvate carboxykinase in gluconeogenesis.  Thus, this study revealed that acetylation plays a major role in metabolic regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbdnDsuudXV7Vg90H21EOLACvtfcHk0lhnP4gqN-dPSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVSjtbo%253D&md5=d2c3c897077b9285842a7c55e8f8737e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.1179689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1179689%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DAn%26aufirst%3DW.%26aulast%3DHancock%26aufirst%3DS.%2BM.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DChin%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLei%26aufirst%3DQ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DGuan%26aufirst%3DK.%2BL.%26atitle%3DRegulation%2520of%2520cellular%2520metabolism%2520by%2520protein%2520lysine%2520acetylation%26jtitle%3DScience%26date%3D2010%26volume%3D327%26spage%3D1000%26epage%3D1004%26doi%3D10.1126%2Fscience.1179689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furumai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horinouchi, S.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase as a New Target for Cancer Chemotherapy</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1007/s002800100300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs002800100300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=11587361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD3MXot1Gisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2001&pages=20-26&author=M.+Yoshidaauthor=R.+Furumaiauthor=M.+Nishiyamaauthor=Y.+Komatsuauthor=N.+Nishinoauthor=S.+Horinouchi&title=Histone+Deacetylase+as+a+New+Target+for+Cancer+Chemotherapy&doi=10.1007%2Fs002800100300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase as a new target for cancer chemotherapy</span></div><div class="casAuthors">Yoshida, Minoru; Furumai, Ryohei; Nishiyama, Makoto; Komatsu, Yasuhiko; Nishino, Norikazu; Horinouchi, Sueharu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S20-S26</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  Trichostatin A (TSA) and trapoxin (TPX), inhibitors of the eukaryotic cell cycle and inducers of morphol. reversion of transformed cells, inhibit histone deacetylase (HDAC) at nanomolar concns.  Recently, FK228 (also known as FR901228 and depsipeptide) and MS-275, antitumor agents structurally unrelated to TSA, have been shown to be potent HDAC inhibitors.  These inhibitors activate the expression of p21Waf1 in a p53-independent manner.  Changes in the expression of regulators of the cell cycle, differentiation, and apoptosis with increased histone acetylation may be responsible for the cell cycle arrest and antitumor activity of HDAC inhibitors.  TSA has been suggested to block the catalytic reaction by chelating a zinc ion in the active site pocket through its hydroxamic acid group.  On the other hand, an epoxyketone has been suggested to be the functional group of TPX capable of alkylating the enzyme.  We synthesized a novel TPX analog contg. a hydroxamic acid instead of the epoxyketone.  The hybrid compd., called cyclic hydroxamic-acid-contg. peptide 1 (CHAP1) inhibited HDAC at low nanomolar concns.  The HDAC1 inhibition by CHAP1 was reversible, as is that by TSA, in contrast to irreversible inhibition by TPX.  Interestingly, HDAC6, but not HDAC1 or HDAC4, was resistant to TPX and CHAP1, while TSA inhibited these HDACs to a similar degree.  CHAP31, the strongest HDAC inhibitor obtained from a variety of CHAP derivs., exhibited antitumor activity in BDF1 mice bearing B16/BL6 tumor cells.  These results suggest that CHAP31 is promising as a novel therapeutic agent for cancer treatment, and that CHAP may serve as a basis for new HDAC inhibitors and be useful for combinatorial synthesis and high-throughput screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5hFVbRKsj-7Vg90H21EOLACvtfcHk0lhnP4gqN-dPSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXot1Gisb4%253D&md5=e99fb4ca4f204f861bcda050bdd88c16</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs002800100300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002800100300%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DFurumai%26aufirst%3DR.%26aulast%3DNishiyama%26aufirst%3DM.%26aulast%3DKomatsu%26aufirst%3DY.%26aulast%3DNishino%26aufirst%3DN.%26aulast%3DHorinouchi%26aufirst%3DS.%26atitle%3DHistone%2520Deacetylase%2520as%2520a%2520New%2520Target%2520for%2520Cancer%2520Chemotherapy%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2001%26volume%3D48%26spage%3D20%26epage%3D26%26doi%3D10.1007%2Fs002800100300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shakespear, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halili, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, M. J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases as regulators of inflammation and immunity</span>. <i>Trends Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1016/j.it.2011.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.it.2011.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=21570914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFagt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=335-343&author=M.+R.+Shakespearauthor=M.+A.+Haliliauthor=K.+M.+Irvineauthor=D.+P.+Fairlieauthor=M.+J.+Sweet&title=Histone+deacetylases+as+regulators+of+inflammation+and+immunity&doi=10.1016%2Fj.it.2011.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases as regulators of inflammation and immunity</span></div><div class="casAuthors">Shakespear, Melanie R.; Halili, Maria A.; Irvine, Katharine M.; Fairlie, David P.; Sweet, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">335-343</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) remove an acetyl group from lysine residues of target proteins to regulate cellular processes.  Small-mol. inhibitors of HDACs cause cellular growth arrest, differentiation and/or apoptosis, and some are used clin. as anticancer drugs.  In animal models, HDAC inhibitors are therapeutic for several inflammatory diseases, but exacerbate atherosclerosis and compromise host defense.  Loss of HDAC function has also been linked to chronic lung diseases in humans.  These contrasting effects might reflect distinct roles for individual HDACs in immune responses.  Here, we review the current understanding of innate and adaptive immune pathways that are regulated by classical HDAC enzymes.  The objective is to provide a rationale for targeting (or not targeting) individual HDAC enzymes with inhibitors for future immune-related applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMfUdRVPPTGrVg90H21EOLACvtfcHk0lgzNkU4ReyikQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFagt7s%253D&md5=b99eac5fe3487afc612c501162a51fca</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2011.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2011.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DShakespear%26aufirst%3DM.%2BR.%26aulast%3DHalili%26aufirst%3DM.%2BA.%26aulast%3DIrvine%26aufirst%3DK.%2BM.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26aulast%3DSweet%26aufirst%3DM.%2BJ.%26atitle%3DHistone%2520deacetylases%2520as%2520regulators%2520of%2520inflammation%2520and%2520immunity%26jtitle%3DTrends%2520Immunol.%26date%3D2011%26volume%3D32%26spage%3D335%26epage%3D343%26doi%3D10.1016%2Fj.it.2011.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagchi, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weeks, K. L.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases in cardiovascular and metabolic diseases</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2019.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.yjmcc.2019.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30978343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVequ74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2019&pages=151-159&author=R.+A.+Bagchiauthor=K.+L.+Weeks&title=Histone+deacetylases+in+cardiovascular+and+metabolic+diseases&doi=10.1016%2Fj.yjmcc.2019.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases in cardiovascular and metabolic diseases</span></div><div class="casAuthors">Bagchi, Rushita A.; Weeks, Kate L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-159</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) regulate gene transcription by catalyzing the removal of acetyl groups from key lysine residues in nucleosomal histones and via the recruitment of other epigenetic regulators to DNA promoter/enhancer regions.  Over the past two decades, HDACs have been implicated in multiple processes pertinent to cardiovascular and metabolic diseases, including cardiac hypertrophy and remodeling, fibrosis, calcium handling, inflammation and energy metab.  The development of small mol. HDAC inhibitors and genetically modified loss- and gain-of-function mouse models has allowed interrogation of the roles of specific HDAC isoforms in these processes.  Isoform-selective HDAC inhibitors may prove to be powerful therapeutic agents for the treatment of cardiovascular diseases, obesity and diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwzAygsk0c0bVg90H21EOLACvtfcHk0lgzNkU4ReyikQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVequ74%253D&md5=e023d2e22d069b9e69f6e6457d15005e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2019.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2019.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DBagchi%26aufirst%3DR.%2BA.%26aulast%3DWeeks%26aufirst%3DK.%2BL.%26atitle%3DHistone%2520deacetylases%2520in%2520cardiovascular%2520and%2520metabolic%2520diseases%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2019%26volume%3D130%26spage%3D151%26epage%3D159%26doi%3D10.1016%2Fj.yjmcc.2019.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A. H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">12460</span>– <span class="NLM_lpage">12484</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00830</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00830" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSisrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=12460-12484&author=T.+C.+S.+Hoauthor=A.+H.+Y.+Chanauthor=A.+Ganesan&title=Thirty+Years+of+HDAC+Inhibitors%3A+2020+Insight+and+Hindsight&doi=10.1021%2Facs.jmedchem.0c00830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight</span></div><div class="casAuthors">Ho, Terence C. S.; Chan, Alex H. Y.; Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12460-12484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared.  Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy while many others are in clin. development for oncol. as well as other therapeutic indications.  This Perspective reviews the biol. and medicinal chem. advances over the past 3 decades with an emphasis on the design of selective inhibitors that discriminate between the 11 human HDAC isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrES4d2gbkB17Vg90H21EOLACvtfcHk0lgzNkU4ReyikQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSisrzP&md5=1deb2ad5787797a9ee98dcf7bdade52c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00830%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DT.%2BC.%2BS.%26aulast%3DChan%26aufirst%3DA.%2BH.%2BY.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DThirty%2520Years%2520of%2520HDAC%2520Inhibitors%253A%25202020%2520Insight%2520and%2520Hindsight%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D12460%26epage%3D12484%26doi%3D10.1021%2Facs.jmedchem.0c00830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmorstein, R.</span></span> <span> </span><span class="NLM_article-title">Structural basis for sirtuin activity and inhibition</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">42428</span>– <span class="NLM_lpage">42435</span>, <span class="refDoi"> DOI: 10.1074/jbc.R112.372300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1074%2Fjbc.R112.372300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=23086949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVeksb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=42428-42435&author=H.+Yuanauthor=R.+Marmorstein&title=Structural+basis+for+sirtuin+activity+and+inhibition&doi=10.1074%2Fjbc.R112.372300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Sirtuin Activity and Inhibition</span></div><div class="casAuthors">Yuan, Hua; Marmorstein, Ronen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">42428-42435</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  Sir2 proteins, or sirtuins, are a family of enzymes that catalyze NAD+-dependent deacetylation reactions and can also process ribosyltransferase, demalonylase, and desuccinylase activities.  More than 40 crystal structures of sirtuins have been detd., alone or in various liganded forms.  These high-resoln. architectural details lay the foundation for understanding the mol. mechanisms of catalysis, regulation, substrate specificity, and inhibition of sirtuins.  In this minireview, we summarize these structural features and discuss their implications for understanding sirtuin function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreG2RWpBd2ILVg90H21EOLACvtfcHk0ljoFq9AyXwYtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVeksb%252FM&md5=c20a154f55db917407f1a1b58edf95fd</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R112.372300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R112.372300%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DMarmorstein%26aufirst%3DR.%26atitle%3DStructural%2520basis%2520for%2520sirtuin%2520activity%2520and%2520inhibition%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D42428%26epage%3D42435%26doi%3D10.1074%2Fjbc.R112.372300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. S.</span></span> <span> </span><span class="NLM_article-title">Targeting histone deacetylase in cancer therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1002/med.20056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fmed.20056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=16450343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFaltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=397-413&author=H.+Y.+Linauthor=C.+S.+Chenauthor=S.+P.+Linauthor=J.+R.+Wengauthor=C.+S.+Chen&title=Targeting+histone+deacetylase+in+cancer+therapy&doi=10.1002%2Fmed.20056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylase in cancer therapy</span></div><div class="casAuthors">Lin, Hsiang-Yu; Chen, Chang-Shi; Lin, Shuan-Pei; Weng, Jing-Ru; Chen, Ching-Shih</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">397-413</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) is recognized as one of the promising targets for cancer treatment as many HDAC inhibitors have entered clin. trials for both solid and liq. tumors.  Nevertheless, the mechanisms underlying the antiproliferative effects of HDAC inhibitors remain elusive.  Although they have been shown to regulate the transcription of a defined set of genes through chromatin remodeling, increasing evidence suggests that modifications of the epigenetic histone code may not be the primary mechanism for HDAC inhibitor-mediated growth inhibition and apoptosis in cancer cells.  While histones still represent a primary target for the physiol. function of HDACs, the antitumor effect of HDAC inhibitors might also be attributed to transcription-independent mechanisms by modulating the acetylation status of a series of nonhistone targets.  Also noteworthy is the effect of HDAC inhibitors on Akt downregulation through the alteration of protein phosphatase 1 (PP1) complex formation.  To provide an overview of the use of HDAC inhibitors in cancer treatment, this review addresses the following subjects: (1) the physiol. relevance of HDAC-mediated acetylation of histone and nonhistone substrates, (2) the chem. biol. of HDACs and development of a novel class of HDAC inhibitors, and (3) the protein acetylation-independent effect of HDAC inhibitors on the activation status of signaling kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsa6h2NkYnN7Vg90H21EOLACvtfcHk0ljoFq9AyXwYtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFaltrc%253D&md5=4d663196ac8258cd0e079b47761f3128</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fmed.20056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20056%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DC.%2BS.%26aulast%3DLin%26aufirst%3DS.%2BP.%26aulast%3DWeng%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DC.%2BS.%26atitle%3DTargeting%2520histone%2520deacetylase%2520in%2520cancer%2520therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2006%26volume%3D26%26spage%3D397%26epage%3D413%26doi%3D10.1002%2Fmed.20056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China</span>. <i>Intractable Rare Dis. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.5582/irdr.2016.01024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.5582%2Firdr.2016.01024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27672541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BC2svkt1Cnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=185-191&author=X.+Luauthor=Z.+Ningauthor=Z.+Liauthor=H.+Caoauthor=X.+Wang&title=Development+of+chidamide+for+peripheral+T-cell+lymphoma%2C+the+first+orphan+drug+approved+in+China&doi=10.5582%2Firdr.2016.01024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China</span></div><div class="casAuthors">Lu Xianping; Ning Zhiqiang; Li Zhibin; Cao Haixiang; Wang Xinhao</div><div class="citationInfo"><span class="NLM_cas:title">Intractable & rare diseases research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">185-91</span>
        ISSN:<span class="NLM_cas:issn">2186-3644</span>.
    </div><div class="casAbstract">Peripheral T-cell lymphoma (PTCL) is a set of rare and highly heterogeneous group of mature T- and NK-cell neoplasms associated with poor outcomes and lack of standard and effective therapies.  The total number of newly diagnosed cases of PTCL yearly in China is estimated about 50,000.  Chidamide (CS055) is a novel and orally active benzamide class of histone deacetylase (HDAC) inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, the enzymes that are involved and play an important role in tumor initiation and development in both tumor cells and their surrounding micro-environment.  Functioning as a genuine epigenetic modulator, chidamide induces growth arrest and apoptosis in tumor cells and enhances cellular antitumor immunity.  Based on the overall results from preclinical and phase I clinical studies, exploratory and pivotal phase II trials of chidamide for relapsed or refractory PTCL were conducted from March 2009 to May 2012, and the results led to CFDA approval of chidamide for the indication in December 2014, being the first approved orphan drug according to the research & development approach of orphan drugs in China, as well as the first orally active drug for PTCL in China and worldwide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSsI-YolguuyLP3FVUi_gf8fW6udTcc2eb--7qeenJhr7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svkt1Cnsg%253D%253D&md5=5c1f310ea15bb4a706f54d5fdc55c7d5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.5582%2Firdr.2016.01024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5582%252Firdr.2016.01024%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DNing%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDevelopment%2520of%2520chidamide%2520for%2520peripheral%2520T-cell%2520lymphoma%252C%2520the%2520first%2520orphan%2520drug%2520approved%2520in%2520China%26jtitle%3DIntractable%2520Rare%2520Dis.%2520Res.%26date%3D2016%26volume%3D5%26spage%3D185%26epage%3D191%26doi%3D10.5582%2Firdr.2016.01024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duvic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazarika, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiao, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricker, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, S. R.</span></span> <span> </span><span class="NLM_article-title">Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1182/blood-2006-06-025999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1182%2Fblood-2006-06-025999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=16960145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivVyrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=31-39&author=M.+Duvicauthor=R.+Talpurauthor=X.+Niauthor=C.+Zhangauthor=P.+Hazarikaauthor=C.+Kellyauthor=J.+H.+Chiaoauthor=J.+F.+Reillyauthor=J.+L.+Rickerauthor=V.+M.+Richonauthor=S.+R.+Frankel&title=Phase+2+trial+of+oral+vorinostat+%28suberoylanilide+hydroxamic+acid%2C+SAHA%29+for+refractory+cutaneous+T-cell+lymphoma+%28CTCL%29&doi=10.1182%2Fblood-2006-06-025999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)</span></div><div class="casAuthors">Duvic, Madeleine; Talpur, Rakshandra; Ni, Xiao; Zhang, Chunlei; Hazarika, Parul; Kelly, Cecilia; Chiao, Judy H.; Reilly, John F.; Ricker, Justin L.; Richon, Victoria M.; Frankel, Stanley R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-39</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL).  Group 1 received vorinostat 400 mg daily, group 2 received vorinostat 300 mg twice daily for 3 days with 4 days rest, and group 3 received vorinostat 300 mg twice daily for 14 days with 7 days rest followed by 200 mg twice daily.  Treatment continued until disease progression or intolerable toxicity.  The primary objective was to det. the complete and partial response (PR) rate.  Time to response (TTR), time to progressive disease (TTP), response duration (DOR), pruritus relief, and safety were detd.  Thirty-three patients who had received a median of 5 prior therapies were enrolled.  Eight patients achieved a PR, including 7 with advanced disease and 4 with Sezary syndrome.  The median TTR, DOR, and TTP for responders were 11.9, 15.1, and 30.2 wk, resp.  Fourteen of 31 evaluable patients had pruritus relief.  The most common drug-related AEs were fatigue, thrombocytopenia, diarrhea, and nausea.  The most common grade 3 or 4 drug-related AEs were thrombocytopenia and dehydration.  Vorinostat demonstrated activity in heavily pretreated patients with CTCL.  The 400 mg daily regimen had the most favorable safety profile and is being further evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo80_rNvPEEgLVg90H21EOLACvtfcHk0ljoFq9AyXwYtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivVyrt7g%253D&md5=b4c8b3c20213eaf692bd9b44266d045f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-06-025999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-06-025999%26sid%3Dliteratum%253Aachs%26aulast%3DDuvic%26aufirst%3DM.%26aulast%3DTalpur%26aufirst%3DR.%26aulast%3DNi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHazarika%26aufirst%3DP.%26aulast%3DKelly%26aufirst%3DC.%26aulast%3DChiao%26aufirst%3DJ.%2BH.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DRicker%26aufirst%3DJ.%2BL.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DFrankel%26aufirst%3DS.%2BR.%26atitle%3DPhase%25202%2520trial%2520of%2520oral%2520vorinostat%2520%2528suberoylanilide%2520hydroxamic%2520acid%252C%2520SAHA%2529%2520for%2520refractory%2520cutaneous%2520T-cell%2520lymphoma%2520%2528CTCL%2529%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D31%26epage%3D39%26doi%3D10.1182%2Fblood-2006-06-025999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiskus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadleigh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ondovik, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K. N.</span></span> <span> </span><span class="NLM_article-title">Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">326</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1111/bjh.12384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1111%2Fbjh.12384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=23701016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2013&pages=326-335&author=D.+J.+DeAngeloauthor=R.+A.+Mesaauthor=W.+Fiskusauthor=A.+Tefferiauthor=C.+Paleyauthor=M.+Wadleighauthor=E.+K.+Ritchieauthor=D.+S.+Snyderauthor=K.+Begnaauthor=S.+Gangulyauthor=M.+S.+Ondovikauthor=J.+Rineauthor=K.+N.+Bhalla&title=Phase+II+trial+of+panobinostat%2C+an+oral+pan-deacetylase+inhibitor+in+patients+with+primary+myelofibrosis%2C+post-essential+thrombocythaemia%2C+and+post-polycythaemia+vera+myelofibrosis&doi=10.1111%2Fbjh.12384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis</span></div><div class="casAuthors">DeAngelo, Daniel J.; Mesa, Ruben A.; Fiskus, Warren; Tefferi, Ayalew; Paley, Carole; Wadleigh, Martha; Ritchie, Ellen K.; Snyder, David S.; Begna, Kebede; Ganguly, Siddhartha; Ondovik, Michael S.; Rine, Jessica; Bhalla, Kapil N.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">326-335</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Myelofibrosis (MF) is a Philadelphia chromosome-neg. stem cell myeloproliferative neoplasm (MPN) assocd. with cytopenias, splenomegaly, constitutional symptoms, and poor prognosis.  MF patients commonly express JAK2V617F mutation and activation of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signalling.  Agents targeting the JAK/STAT pathway have demonstrated efficacy in patients with MF.  This study evaluated panobinostat, a pan-deacetylase inhibitor that depletes JAK2 V617F levels and JAK/STAT signalling in MPN cells, in patients with primary MF, post-essential thrombocythemia MF, and post-polycythemia vera MF.  Patients received panobinostat 40 mg administered three times per wk.  Dose redns. were permitted for toxicities.  The primary endpoint was response rate at 6 mo using International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) consensus criteria.  Analyses of peripheral blood cells from treated patients revealed that panobinostat inhibited JAK/STAT signalling, decreased inflammatory cytokine levels, and decreased JAK2V617F allelic burden.  However, panobinostat was poorly tolerated at the dose and schedule evaluated, and only 16 of 35 patients completed ≥2 cycles of treatment.  One patient (3%) achieved an IWG-MRT response.  Common adverse events were thrombocytopenia (71·4%) and diarrhoea (80·0%).  Although mol. correlative analyses suggested that panobinostat inhibits key intracellular targets, limited clin. activity was obsd. because of poor tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotDmgamqFK27Vg90H21EOLACvtfcHk0lh82BF_e5tq8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnM&md5=584d6afad24b34f916f2120247c2a246</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12384%26sid%3Dliteratum%253Aachs%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DPaley%26aufirst%3DC.%26aulast%3DWadleigh%26aufirst%3DM.%26aulast%3DRitchie%26aufirst%3DE.%2BK.%26aulast%3DSnyder%26aufirst%3DD.%2BS.%26aulast%3DBegna%26aufirst%3DK.%26aulast%3DGanguly%26aufirst%3DS.%26aulast%3DOndovik%26aufirst%3DM.%2BS.%26aulast%3DRine%26aufirst%3DJ.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26atitle%3DPhase%2520II%2520trial%2520of%2520panobinostat%252C%2520an%2520oral%2520pan-deacetylase%2520inhibitor%2520in%2520patients%2520with%2520primary%2520myelofibrosis%252C%2520post-essential%2520thrombocythaemia%252C%2520and%2520post-polycythaemia%2520vera%2520myelofibrosis%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2013%26volume%3D162%26spage%3D326%26epage%3D335%26doi%3D10.1111%2Fbjh.12384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, P.</span></span> <span> </span><span class="NLM_article-title">Inside HDACs with more selective HDAC inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.05.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2016.05.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27318122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWns7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=451-483&author=J.+Rocheauthor=P.+Bertrand&title=Inside+HDACs+with+more+selective+HDAC+inhibitors&doi=10.1016%2Fj.ejmech.2016.05.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inside HDACs with more selective HDAC inhibitors</span></div><div class="casAuthors">Roche, Joelle; Bertrand, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">451-483</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Inhibitors of histone deacetylases (HDACs) are nowadays part of the therapeutic arsenal mainly against cancers, with four compds. approved by the Food and Drug Administration.  During the last five years, several groups have made continuous efforts to improve this class of compds., designing more selective compds. or compds. with multiple capacities.  After a survey of the HDAC biol. and structures, this review summarizes the results of the chemists working in this field, and highlights when possible the behavior of the mols. inside their targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHO5YBuaN7c7Vg90H21EOLACvtfcHk0lh82BF_e5tq8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWns7%252FI&md5=3bbd062c1fb8a402c039e20bacd4af14</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.05.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.05.047%26sid%3Dliteratum%253Aachs%26aulast%3DRoche%26aufirst%3DJ.%26aulast%3DBertrand%26aufirst%3DP.%26atitle%3DInside%2520HDACs%2520with%2520more%2520selective%2520HDAC%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D451%26epage%3D483%26doi%3D10.1016%2Fj.ejmech.2016.05.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassig, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Three proteins define a class of human histone deacetylases related to yeast Hda1p</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">4868</span>– <span class="NLM_lpage">4873</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.9.4868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1073%2Fpnas.96.9.4868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10220385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADyaK1MXjtVKms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=4868-4873&author=C.+M.+Grozingerauthor=C.+A.+Hassigauthor=S.+L.+Schreiber&title=Three+proteins+define+a+class+of+human+histone+deacetylases+related+to+yeast+Hda1p&doi=10.1073%2Fpnas.96.9.4868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Three proteins define a class of human histone deacetylases related to yeast Hda1p</span></div><div class="casAuthors">Grozinger, Christina M.; Hassig, Christian A.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4868-4873</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Gene expression is in part controlled by chromatin remodeling factors and the acetylation state of nucleosomal histones.  The latter process is regulated by histone acetyltransferases and histone deacetylases (HDACs).  Previously, three human and five yeast HDAC enzymes had been identified.  These can be categorized into two classes: the first class represented by yeast Rpd3-like proteins and the second by yeast Hda1-like proteins.  Human HDAC1, HDAC2, and HDAC3 proteins are members of the first class, whereas no class II human HDAC proteins had been identified.  The amino acid sequence of Hda1p was used to search the GenBank/expressed sequence tag databases to identify partial sequences from three putative class II human HDAC proteins.  The corresponding full-length cDNAs were cloned and defined as HDAC4, HDAC5, and HDAC6.  These proteins possess certain features present in the conserved catalytic domains of class I human HDACs, but also contain addnl. sequence domains.  Interestingly, HDAC6 contains an internal duplication of two catalytic domains, which appear to function independently of each other.  These class II HDAC proteins have differential mRNA expression in human tissues and possess in vitro HDAC activity that is inhibited by trichostatin A.  Coimmunopptn. expts. indicate that these HDAC proteins are not components of the previously identified HDAC1 and HDAC2 NRD and mSin3A complexes.  However, HDAC4 and HDAC5 assoc. with HDAC3 in vivo.  This finding suggests that the human class II HDAC enzymes may function in cellular processes distinct from those of HDAC1 and HDAC2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcejIcOOdQtrVg90H21EOLACvtfcHk0lh82BF_e5tq8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtVKms7s%253D&md5=923a1617e1ed850f39fb5247e6baf14f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.9.4868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.9.4868%26sid%3Dliteratum%253Aachs%26aulast%3DGrozinger%26aufirst%3DC.%2BM.%26aulast%3DHassig%26aufirst%3DC.%2BA.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DThree%2520proteins%2520define%2520a%2520class%2520of%2520human%2520histone%2520deacetylases%2520related%2520to%2520yeast%2520Hda1p%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D4868%26epage%3D4873%26doi%3D10.1073%2Fpnas.96.9.4868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravichandran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenzie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, R. G.</span></span> <span> </span><span class="NLM_article-title">Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">2317</span>– <span class="NLM_lpage">2327</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111.273730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1074%2Fjbc.M111.273730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=22069321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC38XpslKqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=2317-2327&author=H.+Ouyangauthor=Y.+O.+Aliauthor=M.+Ravichandranauthor=A.+Dongauthor=W.+Qiuauthor=F.+MacKenzieauthor=S.+Dhe-Paganonauthor=C.+H.+Arrowsmithauthor=R.+G.+Zhai&title=Protein+aggregates+are+recruited+to+aggresome+by+histone+deacetylase+6+via+unanchored+ubiquitin+C+termini&doi=10.1074%2Fjbc.M111.273730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Aggregates Are Recruited to Aggresome by Histone Deacetylase 6 via Unanchored Ubiquitin C Termini</span></div><div class="casAuthors">Ouyang, Hui; Ali, Yousuf O.; Ravichandran, Mani; Dong, Aiping; Qiu, Wei; MacKenzie, Farrell; Dhe-Paganon, Sirano; Arrowsmith, Cheryl H.; Zhai, R. Grace</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2317-2327</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The aggresome pathway is activated when proteasomal clearance of misfolded proteins is hindered.  Misfolded polyubiquitinated protein aggregates are recruited and transported to the aggresome via the microtubule network by a protein complex consisting of histone deacetylase 6 (HDAC6) and the dynein motor complex.  The current model suggests that HDAC6 recognizes protein aggregates by binding directly to polyubiquitinated proteins.  Here, we show that there are substantial amts. of unanchored ubiquitin in protein aggregates with solvent-accessible C termini.  The ubiquitin-binding domain (ZnF-UBP) of HDAC6 binds exclusively to the unanchored C-terminal diglycine motif of ubiquitin instead of conjugated polyubiquitin.  The unanchored ubiquitin C termini in the aggregates are generated in situ by aggregate-assocd. deubiquitinase ataxin-3.  These results provide structural and mechanistic bases for the role of HDAC6 in aggresome formation and further suggest a novel ubiquitin-mediated signaling pathway, where the exposure of ubiquitin C termini within protein aggregates enables HDAC6 recognition and transport to the aggresome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4RKfc994fbbVg90H21EOLACvtfcHk0liwGCivdNU2ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpslKqsQ%253D%253D&md5=1ee8c5479d3936c2da903f023ba9f091</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.273730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.273730%26sid%3Dliteratum%253Aachs%26aulast%3DOuyang%26aufirst%3DH.%26aulast%3DAli%26aufirst%3DY.%2BO.%26aulast%3DRavichandran%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DA.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DMacKenzie%26aufirst%3DF.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DZhai%26aufirst%3DR.%2BG.%26atitle%3DProtein%2520aggregates%2520are%2520recruited%2520to%2520aggresome%2520by%2520histone%2520deacetylase%25206%2520via%2520unanchored%2520ubiquitin%2520C%2520termini%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D2317%26epage%3D2327%26doi%3D10.1074%2Fjbc.M111.273730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guardiola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T. P.</span></span> <span> </span><span class="NLM_article-title">HDAC6 is a microtubule-associated deacetylase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>417</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1038/417455a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2F417455a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=12024216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=455-458&author=C.+Hubbertauthor=A.+Guardiolaauthor=R.+Shaoauthor=Y.+Kawaguchiauthor=A.+Itoauthor=A.+Nixonauthor=M.+Yoshidaauthor=X.+F.+Wangauthor=T.+P.+Yao&title=HDAC6+is+a+microtubule-associated+deacetylase&doi=10.1038%2F417455a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 is a microtubule-associated deacetylase</span></div><div class="casAuthors">Hubbert, Charlotte; Guardiola, Amaris; Shao, Rong; Kawaguchi, Yoshiharu; Ito, Akihiro; Nixon, Andrew; Yoshida, Minoru; Wang, Xiao-Fan; Yao, Tso-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6887</span>),
    <span class="NLM_cas:pages">455-458</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reversible acetylation of α-tubulin has been implicated in regulating microtubule stability and function.  The distribution of acetylated α-tubulin is tightly controlled and stereotypic.  Acetylated α-tubulin is most abundant in stable microtubules but is absent from dynamic cellular structures such as neuronal growth cones and the leading edges of fibroblasts.  However, the enzymes responsible for regulating tubulin acetylation and deacetylation are not known.  Here we report that a member of the histone deacetylase family, HDAC6, functions as a tubulin deacetylase.  HDAC6 is localized exclusively in the cytoplasm, where it assocs. with microtubules and localizes with the microtubule motor complex contg. p150glued.  In vivo, the overexpression of HDAC6 leads to a global deacetylation of α-tubulin, whereas a decrease in HDAC6 increases α-tubulin acetylation.  In vitro, purified HDAC6 potently deacetylates α-tubulin in assembled microtubules.  Furthermore, overexpression of HDAC6 promotes chemotactic cell movement, supporting the idea that HDAC6-mediated deacetylation regulates microtubule-dependent cell motility.  Our results show that HDAC6 is the tubulin deacetylase, and provide evidence that reversible acetylation regulates important biol. processes beyond histone metab. and gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp76Er3MrWtO7Vg90H21EOLACvtfcHk0liwGCivdNU2ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D&md5=f18cbb0af388925c606e822358ba3da6</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2F417455a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F417455a%26sid%3Dliteratum%253Aachs%26aulast%3DHubbert%26aufirst%3DC.%26aulast%3DGuardiola%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DR.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DNixon%26aufirst%3DA.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%2BF.%26aulast%3DYao%26aufirst%3DT.%2BP.%26atitle%3DHDAC6%2520is%2520a%2520microtubule-associated%2520deacetylase%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D455%26epage%3D458%26doi%3D10.1038%2F417455a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cook, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendron, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunmore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeTure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrucelli, L.</span></span> <span> </span><span class="NLM_article-title">Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddt402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1093%2Fhmg%2Fddt402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=23962722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=104-116&author=C.+Cookauthor=Y.+Carlomagnoauthor=T.+F.+Gendronauthor=J.+Dunmoreauthor=K.+Scheffelauthor=C.+Stetlerauthor=M.+Davisauthor=D.+Dicksonauthor=M.+Jarpeauthor=M.+DeTureauthor=L.+Petrucelli&title=Acetylation+of+the+KXGS+motifs+in+tau+is+a+critical+determinant+in+modulation+of+tau+aggregation+and+clearance&doi=10.1093%2Fhmg%2Fddt402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance</span></div><div class="casAuthors">Cook, Casey; Carlomagno, Yari; Gendron, Tania F.; Dunmore, Judy; Scheffel, Kristyn; Stetler, Caroline; Davis, Mary; Dickson, Dennis; Jarpe, Matthew; DeTure, Michael; Petrucelli, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-116</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The accumulation of hyperphosphorylated tau in neurofibrillary tangles (NFTs) is a neuropathol. hallmark of tauopathies, including Alzheimer's disease (AD) and chronic traumatic encephalopathy, but effective therapies directly targeting the tau protein are currently lacking.  Herein, the authors describe a novel mechanism in which the acetylation of tau on KXGS motifs inhibits phosphorylation on this same motif, and also prevents tau aggregation.  Using a site-specific antibody to detect acetylation of KXGS motifs, the authors demonstrate that these sites are hypoacetylated in patients with AD, as well as a mouse model of tauopathy, suggesting that loss of acetylation on KXGS motifs renders tau vulnerable to pathogenic insults.  Furthermore, the authors identify histone deacetylase 6 (HDAC6) as the enzyme responsible for the deacetylation of these residues, and provide proof of concept that acute treatment with a selective and blood-brain barrier-permeable HDAC6 inhibitor enhances acetylation and decreases phosphorylation on tau's KXGS motifs in vivo.  As such, the authors have uncovered a novel therapeutic pathway that can be manipulated to block the formation of pathogenic tau species in disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSzT8uddBwVLVg90H21EOLACvtfcHk0liwGCivdNU2ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegsL3P&md5=fea73049a2ab19c87f56b174d66691cf</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddt402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddt402%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DC.%26aulast%3DCarlomagno%26aufirst%3DY.%26aulast%3DGendron%26aufirst%3DT.%2BF.%26aulast%3DDunmore%26aufirst%3DJ.%26aulast%3DScheffel%26aufirst%3DK.%26aulast%3DStetler%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DM.%26aulast%3DDickson%26aufirst%3DD.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3DDeTure%26aufirst%3DM.%26aulast%3DPetrucelli%26aufirst%3DL.%26atitle%3DAcetylation%2520of%2520the%2520KXGS%2520motifs%2520in%2520tau%2520is%2520a%2520critical%2520determinant%2520in%2520modulation%2520of%2520tau%2520aggregation%2520and%2520clearance%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2014%26volume%3D23%26spage%3D104%26epage%3D116%26doi%3D10.1093%2Fhmg%2Fddt402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salas-Burgos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koomen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olashaw, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">HDAC6 modulates cell motility by altering the acetylation level of cortactin</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2007.05.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.molcel.2007.05.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=17643370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFamtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=197-213&author=X.+Zhangauthor=Z.+Yuanauthor=Y.+Zhangauthor=S.+Yongauthor=A.+Salas-Burgosauthor=J.+Koomenauthor=N.+Olashawauthor=J.+T.+Parsonsauthor=X.+J.+Yangauthor=S.+R.+Dentauthor=T.+P.+Yaoauthor=W.+S.+Laneauthor=E.+Seto&title=HDAC6+modulates+cell+motility+by+altering+the+acetylation+level+of+cortactin&doi=10.1016%2Fj.molcel.2007.05.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 modulates cell motility by altering the acetylation level of cortactin</span></div><div class="casAuthors">Zhang, Xiaohong; Yuan, Zhigang; Zhang, Yingtao; Yong, Sarah; Salas-Burgos, Alexis; Koomen, John; Olashaw, Nancy; Parsons, J. Thomas; Yang, Xiang-Jiao; Dent, Sharon R.; Yao, Tso-Pang; Lane, William S.; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-213</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is a tubulin-specific deacetylase that regulates microtubule-dependent cell movement.  In this study, we identify the F-actin-binding protein cortactin as a HDAC6 substrate.  We demonstrate that HDAC6 binds cortactin and that overexpression of HDAC6 leads to hypoacetylation of cortactin, whereas inhibition of HDAC6 activity leads to cortactin hyperacetylation.  HDAC6 alters the ability of cortactin to bind F-actin by modulating a "charge patch" in its repeat region.  Introduction of charge-preserving or charge-neutralizing mutations in this cortactin repeat region correlates with the gain or loss of F-actin binding ability, resp.  Cells expressing a charge-neutralizing cortactin mutant were less motile than control cells or cells expressing a charge-preserving mutant.  These findings suggest that, in addn. to its role in microtubule-dependent cell motility, HDAC6 influences actin-dependent cell motility by altering the acetylation status of cortactin, which, in turn, changes the F-actin binding activity of cortactin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQSM-mAzzZOrVg90H21EOLACvtfcHk0lgLjIAZSXj0KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFamtLg%253D&md5=752a0203b7cde321c9c5de07fba79ca7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2007.05.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2007.05.033%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYong%26aufirst%3DS.%26aulast%3DSalas-Burgos%26aufirst%3DA.%26aulast%3DKoomen%26aufirst%3DJ.%26aulast%3DOlashaw%26aufirst%3DN.%26aulast%3DParsons%26aufirst%3DJ.%2BT.%26aulast%3DYang%26aufirst%3DX.%2BJ.%26aulast%3DDent%26aufirst%3DS.%2BR.%26aulast%3DYao%26aufirst%3DT.%2BP.%26aulast%3DLane%26aufirst%3DW.%2BS.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DHDAC6%2520modulates%2520cell%2520motility%2520by%2520altering%2520the%2520acetylation%2520level%2520of%2520cortactin%26jtitle%3DMol.%2520Cell%26date%3D2007%26volume%3D27%26spage%3D197%26epage%3D213%26doi%3D10.1016%2Fj.molcel.2007.05.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaillard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicchitta, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toft, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T. P.</span></span> <span> </span><span class="NLM_article-title">HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2005.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.molcel.2005.04.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=15916966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFOksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=601-607&author=J.+J.+Kovacsauthor=P.+J.+Murphyauthor=S.+Gaillardauthor=X.+Zhaoauthor=J.+T.+Wuauthor=C.+V.+Nicchittaauthor=M.+Yoshidaauthor=D.+O.+Toftauthor=W.+B.+Prattauthor=T.+P.+Yao&title=HDAC6+regulates+Hsp90+acetylation+and+chaperone-dependent+activation+of+glucocorticoid+receptor&doi=10.1016%2Fj.molcel.2005.04.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor</span></div><div class="casAuthors">Kovacs, Jeffrey J.; Murphy, Patrick J. M.; Gaillard, Stephanie; Zhao, Xuan; Wu, June-Tai; Nicchitta, Christopher V.; Yoshida, Minoru; Toft, David O.; Pratt, William B.; Yao, Tso-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">601-607</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mol. chaperone heat shock protein 90 (Hsp90) and its accessory cochaperones function by facilitating the structural maturation and complex assembly of client proteins, including steroid hormone receptors and selected kinases.  By promoting the activity and stability of these signaling proteins, Hsp90 has emerged as a crit. modulator in cell signaling.  Here, we present evidence that Hsp90 chaperone activity is regulated by reversible acetylation and controlled by the deacetylase HDAC6.  We show that HDAC6 functions as an Hsp90 deacetylase.  Inactivation of HDAC6 leads to Hsp90 hyperacetylation, its dissocn. from an essential cochaperone, p23, and a loss of chaperone activity.  In HDAC6-deficient cells, Hsp90-dependent maturation of the glucocorticoid receptor (GR) is compromised, resulting in GR defective in ligand binding, nuclear translocation, and transcriptional activation.  Our results identify Hsp90 as a target of HDAC6 and suggest reversible acetylation as a unique mechanism that regulates Hsp90 chaperone complex activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6rzQe2Zsw_7Vg90H21EOLACvtfcHk0lgLjIAZSXj0KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFOksb4%253D&md5=338a8456c56a74d82ad3d28cbccae33f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DKovacs%26aufirst%3DJ.%2BJ.%26aulast%3DMurphy%26aufirst%3DP.%2BJ.%26aulast%3DGaillard%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DJ.%2BT.%26aulast%3DNicchitta%26aufirst%3DC.%2BV.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DToft%26aufirst%3DD.%2BO.%26aulast%3DPratt%26aufirst%3DW.%2BB.%26aulast%3DYao%26aufirst%3DT.%2BP.%26atitle%3DHDAC6%2520regulates%2520Hsp90%2520acetylation%2520and%2520chaperone-dependent%2520activation%2520of%2520glucocorticoid%2520receptor%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D18%26spage%3D601%26epage%3D607%26doi%3D10.1016%2Fj.molcel.2005.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmigiani, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venta-Perez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaneva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">9633</span>– <span class="NLM_lpage">9638</span>, <span class="refDoi"> DOI: 10.1073/pnas.0803749105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1073%2Fpnas.0803749105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=18606987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovVOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=9633-9638&author=R.+B.+Parmigianiauthor=W.+S.+Xuauthor=G.+Venta-Perezauthor=H.+Erdjument-Bromageauthor=M.+Yanevaauthor=P.+Tempstauthor=P.+A.+Marks&title=HDAC6+is+a+specific+deacetylase+of+peroxiredoxins+and+is+involved+in+redox+regulation&doi=10.1073%2Fpnas.0803749105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation</span></div><div class="casAuthors">Parmigiani, R. B.; Xu, W. S.; Venta-Perez, G.; Erdjumen-Bromage, H.; Yaneva, M.; Tempst, P.; Marks, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">9633-9638</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Eighteen histone deacetylases (HDACs) are present in humans, categorized into 2 groups: (1) Zn-dependent enzymes (HDAC1-11) and (2) NAD-dependent enzymes (sirtuins 1-7).  Among Zn-dependent HDACs, HDAC6 is unique.  It has a cytoplasmic localization, 2 catalytic sites, a ubiquitin-binding site, and it selectively deacetylates α-tubulin and Hsp90.  Here, the authors report the discovery that the redox regulatory proteins, peroxiredoxins (Prxs) I and II are specific targets of HDAC6 in human prostate cancer cells.  Prxs are antioxidant enzymes whose main function is H2O2 redn.  Prxs are elevated in many cancers and neurodegenerative diseases.  The acetylated form of Prx accumulates in the absence of an active HDAC6.  Acetylation of Prx increases its reducing activity, its resistance to superoxidn., and its resistance to transition to high-mol.-wt. complexes.  Thus, HDAC6 and Prxs are targets for modulating intracellular redox status in therapeutic strategies for disorders as disparate as cancers and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPhHinn-zsRbVg90H21EOLACvtfcHk0lgLjIAZSXj0KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovVOjt7g%253D&md5=205d33a2f6c154d83b1d1cee59d29108</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0803749105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0803749105%26sid%3Dliteratum%253Aachs%26aulast%3DParmigiani%26aufirst%3DR.%2BB.%26aulast%3DXu%26aufirst%3DW.%2BS.%26aulast%3DVenta-Perez%26aufirst%3DG.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DYaneva%26aufirst%3DM.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DHDAC6%2520is%2520a%2520specific%2520deacetylase%2520of%2520peroxiredoxins%2520and%2520is%2520involved%2520in%2520redox%2520regulation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D9633%26epage%3D9638%26doi%3D10.1073%2Fpnas.0803749105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aldana-Masangkay, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, K. M.</span></span> <span> </span><span class="NLM_article-title">The Role of HDAC6 in Cancer</span>. <i>J. Biomed. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">875824</span>, <span class="refDoi"> DOI: 10.1155/2011/875824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1155%2F2011%2F875824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=21076528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BC3cbmvFKnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=875824&author=G.+I.+Aldana-Masangkayauthor=K.+M.+Sakamoto&title=The+Role+of+HDAC6+in+Cancer&doi=10.1155%2F2011%2F875824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The role of HDAC6 in cancer</span></div><div class="casAuthors">Aldana-Masangkay Grace I; Sakamoto Kathleen M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomedicine & biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">875824</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylase 6 (HDAC6), a member of the HDAC family whose major substrate is α-tubulin, has become a target for drug development to treat cancer due to its major contribution in oncogenic cell transformation.  Overexpression of HDAC6 correlates with tumorigenesis and improved survival; therefore, HDAC6 may be used as a marker for prognosis.  Previous work demonstrated that in multiple myeloma cells, inhibition of HDAC6 results in apoptosis.  Furthermore, HDAC6 is required for the activation of heat-shock factor 1 (HSF1), an activator of heat-shock protein encoding genes (HSPs) and CYLD, a cylindromatosis tumor suppressor gene.  HDAC6 contributes to cancer metastasis since its upregulation increases cell motility in breast cancer MCF-7 cells and its interaction with cortactin regulates motility.  HDAC6 also affects transcription and translation by regulating the heat-shock protein 90 (Hsp90) and stress granules (SGs), respectively.  This review will discuss the role of HDAC6 in the pathogenesis and treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIuDxliM3SH5QHPYJuLg8TfW6udTcc2eaeP2mFyTyn5bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbmvFKnsA%253D%253D&md5=8be7e0edb941ebf8b761778c99ad4c57</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1155%2F2011%2F875824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F875824%26sid%3Dliteratum%253Aachs%26aulast%3DAldana-Masangkay%26aufirst%3DG.%2BI.%26aulast%3DSakamoto%26aufirst%3DK.%2BM.%26atitle%3DThe%2520Role%2520of%2520HDAC6%2520in%2520Cancer%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2011%26volume%3D2011%26spage%3D875824%26doi%3D10.1155%2F2011%2F875824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnekenburger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, M.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 in health and disease</span>. <i>Epigenomics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.2217/epi.14.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.2217%2Fepi.14.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=25687470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislGisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=103-118&author=C.+Seidelauthor=M.+Schnekenburgerauthor=M.+Dicatoauthor=M.+Diederich&title=Histone+deacetylase+6+in+health+and+disease&doi=10.2217%2Fepi.14.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 in health and disease</span></div><div class="casAuthors">Seidel, Carole; Schnekenburger, Michael; Dicato, Mario; Diederich, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Epigenomics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-118</span>CODEN:
                <span class="NLM_cas:coden">EPIGC7</span>;
        ISSN:<span class="NLM_cas:issn">1750-192X</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC)6 is a member of the class IIb HDAC family.  This enzyme is zinc-dependent and mainly localized in the cytoplasm.  HDAC6 is a unique isoenzyme with two functional catalytic domains and specific physiol. roles.  Indeed, HDAC6 deacetylates various substrates including α-tubulin and HSP90α, and is involved in protein trafficking and degrdn., cell shape and migration.  Consequently, deregulation of HDAC6 activity was assocd. to a variety of diseases including cancer, neurodegenerative diseases and pathol. autoimmune response.  Therefore, HDAC6 represents an interesting potential therapeutic target.  In this review, we discuss structural features of this histone deacetylase, regulation of its expression and activity, biol. functions, implication in human disease initiation and progression.  Finally will describe novel and selective HDAC6 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0ng4pDM6Ob7Vg90H21EOLACvtfcHk0lhXVSEnt1-8RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislGisbY%253D&md5=21a22233741335632ae499640d799f8d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2217%2Fepi.14.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fepi.14.69%26sid%3Dliteratum%253Aachs%26aulast%3DSeidel%26aufirst%3DC.%26aulast%3DSchnekenburger%26aufirst%3DM.%26aulast%3DDicato%26aufirst%3DM.%26aulast%3DDiederich%26aufirst%3DM.%26atitle%3DHistone%2520deacetylase%25206%2520in%2520health%2520and%2520disease%26jtitle%3DEpigenomics%26date%3D2015%26volume%3D7%26spage%3D103%26epage%3D118%26doi%3D10.2217%2Fepi.14.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 in cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">111</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0654-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1186%2Fs13045-018-0654-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30176876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=111&author=T.+Liauthor=C.+Zhangauthor=S.+Hassanauthor=X.+Liuauthor=F.+Songauthor=K.+Chenauthor=W.+Zhangauthor=J.+Yang&title=Histone+deacetylase+6+in+cancer&doi=10.1186%2Fs13045-018-0654-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 in cancer</span></div><div class="casAuthors">Li, Ting; Zhang, Chao; Hassan, Shafat; Liu, Xinyue; Song, Fengju; Chen, Kexin; Zhang, Wei; Yang, Jilong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111/1-111/10</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription.  Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone substrates, such as a-tubulin, cortactin, and heat shock protein 90 (HSP90), to regulate cell proliferation, metastasis, invasion, and mitosis in tumors.  Furthermore, HDAC6 also upregulates several crit. factors in the immune system, such as program death receptor-1 (PD-1) and program death receptor ligand-1 (PD-L1) receptor, which are the main targets for cancer immunotherapy.  Several selective HDAC6 inhibitors are currently in clin. trials for cancer treatment and bring hope for patients with malignant tumors.  A fuller understanding of HDAC6 as a crit. regulator of many cellular pathways will help further the development of targeted anti-HDAC6 therapies.  Here, we review the unique features of HDAC6 and its role in cancer, which make HDAC6 an appealing drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-ZU431-gtrVg90H21EOLACvtfcHk0lhXVSEnt1-8RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D&md5=eb9bc73343a7ee078124b017ee00b636</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0654-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0654-9%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHassan%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DHistone%2520deacetylase%25206%2520in%2520cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D111%26doi%3D10.1186%2Fs13045-018-0654-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Auzmendi-Iriarte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saenz-Antoñanzas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikelez-Alonso, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco-Garcia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellaetxe-Abete, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrie, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortajarena, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheu, A.</span></span> <span> </span><span class="NLM_article-title">Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">417</span>, <span class="refDoi"> DOI: 10.1038/s41419-020-2586-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fs41419-020-2586-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32488056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFemt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=417&author=J.+Auzmendi-Iriarteauthor=A.+Saenz-Anto%C3%B1anzasauthor=I.+Mikelez-Alonsoauthor=E.+Carrasco-Garciaauthor=M.+Tellaetxe-Abeteauthor=C.+H.+Lawrieauthor=N.+Sampronauthor=A.+L.+Cortajarenaauthor=A.+Matheu&title=Characterization+of+a+new+small-molecule+inhibitor+of+HDAC6+in+glioblastoma&doi=10.1038%2Fs41419-020-2586-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma</span></div><div class="casAuthors">Auzmendi-Iriarte, Jaione; Saenz-Antonanzas, Ander; Mikelez-Alonso, Idoia; Carrasco-Garcia, Estefania; Tellaetxe-Abete, Maitena; Lawrie, Charles H.; Sampron, Nicolas; Cortajarena, Aitziber L.; Matheu, Ander</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">417</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Histone deacetylase 6 (HDAC6) is an epigenetic modifier that is an attractive pharmacol. target in cancer.  In this work, we show that HDAC6 is elevated in glioblastoma, the most malignant and common brain tumor in adults, in which its high levels correlate with poor patient survival and is more abundant in glioma stem cell subpopulation.  Moreover, we identified a new small-mol. inhibitor of HDAC6, which presents strong sensitivity for HDAC6 inhibition and exerts high cytotoxic activity, alone or in combination with temozolomide.  It is also able to significantly reduce tumor growth in vivo.  Transcriptomic anal. of patient-derived glioma stem cells revealed an increase in cell differentiation and cell death pathways, as well as a decrease in cell-cycle activity and cell division by the treatment with the compd.  Finally, the comparison with a pan-HDAC inhibitor, Vorinostat (SAHA), or HDAC6-specific inhibitor, Tubastatin A, showed higher target specificity and antitumor activity of the new HDAC6 inhibitor.  In conclusion, our data reveal the efficacy of a novel HDAC6 inhibitor in glioblastoma preclin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp53nM_XMZC7LVg90H21EOLACvtfcHk0lgDmn9mBKWXcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFemt7%252FM&md5=fd4fad040bffea9191e1a00e9268a3b5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fs41419-020-2586-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-020-2586-x%26sid%3Dliteratum%253Aachs%26aulast%3DAuzmendi-Iriarte%26aufirst%3DJ.%26aulast%3DSaenz-Anto%25C3%25B1anzas%26aufirst%3DA.%26aulast%3DMikelez-Alonso%26aufirst%3DI.%26aulast%3DCarrasco-Garcia%26aufirst%3DE.%26aulast%3DTellaetxe-Abete%26aufirst%3DM.%26aulast%3DLawrie%26aufirst%3DC.%2BH.%26aulast%3DSampron%26aufirst%3DN.%26aulast%3DCortajarena%26aufirst%3DA.%2BL.%26aulast%3DMatheu%26aufirst%3DA.%26atitle%3DCharacterization%2520of%2520a%2520new%2520small-molecule%2520inhibitor%2520of%2520HDAC6%2520in%2520glioblastoma%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2020%26volume%3D11%26spage%3D417%26doi%3D10.1038%2Fs41419-020-2586-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossaert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bosch, L.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>1733</i></span>,  <span class="NLM_fpage">146692</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2020.146692</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.brainres.2020.146692" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32006555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsVOksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1733&publication_year=2020&pages=146692&author=E.+Rossaertauthor=L.+Van+Den+Bosch&title=HDAC6+inhibitors%3A+Translating+genetic+and+molecular+insights+into+a+therapy+for+axonal+CMT&doi=10.1016%2Fj.brainres.2020.146692"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT</span></div><div class="casAuthors">Rossaert, Elisabeth; Van Den Bosch, Ludo</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">1733</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">146692</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase 6 (HDAC6) plays a central role in various processes that are key for neuronal survival.  In this review, we summarize the current evidence related to disease pathways in the axonal form of Charcot-Marie-Tooth disease (CMT) and highlight the role of HDAC6 in these pathways.  We hypothesize that HDAC6 might in fact actively contribute to the pathogenesis of certain forms of axonal CMT.  HDAC6 plays a deacetylase activity-dependent, neg. role in axonal transport and axonal regeneration, which are both processes implicated in axonal CMT.  On the other hand, HDAC6 coordinates a protective response during elimination of toxic misfolded proteins, but this is mostly mediated independent of its deacetylase activity.  The current mechanistic insights on these functions of HDAC6 in axonal CMT, along with the selective druggability against its deacetylase activity, make the targeting of HDAC6 particularly attractive.  We elaborate on the preclin. studies that demonstrated beneficial effects of HDAC6 inhibitors in axonal CMT models and outline possible modes of action.  Overall, this overview ultimately provides a rationale for the use of small-mol. HDAC6 inhibitors as a therapeutic strategy for this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLQPvMw55ppbVg90H21EOLACvtfcHk0lgDmn9mBKWXcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsVOksbw%253D&md5=3005fe78c94cf2a719d6e031573320c5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2020.146692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2020.146692%26sid%3Dliteratum%253Aachs%26aulast%3DRossaert%26aufirst%3DE.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26atitle%3DHDAC6%2520inhibitors%253A%2520Translating%2520genetic%2520and%2520molecular%2520insights%2520into%2520a%2520therapy%2520for%2520axonal%2520CMT%26jtitle%3DBrain%2520Res.%26date%3D2020%26volume%3D1733%26spage%3D146692%26doi%3D10.1016%2Fj.brainres.2020.146692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraswati, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span> <span> </span><span class="NLM_article-title">Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00924</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00924" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=23-39&author=M.+Brindisiauthor=A.+P.+Saraswatiauthor=S.+Brogiauthor=S.+Gemmaauthor=S.+Butiniauthor=G.+Campiani&title=Old+but+Gold%3A+Tracking+the+New+Guise+of+Histone+Deacetylase+6+%28HDAC6%29+Enzyme+as+a+Biomarker+and+Therapeutic+Target+in+Rare+Diseases&doi=10.1021%2Facs.jmedchem.9b00924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases</span></div><div class="casAuthors">Brindisi, Margherita; Saraswati, A. Prasanth; Brogi, Simone; Gemma, Sandra; Butini, Stefania; Campiani, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-39</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Epigenetic regulation orchestrates many cellular processes and greatly influences key disease mechanisms.  Histone deacetylase (HDAC) enzymes play a crucial role either as biomarkers or therapeutic targets owing to their involvement in specific pathophysiol. pathways.  Beyond their well-characterized role as histone modifiers, HDACs also interact with several non-histone substrates and their increased expression has been highlighted in specific diseases.  HDAC6 isoform, due to its unique cytoplasmic localization, modulates the acetylation status of tubulin, HSP90, TGF-β and peroxiredoxins.  HDAC6 also exerts non-catalytic activities, through its interaction with ubiquitin.  Both catalytic and non-catalytic functions of HDACs are being actively studied in the field of specific rare disorders, beyond the well-established role in carcinogenesis.  This perspective outlines the application of HDAC(6) inhibitors in rare diseases, such as Rett syndrome, inherited retinal disorders, idiopathic pulmonary fibrosis and Charcot-Marie-Tooth disease, highlighting their therapeutic potential as innovative and targeted disease-modifying agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-kzJmRToypbVg90H21EOLACvtfcHk0lgDmn9mBKWXcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbrK&md5=688368246471313ed025f0c230167052</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00924%26sid%3Dliteratum%253Aachs%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DSaraswati%26aufirst%3DA.%2BP.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26atitle%3DOld%2520but%2520Gold%253A%2520Tracking%2520the%2520New%2520Guise%2520of%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529%2520Enzyme%2520as%2520a%2520Biomarker%2520and%2520Therapeutic%2520Target%2520in%2520Rare%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D23%26epage%3D39%26doi%3D10.1021%2Facs.jmedchem.9b00924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span> <span> </span><span class="NLM_article-title">Structure, Functions and Selective Inhibitors of HDAC6</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2429</span>– <span class="NLM_lpage">2447</span>, <span class="refDoi"> DOI: 10.2174/1568026619666181129141822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.2174%2F1568026619666181129141822" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=2429-2447&author=T.+Liangauthor=H.+Fang&title=Structure%2C+Functions+and+Selective+Inhibitors+of+HDAC6&doi=10.2174%2F1568026619666181129141822"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2174%2F1568026619666181129141822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666181129141822%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DT.%26aulast%3DFang%26aufirst%3DH.%26atitle%3DStructure%252C%2520Functions%2520and%2520Selective%2520Inhibitors%2520of%2520HDAC6%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D18%26spage%3D2429%26epage%3D2447%26doi%3D10.2174%2F1568026619666181129141822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014–2019)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1708901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1080%2F13543776.2019.1708901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31865813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVKnsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=121-136&author=S.+Shenauthor=A.+P.+Kozikowski&title=A+patent+review+of+histone+deacetylase+6+inhibitors+in+neurodegenerative+diseases+%282014%E2%80%932019%29&doi=10.1080%2F13543776.2019.1708901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019)</span></div><div class="casAuthors">Shen, Sida; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-136</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase 6 (HDAC6) is unique in comparison with other zinc-dependent HDAC family members.  An increasing amt. of evidence from clin. and preclin. research demonstrates the potential of HDAC6 inhibition as an effective therapeutic approach for the treatment of cancer, autoimmune diseases, as well as neurol. disorders.  The recently disclosed crystal structures of HDAC6-ligand complexes offer further means for achieving pharmacophore refinement, thus further accelerating the pace of HDAC6 inhibitor discovery in the last few years.: This review summarizes the latest clin. status of HDAC6 inhibitors, discusses pharmacol. applications of selective HDAC6 inhibitors in neurodegenerative diseases, and describes the patent applications dealing with HDAC6 inhibitors from 2014-2019 that have not been reported in research articles.: Phenylhydroxamate has proven a very useful scaffold in the discovery of potent and selective HDAC6 inhibitors.  However, weaknesses of the hydroxamate function such as metabolic instability and mutagenic potential limit its application in the neurol. field, where long-term administration is required.  The recent invention of oxadiazole-based ligands by pharmaceutical companies may provide a new opportunity to optimize the druglike properties of HDAC6 inhibitors for the treatment of neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCWThC7SH8r7Vg90H21EOLACvtfcHk0ljuT3RmN6OAFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVKnsb3J&md5=926d00ce3a0153953eb2f933599500b9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1708901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1708901%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DA%2520patent%2520review%2520of%2520histone%2520deacetylase%25206%2520inhibitors%2520in%2520neurodegenerative%2520diseases%2520%25282014%25E2%2580%25932019%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2020%26volume%3D30%26spage%3D121%26epage%3D136%26doi%3D10.1080%2F13543776.2019.1708901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youn, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y. W.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">176</span>, <span class="refDoi"> DOI: 10.1186/s13075-020-02258-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1186%2Fs13075-020-02258-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32711562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVyltrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2020&pages=176&author=J.+K.+Parkauthor=Y.+J.+Jangauthor=B.+R.+Ohauthor=J.+Shinauthor=D.+Baeauthor=N.+Haauthor=Y.+i.+Choiauthor=G.+S.+Younauthor=J.+Parkauthor=E.+Y.+Leeauthor=E.+B.+Leeauthor=Y.+W.+Song&title=Therapeutic+potential+of+CKD-506%2C+a+novel+selective+histone+deacetylase+6+inhibitor%2C+in+a+murine+model+of+rheumatoid+arthritis&doi=10.1186%2Fs13075-020-02258-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis</span></div><div class="casAuthors">Park, Jin Kyun; Jang, Yu Jin; Oh, Bo Ram; Shin, Jieun; Bae, Daekwon; Ha, Nina; Choi, Young il; Youn, Gi Soo; Park, Jinseu; Lee, Eun Young; Lee, Eun Bong; Song, Yeong Wook</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis Research & Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">176</span>CODEN:
                <span class="NLM_cas:coden">ARTRCV</span>;
        ISSN:<span class="NLM_cas:issn">1478-6362</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) 6 promotes inflammation.  We investigated the anti-arthritic effects of CKD-506, a novel HDAC6 inhibitor, in vitro and in a murine model of arthritis as a novel treatment option for rheumatoid arthritis (RA).  HDAC6 was overexpressed in mouse peritoneal macrophages and RAW 264.7 cells, and the effects of a HDAC6 inhibitor CKD-506 on cytokine prodn. and activity of NF-κB and AP-1 signaling were examd.  Peripheral blood mononuclear cells (PBMCs) from RA patients and fibroblast-like synoviocytes (FLS) were activated in the presence of CKD-506.  Next, regulatory T cells (Tregs) were induced from RA patients and co-cultured with healthy effector T cells (Teffs) and cell proliferation was analyzed by flow cytometry.  Finally, the effects of the inhibitor on the severity of arthritis were assessed in a murine model of adjuvant-induced arthritis (AIA).  Overexpression of HDAC6 induced macrophages to produce TNF-α and IL-6.  The inhibitory effect of CKD-506 was mediated via blockade of NF-κB and AP-1 activation.  HDAC6 inhibition reduced TNF-α and IL-6 prodn. by activated RA PBMCs.  CKD-506 inhibited prodn. of MMP-1, MMP-3, IL-6, and IL-8 by activated FLS.  In addn., CKD-506 inhibited proliferation of Teffs directly and indirectly by improving iTreg function.  In AIA rats, oral CKD-506 improved clin. arthritis in a dose-dependent manner.  A combination of sub-therapeutic CKD-506 and methotrexate exerted a synergistic effect.  The novel HDAC6 inhibitor CKD-506 suppresses inflammatory responses by monocytes/macrophages, improves Treg function, and ameliorates arthritis severity in a murine model of RA.  Thus, CKD-506 might be a novel and effective treatment option for RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphLzwIQN7AvbVg90H21EOLACvtfcHk0ljuT3RmN6OAFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVyltrvF&md5=3377bfe25a6d2b7218aa1cc98c3fa3b1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1186%2Fs13075-020-02258-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-020-02258-0%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DJang%26aufirst%3DY.%2BJ.%26aulast%3DOh%26aufirst%3DB.%2BR.%26aulast%3DShin%26aufirst%3DJ.%26aulast%3DBae%26aufirst%3DD.%26aulast%3DHa%26aufirst%3DN.%26aulast%3DChoi%26aufirst%3DY.%2Bi.%26aulast%3DYoun%26aufirst%3DG.%2BS.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BY.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DSong%26aufirst%3DY.%2BW.%26atitle%3DTherapeutic%2520potential%2520of%2520CKD-506%252C%2520a%2520novel%2520selective%2520histone%2520deacetylase%25206%2520inhibitor%252C%2520in%2520a%2520murine%2520model%2520of%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2020%26volume%3D22%26spage%3D176%26doi%3D10.1186%2Fs13075-020-02258-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>208</i></span>,  <span class="NLM_fpage">112831</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2020.112831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32961382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFWmsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=208&publication_year=2020&pages=112831&author=X.+Pengauthor=Z.+Sunauthor=P.+Kuangauthor=J.+Chen&title=Recent+progress+on+HDAC+inhibitors+with+dual+targeting+capabilities+for+cancer+treatment&doi=10.1016%2Fj.ejmech.2020.112831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment</span></div><div class="casAuthors">Peng, Xiaopeng; Sun, Zhiqiang; Kuang, Peihua; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">208</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112831</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a class of enzymes that remove acetyl from the ε-N-acetyl lysine of histones, allowing histones to wrap DNA more tightly.  HDACs play an essential role in many biol. processes such as gene regulation, transcription, cell proliferation, angiogenesis, migration, differentiation and metastasis.  As a result, HDACs represent an excellent target for anti-cancer drug discovery.  The search for histone deacetylase inhibitors (HDACis) has been intensified in the last decade with numerous HDACis being discovered, and some of them have reached the market.  However, currently available HDACis are mostly non-isoform selective and suffer from several drawbacks such as limited efficacy, drug resistance, and toxicities.  Therefore, isoform-selective HDACis and HDACis with dual targeting capabilities have attracted much attention from academia to industry in the past 5 years, and great advances have been achieved in this area.  In this paper, we summarize recent progress on HDACis with dual targeting capabilities and their potential application to cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTHs5GEjS8RbVg90H21EOLACvtfcHk0ljuT3RmN6OAFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFWmsbvM&md5=d6f340dc0222b3f22a702c963cb1728b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112831%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DKuang%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DRecent%2520progress%2520on%2520HDAC%2520inhibitors%2520with%2520dual%2520targeting%2520capabilities%2520for%2520cancer%2520treatment%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D208%26spage%3D112831%26doi%3D10.1016%2Fj.ejmech.2020.112831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woan, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienlaf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Villaroel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahakian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marante, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla-Ibarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1447</span>– <span class="NLM_lpage">1457</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2015.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.molonc.2015.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=25957812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsF2gtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=1447-1457&author=K.+V.+Woanauthor=M.+Lienlafauthor=P.+Perez-Villaroelauthor=C.+Leeauthor=F.+Chengauthor=T.+Knoxauthor=D.+M.+Woodsauthor=K.+Barriosauthor=J.+Powersauthor=E.+Sahakianauthor=H.+W.+Wangauthor=J.+Canalesauthor=D.+Maranteauthor=K.+S.+M.+Smalleyauthor=J.+Bergmanauthor=E.+Setoauthor=A.+Kozikowskiauthor=J.+Pinilla-Ibarzauthor=A.+Sarnaikauthor=E.+Celisauthor=J.+Weberauthor=E.+M.+Sotomayorauthor=A.+Villagra&title=Targeting+histone+deacetylase+6+mediates+a+dual+anti-melanoma+effect%3A+Enhanced+antitumor+immunity+and+impaired+cell+proliferation&doi=10.1016%2Fj.molonc.2015.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation</span></div><div class="casAuthors">Woan, K. V.; Lienlaf, M.; Perez-Villaroel, P.; Lee, C.; Cheng, F.; Knox, T.; Woods, D. M.; Barrios, K.; Powers, J.; Sahakian, E.; Wang, H. W.; Canales, J.; Marante, D.; Smalley, K. S. M.; Bergman, J.; Seto, E.; Kozikowski, A.; Pinilla-Ibarz, J.; Sarnaik, A.; Celis, E.; Weber, J.; Sotomayor, E. M.; Villagra, A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1447-1457</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The median survival for metastatic melanoma is in the realm of 8-16 mo and there are few therapies that offer significant improvement in overall survival.  One of the recent advances in cancer treatment focuses on epigenetic modifiers to alter the survivability and immunogenicity of cancer cells.  Our group and others have previously demonstrated that pan-HDAC inhibitors induce apoptosis, cell cycle arrest and changes in the immunogenicity of melanoma cells.  Here we interrogated specific HDACs which may be responsible for this effect.  We found that both genetic abrogation and pharmacol. inhibition of HDAC6 decreases in vitro proliferation and induces G1 arrest of melanoma cell lines without inducing apoptosis.  Moreover, targeting this mol. led to an important upregulation in the expression of tumor assocd. antigens and MHC class I, suggesting a potential improvement in the immunogenicity of these cells.  Of note, this anti-melanoma activity was operative regardless of mutational status of the cells.  These effects translated into a pronounced delay of in vivo melanoma tumor growth which was, at least in part, dependent on intact immunity as evidenced by the restoration of tumor growth after CD4+ and CD8+ depletion.  Given our findings, we provide the initial rationale for the further development of selective HDAC6 inhibitors as potential therapeutic anti-melanoma agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDIQ5LKbZF8bVg90H21EOLACvtfcHk0lhoOEpCxT_cbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsF2gtLw%253D&md5=7534df9db01f52a71f97f0e112db37cc</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2015.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2015.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DWoan%26aufirst%3DK.%2BV.%26aulast%3DLienlaf%26aufirst%3DM.%26aulast%3DPerez-Villaroel%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DWoods%26aufirst%3DD.%2BM.%26aulast%3DBarrios%26aufirst%3DK.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DSahakian%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DH.%2BW.%26aulast%3DCanales%26aufirst%3DJ.%26aulast%3DMarante%26aufirst%3DD.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DBergman%26aufirst%3DJ.%26aulast%3DSeto%26aufirst%3DE.%26aulast%3DKozikowski%26aufirst%3DA.%26aulast%3DPinilla-Ibarz%26aufirst%3DJ.%26aulast%3DSarnaik%26aufirst%3DA.%26aulast%3DCelis%26aufirst%3DE.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DTargeting%2520histone%2520deacetylase%25206%2520mediates%2520a%2520dual%2520anti-melanoma%2520effect%253A%2520Enhanced%2520antitumor%2520immunity%2520and%2520impaired%2520cell%2520proliferation%26jtitle%3DMol.%2520Oncol.%26date%3D2015%26volume%3D9%26spage%3D1447%26epage%3D1457%26doi%3D10.1016%2Fj.molonc.2015.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustinova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlicek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noonepalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bařinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8557</span>– <span class="NLM_lpage">8577</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00946</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00946" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8557-8577&author=S.+Shenauthor=M.+Hadleyauthor=K.+Ustinovaauthor=J.+Pavlicekauthor=T.+Knoxauthor=S.+Noonepalleauthor=M.+T.+Tavaresauthor=C.+A.+Zimprichauthor=G.+Zhangauthor=M.+B.+Robersauthor=C.+Ba%C5%99inkaauthor=A.+P.+Kozikowskiauthor=A.+Villagra&title=Discovery+of+a+New+Isoxazole-3-hydroxamate-Based+Histone+Deacetylase+6+Inhibitor+SS-208+with+Antitumor+Activity+in+Syngeneic+Melanoma+Mouse+Models&doi=10.1021%2Facs.jmedchem.9b00946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models</span></div><div class="casAuthors">Shen, Sida; Hadley, Melissa; Ustinova, Kseniya; Pavlicek, Jiri; Knox, Tessa; Noonepalle, Satish; Tavares, Mauricio T.; Zimprich, Chad A.; Zhang, Guiping; Robers, Matthew B.; Barinka, Cyril; Kozikowski, Alan P.; Villagra, Alejandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8557-8577</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Isoxazole is a five-membered heterocycle that is widely used in drug discovery endeavors.  Here, the authors report the design, synthesis, and structural and biol. characterization of SS-208, a novel HDAC6-selective inhibitor contg. the isoxazole-3-hydroxamate moiety as a zinc-binding group as well as a hydrophobic linker.  A crystal structure of the Danio rerio HDAC6/SS-208 complex reveals a bidentate coordination of the active-site zinc ion that differs from the preferred monodentate coordination obsd. for HDAC6 complexes with phenylhydroxamate-based inhibitors.  While SS-208 has minimal effects on the viability of murine SM1 melanoma cells in vitro, it significantly reduced in vivo tumor growth in a murine SM1 syngeneic melanoma mouse model.  These findings suggest that the antitumor activity of SS-208 is mainly mediated by immune-related antitumor activity as evidenced by the increased infiltration of CD8+ and NK+ T cells and the enhanced ratio of M1 and M2 macrophages in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUagVGHIiRHbVg90H21EOLACvtfcHk0lhoOEpCxT_cbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbzI&md5=53b4c45ce582d8752869430407d44649</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00946%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DUstinova%26aufirst%3DK.%26aulast%3DPavlicek%26aufirst%3DJ.%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DNoonepalle%26aufirst%3DS.%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DBa%25C5%2599inka%26aufirst%3DC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520New%2520Isoxazole-3-hydroxamate-Based%2520Histone%2520Deacetylase%25206%2520Inhibitor%2520SS-208%2520with%2520Antitumor%2520Activity%2520in%2520Syngeneic%2520Melanoma%2520Mouse%2520Models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8557%26epage%3D8577%26doi%3D10.1021%2Facs.jmedchem.9b00946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Development of the first small molecule histone deacetylase 6 (HDAC6) degraders</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2493</span>– <span class="NLM_lpage">2497</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.05.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmcl.2018.05.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29871848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2493-2497&author=K.+Yangauthor=Y.+Songauthor=H.+Xieauthor=H.+Wuauthor=Y.+T.+Wuauthor=E.+D.+Leistenauthor=W.+Tang&title=Development+of+the+first+small+molecule+histone+deacetylase+6+%28HDAC6%29+degraders&doi=10.1016%2Fj.bmcl.2018.05.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Development of the first small molecule histone deacetylase 6 (HDAC6) degraders</span></div><div class="casAuthors">Yang, Ka; Song, Yanling; Xie, Haibo; Wu, Hao; Wu, Yi-Ting; Leisten, Eric D.; Tang, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2493-2497</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) decrease the acetylation level of histones and other non-histone proteins.  Over expression of HDACs have been obsd. in cancers and other diseases.  Targeted protein degrdn. by "hijacking" the natural ubiquitin-proteasome-system (UPS) recently emerged as a novel technol. to "knock-out" endogenous disease-causing proteins.  The authors applied this strategy to the development of the first small mol. degraders for zinc-dependent HDACs by conjugating non-selective HDAC inhibitors with E3 ubiquitin ligase ligands.  Through cell-based assays, the authors discovered novel bifunctional mols. (dHDAC6) that could selectively degrade HDAC6.  Further mechanistic studies indicated that HDAC6 was selectively removed by the UPS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9t1stJ7Qkf7Vg90H21EOLACvtfcHk0lg6mkFg4Rdr_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsrfF&md5=20be52b05a327184f824ccf9cf88333f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.05.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.05.057%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DK.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%2BT.%26aulast%3DLeisten%26aufirst%3DE.%2BD.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520the%2520first%2520small%2520molecule%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529%2520degraders%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2493%26epage%3D2497%26doi%3D10.1016%2Fj.bmcl.2018.05.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">Developing potent PROTACs tools for selective degradation of HDAC6 protein</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">609</span>, <span class="refDoi"> DOI: 10.1007/s13238-018-0602-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs13238-018-0602-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30603959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVCktLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=606-609&author=Z.+Anauthor=W.+Lvauthor=S.+Suauthor=W.+Wuauthor=Y.+Rao&title=Developing+potent+PROTACs+tools+for+selective+degradation+of+HDAC6+protein&doi=10.1007%2Fs13238-018-0602-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Developing potent PROTACs tools for selective degradation of HDAC6 protein</span></div><div class="casAuthors">An, Zixuan; Lv, Wenxing; Su, Shang; Wu, Wei; Rao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">606-609</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">The present article describes about developing potent PROTACs tools for selective degrdn. of HDAC6 protein.  To evaluate the degrdn. capability of our PROTACs for HDAC6 protein, analyzed the cellular levels of HDAC6 in HeLa cells by Western blot after incubation with four different PROTACs.  It was found that all PROTACs can effectively induce HDAC6 degrdn. after 24 h.  Among them, NP8 was the most potent degrader which can significantly reduce the HDAC6 protein level at 100 nmol/L.  Then went on to evaluate the degrdn. potential of NP8 in a panel of cell lines from different origin.  NP8 consistently induced significant degrdn. of HDAC6 in all the cell lines we tested, while the multiple myeloma cell line MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0CReXjWgVRbVg90H21EOLACvtfcHk0lg6mkFg4Rdr_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVCktLjL&md5=f3c3a4afb585f9d09b753b005d5b6428</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs13238-018-0602-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-018-0602-z%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DZ.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DDeveloping%2520potent%2520PROTACs%2520tools%2520for%2520selective%2520degradation%2520of%2520HDAC6%2520protein%26jtitle%3DProtein%2520Cell%26date%3D2019%26volume%3D10%26spage%3D606%26epage%3D609%26doi%3D10.1007%2Fs13238-018-0602-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 structure and molecular basis of catalysis and inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fnchembio.2134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27454933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=741-747&author=Y.+Haiauthor=D.+W.+Christianson&title=Histone+deacetylase+6+structure+and+molecular+basis+of+catalysis+and+inhibition&doi=10.1038%2Fnchembio.2134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 structure and molecular basis of catalysis and inhibition</span></div><div class="casAuthors">Hai, Yang; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">741-747</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is a crit. target for drug design because of its role in oncogenic transformation and cancer metastasis, and is unique among all histone deacetylases in that it contains tandem catalytic domains designated CD1 and CD2.  We now report the crystal structures of CD2 from Homo sapiens HDAC6 and of CD1 and CD2 from Danio rerio HDAC6.  We correlated these structures with activity measurements using 13 different substrates.  The catalytic activity of CD2 from both species exhibited broad substrate specificity, whereas that of CD1 was highly specific for substrates bearing C-terminal acetyllysine residues.  Crystal structures of substrate complexes yielded unprecedented snapshots of the catalytic mechanism.  Addnl., crystal structures of complexes with eight different inhibitors, including belinostat and panobinostat (currently used in cancer chemotherapy), the macrocyclic tetrapeptide HC toxin, and the HDAC6-specific inhibitor N-hydroxy-4-(2-((2-hydroxyethyl)(phenyl)amino)-2-oxoethyl)benzamide, revealed surprising new insight regarding changes in Zn2+ coordination and isoenzyme-specific inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqCfziGBHBRLVg90H21EOLACvtfcHk0lg6mkFg4Rdr_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ&md5=e167bc6f66e00923da4f2bced2b306b9</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2134%26sid%3Dliteratum%253Aachs%26aulast%3DHai%26aufirst%3DY.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHistone%2520deacetylase%25206%2520structure%2520and%2520molecular%2520basis%2520of%2520catalysis%2520and%2520inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D741%26epage%3D747%26doi%3D10.1038%2Fnchembio.2134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keusch, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melancon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helquist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthias, P.</span></span> <span> </span><span class="NLM_article-title">Structural insights into HDAC6 tubulin deacetylation and its selective inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fnchembio.2140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27454931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=748-754&author=Y.+Miyakeauthor=J.+J.+Keuschauthor=L.+Wangauthor=M.+Saitoauthor=D.+Hessauthor=X.+Wangauthor=B.+J.+Melanconauthor=P.+Helquistauthor=H.+Gutauthor=P.+Matthias&title=Structural+insights+into+HDAC6+tubulin+deacetylation+and+its+selective+inhibition&doi=10.1038%2Fnchembio.2140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into HDAC6 tubulin deacetylation and its selective inhibition</span></div><div class="casAuthors">Miyake, Yasuyuki; Keusch, Jeremy J.; Wang, Longlong; Saito, Makoto; Hess, Daniel; Wang, Xiaoning; Melancon, Bruce J.; Helquist, Paul; Gut, Heinz; Matthias, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">748-754</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors report crystal structures of zebrafish histone deacetylase 6 (HDAC6) catalytic domains in tandem or as single domains in complex with the (R) and (S) enantiomers of trichostatin A (TSA) or with the HDAC6-specific inhibitor, nexturastat A.  The tandem domains formed, together with the inter-domain linker, an ellipsoid-shaped complex with pseudo-twofold symmetry.  The authors identified important active site differences between both catalytic domains and revealed the binding mode of HDAC6 selective inhibitors.  HDAC inhibition assays with (R)- and (S)-TSA showed that (R)-TSA was a broad-range inhibitor, whereas (S)-TSA had moderate selectivity for HDAC6.  The authors identified a uniquely positioned α-helix and a flexible Trp residue in the loop joining α-helixes H20 to H21 as crit. for deacetylation of the physiol. substrate, tubulin.  Using single-mol. measurements and biochem. assays, the authors demonstrated that HDAC6 catalytic domain 2 deacetylated α-tubulin Lys-40 in the lumen of microtubules, but that its preferred substrate was unpolymd. tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpERJRurS1cC7Vg90H21EOLACvtfcHk0ljpoAGbfXPDiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rM&md5=4abe529ab89615df33f54350a1a8c69a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2140%26sid%3Dliteratum%253Aachs%26aulast%3DMiyake%26aufirst%3DY.%26aulast%3DKeusch%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMelancon%26aufirst%3DB.%2BJ.%26aulast%3DHelquist%26aufirst%3DP.%26aulast%3DGut%26aufirst%3DH.%26aulast%3DMatthias%26aufirst%3DP.%26atitle%3DStructural%2520insights%2520into%2520HDAC6%2520tubulin%2520deacetylation%2520and%2520its%2520selective%2520inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D748%26epage%3D754%26doi%3D10.1038%2Fnchembio.2140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4912</span>– <span class="NLM_lpage">4924</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00934</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00934" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Snsb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=4912-4924&author=J.+D.+Oskoauthor=D.+W.+Christianson&title=Structural+Basis+of+Catalysis+and+Inhibition+of+HDAC6+CD1%2C+the+Enigmatic+Catalytic+Domain+of+Histone+Deacetylase+6&doi=10.1021%2Facs.biochem.9b00934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6</span></div><div class="casAuthors">Osko, Jeremy D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">4912-4924</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is emerging as a target for inhibition in therapeutic strategies aimed at treating cancer, neurodegenerative disease, and other disorders.  Among the metal-dependent HDAC isoenzymes, HDAC6 is unique in that it contains two catalytic domains, CD1 and CD2.  CD2 is a tubulin deacetylase and a tau deacetylase, and the development of HDAC6-selective inhibitors has focused exclusively on this domain.  In contrast, there is a dearth of structural and functional information regarding CD1, which exhibits much narrower substrate specificity in comparison with CD2.  As the first step in addressing the CD1 information gap, we now present X-ray crystal structures of seven inhibitor complexes with wild-type, Y363F, and K330L HDAC6 CD1.  These structures broaden our understanding of mol. features important for catalysis and inhibitor binding.  The active site of HDAC6 CD1 is wider than that of CD2, which is unexpected in view of the narrow substrate specificity of CD1.  Amino acid substitutions between HDAC6 CD1 and CD2, as well as conformational differences in conserved residues, define striking differences in active site contours.  Catalytic activity measurements with HDAC6 CD1 confirm the preference for peptide substrates contg. C-terminal acetyllysine residues.  However, these measurements also show that CD1 exhibits weak activity for peptide substrates bearing certain small amino acids on the carboxyl side of the scissile acetyllysine residue.  Taken together, these results establish a foundation for understanding the structural basis of HDAC6 CD1 catalysis and inhibition, pointing to possible avenues for the development of HDAC6 CD1-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk6bd_6kU9erVg90H21EOLACvtfcHk0ljpoAGbfXPDiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Snsb3P&md5=4bebfc15825270bceeb7b87ca61c0f10</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00934%26sid%3Dliteratum%253Aachs%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructural%2520Basis%2520of%2520Catalysis%2520and%2520Inhibition%2520of%2520HDAC6%2520CD1%252C%2520the%2520Enigmatic%2520Catalytic%2520Domain%2520of%2520Histone%2520Deacetylase%25206%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D4912%26epage%3D4924%26doi%3D10.1021%2Facs.biochem.9b00934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">13459</span>– <span class="NLM_lpage">13464</span>, <span class="refDoi"> DOI: 10.1073/pnas.1718823114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1073%2Fpnas.1718823114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29203661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWgsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=13459-13464&author=N.+J.+Porterauthor=A.+Mahendranauthor=R.+Breslowauthor=D.+W.+Christianson&title=Unusual+zinc-binding+mode+of+HDAC6-selective+hydroxamate+inhibitors&doi=10.1073%2Fpnas.1718823114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors</span></div><div class="casAuthors">Porter, Nicholas J.; Mahendran, Adaickapillai; Breslow, Ronald; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">13459-13464</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) regulate myriad cellular processes by catalyzing the hydrolysis of acetyl-L-lysine residues in histone and nonhistone proteins.  The Zn2+-dependent class IIb enzyme HDAC6 regulates microtubule function by deacetylating α-tubulin, which suppresses microtubule dynamics and leads to cell cycle arrest and apoptosis.  Accordingly, HDAC6 is a target for the development of selective inhibitors that might be useful in new therapeutic approaches for the treatment of cancer, neurodegenerative diseases, and other disorders.  Here, we present high-resoln. structures of catalytic domain 2 from Danio rerio HDAC6 (henceforth simply "HDAC6") complexed with compds. that selectively inhibit HDAC6 while maintaining nanomolar inhibitory potency: N-hydroxy-4-((N(2-hydroxyethyl)-2-phenylacetamido)methyl)-benzamide (HPB), ACY-1215 (Ricolinostat), and ACY-1083.  These structures reveal that an unusual monodentate Zn2+ coordination mode is exploited by sterically bulky HDAC6-selective phenylhydroxamate inhibitors.  We addnl. report the ultrahigh-resoln. structure of the HDAC6-trichostatin A complex, which reveals two Zn2+-binding conformers for the inhibitor: a major conformer (70%) with canonical bidentate hydroxamate-Zn2+ coordination geometry and a minor conformer (30%) with monodentate hydroxamate-Zn2+ coordination geometry, reflecting a free energy difference of only 0.5 kcal/mol.  The minor conformer is not visible in lower resoln. structure detns.  Structural comparisons of HDAC6-inhibitor complexes with class I HDACs suggest active site features that contribute to the isoenzyme selectivity obsd. in biochem. assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0oUH1X_04p7Vg90H21EOLACvtfcHk0ljpoAGbfXPDiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWgsrbI&md5=07180756239eac4891642cf59a2e6992</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1718823114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1718823114%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DMahendran%26aufirst%3DA.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DUnusual%2520zinc-binding%2520mode%2520of%2520HDAC6-selective%2520hydroxamate%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D13459%26epage%3D13464%26doi%3D10.1073%2Fpnas.1718823114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayana
Reddy, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rokka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvino, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01540</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01540" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12jsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=295-308&author=J.+D.+Oskoauthor=N.+J.+Porterauthor=P.+A.+Narayana%0AReddyauthor=Y.+C.+Xiaoauthor=J.+Rokkaauthor=M.+Jungauthor=J.+M.+Hookerauthor=J.+M.+Salvinoauthor=D.+W.+Christianson&title=Exploring+Structural+Determinants+of+Inhibitor+Affinity+and+Selectivity+in+Complexes+with+Histone+Deacetylase+6&doi=10.1021%2Facs.jmedchem.9b01540"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6</span></div><div class="casAuthors">Osko, Jeremy D.; Porter, Nicholas J.; Narayana Reddy, Poli Adi; Xiao, You-Cai; Rokka, Johanna; Jung, Manfred; Hooker, Jacob M.; Salvino, Joseph M.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">295-308</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of histone deacetylase 6 (HDAC6) has emerged as a promising therapeutic strategy for the treatment of cancer, chemotherapy-induced peripheral neuropathy, and neurodegenerative disease.  The recent X-ray crystal structure detn. of HDAC6 enables an understanding of structural features directing affinity and selectivity in the active site.  Here, we present the X-ray crystal structures of five HDAC6-inhibitor complexes that illuminate key mol. features of the inhibitor linker and capping groups that facilitate and differentiate binding to HDAC6.  In particular, arom. and heteroarom. linkers nestle within an arom. cleft defined by F583 and F643, and different arom. linkers direct the capping group toward shallow pockets defined by the L1 loop, the L2 loop, or somewhere in between these pockets.  These results expand our understanding of factors contributing to the selective inhibition of HDAC6, particularly regarding interactions that can be targeted in the region of the L2 pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBosfiCC-DubVg90H21EOLACvtfcHk0ljfwQGgV2Kq7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit12jsr3N&md5=0ebd3729b8a0ed03629c4ecca475b02e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01540%26sid%3Dliteratum%253Aachs%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DNarayana%2BReddy%26aufirst%3DP.%2BA.%26aulast%3DXiao%26aufirst%3DY.%2BC.%26aulast%3DRokka%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DSalvino%26aufirst%3DJ.%2BM.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DExploring%2520Structural%2520Determinants%2520of%2520Inhibitor%2520Affinity%2520and%2520Selectivity%2520in%2520Complexes%2520with%2520Histone%2520Deacetylase%25206%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D295%26epage%3D308%26doi%3D10.1021%2Facs.jmedchem.9b01540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127023</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmcl.2020.127023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32067866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFGqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127023&author=J.+D.+Oskoauthor=D.+W.+Christianson&title=Structural+determinants+of+affinity+and+selectivity+in+the+binding+of+inhibitors+to+histone+deacetylase+6&doi=10.1016%2Fj.bmcl.2020.127023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6</span></div><div class="casAuthors">Osko, Jeremy D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">127023</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review. Digest.  Histone deacetylase 6 (HDAC6) is assocd. with multiple neurol. disorders as well as aggressive cancers, making its selective inhibition highly desirable for therapeutic purposes.  The basic mol. design of an effective HDAC6 inhibitor consists of a zinc-binding group, a linker, and a capping group capable of making interactions at the mouth of the active site.  To date, more than 50 high-resoln. X-ray crystal structures of HDAC6-inhibitor complexes have been reported, many of which reveal intermol. interactions that contribute to isoenzyme affinity and selectivity.  Here, we review the key features of HDAC6 inhibitor design illuminated by these structural studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEHMdvmF9TPLVg90H21EOLACvtfcHk0ljfwQGgV2Kq7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFGqs70%253D&md5=df46fa5e4720d8340d728e6269dadb90</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127023%26sid%3Dliteratum%253Aachs%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructural%2520determinants%2520of%2520affinity%2520and%2520selectivity%2520in%2520the%2520binding%2520of%2520inhibitors%2520to%2520histone%2520deacetylase%25206%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127023%26doi%3D10.1016%2Fj.bmcl.2020.127023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span> <span> </span><span class="NLM_article-title">Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">112887</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2020.112887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=33035922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOqsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2021&pages=112887&author=M.+T.+Tavaresauthor=A.+P.+Kozikowskiauthor=S.+Shen&title=Mercaptoacetamide%3A+A+promising+zinc-binding+group+for+the+discovery+of+selective+histone+deacetylase+6+inhibitors&doi=10.1016%2Fj.ejmech.2020.112887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors</span></div><div class="casAuthors">Tavares, Mauricio T.; Kozikowski, Alan P.; Shen, Sida</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112887</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is a zinc-dependent HDAC that mainly modulates the acetylation status of non-histone substrates, such as α-tubulin and heat shock protein 90 (HSP90).  The activity of HDAC6 plays a crit. role in cell proliferation, protein trafficking and degrdn., cell shape, migration, as well as regulation of immunomodulatory factors.  For this reason, HDAC6 influences the progress of cancers, neurodegenerative disorders, and autoimmune responses.  In the last few years, the discovery of selective HDAC6 inhibitors (HDAC6is) has become an attractive research area as five HDAC6is are being investigated in phase I/II clin. trials.  However, the hydroxamic acid functional group still represents the predominant zinc-binding group (ZBG), that often suffers from poor pharmacokinetics and mutagenic potential, thus impairing the application of hydroxamate-based HDAC6is for long-term therapies.  On the other hand, mercaptoacetamide (MCA)-based HDAC6is comprise a class of compds. that, in some cases, display nanomolar HDAC6 potency and a thousand-fold selectivity over class I HDAC isoenzymes.  Moreover, MCA-based HDAC6is lack the mutagenicity assocd. with the hydroxamate function and display pharmacol. effects, demonstrating the potential of this particular ZBG to improve upon the drug-like properties of HDAC6is.  Herein, we summarize for the first time the structure-activity relationships (SARs) of MCA-based HDAC6is, discuss their HDAC6 selectivity at the mol. level using inhibitor-HDAC co-crystal structures, and further provide our perspective regarding their drug metab., pharmacokinetics, and pharmacol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxMKQVo-QIlrVg90H21EOLACvtfcHk0ljfwQGgV2Kq7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOqsbfJ&md5=54ac6badbc1575a7295a84db3934d6f3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112887%26sid%3Dliteratum%253Aachs%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DShen%26aufirst%3DS.%26atitle%3DMercaptoacetamide%253A%2520A%2520promising%2520zinc-binding%2520group%2520for%2520the%2520discovery%2520of%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D209%26spage%3D112887%26doi%3D10.1016%2Fj.ejmech.2020.112887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. P.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the discovery of potent and selective HDAC6 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1406</span>– <span class="NLM_lpage">1418</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.10.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2017.10.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29133060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2ntbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1406-1418&author=X.+X.+Wangauthor=R.+Z.+Wanauthor=Z.+P.+Liu&title=Recent+advances+in+the+discovery+of+potent+and+selective+HDAC6+inhibitors&doi=10.1016%2Fj.ejmech.2017.10.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the discovery of potent and selective HDAC6 inhibitors</span></div><div class="casAuthors">Wang, Xiu-Xiu; Wan, Ren-Zhong; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1406-1418</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase HDAC6, a member of the class IIb HDAC family, is unique among HDAC enzymes in having two active catalytic domains, and has unique physiol. function.  In addn. to the modification of histone, HDAC6 targets specific substrates including α-tubulin and HSP90, and are involved in protein trafficking and degrdn., cell shape and migration.  Selective HDAC6 inhibitors are an emerging class of pharmaceuticals due to the involvement of HDAC6 in different pathways related to neurodegenerative diseases, cancer, and immunol.  Therefore, extensive investigations have been made in the discovery of selective HDAC6 inhibitors.  Based on their different zinc binding groups (ZBGs), in this review, HDAC6 inhibitors are grouped as hydroxamic acids, a sulfur contg. ZBG based derivs. and other ZBG-derived compds., and their enzymic inhibitory activity, selectivity and other biol. activities are introduced and summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdsNBEWGhpCrVg90H21EOLACvtfcHk0ljfwQGgV2Kq7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2ntbrM&md5=f24fea971dbed247e1bb2568f85d1703</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.10.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.10.040%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BX.%26aulast%3DWan%26aufirst%3DR.%2BZ.%26aulast%3DLiu%26aufirst%3DZ.%2BP.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520of%2520potent%2520and%2520selective%2520HDAC6%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1406%26epage%3D1418%26doi%3D10.1016%2Fj.ejmech.2017.10.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Codd, R.</span></span> <span> </span><span class="NLM_article-title">Traversing the coordination chemistry and chemical biology of hydroxamic acids</span>. <i>Coord. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>252</i></span>,  <span class="NLM_fpage">1387</span>– <span class="NLM_lpage">1408</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2007.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ccr.2007.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvFyntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=252&publication_year=2008&pages=1387-1408&author=R.+Codd&title=Traversing+the+coordination+chemistry+and+chemical+biology+of+hydroxamic+acids&doi=10.1016%2Fj.ccr.2007.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Traversing the coordination chemistry and chemical biology of hydroxamic acids</span></div><div class="casAuthors">Codd, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">252</span>
        (<span class="NLM_cas:issue">12-14</span>),
    <span class="NLM_cas:pages">1387-1408</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hydroxamic acids, R CC(O)N(R N)OH (R C = alkyl/aryl; R N = alkyl/aryl or H), coordinate a wide variety of transition metal ions predominantly as the monoanionic hydroxamato or dianionic (R N = H) hydroximato O,O'-bidentate chelate.  Anal. of x-ray crystallog. data from 25 hydroxamato and 17 hydroximato mononuclear non-oxo-contg. complexes with bidentate O,O'-coordination from monohydroxamic acids shows a strong (R ≥ 0.92) pos. correlation between the metal ion radius and the M-OC or M-ON bond lengths; in almost all complexes, M-OC > M-ON.  A map of bond lengths in the second coordination sphere (C-N, C-O, N-O), compared to the corresponding bond lengths in free hydroxamic acids, provides insight into the dominant resonance structures of the coordinated ligands.  The diverse coordination chem. of hydroxamic acids is reflected in the groups of complexes which have been characterized by x-ray crystallog.: homo- and hetero-metallic complexes of higher nuclearity, metallacrowns, and Pt(II) and Pd(II) complexes, which show non-O,O'-type coordination modes.  The coordination chem. of hydroxamic acids is relevant in the context of chem. biol. since these bioligands: (i) coordinate metal sites in the Ni(II)-contg. metalloprotein, urease, and the Zn(II)-contg. metalloproteins, matrix metalloproteases (MMPs), carbonic anhydrase and tumor necrosis factor-α converting enzyme (TACE); and (ii) feature as the Fe(III)-binding functional groups in bacterially derived Fe(III) sequestration mols. called siderophores.  Each of (i) and (ii) couples into aspects of human medicine, in terms of hydroxamic acid-based inhibition of MMPs and related enzymes and the treatment of Fe(III) overload disease, which is currently treated using the mesylate salt of desferrioxamine B (DFOB), a linear trihydroxamic acid originally sourced from the soil bacterium, Streptomyces pilosus.  The x-ray crystal structure of Fe(III)-loaded DFOB (ferrioxamine B: FOB) bound to the iron-siderophore periplasmic transport protein from Escherichia coli (FhuD) shows that FOB adopts a chiral and geometric form in the binary FOB-FhuD complex that is distinct from that obsd. in free FOB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLPR-i9AgPHLVg90H21EOLACvtfcHk0lgG9op5FmztMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvFyntrg%253D&md5=1f9db151c02645e39493beae339adbcb</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2007.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2007.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DCodd%26aufirst%3DR.%26atitle%3DTraversing%2520the%2520coordination%2520chemistry%2520and%2520chemical%2520biology%2520of%2520hydroxamic%2520acids%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2008%26volume%3D252%26spage%3D1387%26epage%3D1408%26doi%3D10.1016%2Fj.ccr.2007.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marmion, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, K. B.</span></span> <span> </span><span class="NLM_article-title">Hydroxamic Acids - An Intriguing Family of Enzyme Inhibitors and Biomedical Ligands</span>. <i>Eur. J. Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>2004</i></span>,  <span class="NLM_fpage">3003</span>– <span class="NLM_lpage">3016</span>, <span class="refDoi"> DOI: 10.1002/ejic.200400221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fejic.200400221" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2004&publication_year=2004&pages=3003-3016&author=C.+J.+Marmionauthor=D.+Griffithauthor=K.+B.+Nolan&title=Hydroxamic+Acids+-+An+Intriguing+Family+of+Enzyme+Inhibitors+and+Biomedical+Ligands&doi=10.1002%2Fejic.200400221"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Fejic.200400221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejic.200400221%26sid%3Dliteratum%253Aachs%26aulast%3DMarmion%26aufirst%3DC.%2BJ.%26aulast%3DGriffith%26aufirst%3DD.%26aulast%3DNolan%26aufirst%3DK.%2BB.%26atitle%3DHydroxamic%2520Acids%2520-%2520An%2520Intriguing%2520Family%2520of%2520Enzyme%2520Inhibitors%2520and%2520Biomedical%2520Ligands%26jtitle%3DEur.%2520J.%2520Inorg.%2520Chem.%26date%3D2004%26volume%3D2004%26spage%3D3003%26epage%3D3016%26doi%3D10.1002%2Fejic.200400221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pikul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almstead, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchus, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhail, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snider, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taiwo, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunaway, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mieling, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janusz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang-Weigand, S.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Piperazine-Based Matrix Metalloproteinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1021/jm990366q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990366q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVSluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=369-380&author=M.+Chengauthor=B.+Deauthor=S.+Pikulauthor=N.+G.+Almsteadauthor=M.+G.+Natchusauthor=M.+V.+Anastasioauthor=S.+J.+McPhailauthor=C.+E.+Sniderauthor=Y.+O.+Taiwoauthor=L.+Chenauthor=C.+M.+Dunawayauthor=F.+Guauthor=M.+E.+Dowtyauthor=G.+E.+Mielingauthor=M.+J.+Januszauthor=S.+Wang-Weigand&title=Design+and+Synthesis+of+Piperazine-Based+Matrix+Metalloproteinase+Inhibitors&doi=10.1021%2Fjm990366q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Piperazine-Based Matrix Metalloproteinase Inhibitors</span></div><div class="casAuthors">Cheng, Menyan; De, Biswanath; Pikul, Stanislaw; Almstead, Neil G.; Natchus, Michael G.; Anastasio, Melanie V.; McPhail, Sara J.; Snider, Catherine E.; Taiwo, Yetunde O.; Chen, Longyin; Dunaway, C. Michelle; Gu, Fei; Dowty, Martin E.; Mieling, Glen E.; Janusz, Michael J.; Wang-Weigand, Sherry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">369-380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new generation of cyclic matrix metalloproteinase (MMP) inhibitors derived from dl-piperazinecarboxylic acid was described.  The design involves: incorporation of hydroxamic acid as the bidentate chelating agent for catalytic Zn2+, placement of a sulfonamide group at the 1N-position of the piperazine ring to fill the S1' pocket of the enzyme, and finally attachment of diverse functional groups at the 4N-position to optimize potency and peroral absorption.  A unique combination of all three elements produced 3-[(hydroxyamino)carbonyl]-4-[(4-methoxyphenyl)sulfonyl]-1-piperazinecarboxylic acid phenylmethyl ester with high affinity for MMP-1, MMP-3, MMP-9, and MMP-13 (24, 18, 1.9, and 1.3 nM, resp.).  X-ray crystallog. data obtained for MMP-3 co-crystd. with 3-[(hydroxyamino)carbonyl]-4-[(4-methoxyphenyl)sulfonyl]-1-piperazinecarboxylic acid phenylmethyl ester gave detailed information on key binding interactions defining an overall scaffold geometry for piperazine-based MMP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9QAn3BVmNX7Vg90H21EOLACvtfcHk0lgG9op5FmztMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVSluw%253D%253D&md5=471d82becec78b52f34b755a9ad7484c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm990366q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990366q%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DDe%26aufirst%3DB.%26aulast%3DPikul%26aufirst%3DS.%26aulast%3DAlmstead%26aufirst%3DN.%2BG.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DAnastasio%26aufirst%3DM.%2BV.%26aulast%3DMcPhail%26aufirst%3DS.%2BJ.%26aulast%3DSnider%26aufirst%3DC.%2BE.%26aulast%3DTaiwo%26aufirst%3DY.%2BO.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDunaway%26aufirst%3DC.%2BM.%26aulast%3DGu%26aufirst%3DF.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DMieling%26aufirst%3DG.%2BE.%26aulast%3DJanusz%26aufirst%3DM.%2BJ.%26aulast%3DWang-Weigand%26aufirst%3DS.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Piperazine-Based%2520Matrix%2520Metalloproteinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D369%26epage%3D380%26doi%3D10.1021%2Fjm990366q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel benzofuroxan-based pyrrolidine hydroxamates as matrix metalloproteinase inhibitors with nitric oxide releasing activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4363</span>– <span class="NLM_lpage">4374</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmc.2018.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30093347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGitrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4363-4374&author=H.+Zhangauthor=X.+Wangauthor=J.+Maoauthor=Y.+Huangauthor=W.+Xuauthor=Y.+Duanauthor=J.+Zhang&title=Synthesis+and+biological+evaluation+of+novel+benzofuroxan-based+pyrrolidine+hydroxamates+as+matrix+metalloproteinase+inhibitors+with+nitric+oxide+releasing+activity&doi=10.1016%2Fj.bmc.2018.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel benzofuroxan-based pyrrolidine hydroxamates as matrix metalloproteinase inhibitors with nitric oxide releasing activity</span></div><div class="casAuthors">Zhang, Hao; Wang, Xuejian; Mao, Jing; Huang, Yongxue; Xu, Wenfang; Duan, Yu; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4363-4374</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">On the basis of the strategy of "multifunctional drugs", a series of novel matrix metalloproteinase inhibitors (MMPIs) contg. benzofuroxan scaffold as a nitric oxide donor were designed, synthesized and evaluated.  All synthesized compds., esp. 16a (5-(6)-(((3S,5S)-5-(hydroxycarbamoyl)-1-((4-phenoxyphenyl)sulfonyl)pyrrolidin-3-yl)carbamoyl)benzo[c][1,2,5]oxadiazole 1-oxide), exhibited potent MMP-2,-9 inhibitory activities, anti-proliferative activities and could produce high levels of NO in Hela cells.  They were also evaluated for both of their anti-invasion and anti-angiogenesis effects.  Furthermore, compared with LY52, 16a demonstrated competitive antitumor activity in vivo.  These hybrid NO-MMPIs might offer suitable scaffolds to develop valuable MMP inhibitors for the further discovery of novel anti-cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCsBjuGxdEzLVg90H21EOLACvtfcHk0lh2vtxVXdTBdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGitrzJ&md5=cdf427e8768cdfe55f5c314ea0e6e229</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520benzofuroxan-based%2520pyrrolidine%2520hydroxamates%2520as%2520matrix%2520metalloproteinase%2520inhibitors%2520with%2520nitric%2520oxide%2520releasing%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4363%26epage%3D4374%26doi%3D10.1016%2Fj.bmc.2018.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vannini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filocamo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavola, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renzoni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paolini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallinari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinkuhler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marco, S.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">15064</span>– <span class="NLM_lpage">15069</span>, <span class="refDoi"> DOI: 10.1073/pnas.0404603101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1073%2Fpnas.0404603101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=15477595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVShurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=15064-15069&author=A.+Vanniniauthor=C.+Volpariauthor=G.+Filocamoauthor=E.+C.+Casavolaauthor=M.+Brunettiauthor=D.+Renzoniauthor=P.+Chakravartyauthor=C.+Paoliniauthor=R.+De+Francescoauthor=P.+Gallinariauthor=C.+Steinkuhlerauthor=S.+Di+Marco&title=Crystal+structure+of+a+eukaryotic+zinc-dependent+histone+deacetylase%2C+human+HDAC8%2C+complexed+with+a+hydroxamic+acid+inhibitor&doi=10.1073%2Fpnas.0404603101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor</span></div><div class="casAuthors">Vannini, Alessandro; Volpari, Cinzia; Filocamo, Gessica; Casavola, Elena Caroli; Brunetti, Mirko; Renzoni, Debora; Chakravarty, Prasun; Paolini, Chantal; De Francesco, Raffaele; Gallinari, Paola; Steinkuehler, Christian; Di Marco, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">15064-15069</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a family of enzymes involved in the regulation of gene expression, DNA repair, and stress response.  These processes often are altered in tumors, and HDAC inhibitors have had pronounced antitumor activity with promising results in clin. trials.  Here, we report the crystal structure of human HDAC8 in complex with a hydroxamic acid inhibitor.  Such a structure of a eukaryotic zinc-dependent HDAC has not be described previously.  Similar to bacterial HDAC-like protein, HDAC8 folds in a single α/β domain.  The inhibitor and the zinc-binding sites are similar in both proteins.  However, significant differences are obsd. in the length and structure of the loops surrounding the active site, including the presence of two potassium ions in HDAC8 structure, one of which interacts with key catalytic residues.  CD data suggest a direct role of potassium in the fold stabilization of HDAC8.  Knockdown of HDAC8 by RNA interference inhibits growth of human lung, colon, and cervical cancer cell lines, highlighting the importance of this HDAC subtype for tumor cell proliferation.  Our findings open the way for the design and development of selective inhibitors of HDAC8 as possible antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs_auq2Wf8RLVg90H21EOLACvtfcHk0lh2vtxVXdTBdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVShurY%253D&md5=86bf33830743d2169514f686b7a30ed8</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0404603101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0404603101%26sid%3Dliteratum%253Aachs%26aulast%3DVannini%26aufirst%3DA.%26aulast%3DVolpari%26aufirst%3DC.%26aulast%3DFilocamo%26aufirst%3DG.%26aulast%3DCasavola%26aufirst%3DE.%2BC.%26aulast%3DBrunetti%26aufirst%3DM.%26aulast%3DRenzoni%26aufirst%3DD.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DPaolini%26aufirst%3DC.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DGallinari%26aufirst%3DP.%26aulast%3DSteinkuhler%26aufirst%3DC.%26aulast%3DDi%2BMarco%26aufirst%3DS.%26atitle%3DCrystal%2520structure%2520of%2520a%2520eukaryotic%2520zinc-dependent%2520histone%2520deacetylase%252C%2520human%2520HDAC8%252C%2520complexed%2520with%2520a%2520hydroxamic%2520acid%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D15064%26epage%3D15069%26doi%3D10.1073%2Fpnas.0404603101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finnin, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donigian, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rifkind, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">Structures of a histone deacetylase homologue bound to theTSA and SAHA inhibitoors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>401</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1038/43710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2F43710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10490031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=1999&pages=188-193&author=M.+S.+Finninauthor=J.+R.+Donigianauthor=A.+Cohenauthor=V.+M.+Richonauthor=R.+A.+Rifkindauthor=P.+A.+Marksauthor=R.+Breslowauthor=N.+P.+Pavletich&title=Structures+of+a+histone+deacetylase+homologue+bound+to+theTSA+and+SAHA+inhibitoors&doi=10.1038%2F43710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors</span></div><div class="casAuthors">Finnin, Michael S.; Donigian, Jill R.; Cohen, Alona; Richon, Victoria M.; Rifkind, Richard A.; Marks, Paul A.; Breslow, Ronald; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">401</span>
        (<span class="NLM_cas:issue">6749</span>),
    <span class="NLM_cas:pages">188-193</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression.  HDACs are involved in cell-cycle progression and differentiation, and their deregulation is assocd. with several cancers.  HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumor effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumors in mice models, and they are effective in the treatment of promyelocytic leukemia.  Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homolog from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA.  The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition.  The residues that make up the active site and contact the inhibitors are conserved across the HDAC family.  These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrG0lsZMMo37Vg90H21EOLACvtfcHk0lh2vtxVXdTBdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D&md5=29bbc6d3ba9a9d2a8c330349ae8199a8</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2F43710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F43710%26sid%3Dliteratum%253Aachs%26aulast%3DFinnin%26aufirst%3DM.%2BS.%26aulast%3DDonigian%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DStructures%2520of%2520a%2520histone%2520deacetylase%2520homologue%2520bound%2520to%2520theTSA%2520and%2520SAHA%2520inhibitoors%26jtitle%3DNature%26date%3D1999%26volume%3D401%26spage%3D188%26epage%3D193%26doi%3D10.1038%2F43710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogier, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canavese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span> <span> </span><span class="NLM_article-title">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2579</span>– <span class="NLM_lpage">2589</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-10-387365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1182%2Fblood-2011-10-387365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=22262760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2579-2589&author=L.+Santoauthor=T.+Hideshimaauthor=A.+L.+Kungauthor=J.-C.+Tsengauthor=D.+Tamangauthor=M.+Yangauthor=M.+Jarpeauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=W.+C.+Ogierauthor=D.+Cirsteaauthor=S.+Rodigauthor=H.+Edaauthor=T.+Scullenauthor=M.+Canaveseauthor=J.+Bradnerauthor=K.+C.+Andersonauthor=S.+S.+Jonesauthor=N.+Raje&title=Preclinical+activity%2C+pharmacodynamic%2C+and+pharmacokinetic+properties+of+a+selective+HDAC6+inhibitor%2C+ACY-1215%2C+in+combination+with+bortezomib+in+multiple+myeloma&doi=10.1182%2Fblood-2011-10-387365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span></div><div class="casAuthors">Santo, Loredana; Hideshima, Teru; Kung, Andrew L.; Tseng, Jen-Chieh; Tamang, David; Yang, Min; Jarpe, Matthew; van Duzer, John H.; Mazitschek, Ralph; Ogier, Walter C.; Cirstea, Diana; Rodig, Scott; Eda, Homare; Scullen, Tyler; Canavese, Miriam; Bradner, James; Anderson, Kenneth C.; Jones, Simon S.; Raje, Noopur</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2579-2589</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) enzymic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM).  Therefore, HDAC inhibitors used alone and in combination are being actively studied as novel therapies in MM.  In the present study, we investigated the preclin. activity of ACY-1215, an HDAC6-selective inhibitor, alone and in combination with bortezomib in MM.  Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase.  In vivo, the anti-MM activity of ACY-1215 in combination with bortezomib was confirmed using 2 different xenograft SCID mouse models: human MM injected s.c. (the plasmacytoma model) and luciferase-expressing human MM injected i.v. (the disseminated MM model).  Tumor growth was significantly delayed and overall survival was significantly prolonged in animals treated with the combination therapy.  Pharmacokinetic data showed peak plasma levels of ACY-1215 at 4 h after treatment coincident with an increase in acetylated α-tubulin, a marker of HDAC6 inhibition, by immunohistochem. and Western blot anal.  These studies provide preclin. rationale for acetylated α-tubulin use as a pharmacodynamic biomarker in future clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoelmsk1wo_LVg90H21EOLACvtfcHk0lihiXLHreU1qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D&md5=094298bdd3d5b91c7060d8b294857846</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-10-387365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-10-387365%26sid%3Dliteratum%253Aachs%26aulast%3DSanto%26aufirst%3DL.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DTseng%26aufirst%3DJ.-C.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DOgier%26aufirst%3DW.%2BC.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DEda%26aufirst%3DH.%26aulast%3DScullen%26aufirst%3DT.%26aulast%3DCanavese%26aufirst%3DM.%26aulast%3DBradner%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DRaje%26aufirst%3DN.%26atitle%3DPreclinical%2520activity%252C%2520pharmacodynamic%252C%2520and%2520pharmacokinetic%2520properties%2520of%2520a%2520selective%2520HDAC6%2520inhibitor%252C%2520ACY-1215%252C%2520in%2520combination%2520with%2520bortezomib%2520in%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2579%26epage%3D2589%26doi%3D10.1182%2Fblood-2011-10-387365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeciga-Pinto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span> <span> </span><span class="NLM_article-title">Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2694</span>– <span class="NLM_lpage">2707</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.18632%2Foncotarget.13738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27926524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BC2sjksVSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=2694-2707&author=P.+Huangauthor=I.+Almeciga-Pintoauthor=M.+Jarpeauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=M.+Yangauthor=S.+S.+Jonesauthor=S.+N.+Quayle&title=Selective+HDAC+inhibition+by+ACY-241+enhances+the+activity+of+paclitaxel+in+solid+tumor+models&doi=10.18632%2Foncotarget.13738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models</span></div><div class="casAuthors">Huang Pengyu; Almeciga-Pinto Ingrid; Jarpe Matthew; van Duzer John H; Yang Min; Jones Simon S; Quayle Steven N; Mazitschek Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2694-2707</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242).  Like the structurally related drug ACY-1215 (ricolinostat), ACY-241 has the potential for a substantially reduced side effect profile versus current nonselective HDAC inhibitor drug candidates due to reduced potency against Class I HDACs while retaining the potential for anticancer effectiveness.  We now show that combination treatment of xenograft models with paclitaxel and either ricolinostat or ACY-241 significantly suppresses solid tumor growth.  In cell lines from multiple solid tumor lineages, combination treatment with ACY-241 and paclitaxel enhanced inhibition of proliferation and increased cell death relative to either single agent alone.  Combination treatment with ACY-241 and paclitaxel also resulted in more frequent occurrence of mitotic cells with abnormal multipolar spindles and aberrant mitoses, consistent with the observed increase of aneuploid cells.  At the molecular level, multipolar mitotic spindle formation was observed to be NuMA-dependent and γ-tubulin independent, suggesting that treatment-induced multipolar spindle formation does not depend on centrosomal amplification.  The significantly enhanced efficacy of ACY-241 plus paclitaxel observed here, in addition to the anticipated superior safety profile of a selective HDAC6 inhibitor versus pan-HDAC inhibitors, provides a strong rationale for clinical development of this combination in patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFLMaYGUFFIBfKb6ELK8t0fW6udTcc2ebpIArHihlpX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjksVSmuw%253D%253D&md5=b8a516375b03fc65536598ab9c0e4a21</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13738%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DAlmeciga-Pinto%26aufirst%3DI.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26atitle%3DSelective%2520HDAC%2520inhibition%2520by%2520ACY-241%2520enhances%2520the%2520activity%2520of%2520paclitaxel%2520in%2520solid%2520tumor%2520models%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D2694%26epage%3D2707%26doi%3D10.18632%2Foncotarget.13738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span> <span> </span><span class="NLM_article-title">Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">817</span>, <span class="refDoi"> DOI: 10.1038/s41419-018-0788-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fs41419-018-0788-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30050135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3c7itlKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=817&author=J.+Caoauthor=W.+Lvauthor=L.+Wangauthor=J.+Xuauthor=P.+Yuanauthor=S.+Huangauthor=Z.+Heauthor=J.+Hu&title=Ricolinostat+%28ACY-1215%29+suppresses+proliferation+and+promotes+apoptosis+in+esophageal+squamous+cell+carcinoma+via+miR-30d%2FPI3K%2FAKT%2FmTOR+and+ERK+pathways&doi=10.1038%2Fs41419-018-0788-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways</span></div><div class="casAuthors">Cao Jinlin; Lv Wang; Wang Luming; Xu Jinming; Yuan Ping; Huang Sha; He Zhehao; Hu Jian</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">817</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ricolinostat (ACY-1215), a first-in-class selective HDAC6 inhibitor, exhibits antitumor effects alone or in combination with other drugs in various cancers.  However, its efficacy in esophageal cancer remains unclear.  In this study, we found that the high expression of HDAC6 was associated with poor prognosis in esophageal squamous cell carcinoma (ESCC) tissues.  Then, we identified that ACY-1215 significantly inhibited cellular proliferation in ESCC, and caused G2/M phase arrest and apoptosis.  We further demonstrated that ACY-1215 treatment reduced the expression of PI3K, P-AKT, P-mTOR, and P-ERK1/2 and increased that of Ac-H3K9 and Ac-H4K8.  In addition, using miRNA microarray and bioinformatics analysis, we detected that ACY-1215 promoted miR-30d expression, and PI3K regulatory subunit 2 (PIK3R2) was a direct target of miR-30d.  Anti-miR-30d partially rescued the G2/M phase arrest and apoptosis caused by ACY-1215 treatment.  The reductions in PI3K, P-AKT, and P-mTOR expression were also partially reversed by miR-30d inhibitor.  Furthermore, the effects of ACY-1215 inhibited ESCC proliferation were validated in a mouse xenograft model in vivo.  In conclusion, our study showed that ACY-1215 suppressed proliferation and promoted apoptosis in ESCC via miR-30d/PI3K/AKT/mTOR and ERK pathways and that ACY-1215 may be a promising antitumor agent in ESCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIrxW4JKD57hwLZxei1HN8fW6udTcc2ebpIArHihlpX7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7itlKktw%253D%253D&md5=574b62b346c61c362303e49c7c1311d5</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fs41419-018-0788-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-018-0788-2%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DJ.%26atitle%3DRicolinostat%2520%2528ACY-1215%2529%2520suppresses%2520proliferation%2520and%2520promotes%2520apoptosis%2520in%2520esophageal%2520squamous%2520cell%2520carcinoma%2520via%2520miR-30d%252FPI3K%252FAKT%252FmTOR%2520and%2520ERK%2520pathways%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2018%26volume%3D9%26spage%3D817%26doi%3D10.1038%2Fs41419-018-0788-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1111/jnc.14849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1111%2Fjnc.14849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31390677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1aqsb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2020&pages=221-234&author=Z.+Huangauthor=Y.+Xiaauthor=K.+Huauthor=S.+Zengauthor=L.+Wuauthor=S.+Liuauthor=C.+Zhiauthor=M.+Laiauthor=D.+Chenauthor=L.+Xieauthor=Z.+Yuan&title=Histone+deacetylase+6+promotes+growth+of+glioblastoma+through+the+MKK7%2FJNK%2Fc-Jun+signaling+pathway&doi=10.1111%2Fjnc.14849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway</span></div><div class="casAuthors">Huang, Ziyan; Xia, Yong; Hu, Kunhua; Zeng, Shulian; Wu, Liqiang; Liu, Sisi; Zhi, Cheng; Lai, Miaoling; Chen, Danmin; Xie, Longchang; Yuan, Zhongmin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-234</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) activity contributes to the malignant proliferation, invasion, and migration of glioma cells (GCs), but the mol. mechanisms underlying the processes remains elusive.  Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth.  Further investigation showed that these effects resulted from HDAC6 inhibitor-induced suppression of MAPK kinase 7 (MKK7), which was identified to be crit. for JNK activation and exerts the oncogenic roles in GCs.  Selectively silencing HDAC6 by siRNAs had the same responses, whereas transient transfections expressing HDAC6 promoted MKK7 expression.  Interestingly, by performing Q-PCR, HDAC6 inhibition did not cause a down-regulation of MKK7 mRNA level, whereas the suppressive effects on MKK7 protein can be efficiently blocked by the proteasomal inhibitor MG132.  As a further test, elevating MKK7-JNK activity was sufficient to rescue HDAC6 inhibitor-mediated-suppressive effects on c-Jun activation and the malignant features.  The suppression of both MKK7 expression and JNK/c-Jun activities was involved in the tumor-growth inhibitory effects induced by CAY10603 in U87-xenograft mice.  Collectively, our findings provide new insights into the mol. mechanism of glioma malignancy regarding HDAC6 in the selective regulation of MKK7 expression and JNK/c-Jun activity.  MKK7 protein stability critically depends on HDAC6 activity, and inhibition of HDAC6 probably presents a potential strategy for suppressing the oncogenic roles of MKK7/JNK/c-Jun axis in GCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV6ciEffisZrVg90H21EOLACvtfcHk0liNX1ovHXUHoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1aqsb%252FJ&md5=239541d1b4051ddaa1a5b7aa42d109d3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1111%2Fjnc.14849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.14849%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DZeng%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhi%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DZ.%26atitle%3DHistone%2520deacetylase%25206%2520promotes%2520growth%2520of%2520glioblastoma%2520through%2520the%2520MKK7%252FJNK%252Fc-Jun%2520signaling%2520pathway%26jtitle%3DJ.%2520Neurochem.%26date%3D2020%26volume%3D152%26spage%3D221%26epage%3D234%26doi%3D10.1111%2Fjnc.14849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adeegbe, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lizotte, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almonte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dries, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner-Hatten, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrillon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poudel-Neupane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerriero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awad, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span> <span> </span><span class="NLM_article-title">Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">852</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-1020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1158%2F2159-8290.CD-16-1020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=28408401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1GgsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=852-867&author=D.+O.+Adeegbeauthor=Y.+Liuauthor=P.+H.+Lizotteauthor=Y.+Kamiharaauthor=A.+R.+Arefauthor=C.+Almonteauthor=R.+Driesauthor=Y.+Liauthor=S.+Liuauthor=X.+Wangauthor=T.+Warner-Hattenauthor=J.+Castrillonauthor=G.+C.+Yuanauthor=N.+Poudel-Neupaneauthor=H.+Zhangauthor=J.+L.+Guerrieroauthor=S.+Hanauthor=M.+M.+Awadauthor=D.+A.+Barbieauthor=J.+Ritzauthor=S.+S.+Jonesauthor=P.+S.+Hammermanauthor=J.+Bradnerauthor=S.+N.+Quayleauthor=K.+K.+Wong&title=Synergistic+Immunostimulatory+Effects+and+Therapeutic+Benefit+of+Combined+Histone+Deacetylase+and+Bromodomain+Inhibition+in+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F2159-8290.CD-16-1020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Adeegbe, Dennis O.; Liu, Yan; Lizotte, Patrick H.; Kamihara, Yusuke; Aref, Amir R.; Almonte, Christina; Dries, Ruben; Li, Yuyang; Liu, Shengwu; Wang, Xiaoen; Warner-Hatten, Tiquella; Castrillon, Jessica; Yuan, Guo-Cheng; Poudel-Neupane, Neermala; Zhang, Haikuo; Guerriero, Jennifer L.; Han, Shiwei; Awad, Mark M.; Barbie, David A.; Ritz, Jerome; Jones, Simon S.; Hammerman, Peter S.; Bradner, James; Quayle, Steven N.; Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">852-867</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Effective therapies for non-small cell lung cancer (NSCLC) remain challenging despite an increasingly comprehensive understanding of somatically altered oncogenic pathways.  It is now clear that therapeutic agents with potential to impact the tumor immune microenvironment potentiate immune-orchestrated therapeutic benefit.  Herein, we evaluated the immunoregulatory properties of histone deacetylase (HDAC) and bromodomain inhibitors, two classes of drugs that modulate the epigenome, with a focus on key cell subsets that are engaged in an immune response.  By evaluating human peripheral blood and NSCLC tumors, we show that the selective HDAC6 inhibitor ricolinostat promotes phenotypic changes that support enhanced T-cell activation and improved function of antigen-presenting cells.  The bromodomain inhibitor JQ1 attenuated CD4+FOXP3+ T regulatory cell suppressive function and synergized with ricolinostat to facilitate immune-mediated tumor growth arrest, leading to prolonged survival of mice with lung adenocarcinomas.  Collectively, our findings highlight the immunomodulatory effects of two epigenetic modifiers that, together, promote T cell-mediated antitumor immunity and demonstrate their therapeutic potential for treatment of NSCLC.  Significance: Selective inhibition of HDACs and bromodomain proteins modulates tumor-assocd. immune cells in a manner that favors improved T-cell function and reduced inhibitory cellular mechanisms.  These effects facilitated robust antitumor responses in tumor-bearing mice, demonstrating the therapeutic potential of combining these epigenetic modulators for the treatment of NSCLC.  Cancer Discov; 7(8); 852-67. ©2017 AACR.  This article is highlighted in the In This Issue feature, p.  783.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqcW56lDCg-LVg90H21EOLACvtfcHk0lgzivX2LfWJ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1GgsrrP&md5=abb4406e10448c960a621df6505177cf</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-1020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-1020%26sid%3Dliteratum%253Aachs%26aulast%3DAdeegbe%26aufirst%3DD.%2BO.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLizotte%26aufirst%3DP.%2BH.%26aulast%3DKamihara%26aufirst%3DY.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DAlmonte%26aufirst%3DC.%26aulast%3DDries%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWarner-Hatten%26aufirst%3DT.%26aulast%3DCastrillon%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DG.%2BC.%26aulast%3DPoudel-Neupane%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGuerriero%26aufirst%3DJ.%2BL.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DRitz%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DBradner%26aufirst%3DJ.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DSynergistic%2520Immunostimulatory%2520Effects%2520and%2520Therapeutic%2520Benefit%2520of%2520Combined%2520Histone%2520Deacetylase%2520and%2520Bromodomain%2520Inhibition%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D852%26epage%3D867%26doi%3D10.1158%2F2159-8290.CD-16-1020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adeegbe, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dries, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buczkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span> <span> </span><span class="NLM_article-title">NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">3709</span>– <span class="NLM_lpage">3717</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-0161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1158%2F0008-5472.CAN-18-0161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29760044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1altbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=3709-3717&author=Y.+Liuauthor=Y.+Liauthor=S.+Liuauthor=D.+O.+Adeegbeauthor=C.+L.+Christensenauthor=M.+M.+Quinnauthor=R.+Driesauthor=S.+Hanauthor=K.+Buczkowskiauthor=X.+Wangauthor=T.+Chenauthor=P.+Gaoauthor=H.+Zhangauthor=F.+Liauthor=P.+S.+Hammermanauthor=J.+E.+Bradnerauthor=S.+N.+Quayleauthor=K.+K.+Wong&title=NK+Cells+Mediate+Synergistic+Antitumor+Effects+of+Combined+Inhibition+of+HDAC6+and+BET+in+a+SCLC+Preclinical+Model&doi=10.1158%2F0008-5472.CAN-18-0161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model</span></div><div class="casAuthors">Liu, Yan; Li, Yuyang; Liu, Shengwu; Adeegbe, Dennis O.; Christensen, Camilla L.; Quinn, Max M.; Dries, Ruben; Han, Shiwei; Buczkowski, Kevin; Wang, Xiaoen; Chen, Ting; Gao, Peng; Zhang, Hua; Li, Fei; Hammerman, Peter S.; Bradner, James E.; Quayle, Steven N.; Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3709-3717</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Small-cell lung cancer (SCLC) has the highest malignancy among all lung cancers, exhibiting aggressive growth and early metastasis to distant sites.  For 30 years, treatment options for SCLC have been limited to chemotherapy, warranting the need for more effective treatments.  Frequent inactivation of TP53 and RB1 as well as histone dysmodifications in SCLC suggest that transcriptional and epigenetic regulations play a major role in SCLC disease evolution.  Here we performed a synthetic lethal screen using the BET inhibitor JQ1 and an shRNA library targeting 550 epigenetic genes in treatment-refractory SCLC xenograft models and identified HDAC6 as a synthetic lethal target in combination with JQ1.  Combined treatment of human and mouse SCLC cell line-derived xenograft tumors with the HDAC6 inhibitor ricolinostat (ACY-1215) and JQ1 demonstrated significant inhibition of tumor growth; this effect was abolished upon depletion of NK cells, suggesting that these innate immune lymphoid cells play a role in SCLC tumor treatment response.  Collectively, these findings suggest a potential new treatment for recurrent SCLC.  Significance: These findings identify a novel therapeutic strategy for SCLC using a combination of HDAC6 and BET inhibitors.  Cancer Res; 78(13); 3709-17. 2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiaTtuegpOv7Vg90H21EOLACvtfcHk0lgzivX2LfWJ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1altbvP&md5=c254a1767c6ade0a7db7641ba7ed10d5</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-0161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-0161%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DAdeegbe%26aufirst%3DD.%2BO.%26aulast%3DChristensen%26aufirst%3DC.%2BL.%26aulast%3DQuinn%26aufirst%3DM.%2BM.%26aulast%3DDries%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DBuczkowski%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DNK%2520Cells%2520Mediate%2520Synergistic%2520Antitumor%2520Effects%2520of%2520Combined%2520Inhibition%2520of%2520HDAC6%2520and%2520BET%2520in%2520a%2520SCLC%2520Preclinical%2520Model%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D3709%26epage%3D3717%26doi%3D10.1158%2F0008-5472.CAN-18-0161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S. H.</span></span> <span> </span><span class="NLM_article-title">The HDAC6 inhibitor ACY1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">844</span>– <span class="NLM_lpage">854</span>, <span class="refDoi"> DOI: 10.3892/ijo.2018.4405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3892%2Fijo.2018.4405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29749542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2018&pages=844-854&author=D.+H.+Leeauthor=H.+R.+Wonauthor=H.+W.+Ryuauthor=J.+M.+Hanauthor=S.+H.+Kwon&title=The+HDAC6+inhibitor+ACY1215+enhances+the+anticancer+activity+of+oxaliplatin+in+colorectal+cancer+cells&doi=10.3892%2Fijo.2018.4405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The HDAC6 inhibitor ACY-1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells</span></div><div class="casAuthors">Lee, Dong Hoon; Won, Hye-Rim; Ryu, Hyun-Wook; Han, Jung Min; Kwon, So Hee</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">844-854</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">ACY-1215, also known as ricolinostat, is a leading histone deacetylase 6 inhibitor, which is currently being tested in clin. trials for hematol. malignancies.  Previous studies have reported that ACY-1215 is not potent enough as a monotherapy for the treatment of colorectal cancer (CRC), which generally requires combination therapy for successful treatment.  Therefore, the present study aimed to det. whether the synergistic interaction detected between ACY-1215 and anticancer agents in hematol. cancers could occur in solid tumors.  The results of the present study indicated that ACY-1215 exerted a potent synergistic anti-proliferative effect when used in combination with anticancer agents in CRC cells.  The combination of ACY-1215 and oxaliplatin was more potent than either drug alone, as indicated by an increase in apoptotic cells and their effects on the apoptotic pathway; ACY-1215 and oxaliplatin cotreatment activated caspase-3 and poly (ADP ribose) polymerase, increased B-cell lymphoma (Bcl)-2 homologous antagonist/killer expression, and decreased Bcl-extra large protein, phosphorylated-extracellular signal-regulated kinase and phosphorylated-protein kinase B expression.  In addn., combined treatment of ACY-1215 and anticancer agents induced synergistic upregulation of programmed death-ligand 1.  These findings suggested that a therapeutic strategy that combines ACY-1215 and oxaliplatin warrants attention for the treatment of solid tumors, including CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodrgw5rTr-hLVg90H21EOLACvtfcHk0lgzivX2LfWJ5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCru7g%253D&md5=ca18c069afe82350383d92de6c962c19</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.3892%2Fijo.2018.4405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2018.4405%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DWon%26aufirst%3DH.%2BR.%26aulast%3DRyu%26aufirst%3DH.%2BW.%26aulast%3DHan%26aufirst%3DJ.%2BM.%26aulast%3DKwon%26aufirst%3DS.%2BH.%26atitle%3DThe%2520HDAC6%2520inhibitor%2520ACY1215%2520enhances%2520the%2520anticancer%2520activity%2520of%2520oxaliplatin%2520in%2520colorectal%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2018%26volume%3D53%26spage%3D844%26epage%3D854%26doi%3D10.3892%2Fijo.2018.4405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forsythe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Refaat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khawaja, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkamp, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovici, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jithesh, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labonte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Schaeybroeck, S.</span></span> <span> </span><span class="NLM_article-title">The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1280</span>– <span class="NLM_lpage">1290</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1158%2F1535-7163.MCT-17-0603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29483217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1280-1290&author=N.+Forsytheauthor=A.+Refaatauthor=A.+Javadiauthor=H.+Khawajaauthor=J.+A.+Weirauthor=H.+Emamauthor=W.+L.+Allenauthor=F.+Burkampauthor=V.+Popoviciauthor=P.+V.+Jitheshauthor=C.+Isellaauthor=M.+J.+Labonteauthor=I.+G.+Millsauthor=P.+G.+Johnstonauthor=S.+Van+Schaeybroeck&title=The+Unfolded+Protein+Response%3A+A+Novel+Therapeutic+Target+for+Poor+Prognostic+BRAF+Mutant+Colorectal+Cancer&doi=10.1158%2F1535-7163.MCT-17-0603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer</span></div><div class="casAuthors">Forsythe, Nicholas; Refaat, Alaa; Javadi, Arman; Khawaja, Hajrah; Weir, Jessica-Anne; Emam, Heba; Allen, Wendy L.; Burkamp, Frank; Popovici, Vlad; Jithesh, Puthen V.; Isella, Claudio; Labonte, Melissa J.; Mills, Ian G.; Johnston, Patrick G.; Van Schaeybroeck, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1280-1290</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BRAFV600E mutations occur in ∼10% of colorectal cancer cases, are assocd. with poor survival, and have limited responses to BRAF/MEK inhibition with or without EGFR inhibition.  There is an unmet need to understand the biol. of poor prognostic BRAFMT colorectal cancer.  We have used differential gene expression and pathway analyses of untreated stage II and stage III BRAFMT (discovery set: n = 31; validation set: n = 26) colorectal cancer, and an siRNA screen to characterize the biol. underpinning the BRAFMT subgroup with poorest outcome.  These analyses identified the unfolded protein response (UPR) as a novel and druggable pathway assocd. with the BRAFMT colorectal cancer subgroup with poorest outcome.  We also found that oncogenic BRAF drives endoplasmic reticulum (ER) stress and UPR pathway activation through MEK/ERK.  Furthermore, inhibition of GRP78, the master regulator of the UPR, using siRNA or small mol. inhibition, resulted in acute ER stress and apoptosis, in particular in BRAFMT colorectal cancer cells.  In addn., dual targeting of protein degrdn. using combined Carfilzomib (proteasome inhibitor) and ACY-1215 (HDAC6-selective inhibitor) treatment resulted in marked accumulation of protein aggregates, acute ER stress, apoptosis, and therapeutic efficacy in BRAFMT in vitro and xenograft models.  Mechanistically, we found that the apoptosis following combined Carfilzomib/ACY-1215 treatment is mediated through increased CHOP expression.  Taken together, our findings indicate that oncogenic BRAF induces chronic ER stress and that inducers of acute ER stress could be a novel treatment strategy for poor prognostic BRAFMT colorectal cancer.  Mol Cancer Ther; 17(6); 1280-90. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojEaeZfSfm6rVg90H21EOLACvtfcHk0ljAGnsD41POeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsLzN&md5=ae28640f42ca299afe9c6299b083d387</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0603%26sid%3Dliteratum%253Aachs%26aulast%3DForsythe%26aufirst%3DN.%26aulast%3DRefaat%26aufirst%3DA.%26aulast%3DJavadi%26aufirst%3DA.%26aulast%3DKhawaja%26aufirst%3DH.%26aulast%3DWeir%26aufirst%3DJ.%2BA.%26aulast%3DEmam%26aufirst%3DH.%26aulast%3DAllen%26aufirst%3DW.%2BL.%26aulast%3DBurkamp%26aufirst%3DF.%26aulast%3DPopovici%26aufirst%3DV.%26aulast%3DJithesh%26aufirst%3DP.%2BV.%26aulast%3DIsella%26aufirst%3DC.%26aulast%3DLabonte%26aufirst%3DM.%2BJ.%26aulast%3DMills%26aufirst%3DI.%2BG.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26aulast%3DVan%2BSchaeybroeck%26aufirst%3DS.%26atitle%3DThe%2520Unfolded%2520Protein%2520Response%253A%2520A%2520Novel%2520Therapeutic%2520Target%2520for%2520Poor%2520Prognostic%2520BRAF%2520Mutant%2520Colorectal%2520Cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D1280%26epage%3D1290%26doi%3D10.1158%2F1535-7163.MCT-17-0603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan-Wasielewski, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulonis, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birrer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinopoulos, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. F.</span></span> <span> </span><span class="NLM_article-title">Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer</span>. <i>Gynecologic oncology reports</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.gore.2019.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.gore.2019.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31467965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3MrjsVOltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=118-122&author=E.+K.+Leeauthor=Z.+Tan-Wasielewskiauthor=U.+A.+Matulonisauthor=M.+J.+Birrerauthor=A.+A.+Wrightauthor=N.+Horowitzauthor=P.+A.+Konstantinopoulosauthor=J.+Curtisauthor=J.+F.+Liu&title=Results+of+an+abbreviated+Phase+Ib+study+of+the+HDAC6+inhibitor+ricolinostat+and+paclitaxel+in+recurrent+ovarian%2C+fallopian+tube%2C+or+primary+peritoneal+cancer&doi=10.1016%2Fj.gore.2019.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer</span></div><div class="casAuthors">Lee Elizabeth K; Matulonis Ursula A; Wright Alexi A; Konstantinopoulos Panagiotis A; Liu Joyce F; Tan-Wasielewski Zhenying; Matulonis Ursula A; Wright Alexi A; Horowitz Neil; Konstantinopoulos Panagiotis A; Curtis Jennifer; Liu Joyce F; Birrer Michael J; Horowitz Neil</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic oncology reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">118-122</span>
        ISSN:<span class="NLM_cas:issn">2352-5789</span>.
    </div><div class="casAbstract">Peripheral neuropathy is a common side effect of chemotherapeutic agents that frequently necessitates dose-reduction, truncation of, or change in therapy.  HDAC6 inhibition has demonstrated preclinical efficacy in preventing and/or reversing chemotherapy-induced peripheral neuropathy and furthermore has demonstrated synergistic antitumor activity with various chemotherapies.  Here, we report the abbreviated results of a Phase Ib trial of ricolinostat, an HDAC6-specific inhibitor, in combination with paclitaxel, in the treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZvz9w1O_ds2BAiYWy6n3SfW6udTcc2eaHB1QnI7QfgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrjsVOltg%253D%253D&md5=d3b9607e4cab2217a5f2c28c7fef4e32</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.gore.2019.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gore.2019.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DE.%2BK.%26aulast%3DTan-Wasielewski%26aufirst%3DZ.%26aulast%3DMatulonis%26aufirst%3DU.%2BA.%26aulast%3DBirrer%26aufirst%3DM.%2BJ.%26aulast%3DWright%26aufirst%3DA.%2BA.%26aulast%3DHorowitz%26aufirst%3DN.%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26aulast%3DCurtis%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26atitle%3DResults%2520of%2520an%2520abbreviated%2520Phase%2520Ib%2520study%2520of%2520the%2520HDAC6%2520inhibitor%2520ricolinostat%2520and%2520paclitaxel%2520in%2520recurrent%2520ovarian%252C%2520fallopian%2520tube%252C%2520or%2520primary%2520peritoneal%2520cancer%26jtitle%3DGynecologic%2520oncology%2520reports%26date%3D2019%26volume%3D29%26spage%3D118%26epage%3D122%26doi%3D10.1016%2Fj.gore.2019.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laschanzky, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enke, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brattain, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, Q. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, J. D.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1327</span>, <span class="refDoi"> DOI: 10.3390/cancers11091327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3390%2Fcancers11091327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtVWmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1327&author=R.+S.+Laschanzkyauthor=L.+E.+Humphreyauthor=J.+Maauthor=L.+M.+Smithauthor=T.+J.+Enkeauthor=S.+K.+Shuklaauthor=A.+Dasguptaauthor=P.+K.+Singhauthor=G.+M.+Howellauthor=M.+G.+Brattainauthor=Q.+P.+Lyauthor=A.+R.+Blackauthor=J.+D.+Black&title=Selective+Inhibition+of+Histone+Deacetylases+1%2F2%2F6+in+Combination+with+Gemcitabine%3A+A+Promising+Combination+for+Pancreatic+Cancer+Therapy&doi=10.3390%2Fcancers11091327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of histone deacetylases 1/2/6 in combination with gemcitabine: a promising combination for pancreatic cancer therapy</span></div><div class="casAuthors">Laschanzky, Richard S.; Humphrey, Lisa E.; Ma, Jihyun; Smith, Lynette M.; Enke, Thomas J.; Shukla, Surendra K.; Dasgupta, Aneesha; Singh, Pankaj K.; Howell, Gillian M.; Brattain, Michael G.; Ly, Quan P.; Black, Adrian R.; Black, Jennifer D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1327</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of <10% due in part to a lack of effective therapies.  Pan-histone deacetylase (HDAC) inhibitors have shown preclin. efficacy against PDAC but have failed in the clinic due to toxicity.  Selective HDAC inhibitors may reduce toxicity while retaining therapeutic efficacy.  However, their use requires identification of the specific HDACs that mediate the therapeutic effects of HDAC inhibitors in PDAC.  We detd. that the HDAC1/2/3 inhibitor Mocetinostat synergizes with the HDAC4/5/6 inhibitor LMK-235 in a panel of PDAC cell lines.  Furthermore, while neither drug alone synergizes with gemcitabine, the combination of Mocetinostat, LMK-235, and gemcitabine showed strong synergy.  Using small interfering (si)RNA-mediated knockdown, this synergy was attributed to inhibition of HDACs 1, 2, and 6.  Pharmacol. inhibition of HDACs 1 and 2 with Romidepsin and HDAC6 with ACY-1215 also potently synergized with gemcitabine in a panel of PDAC cell lines, and this drug combination potentiated the antitumor effects of gemcitabine against PDAC xenografts in vivo.  Collectively, our data show that inhibition of multiple HDACs is required for therapeutic effects of HDAC inhibitors and support the development of novel strategies to inhibit HDACs 1, 2, and 6 for PDAC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof_zMSnNYGkrVg90H21EOLACvtfcHk0lhTltFn0dI9-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtVWmsLo%253D&md5=dd724c10e07e94ffe21af163507fa7c9</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.3390%2Fcancers11091327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11091327%26sid%3Dliteratum%253Aachs%26aulast%3DLaschanzky%26aufirst%3DR.%2BS.%26aulast%3DHumphrey%26aufirst%3DL.%2BE.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DL.%2BM.%26aulast%3DEnke%26aufirst%3DT.%2BJ.%26aulast%3DShukla%26aufirst%3DS.%2BK.%26aulast%3DDasgupta%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DHowell%26aufirst%3DG.%2BM.%26aulast%3DBrattain%26aufirst%3DM.%2BG.%26aulast%3DLy%26aufirst%3DQ.%2BP.%26aulast%3DBlack%26aufirst%3DA.%2BR.%26aulast%3DBlack%26aufirst%3DJ.%2BD.%26atitle%3DSelective%2520Inhibition%2520of%2520Histone%2520Deacetylases%25201%252F2%252F6%2520in%2520Combination%2520with%2520Gemcitabine%253A%2520A%2520Promising%2520Combination%2520for%2520Pancreatic%2520Cancer%2520Therapy%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26spage%3D1327%26doi%3D10.3390%2Fcancers11091327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yanda, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebotaru, L.</span></span> <span> </span><span class="NLM_article-title">An inhibitor of histone deacetylase 6 activity, ACY-1215, reduces cAMP and cyst growth in polycystic kidney disease</span>. <i>American journal of physiology. Renal physiology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>313</i></span>,  <span class="NLM_fpage">F997</span>– <span class="NLM_lpage">F1004</span>, <span class="refDoi"> DOI: 10.1152/ajprenal.00186.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1152%2Fajprenal.00186.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=28747357" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2017&pages=F997-F1004&author=M.+K.+Yandaauthor=Q.+Liuauthor=L.+Cebotaru&title=An+inhibitor+of+histone+deacetylase+6+activity%2C+ACY-1215%2C+reduces+cAMP+and+cyst+growth+in+polycystic+kidney+disease&doi=10.1152%2Fajprenal.00186.2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.00186.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.00186.2017%26sid%3Dliteratum%253Aachs%26aulast%3DYanda%26aufirst%3DM.%2BK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DCebotaru%26aufirst%3DL.%26atitle%3DAn%2520inhibitor%2520of%2520histone%2520deacetylase%25206%2520activity%252C%2520ACY-1215%252C%2520reduces%2520cAMP%2520and%2520cyst%2520growth%2520in%2520polycystic%2520kidney%2520disease%26jtitle%3DAmerican%2520journal%2520of%2520physiology.%2520Renal%2520physiology%26date%3D2017%26volume%3D313%26spage%3DF997%26epage%3DF1004%26doi%3D10.1152%2Fajprenal.00186.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzo
Pisarello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masyuk, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradilone, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masyuk, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRusso, N. F.</span></span> <span> </span><span class="NLM_article-title">Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">994</span>, <span class="refDoi"> DOI: 10.1016/j.ajpath.2017.12.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ajpath.2017.12.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29366679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsF2ntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2018&pages=981-994&author=M.+Lorenzo%0APisarelloauthor=T.+V.+Masyukauthor=S.+A.+Gradiloneauthor=A.+I.+Masyukauthor=J.+F.+Dingauthor=P.+Y.+Leeauthor=N.+F.+LaRusso&title=Combination+of+a+Histone+Deacetylase+6+Inhibitor+and+a+Somatostatin+Receptor+Agonist+Synergistically+Reduces+Hepatorenal+Cystogenesis+in+an+Animal+Model+of+Polycystic+Liver+Disease&doi=10.1016%2Fj.ajpath.2017.12.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease</span></div><div class="casAuthors">Lorenzo Pisarello, Maria; Masyuk, Tatyana V.; Gradilone, Sergio A.; Masyuk, Anatoliy I.; Ding, Jingyi F.; Lee, Pui-Yuen; La Russo, Nicholas F.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">981-994</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hepatic cystogenesis in polycystic liver disease (PLD) is assocd. with abnormalities in multiple cellular processes, including elevated cAMP and overexpression of histone deacetylase 6 (HDAC6).  Disease progression in polycystic kidney (PCK) rats (an animal model of PLD) is attenuated by inhibition of either cAMP prodn. or HDAC6.  Therefore, we hypothesized that concurrent targeting of HDAC6 and cAMP would synergistically reduce cyst growth.  Changes in hepatorenal cystogenesis were examd. in PCK rats treated with a pan-HDAC inhibitor, panobinostat; three specific HDAC6 inhibitors, ACY-1215, ACY-738, and ACY-241; and a combination of ACY-1215 and the somatostatin receptor analog, pasireotide.  We also assessed effects of ACY-1215 and pasireotide alone and in combination on cell proliferation, cAMP prodn., and expression of acetylated α-tubulin in vitro in cultured cholangiocytes and the length of primary cilia and the frequency of ciliated cholangiocytes in vivo in PCK rats.  Panobinostat and all three HDAC6 inhibitors decreased hepatorenal cystogenesis in PCK rats.  ACY-1215 was more effective than other HDAC inhibitors and was chosen for combinational treatment.  ACY-1215 + pasireotide combination synergistically reduced cyst growth and increased length of primary cilia in PCK rats.  In cultured cystic cholangiocytes, ACY-1215 + pasireotide combination concurrently decreased cell proliferation and inhibited cAMP levels.  These data suggest that the combination of drugs that inhibit HDAC6 and cAMP may be an effective therapy for PLD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQXU3e9EqT5bVg90H21EOLACvtfcHk0lhTltFn0dI9-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsF2ntbk%253D&md5=a2979ff3a1c3849bf372e89e22f43f49</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2017.12.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2017.12.016%26sid%3Dliteratum%253Aachs%26aulast%3DLorenzo%2BPisarello%26aufirst%3DM.%26aulast%3DMasyuk%26aufirst%3DT.%2BV.%26aulast%3DGradilone%26aufirst%3DS.%2BA.%26aulast%3DMasyuk%26aufirst%3DA.%2BI.%26aulast%3DDing%26aufirst%3DJ.%2BF.%26aulast%3DLee%26aufirst%3DP.%2BY.%26aulast%3DLaRusso%26aufirst%3DN.%2BF.%26atitle%3DCombination%2520of%2520a%2520Histone%2520Deacetylase%25206%2520Inhibitor%2520and%2520a%2520Somatostatin%2520Receptor%2520Agonist%2520Synergistically%2520Reduces%2520Hepatorenal%2520Cystogenesis%2520in%2520an%2520Animal%2520Model%2520of%2520Polycystic%2520Liver%2520Disease%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2018%26volume%3D188%26spage%3D981%26epage%3D994%26doi%3D10.1016%2Fj.ajpath.2017.12.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, F. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Z. J.</span></span> <span> </span><span class="NLM_article-title">Quantitative Proteomic Analysis Reveals the Sites Related to Acetylation and Mechanism of ACY-1215 in Acute Liver Failure Mice</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">653</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3389%2Ffphar.2019.00653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31244662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkt12isLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=653&author=W.+B.+Zhangauthor=H.+Y.+Zhangauthor=Y.+Wangauthor=F.+Z.+Jiaoauthor=L.+W.+Wangauthor=Z.+J.+Gong&title=Quantitative+Proteomic+Analysis+Reveals+the+Sites+Related+to+Acetylation+and+Mechanism+of+ACY-1215+in+Acute+Liver+Failure+Mice&doi=10.3389%2Ffphar.2019.00653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative proteomic analysis reveals the sites related to acetylation and mechanism of ACY-1215 in acute liver failure mice</span></div><div class="casAuthors">Zhang, Wen-bin; Zhang, Hai-yue; Wang, Yao; Jiao, Fang-zhou; Wang, Lu-Wen; Gong, Zuo-jiong</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">653</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">In this study, we aim to investigate whether ACY-1215 has inhibitory effects and mechanism on the necrosis of hepatocytes; moreover, the impact of ACY-1215 treatment on histone lysine acetylation still needs further elucidation.  Male C57/BL6 mice were divided into normal, model, and ACY-1215 groups.  ACY-1215 (25 mg/kg) and same amts. of saline were injected i.p. to the mice before the establishment of ALF model induced by lipopolysaccharide (LPS) (100μg/kg) combined with D-gal (400 mg/kg).  All animals were sacrificed after 24 h.  In this study, detection programs, including quant. proteomic anal., transmission electron microscopy (TEM) micrographs, pathol. staining, protein expression, the detection of reactive oxygen species (ROS) as well as glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) measurement.  The function of liver and the necrosis of hepatocytes in ALF mice were significantly normalized by ACY-1215 pretreatment.  The quant. proteomic anal. revealed that ACY-1215-restrained oxidative phosphorylation normalized the function respiratory electron-transport chain in the mitochondria.  Moreover, pretreatment of ACY- 1215 not only normalized the structure of mitochondria but also inhibited the generation of reactive oxygen species (ROS).  ACY-1215 was able to inhibit necrosis of hepatocytes in ALF mice through regulating the mitochondrial-mediated oxidative stress, and we identified the common sites related to acetylation level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHZr7krOIsW7Vg90H21EOLACvtfcHk0lhTltFn0dI9-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkt12isLg%253D&md5=c3f7f5d38cd58f83a6b2e1ecde8816ca</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00653%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%2BB.%26aulast%3DZhang%26aufirst%3DH.%2BY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiao%26aufirst%3DF.%2BZ.%26aulast%3DWang%26aufirst%3DL.%2BW.%26aulast%3DGong%26aufirst%3DZ.%2BJ.%26atitle%3DQuantitative%2520Proteomic%2520Analysis%2520Reveals%2520the%2520Sites%2520Related%2520to%2520Acetylation%2520and%2520Mechanism%2520of%2520ACY-1215%2520in%2520Acute%2520Liver%2520Failure%2520Mice%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D653%26doi%3D10.3389%2Ffphar.2019.00653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span> <span> </span><span class="NLM_article-title">Protective Effects of ACY-1215 Against Chemotherapy-Related Cognitive Impairment and Brain Damage in Mice</span>. <i>Neurochem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2460</span>– <span class="NLM_lpage">2469</span>, <span class="refDoi"> DOI: 10.1007/s11064-019-02882-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs11064-019-02882-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31571096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOqu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=2460-2469&author=D.+Wangauthor=B.+Wangauthor=Y.+Liuauthor=X.+Dongauthor=Y.+Suauthor=S.+Li&title=Protective+Effects+of+ACY-1215+Against+Chemotherapy-Related+Cognitive+Impairment+and+Brain+Damage+in+Mice&doi=10.1007%2Fs11064-019-02882-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Protective Effects of ACY-1215 Against Chemotherapy-Related Cognitive Impairment and Brain Damage in Mice</span></div><div class="casAuthors">Wang, Dongmei; Wang, Bei; Liu, Yumei; Dong, Xiaohui; Su, Yanwei; Li, Sanqiang</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemical Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2460-2469</span>CODEN:
                <span class="NLM_cas:coden">NEREDZ</span>;
        ISSN:<span class="NLM_cas:issn">0364-3190</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Chemotherapy-related cognitive impairment (CRCI) is a potential long-term side effect during cancer treatment.  There are currently no effective treatments for CRCI.  Redn. or inhibition of histone deacetylase 6 (HDAC6) has been considered a possible therapeutic strategy for cognitive deficits.  HDAC6 inhibition recently has been shown to reverse chemotherapy-induced peripheral neuropathy effectively.  In the present study, we examd. the effect of HDAC6 inhibitor ACY-1215 (Ricolinostat) on cisplatin-induced brain damage and cognitive deficits in mice.  Our results showed that ACY-1215 ameliorated behavioral deficits and dendritic spine loss and increased synaptic d. in cisplatin-treated mice.  Mechanistically, HDAC6 inhibitor ACY-1215 enhanced a-tubulin acetylation in the hippocampus of cisplatin-treated mice.  Furthermore, ACY-1215 recovered cisplatin-induced impaired mitochondrial transport and mitochondrial dysfunction in the hippocampus.  Our results suggest that inhibition of HDAC6 improves established cisplatin-induced cognitive deficits by the restoration of mitochondrial and synaptic impairments.  These results offer prospective approaches for CRCI, esp. because ACY1215 currently serves as an add-on cancer therapy during clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbB1UtHwvL37Vg90H21EOLACvtfcHk0lgnb4haxj0xig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOqu7rN&md5=54b67a5f2b00ba3dfa32cdaca718a081</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs11064-019-02882-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11064-019-02882-6%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DProtective%2520Effects%2520of%2520ACY-1215%2520Against%2520Chemotherapy-Related%2520Cognitive%2520Impairment%2520and%2520Brain%2520Damage%2520in%2520Mice%26jtitle%3DNeurochem.%2520Res.%26date%3D2019%26volume%3D44%26spage%3D2460%26epage%3D2469%26doi%3D10.1007%2Fs11064-019-02882-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanden Berghe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robberecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bosch, L.</span></span> <span> </span><span class="NLM_article-title">Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">428</span>, <span class="refDoi"> DOI: 10.1007/s13311-016-0501-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs13311-016-0501-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27957719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2ku7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=417-428&author=V.+Benoyauthor=P.+Vanden+Bergheauthor=M.+Jarpeauthor=P.+Van+Dammeauthor=W.+Robberechtauthor=L.+Van+Den+Bosch&title=Development+of+Improved+HDAC6+Inhibitors+as+Pharmacological+Therapy+for+Axonal+Charcot-Marie-Tooth+Disease&doi=10.1007%2Fs13311-016-0501-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease</span></div><div class="casAuthors">Benoy, Veronick; Vanden Berghe, Pieter; Jarpe, Matthew; Van Damme, Philip; Robberecht, Wim; Van Den Bosch, Ludo</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">417-428</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Recently, we identified histone deacetylase 6, which deacetylates α-tubulin, as a potential therapeutic target in axonal CMT.  Pharmacol. inhibition of the deacetylating function of HDAC6 reversed the motor and sensory deficits in a mouse model for mutant "small heat shock protein B1"-induced CMT2 at the behavioral and electrophysiol. level.  In order to translate this potential therapeutic strategy into a clin. application, small drug-like mols. that are potent and selective HDAC6 inhibitors are essential.  To screen for these, we developed a method that consisted of 3 distinct phases and that was based on the pathol. findings in the mutant HSPB1-induced CMT2 mouse model.  Three different inhibitors (ACY-738, ACY-775, and ACY-1215) were tested and demonstrated to be both potent and selective HDAC6 inhibitors.  Moreover, these inhibitors increased the innervation of the neuromuscular junctions in the gastrocnemius muscle and improved the motor and sensory nerve conduction, confirming that HDAC6 inhibition is a potential therapeutic strategy in CMT2.  Furthermore, ACY-1215 is an interesting lead mol. as it is currently tested in clin. trials for cancer.  Taken together, these results may speed up the translation of pharmacol. inhibition of HDAC6 into a therapy against CMT2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmJr47ap41l7Vg90H21EOLACvtfcHk0lgnb4haxj0xig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2ku7vO&md5=cb382132da19455955c1b432cf59aa5e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs13311-016-0501-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-016-0501-z%26sid%3Dliteratum%253Aachs%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DVanden%2BBerghe%26aufirst%3DP.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3DVan%2BDamme%26aufirst%3DP.%26aulast%3DRobberecht%26aufirst%3DW.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520Improved%2520HDAC6%2520Inhibitors%2520as%2520Pharmacological%2520Therapy%2520for%2520Axonal%2520Charcot-Marie-Tooth%2520Disease%26jtitle%3DNeurotherapeutics%26date%3D2017%26volume%3D14%26spage%3D417%26epage%3D428%26doi%3D10.1007%2Fs13311-016-0501-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span> <span> </span><span class="NLM_article-title">ACY-1215 exhibits anti-inflammatory and chondroprotective effects in human osteoarthritis chondrocytes via inhibition of STAT3 and NF-kappaB signaling pathways</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2464</span>– <span class="NLM_lpage">2471</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2018.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.biopha.2018.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30551507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVWjs7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2019&pages=2464-2471&author=C.+Chengauthor=W.+Shanauthor=W.+Huangauthor=Z.+Dingauthor=G.+Cuiauthor=F.+Liuauthor=W.+Luauthor=J.+Xuauthor=W.+Heauthor=Z.+Yin&title=ACY-1215+exhibits+anti-inflammatory+and+chondroprotective+effects+in+human+osteoarthritis+chondrocytes+via+inhibition+of+STAT3+and+NF-kappaB+signaling+pathways&doi=10.1016%2Fj.biopha.2018.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">ACY-1215 exhibits anti-inflammatory and chondroprotective effects in human osteoarthritis chondrocytes via inhibition of STAT3 and NF-κB signaling pathways</span></div><div class="casAuthors">Cheng, Chao; Shan, Wenshan; Huang, Wei; Ding, Zhenfei; Cui, Guanjun; Liu, Fuen; Lu, Wei; Xu, Jiegou; He, Wei; Yin, Zongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2464-2471</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Cartilage degeneration is a basic pathol. feature of osteoarthritis (OA), and there is growing evidence that it is assocd. with inflammation.  ACY-1215, a selective HDAC6 inhibitor, has been reported to have anti-inflammatory effects.  Here, we investigated the anti-inflammatory and chondroprotective effects of ACY-1215 in IL-1β-stimulated human primary chondrocytes and C28/I2 cells.  The results suggested that ACY-1215 can markedly suppress the expression of inflammatory factors, including IL-1β and IL-6 in human primary chondrocytes and C28/I2 cells.  Furthermore, ACY-1215 exerts potent chondroprotection through the amelioration of cartilage degrdn. by inhibiting the expression of matrix-degrading proteases, including MMP-1 and MMP-13 in chondrocytes.  These effects may be related to ACY-1215 induced down-regulation of NF-κB and STAT3 pathways in OA chondrocytes.  Taken together, our results show that ACY-1215 may be a potential and promising therapeutic drug for the management of OA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9MqASkPCwb7Vg90H21EOLACvtfcHk0lgnb4haxj0xig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVWjs7jL&md5=7eec7657f80365a3f3605e67cc67f56e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2018.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2018.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DZ.%26aulast%3DCui%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DYin%26aufirst%3DZ.%26atitle%3DACY-1215%2520exhibits%2520anti-inflammatory%2520and%2520chondroprotective%2520effects%2520in%2520human%2520osteoarthritis%2520chondrocytes%2520via%2520inhibition%2520of%2520STAT3%2520and%2520NF-kappaB%2520signaling%2520pathways%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2019%26volume%3D109%26spage%3D2464%26epage%3D2471%26doi%3D10.1016%2Fj.biopha.2018.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span> <span> </span><span class="NLM_article-title">Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">109357</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2019.109357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.biopha.2019.109357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31548177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1arurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2019&pages=109357&author=L.+Liauthor=F.+Liuauthor=W.+Huangauthor=J.+Wangauthor=Y.+Wanauthor=M.+Liauthor=Y.+Pangauthor=Z.+Yin&title=Ricolinostat+%28ACY-1215%29+inhibits+VEGF+expression+via+PI3K%2FAKT+pathway+and+promotes+apoptosis+in+osteoarthritic+osteoblasts&doi=10.1016%2Fj.biopha.2019.109357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Ricolinostat (ACY-1215) inhibits VEGF expression viaPI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts</span></div><div class="casAuthors">Li, Lei; Yin, Zongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109357</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Osteoarthritis (OA) is involved in these pathophysiol. changes of articular cartilage, subchondral bone and synovium.  As a selective HDAC6 inhibitor, Ricolinostat (ACY-1215) has demonstrated chondroprotective effects in OA.  However, its efficacy remains unclear in subchondral bone.  In this study, we found that the mRNA and protein levels of HDAC6 were elevated in human OA osteoblasts in vitro.  PI3K/AKT signaling pathway was suppressed with downregulation of VEGF expression in osteoblasts after ACY-1215 treatment.  ACY-1215 promoted apoptosis of OA osteoblast in a concn.-dependent manner, and the expression of apoptosis-related proteins was also changed by activating caspase pathway.  Moreover, western blotting showed decreased expression of MMP9 and MMP13 in IL-1β-induced chondrocytes after co-culture with ACY-1215-stimulated osteoblasts.  These data of immunohistochem. and micro-CT from OA model mice also demonstrated the weak staining of MMPs in cartilage and prevention of aberrant subchondral bone formation after ACY-1215 injection.  Therefore, high expression of HDAC6 in osteoblasts also contributed to the OA progression, and our study provided a new evidence that HDAC6 inhibitor may be a potential therapeutic drug for OA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK4RIcdsW_A7Vg90H21EOLACvtfcHk0lhAu2R1mFBhLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1arurbM&md5=5fd57240090759e2dffe1ba17fd9fb84</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2019.109357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2019.109357%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DPang%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DZ.%26atitle%3DRicolinostat%2520%2528ACY-1215%2529%2520inhibits%2520VEGF%2520expression%2520via%2520PI3K%252FAKT%2520pathway%2520and%2520promotes%2520apoptosis%2520in%2520osteoarthritic%2520osteoblasts%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2019%26volume%3D118%26spage%3D109357%26doi%3D10.1016%2Fj.biopha.2019.109357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pulya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, B.</span></span> <span> </span><span class="NLM_article-title">HDAC6 as privileged target in drug discovery: A perspective</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">105274</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2020.105274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.phrs.2020.105274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=33171304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFOrsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2021&pages=105274&author=S.+Pulyaauthor=S.+A.+Aminauthor=N.+Adhikariauthor=S.+Biswasauthor=T.+Jhaauthor=B.+Ghosh&title=HDAC6+as+privileged+target+in+drug+discovery%3A+A+perspective&doi=10.1016%2Fj.phrs.2020.105274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 as privileged target in drug discovery: A perspective</span></div><div class="casAuthors">Pulya, Sravani; Amin, Sk. Abdul; Adhikari, Nilanjan; Biswas, Swati; Jha, Tarun; Ghosh, Balaram</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105274</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  HDAC6, a class IIB HDAC isoenzyme, stands unique in its structural and physiol. functions.  Besides histone modification, largely due to its cytoplasmic localization, HDAC6 also targets several non-histone proteins including Hsp90, α-tubulin, cortactin, HSF1, etc.  Thus, it is one of the key regulators of different physiol. and pathol. disease conditions.  HDAC6 is involved in different signaling pathways assocd. with several neurol. disorders, various cancers at early and advanced stage, rare diseases and immunol. conditions.  Therefore, targeting HDAC6 has been found to be effective for various therapeutic purposes in recent years.  Though several HDAC6 inhibitors (HDAC6is) have been developed till date, only two ACY-1215 (ricolinostat) and ACY-241 (citarinostat) are in the clin. trials.  Considering the recent crystal structure of HDAC6, novel HDAC6is of significant therapeutic value can be designed.  Notably, the canonical pharmacophore features of HDAC6is consist of a zinc binding group (ZBG), a linker function and a cap group.  Significant modifications of cap function may lead to achieve better selectivity of the inhibitors.  This review details the study about the structural biol. of HDAC6, the physiol. and pathol. role of HDAC6 in several disease states and the detailed structure-activity relationships (SARs) of the known HDAC6is.  This detailed review will provide key insights to design novel and highly effective HDAC6i in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwt5FbALiEZbVg90H21EOLACvtfcHk0lhAu2R1mFBhLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFOrsbzE&md5=78f2436f1aed4061650c812de9edb1ae</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2020.105274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2020.105274%26sid%3Dliteratum%253Aachs%26aulast%3DPulya%26aufirst%3DS.%26aulast%3DAmin%26aufirst%3DS.%2BA.%26aulast%3DAdhikari%26aufirst%3DN.%26aulast%3DBiswas%26aufirst%3DS.%26aulast%3DJha%26aufirst%3DT.%26aulast%3DGhosh%26aufirst%3DB.%26atitle%3DHDAC6%2520as%2520privileged%2520target%2520in%2520drug%2520discovery%253A%2520A%2520perspective%26jtitle%3DPharmacol.%2520Res.%26date%3D2021%26volume%3D163%26spage%3D105274%26doi%3D10.1016%2Fj.phrs.2020.105274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Guerrero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Gil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nerreter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortum, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Simon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudecek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danhof, S.</span></span> <span> </span><span class="NLM_article-title">Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1038/s41375-020-0840-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fs41375-020-0840-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32350373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotlSkurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2021&pages=201-214&author=E.+Garcia-Guerreroauthor=R.+Gotzauthor=S.+Dooseauthor=M.+Sauerauthor=A.+Rodriguez-Gilauthor=T.+Nerreterauthor=K.+M.+Kortumauthor=J.+A.+Perez-Simonauthor=H.+Einseleauthor=M.+Hudecekauthor=S.+Danhof&title=Upregulation+of+CD38+expression+on+multiple+myeloma+cells+by+novel+HDAC6+inhibitors+is+a+class+effect+and+augments+the+efficacy+of+daratumumab&doi=10.1038%2Fs41375-020-0840-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab</span></div><div class="casAuthors">Garcia-Guerrero, Estefania; Gotz, Ralph; Doose, Soren; Sauer, Markus; Rodriguez-Gil, Alfonso; Nerreter, Thomas; Kortum, K. Martin; Perez-Simon, Jose A.; Einsele, Hermann; Hudecek, Michael; Danhof, Sophia</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">201-214</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Multiple myeloma (MM) is incurable, so there is a significant unmet need for effective therapy for patients with relapsed or refractory disease.  This situation has not changed despite the recent approval of the anti-CD38 antibody daratumumab, one of the most potent agents in MM treatment.  The efficiency of daratumumab might be improved by combining it with synergistic anti-MM agents.  We therefore investigated the potential of the histone deacetylase (HDAC) inhibitor ricolinostat to up-regulate CD38 on MM cells, thereby enhancing the performance of CD38-specific therapies.  Using quant. reverse transcription polymerase chain reaction and flow cytometry, we obsd. that ricolinostat significantly increases CD38 RNA levels and CD38 surface expression on MM cells.  Super-resoln. microscopy imaging of MM cells by direct stochastic optical reconstruction microscopy confirmed this rise with mol. resoln. and revealed homogeneous distribution of CD38 mols. on the cell membrane.  Particularly important is that combining ricolinostat with daratumumab induced enhanced lysis of MM cells.  We also evaluated next-generation HDAC6 inhibitors (ACY-241, WT-161) and obsd. similar increase of CD38 levels suggesting that the upregulation of CD38 expression on MM cells by HDAC6 inhibitors is a class effect.  This proof-of-concept illustrates the potential benefit of combining HDAC6 inhibitors and CD38-directed immunotherapy for MM treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTQ7Zn-kiub7Vg90H21EOLACvtfcHk0lhAu2R1mFBhLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotlSkurY%253D&md5=f226989703f664bf1d98b6ddc66b45e6</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fs41375-020-0840-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-020-0840-y%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Guerrero%26aufirst%3DE.%26aulast%3DGotz%26aufirst%3DR.%26aulast%3DDoose%26aufirst%3DS.%26aulast%3DSauer%26aufirst%3DM.%26aulast%3DRodriguez-Gil%26aufirst%3DA.%26aulast%3DNerreter%26aufirst%3DT.%26aulast%3DKortum%26aufirst%3DK.%2BM.%26aulast%3DPerez-Simon%26aufirst%3DJ.%2BA.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DHudecek%26aufirst%3DM.%26aulast%3DDanhof%26aufirst%3DS.%26atitle%3DUpregulation%2520of%2520CD38%2520expression%2520on%2520multiple%2520myeloma%2520cells%2520by%2520novel%2520HDAC6%2520inhibitors%2520is%2520a%2520class%2520effect%2520and%2520augments%2520the%2520efficacy%2520of%2520daratumumab%26jtitle%3DLeukemia%26date%3D2021%26volume%3D35%26spage%3D201%26epage%3D214%26doi%3D10.1038%2Fs41375-020-0840-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laino, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veerapathran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgalev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, D. M.</span></span> <span> </span><span class="NLM_article-title">HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics</span>. <i>J. Immunother. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">33</span>, <span class="refDoi"> DOI: 10.1186/s40425-019-0517-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1186%2Fs40425-019-0517-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30728070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3cjpvVKmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=33&author=A.+S.+Lainoauthor=B.+C.+Bettsauthor=A.+Veerapathranauthor=I.+Dolgalevauthor=A.+Sarnaikauthor=S.+N.+Quayleauthor=S.+S.+Jonesauthor=J.+S.+Weberauthor=D.+M.+Woods&title=HDAC6+selective+inhibition+of+melanoma+patient+T-cells+augments+anti-tumor+characteristics&doi=10.1186%2Fs40425-019-0517-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics</span></div><div class="casAuthors">Laino Andressa S; Dolgalev I; Weber J S; Woods David M; Betts B C; Veerapathran A; Sarnaik A; Quayle S N; Jones S S</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Therapies targeting anti-tumor T-cell responses have proven successful in the treatment of a variety of malignancies.  However, as most patients still fail to respond, approaches to augment immunotherapeutic efficacy are needed.  Here, we investigated the ability of histone deacetylase 6 (HDAC6)-selective inhibitors to decrease immunosuppression and enhance immune function of melanoma patient T-cells in ex vivo cultures.  METHODS:  T-cells were harvested from peripheral blood or tumor biopsies of metastatic melanoma patients and cultured in the presence of pan-, class-specific or class-selective histone deacetylase (HDAC) inhibitors.  Changes in cytokine production were evaluated by Luminex and intracellular flow cytometry staining.  Expression of surface markers, transcription factors, protein phosphorylation, and cell viability were assessed by flow cytometry.  Changes in chromatin structure were determined by ATAC-seq.  RESULTS:  T-cell viability was impaired with low doses of pan-HDAC inhibitors but not with specific or selective HDAC inhibitors.  The HDAC6-selective inhibitors ACY-1215 (ricolinostat) and ACY-241 (citarinostat) decreased Th2 cytokine production (i.e.  IL-4, IL-5, IL-6, IL-10 and IL-13).  Expansion of peripheral blood T-cells from melanoma patients in the presence of these inhibitors resulted in downregulation of the Th2 transcription factor GATA3, upregulation of the Th1 transcription factor T-BET, accumulation of central memory phenotype T-cells (CD45RA-CD45RO + CD62L + CCR7+), reduced exhaustion-associated phenotypes (i.e.  TIM3 + LAG3 + PD1+ and EOMES+PD1+), and enhanced killing in mixed lymphocyte reactions.  The frequency, FOXP3 expression, and suppressive function of T regulatory cells (Tregs) were decreased after exposure to ACY-1215 or ACY-241.  Higher frequencies of T-cells expressing CD107a + IFNγ+ and central memory markers were observed in melanoma tumor-infiltrating lymphocytes (TIL), which persisted after drug removal and further expansion.  After ACY-1215 treatment, increased chromatin accessibility was observed in regions associated with T-cell effector function and memory phenotypes, while condensed chromatin was found in regions encoding the mTOR downstream molecules AKT, SGK1 and S6K.  Decreased phosphorylation of these proteins was observed in ACY-1215 and ACY-241-treated T-cells.  AKT- and SGK1-specific inhibition recapitulated the increase in central memory frequency and decrease in IL-4 production, respectively, similar to the observed effects of HDAC6-selective inhibition.  CONCLUSIONS:  HDAC6-selective inhibitors augmented melanoma patient T-cell immune properties, providing a rationale for translational investigation assessing their potential clinical efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJrQDSufBIrJdYoSR9eyvsfW6udTcc2eZ2LSYdKU7927ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjpvVKmtQ%253D%253D&md5=8499e2d6ce440a7b7110b4749a873595</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1186%2Fs40425-019-0517-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-019-0517-0%26sid%3Dliteratum%253Aachs%26aulast%3DLaino%26aufirst%3DA.%2BS.%26aulast%3DBetts%26aufirst%3DB.%2BC.%26aulast%3DVeerapathran%26aufirst%3DA.%26aulast%3DDolgalev%26aufirst%3DI.%26aulast%3DSarnaik%26aufirst%3DA.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DWoods%26aufirst%3DD.%2BM.%26atitle%3DHDAC6%2520selective%2520inhibition%2520of%2520melanoma%2520patient%2520T-cells%2520augments%2520anti-tumor%2520characteristics%26jtitle%3DJ.%2520Immunother.%2520Cancer%26date%3D2019%26volume%3D7%26spage%3D33%26doi%3D10.1186%2Fs40425-019-0517-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2786</span>– <span class="NLM_lpage">2796</span>, <span class="refDoi"> DOI: 10.1038/s41388-020-1172-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fs41388-020-1172-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32024967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXislSgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&pages=2786-2796&author=A.+Rayauthor=Y.+Songauthor=T.+Duauthor=D.+Chauhanauthor=K.+C.+Anderson&title=Preclinical+validation+of+Alpha-Enolase+%28ENO1%29+as+a+novel+immunometabolic+target+in+multiple+myeloma&doi=10.1038%2Fs41388-020-1172-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma</span></div><div class="casAuthors">Ray, Arghya; Song, Yan; Du, Ting; Chauhan, Dharminder; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2786-2796</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Bone marrow plasmacytoid dendritic cells (pDCs) in patients with multiple myeloma (MM) promote tumor growth, survival, drug resistance, and immune suppression.  Understanding the mol. signaling crosstalk among the tumor cells, pDCs and immune cells will identify novel therapeutic approaches to enhance anti-MM immunity.  Using oligonucleotide arrays, we found that pDC-MM interactions induce metabolic enzyme Alpha-Enolase (ENO1) in both pDCs and MM cells.  Anal. of MM patient gene expression profiling database showed that ENO1 expression inversely correlates with overall survival.  Protein expression anal. showed that ENO1 is expressed in pDC and MM cells; and importantly, that pDC-MM coculture further increases ENO1 expression in both MM cells and pDCs.  Using our coculture models of patient autologous pDC-T-NK-MM cells, we examd. whether targeting ENO1 can enhance anti-MM immunity.  Biochem. inhibition of ENO1 with ENO1 inhibitor (ENO1i) activates pDCs, as well as increases pDC-induced MM-specific CD8+ CTL and NK cell activity against autologous tumor cells.  Combination of ENO1i and anti-PD-L1 Ab or HDAC6i ACY-241 enhances autologous MM-specific CD8+ CTL activity.  Our preclin. data therefore provide the basis for novel immune-based therapeutic approaches targeting ENO1, alone or in combination with anti-PD-L1 Ab or ACY241, to restore anti-MM immunity, enhance MM cytotoxicity, and improve patient outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZZmUPt3iML7Vg90H21EOLACvtfcHk0li60bHN_9TceQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXislSgt78%253D&md5=909625faf96ff50563fef1f00495df9b</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fs41388-020-1172-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-020-1172-0%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DT.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DPreclinical%2520validation%2520of%2520Alpha-Enolase%2520%2528ENO1%2529%2520as%2520a%2520novel%2520immunometabolic%2520target%2520in%2520multiple%2520myeloma%26jtitle%3DOncogene%26date%3D2020%26volume%3D39%26spage%3D2786%26epage%3D2796%26doi%3D10.1038%2Fs41388-020-1172-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">North, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeciga-Pinto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span> <span> </span><span class="NLM_article-title">Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0173507</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0173507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1371%2Fjournal.pone.0173507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=28264055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVGjtrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=B.+J.+Northauthor=I.+Almeciga-Pintoauthor=D.+Tamangauthor=M.+Yangauthor=S.+S.+Jonesauthor=S.+N.+Quayle&title=Enhancement+of+pomalidomide+anti-tumor+response+with+ACY-241%2C+a+selective+HDAC6+inhibitor&doi=10.1371%2Fjournal.pone.0173507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor</span></div><div class="casAuthors">North, Brian J.; Almeciga-Pinto, Ingrid; Tamang, David; Yang, Min; Jones, Simon S.; Quayle, Steven N.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0173507/1-e0173507/16</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Thalidomide-based Immunomodulatory Drugs (IMiDs), including lenalidomide and pomalidomide, are effective therapeutics for multiple myeloma.  These agents have been approved with, or are under clin. development with, other targeted therapies including proteasome inhibitors, αCD38 monoclonal antibodies, as well as histone deacetylase (HDAC) inhibitors for combination therapy.  HDAC inhibitors broadly targeting Class I and IIb HDACs have shown potent preclin. efficacy but have frequently demonstrated an undesirable safety profile in combination therapy approaches in clin. studies.  Therefore, development of more selective HDAC inhibitors could provide enhanced efficacy with reduced side effects in combination with IMiDs for the treatment of B-cell malignancies, including multiple myeloma.  Here, the second generation selective HDAC6 inhibitor citarinostat (ACY-241), with a more favorable safety profile than non-selective pan-HDAC inhibitors, is shown to synergize with pomalidomide in in vitro assays through promoting greater apoptosis and cell cycle arrest.  Furthermore, utilizing a multiple myeloma in vivo murine xenograft model, combination treatment with pomalidomide and ACY-241 leads to increased tumor growth inhibition.  At the mol. level, combination treatment with ACY-241 and pomalidomide leads to greater suppression of the pro-survival factors survivin, Myc, and IRF4.  The results presented here demonstrate synergy between pomalidomide and ACY-241 in both in vitro and in vivo preclin. models, providing further impetus for clin. development of ACY-241 for use in combination with IMiDs for patients with multiple myeloma and potentially other B-cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaSAg6exJCNbVg90H21EOLACvtfcHk0li60bHN_9TceQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVGjtrfL&md5=175ef137cd119027f0462d07784375b5</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0173507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0173507%26sid%3Dliteratum%253Aachs%26aulast%3DNorth%26aufirst%3DB.%2BJ.%26aulast%3DAlmeciga-Pinto%26aufirst%3DI.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26atitle%3DEnhancement%2520of%2520pomalidomide%2520anti-tumor%2520response%2520with%2520ACY-241%252C%2520a%2520selective%2520HDAC6%2520inhibitor%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0173507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fleu.2017.322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29104288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvFWrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=843-846&author=A.+Rayauthor=D.+S.+Dasauthor=Y.+Songauthor=T.+Hideshimaauthor=Y.+T.+Taiauthor=D.+Chauhanauthor=K.+C.+Anderson&title=Combination+of+a+novel+HDAC6+inhibitor+ACY-241+and+anti-PD-L1+antibody+enhances+anti-tumor+immunity+and+cytotoxicity+in+multiple+myeloma&doi=10.1038%2Fleu.2017.322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma</span></div><div class="casAuthors">Ray, A.; Das, D. S.; Song, Y.; Hideshima, T.; Tai, Y.-T.; Chauhan, D.; Anderson, K. C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">843-846</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are attractive therapeutic targets, and selective HDAC inhibitors (HDACi), alone or in combination with other anti-cancer agents, are promising treatment strategies in multiple myeloma (MM).1234To date, however, the effect of HDACi on immune regulation in the MM bone marrow (BM) microenvironment, as well as the therapeutic potential of combining selective HDACi with immune-based therapies, is undefined.  Recent studies showed that besides histone modification, HDACs also modulate non-histone targets including immune regulatory mols.5, 6 For example, blockade of HDACs upregulates immunecheckpoints such as PD-1 ligand (PD-L1).6 Moreover, the combination of HDACi with PD-1/PD-L1 checkpoint blockade significantly improves immunotherapy in a murine B16F10 model.6 In MM, PD-L1 expression directly correlates with progression of disease, with highest levels in patients with relapsed/refractory MM.7, 8 Here, we utilized an orally bioavalable HDAC6 selective inhibitor ACY-241, currently in clin. trials,9 to examine whether the combination of ACY-241 with anti-PD-L1 antibody enhances anti-MM immunity in the MM BM microenvironment.  For our studies, we utilized a co-culture model of immune effector cells (plasmacytoid dendritic cells (pDCs), T cells, NK cells) and MM cells.7, 10 Specifically, we have identified that interactions of MM cells with innate and adaptive immune cells in the BM milieu confer immune suppression via PD-1/PD-L1 signaling axis (Figure 1a: Schema).7, 10 This is exemplified in our studies demonstrating a novel functional interaction between pDCs (Lin- MHC-II+ CD123+ CD4+ CD303/BDCA-2+ CD304/BDCA-4+) and MM cells, implicating pDCs in both MM pathogenesis and immune suppression.  We showed that increased nos. of pDCs are present in MM patient BM vs. normal BM.  Importantly, pDCs in MM BM are relatively resistant to current therapies; protect tumor cells from therapy-induced cytotoxicity; promote tumor growth and survival; and confer immune dysfunction.7, 10 Using our co-culture model, we further delineated the immunosuppressive mechanism(s) that have a role during pDC-T-NK cell interactions with tumor cells.  Specifically, we found that: (1) MM cells and pDCs expressed high surface levels of PD-L1, whereas T cells showed high PD-1 levels; and (2) PD-L1 on MM pDCs suppresses PD-1 expressing T-cell and NK cell immune function; and (3) blockade of PD-L1-PD-1 signaling axis by anti-PD-L1 Ab generates MM-specific CD8+ ctotoxic T lymphocyte (CTL) activity, as well as enhances NK cell-mediated MM cell cytolytic activity.  Importantly, our co-culture model allows for evaluation of the effect of anti-MM drugs on immune regulatory mols. expressed on immune cells and tumor cells, as well as provides a platform for validating all immune-based combination strategies, esp. in the context of immune cells within the MM BM microenvironment.  In the current study, we utilized these models to specifically examine whether the combination of ACY-241 with anti-PD-L1 Ab increases anti-tumor immunity and cytotoxicity in MM.  We first evaluated whether the combination of ACY-241 and anti-PD-L1 Ab enhances MM patient NK cell-mediated cytolytic activity.  For these studies, we utilized low concn. of ACY-241 that do not significantly affect the viability of pDCs, T cells or NK cells (Supplementary Figure 1 A-C).  Freshly isolated NK cells from MM patient BM (n=7) were co-cultured with autologous pDCs in the presence of anti-PD-L1 Ab (5 μg/mL), ACY-241 (0.2 μ) or ACY-241 plus anti-PD-L1 Ab for 5 days.  Cells were washed and resuspended in complete medium without drugs and cultured with autologous MM cells prestained with Celltrace violet for 24 h, followed by 7-AAD staining and quantification of MM cell lysis by flow cytometry.  The combination of ACY-241 and anti-PD-L1 Ab triggered a more robust NK cell-mediated cytotlytic activity against MM cells than either agent alone (Figure 1b and c).  No significant NK cell-mediated cytotoxicity was noted in the absence of pDCs in these expts. (Supplementary Figure 2B), confirming a key role of pDCs in NK cell functioning in response to treatment with ACY-241 and/or anti-PD-L1 Ab.  To further confirm our findings, we next performed anal. of CD107a as a marker of NK cell function.  MM patient pDCs and autologous NK cells were treated with ACY-241, anti-PD-L1 Ab or ACY-241 plus anti-PD-L1 Ab, followed by degranulation assay to assess surface CD107a expressing CD3-/CD56+ NK cells by multi-parameter flow cytometry.  In concert with our finding shown in Figures 1b and c, ACY-241 plus anti-PD-L1 Ab increases CD107a+ degranulated cytolytic NK cells (Supplementary Figure 3).  As in our prior study,7 anti-PD-L1 Ab alone restored NK cell-mediated anti-MM activity.  Interestingly, treatment of pDC-NK cells co-cultured with ACY-241 alone triggerred NK cell cytolytic activity against MM cells (Figures 1b and c).  In this context, a recent study showed a role of HDAC6 in the regulation of PD-L1 in melanoma.11 We hypothesized that ACY-241 may downregulate PD-L1/PD-1-mediated NK cell immune suppression during pDC-NK cell interactions.  Indeed, ACY-241 significantly decreases PD-L1 expression on pDCs (Supplementary Figure 5), which in turn attentuates PD-L1/PD-1-mediated NK suppression and thereby enhances NK cell-mediated MM cell cytotoxicity.  Although not examd. here, other possibilities may account for ACY-241 activity.  Similar to immunomodulatory agent Lenalidomide, ACY-241 may skew effector cytokine (IFN-γ; TNFα) prodn. toward enhancing NK cell anti-MM activity.  Alternatively, ACY-241 may act as reported for HDACi LBH589, which upregulates activation marker CD69 on NK cells.12 Finally, ACY-241 may enhance NK cell anti-MM activity by altering receptor-ligand (for example, NKG2D or KIR) expression-mediated tumor cell killing.  These issues remain to be examd.  Nonetheless, we here show that: (1) pDC-MM cell interactions modulate NK cell cytotoxic activity; (2) combined ACY-241 and anti-PD-L1 Ab enhances MM patient pDC-induced NK cell-mediated cytolytic activities against autologous MM cells; (3) ACY-241 or anti-PD-L1 alone have the ability to stimulate NK cell effector function, albiet to a lesser extent than in combination; and (4) ACY-241 is an immune-modulating agent as it triggers significant NK cell anti-MM activity.  A recent study showed that a HDAC6i ricolinostat triggers T-cell activation and APC function.13 We therefore next examd. whether ACY-241, anti-PD-L1 or their combination triggers the generation of MM-specific CTLs ex vivo.  MM patient BM CD8+T cells (n=7) were co-cultured with autologous pDCs (pDC:T; 1:10 ratio) in the presence of anti-PD-L1 Ab, ACY-241 or ACY-241 plus anti-PD-L1 Ab for 5 days.  Cells were washed and resuspended in complete medium without drugs and cultured with autologous MM cells that were prestained with CellTracker Green for 24 h, followed by 7-AAD staining and quantification of CTLs-mediated MM cell lysis by FACS.  The combination of ACY-241 and anti-PD-L1 Ab triggered a more robust autologous MM-specific CD8+ CTL activity than either agent alone, evidenced by decreased no. of viable CellTracker Green-pos. MM cells (Figure 2a and Supplementary Figure 4).  MM cells were also cultured alone without immune effector cells for the same time period, and data obtained from flow anal. were used for normalization to account for the spontaneous MM cells death.  We next performed CD107a degranulation assays to confirm the generation of CD8+ T-cell cytolytic activity.  MM patient pDCs were co-cultured with autologous T cells and treated with ACY-241, anti-PD-L1 Ab, or ACY-241 plus anti-PD-L1 Ab, followed by degranulation assay to measure CD107a on the cell surface of activated CD3+/CD8+ T cells using flow cytometry.  In agreement with our findings from CTL assays (Figure 2a and Supplementary Figure 4), a more robust increase in surface CD107a+ cytotoxic T cells was noted upon treatment with combined ACY-241 and anti-PD-L1 Ab vs. either ACY-241 or anti-PD-L1 Ab alone (Figure 2b).  No significant MM patient CTL activity was noticed in the absence of pDCs (Supplementary Figure 2C).  Collectively, our data show that combination of selective HDAC6 inhibitor ACY-241 with anti-PD-L1 Ab triggers both CTLs- and NK cells-mediated MM cell killing (Supplementary Figures 6 and 7; Schema).  Mechanistic studies show that combined activity of ACY-241 and anti-PD-L1 is due to downregulation of immunosuppressive PD-L1/PD-1 signaling during pDC-T cells and pDC-NK cells interactions.  It is likely that besides blockade of PD-L1/PD-1, this combination regimen also abrogates other immunosuppressive mechanisms and/or activates immune-activating pathways among pDCs, NK or T cells that together contribute in restoration of anti-MM immunity.  Ongoing studies are focused on investigating these immune mechanism(s).  Finally, recent data indicate potential toxicity assocd. with checkpoint inhibitors in MM.  However, in contrast to inhibitor of checkpoint PD-1 (pembrolizumab), clin. trials of anti-PD-L1 Abs to date show safety, without any significant adverse events in MM patients.14 Moreover, a recent study found a better response rate in patients with higher PD-L1 levels on MM cells, and PD-1 expression on lymphocytes correlated weakly with progression-free survival in a small subset of patients.15 These findings, coupled with our data, support translation of combined ACY-241 and anti-PD-L1 Ab into clin. trials to restore immune function, enhance MM cytotoxicity and improve patient outcome in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiLF586f3pxrVg90H21EOLACvtfcHk0ljGvHKcqLBmMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvFWrtr0%253D&md5=b186fa9563c1e48519b4831dc3cebc3e</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.322%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DA.%26aulast%3DDas%26aufirst%3DD.%2BS.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DTai%26aufirst%3DY.%2BT.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DCombination%2520of%2520a%2520novel%2520HDAC6%2520inhibitor%2520ACY-241%2520and%2520anti-PD-L1%2520antibody%2520enhances%2520anti-tumor%2520immunity%2520and%2520cytotoxicity%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D843%26epage%3D846%26doi%3D10.1038%2Fleu.2017.322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civallero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcheselli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzi, S.</span></span> <span> </span><span class="NLM_article-title">Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">370</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1007/s10495-020-01607-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs10495-020-01607-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32394008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpt1Kiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=370-387&author=M.+Cosenzaauthor=M.+Civalleroauthor=L.+Marcheselliauthor=S.+Sacchiauthor=S.+Pozzi&title=Citarinostat+and+Momelotinib+co-target+HDAC6+and+JAK2%2FSTAT3+in+lymphoid+malignant+cell+lines%3A+a+potential+new+therapeutic+combination&doi=10.1007%2Fs10495-020-01607-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination</span></div><div class="casAuthors">Cosenza, Maria; Civallero, Monica; Marcheselli, Luigi; Sacchi, Stefano; Pozzi, Samantha</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">370-387</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors represent an encouraging class of antitumor drugs.  HDAC inhibitors induce a series of mol. and biol. responses and minimal toxicity to normal cells.  Citarinostat is a second generation, orally administered, HDAC6-selective inhibitor.  Momelotinib is an orally administered inhibitor of JAK/STAT3 signaling.  Momelotinib showed efficacy in patients with myelofibrosis.  We hypothesized that both HDAC and JAK/STAT pathways were important in lymphoproliferative disorders, and that inhibiting JAK/STAT3 and HDAC simultaneously might enhance the efficacy of momelotinib and citarinostat without increasing toxicity.  Accordingly, we tested the citarinostat + momelotinib combination in lymphoid cell lines.  Citarinostat + momelotinib showed strong cytotoxicity; it significantly reduced mitochondrial membrane potential, down-regulated Bcl-2 and Bcl-xL, and activated caspases 9 and 3.  Caspase-8 was upregulated in only two lymphoid cell lines, which indicated activation of the extrinsic apoptotic pathway.  We identified a lymphoid cell line that was only slightly sensitive to the combination treatment.  We knocked down thioredoxin expression by transfecting with small interfering RNA that targeted thioredoxin.  This knockdown increased cell sensitivity to the combination-induced cell death.  The combination treatment reduced Bcl-2 expression, activated caspase 3, and significantly inhibited cell viability and clonogenic survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA9gyd6V5mR7Vg90H21EOLACvtfcHk0ljGvHKcqLBmMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpt1Kiurw%253D&md5=fd17a3c8cb7bebdbe050c7d6622488df</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs10495-020-01607-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-020-01607-3%26sid%3Dliteratum%253Aachs%26aulast%3DCosenza%26aufirst%3DM.%26aulast%3DCivallero%26aufirst%3DM.%26aulast%3DMarcheselli%26aufirst%3DL.%26aulast%3DSacchi%26aufirst%3DS.%26aulast%3DPozzi%26aufirst%3DS.%26atitle%3DCitarinostat%2520and%2520Momelotinib%2520co-target%2520HDAC6%2520and%2520JAK2%252FSTAT3%2520in%2520lymphoid%2520malignant%2520cell%2520lines%253A%2520a%2520potential%2520new%2520therapeutic%2520combination%26jtitle%3DApoptosis%26date%3D2020%26volume%3D25%26spage%3D370%26epage%3D387%26doi%3D10.1007%2Fs10495-020-01607-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colling, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiest, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">13162</span>– <span class="NLM_lpage">13167</span>, <span class="refDoi"> DOI: 10.1073/pnas.1608067113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1073%2Fpnas.1608067113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27799547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKnu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=13162-13167&author=T.+Hideshimaauthor=J.+Qiauthor=R.+M.+Paranalauthor=W.+Tangauthor=E.+Greenbergauthor=N.+Westauthor=M.+E.+Collingauthor=G.+Estiuauthor=R.+Mazitschekauthor=J.+A.+Perryauthor=H.+Ohguchiauthor=F.+Cottiniauthor=N.+Mimuraauthor=G.+Gorgunauthor=Y.+T.+Taiauthor=P.+G.+Richardsonauthor=R.+D.+Carrascoauthor=O.+Wiestauthor=S.+L.+Schreiberauthor=K.+C.+Andersonauthor=J.+E.+Bradner&title=Discovery+of+selective+small-molecule+HDAC6+inhibitor+for+overcoming+proteasome+inhibitor+resistance+in+multiple+myeloma&doi=10.1073%2Fpnas.1608067113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma</span></div><div class="casAuthors">Hideshima, Teru; Qi, Jun; Paranal, Ronald M.; Tang, Weiping; Greenberg, Edward; West, Nathan; Colling, Meaghan E.; Estiu, Guillermina; Mazitschek, Ralph; Perry, Jennifer A.; Ohguchi, Hiroto; Cottini, Francesca; Mimura, Naoya; Gorgun, Gullu; Tai, Yu-Tzu; Richardson, Paul G.; Carrasco, Ruben D.; Wiest, Olaf; Schreiber, Stuart L.; Anderson, Kenneth C.; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">13162-13167</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) has proven clin. susceptible to modulation of pathways of protein homeostasis.  Blockade of proteasomal degrdn. of polyubiquitinated misfolded proteins by the proteasome inhibitor bortezomib (BTZ) achieves responses and prolongs survival in MM, but long-term treatment with BTZ leads to drug-resistant relapse in most patients.  In a proof-of-concept study, the authors previously demonstrated that blocking aggresomal breakdown of polyubiquitinated misfolded proteins with the histone deacetylase 6 (HDAC6) inhibitor tubacin enhances BTZ-induced cytotoxicity in MM cells in vitro.  However, these foundational studies were limited by the pharmacol. liabilities of tubacin as a chem. probe with only in vitro utility.  Emerging from a focused library synthesis, a potent, selective, and bioavailable HDAC6 inhibitor, WT161, was created to study the mechanism of action of HDAC6 inhibition in MM alone and in combination with BTZ.  WT161 in combination with BTZ triggers significant accumulation of polyubiquitinated proteins and cell stress, followed by caspase activation and apoptosis.  More importantly, this combination treatment was effective in BTZ-resistant cells and in the presence of bone marrow stromal cells, which have been shown to mediate MM cell drug resistance.  The activity of WT161 was confirmed in the human MM cell xenograft mouse model and established the framework for clin. trials of the combination treatment to improve patient outcomes in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxE_VYaPFUSbVg90H21EOLACvtfcHk0lg7jLl175s7sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKnu73M&md5=2515fcba03631917d0ca7656d1f62a7e</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1608067113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1608067113%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DGreenberg%26aufirst%3DE.%26aulast%3DWest%26aufirst%3DN.%26aulast%3DColling%26aufirst%3DM.%2BE.%26aulast%3DEstiu%26aufirst%3DG.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DPerry%26aufirst%3DJ.%2BA.%26aulast%3DOhguchi%26aufirst%3DH.%26aulast%3DCottini%26aufirst%3DF.%26aulast%3DMimura%26aufirst%3DN.%26aulast%3DGorgun%26aufirst%3DG.%26aulast%3DTai%26aufirst%3DY.%2BT.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DCarrasco%26aufirst%3DR.%2BD.%26aulast%3DWiest%26aufirst%3DO.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DDiscovery%2520of%2520selective%2520small-molecule%2520HDAC6%2520inhibitor%2520for%2520overcoming%2520proteasome%2520inhibitor%2520resistance%2520in%2520multiple%2520myeloma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D13162%26epage%3D13167%26doi%3D10.1073%2Fpnas.1608067113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">80109</span>– <span class="NLM_lpage">80123</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.19019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.18632%2Foncotarget.19019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29113288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BC1M7oslOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=80109-80123&author=T.+Hideshimaauthor=R.+Mazitschekauthor=J.+Qiauthor=N.+Mimuraauthor=J.-C.+Tsengauthor=A.+L.+Kungauthor=J.+E.+Bradnerauthor=K.+C.+Anderson&title=HDAC6+inhibitor+WT161+downregulates+growth+factor+receptors+in+breast+cancer&doi=10.18632%2Foncotarget.19019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer</span></div><div class="casAuthors">Hideshima Teru; Qi Jun; Mimura Naoya; Bradner James E; Anderson Kenneth C; Mazitschek Ralph; Mimura Naoya; Tseng Jen-Chieh; Kung Andrew L; Tseng Jen-Chieh; Kung Andrew L; Kung Andrew L; Bradner James E</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">80109-80123</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We have shown that WT-161, a histone deacetylase 6 (HDAC6) inhibitor, shows remarkable anti-tumor activity in multiple myeloma (MM) in preclinical models.  However, its activity in other type of cancers has not yet been shown.  In this study, we further evaluated the biologic sequelae of WT161 in breast cancer cell lines.  WT161 triggers apoptotic cell death in MCF7, T47D, BT474, and MDA-MB231 cells, associated with decreased expression of EGFR, HER2, and ERα and downstream signaling.  However, HDAC6 knockdown shows that cytotoxicity and destabilization of these receptors triggered by WT161 are not dependent on HDAC6 inhibition.  Moreover WT161 analog MAZ1793, which lacks HDAC inhibitory effect, similarly triggers cell line growth inhibition and downregulation of these receptors.  We also confirm that WT161 significantly inhibits in vivo MCF7 cell growth, associated with downregulation of ERα, in a murine xenograft model.  Finally, WT161 synergistically enhances bortezomib-induced cytotoxicity, even in bortezomib-resistant breast cancer cells.  Our results therefore provide the rationale to develop a novel class of therapeutic agents targeting growth pathways central to the pathogenesis of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWi2bvABUN7K2q3xNe7a7QfW6udTcc2ebrJ4EoAMifp7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7oslOksg%253D%253D&md5=50fcf37b8db1e8acb520e650f6702bf5</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.19019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.19019%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DMimura%26aufirst%3DN.%26aulast%3DTseng%26aufirst%3DJ.-C.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DHDAC6%2520inhibitor%2520WT161%2520downregulates%2520growth%2520factor%2520receptors%2520in%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D80109%26epage%3D80123%26doi%3D10.18632%2Foncotarget.19019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapadar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchini, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D. D.</span></span> <span> </span><span class="NLM_article-title">Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4370</span>– <span class="NLM_lpage">4373</span>, <span class="refDoi"> DOI: 10.1021/jm8002894</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8002894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovVGmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4370-4373&author=A.+P.+Kozikowskiauthor=S.+Tapadarauthor=D.+N.+Luchiniauthor=K.+H.+Kimauthor=D.+D.+Billadeau&title=Use+of+the+Nitrile+Oxide+Cycloaddition+%28NOC%29+Reaction+for+Molecular+Probe+Generation%3A+A+New+Class+of+Enzyme+Selective+Histone+Deacetylase+Inhibitors+%28HDACIs%29+Showing+Picomolar+Activity+at+HDAC6&doi=10.1021%2Fjm8002894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6</span></div><div class="casAuthors">Kozikowski, Alan P.; Tapadar, Subhasish; Luchini, Doris N.; Kim, Ki Hwan; Billadeau, Daniel D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4370-4373</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of hydroxamate based HDAC inhibitors contg. a phenylisoxazole as the CAP group has been synthesized using nitrile oxide cycloaddn. chem.  An HDAC6 selective inhibitor having a potency of ∼2 picomolar was identified.  Some of the compds. were examd. for their ability to block pancreatic cancer cell growth and found to be about 10-fold more potent than SAHA (suberoylanilidehydroxamic acid).  This research provides valuable, new mol. probes for use in exploring HDAC biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ7Ca9tXdBvbVg90H21EOLACvtfcHk0lg7jLl175s7sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovVGmtbk%253D&md5=006c71fe6f2bb09c2c65196e134a695e</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fjm8002894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8002894%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DTapadar%26aufirst%3DS.%26aulast%3DLuchini%26aufirst%3DD.%2BN.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DBilladeau%26aufirst%3DD.%2BD.%26atitle%3DUse%2520of%2520the%2520Nitrile%2520Oxide%2520Cycloaddition%2520%2528NOC%2529%2520Reaction%2520for%2520Molecular%2520Probe%2520Generation%253A%2520A%2520New%2520Class%2520of%2520Enzyme%2520Selective%2520Histone%2520Deacetylase%2520Inhibitors%2520%2528HDACIs%2529%2520Showing%2520Picomolar%2520Activity%2520at%2520HDAC6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4370%26epage%3D4373%26doi%3D10.1021%2Fjm8002894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sixto-Lopez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Fonseca, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales-Hernandez, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Archundia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Vidal, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa-Basurto, J.</span></span> <span> </span><span class="NLM_article-title">Searching the conformational complexity and binding properties of HDAC6 through docking and molecular dynamic simulations</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">2794</span>– <span class="NLM_lpage">2814</span>, <span class="refDoi"> DOI: 10.1080/07391102.2016.1231084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1080%2F07391102.2016.1231084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27589363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGqs7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=2794-2814&author=Y.+Sixto-Lopezauthor=M.+Belloauthor=R.+A.+Rodriguez-Fonsecaauthor=M.+C.+Rosales-Hernandezauthor=M.+Martinez-Archundiaauthor=J.+A.+Gomez-Vidalauthor=J.+Correa-Basurto&title=Searching+the+conformational+complexity+and+binding+properties+of+HDAC6+through+docking+and+molecular+dynamic+simulations&doi=10.1080%2F07391102.2016.1231084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Searching the conformational complexity and binding properties of HDAC6 through docking and molecular dynamic simulations</span></div><div class="casAuthors">Sixto-Lopez, Yudibeth; Bello, Martiniano; Rodriguez-Fonseca, Rolando Alberto; Rosales-Hernandez, Martha Cecilia; Martinez-Archundia, Marlet; Gomez-Vidal, Jose Antonio; Correa-Basurto, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2794-2814</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a family of proteins involved in the deacetylation of histones and other non-histones substrates.  HDAC6 belongs to class II and shares similar biol. functions with others of its class.  Nevertheless, its three-dimensional structure that involves the catalytic site remains unknown for exploring the ligand recognition properties.  Therefore, in this contribution, homol. modeling, 100-ns-long Mol. Dynamics (MD) simulation and docking calcns. were combined to explore the conformational complexity and binding properties of the catalytic domain 2 from HDAC6 (DD2-HDAC6), for which activity and affinity toward five different ligands have been reported.  Clustering anal. allowed identifying the most populated conformers present during the MD simulation, which were used as starting models to perform docking calcns. with five DD2-HDAC6 inhibitors: Cay10603 (CAY), Rocilinostat (RCT), Tubastatin A (TBA), Tubacin (TBC), and Nexturastat (NXT), and then were also submitted to 100-ns-long MD simulations.  Docking calcns. revealed that the five inhibitors bind at the DD2-HDAC6 binding site with the lowest binding free energy, the same binding mode is maintained along the 100-ns-long MD simulations.  Overall, our results provide structural information about the mol. flexibility of apo and holo DD2-HDAC6 states as well as insight of the map of interactions between DD2-HDAC6 and five well-known DD2-HDAC6 inhibitors allowing structural details to guide the drug design.  Finally, we highlight the importance of combining different theor. approaches to provide suitable structural models for structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEjhU2jaMvbbVg90H21EOLACvtfcHk0lje7tJd1dMf8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGqs7bI&md5=75556fa931fbc8dd3b1276216a309366</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1080%2F07391102.2016.1231084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2016.1231084%26sid%3Dliteratum%253Aachs%26aulast%3DSixto-Lopez%26aufirst%3DY.%26aulast%3DBello%26aufirst%3DM.%26aulast%3DRodriguez-Fonseca%26aufirst%3DR.%2BA.%26aulast%3DRosales-Hernandez%26aufirst%3DM.%2BC.%26aulast%3DMartinez-Archundia%26aufirst%3DM.%26aulast%3DGomez-Vidal%26aufirst%3DJ.%2BA.%26aulast%3DCorrea-Basurto%26aufirst%3DJ.%26atitle%3DSearching%2520the%2520conformational%2520complexity%2520and%2520binding%2520properties%2520of%2520HDAC6%2520through%2520docking%2520and%2520molecular%2520dynamic%2520simulations%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2017%26volume%3D35%26spage%3D2794%26epage%3D2814%26doi%3D10.1080%2F07391102.2016.1231084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sixto-Lopez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa-Basurto, J.</span></span> <span> </span><span class="NLM_article-title">Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">4701</span>– <span class="NLM_lpage">4720</span>, <span class="refDoi"> DOI: 10.1080/07391102.2018.1557560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1080%2F07391102.2018.1557560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30558483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivVaisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=4701-4720&author=Y.+Sixto-Lopezauthor=M.+Belloauthor=J.+Correa-Basurto&title=Structural+and+energetic+basis+for+the+inhibitory+selectivity+of+both+catalytic+domains+of+dimeric+HDAC6&doi=10.1080%2F07391102.2018.1557560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6</span></div><div class="casAuthors">Sixto-Lopez, Yudibeth; Bello, Martiniano; Correa-Basurto, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4701-4720</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">HDAC6 is a protein involved in cancer, neurodegenerative disease and inflammatory disorders.  To date, the full three-dimensional (3D) structure of human HDAC6 has not been elucidated; however, there are some exptl. 3D structural homologs to HDAC6 that can be used as templates.  In this work, we utilized mol. modeling procedures to model both of the catalytic domains of HDAC6 connected by the linker region where DMB region is placed.  Once the 3D structure of human HDAC6 was obtained, it was structurally evaluated and submitted to docking and mol. dynamic (MD) simulations along with Mol. Mechanics/Generalized Born Surface Area (MM/GBSA) method to explore the stability and the binding free energy properties of the HDAC6-ligand complexes.  In addn., its structural and energetic behavior was explored with each one of the catalytic domains in the mol. recognition of six selective HDAC6 inhibitors, HPOB, CAY10603, Nexturastat, Rocilinostat, Tubacin and Tubastatin A for DD2, and with the so-called 9-peptide which is DD1-HDAC6 selective substrate.  The use of the whole system (DD1-DMB-DD2) showed a tendency toward the ligand affinity of DD2, CAY10603> Tubacin > Rocilinostat > Nexturastat > HPOB > Tubastatin > 9-peptide, which is in line with exptl. reports.  However, 9-peptide showed a higher affinity for DD1, which agrees with exptl. reports elsewhere.  Principal component anal. provided important information about the structural changes linked to the mol. recognition process, whereas per-residue decompn. anal. revealed the energetic contribution of the key residues in the mol. binding and structural characteristics that could assist in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaDDSCE5cAdLVg90H21EOLACvtfcHk0lje7tJd1dMf8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivVaisLg%253D&md5=7029672cda1c077774128f90422209d3</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1080%2F07391102.2018.1557560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2018.1557560%26sid%3Dliteratum%253Aachs%26aulast%3DSixto-Lopez%26aufirst%3DY.%26aulast%3DBello%26aufirst%3DM.%26aulast%3DCorrea-Basurto%26aufirst%3DJ.%26atitle%3DStructural%2520and%2520energetic%2520basis%2520for%2520the%2520inhibitory%2520selectivity%2520of%2520both%2520catalytic%2520domains%2520of%2520dimeric%2520HDAC6%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2019%26volume%3D37%26spage%3D4701%26epage%3D4720%26doi%3D10.1080%2F07391102.2018.1557560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span> <span> </span><span class="NLM_article-title">HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">597</span>, <span class="refDoi"> DOI: 10.3892/or.2016.4811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3892%2For.2016.4811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27221381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtl2mtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=589-597&author=Z.+Wangauthor=F.+Tangauthor=P.+Huauthor=Y.+Wangauthor=J.+Gongauthor=S.+Sunauthor=C.+Xie&title=HDAC6+promotes+cell+proliferation+and+confers+resistance+to+gefitinib+in+lung+adenocarcinoma&doi=10.3892%2For.2016.4811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma</span></div><div class="casAuthors">Wang, Zhihao; Tang, Fang; Hu, Pengchao; Wang, Ying; Gong, Jun; Sun, Shaoxing; Xie, Conghua</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">589-597</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are promising targets for cancer therapy, and first-generation HDAC inhibitors are currently in clin. trials for the treatment of cancer patients.  HDAC6, which is a key regulator of many signaling pathways that are linked to cancer, has recently emerged as an attractive target for the treatment of cancer.  In the present study, HDAC6 was found to be overexpressed in lung adenocarcinoma cell lines and was neg. correlated with the prognosis of patients with lung adenocarcinoma.  Overexpression of HDAC6 promoted the proliferation of lung adenocarcinoma cells in a deacetylase activity-dependent manner.  HDAC6 overexpression conferred resistance to gefitinib via the stabilization of epidermal growth factor receptor (EGFR).  The inhibition of HDAC6 by CAY10603, a potent and selective inhibitor of HDAC6, inhibited the proliferation of lung adenocarcinoma cells and induced apoptosis.  CAY10603 downregulated the levels of EGFR protein, which in turn inhibited activation of the EGFR signaling pathway.  Moreover, CAY10603 synergized with gefitinib to induce apoptosis of the lung adenocarcinoma cell lines via the destabilization of EGFR.  Taken together, our results suggest that the inhibition of HDAC6 may be a promising strategy for the treatment of lung adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4lXuah65G6bVg90H21EOLACvtfcHk0lje7tJd1dMf8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtl2mtLk%253D&md5=3a2778e81b86443b5e4fcc37bc11f11e</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.3892%2For.2016.4811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2016.4811%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DC.%26atitle%3DHDAC6%2520promotes%2520cell%2520proliferation%2520and%2520confers%2520resistance%2520to%2520gefitinib%2520in%2520lung%2520adenocarcinoma%26jtitle%3DOncol.%2520Rep.%26date%3D2016%26volume%3D36%26spage%3D589%26epage%3D597%26doi%3D10.3892%2For.2016.4811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shetty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2019.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.taap.2019.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30910594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtVylsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2019&pages=178-183&author=L.+Liuauthor=X.+Zhouauthor=S.+Shettyauthor=G.+Houauthor=Q.+Wangauthor=J.+Fu&title=HDAC6+inhibition+blocks+inflammatory+signaling+and+caspase-1+activation+in+LPS-induced+acute+lung+injury&doi=10.1016%2Fj.taap.2019.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury</span></div><div class="casAuthors">Liu, Li; Zhou, Xiaoming; Shetty, Sreerama; Hou, Gang; Wang, Qiuyue; Fu, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">178-183</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">HDAC6 is a member of the class II histone deacetylase.  HDAC6 inhibition possesses anti-inflammatory effects.  However, the effects of HDAC6 inhibition in acute lung inflammation have not been studied.  Here, we investigated the effects of a highly selective and potent HDAC6 inhibitor CAY10603 in LPS-induced acute inflammatory lung injury.  We also conducted a series of expts. including immunoblotting, ELISA, and histol. assays to explore the inflammatory signaling pathways modulated by the selective HDAC6 inhibition.  We obsd. that HDAC6 activity was increased in the lung tissues after LPS challenge, which was assocd. with a decreased level of α-tubulin acetylation in the lung tissues.  HDAC6 inhibition by CAY10603 prevented LPS-induced α-tubulin deacetylation in the lung tissues.  HDAC6 inhibition also exhibited protective effects against LPS-induced acute lung inflammation, which was demonstrated by the reduced prodn. of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 and decreased leukocyte infiltration.  Furthermore, HDAC6 inhibition blocked the decrease of E-cadherin level and inhibited the increase of MMP9 expression in the lung tissues, which could prevent the destruction of the lung architecture in LPS-induced inflammatory injury.  Given the important roles of NFkB and inflammasome activation in inflammatory responses, we investigated their regulation by HDAC6 inhibition in LPS-induced lung injury.  Our results showed that HDAC6 inhibition blocked the activation of NFkB by inhibiting IkB phosphorylation in LPS-induced acute lung injury, and LPS-induced-inflammasome activity was reduced by HDAC6 inhibition as demonstrated by the decreased IL-1β and caspase-1 cleavage and activation.  Collectively, our data suggest that selective HDAC6 inhibition suppresses inflammatory signaling pathways and alleviates LPS-induced acute lung inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOnbD8x2_VybVg90H21EOLACvtfcHk0lgFBIFm2A8PNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtVylsr8%253D&md5=c4c22ef2bbad18471b9464018f24a389</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2019.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2019.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DShetty%26aufirst%3DS.%26aulast%3DHou%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DHDAC6%2520inhibition%2520blocks%2520inflammatory%2520signaling%2520and%2520caspase-1%2520activation%2520in%2520LPS-induced%2520acute%2520lung%2520injury%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2019%26volume%3D370%26spage%3D178%26epage%3D183%26doi%3D10.1016%2Fj.taap.2019.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibitor Cay10603 inhibits high glucose-induced oxidative stress, inflammation and apoptosis in retinal pigment epithelial cells via regulating NF-kappaB and NLRP3 inflammasome pathway</span>. <i>General physiology and biophysics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.4149/gpb_2019058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.4149%2Fgpb_2019058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32329444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1SqtrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&pages=169-177&author=Q.+Yangauthor=S.+Liauthor=Z.+Zhouauthor=M.+Fuauthor=X.+Yangauthor=K.+Haoauthor=Y.+Liu&title=HDAC6+inhibitor+Cay10603+inhibits+high+glucose-induced+oxidative+stress%2C+inflammation+and+apoptosis+in+retinal+pigment+epithelial+cells+via+regulating+NF-kappaB+and+NLRP3+inflammasome+pathway&doi=10.4149%2Fgpb_2019058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibitor Cay10603 inhibits high glucose-induced oxidative stress, inflammation and apoptosis in retinal pigment epithelial cells via regulating NF-kappaB and NLRP3 inflammasome pathway</span></div><div class="casAuthors">Yang, Qingsong; Li, Sizhen; Zhou, Zixiu; Fu, Min; Yang, Xiaodong; Hao, Kuanxiao; Liu, Yating</div><div class="citationInfo"><span class="NLM_cas:title">General Physiology and Biophysics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-177</span>CODEN:
                <span class="NLM_cas:coden">GPBIE2</span>;
        ISSN:<span class="NLM_cas:issn">0231-5882</span>.
    
            (<span class="NLM_cas:orgname">Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences</span>)
        </div><div class="casAbstract">The present study aimed to investigate the effects of histone deacetylase 6 (HDAC6) inhibitor Cay10603 (Cay) on high glucose (HG)-stimulated human retinal pigment epithelium (RPE) cells and its underlying mechanisms.  ARPE-19 cells were cultured under normal glucose (NG) or high glucose (HG) conditions.  The results revealed that HDAC6 was upregulated in HG-stimulated ARPE-19 cells.  Cay treatment caused a decrease in intracellular reactive oxygen species (ROS).  The levels of malondialdehyde (MDA) and myeloperoxidase (MPO) were reduced accompanied by increase in the activities of superoxide dismutase (SOD) and catalase (CAT) after treatment with Cay.  Besides, Cay decreased the levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-6 and monocyte chemoattractant protein-1 (MCP-1) in supernatant.  Meanwhile, the apoptotic rate in Cay-treated ARPE-19 cells notably reduced, coupled with an upregulation in Bcl-2 expression and a downregulation in cleaved caspase-3 and cleaved caspase-9 expression.  Cay decreased the expression of phospho (p)-NF-κB p65, p-IκB-α, NLRP3, cleaved caspase-1 and ASC while increased the expression of NF-κB p65 (cytoplasm).  Taken together, these findings demonstrated that Cay suppressed HG-induced oxidative stress, inflammation and apoptosis via regulating NF-κB and NLRP3 inflammasome pathway in HG-induced ARPE-19 cells, suggesting that Cay might be a therapeutic agent for the treatment of diabetic retinopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgDch-bOWQ2bVg90H21EOLACvtfcHk0lgFBIFm2A8PNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1SqtrjN&md5=3ebdcf6ed1a56c032e14c3c565076b75</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.4149%2Fgpb_2019058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4149%252Fgpb_2019058%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DFu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHao%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DHDAC6%2520inhibitor%2520Cay10603%2520inhibits%2520high%2520glucose-induced%2520oxidative%2520stress%252C%2520inflammation%2520and%2520apoptosis%2520in%2520retinal%2520pigment%2520epithelial%2520cells%2520via%2520regulating%2520NF-kappaB%2520and%2520NLRP3%2520inflammasome%2520pathway%26jtitle%3DGeneral%2520physiology%2520and%2520biophysics%26date%3D2020%26volume%3D39%26spage%3D169%26epage%3D177%26doi%3D10.4149%2Fgpb_2019058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span> <span> </span><span class="NLM_article-title">HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt’s Lymphoma Cells by Impeding the Cell Cycle</span>. <i>Current Medical Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1007/s11596-019-2024-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs11596-019-2024-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31016515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FosFOitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=228-236&author=X.+J.+Maauthor=G.+Xuauthor=Z.+J.+Liauthor=F.+Chenauthor=D.+Wuauthor=J.+N.+Miaoauthor=Y.+Zhanauthor=Y.+Fan&title=HDAC-selective+Inhibitor+Cay10603+Has+Single+Anti-tumour+Effect+in+Burkitt%E2%80%99s+Lymphoma+Cells+by+Impeding+the+Cell+Cycle&doi=10.1007%2Fs11596-019-2024-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt's Lymphoma Cells by Impeding the Cell Cycle</span></div><div class="casAuthors">Ma Xiu-Juan; Li Zhi-Jie; Wu Di; Miao Jia-Ning; Zhan Yue; Fan Yang; Xu Gang; Chen Fang</div><div class="citationInfo"><span class="NLM_cas:title">Current medical science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">228-236</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) inhibitors are novel in cancer therapy nowadays.  HDAC6-selective inhibitors exert advantageous effects due to higher selectivity and less toxicity.  We explored the anti-tumor effect and the molecular mechanism of cay10603, a potent HDAC6 inhibitor in Burkitt's lymphoma cells.  Our study revealed cay10603 inhibited the proliferation of Burkitt's lymphoma cell lines, and induced caspase-dependent apoptosis.  Cay10603 inhibited the expression of CDKs and cyclins to impede cell cycle progression in both Burkitt's lymphoma cell lines.  Cay10603 also showed the additive effect with vp16 notably.  Our data presented the promising anti-tumor effect of cay10603 in the Burkitt's lymphoma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYxaenw9OQZb7NkxioyDXTfW6udTcc2eb42Q5Ap6YRj7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FosFOitw%253D%253D&md5=beb0659f8068c10c84847566f487abe2</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1007%2Fs11596-019-2024-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11596-019-2024-4%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%2BJ.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DZ.%2BJ.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DMiao%26aufirst%3DJ.%2BN.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DY.%26atitle%3DHDAC-selective%2520Inhibitor%2520Cay10603%2520Has%2520Single%2520Anti-tumour%2520Effect%2520in%2520Burkitt%25E2%2580%2599s%2520Lymphoma%2520Cells%2520by%2520Impeding%2520the%2520Cell%2520Cycle%26jtitle%3DCurrent%2520Medical%2520Science%26date%3D2019%26volume%3D39%26spage%3D228%26epage%3D236%26doi%3D10.1007%2Fs11596-019-2024-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span> <span> </span><span class="NLM_article-title">Structure and property based design, synthesis and biological evaluation of gamma-lactam based HDAC inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1218</span>– <span class="NLM_lpage">1221</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmcl.2010.12.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=21256006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1amt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1218-1221&author=E.+Choiauthor=C.+Leeauthor=J.+E.+Parkauthor=J.+J.+Seoauthor=M.+Choauthor=J.+S.+Kangauthor=H.+M.+Kimauthor=S.+K.+Parkauthor=K.+Leeauthor=G.+Han&title=Structure+and+property+based+design%2C+synthesis+and+biological+evaluation+of+gamma-lactam+based+HDAC+inhibitors&doi=10.1016%2Fj.bmcl.2010.12.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors</span></div><div class="casAuthors">Choi, Eunhyun; Lee, Chulho; Park, Jung Eun; Seo, Jeong Jea; Cho, Misun; Kang, Jong Soon; Kim, Hwan Mook; Park, Song-Kyu; Lee, Kiho; Han, Gyoonhee</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1218-1221</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are involved in post-translational modification and gene expression.  Cancer cells recruited amts. of HDACs for their survival by epi-genetic down regulation of tumor suppressor genes.  HDACs have been the promising targets for treatment of cancer, and many HDAC inhibitors have been investigated nowadays.  δ-Lactam core HDAC inhibitors which showed potent HDAC inhibitory activities as well as cancer cell growth inhibitory activities were previously synthesized.  Through QSAR study of the δ-lactam based inhibitors, the smaller core is suggested as more active than larger one because it fits better in narrow hydrophobic tunnel of the active pocket of HDAC enzyme.  The smaller γ-lactam core HDAC inhibitors were designed and synthesized for biol. and property optimization.  Ph, naphthyl and thiophenyl groups were introduced as the cap groups.  Hydrophobic and bulky cap groups increase potency of HDAC inhibition because of hydrophobic interaction between HDAC and inhibitors.  In overall, γ-lactam based HDAC inhibitors showed more potent than δ-lactam analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYjGdqmHi9ZrVg90H21EOLACvtfcHk0ljr4IVsGeeN2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1amt7w%253D&md5=30e06e53027b322aff25cf2e07dfb474</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.079%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DSeo%26aufirst%3DJ.%2BJ.%26aulast%3DCho%26aufirst%3DM.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DH.%2BM.%26aulast%3DPark%26aufirst%3DS.%2BK.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DHan%26aufirst%3DG.%26atitle%3DStructure%2520and%2520property%2520based%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520gamma-lactam%2520based%2520HDAC%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1218%26epage%3D1221%26doi%3D10.1016%2Fj.bmcl.2010.12.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4068</span>– <span class="NLM_lpage">4070</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.04.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmcl.2006.04.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=16723227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmt1GgtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4068-4070&author=H.+M.+Kimauthor=K.+Leeauthor=B.+W.+Parkauthor=D.+K.+Ryuauthor=K.+Kimauthor=C.+W.+Leeauthor=S.+K.+Parkauthor=J.+W.+Hanauthor=H.+Y.+Leeauthor=H.+Y.+Leeauthor=G.+Han&title=Synthesis%2C+enzymatic+inhibition%2C+and+cancer+cell+growth+inhibition+of+novel+delta-lactam-based+histone+deacetylase+%28HDAC%29+inhibitors&doi=10.1016%2Fj.bmcl.2006.04.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel δ-lactam-based histone deacetylase (HDAC) inhibitors</span></div><div class="casAuthors">Kim, Hwan Mook; Lee, Kiho; Park, Bum Woo; Ryu, Dong Kyu; Kim, Kangjeon; Lee, Chang Woo; Park, Song-Kyu; Han, Jung Whan; Lee, Hee Yoon; Lee, Hyun Yong; Han, Gyoonhee</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4068-4070</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">δ-Lactam-based hydroxamic acids such as I (R = NHOH, II), inhibitors of histone deacetylase (HDAC), have been synthesized via ring closure metathesis of diene ester intermediates, e.g., III, followed by condensation with KONH2.  Three hydroxamic acids including II showed potent inhibitory activity in HDAC enzyme assay.  II also exhibited growth inhibitory activity on five human tumor cell lines, showing good sensitivity on the MDA-MB-231 breast tumor cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLnVqNNIEuvbVg90H21EOLACvtfcHk0ljr4IVsGeeN2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmt1GgtLY%253D&md5=4e24d35e0eed8be90818cd09298e9864</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.04.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.04.091%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BM.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DB.%2BW.%26aulast%3DRyu%26aufirst%3DD.%2BK.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DC.%2BW.%26aulast%3DPark%26aufirst%3DS.%2BK.%26aulast%3DHan%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DHan%26aufirst%3DG.%26atitle%3DSynthesis%252C%2520enzymatic%2520inhibition%252C%2520and%2520cancer%2520cell%2520growth%2520inhibition%2520of%2520novel%2520delta-lactam-based%2520histone%2520deacetylase%2520%2528HDAC%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4068%26epage%3D4070%26doi%3D10.1016%2Fj.bmcl.2006.04.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S. H.</span></span> <span> </span><span class="NLM_article-title">A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1093/carcin/bgx121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1093%2Fcarcin%2Fbgx121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29106445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlemu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=72-83&author=H.+W.+Ryuauthor=D.+H.+Shinauthor=D.+H.+Leeauthor=H.+R.+Wonauthor=S.+H.+Kwon&title=A+potent+hydroxamic+acid-based%2C+small-molecule+inhibitor+A452+preferentially+inhibits+HDAC6+activity+and+induces+cytotoxicity+toward+cancer+cells+irrespective+of+p53+status&doi=10.1093%2Fcarcin%2Fbgx121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status</span></div><div class="casAuthors">Ryu, Hyun-Wook; Shin, Dong-Hee; Lee, Dong Hoon; Won, Hye-Rim; Kwon, So Hee</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-83</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">1460-2180</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">HDAC6-selective inhibitors are novel epigenetic anticancer agents.  However, their precise mechanisms of action are incompletely understood.  We investigated the anticancer mechanisms of the novel potent and selective HDAC6 inhibitor A452 compared with current clin. tested HDAC6 inhibitor ACY-1215.  We demonstrate that A452 effectively inhibits the cell growth and viability of various cancer cell types, irresp. of p53 status.  A452-induced apoptosis as evidenced by activated caspase 3 and PARP, increased Bak and Bax and decreased Bcl-xL.  Moreover, A452 shifted cells away from antiapoptotic (AKT and ERK) pathways and toward proapoptotic (p38) pathways.  A452 triggered DNA damage via increased H2AX and activation of the checkpoint kinase Chk2.  A452 induced the suppression of cell migration and invasion.  Interestingly, A452 upregulated the expression of PD-L1, which regulates the PD-1 inhibitory pathway in T cells.  Overall, our results suggest that A452 is more effective as an anticancer agent than ACY-1215.  Therefore, therapeutically targeting HDAC6 may represent a novel strategy for cancer treatment irresp. of the p53 mutation status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsO6pjmaUP9bVg90H21EOLACvtfcHk0ljr4IVsGeeN2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlemu7fI&md5=d933dce5755e119cac9a6d9ae6a6f4b2</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgx121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgx121%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DH.%2BW.%26aulast%3DShin%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DWon%26aufirst%3DH.%2BR.%26aulast%3DKwon%26aufirst%3DS.%2BH.%26atitle%3DA%2520potent%2520hydroxamic%2520acid-based%252C%2520small-molecule%2520inhibitor%2520A452%2520preferentially%2520inhibits%2520HDAC6%2520activity%2520and%2520induces%2520cytotoxicity%2520toward%2520cancer%2520cells%2520irrespective%2520of%2520p53%2520status%26jtitle%3DCarcinogenesis%26date%3D2018%26volume%3D39%26spage%3D72%26epage%3D83%26doi%3D10.1093%2Fcarcin%2Fbgx121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Won, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeon, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S. H.</span></span> <span> </span><span class="NLM_article-title">A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1383</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1002/mc.22852</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fmc.22852" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29917295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2jtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=1383-1395&author=H.+R.+Wonauthor=H.+W.+Ryuauthor=D.+H.+Shinauthor=S.+K.+Yeonauthor=D.+H.+Leeauthor=S.+H.+Kwon&title=A452%2C+an+HDAC6-selective+inhibitor%2C+synergistically+enhances+the+anticancer+activity+of+chemotherapeutic+agents+in+colorectal+cancer+cells&doi=10.1002%2Fmc.22852"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells</span></div><div class="casAuthors">Won, Hye-Rim; Ryu, Hyun-Wook; Shin, Dong-Hee; Yeon, Soo-Keun; Lee, Dong Hoon; Kwon, So Hee</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1383-1395</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Although histone deacetylase inhibitors (HDACi) alone could be clin. useful, these are most recently used in combination with other anticancer agents in clin. trials for cancer treatment.  Recently, we reported the anticancer activity of an HDAC6-selective inhibitor A452 toward various cancer cell types.  This study aims to present a potent synergistic antiproliferative effect of A452/anticancer agent treatment in colorectal cancer cells (CRC) cells, independently of the p53 status.  A452 in combination with irinotecan, or SAHA is more potent than either drug alone in the apoptotic pathway as evidenced by activated caspase-3 and PARP, increased Bak and pp38, decreased Bcl-xL, pERK, and pAKT, and induced apoptotic cells.  Furthermore, A452 enhances DNA damage induced by anticancer agents as indicated by the increased accumulation of γH2AX and the activation of the checkpoint kinase Chk2.  The silencing of HDAC6 enhances the cell growth inhibition and cell death caused by anticancer agents.  In addn., A452 induces the synergistic suppression of cell migration and invasion.  This study suggests a mechanism by which HDAC6-selective inhibition can enhance the efficacy of specific anticancer agents in CRC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMCWkUJ3QG8bVg90H21EOLACvtfcHk0lj-tF3_2u-O6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2jtL7L&md5=786e26a4d2755a4407ebf437b3eb97e0</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1002%2Fmc.22852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.22852%26sid%3Dliteratum%253Aachs%26aulast%3DWon%26aufirst%3DH.%2BR.%26aulast%3DRyu%26aufirst%3DH.%2BW.%26aulast%3DShin%26aufirst%3DD.%2BH.%26aulast%3DYeon%26aufirst%3DS.%2BK.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DKwon%26aufirst%3DS.%2BH.%26atitle%3DA452%252C%2520an%2520HDAC6-selective%2520inhibitor%252C%2520synergistically%2520enhances%2520the%2520anticancer%2520activity%2520of%2520chemotherapeutic%2520agents%2520in%2520colorectal%2520cancer%2520cells%26jtitle%3DMol.%2520Carcinog.%26date%3D2018%26volume%3D57%26spage%3D1383%26epage%3D1395%26doi%3D10.1002%2Fmc.22852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeon, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S. H.</span></span> <span> </span><span class="NLM_article-title">A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">106398</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2020.106398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.leukres.2020.106398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32512378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFegtrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2020&pages=106398&author=G.+W.+Kimauthor=J.+Yooauthor=H.+R.+Wonauthor=S.+K.+Yeonauthor=S.+W.+Leeauthor=D.+H.+Leeauthor=Y.+H.+Jeonauthor=S.+H.+Kwon&title=A452%2C+HDAC6-selective+inhibitor+synergistically+enhances+the+anticancer+activity+of+immunomodulatory+drugs+in+IMiDs-resistant+multiple+myeloma&doi=10.1016%2Fj.leukres.2020.106398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma</span></div><div class="casAuthors">Kim, Go Woon; Yoo, Jung; Won, Hye-Rim; Yeon, Soo-Keun; Lee, Sang Woo; Lee, Dong Hoon; Jeon, Yu Hyun; Kwon, So Hee</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">106398</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Multiple Myeloma (MM) is a hematol. malignancy of plasma cells.  Although advanced therapies have elevated MM survival rate, MM eventually relapses.  Relapsed/refractory MM (R/R MM) cells gain resistance to previously used drugs, which reduces treatment options.  In this study, we propose a newly synthesized HDAC6-selective inhibitor, A452, as a strategy to overcome resistance to immunomodulatory drugs (IMiDs), the principal MM therapeutic drugs.  Here, we identified that A452 alone reduces the viability and growth of IMiDs-resistant cells as well as synergistically reduces viability when combined with IMiDs.  We confirmed that this anticancer activity occurrs by inducing apoptosis.  To det. if A452 overcomes IMiDs resistance, we checked the change in the protein level of IMiDs direct/indirect targets.  As a result, the combination of A452 and IMiDs slightly increased CRBN and decreased Aiolos and Ikaros, the targets of CRBN.  Moreover, A452 decreased c-Myc and IRF-4 when combined with IMiDs.  These data suggest that A452 helps to overcome the resistance of IMiDs.  Finally, significant synergy of anticancer activity was detected when using triple combinations of A452, IMiDs, and dexamethasone.  In conclusion, the novel HDAC6-selective inhibitor A452 would be beneficial to combination therapy, including IMiDs in R/R MM as a strategy for overcoming IMiDs resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHANzDF9SDg7Vg90H21EOLACvtfcHk0lj-tF3_2u-O6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFegtrbL&md5=dc70a6cf2ae296455a53814991515bdf</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2020.106398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2020.106398%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DG.%2BW.%26aulast%3DYoo%26aufirst%3DJ.%26aulast%3DWon%26aufirst%3DH.%2BR.%26aulast%3DYeon%26aufirst%3DS.%2BK.%26aulast%3DLee%26aufirst%3DS.%2BW.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DJeon%26aufirst%3DY.%2BH.%26aulast%3DKwon%26aufirst%3DS.%2BH.%26atitle%3DA452%252C%2520HDAC6-selective%2520inhibitor%2520synergistically%2520enhances%2520the%2520anticancer%2520activity%2520of%2520immunomodulatory%2520drugs%2520in%2520IMiDs-resistant%2520multiple%2520myeloma%26jtitle%3DLeuk.%2520Res.%26date%3D2020%26volume%3D95%26spage%3D106398%26doi%3D10.1016%2Fj.leukres.2020.106398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeng, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. J.</span></span> <span> </span><span class="NLM_article-title">Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2016.03.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27060764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2htLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=126-135&author=J.+Yooauthor=S.+J.+Kimauthor=D.+Sonauthor=H.+Seoauthor=S.+Y.+Baekauthor=C.+Y.+Maengauthor=C.+Leeauthor=I.+S.+Kimauthor=Y.+H.+Jungauthor=S.+M.+Leeauthor=H.+J.+Park&title=Computer-aided+identification+of+new+histone+deacetylase+6+selective+inhibitor+with+anti-sepsis+activity&doi=10.1016%2Fj.ejmech.2016.03.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity</span></div><div class="casAuthors">Yoo, Jakyung; Kim, So-Jin; Son, Dohyun; Seo, Heewon; Baek, Seung Yeop; Maeng, Cheol-Young; Lee, Changsik; Kim, In Su; Jung, Young Hoon; Lee, Sun-Mee; Park, Hyun-Ju</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">126-135</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have been recognized as promising approaches to the treatment of various human diseases including cancer, inflammation, neurodegenerative diseases, and metabolic disorders.  Several pan-HDAC inhibitors are currently approved only as anticancer drugs.  Interestingly, SAHA (vorinostat), one of clin. available pan-HDAC inhibitors, shows an anti-inflammatory effect at concns. lower than those required for inhibition of tumor cell growth.  It was also reported that HDAC6 selective inhibitor tubastatin A has anti-inflammatory and anti-rheumatic effect.  In our efforts to develop novel HDAC inhibitors, we rationally designed various HDAC inhibitors based on the structures of two hit compds. identified by virtual screening of chem. database.  Among them, 9a ((E)-N-hydroxy-4-(2-styrylthiazol-4-yl)butanamide) was identified as a HDAC6 selective inhibitor (IC50 values of 0.199 μM for HDAC6 vs. 13.8 μM for HDAC1), and it did not show significant cytotoxicity against HeLa cells.  In vivo biol. evaluation of 9a was conducted on a lipopolysaccharide (LPS)-induced mouse model of sepsis.  The compd. 9a significantly improved 40% survival rate (P = 0.0483), and suppressed the LPS-induced increase of TNF-α and IL-6 mRNA expression in the liver of mice.  Our study identified novel HDAC6 selective inhibitor 9a, which may serve as a potential lead for the development of anti-inflammatory or anti-sepsis agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd0iuSLahJ6bVg90H21EOLACvtfcHk0lj-tF3_2u-O6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2htLc%253D&md5=96bc037397ef5e1275c09085b6089d2e</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DYoo%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DSon%26aufirst%3DD.%26aulast%3DSeo%26aufirst%3DH.%26aulast%3DBaek%26aufirst%3DS.%2BY.%26aulast%3DMaeng%26aufirst%3DC.%2BY.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DI.%2BS.%26aulast%3DJung%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DS.%2BM.%26aulast%3DPark%26aufirst%3DH.%2BJ.%26atitle%3DComputer-aided%2520identification%2520of%2520new%2520histone%2520deacetylase%25206%2520selective%2520inhibitor%2520with%2520anti-sepsis%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D116%26spage%3D126%26epage%3D135%26doi%3D10.1016%2Fj.ejmech.2016.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nam, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. H.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3408</span>– <span class="NLM_lpage">3420</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmc.2019.06.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31235266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1entbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=3408-3420&author=G.+Namauthor=J.+M.+Jungauthor=H.+J.+Parkauthor=S.+Y.+Baekauthor=K.+S.+Baekauthor=H.+Y.+Mokauthor=D.+E.+Kimauthor=Y.+H.+Jung&title=Structure-activity+relationship+study+of+thiazolyl-hydroxamate+derivatives+as+selective+histone+deacetylase+6+inhibitors&doi=10.1016%2Fj.bmc.2019.06.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors</span></div><div class="casAuthors">Nam, Gibeom; Jung, Jun Min; Park, Hyun-Ju; Baek, Seung Yeop; Baek, Ki Seon; Mok, Hui yeon; Kim, Da Eun; Jung, Young Hoon</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3408-3420</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Several human diseases are assocd. with aberrant epigenetic pathways mediated by histone deacetylases (HDACs), esp. HDAC6, a class IIb HDACs, which has emerged as an attractive target for neurodegenerative and autoimmune disease therapeutics.  In a previous study, we developed the novel HDAC6-selective inhibitor 9a ((E)-N-hydroxy-4-(2-styrylthiazol-4-yl)butanamide) and showed that it has anti-sepsis activity in vivo.  In this study, we conducted structure-activity relationship (SAR) studies to optimize the activity and selectivity of HDAC6, synthesizing its derivs. with various aliph. linker sizes and cap structures.  We identified 6u ((E)-N-hydroxy-3-(2-(4-fluorostyryl)thiazol-4-yl)propanamide), which has nanomolar inhibition activity and a 126-fold selectivity for HDAC6 over HDAC1.  Through the docking analyses of 6u against HDAC subtypes, we revealed the importance of the optimal aliph. linker size, as well as the electronic substituent effect and rigidity of the aryl cap group.  Thus, we suggest a new rationale for the design of HDAC6-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkTunBiRHSA7Vg90H21EOLACvtfcHk0ljd7_445vdQIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1entbvI&md5=935aee709f4eb38e54fe2a5b28a7766d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DG.%26aulast%3DJung%26aufirst%3DJ.%2BM.%26aulast%3DPark%26aufirst%3DH.%2BJ.%26aulast%3DBaek%26aufirst%3DS.%2BY.%26aulast%3DBaek%26aufirst%3DK.%2BS.%26aulast%3DMok%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DD.%2BE.%26aulast%3DJung%26aufirst%3DY.%2BH.%26atitle%3DStructure-activity%2520relationship%2520study%2520of%2520thiazolyl-hydroxamate%2520derivatives%2520as%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D3408%26epage%3D3420%26doi%3D10.1016%2Fj.bmc.2019.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedi, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, K. L.</span></span> <span> </span><span class="NLM_article-title">Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2014.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=24685980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVSjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2014&pages=422-487&author=K.+Nepaliauthor=S.+Sharmaauthor=M.+Sharmaauthor=P.+M.+Bediauthor=K.+L.+Dhar&title=Rational+approaches%2C+design+strategies%2C+structure+activity+relationship+and+mechanistic+insights+for+anticancer+hybrids&doi=10.1016%2Fj.ejmech.2014.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids</span></div><div class="casAuthors">Nepali, Kunal; Sharma, Sahil; Sharma, Manmohan; Bedi, P. M. S.; Dhar, K. L.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">422-487</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  A Hybrid drug which comprises the incorporation of two drug pharmacophores in one single mol. are basically designed to interact with multiple targets or to amplify its effect through action on another bio target as one single mol. or to counterbalance the known side effects assocd. with the other hybrid part.  The present review article offers a detailed account of the design strategies employed for the synthesis of anticancer agents via mol. hybridization techniques.  Over the years, the researchers have employed this technique to discover some promising chem. architectures displaying significant anticancer profiles.  Mol. hybridization as a tool has been particularly utilized for targeting tubulin protein as exemplified through the no. of research papers.  The microtubule inhibitors such as taxol, colchicine, chalcones, combretastatin, phenstatins and vinca alkaloids have been utilized as one of the functionality of the hybrids and promising results have been obtained in most of the cases with some of the tubulin based hybrids exhibiting anticancer activity at nanomolar level.  Linkage with steroids as biol. carrier vector for anticancer drugs and the inclusion of pyrrolo [2,1-c] [1,4]benzodiazepines (PBDs), a family of DNA interactive antitumor antibiotics derived from Streptomyces species in hybrid structure based drug design has also emerged as a potential strategy.  Various heteroaryl based hybrids in particular isatin and coumarins have also been designed and reported to possess' remarkable inhibitory potential.  Apart from presenting the design strategies, the article also highlights the structure activity relationship along with mechanistic insights revealed during the biol. evaluation of the hybrids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWJz5umKzC17Vg90H21EOLACvtfcHk0ljd7_445vdQIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVSjtb0%253D&md5=a85f1e69cf9db79f9b7ff18047a14395</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DM.%26aulast%3DBedi%26aufirst%3DP.%2BM.%26aulast%3DDhar%26aufirst%3DK.%2BL.%26atitle%3DRational%2520approaches%252C%2520design%2520strategies%252C%2520structure%2520activity%2520relationship%2520and%2520mechanistic%2520insights%2520for%2520anticancer%2520hybrids%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D77%26spage%3D422%26epage%3D487%26doi%3D10.1016%2Fj.ejmech.2014.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span> <span> </span><span class="NLM_article-title">Multi-Targeted Anticancer Agents</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3084</span>– <span class="NLM_lpage">3098</span>, <span class="refDoi"> DOI: 10.2174/1568026617666170707124126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.2174%2F1568026617666170707124126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=28685693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFens7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=3084-3098&author=W.+Zhengauthor=Y.+Zhaoauthor=Q.+Luoauthor=Y.+Zhangauthor=K.+Wuauthor=F.+Wang&title=Multi-Targeted+Anticancer+Agents&doi=10.2174%2F1568026617666170707124126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Targeted Anticancer Agents</span></div><div class="casAuthors">Zheng, Wei; Zhao, Yao; Luo, Qun; Zhang, Yang; Wu, Kui; Wang, Fuyi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3084-3098</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">There is a great demand for the development of novel anticancer drugs, due to the increasing morbidity and high mortality of cancer.  To date, chemotherapy still plays a central role in the clin. treatment of cancer, but this role is being reduced by targeted therapies.  Since cancer is a complicated and multiple genes involved disease, drugs that act at multiple targets can enhance efficacy and lower drug resistance, and are thought to be the future of novel anticancer drug development.  In this paper, we discuss the recent development of "single mol., multi-target" anticancer agents that combine two or more pharmacophores in a single mol., including org. multitargeted anticancer agents and metal based complexes such as platinum, ruthenium, iridium and rhodium complexes.  These efforts will contribute to clin. cancer therapy and benefit patients in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj7unFBNhn3rVg90H21EOLACvtfcHk0ljd7_445vdQIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFens7fJ&md5=b9f6834bf2af9c3e9460badd9ca133c8</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.2174%2F1568026617666170707124126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026617666170707124126%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DF.%26atitle%3DMulti-Targeted%2520Anticancer%2520Agents%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2017%26volume%3D17%26spage%3D3084%26epage%3D3098%26doi%3D10.2174%2F1568026617666170707124126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S. L.</span></span> <span> </span><span class="NLM_article-title">HSP90 and the chaperoning of cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1038/nrc1716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fnrc1716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=16175177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=761-772&author=L.+Whitesellauthor=S.+L.+Lindquist&title=HSP90+and+the+chaperoning+of+cancer&doi=10.1038%2Fnrc1716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 and the chaperoning of cancer</span></div><div class="casAuthors">Whitesell, Luke; Lindquist, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Standing watch over the proteome, mol. chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival.  This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution.  Pharmacol. 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Vmb5bGXgDLVg90H21EOLACvtfcHk0ljd7_445vdQIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF&md5=c418ec249a29c70047081cd241938931</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Fnrc1716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1716%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%2BL.%26atitle%3DHSP90%2520and%2520the%2520chaperoning%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D761%26epage%3D772%26doi%3D10.1038%2Fnrc1716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nouri-Vaskeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alizadeh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajiasgharzadeh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhtarzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baradaran, B.</span></span> <span> </span><span class="NLM_article-title">The role of HSP90 molecular chaperones in hepatocellular carcinoma</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>235</i></span>,  <span class="NLM_fpage">9110</span>– <span class="NLM_lpage">9120</span>, <span class="refDoi"> DOI: 10.1002/jcp.29776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fjcp.29776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32452023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFajur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2020&pages=9110-9120&author=M.+Nouri-Vaskehauthor=L.+Alizadehauthor=K.+Hajiasgharzadehauthor=A.+Mokhtarzadehauthor=M.+Halimiauthor=B.+Baradaran&title=The+role+of+HSP90+molecular+chaperones+in+hepatocellular+carcinoma&doi=10.1002%2Fjcp.29776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">The role of HSP90 molecular chaperones in hepatocellular carcinoma</span></div><div class="casAuthors">Nouri-Vaskeh, Masoud; Alizadeh, Leila; Hajiasgharzadeh, Khalil; Mokhtarzadeh, Ahad; Halimi, Monireh; Baradaran, Behzad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">9110-9120</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Misfolded proteins have enhanced formation of toxic oligomers and nonfunctional protein copies lead to recruiting wild-type protein types.  Heat shock protein 90 (HSP90) is a mol. chaperone generated by cells that are involved in many cellular functions through regulation of folding and/or localization of large multi-protein complexes as well as client proteins.  HSP90 can regulate a no. of different cellular processes including cell proliferation, motility, angiogenesis, signal transduction, and adaptation to stress.  HSP90 makes the mutated oncoproteins able to avoid misfolding and degrdn. and permits the malignant transformation.  As a result, HSP90 is an important factor in several signaling pathways assocd. with tumorigenicity, therapy resistance, and inhibiting apoptosis.  Clin., the upregulation of HSP90 expression in hepatocellular carcinoma (HCC) is linked with advanced stages and inappropriate survival in cases suffering from this kind of cancer.  The present review comprehensively assesses HSP90 functions and its possible usefulness as a potential diagnostic biomarker and therapeutic option for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuf4B7xQE8vbVg90H21EOLACvtfcHk0li775Kf0Bs9fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFajur%252FE&md5=f2357586d96e9b9d67a65cff5a5f5331</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1002%2Fjcp.29776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.29776%26sid%3Dliteratum%253Aachs%26aulast%3DNouri-Vaskeh%26aufirst%3DM.%26aulast%3DAlizadeh%26aufirst%3DL.%26aulast%3DHajiasgharzadeh%26aufirst%3DK.%26aulast%3DMokhtarzadeh%26aufirst%3DA.%26aulast%3DHalimi%26aufirst%3DM.%26aulast%3DBaradaran%26aufirst%3DB.%26atitle%3DThe%2520role%2520of%2520HSP90%2520molecular%2520chaperones%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2020%26volume%3D235%26spage%3D9110%26epage%3D9120%26doi%3D10.1002%2Fjcp.29776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. L.</span></span> <span> </span><span class="NLM_article-title">Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1798</span>– <span class="NLM_lpage">1822</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00940</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00940" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKkurvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1798-1822&author=L.+Liauthor=L.+Wangauthor=Q.+D.+Youauthor=X.+L.+Xu&title=Heat+Shock+Protein+90+Inhibitors%3A+An+Update+on+Achievements%2C+Challenges%2C+and+Future+Directions&doi=10.1021%2Facs.jmedchem.9b00940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions</span></div><div class="casAuthors">Li, Li; Wang, Lei; You, Qi-Dong; Xu, Xiao-Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1798-1822</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Hsp90 is one of the most important chaperones involved in regulating the maturation of more than 300 client proteins, many of which are closely assocd. with refractory diseases, including cancer, neurodegenerative diseases and viral infections.  Clin. Hsp90 inhibitors bind to the ATP pocket in the N-terminal domain of Hsp90 and subsequently suppress the ATPase activity of Hsp90.  Recently, with the increased understanding of the discrepancies in the isoforms of Hsp90 and the modes of Hsp90-cochaperone-client complex interactions, some new strategies for Hsp90 inhibition have emerged.  Novel Hsp90 inhibitors that offer selective suppression of Hsp90 isoforms or specific disruption of Hsp90-cochaperone protein-protein interactions are expected to breakthrough with satisfactory efficacy and safety profiles.  This review summarizes the recent progress in Hsp90 inhibitors.  Addnl., Hsp90 inhibitory strategies are emphasized in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkbKTcDYjrzrVg90H21EOLACvtfcHk0li775Kf0Bs9fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKkurvO&md5=972a35d1b12f5e21a7fa27cbb6bfc0cd</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00940%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYou%26aufirst%3DQ.%2BD.%26aulast%3DXu%26aufirst%3DX.%2BL.%26atitle%3DHeat%2520Shock%2520Protein%252090%2520Inhibitors%253A%2520An%2520Update%2520on%2520Achievements%252C%2520Challenges%252C%2520and%2520Future%2520Directions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1798%26epage%3D1822%26doi%3D10.1021%2Facs.jmedchem.9b00940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dutta
Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C. H.</span></span> <span> </span><span class="NLM_article-title">Recent update on discovery and development of Hsp90 inhibitors as senolytic agents</span>. <i>Int. J. Biol. Macromol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">1086</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1016/j.ijbiomac.2020.06.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ijbiomac.2020.06.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32561284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSiurzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2020&pages=1086-1098&author=S.+Dutta%0AGuptaauthor=C.+H.+Pan&title=Recent+update+on+discovery+and+development+of+Hsp90+inhibitors+as+senolytic+agents&doi=10.1016%2Fj.ijbiomac.2020.06.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Recent update on discovery and development of Hsp90 inhibitors as senolytic agents</span></div><div class="casAuthors">Dutta Gupta, Sayan; Pan, Cheol Ho</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biological Macromolecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1086-1098</span>CODEN:
                <span class="NLM_cas:coden">IJBMDR</span>;
        ISSN:<span class="NLM_cas:issn">0141-8130</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hsp90 chaperone is an encouraging target for the development of novel anticancer agents.  The failure of Hsp90 inhibitors to get regulatory approval for the treatment of cancer is hindered due to toxicity, cost involved in their development and formulation issues.  The inhibitors against this chaperone are also being evaluated in pre-clin. models for the treatment of diseases other than cancer (Alzheimer, malaria, AIDS, etc.).  Recently, Hsp90 inhibitors have shown promising senolytic effect that is helpful in increasing the health and life span of mice.  The senolytic property of Hsp90 inhibitors will make them less toxic for use in humans.  The review focuses on Hsp90 inhibitors discovered till date as senolytic agents along with their future prospects.  Further, the various models used for the evaluation of senolytic effect are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1uoonUYdu6rVg90H21EOLACvtfcHk0li775Kf0Bs9fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSiurzP&md5=4a7639b075844edd1dca85da3ecc705d</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2Fj.ijbiomac.2020.06.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijbiomac.2020.06.115%26sid%3Dliteratum%253Aachs%26aulast%3DDutta%2BGupta%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DC.%2BH.%26atitle%3DRecent%2520update%2520on%2520discovery%2520and%2520development%2520of%2520Hsp90%2520inhibitors%2520as%2520senolytic%2520agents%26jtitle%3DInt.%2520J.%2520Biol.%2520Macromol.%26date%3D2020%26volume%3D161%26spage%3D1086%26epage%3D1098%26doi%3D10.1016%2Fj.ijbiomac.2020.06.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ojha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HuangFu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2018.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29567459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1OhtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=667-677&author=R.+Ojhaauthor=H.+L.+Huangauthor=W.+C.+HuangFuauthor=Y.+W.+Wuauthor=K.+Nepaliauthor=M.+J.+Laiauthor=C.+J.+Suauthor=T.+Y.+Sungauthor=Y.+L.+Chenauthor=S.+L.+Panauthor=J.+P.+Liou&title=1-Aroylindoline-hydroxamic+acids+as+anticancer+agents%2C+inhibitors+of+HSP90+and+HDAC&doi=10.1016%2Fj.ejmech.2018.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC</span></div><div class="casAuthors">Ojha, Ritu; Huang, Han-Li; Huang Fu, Wei-Chun; Wu, Yi-Wen; Nepali, Kunal; Lai, Mei-Jung; Su, Chih-Jou; Sung, Ting-Yi; Chen, Yi-Lin; Pan, Shiow-Lin; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">667-677</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 1-aroylindoline-hydroxamic acids I [n = 2 - 8] and II were synthesized.  The results of the biol. evaluation led to the identification of compd. I [n = 6] as dual HDAC6/HSP90 inhibitor.  Compd. I [n = 6] displayed striking inhibitory effects towards the HDAC6 isoform and HSP90 protein with IC50 values of 1.15 nM (HDAC6) and 46.3 nM (HSP90).  Compd. I [n = 6] also exhibited 113, 139 and 246 fold higher selectivity for HDAC6 over HDAC 1, HDAC 3 and HDAC 8 isoforms and was endowed with significant cytotoxic effects with GI50 values ranging 1.04-1.61 μM against lung A549, colorectal HCT116, leukemia HL60 and EGFR T790M mutant lung H1975 cell lines.  Another interesting finding of the study was substantial cytotoxic effects of compd. I particularly against lung H1975 (NSCLC) cell lines with IC50 = 0.26 μM which was mediated through HSP90 inhibition.  Compd. I [n = 2] as such was devoid of HDAC inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgF2Cb1sTQY7Vg90H21EOLACvtfcHk0ljV7BpUG4COLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1OhtLk%253D&md5=7c6b877c774d207150bf49c45f9a9303</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DOjha%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DHuangFu%26aufirst%3DW.%2BC.%26aulast%3DWu%26aufirst%3DY.%2BW.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DSu%26aufirst%3DC.%2BJ.%26aulast%3DSung%26aufirst%3DT.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3D1-Aroylindoline-hydroxamic%2520acids%2520as%2520anticancer%2520agents%252C%2520inhibitors%2520of%2520HSP90%2520and%2520HDAC%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D150%26spage%3D667%26epage%3D677%26doi%3D10.1016%2Fj.ejmech.2018.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ojha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">112086</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2020.112086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32058238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFSqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=112086&author=R.+Ojhaauthor=K.+Nepaliauthor=C.+H.+Chenauthor=K.+H.+Chuangauthor=T.+Y.+Wuauthor=T.+E.+Linauthor=K.+C.+Hsuauthor=M.+W.+Chaoauthor=M.+J.+Laiauthor=M.+H.+Linauthor=H.+L.+Huangauthor=C.+D.+Changauthor=S.+L.+Panauthor=M.+C.+Chenauthor=J.+P.+Liou&title=Isoindoline+scaffold-based+dual+inhibitors+of+HDAC6+and+HSP90+suppressing+the+growth+of+lung+cancer+in+vitro+and+in+vivo&doi=10.1016%2Fj.ejmech.2020.112086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo</span></div><div class="casAuthors">Ojha, Ritu; Nepali, Kunal; Chen, Chun-Han; Chuang, Kuo-Hsiang; Wu, Tung-Yun; Lin, Tony Eight; Hsu, Kai-Cheng; Chao, Min-Wu; Lai, Mei-Jung; Lin, Mei-Hsiang; Huang, Han-Li; Chang, Chao-Di; Pan, Shiow-Lin; Chen, Mei-Chuan; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112086pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">This study reported the synthesis of a series of 2-aroylisoindoline hydroxamic acids I [R = HOHNC(O)CH=CH, HOHNC(O)(CH2)2C(O)NH, HOHNC(O)C6H4CH2N, etc.] employing N-benzyl, long alkyl chain and acrylamide units as diverse linkers.  In-vitro studies led to the identification of N-benzyl linker-bearing compd. I [R = HOHNC(O)C6H4CH2N] and long chain linker-contg. compd. I [R = HOHNC(O)(CH2)8C(O)NH] as dual selective HDAC6/HSP90 inhibitors.  Compd. I [R = HOHNC(O)(CH2)8C(O)NH] displayed potent inhibition of HDAC6 isoform (IC50 = 4.3 nM) and HSP90a inhibition (IC50 = 46.8 nM) along with substantial cell growth inhibitory effects with GI50 = 0.76μM (lung A549) and GI50 = 0.52μM (lung EGFR resistant H1975).  Compd. I [R = HOHNC(O)C6H4CH2N] displayed potent antiproliferative activity against lung A549 (GI50 = 0.37μM) and lung H1975 cell lines (GI50 = 0.13μM) mediated through selective HDAC6 inhibition and HSP90 inhibition.  In the in vivo efficacy evaluation in human H1975 xenografts, compd. I [R = HOHNC(O)C6H4CH2N] induced slightly remarkable suppression of tumor growth both in monotherapy as well as the combination therapy with afatinib (20 mg/kg).  In addn., compd. I [R = HOHNC(O)(CH2)8C(O)NH] also modulated the expression of signatory biomarkers assocd. with HDAC6 and HSP90 inhibition.  Moreover, compd. I [R = HOHNC(O)C6H4CH2N] could effectively reduce programmed death-ligand 1 (PD-L1) expression in IFN-γ treated lung H1975 cells in a dose dependent manner suggesting that dual inhibition of HDAC6 and HSP90 can modulate immunosuppressive ability of tumor area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHtq06XN7-IrVg90H21EOLACvtfcHk0ljV7BpUG4COLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFSqs7w%253D&md5=eb9c93f039c112251848f9a4fb644955</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112086%26sid%3Dliteratum%253Aachs%26aulast%3DOjha%26aufirst%3DR.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChuang%26aufirst%3DK.%2BH.%26aulast%3DWu%26aufirst%3DT.%2BY.%26aulast%3DLin%26aufirst%3DT.%2BE.%26aulast%3DHsu%26aufirst%3DK.%2BC.%26aulast%3DChao%26aufirst%3DM.%2BW.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DChang%26aufirst%3DC.%2BD.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3DIsoindoline%2520scaffold-based%2520dual%2520inhibitors%2520of%2520HDAC6%2520and%2520HSP90%2520suppressing%2520the%2520growth%2520of%2520lung%2520cancer%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D190%26spage%3D112086%26doi%3D10.1016%2Fj.ejmech.2020.112086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rane, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">Janus kinases: components of multiple signaling pathways</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5662</span>– <span class="NLM_lpage">5679</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1203925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fsj.onc.1203925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=11114747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosl2nurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=5662-5679&author=S.+G.+Raneauthor=E.+P.+Reddy&title=Janus+kinases%3A+components+of+multiple+signaling+pathways&doi=10.1038%2Fsj.onc.1203925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases: components of multiple signaling pathways</span></div><div class="casAuthors">Rane, Sushil G.; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">5662-5679</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with ∼200 refs.  Cytoplasmic Janus protein tyrosine kinases (JAKs) are crucial components of diverse signal transduction pathways that govern cellular survival, proliferation, differentiation, and apoptosis.  Evidence to date, indicates that JAK kinase function may integrate components of diverse signaling cascades.  While it is likely that activation of STAT proteins may be an important function attributed to the JAK kinases, it is certainly not the only function performed by this key family of cytoplasmic tyrosine kinases.  Emerging evidence indicates that phosphorylation of cytokine and growth factor receptors may be the primary functional attribute of JAK kinases.  The JAK-triggered receptor phosphorylation can potentially be a rate-limiting event for a successful culmination of downstream signaling events.  In support of this hypothesis, it has been found that JAK kinase function is required for optimal activation of the Src-kinase cascade, the Ras-MAP kinase pathway, the PI3K-AKT pathway and STAT signaling following the interaction of cytokine/interferon receptors with their ligands.  Aberrations in JAK kinase activity, that may lead to derailment of ≥1 of the above mentioned pathways could disrupt normal cellular responses and result in disease states.  Thus, over-activation of JAK kinases has been implicated in tumorigenesis.  In contrast, loss of JAK kinase function has been found to result in disease states such as severe-combined immunodeficiency.  In summary, optimal JAK kinase activity is a crit. determinant of normal transmission of cytokine and growth factor signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCdAspuPThPbVg90H21EOLACvtfcHk0ljV7BpUG4COLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosl2nurY%253D&md5=e81c62f068d906d0b847c6a2ef4f22ee</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203925%26sid%3Dliteratum%253Aachs%26aulast%3DRane%26aufirst%3DS.%2BG.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DJanus%2520kinases%253A%2520components%2520of%2520multiple%2520signaling%2520pathways%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D5662%26epage%3D5679%26doi%3D10.1038%2Fsj.onc.1203925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaoka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saharinen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Shea, J. J</span></span> <span> </span><span class="NLM_article-title">The Janus kinases (Jaks)</span>. <i>Genome Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">253</span>, <span class="refDoi"> DOI: 10.1186/gb-2004-5-12-253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1186%2Fgb-2004-5-12-253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=15575979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BD2cngtlKktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=253&author=K.+Yamaokaauthor=P.+Saharinenauthor=M.+Pesuauthor=V.+E.+Holtauthor=O.+Silvennoinenauthor=J.+J+O%27Shea&title=The+Janus+kinases+%28Jaks%29&doi=10.1186%2Fgb-2004-5-12-253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus kinases (Jaks)</span></div><div class="casAuthors">Yamaoka Kunihiro; Saharinen Pipsa; Pesu Marko; Holt Vance E T 3rd; Silvennoinen Olli; O'Shea John J</div><div class="citationInfo"><span class="NLM_cas:title">Genome biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">253</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Janus kinase (Jak) family is one of ten recognized families of non-receptor tyrosine kinases.  Mammals have four members of this family, Jak1, Jak2, Jak3 and Tyrosine kinase 2 (Tyk2).  Birds, fish and insects also have Jaks.  Each protein has a kinase domain and a catalytically inactive pseudo-kinase domain, and they each bind cytokine receptors through amino-terminal FERM (Band-4.1, ezrin, radixin, moesin) domains.  Upon binding of cytokines to their receptors, Jaks are activated and phosphorylate the receptors, creating docking sites for signaling molecules, especially members of the signal transducer and activator of transcription (Stat) family.  Mutations of the Drosophila Jak (Hopscotch) have revealed developmental defects, and constitutive activation of Jaks in flies and humans is associated with leukemia-like syndromes.  Through the generation of Jak-deficient cell lines and gene-targeted mice, the essential, nonredundant functions of Jaks in cytokine signaling have been established.  Importantly, deficiency of Jak3 is the basis of human autosomal recessive severe combined immunodeficiency (SCID); accordingly, a selective Jak3 inhibitor has been developed, forming a new class of immunosuppressive drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0BwDh7EYTsV1C8OJBvdfbfW6udTcc2ebyrGavhEeSXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cngtlKktg%253D%253D&md5=4f8335c37dc8c20245e771224c1d5b12</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1186%2Fgb-2004-5-12-253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb-2004-5-12-253%26sid%3Dliteratum%253Aachs%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DHolt%26aufirst%3DV.%2BE.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ%26atitle%3DThe%2520Janus%2520kinases%2520%2528Jaks%2529%26jtitle%3DGenome%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D253%26doi%3D10.1186%2Fgb-2004-5-12-253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musumeci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacchello, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallacara, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brullo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span> <span> </span><span class="NLM_article-title">An Update on JAK Inhibitors</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1806</span>– <span class="NLM_lpage">1832</span>, <span class="refDoi"> DOI: 10.2174/0929867325666180327093502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.2174%2F0929867325666180327093502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29589523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ensbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=1806-1832&author=F.+Musumeciauthor=C.+Grecoauthor=I.+Giacchelloauthor=A.+L.+Fallacaraauthor=M.+M.+Ibrahimauthor=G.+Grossiauthor=C.+Brulloauthor=S.+Schenone&title=An+Update+on+JAK+Inhibitors&doi=10.2174%2F0929867325666180327093502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">An Update on JAK Inhibitors</span></div><div class="casAuthors">Musumeci, Francesca; Greco, Chiara; Giacchello, Ilaria; Fallacara, Anna Lucia; Ibrahim, Munjed M.; Grossi, Giancarlo; Brullo, Chiara; Schenone, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1806-1832</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are a family of non-receptor tyrosine kinases, composed by four members, JAK1, JAK2, JAK3 and TYK2.  JAKs are involved in different inflammatory and autoimmune diseases, as well as in malignancies, through the activation of the JAK/STAT signalling pathway.  Furthermore, the V617F mutation in JAK2 was identified in patients affected by myeloproliferative neoplasms.  This knowledge prompted researchers from academia and pharmaceutical companies to investigate this field in order to discover small mol. JAK inhibitors.  These efforts recently afforded to the market approval of four JAK inhibitors.  Despite the fact that all these drugs are pyrrolo[2,3-d]pyrimidine derivs., many compds. endowed with different heterocyclic scaffolds have been reported in the literature as selective or multi-JAK inhibitors, and a no. of them is currently being evaluated in clin. trials.  In this review we will report many representative compds. that have been published in articles or patents in the last five years (period 2013-2017).  The inhibitors will be classified on the basis of their chem. structure, focusing, when possible, on their structure activity relationships, selectivity and biol. activity.  For every class of derivs., compds. disclosed before 2013 that have entered clin. trials will also be briefly reported, to underline the importance of a particular chem. scaffold in the search for new inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkh7oMXXE96bVg90H21EOLACvtfcHk0lhFU4q_K05BLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ensbbN&md5=a453e5d90429f481c45a18257ea62b71</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.2174%2F0929867325666180327093502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867325666180327093502%26sid%3Dliteratum%253Aachs%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DGreco%26aufirst%3DC.%26aulast%3DGiacchello%26aufirst%3DI.%26aulast%3DFallacara%26aufirst%3DA.%2BL.%26aulast%3DIbrahim%26aufirst%3DM.%2BM.%26aulast%3DGrossi%26aufirst%3DG.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DSchenone%26aufirst%3DS.%26atitle%3DAn%2520Update%2520on%2520JAK%2520Inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2019%26volume%3D26%26spage%3D1806%26epage%3D1832%26doi%3D10.2174%2F0929867325666180327093502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>– <span class="NLM_lpage">8262</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Yenauthor=B.+W.+Dymock&title=Design+and+Synthesis+of+Janus+Kinase+2+%28JAK2%29+and+Histone+Deacetlyase+%28HDAC%29+Bispecific+Inhibitors+Based+on+Pacritinib+and+Evidence+of+Dual+Pathway+Inhibition+in+Hematological+Cell+Lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0lhFU4q_K05BLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Janus%2520Kinase%25202%2520%2528JAK2%2529%2520and%2520Histone%2520Deacetlyase%2520%2528HDAC%2529%2520Bispecific%2520Inhibitors%2520Based%2520on%2520Pacritinib%2520and%2520Evidence%2520of%2520Dual%2520Pathway%2520Inhibition%2520in%2520Hematological%2520Cell%2520Lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2636</span>– <span class="NLM_lpage">2640</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.06.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmcl.2018.06.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29945795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2qtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2636-2640&author=L.+Yaoauthor=P.+M.+Ramanujuluauthor=A.+Poulsenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Merging+of+ruxolitinib+and+vorinostat+leads+to+highly+potent+inhibitors+of+JAK2+and+histone+deacetylase+6+%28HDAC6%29&doi=10.1016%2Fj.bmcl.2018.06.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6)</span></div><div class="casAuthors">Yao, Lianbin; Ramanujulu, Pondy Murugappan; Poulsen, Anders; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2636-2640</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inhibition of more than one pathway in a cancer cell with a single mol. could result in better therapies with less complex dosing regimens.  In this work multi-component ligands have been prepd. by joining together key pharmacophores of two different enzyme inhibitors in a way which increases potency against the individual pathways.  Selective JAK1/2 inhibitor, ruxolitinib (3), and pan-HDAC inhibitor vorinostat (4) were linked together by a single nitrogen atom to create a new series of compds. with very potent JAK2 and HDAC6 inhibition with selectivity against HDAC1.  A preferred compd., I, had unprecedented sub-nanomolar JAK2 potency with an IC50 of 41 pM and a sub-nanomolar IC50 against HDAC6 of 200 pM.  Binding models show a good fit into both JAK2 and HDAC6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF3j4Hop3jqrVg90H21EOLACvtfcHk0ljUYlvZwdWEZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2qtb7M&md5=78776f7cd6ac7384c701edd2fd4a6940</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.06.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.06.037%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DMerging%2520of%2520ruxolitinib%2520and%2520vorinostat%2520leads%2520to%2520highly%2520potent%2520inhibitors%2520of%2520JAK2%2520and%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2636%26epage%3D2640%26doi%3D10.1016%2Fj.bmcl.2018.06.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu-Farseeva, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2018.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30243158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=593-619&author=Y.+Y.+Chu-Farseevaauthor=N.+Mustafaauthor=A.+Poulsenauthor=E.+C.+Tanauthor=J.+J.+Y.+Yenauthor=W.+J.+Chngauthor=B.+W.+Dymock&title=Design+and+synthesis+of+potent+dual+inhibitors+of+JAK2+and+HDAC+based+on+fusing+the+pharmacophores+of+XL019+and+vorinostat&doi=10.1016%2Fj.ejmech.2018.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat</span></div><div class="casAuthors">Chu-Farseeva, Yu-yi; Mustafa, Nurulhuda; Poulsen, Anders; Tan, Eng Chong; Yen, Jeffrey J. Y.; Chng, Wee Joo; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">593-619</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Specifically blocking more than one oncogenic pathway simultaneously in a cancer cell with a combination of different drugs is the mainstay of the majority of cancer treatments.  Being able to do this via two targeted pathways without inducing side effects through a general mechanism, such as chemotherapy, could bring benefit to patients.  In this work we describe a new dual inhibitor of the JAK-STAT and HDAC pathways through designing and developing two types of mol. based on the JAK2 selective inhibitor XL019 and the pan-HDAC inhibitor, vorinostat.  Both series of compds. had examples with low nanomolar JAK2 and HDAC1/6 inhibition.  In some cases good HDAC1 selectivity was achieved while retaining HDAC6 activity.  The obsd. potency is explained through mol. docking studies of all three enzymes.  One example, 69c had 16-25 fold selectivity against the three other JAK-family proteins JAK1, JAK3 and TYK2.  A no. of compds. had sub-micromolar potencies against a panel of 4 solid tumor cell lines and 4 hematol. cell lines with the most potent compd., 45h, having a cellular IC50 of 70 nM against the multiple myeloma cell line KMS-12-BM.  Evidence of both JAK and HDAC pathway inhibition is presented in Hela cells showing that both pathways are modulated.  Evidence of apoptosis with two compds. in 4 sold tumor cell lines is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppP3twGjwSkLVg90H21EOLACvtfcHk0ljUYlvZwdWEZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FK&md5=a6a1456126270e44dfa2f28916f7b7c0</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DChu-Farseeva%26aufirst%3DY.%2BY.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%2520dual%2520inhibitors%2520of%2520JAK2%2520and%2520HDAC%2520based%2520on%2520fusing%2520the%2520pharmacophores%2520of%2520XL019%2520and%2520vorinostat%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D158%26spage%3D593%26epage%3D619%26doi%3D10.1016%2Fj.ejmech.2018.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6). 1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4638</span>– <span class="NLM_lpage">4658</span>, <span class="refDoi"> DOI: 10.1021/jm200326p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.+1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma&doi=10.1021%2Fjm200326p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Tan, Evelyn; Chen, Dizhong; Williams, Meredith; Sun, Eric T.; Goh, Kee Chuan; Ong, Wai Chung; Goh, Siok Kun; Hart, Stefan; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4638-4658</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF).  Herein, we describe the design and synthesis of a series of small mol. 4-aryl-2-aminopyrimidine macrocycles and their biol. evaluation against the JAK family of kinase enzymes and FLT3.  The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of I, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, resp.) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, resp.).  Further profiling of I in preclin. species and mouse xenograft and allograft models is described.  Compd. I (SB1518) was selected as a development candidate and progressed into clin. trials where it is currently in phase 2 for MF and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtMiC4eaIMLVg90H21EOLACvtfcHk0ljUYlvZwdWEZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D&md5=1fa1a5250cae6ec8c59db67e593fb1f6</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.%25201%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658%26doi%3D10.1021%2Fjm200326p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintás-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeltz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3109</span>– <span class="NLM_lpage">3117</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-04-214957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1182%2Fblood-2009-04-214957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=20130243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3109-3117&author=A.+Quint%C3%A1s-Cardamaauthor=K.+Vaddiauthor=P.+Liuauthor=T.+Manshouriauthor=J.+Liauthor=P.+A.+Scherleauthor=E.+Caulderauthor=X.+Wenauthor=Y.+Liauthor=P.+Waeltzauthor=M.+Ruparauthor=T.+Burnauthor=Y.+Loauthor=J.+Kelleyauthor=M.+Covingtonauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=P.+Haleyauthor=H.+Kantarjianauthor=J.+S.+Fridmanauthor=S.+Verstovsek&title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1182%2Fblood-2009-04-214957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Vaddi, Kris; Liu, Phillip; Manshouri, Taghi; Li, Jun; Scherle, Peggy A.; Caulder, Eian; Wen, Xiaoming; Li, Yanlong; Waeltz, Paul; Rupar, Mark; Burn, Timothy; Lo, Yvonne; Kelley, Jennifer; Covington, Maryanne; Shepard, Stacey; Rodgers, James D.; Haley, Patrick; Kantarjian, Hagop; Fridman, Jordan S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3109-3117</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy.  Although most polycythemia vera patients carry the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mechanisms for constitutive JAK-STAT signaling in MPNs.  Most patients with primary myelofibrosis have elevated levels of JAK-dependent proinflammatory cytokines (eg, interleukin-6) consistent with our observation of JAK1 hyperactivation.  Accordingly, we evaluated the effectiveness of selective JAK1/2 inhibition in exptl. models relevant to MPNs and report on the effects of INCB018424, the first potent, selective, oral JAK1/JAK2 inhibitor to enter the clinic.  INCB018424 inhibited interleukin-6 signaling (50% inhibitory concn. [IC50] = 281nM), and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127nM).  In primary cultures, INCB018424 preferentially suppressed erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67nM) vs. healthy donors (IC50 > 400nM).  In a mouse model of JAK2V617F+ MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects.  Preliminary clin. results support these preclin. data and establish INCB018424 as a promising oral agent for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKGz1l6Y-CbVg90H21EOLACvtfcHk0lhGfqXle9GH8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D&md5=cd52b7013d76ed00ca2df22444c45160</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-04-214957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-04-214957%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWaeltz%26aufirst%3DP.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DKelley%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520selective%2520JAK1%252F2%2520inhibitor%2520INCB018424%253A%2520therapeutic%2520implications%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3109%26epage%3D3117%26doi%3D10.1182%2Fblood-2009-04-214957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forsyth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kearney, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcalas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epshteyn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galan, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyr, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pack, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridgway, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendreau, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassees, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolfrey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span> <span> </span><span class="NLM_article-title">SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">7653</span>– <span class="NLM_lpage">7658</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmcl.2012.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=23127890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1aqsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7653-7658&author=T.+Forsythauthor=P.+C.+Kearneyauthor=B.+G.+Kimauthor=H.+W.+Johnsonauthor=N.+Aayauthor=A.+Arcalasauthor=D.+S.+Brownauthor=V.+Chanauthor=J.+Chenauthor=H.+Duauthor=S.+Epshteynauthor=A.+A.+Galanauthor=T.+P.+Huynhauthor=M.+A.+Ibrahimauthor=B.+Kaneauthor=E.+S.+Koltunauthor=G.+Mannauthor=L.+E.+Meyrauthor=M.+S.+Leeauthor=G.+L.+Lewisauthor=R.+T.+Noguchiauthor=M.+Packauthor=B.+H.+Ridgwayauthor=X.+Shiauthor=C.+S.+Takeuchiauthor=P.+Zuauthor=J.+W.+Leahyauthor=J.+M.+Nussauthor=R.+Aoyamaauthor=S.+Engstauthor=S.+B.+Gendreauauthor=R.+Kasseesauthor=J.+Liauthor=S.+H.+Linauthor=J.+F.+Martiniauthor=T.+Stoutauthor=P.+Tongauthor=J.+Woolfreyauthor=W.+Zhangauthor=P.+Yu&title=SAR+and+in+vivo+evaluation+of+4-aryl-2-aminoalkylpyrimidines+as+potent+and+selective+Janus+kinase+2+%28JAK2%29+inhibitors&doi=10.1016%2Fj.bmcl.2012.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors</span></div><div class="casAuthors">Forsyth, Timothy; Kearney, Patrick C.; Kim, Byung Gyu; Johnson, Henry W. B.; Aay, Naing; Arcalas, Arlyn; Brown, David S.; Chan, Vicky; Chen, Jeff; Du, Hongwang; Epshteyn, Sergey; Galan, Adam A.; Huynh, Tai P.; Ibrahim, Mohamed A.; Kane, Brian; Koltun, Elena S.; Mann, Grace; Meyr, Lisa E.; Lee, Matthew S.; Lewis, Gary L.; Noguchi, Robin T.; Pack, Michael; Ridgway, Brian H.; Shi, Xian; Takeuchi, Craig S.; Zu, Peiwen; Leahy, James W.; Nuss, John M.; Aoyama, Ron; Engst, Stefan; Gendreau, Steven B.; Kassees, Robert; Li, Jia; Lin, Shwu-Hwa; Martini, Jean-Francois; Stout, Thomas; Tong, Philip; Woolfrey, John; Zhang, Wentao; Yu, Peiwen</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7653-7658</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report the discovery of a series of 4-aryl-2-aminoalkylpyrimidine derivs. as potent and selective JAK2 inhibitors.  High throughput screening of our inhouse compd. library led to the identification of hit 1 (I), from which optimization resulted in the discovery of highly potent and selective JAK2 inhibitors.  Advanced lead 10d demonstrated a significant dose-dependent pharmacodynamic and antitumor effect in a mouse xenograft model.  Based upon the desirable profile of 10d (XL019) it was advanced into clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNDaIhqnMysrVg90H21EOLACvtfcHk0lhGfqXle9GH8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1aqsr%252FJ&md5=4c193c7978bc54a4999ccbc537b9f292</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DForsyth%26aufirst%3DT.%26aulast%3DKearney%26aufirst%3DP.%2BC.%26aulast%3DKim%26aufirst%3DB.%2BG.%26aulast%3DJohnson%26aufirst%3DH.%2BW.%26aulast%3DAay%26aufirst%3DN.%26aulast%3DArcalas%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DD.%2BS.%26aulast%3DChan%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDu%26aufirst%3DH.%26aulast%3DEpshteyn%26aufirst%3DS.%26aulast%3DGalan%26aufirst%3DA.%2BA.%26aulast%3DHuynh%26aufirst%3DT.%2BP.%26aulast%3DIbrahim%26aufirst%3DM.%2BA.%26aulast%3DKane%26aufirst%3DB.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DMann%26aufirst%3DG.%26aulast%3DMeyr%26aufirst%3DL.%2BE.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DLewis%26aufirst%3DG.%2BL.%26aulast%3DNoguchi%26aufirst%3DR.%2BT.%26aulast%3DPack%26aufirst%3DM.%26aulast%3DRidgway%26aufirst%3DB.%2BH.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTakeuchi%26aufirst%3DC.%2BS.%26aulast%3DZu%26aufirst%3DP.%26aulast%3DLeahy%26aufirst%3DJ.%2BW.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DAoyama%26aufirst%3DR.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DGendreau%26aufirst%3DS.%2BB.%26aulast%3DKassees%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DS.%2BH.%26aulast%3DMartini%26aufirst%3DJ.%2BF.%26aulast%3DStout%26aufirst%3DT.%26aulast%3DTong%26aufirst%3DP.%26aulast%3DWoolfrey%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DP.%26atitle%3DSAR%2520and%2520in%2520vivo%2520evaluation%2520of%25204-aryl-2-aminoalkylpyrimidines%2520as%2520potent%2520and%2520selective%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7653%26epage%3D7658%26doi%3D10.1016%2Fj.bmcl.2012.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Champoux, J. J.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerases: Structure, Function and Mechanism</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.70.1.369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1146%2Fannurev.biochem.70.1.369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=11395412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsVeht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2001&pages=369-413&author=J.+J.+Champoux&title=DNA+topoisomerases%3A+Structure%2C+Function+and+Mechanism&doi=10.1146%2Fannurev.biochem.70.1.369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">DNA topoisomerases: structure, function, and mechanism</span></div><div class="casAuthors">Champoux, James J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">369-413</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 196 refs.  DNA topoisomerases solve the topol. problems assocd. with DNA replication, transcription, recombination, and chromatin remodeling by introducing temporary single- or double-strand breaks in the DNA.  In addn., these enzymes fine-tune the steady-state level of DNA supercoiling both to facilitate protein interactions with the DNA and to prevent excessive supercoiling that is deleterious.  In recent years, the crystal structures of a no. of topoisomerase fragments, representing nearly all of the known classes of enzymes, have been solved.  These structures provide remarkable insights into the mechanisms of these enzymes and complement previous conclusions based on biochem. analyses.  Surprisingly, despite little or no sequence homol., both type IA and type IIA topoisomerases from prokaryotes and the type IIA enzymes from eukaryotes share structural folds that appear to reflect functional motifs within crit. regions of the enzymes.  The type IB enzymes are structurally distinct from all other known topoisomerases but are similar to a class of enzymes referred to as tyrosine recombinases.  The structural themes common to all topoisomerases include hinged clamps that open and close to bind DNA, the presence of DNA binding cavities for temporary storage of DNA segments, and the coupling of protein conformational changes to DNA rotation or DNA movement.  For the type II topoisomerases, the binding and hydrolysis of ATP further modulate conformational changes in the enzymes to effect changes in DNA topol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Y4rDyIYy17Vg90H21EOLACvtfcHk0li1b9YQlaadSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsVeht7Y%253D&md5=67c3e38eb4fcb85527b33d7077309482</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.70.1.369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.70.1.369%26sid%3Dliteratum%253Aachs%26aulast%3DChampoux%26aufirst%3DJ.%2BJ.%26atitle%3DDNA%2520topoisomerases%253A%2520Structure%252C%2520Function%2520and%2520Mechanism%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2001%26volume%3D70%26spage%3D369%26epage%3D413%26doi%3D10.1146%2Fannurev.biochem.70.1.369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stiborova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckschlager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poljakova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabeta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frei, E.</span></span> <span> </span><span class="NLM_article-title">The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4218</span>– <span class="NLM_lpage">4238</span>, <span class="refDoi"> DOI: 10.2174/092986712802884286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.2174%2F092986712802884286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=22680633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlensL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=4218-4238&author=M.+Stiborovaauthor=T.+Eckschlagerauthor=J.+Poljakovaauthor=J.+Hrabetaauthor=V.+Adamauthor=R.+Kizekauthor=E.+Frei&title=The+Synergistic+Effects+of+DNA-Targeted+Chemotherapeutics+and+Histone+Deacetylase+Inhibitors+As+Therapeutic+Strategies+for+Cancer+Treatment&doi=10.2174%2F092986712802884286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment</span></div><div class="casAuthors">Stiborova, M.; Eckschlager, T.; Poljakova, J.; Hrabeta, J.; Adam, V.; Kizek, R.; Frei, E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4218-4238</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are a group of anticancer drugs which cause growth arrest and apoptosis of several tumor cells.  HDAC inhibitors have been also found to increase the anticancer efficacy of several treatment modalities i.e. chemotherapy or radiotherapy.  Here, we review the literature on combinations of HDAC inhibitors both with ionizing radiation and with other drugs, highlighting DNA-damaging compds.  The results of numerous studies with several types of cancer cells discussed in this review demonstrate that HDAC inhibitors enhance the effect of DNA damaging agents, such as inhibitors of topoisomerases, inhibitors of DNA synthesis, DNA-intercalators and agents covalently modifying DNA (i.e. doxorubicin, etoposid, 5-fluorouracil, cisplatin, melphalan, temozolomide and ellipticine) or of irradn.  Hence, the use of HDAC inhibitors combined with these antitumor drugs or ionizing radiation is a promising tool which may make treatment of patients suffering from many types of cancer more efficient.  Several mol. mechanisms are responsible for the obsd. higher sensitivity of tumor cells towards therapeutic agents elicited by HDAC inhibitors.  These mechanisms are discussed also in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0aVL3K8P2R7Vg90H21EOLACvtfcHk0li1b9YQlaadSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlensL8%253D&md5=a64b33f20e5a0880fd0a4f3dda6aec49</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.2174%2F092986712802884286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712802884286%26sid%3Dliteratum%253Aachs%26aulast%3DStiborova%26aufirst%3DM.%26aulast%3DEckschlager%26aufirst%3DT.%26aulast%3DPoljakova%26aufirst%3DJ.%26aulast%3DHrabeta%26aufirst%3DJ.%26aulast%3DAdam%26aufirst%3DV.%26aulast%3DKizek%26aufirst%3DR.%26aulast%3DFrei%26aufirst%3DE.%26atitle%3DThe%2520Synergistic%2520Effects%2520of%2520DNA-Targeted%2520Chemotherapeutics%2520and%2520Histone%2520Deacetylase%2520Inhibitors%2520As%2520Therapeutic%2520Strategies%2520for%2520Cancer%2520Treatment%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D4218%26epage%3D4238%26doi%3D10.2174%2F092986712802884286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cincinelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmi, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Porta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardile, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Signorino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frusciante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallavalle, S.</span></span> <span> </span><span class="NLM_article-title">Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0205018</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0205018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1371%2Fjournal.pone.0205018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30300374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtV2lt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=R.+Cincinelliauthor=L.+Mussoauthor=R.+Artaliauthor=M.+B.+Guglielmiauthor=I.+La+Portaauthor=C.+Melitoauthor=F.+Colelliauthor=F.+Cardileauthor=G.+Signorinoauthor=A.+Fucciauthor=M.+Fruscianteauthor=C.+Pisanoauthor=S.+Dallavalle&title=Hybrid+topoisomerase+I+and+HDAC+inhibitors+as+dual+action+anticancer+agents&doi=10.1371%2Fjournal.pone.0205018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents</span></div><div class="casAuthors">Cincinelli, Raffaella; Musso, Loana; Artali, Roberto; Guglielmi, Mario B.; La Porta, Ilaria; Melito, Carmela; Colelli, Fabiana; Cardile, Francesco; Signorino, Giacomo; Fucci, Alessandra; Frusciante, Martina; Pisano, Claudio; Dallavalle, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0205018/1-e0205018/22</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Recent studies have shown that HDAC inhibitors act synergistically with camptothecin derivs. in combination therapies.  To exploit this synergy, new hybrid mols. targeting simultaneously topoisomerase I and HDAC were designed.  In particular, a selected multivalent agent contg. a camptothecin and a SAHA-like template showed a broad spectrum of antiproliferative activity, with IC50 values in the nanomolar range.  Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzxTP2b69aALVg90H21EOLACvtfcHk0lgP-fAGBO8UHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtV2lt7g%253D&md5=8a96bd41321339c6ac43f108dd478cef</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0205018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0205018%26sid%3Dliteratum%253Aachs%26aulast%3DCincinelli%26aufirst%3DR.%26aulast%3DMusso%26aufirst%3DL.%26aulast%3DArtali%26aufirst%3DR.%26aulast%3DGuglielmi%26aufirst%3DM.%2BB.%26aulast%3DLa%2BPorta%26aufirst%3DI.%26aulast%3DMelito%26aufirst%3DC.%26aulast%3DColelli%26aufirst%3DF.%26aulast%3DCardile%26aufirst%3DF.%26aulast%3DSignorino%26aufirst%3DG.%26aulast%3DFucci%26aufirst%3DA.%26aulast%3DFrusciante%26aufirst%3DM.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DDallavalle%26aufirst%3DS.%26atitle%3DHybrid%2520topoisomerase%2520I%2520and%2520HDAC%2520inhibitors%2520as%2520dual%2520action%2520anticancer%2520agents%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0205018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of DNA topoisomerase II-targeted nucleosides</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4133</span>– <span class="NLM_lpage">4144</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmc.2017.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=28619446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWrtLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=4133-4144&author=H.+Matsumotoauthor=M.+Yamashitaauthor=T.+Taharaauthor=S.+Hayakawaauthor=S.+I.+Wadaauthor=K.+Tomiokaauthor=A.+Iida&title=Design%2C+synthesis%2C+and+evaluation+of+DNA+topoisomerase+II-targeted+nucleosides&doi=10.1016%2Fj.bmc.2017.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and evaluation of DNA topoisomerase II-targeted nucleosides</span></div><div class="casAuthors">Matsumoto, Hironobu; Yamashita, Mitsuaki; Tahara, Teruyuki; Hayakawa, Shinya; Wada, Shun-ichi; Tomioka, Kiyoshi; Iida, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4133-4144</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We developed novel nucleoside-based topoisomerase II selective inhibitors, e.g. I, and showed that small structural units, such as catechols, are essential for DNA topoisomerase II inhibitory activity.  Moreover, nucleoside analogs contg. TBS and 1,3-dithian moieties had potent and selective DNA topoisomerase II inhibitory activities.  In further expts., compd. I having aβconfiguration of the thymine moiety showed relatively strong growth inhibitory activity against cancer cell lines, and was more potent against all cancer cell lines than compd. II, which carries a thymine moiety in the α-configuration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ceB57cuFXrVg90H21EOLACvtfcHk0lgP-fAGBO8UHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWrtLjN&md5=acdd0e2f861441d80ee6eec4137bc611</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DH.%26aulast%3DYamashita%26aufirst%3DM.%26aulast%3DTahara%26aufirst%3DT.%26aulast%3DHayakawa%26aufirst%3DS.%26aulast%3DWada%26aufirst%3DS.%2BI.%26aulast%3DTomioka%26aufirst%3DK.%26aulast%3DIida%26aufirst%3DA.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520DNA%2520topoisomerase%2520II-targeted%2520nucleosides%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D4133%26epage%3D4144%26doi%3D10.1016%2Fj.bmc.2017.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1920</span>– <span class="NLM_lpage">1928</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.02.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmc.2018.02.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29519604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVGhsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=1920-1928&author=M.+Yamashitaauthor=T.+Taharaauthor=S.+Hayakawaauthor=H.+Matsumotoauthor=S.+I.+Wadaauthor=K.+Tomiokaauthor=A.+Iida&title=Synthesis+and+biological+evaluation+of+histone+deacetylase+and+DNA+topoisomerase+II-Targeted+inhibitors&doi=10.1016%2Fj.bmc.2018.02.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors</span></div><div class="casAuthors">Yamashita, Mitsuaki; Tahara, Teruyuki; Hayakawa, Shinya; Matsumoto, Hironobu; Wada, Shun-ichi; Tomioka, Kiyoshi; Iida, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1920-1928</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HDAC inhibitors enable histones to maintain a high degree of acetylation.  The resulting looser state of chromatin DNA may increase the accessibility of DNA drug targets and consequently improve the efficiency of anticancer drugs targeting DNA, such as Topo II inhibitors.  A novel class of nucleoside-SAHA derivs. has been designed and synthesized based on the synergistic antitumor effects of topoisomerase II and histone deacetylase inhibitors.  Their inhibitory activities toward histone deacetylases and Topo II, and their cytotoxicities in cancer cell lines, were evaluated.  Among the synthesized hybrid compds., compd. 16b showed the potent HDAC inhibitory activity at a low nanomolar level and exhibited antiproliferative activity toward cancer cell lines including MCF-7 (breast), HCT-116 (colon), and DU-145 (prostate) cancer cells at a low micromolar level.  Moreover, compd. 16a showed HDAC6-selectivity 20-fold over HDAC1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-RP6VIX6qLVg90H21EOLACvtfcHk0lgP-fAGBO8UHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVGhsro%253D&md5=99154f34a66242dc1a2501474a0bf091</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.02.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.02.042%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DM.%26aulast%3DTahara%26aufirst%3DT.%26aulast%3DHayakawa%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DH.%26aulast%3DWada%26aufirst%3DS.%2BI.%26aulast%3DTomioka%26aufirst%3DK.%26aulast%3DIida%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520histone%2520deacetylase%2520and%2520DNA%2520topoisomerase%2520II-Targeted%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D1920%26epage%3D1928%26doi%3D10.1016%2Fj.bmc.2018.02.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span> <span> </span><span class="NLM_article-title">Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor Interactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">908</span>, <span class="refDoi"> DOI: 10.1021/jm020449y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020449y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtl2ku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=883-908&author=V.+C.+Jordan&title=Antiestrogens+and+Selective+Estrogen+Receptor+Modulators+as+Multifunctional+Medicines.+1.+Receptor+Interactions&doi=10.1021%2Fjm020449y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor Interactions</span></div><div class="casAuthors">Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">883-908</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Antiestrogens and selective Estrogen receptor modulators as multifunctional medicines are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYmuDHzDbu5LVg90H21EOLACvtfcHk0lgP-fAGBO8UHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtl2ku78%253D&md5=b86cc4c3c4a4698a51eac9ab69ae9122</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm020449y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020449y%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DAntiestrogens%2520and%2520Selective%2520Estrogen%2520Receptor%2520Modulators%2520as%2520Multifunctional%2520Medicines.%25201.%2520Receptor%2520Interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D883%26epage%3D908%26doi%3D10.1021%2Fjm020449y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. B.</span></span> <span> </span><span class="NLM_article-title">Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4550</span>– <span class="NLM_lpage">4572</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVShsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4550-4572&author=C.+Tangauthor=C.+Liauthor=S.+Zhangauthor=Z.+Huauthor=J.+Wuauthor=C.+Dongauthor=J.+Huangauthor=H.+B.+Zhou&title=Novel+Bioactive+Hybrid+Compound+Dual+Targeting+Estrogen+Receptor+and+Histone+Deacetylase+for+the+Treatment+of+Breast+Cancer&doi=10.1021%2Facs.jmedchem.5b00099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer</span></div><div class="casAuthors">Tang, Chu; Li, Changhao; Zhang, Silong; Hu, Zhiye; Wu, Jun; Dong, Chune; Huang, Jian; Zhou, Hai-Bing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4550-4572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A strategy to develop chemotherapeutic agents by combining several active groups into a single mol. as a conjugate that can modulate multiple cellular pathways may produce compds. having higher efficacy compared to that of single-target drugs.  In this article, we describe the synthesis and evaluation of an array of dual-acting ER and histone deacetylase inhibitors.  These novel hybrid compds. combine an indirect antagonism structure motif of ER (OBHS, oxabicycloheptene sulfonate) with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA).  These OBHS-HDACi conjugates I (R = OH, NHOH; Ar = Ph, 1-naphthyl, 2-naphthyl, 4-MeC6H5, 3-MeC6H5, 2-MeC6H5, 2-MeOC6H5, etc.) exhibited good ER binding affinity and excellent ERα antagonistic activity, and they also exhibited potent inhibitory activities against HDACs.  Compared with the approved drug tamoxifen, these conjugates exhibited higher antitumor potency in ERα-pos. breast cancer cells (MCF-7).  Moreover, these conjugates not only showed selective anticancer activity that was more potent against MCF-7 cells than DU 145 (prostate cancer), but they had no toxicity toward normal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokzR9bn5jLU7Vg90H21EOLACvtfcHk0liDTZFeuzp3Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVShsbk%253D&md5=223b9c3c43e1f8f012efcd1771547ee1</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00099%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DH.%2BB.%26atitle%3DNovel%2520Bioactive%2520Hybrid%2520Compound%2520Dual%2520Targeting%2520Estrogen%2520Receptor%2520and%2520Histone%2520Deacetylase%2520for%2520the%2520Treatment%2520of%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4550%26epage%3D4572%26doi%3D10.1021%2Facs.jmedchem.5b00099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span> <span> </span><span class="NLM_article-title">A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>828</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2018.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejphar.2018.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29563065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXms1Glu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=828&publication_year=2018&pages=67-79&author=J.+Dongauthor=N.+Zhengauthor=X.+Wangauthor=C.+Tangauthor=P.+Yanauthor=H.+B.+Zhouauthor=J.+Huang&title=A+novel+HDAC6+inhibitor+exerts+an+anti-cancer+effect+by+triggering+cell+cycle+arrest+and+apoptosis+in+gastric+cancer&doi=10.1016%2Fj.ejphar.2018.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer</span></div><div class="casAuthors">Dong, Jing; Zheng, Nan; Wang, Xue; Tang, Chu; Yan, Ping; Zhou, Hai-bing; Huang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">828</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">67-79</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Gastric cancer is the second leading cause of cancer-related deaths in the world.  SAHA, one of the emerging HDAC inhibitor widely used for cancer treatment, has unignorable side effects, as it is a multi-target HDAC inhibitor.  However, it is believed that specifically targeting against fewer HDACs might decrease this cytoxic effect.  In our previous work, we have designed and synthesized a series of new compds., which specifically targets to HDAC6, and TC24 was one of them.  In this study, we further demonstrated that TC24 selectively inhibited the activity of HDAC6 other than class I HDACs.  TC24 exhibited strong anti-proliferation and anti-motility ability toward gastric cancer cells but had no obvious cytoxic effect on gastric normal GES-1 cells.  The anti-cancer effect of TC24 was triggered by G2/M cell cycle arrest, apoptosis and the loss of mitochondrial membrane potential.  Bcl-2, cdc 2 and cyclin B1 were decreased while Bax and cleaved-PARP were increased.  Also, TC24 suppressed tumor angiogenesis via the redn. of HIF-1α and VEGF.  All the above data supported that TC24 was a selective inhibitor of HDAC6 and strongly suppressed the proliferation of gastric cancer cells via inducing cell cycle arrest and cell apoptosis and tumor angiogenesis inhibition, suggesting TC24 is potentially a novel therapeutic agent for gastric cancer and the research on chem. structure of TC24 would promote the understanding of the drug design of related compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp0eAYChmLArVg90H21EOLACvtfcHk0liDTZFeuzp3Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXms1Glu7w%253D&md5=884a1ad92720fe980f8829c6ff412f52</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2018.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2018.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DH.%2BB.%26aulast%3DHuang%26aufirst%3DJ.%26atitle%3DA%2520novel%2520HDAC6%2520inhibitor%2520exerts%2520an%2520anti-cancer%2520effect%2520by%2520triggering%2520cell%2520cycle%2520arrest%2520and%2520apoptosis%2520in%2520gastric%2520cancer%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D828%26spage%3D67%26epage%3D79%26doi%3D10.1016%2Fj.ejphar.2018.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comninos, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stossi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of Estrogen Receptor Ligands with Bridged Oxabicyclic Cores Containing a Diarylethylene Motif: Estrogen Antagonists of Unusual Structure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">7261</span>– <span class="NLM_lpage">7274</span>, <span class="refDoi"> DOI: 10.1021/jm0506773</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0506773" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWku7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7261-7274&author=H.+B.+Zhouauthor=J.+S.+Comninosauthor=F.+Stossiauthor=B.+S.+Katzenellenbogenauthor=J.+A.+Katzenellenbogen&title=Synthesis+and+Evaluation+of+Estrogen+Receptor+Ligands+with+Bridged+Oxabicyclic+Cores+Containing+a+Diarylethylene+Motif%3A+Estrogen+Antagonists+of+Unusual+Structure&doi=10.1021%2Fjm0506773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of estrogen receptor ligands with bridged oxabicyclic cores containing a diarylethylene motif: estrogen antagonists of unusual structure</span></div><div class="casAuthors">Zhou, Hai-Bing; Comninos, John S.; Stossi, Fabio; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7261-7274</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of ligands for the estrogen receptor (ER), e.g., I, based on a three-dimensional structural motif consisting of a bridged oxabicyclic core (7-oxabicyclo[2.2.1]heptene or heptadiene) were synthesized and examd. for their receptor binding activity and as regulators of transcription through the two ER subtypes, ERα and ERβ.  The prototypical ligands also contain a 1,2-diarylethylene motif, common to many nonsteroidal estrogens, as an embellishment on the oxabicyclic core.  Thus, these ligands bear peripheral groups typically found in ER ligands, built here upon an overall three-dimensional core topol. that is unusual for these targets.  Most of these compds. were conveniently synthesized by a Diels-Alder reaction of various 3,4-diarylfurans with a variety of dienophiles, neat and under mild conditions in the absence of catalysts.  Some of the synthesized compds. display good binding affinity for the ER, and in transcription assays, the highest affinity compds. are antagonists on both ERs.  Mol. modeling studies suggest a structural basis for the antagonist activity of these compds.  These compds., based on the bicyclo[2.2.1]core system, expand the structural diversity of ligands that can be antagonists for the estrogen receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnZfRMyrwbwbVg90H21EOLACvtfcHk0liDTZFeuzp3Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWku7bN&md5=5e47c9d21b912183248dd66e22d0a5da</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm0506773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0506773%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%2BB.%26aulast%3DComninos%26aufirst%3DJ.%2BS.%26aulast%3DStossi%26aufirst%3DF.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520Estrogen%2520Receptor%2520Ligands%2520with%2520Bridged%2520Oxabicyclic%2520Cores%2520Containing%2520a%2520Diarylethylene%2520Motif%253A%2520Estrogen%2520Antagonists%2520of%2520Unusual%2520Structure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D7261%26epage%3D7274%26doi%3D10.1021%2Fjm0506773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puvvada, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerecitano, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gressick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunbar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitner Enschede, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humerickhouse, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J. F.</span></span> <span> </span><span class="NLM_article-title">Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1513257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1056%2FNEJMoa1513257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=26639348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2murrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=311-322&author=A.+W.+Robertsauthor=M.+S.+Davidsauthor=J.+M.+Pagelauthor=B.+S.+Kahlauthor=S.+D.+Puvvadaauthor=J.+F.+Gerecitanoauthor=T.+J.+Kippsauthor=M.+A.+Andersonauthor=J.+R.+Brownauthor=L.+Gressickauthor=S.+Wongauthor=M.+Dunbarauthor=M.+Zhuauthor=M.+B.+Desaiauthor=E.+Cerriauthor=S.+Heitner+Enschedeauthor=R.+A.+Humerickhouseauthor=W.+G.+Wierdaauthor=J.+F.+Seymour&title=Targeting+BCL2+with+Venetoclax+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1513257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Roberts, Andrew W.; Davids, Matthew S.; Pagel, John M.; Kahl, Brad S.; Puvvada, Soham D.; Gerecitano, John F.; Kipps, Thomas J.; Anderson, Mary Ann; Brown, Jennifer R.; Gressick, Lori; Wong, Shekman; Dunbar, Martin; Zhu, Ming; Desai, Monali B.; Cerri, Elisa; Enschede, Sari Heitner; Humerickhouse, Rod A.; Wierda, William G.; Seymour, John F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-322</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon.  Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells.  METHODS We conducted a phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL or small lymphocytic lymphoma (SLL) to assess safety, pharmacokinetic profile, and efficacy.  In the dose-escalation phase, 56 patients received active treatment in one of eight dose groups that ranged from 150 to 1200 mg per day.  In an expansion cohort, 60 addnl. patients were treated with a weekly stepwise ramp-up in doses as high as 400 mg per day.  RESULTS The majority of the study patients had received multiple previous treatments, and 89% had poor prognostic clin. or genetic features.  Venetoclax was active at all dose levels.  Clin. tumor lysis syndrome occurred in 3 of 56 patients in the dose-escalation cohort, with one death.  After adjustments to the dose-escalation schedule, clin. tumor lysis syndrome did not occur in any of the 60 patients in the expansion cohort.  Other toxic effects included mild diarrhea (in 52% of the patients), upper respiratory tract infection (in 48%), nausea (in 47%), and grade 3 or 4 neutropenia (in 41%).  A max. tolerated dose was not identified.  Among the 116 patients who received venetoclax, 92 (79%) had a response.  Response rates ranged from 71 to 79% among patients in subgroups with an adverse prognosis, including those with resistance to fludarabine, those with chromosome 17p deletions (deletion 17p CLL), and those with unmutated IGHV.  Complete remissions occurred in 20% of the patients, including 5% who had no minimal residual disease on flow cytometry.  The 15-mo progression-free survival est. for the 400-mg dose groups was 69%.  CONCLUSIONS Selective targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial responses in patients with relapsed CLL or SLL, including those with poor prognostic features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHQgYgnKl88rVg90H21EOLACvtfcHk0lgIcC7v3n6Iew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2murrP&md5=b371a37b76ee88cfc6ac47ea0eeea0e6</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1513257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1513257%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DPuvvada%26aufirst%3DS.%2BD.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DAnderson%26aufirst%3DM.%2BA.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DGressick%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DDunbar%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DDesai%26aufirst%3DM.%2BB.%26aulast%3DCerri%26aufirst%3DE.%26aulast%3DHeitner%2BEnschede%26aufirst%3DS.%26aulast%3DHumerickhouse%26aufirst%3DR.%2BA.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26atitle%3DTargeting%2520BCL2%2520with%2520Venetoclax%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D311%26epage%3D322%26doi%3D10.1056%2FNEJMoa1513257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, C.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.12.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmcl.2018.12.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30594434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Whu7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=349-352&author=R.+Zhouauthor=S.+Fangauthor=M.+Zhangauthor=Q.+Zhangauthor=J.+Huauthor=M.+Wangauthor=C.+Wangauthor=J.+Zhuauthor=A.+Shenauthor=X.+Chenauthor=C.+Zheng&title=Design%2C+synthesis%2C+and+bioactivity+evaluation+of+novel+Bcl-2%2FHDAC+dual-target+inhibitors+for+the+treatment+of+multiple+myeloma&doi=10.1016%2Fj.bmcl.2018.12.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma</span></div><div class="casAuthors">Zhou, Ruolan; Fang, Shaoyu; Zhang, Minmin; Zhang, Qingsen; Hu, Jian; Wang, Mingping; Wang, Chongqing; Zhu, Ju; Shen, Aijun; Chen, Xin; Zheng, Canhui</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-352</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is the second most common hematol. malignancy.  Almost all patients with MM eventually relapse, and most recommended treatment protocols for the patients with relapsed refractory MM comprise a combination of drugs with different mechanisms of action.  Therefore novel drugs are in urgent need in clinic.  Bcl-2 inhibitors and HDAC inhibitors were proved their anti-MM effect in clinic or under clin. trials, and they were further discovered to have synergistic interactions.  A series of Bcl-2/HDAC dual-target inhibitors were designed and synthesized.  Among them, compds. 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((6-(hydroxyamino)-6-oxohexyl)amino)-3-nitrophenyl)sulfonyl)benzamide, 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((6-(hydroxyamino)-6-oxohexyl)amino)-3-nitrophenyl)sulfonyl)benzamideoheptyl-amino-3-nitrophenyl-sulfonylbenzamide, 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((8-(hydroxyamino)-8-oxooctyl)amino)-3-nitrophenyl)sulfonyl)benzamide showed good inhibitory activities against HDAC6 and high binding affinities to Bcl-2 protein simultaneously.  They also displayed good growth inhibitory activities against human MM cell line RPMI-<8226≥, which proved their potential value for the treatment of multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqAqtNXkzMhbVg90H21EOLACvtfcHk0lgIcC7v3n6Iew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Whu7bO&md5=b320094c8d301d20a7b45bfb6bf899c2</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.052%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DFang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DC.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520bioactivity%2520evaluation%2520of%2520novel%2520Bcl-2%252FHDAC%2520dual-target%2520inhibitors%2520for%2520the%2520treatment%2520of%2520multiple%2520myeloma%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D349%26epage%3D352%26doi%3D10.1016%2Fj.bmcl.2018.12.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidanze, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasvold, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longenecker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovar, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faivre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magoc, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajaraman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kati, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, K. F.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">5585</span>– <span class="NLM_lpage">5623</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00628</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00628" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvVeisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=5585-5623&author=G.+S.+Sheppardauthor=L.+Wangauthor=S.+D.+Fidanzeauthor=L.+A.+Hasvoldauthor=D.+Liuauthor=J.+K.+Prattauthor=C.+H.+Parkauthor=K.+Longeneckerauthor=W.+Qiuauthor=M.+Torrentauthor=P.+J.+Kovarauthor=M.+Buiauthor=E.+Faivreauthor=X.+Huangauthor=X.+Linauthor=D.+Wilcoxauthor=L.+Zhangauthor=Y.+Shenauthor=D.+H.+Albertauthor=T.+J.+Magocauthor=G.+Rajaramanauthor=W.+M.+Katiauthor=K.+F.+McDaniel&title=Discovery+of+N-Ethyl-4-%5B2-%284-fluoro-2%2C6-dimethyl-phenoxy%29-5-%281-hydroxy-1-methyl-ethyl%29phenyl%5D-6-methyl-7-oxo-1H-pyrrolo%5B2%2C3-c%5Dpyridine-2-carboxamide+%28ABBV-744%29%2C+a+BET+Bromodomain+Inhibitor+with+Selectivity+for+the+Second+Bromodomain&doi=10.1021%2Facs.jmedchem.0c00628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain</span></div><div class="casAuthors">Sheppard, George S.; Wang, Le; Fidanze, Steven D.; Hasvold, Lisa A.; Liu, Dachun; Pratt, John K.; Park, Chang H.; Longenecker, Kenton; Qiu, Wei; Torrent, Maricel; Kovar, Peter J.; Bui, Mai; Faivre, Emily; Huang, Xiaoli; Lin, Xiaoyu; Wilcox, Denise; Zhang, Lu; Shen, Yu; Albert, Daniel H.; Magoc, Terrance J.; Rajaraman, Ganesh; Kati, Warren M.; McDaniel, Keith F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5585-5623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The BET family of proteins consists of BRD2, BRD3, BRD4, and BRDt.  Each protein contains two distinct bromodomains (BD1 and BD2).  BET family bromodomain inhibitors under clin. development for oncol. bind to each of the eight bromodomains with similar affinities.  We hypothesized that it may be possible to achieve an improved therapeutic index by selectively targeting subsets of the BET bromodomains.  Both BD1 and BD2 are highly conserved across family members (>70% identity), whereas BD1 and BD2 from the same protein exhibit a larger degree of divergence (~ 40% identity), suggesting selectivity between BD1 and BD2 of all family members would be more straightforward to achieve.  Exploiting the Asp144/His437 and Ile146/Val439 sequence differences (BRD4 BD1/BD2 numbering) allowed the identification of compd. 27 demonstrating greater than 100-fold selectivity for BRD4 BD2 over BRD4 BD1.  Further optimization to improve BD2 selectivity and oral bioavailability resulted in the clin. development compd. 46 (ABBV-744).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJtZIcWro0xLVg90H21EOLACvtfcHk0lgPhFG6dHZhew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvVeisrk%253D&md5=675827659c3c7b6099ccd667f4c60f95</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00628%26sid%3Dliteratum%253Aachs%26aulast%3DSheppard%26aufirst%3DG.%2BS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFidanze%26aufirst%3DS.%2BD.%26aulast%3DHasvold%26aufirst%3DL.%2BA.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DPratt%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLongenecker%26aufirst%3DK.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DKovar%26aufirst%3DP.%2BJ.%26aulast%3DBui%26aufirst%3DM.%26aulast%3DFaivre%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DWilcox%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DMagoc%26aufirst%3DT.%2BJ.%26aulast%3DRajaraman%26aufirst%3DG.%26aulast%3DKati%26aufirst%3DW.%2BM.%26aulast%3DMcDaniel%26aufirst%3DK.%2BF.%26atitle%3DDiscovery%2520of%2520N-Ethyl-4-%255B2-%25284-fluoro-2%252C6-dimethyl-phenoxy%2529-5-%25281-hydroxy-1-methyl-ethyl%2529phenyl%255D-6-methyl-7-oxo-1H-pyrrolo%255B2%252C3-c%255Dpyridine-2-carboxamide%2520%2528ABBV-744%2529%252C%2520a%2520BET%2520Bromodomain%2520Inhibitor%2520with%2520Selectivity%2520for%2520the%2520Second%2520Bromodomain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D5585%26epage%3D5623%26doi%3D10.1021%2Facs.jmedchem.0c00628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">112868</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2020.112868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=33077265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFaht7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2021&pages=112868&author=J.+Chenauthor=Y.+Liauthor=J.+Zhangauthor=M.+Zhangauthor=A.+Weiauthor=H.+Liuauthor=Z.+Xieauthor=W.+Renauthor=W.+Duanauthor=Z.+Zhangauthor=A.+Shenauthor=Y.+Hu&title=Discovery+of+selective+HDAC%2FBRD4+dual+inhibitors+as+epigenetic+probes&doi=10.1016%2Fj.ejmech.2020.112868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes</span></div><div class="casAuthors">Chen, Jingjing; Li, Yalei; Zhang, Jie; Zhang, Minmin; Wei, Aihuan; Liu, Hongchun; Xie, Zhicheng; Ren, Wenming; Duan, Wenwen; Zhang, Zhuo; Shen, Aijun; Hu, Youhong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112868</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">According to the binding mode of ABBV-744 with bromodomains and the cape space of HDAC, the novel selective HDAC/BRD4 dual inhibitors were designed and synthesized by the pharmacophore fusion strategy.  Evaluating the biomol. activities through SARs exploration identified three kinds of selective dual inhibitors 41c (HDAC1/BRD4), 43a (pan-HDAC/BRD4) and 43d (HDAC6/BRD4(BD2)), whose target-related cellular activities in MV-4-11 cells were also confirmed.  Significantly, the selective dual inhibitor 41c (HDAC1/BRD4) exhibited synergistic effects against MV-4-11 cells, which strongly induced G0/G1 cell cycle arrest and apoptosis, and the first HDAC6/BRD4(BD2) dual inhibitor was found.  This study provides support for selective HDAC/BRD4 dual inhibitors as epigenetic probes based on pyrrolopyridone core for the future biol. evaluation in different cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbMygNv9rC2bVg90H21EOLACvtfcHk0lgPhFG6dHZhew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFaht7nE&md5=b39c2be6ed98f0f5ffee7bf8ac1f7cf4</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112868%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DW.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520selective%2520HDAC%252FBRD4%2520dual%2520inhibitors%2520as%2520epigenetic%2520probes%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D209%26spage%3D112868%26doi%3D10.1016%2Fj.ejmech.2020.112868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venta-Perez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ham, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">Development of a histone deacetylase 6 inhibitor and its biological effects</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">15704</span>– <span class="NLM_lpage">15709</span>, <span class="refDoi"> DOI: 10.1073/pnas.1313893110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1073%2Fpnas.1313893110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=24023063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1WlurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=15704-15709&author=J.+H.+Leeauthor=A.+Mahendranauthor=Y.+S.+Yaoauthor=L.+Ngoauthor=G.+Venta-Perezauthor=M.+L.+Choyauthor=N.+Kimauthor=W.+S.+Hamauthor=R.+Breslowauthor=P.+A.+Marks&title=Development+of+a+histone+deacetylase+6+inhibitor+and+its+biological+effects&doi=10.1073%2Fpnas.1313893110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a histone deacetylase 6 inhibitor and its biological effects</span></div><div class="casAuthors">Lee, Ju-Hee; Mahendran, Adaickapillai; Yao, Yuanshan; Ngo, Lang; Venta-Perez, Gisela; Choy, Megan L.; Kim, Nathaniel; Ham, Won-Seok; Breslow, Ronald; Marks, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">15704-15709,S15704/1-S15704/2</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Development of isoform-selective histone deacetylase (HDAC) inhibitors is important in elucidating the function of individual HDAC enzymes and their potential as therapeutic agents.  Among the eleven zinc-dependent HDACs in humans, HDAC6 is structurally and functionally unique.  Here, we show that a hydroxamic acid-based small-mol. N-hydroxy-4-(2-[(2-hydroxyethyl)(phenyl)amino]-2-oxoethyl)benzamide (HPOB) selectively inhibits HDAC6 catalytic activity in vivo and in vitro.  HPOB causes growth inhibition of normal and transformed cells but does not induce cell death.  HPOB enhances the effectiveness of DNA-damaging anticancer drugs in transformed cells but not normal cells.  HPOB does not block the ubiquitin-binding activity of HDAC6.  The HDAC6-selective inhibitor HPOB has therapeutic potential in combination therapy to enhance the potency of anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvynfT8vxTmLVg90H21EOLACvtfcHk0lgPhFG6dHZhew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1WlurjP&md5=e32e88dfc23a049ebe59b8d62beb8a8c</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313893110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313893110%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMahendran%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DY.%2BS.%26aulast%3DNgo%26aufirst%3DL.%26aulast%3DVenta-Perez%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DM.%2BL.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DHam%26aufirst%3DW.%2BS.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DDevelopment%2520of%2520a%2520histone%2520deacetylase%25206%2520inhibitor%2520and%2520its%2520biological%2520effects%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D15704%26epage%3D15709%26doi%3D10.1073%2Fpnas.1313893110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. P.</span></span> <span> </span><span class="NLM_article-title">HPOB, an HDAC6 inhibitor, attenuates corticosterone-induced injury in rat adrenal pheochromocytoma PC12 cells by inhibiting mitochondrial GR translocation and the intrinsic apoptosis pathway</span>. <i>Neurochem. Int.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1016/j.neuint.2016.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.neuint.2016.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27522966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWmsbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2016&pages=239-251&author=Z.+Y.+Liauthor=Q.+Z.+Liauthor=L.+Chenauthor=B.+D.+Chenauthor=C.+Zhangauthor=X.+Wangauthor=W.+P.+Li&title=HPOB%2C+an+HDAC6+inhibitor%2C+attenuates+corticosterone-induced+injury+in+rat+adrenal+pheochromocytoma+PC12+cells+by+inhibiting+mitochondrial+GR+translocation+and+the+intrinsic+apoptosis+pathway&doi=10.1016%2Fj.neuint.2016.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">HPOB, an HDAC6 inhibitor, attenuates corticosterone-induced injury in rat adrenal pheochromocytoma PC12 cells by inhibiting mitochondrial GR translocation and the intrinsic apoptosis pathway</span></div><div class="casAuthors">Li, Zong-yang; Li, Qing-zhong; Chen, Lei; Chen, Bao-dong; Zhang, Ce; Wang, Xiang; Li, Wei-ping</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry International</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">239-251</span>CODEN:
                <span class="NLM_cas:coden">NEUIDS</span>;
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">High levels of glucocorticoids (GCs) have been reported to damage normal hippocampal neurons, and such damage has been pos. correlated with major depression (MD) and chronic stress.  Our previous study showed that HDAC6 might be a potential target to regulate GC-induced glucocorticoid receptor (GR) translocation to the mitochondria and subsequent apoptosis.  In the present study, we investigated the effect of HPOB, a selective HDAC6 inhibitor, on corticosterone (Cort)-induced apoptosis and explored the possible mechanism of action of HPOB in rat adrenal pheochromocytoma (PC12) cells, which possesses typical neuron features and expresses high levels of glucocorticoid receptors.  We demonstrated that pre-treatment with HPOB remarkably reduced Cort-induced cytotoxicity and confirmed the anti-apoptotic effect of HPOB via the caspase-3 activity assay and H33342/PI and TUNEL double staining.  Mechanistically, we demonstrated that HPOB reversed the Cort-induced elevation of GR levels in the mitochondria and blocked concomitant mitochondrial dysfunction and the intrinsic apoptosis pathway.  Furthermore, HPOB was shown to attenuate expression of the multi-chaperone machinery (Hsp90-Hop-Hsp70) and cooperate with mitochondrial translocase of the outer/inner membrane (TOM/TIM) complex recruitment by triggering hyperacetylation of Hsps through HDAC6 inhibition.  Considering all of these findings, the neuroprotective effect of HPOB demonstrated the crucial role of HDAC6 inhibition in reducing Cort-induced apoptosis in PC12 cells.  The data further suggested that the anti-apoptotic activity of HDAC6 inhibition against the mitochondria-mediated impairment pathway might be mechanistically linked to the hyperacetylation of Hsps and consequent suppression of GR translocation to the mitochondria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0ofsFDJa8VbVg90H21EOLACvtfcHk0lhYtI55mSJymg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWmsbzK&md5=75814b2bc8c066e8899b8cbd8be414e5</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.neuint.2016.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuint.2016.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%2BY.%26aulast%3DLi%26aufirst%3DQ.%2BZ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DB.%2BD.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DW.%2BP.%26atitle%3DHPOB%252C%2520an%2520HDAC6%2520inhibitor%252C%2520attenuates%2520corticosterone-induced%2520injury%2520in%2520rat%2520adrenal%2520pheochromocytoma%2520PC12%2520cells%2520by%2520inhibiting%2520mitochondrial%2520GR%2520translocation%2520and%2520the%2520intrinsic%2520apoptosis%2520pathway%26jtitle%3DNeurochem.%2520Int.%26date%3D2016%26volume%3D99%26spage%3D239%26epage%3D251%26doi%3D10.1016%2Fj.neuint.2016.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boo, Y. C.</span></span> <span> </span><span class="NLM_article-title">Screening of an Epigenetic Drug Library Identifies 4-((hydroxyamino)carbonyl)-N-(2-hydroxyethyl)-N-Phenyl-Benzeneacetamide that Reduces Melanin Synthesis by Inhibiting Tyrosinase Activity Independently of Epigenetic Mechanisms</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4589</span>, <span class="refDoi"> DOI: 10.3390/ijms21134589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3390%2Fijms21134589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFymsbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=4589&author=H.+Songauthor=Y.+J.+Hwangauthor=J.+W.+Haauthor=Y.+C.+Boo&title=Screening+of+an+Epigenetic+Drug+Library+Identifies+4-%28%28hydroxyamino%29carbonyl%29-N-%282-hydroxyethyl%29-N-Phenyl-Benzeneacetamide+that+Reduces+Melanin+Synthesis+by+Inhibiting+Tyrosinase+Activity+Independently+of+Epigenetic+Mechanisms&doi=10.3390%2Fijms21134589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Screening of an epigenetic drug library identifies 4-((hydroxyamino)carbonyl)-N-(2-hydroxyethyl)-N-phenyl-benzeneacetamide that reduces melanin synthesis by inhibiting tyrosinase activity independently of epigenetic mechanisms</span></div><div class="casAuthors">Song, Hyerim; Hwang, Yun Jeong; Ha, Jae Won; Boo, Yong Chool</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4589</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The aim of this study was to identify novel antimelanogenic drugs from an epigenetic screening library contg. various modulators targeting DNA methyltransferases, histone deacetylases, and other related enzymes/proteins.  Of 141 drugs tested, K8 (4-((hydroxyamino)carbonyl)-N-(2-hydroxyethyl)-N-phenyl-benzeneacetamide; HPOB) was found to effectively inhibit the α-MSH (α-MSH)-induced melanin synthesis in B16-F10 murine melanoma cells without accompanying cytotoxicity.  Addnl. expts. showed that K8 did not significantly reduce the mRNA and protein level of tyrosinase (TYR) or microphthalmia-assocd. transcription factor (MITF) in cells, but it potently inhibited the catalytic activity TYR in vitro (IC50, 1.1-1.5μM) as compared to β-arbutin (IC50, 500-700μM) or kojic acid (IC50, 63μM).  K8 showed copper chelating activity similar to kojic acid.  Therefore, these data suggest that K8 inhibits cellular melanin synthesis not by downregulation of TYR protein expression through an epigenetic mechanism, but by direct inhibition of TYR catalytic activity through copper chelation.  Metal chelating activity of K8 is not surprising because it is known to inhibit histone deacetylase (HDAC) 6 through zinc chelation.  This study identified K8 as a potent inhibitor of cellular melanin synthesis, which may be useful for the treatment of hyperpigmentation disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovjTeOq5Eo8rVg90H21EOLACvtfcHk0lhYtI55mSJymg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFymsbjI&md5=5d4986f5dd34d3b8dc4ec031ab0e672f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.3390%2Fijms21134589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21134589%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DH.%26aulast%3DHwang%26aufirst%3DY.%2BJ.%26aulast%3DHa%26aufirst%3DJ.%2BW.%26aulast%3DBoo%26aufirst%3DY.%2BC.%26atitle%3DScreening%2520of%2520an%2520Epigenetic%2520Drug%2520Library%2520Identifies%25204-%2528%2528hydroxyamino%2529carbonyl%2529-N-%25282-hydroxyethyl%2529-N-Phenyl-Benzeneacetamide%2520that%2520Reduces%2520Melanin%2520Synthesis%2520by%2520Inhibiting%2520Tyrosinase%2520Activity%2520Independently%2520of%2520Epigenetic%2520Mechanisms%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D4589%26doi%3D10.3390%2Fijms21134589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demyanenko, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzreyan, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzdensky, A. B.</span></span> <span> </span><span class="NLM_article-title">Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of alpha-phenyl tropolone, HPOB, and sodium valproate</span>. <i>Brain Res. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1016/j.brainresbull.2020.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.brainresbull.2020.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32592806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSku7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2020&pages=151-165&author=S.+V.+Demyanenkoauthor=V.+A.+Dzreyanauthor=A.+B.+Uzdensky&title=Overexpression+of+HDAC6%2C+but+not+HDAC3+and+HDAC4+in+the+penumbra+after+photothrombotic+stroke+in+the+rat+cerebral+cortex+and+the+neuroprotective+effects+of+alpha-phenyl+tropolone%2C+HPOB%2C+and+sodium+valproate&doi=10.1016%2Fj.brainresbull.2020.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of α-phenyl tropolone, HPOB, and sodium valproate</span></div><div class="casAuthors">Demyanenko, S. V.; Dzreyan, V. A.; Uzdensky, A. B.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-165</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We studied effects of photothrombotic stroke on intracellular level and cellular localization of histone deacetylases HDAC3, HDAC4 and HDAC6 in rat brain cortex, and tested the potential neuroprotector ability of their inhibitors.  The background level of HDAC3, HDAC4 and HDAC6 in the rat cerebral cortex was relatively low.  HDAC3 localized in the nuclei of some neurons and few astrocytes.  HDAC4 was found in the neuronal cytoplasm.  After PTS, their levels in penumbra did not change, but HDAC4 appeared in the nuclei of some cells.  Its level in the cytoplasmic, but not nuclear fraction of penumbra decreased at 24, but not 4 h after PTS.  HDAC6 was upregulated in neurons and astrocytes in the PTS-induced penumbra, esp. in the nuclear fraction.  Unlike HDAC3 and HDAC4, HDAC6 co-localized with TUNEL-pos. apoptotic cells.  Inhibitory anal. confirmed the involvement of HDAC6, but not HDAC3 and HDAC4 in neurodegeneration.  HDAC6 inhibitor HPOB, HDAC2/8 inhibitor α-Ph tropolone, and non-specific histone deacetylase inhibitor sodium valproate, but not HDAC3 inhibitor BRD3308, or HDAC4 inhibitor LMK235, decreased PTS-induced infarction vol. in the mouse brain, reduced apoptosis, and recovered the motor behavior.  HPOB also restored PTS-impaired acetylation of α-tubulin. α-Ph tropolone restored acetylation of histone H4 in penumbra cells.  These results suggest that histone deacetylases HDAC6 and HDAC2 are the possible mol. targets for anti-ischemic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdpe4-voSvY7Vg90H21EOLACvtfcHk0lhYtI55mSJymg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSku7zJ&md5=b40bc6d52f2899cb2c72c03e34099874</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresbull.2020.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresbull.2020.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DDemyanenko%26aufirst%3DS.%2BV.%26aulast%3DDzreyan%26aufirst%3DV.%2BA.%26aulast%3DUzdensky%26aufirst%3DA.%2BB.%26atitle%3DOverexpression%2520of%2520HDAC6%252C%2520but%2520not%2520HDAC3%2520and%2520HDAC4%2520in%2520the%2520penumbra%2520after%2520photothrombotic%2520stroke%2520in%2520the%2520rat%2520cerebral%2520cortex%2520and%2520the%2520neuroprotective%2520effects%2520of%2520alpha-phenyl%2520tropolone%252C%2520HPOB%252C%2520and%2520sodium%2520valproate%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D2020%26volume%3D162%26spage%3D151%26epage%3D165%26doi%3D10.1016%2Fj.brainresbull.2020.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venta-Perez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">Creation of a histone deacetylase 6 inhibitor and its biological effects</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">12005</span>– <span class="NLM_lpage">12010</span>, <span class="refDoi"> DOI: 10.1073/pnas.1515882112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1073%2Fpnas.1515882112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=26371309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2ntLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=12005-12010&author=J.+H.+Leeauthor=Y.+Yaoauthor=A.+Mahendranauthor=L.+Ngoauthor=G.+Venta-Perezauthor=M.+L.+Choyauthor=R.+Breslowauthor=P.+A.+Marks&title=Creation+of+a+histone+deacetylase+6+inhibitor+and+its+biological+effects&doi=10.1073%2Fpnas.1515882112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a histone deacetylase 6 inhibitor and its biological effects</span></div><div class="casAuthors">Lee, Ju-Hee; Yao, Yuanshan; Mahendran, Adaickapillai; Ngo, Lang; Venta-Perez, Gisela; Choy, Megan L.; Breslow, Ronald; Marks, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">12005-12010</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The authors report the development of a potent, selective histone deacetylase 6 (HDAC6) inhibitor, HPB (N-hydroxy-4-[(N-(((2-hydroxyethyl)-2-phenylacetamido)methyl)benzamide)]).  This HDAC6 inhibitor blocks growth of normal and transformed cells but does not induce death of normal cells.  The HDAC6 inhibitor alone is as effective as paclitaxel in anticancer activity in tumor-bearing mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonHNFE0-PzyLVg90H21EOLACvtfcHk0ljP1IXZ5kdSEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2ntLjK&md5=d6dc50c8c83e0b03c5ecebc3da3a96c7</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1515882112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1515882112%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DMahendran%26aufirst%3DA.%26aulast%3DNgo%26aufirst%3DL.%26aulast%3DVenta-Perez%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DM.%2BL.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DCreation%2520of%2520a%2520histone%2520deacetylase%25206%2520inhibitor%2520and%2520its%2520biological%2520effects%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D12005%26epage%3D12010%26doi%3D10.1073%2Fpnas.1515882112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Villarroel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9891</span>– <span class="NLM_lpage">9899</span>, <span class="refDoi"> DOI: 10.1021/jm301098e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301098e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9891-9899&author=J.+A.+Bergmanauthor=K.+Woanauthor=P.+Perez-Villarroelauthor=A.+Villagraauthor=E.+M.+Sotomayorauthor=A.+P.+Kozikowski&title=Selective+histone+deacetylase+6+inhibitors+bearing+substituted+urea+linkers+inhibit+melanoma+cell+growth&doi=10.1021%2Fjm301098e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth</span></div><div class="casAuthors">Bergman, Joel A.; Woan, Karrune; Perez-Villarroel, Patricio; Villagra, Alejandro; Sotomayor, Eduardo M.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9891-9899</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The incidence of malignant melanoma has dramatically increased in recent years thus requiring the need for improved therapeutic strategies.  In our efforts to design selective histone deactylase inhibitors (HDACI), we discovered that the aryl urea 1 is a modestly potent yet nonselective inhibitor.  Structure-activity relationship studies revealed that adding substituents to the nitrogen atom of the urea so as to generate compds. bearing a branched linker group results in increased potency and selectivity for HDAC6.  Compd. 5g shows low nanomolar inhibitory potency against HDAC6 and a selectivity of ∼600-fold relative to the inhibition of HDAC1.  These HDACIs were evaluated for their ability to inhibit the growth of B16 melanoma cells with the most potent and selective HDAC6I being found to decrease tumor cell growth.  To the best of our knowledge, this work constitutes the first report of HDAC6-selective inhibitors that possess antiproliferative effects against melanoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkTtPLqvwsrVg90H21EOLACvtfcHk0ljP1IXZ5kdSEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrbJ&md5=d6be4c0efb3922fc35d814ba00ae9ed1</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fjm301098e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301098e%26sid%3Dliteratum%253Aachs%26aulast%3DBergman%26aufirst%3DJ.%2BA.%26aulast%3DWoan%26aufirst%3DK.%26aulast%3DPerez-Villarroel%26aufirst%3DP.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSelective%2520histone%2520deacetylase%25206%2520inhibitors%2520bearing%2520substituted%2520urea%2520linkers%2520inhibit%2520melanoma%2520cell%2520growth%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9891%26epage%3D9899%26doi%3D10.1021%2Fjm301098e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ledezma, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano-Mejia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollard, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, R.</span></span> <span> </span><span class="NLM_article-title">Indocyanine Green-Nexturastat A-PLGA Nanoparticles Combine Photothermal and Epigenetic Therapy for Melanoma</span>. <i>Nanomaterials</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">161</span>, <span class="refDoi"> DOI: 10.3390/nano10010161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3390%2Fnano10010161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFWhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=161&author=D.+K.+Ledezmaauthor=P.+B.+Balakrishnanauthor=J.+Cano-Mejiaauthor=E.+E.+Sweeneyauthor=M.+Hadleyauthor=C.+M.+Bollardauthor=A.+Villagraauthor=R.+Fernandes&title=Indocyanine+Green-Nexturastat+A-PLGA+Nanoparticles+Combine+Photothermal+and+Epigenetic+Therapy+for+Melanoma&doi=10.3390%2Fnano10010161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Indocyanine green-nexturastat A-PLGA nanoparticles combine photothermal and epigenetic therapy for melanoma</span></div><div class="casAuthors">Ledezma, Debbie K.; Balakrishnan, Preethi B.; Cano-Mejia, Juliana; Sweeney, Elizabeth E.; Hadley, Melissa; Bollard, Catherine M.; Villagra, Alejandro; Fernandes, Rohan</div><div class="citationInfo"><span class="NLM_cas:title">Nanomaterials</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">161</span>CODEN:
                <span class="NLM_cas:coden">NANOKO</span>;
        ISSN:<span class="NLM_cas:issn">2079-4991</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In this study, we describe poly (lactic-co-glycolic) acid (PLGA)-based nanoparticles that combine photothermal therapy (PTT) with epigenetic therapy for melanoma.  Specifically, we co-encapsulated indocyanine green (ICG), a PTT agent, and Nexturastat A (NextA), an epigenetic drug within PLGA nanoparticles (ICG-NextA-PLGA; INAPs).  We hypothesized that combining PTT with epigenetic therapy elicits favorable cytotoxic and immunomodulatory responses that result in improved survival in melanoma-bearing mice.  We utilized a nanoemulsion synthesis scheme to co-encapsulate ICG and NextA within stable and monodispersed INAPs.  The INAPs exhibited concn.-dependent and near-IR (NIR) laser power-dependent photothermal heating characteristics, and functioned as effective single-use agents for PTT of melanoma cells in vitro.  The INAPs functioned as effective epigenetic therapy agents by inhibiting the expression of pan-histone deacetylase (HDAC) and HDAC6-specific activity in melanoma cells in vitro.  When used for both PTT and epigenetic therapy in vitro, the INAPs increased the expression of co-stimulatory mols. and major histocompatibility complex (MHC) Class I in melanoma cells relative to controls.  These advantages persisted in vivo in a syngeneic murine model of melanoma, where the combination therapy slowed tumor progression and improved median survival.  These findings demonstrate the potential of INAPs as agents of PTT and epigenetic therapy for melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMLSZ-4Na_P7Vg90H21EOLACvtfcHk0ljP1IXZ5kdSEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFWhsbg%253D&md5=5422f34dcb9de9957dc53552c20393ee</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.3390%2Fnano10010161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fnano10010161%26sid%3Dliteratum%253Aachs%26aulast%3DLedezma%26aufirst%3DD.%2BK.%26aulast%3DBalakrishnan%26aufirst%3DP.%2BB.%26aulast%3DCano-Mejia%26aufirst%3DJ.%26aulast%3DSweeney%26aufirst%3DE.%2BE.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DBollard%26aufirst%3DC.%2BM.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DFernandes%26aufirst%3DR.%26atitle%3DIndocyanine%2520Green-Nexturastat%2520A-PLGA%2520Nanoparticles%2520Combine%2520Photothermal%2520and%2520Epigenetic%2520Therapy%2520for%2520Melanoma%26jtitle%3DNanomaterials%26date%3D2020%26volume%3D10%26spage%3D161%26doi%3D10.3390%2Fnano10010161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahakian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noonepalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia-Hernandez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla-Ibarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">6136</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-42237-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fs41598-019-42237-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30992475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FmtFOrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=6136&author=T.+Knoxauthor=E.+Sahakianauthor=D.+Banikauthor=M.+Hadleyauthor=E.+Palmerauthor=S.+Noonepalleauthor=J.+Kimauthor=J.+Powersauthor=M.+Gracia-Hernandezauthor=V.+Oliveiraauthor=F.+Chengauthor=J.+Chenauthor=C.+Barinkaauthor=J.+Pinilla-Ibarzauthor=N.+H.+Leeauthor=A.+Kozikowskiauthor=A.+Villagra&title=Selective+HDAC6+inhibitors+improve+anti-PD-1+immune+checkpoint+blockade+therapy+by+decreasing+the+anti-inflammatory+phenotype+of+macrophages+and+down-regulation+of+immunosuppressive+proteins+in+tumor+cells&doi=10.1038%2Fs41598-019-42237-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells</span></div><div class="casAuthors">Knox Tessa; Banik Debarati; Hadley Melissa; Palmer Erica; Noonepalle Satish; Kim Jennifer; Gracia-Hernandez Maria; Cheng Fengdong; Chen Jie; Lee Norman H; Villagra Alejandro; Sahakian Eva; Powers John; Pinilla-Ibarz Javier; Oliveira Vasco; Barinka Cyril; Kozikowski Alan</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6136</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) are involved in diverse cellular regulatory mechanisms including non-canonical functions outside the chromatin environment.  Several publications have demonstrated that selective HDAC inhibitors (HDACi) can influence tumor immunogenicity and the functional activity of specific immune cells.  In particular, the selective inhibition of HDAC6 has been reported to decrease tumor growth in several malignancies.  However, there is still no clarity about the cellular components mediating this effect.  In this study, we evaluated the HDAC6i Nexturastat A as a priming agent to facilitate the transition of the tumor microenvironment from "cold" to "hot", and potentially augment immune check-point blockade therapies.  This combination modality demonstrated to significantly reduce tumor growth in syngeneic melanoma tumor models.  Additionally, we observed a complete neutralization of the up-regulation of PD-L1 and other immunosuppressive pathways induced by the treatment with anti-PD-1 blockade.  This combination also showed profound changes in the tumor microenvironment such as enhanced infiltration of immune cells, increased central and effector T cell memory, and a significant reduction of pro-tumorigenic M2 macrophages.  The evaluation of individual components of the tumor microenvironment suggested that the in vivo anti-tumor activity of HDAC6i is mediated by its effect on tumor cells and tumor-associated macrophages, and not directly over T cells.  Overall, our results indicate that selective HDAC6i could be used as immunological priming agents to sensitize immunologically "cold" tumors and subsequently improve ongoing immune check-point blockade therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSl6RaBRQ4Kdw8IxFYvehhofW6udTcc2ebIzTFxmfbmEbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FmtFOrsg%253D%253D&md5=137a9261e021e60b002d9312608eba76</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-42237-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-42237-3%26sid%3Dliteratum%253Aachs%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DSahakian%26aufirst%3DE.%26aulast%3DBanik%26aufirst%3DD.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DE.%26aulast%3DNoonepalle%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DGracia-Hernandez%26aufirst%3DM.%26aulast%3DOliveira%26aufirst%3DV.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DPinilla-Ibarz%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DN.%2BH.%26aulast%3DKozikowski%26aufirst%3DA.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DSelective%2520HDAC6%2520inhibitors%2520improve%2520anti-PD-1%2520immune%2520checkpoint%2520blockade%2520therapy%2520by%2520decreasing%2520the%2520anti-inflammatory%2520phenotype%2520of%2520macrophages%2520and%2520down-regulation%2520of%2520immunosuppressive%2520proteins%2520in%2520tumor%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D6136%26doi%3D10.1038%2Fs41598-019-42237-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span> <span> </span><span class="NLM_article-title">The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma</span>. <i>Biosci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">BSR20181916</span>, <span class="refDoi"> DOI: 10.1042/BSR20181916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1042%2FBSR20181916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30782785" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=BSR20181916&author=X.+Sunauthor=Y.+Xieauthor=X.+Sunauthor=Y.+Yaoauthor=H.+Liauthor=Z.+Liauthor=R.+Yaoauthor=K.+Xu&title=The+selective+HDAC6+inhibitor+Nexturastat+A+induces+apoptosis%2C+overcomes+drug+resistance+and+inhibits+tumor+growth+in+multiple+myeloma&doi=10.1042%2FBSR20181916"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1042%2FBSR20181916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBSR20181916%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DK.%26atitle%3DThe%2520selective%2520HDAC6%2520inhibitor%2520Nexturastat%2520A%2520induces%2520apoptosis%252C%2520overcomes%2520drug%2520resistance%2520and%2520inhibits%2520tumor%2520growth%2520in%2520multiple%2520myeloma%26jtitle%3DBiosci.%2520Rep.%26date%3D2019%26volume%3D39%26spage%3DBSR20181916%26doi%3D10.1042%2FBSR20181916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00223</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1031-1036&author=M.+T.+Tavaresauthor=S.+Shenauthor=T.+Knoxauthor=M.+Hadleyauthor=Z.+Kutilauthor=C.+Barinkaauthor=A.+Villagraauthor=A.+P.+Kozikowski&title=Synthesis+and+Pharmacological+Evaluation+of+Selective+Histone+Deacetylase+6+Inhibitors+in+Melanoma+Models&doi=10.1021%2Facsmedchemlett.7b00223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models</span></div><div class="casAuthors">Tavares, Mauricio T.; Shen, Sida; Knox, Tessa; Hadley, Melissa; Kutil, Zsofia; Barinka, Cyril; Villagra, Alejandro; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1031-1036</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Only a handful of therapies offer significant improvement in the overall survival in cases of melanoma, a cancer whose incidence has continued to rise in the past 30 years.  In our effort to identify potent and isoform-selective histone deacetylase (HDAC) inhibitors as a therapeutic approach to melanoma, a series of new HDAC6 inhibitors based on the nexturastat A scaffold were prepd.  The new analogs bearing added hydrophilic substituents, so as to establish addnl. hydrogen bonding on the rim of the HDAC6 catalytic pocket, exhibit improved potency against HDAC6 and retain selectivity over HDAC1.  Compd. I exhibits antiproliferative effects on several types of melanoma and lymphoma cells.  Further studies indicates that I selectively increases acetylated tubulin levels in vitro and elicits an immune response through down-regulating cytokine IL-10.  A preliminary in vivo efficacy study indicates that I possesses improved capability to inhibit melanoma tumor growth and that this effect is based on the regulation of inflammatory and immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6cF7frE1ffLVg90H21EOLACvtfcHk0liSj-vSkaNC9Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7zL&md5=305123b6d7ecc3e4273d5fa02565367f</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00223%26sid%3Dliteratum%253Aachs%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Evaluation%2520of%2520Selective%2520Histone%2520Deacetylase%25206%2520Inhibitors%2520in%2520Melanoma%2520Models%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1031%26epage%3D1036%26doi%3D10.1021%2Facsmedchemlett.7b00223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noonepalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ptáček, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stránský, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlíček, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelaez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bařinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10246</span>– <span class="NLM_lpage">10262</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00567</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00567" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1ers7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10246-10262&author=S.+Noonepalleauthor=S.+Shenauthor=J.+Pt%C3%A1%C4%8Dekauthor=M.+T.+Tavaresauthor=G.+Zhangauthor=J.+Str%C3%A1nsk%C3%BDauthor=J.+Pavl%C3%AD%C4%8Dekauthor=G.+M.+Ferreiraauthor=M.+Hadleyauthor=G.+Pelaezauthor=C.+Ba%C5%99inkaauthor=A.+P.+Kozikowskiauthor=A.+Villagra&title=Rational+Design+of+Suprastat%3A+A+Novel+Selective+Histone+Deacetylase+6+Inhibitor+with+the+Ability+to+Potentiate+Immunotherapy+in+Melanoma+Models&doi=10.1021%2Facs.jmedchem.0c00567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models</span></div><div class="casAuthors">Noonepalle, Satish; Shen, Sida; Ptacek, Jakub; Tavares, Mauricio T.; Zhang, Guiping; Stransky, Jan; Pavlicek, Jiri; Ferreira, Glaucio M.; Hadley, Melissa; Pelaez, Guido; Barinka, Cyril; Kozikowski, Alan P.; Villagra, Alejandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10246-10262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective inhibition of histone deacetylase 6 (HDAC6) is being recognized as a therapeutic approach for cancers.  In this study, we designed a new HDAC6 inhibitor, named Suprastat(I), using in silico simulations.  X-ray crystallog. and mol. dynamics simulations provide strong evidence to support the notion that the aminomethyl and hydroxyl groups in the capping group of Suprastat establish significant hydrogen bond interactions, either direct or water-mediated, with residues D460, N530, and S531, which play a vital role in regulating the deacetylase function of the enzyme and which are absent in other isoforms.  In vitro characterization of Suprastat demonstrates subnanomolar HDAC6 inhibitory potency and a hundred- to a thousand-fold HDAC6 selectivity over the other HDAC isoforms.  In vivo studies reveal that a combination of Suprastat and anti-PD1 immunotherapy enhances antitumor immune response, mediated by a decrease of protumoral M2 macrophages and increased infiltration of antitumor CD8+ effector and memory T-cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk6yLAJTV90rVg90H21EOLACvtfcHk0liKVAvGCoBJng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1ers7%252FP&md5=dfe4a0aed15153f03b49144392e746fe</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00567%26sid%3Dliteratum%253Aachs%26aulast%3DNoonepalle%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DPt%25C3%25A1%25C4%258Dek%26aufirst%3DJ.%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DStr%25C3%25A1nsk%25C3%25BD%26aufirst%3DJ.%26aulast%3DPavl%25C3%25AD%25C4%258Dek%26aufirst%3DJ.%26aulast%3DFerreira%26aufirst%3DG.%2BM.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DPelaez%26aufirst%3DG.%26aulast%3DBa%25C5%2599inka%26aufirst%3DC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DRational%2520Design%2520of%2520Suprastat%253A%2520A%2520Novel%2520Selective%2520Histone%2520Deacetylase%25206%2520Inhibitor%2520with%2520the%2520Ability%2520to%2520Potentiate%2520Immunotherapy%2520in%2520Melanoma%2520Models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10246%26epage%3D10262%26doi%3D10.1021%2Facs.jmedchem.0c00567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">10842</span>– <span class="NLM_lpage">10846</span>, <span class="refDoi"> DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+Design+and+Simple+Chemistry+Yield+a+Superior%2C+Neuroprotective+HDAC6+Inhibitor%2C+Tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0liKVAvGCoBJng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520Design%2520and%2520Simple%2520Chemistry%2520Yield%2520a%2520Superior%252C%2520Neuroprotective%2520HDAC6%2520Inhibitor%252C%2520Tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svoboda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavasin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motlova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinsey, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00560</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00560" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFarsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=706-712&author=S.+Shenauthor=M.+Svobodaauthor=G.+Zhangauthor=M.+A.+Cavasinauthor=L.+Motlovaauthor=T.+A.+McKinseyauthor=J.+H.+Eubanksauthor=C.+Barinkaauthor=A.+P.+Kozikowski&title=Structural+and+in+Vivo+Characterization+of+Tubastatin+A%2C+a+Widely+Used+Histone+Deacetylase+6+Inhibitor&doi=10.1021%2Facsmedchemlett.9b00560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor</span></div><div class="casAuthors">Shen, Sida; Svoboda, Michal; Zhang, Guangming; Cavasin, Maria A.; Motlova, Lucia; McKinsey, Timothy A.; Eubanks, James H.; Barinka, Cyril; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">706-712</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tubastatin A, a tetrahydro-γ-carboline-capped selective HDAC6 inhibitor (HDAC6i), was rationally designed 10 years ago, and has become the best investigated HDAC6i to date.  It shows efficacy in various neurol. disease animal models, as HDAC6 plays a crucial regulatory role in axonal transport deficits, protein aggregation, as well as oxidative stress.  In this work, we provide new insights into this HDAC6i by investigating the mol. basis of its interactions with HDAC6 through X-ray crystallog., detg. its functional capability to elevate the levels of acetylated α-tubulin in vitro and in vivo, correlating PK/PD profiles to det. EDs in plasma and brain, and finally assessing its therapeutic potential toward psychiatric diseases through use of the SmartCube screening platform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi67K0VhCsP7Vg90H21EOLACvtfcHk0liKVAvGCoBJng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFarsr8%253D&md5=431ff199537a679fc09f19f95e528219</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00560%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DSvoboda%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DCavasin%26aufirst%3DM.%2BA.%26aulast%3DMotlova%26aufirst%3DL.%26aulast%3DMcKinsey%26aufirst%3DT.%2BA.%26aulast%3DEubanks%26aufirst%3DJ.%2BH.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DStructural%2520and%2520in%2520Vivo%2520Characterization%2520of%2520Tubastatin%2520A%252C%2520a%2520Widely%2520Used%2520Histone%2520Deacetylase%25206%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D706%26epage%3D712%26doi%3D10.1021%2Facsmedchemlett.9b00560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenechukwu, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HDAC6 alleviating lipopolysaccharide-induced p38MAPK phosphorylation and neuroinflammation in mice</span>. <i>Pharm. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1080/13880209.2018.1563620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1080%2F13880209.2018.1563620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31124385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ptlWntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2019&pages=263-268&author=Y.+Songauthor=L.+Qinauthor=R.+Yangauthor=F.+Yangauthor=N.+A.+Kenechukwuauthor=X.+Zhaoauthor=X.+Zhouauthor=X.+Wenauthor=L.+Li&title=Inhibition+of+HDAC6+alleviating+lipopolysaccharide-induced+p38MAPK+phosphorylation+and+neuroinflammation+in+mice&doi=10.1080%2F13880209.2018.1563620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HDAC6 alleviating lipopolysaccharide-induced p38MAPK phosphorylation and neuroinflammation in mice</span></div><div class="casAuthors">Song Yuanjian; Yang Fan; Kenechukwu Nwobodo Alexander; Zhao Xiaofang; Li Lei; Song Yuanjian; Yang Fan; Kenechukwu Nwobodo Alexander; Wen Xiangru; Li Lei; Song Yuanjian; Qin Li; Yang Rongli; Li Lei; Zhou Xiaoyan</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">263-268</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Context: Researchers in a variety of fields have extensively focused on histone deacetylase 6 (HDAC6) due to its aggravation of inflammatory reaction.  However, relevant studies examining whether HDAC6 could exacerbate lipopolysaccharide (LPS)-induced inflammation are still lacking.  Objective: We assessed the role of HDAC6 in LPS-induced brain inflammation and used the HDAC6-selective inhibitor Tubastatin A (TBSA) to investigate the potential mechanisms further.  Materials and methods: Brain inflammation was induced in Kunming (KM) mice via intraperitoneal (I.P.), injection of Lipopolysaccharide (LPS) (1 mg/kg), the TBSA (0.5 mg/kg) was delivered via intraperitoneal.  The phosphorylated p38 (p-p38) Mitogen-activated protein kinases (MAPK) and expression of typical inflammatory mediators, including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in both the hippocampus and cortex, were examined by immunoblotting.  Nissl staining was used to detect the neuronal damage in the hippocampus and the cortex.  Results: About 1 mg/kg LPS via daily intraperitoneal (I.P.) injections for 12 days significantly increased p38 MAPK phosphorylation, TNF-α and IL-6 expression, and neuronal loss.  However, 0.5 mg/kg TBSA (three days before LPS treatment) by I.P. injections for 15 days could reverse the above results.  Conclusions: This present study provided evidence that TBSA significantly suppressed LPS-induced neuroinflammation and the expression of p-p38.  Results derived from our study might help reveal the effective targeting strategies of LPS-induced brain inflammation through inhibiting HDAC6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuCv_wHdytl5HZzFRCXxVKfW6udTcc2eav2AYxPuc2bLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ptlWntg%253D%253D&md5=ce35a28b2a3843f2ca7cc306cee0e2bd</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1080%2F13880209.2018.1563620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13880209.2018.1563620%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DKenechukwu%26aufirst%3DN.%2BA.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520HDAC6%2520alleviating%2520lipopolysaccharide-induced%2520p38MAPK%2520phosphorylation%2520and%2520neuroinflammation%2520in%2520mice%26jtitle%3DPharm.%2520Biol.%26date%3D2019%26volume%3D57%26spage%3D263%26epage%3D268%26doi%3D10.1080%2F13880209.2018.1563620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving alpha-tubulin acetylation</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2018.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.yjmcc.2018.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30315806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFejtbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=58-69&author=R.+Songauthor=Y.+Yangauthor=H.+Leiauthor=G.+Wangauthor=Y.+Huangauthor=W.+Xueauthor=Y.+Wangauthor=L.+Yaoauthor=Y.+Zhu&title=HDAC6+inhibition+protects+cardiomyocytes+against+doxorubicin-induced+acute+damage+by+improving+alpha-tubulin+acetylation&doi=10.1016%2Fj.yjmcc.2018.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving a-tubulin acetylation</span></div><div class="casAuthors">Song, Rui; Yang, Yurong; Lei, Han; Wang, Guangxue; Huang, Yong; Xue, Wenlong; Wang, Yinfang; Yao, Lingling; Zhu, Yichun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-69</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Doxorubicin (Dox) is an efficacious antineoplastic drug but is limited used for its cardiotoxicity.  Histone Deacetylase 6 (HDAC6) has been indicated to participate in cardiomyopathies, however, its role in Dox-induced cardiac injury is largely unknown.  In this study, we firstly aimed to det. the role of HDAC6 in Dox-induced cardiomyopathy.  Immunoblotting revealed that Dox increased HDAC6 protein level and activity and decreased a-tubulin acetylation level in vitro and vivo.  HDAC6 knockout (HDAC6-/-) mice showed obvious anti-Dox cardiotoxicity by conserved cardiac function monitored by echocardiog. and the protection was reversed by Nocodazole, one drug lowering a-tubulin acetylation.  Further mechanism investigation showed that improvement of mitochondria function and autophagy flux was partially inhibited by Nocodazole and Colchicine which lowers a-tubulin acetylation in neonatal rat cardiac myocytes.  Aiming at transforming this research to clin. application, we then explored the effect of combined utilization of HDAC6 inhibitor and Dox on tumor and cardiac function.  Results showed that Tubastatin A, one HDAC6 selective inhibitor, protected against Dox-induced acute cardiomyopathy without influencing the effect of Dox on inhibiting MDA-MB-231 s.c. tumor growth.  These findings suggest a new treatment for cancer with Dox by combined utilization with HDAC6 selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok6lfEJPZCOLVg90H21EOLACvtfcHk0lgkwc0tkHQTfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFejtbfL&md5=bdef80de06b2be55f47036d8183d144a</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2018.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2018.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLei%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DY.%26atitle%3DHDAC6%2520inhibition%2520protects%2520cardiomyocytes%2520against%2520doxorubicin-induced%2520acute%2520damage%2520by%2520improving%2520alpha-tubulin%2520acetylation%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2018%26volume%3D124%26spage%3D58%26epage%3D69%26doi%3D10.1016%2Fj.yjmcc.2018.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, S.</span></span> <span> </span><span class="NLM_article-title">Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1042/CS20171417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1042%2FCS20171417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1GktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=339-359&author=J.+Tangauthor=Y.+Shiauthor=N.+Liuauthor=L.+Xuauthor=X.+Zangauthor=P.+Liauthor=J.+Zhangauthor=X.+Zhengauthor=A.+Qiuauthor=S.+Zhuang&title=Blockade+of+histone+deacetylase+6+protects+against+cisplatin-induced+acute+kidney+injury&doi=10.1042%2FCS20171417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury</span></div><div class="casAuthors">Tang, Jinhua; Shi, Yingfeng; Liu, Na; Xu, Liuqing; Zang, Xiujuan; Li, Peibin; Zhang, Juanlian; Zheng, Xiaoqing; Qiu, Andong; Zhuang, Shougang</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">339-359</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) has been shown to be involved in various pathol. conditions, including cancer, neurodegenerative disorders and inflammatory diseases.  Nonetheless, its specific role in drug-induced nephrotoxicity is poorly understood.  Cisplatin (dichlorodiamino platinum) belongs to an inorg. platinum - fundamental chemotherapeutic drug utilized in the therapy of various solid malignant tumors.  However, the use of cisplatin is extremely limited by obvious side effects, for instance bone marrow suppression and nephrotoxicity.  In the present study, we utilized a murine model of cisplatin-induced acute kidney injury (AKI) and a highly selective inhibitor of HDAC6, tubastatin A (TA), to assess the role of HDAC6 in nephrotoxicity and its assocd. mechanisms.  Cisplatin-induced AKI was accompanied by increased expression and activation of HDAC6; blocking HDAC6 with TA lessened renal dysfunction, attenuated renal pathol. changes, reduced expression of neutrophil gelatinase-assocd. lipocalin and kidney injury mol. 1, and decreased tubular cell apoptosis.  In cultured human epithelial cells, TA or HDAC6 siRNA treatment also inhibited cisplatin-induced apoptosis.  Mechanistic studies demonstrated that cisplatin treatment induced phosphorylation of AKT and loss of E-cadherin in the nephrotoxic kidney, and administration of TA enhanced AKT phosphorylation and preserved E-cadherin expression.  HDAC6 inhibition also potentiated autophagy as evidenced by increased expression of autophagy-related gene (Atg) 7 (Atg7), Beclin-1, and decreased renal oxidative stress as demonstrated by up-regulation of superoxide dismutase (SOD) activity and down-regulation of malondialdehyde levels.  Moreover, TA was effective in inhibiting nuclear factor-κ B (NF-κB) phosphorylation and suppressing the expression of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6).  Collectively, these data provide strong evidence that HDAC6 inhibition is protective against cisplatin-induced AKI and suggest that HDAC6 may be a potential therapeutic target for AKI treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz2-zTf1M8F7Vg90H21EOLACvtfcHk0lgkwc0tkHQTfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1GktLo%253D&md5=f3e12eabc8eaa36cd4db0d6af15e615e</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1042%2FCS20171417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20171417%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DZang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DQiu%26aufirst%3DA.%26aulast%3DZhuang%26aufirst%3DS.%26atitle%3DBlockade%2520of%2520histone%2520deacetylase%25206%2520protects%2520against%2520cisplatin-induced%2520acute%2520kidney%2520injury%26jtitle%3DClin.%2520Sci.%26date%3D2018%26volume%3D132%26spage%3D339%26epage%3D359%26doi%3D10.1042%2FCS20171417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennahy, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatti, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Protective Effect of Tubastatin A in CLP-Induced Lethal Sepsis</span>. <i>Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2101</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1007/s10753-018-0853-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs10753-018-0853-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30047002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVCgsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=2101-2109&author=Q.+Dengauthor=T.+Zhaoauthor=B.+Panauthor=I.+S.+Dennahyauthor=X.+Duanauthor=A.+M.+Williamsauthor=B.+Liuauthor=N.+Linauthor=U.+F.+Bhattiauthor=E.+Chenauthor=H.+B.+Alamauthor=Y.+Li&title=Protective+Effect+of+Tubastatin+A+in+CLP-Induced+Lethal+Sepsis&doi=10.1007%2Fs10753-018-0853-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Protective Effect of Tubastatin A in CLP-Induced Lethal Sepsis</span></div><div class="casAuthors">Deng, Qiufang; Zhao, Ting; Pan, Baihong; Dennahy, Isabel S.; Duan, Xiuzhen; Williams, Aaron M.; Liu, Baoling; Lin, Nan; Bhatti, Umar F.; Chen, Eric; Alam, Hasan B.; Li, Yongqing</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2101-2109</span>CODEN:
                <span class="NLM_cas:coden">INFLD4</span>;
        ISSN:<span class="NLM_cas:issn">0360-3997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We have found earlier that Tubastatin A (TubA), a selective inhibitor of histone deacetylase 6 (HDAC6), improves survival in a mouse model of lethal cecal ligation and puncture (CLP)-induced sepsis.  However, the underlying mechanisms have not been fully established.  This study sought to test the hypothesis that TubA could affect both lung and splenic functions.  C57BL/6J mice were subjected to CLP, and randomized to receive either TubA (70 mg/kg) dissolved in DMSO (DMSO), or DMSO alone, 1 h following CLP.  Sham animals acted as control.  Twenty-four hours later, lung tissue was harvested for pathol. examn., and splenic tissue was harvested for bacterial colonization.  In a parallel study, the spleen was collected 48 h following CLP, and single cell suspension was prepd.  Splenocytes then underwent flow cytometry to analyze the immune cell population.  RAW264.7 macrophages were treated with lipopolysaccharide (LPS) with or without the presence of TubA (10 μM) at 37 °C for 3 h to assess the effect on macrophage phagocytosis.  We found that acute lung injury secondary to lethal sepsis was attenuated by TubA.  Treatment with TubA restored the percentage of B lymphocytes, and significantly increased percentages of innate immune cells and macrophages compared to the vehicle-treated CLP group.  Moreover, TubA significantly decreased the bacterial load in the spleen, and improved the phagocytic ability of RAW264.7 murine macrophages in vitro.  Such findings may help to explain the beneficial effects of TubA treatment in a model of lethal sepsis, as previously reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWLxMIukM0ybVg90H21EOLACvtfcHk0lg6XYENP1PeKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVCgsb7E&md5=6cd0ff46eedd061059b3f29901acb706</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1007%2Fs10753-018-0853-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10753-018-0853-0%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DT.%26aulast%3DPan%26aufirst%3DB.%26aulast%3DDennahy%26aufirst%3DI.%2BS.%26aulast%3DDuan%26aufirst%3DX.%26aulast%3DWilliams%26aufirst%3DA.%2BM.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DN.%26aulast%3DBhatti%26aufirst%3DU.%2BF.%26aulast%3DChen%26aufirst%3DE.%26aulast%3DAlam%26aufirst%3DH.%2BB.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DProtective%2520Effect%2520of%2520Tubastatin%2520A%2520in%2520CLP-Induced%2520Lethal%2520Sepsis%26jtitle%3DInflammation%26date%3D2018%26volume%3D41%26spage%3D2101%26epage%3D2109%26doi%3D10.1007%2Fs10753-018-0853-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Inhibition of HDAC6 Attenuates NLRP3 Inflammatory Response and Protects Dopaminergic Neurons in Experimental Models of Parkinson’s Disease</span>. <i>Front. Aging Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">78</span>, <span class="refDoi"> DOI: 10.3389/fnagi.2020.00078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3389%2Ffnagi.2020.00078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32296327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1Ols77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=78&author=S.+Yanauthor=X.+Weiauthor=W.+Jianauthor=Y.+Qinauthor=J.+Liuauthor=S.+Zhuauthor=F.+Jiangauthor=H.+Louauthor=B.+Zhang&title=Pharmacological+Inhibition+of+HDAC6+Attenuates+NLRP3+Inflammatory+Response+and+Protects+Dopaminergic+Neurons+in+Experimental+Models+of+Parkinson%E2%80%99s+Disease&doi=10.3389%2Ffnagi.2020.00078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological inhibition of HDAC6 attenuates NLRP3 inflammatory response and protects dopaminergic neurons in experimental models of Parkinson's disease</span></div><div class="casAuthors">Yan, Shaoqi; Wei, Xinbing; Jian, Wencheng; Qin, Yue; Liu, Jia; Zhu, Shaowei; Jiang, Fan; Lou, Haiyan; Zhang, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Aging Neuroscience</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">78</span>CODEN:
                <span class="NLM_cas:coden">FANRC5</span>;
        ISSN:<span class="NLM_cas:issn">1663-4365</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Aim: To investigate the role of histone deacetylase 6 (HDAC6) deacetylation activity in nucleotide-binding oligomerization domain and leucine-rich repeat pyrin 3 domain (NLRP3) inflammatory response and explore the effects of pharmacol. inhibition of HDAC6 with tubastatin A (TBA) on dopaminergic injury.  Methods: Using 6-OHDA-induced Parkinson's disease (PD) models, we examd. the effects of TBA on NLRP3 activation and cell injury in SH-SY5Y cells.  We also investigated the effects of TBA on NLRP3 inflammatory responses and dopaminergic injury in the nigrostriatal system in mice and analyzed the acetylation levels of peroxiredoxin2 (Prx2) and oxidative stress.  Results: TBA inhibited 6-OHDA-induced NLRP3 activation, as demonstrated by decreased expressions of NLRP3 and matured caspase-1 and IL-1β, and also alleviated glial proliferation and dopaminergic neuronal degeneration.  Notably, TBA recovered acetylation levels of Prx2 and reduced oxidative stress.  Conclusion: Our findings indicate that pharmacol. inhibition of HDAC6 with TBA attenuates NLRP3 inflammation and protects dopaminergic neurons, probably through Prx2 acetylation.  This study suggests that the deacetylase catalytic domain of HDAC6 is a potential target for PD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3pE2ZWtQtYrVg90H21EOLACvtfcHk0lg6XYENP1PeKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1Ols77F&md5=4622e8a74eb253f193e5d82b02491ed4</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.3389%2Ffnagi.2020.00078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnagi.2020.00078%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DJian%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DLou%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DB.%26atitle%3DPharmacological%2520Inhibition%2520of%2520HDAC6%2520Attenuates%2520NLRP3%2520Inflammatory%2520Response%2520and%2520Protects%2520Dopaminergic%2520Neurons%2520in%2520Experimental%2520Models%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DFront.%2520Aging%2520Neurosci.%26date%3D2020%26volume%3D12%26spage%3D78%26doi%3D10.3389%2Ffnagi.2020.00078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abouhish, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thounaojam, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadeja, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutsaeva, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khriza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartoli, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HDAC6 Attenuates Diabetes-Induced Retinal Redox Imbalance and Microangiopathy</span>. <i>Antioxidants</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">599</span>, <span class="refDoi"> DOI: 10.3390/antiox9070599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3390%2Fantiox9070599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Ciu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=599&author=H.+Abouhishauthor=M.+C.+Thounaojamauthor=R.+N.+Jadejaauthor=D.+R.+Gutsaevaauthor=F.+L.+Powellauthor=M.+Khrizaauthor=P.+M.+Martinauthor=M.+Bartoli&title=Inhibition+of+HDAC6+Attenuates+Diabetes-Induced+Retinal+Redox+Imbalance+and+Microangiopathy&doi=10.3390%2Fantiox9070599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HDAC6 attenuates diabetes-induced retinal redox imbalance and microangiopathy</span></div><div class="casAuthors">Abouhish, Hossameldin; Thounaojam, Menaka C.; Jadeja, Ravirajsinh N.; Gutsaeva, Diana R.; Powell, Folami L.; Khriza, Mohamed; Martin, Pamela M.; Bartoli, Manuela</div><div class="citationInfo"><span class="NLM_cas:title">Antioxidants</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">599</span>CODEN:
                <span class="NLM_cas:coden">ANTIGE</span>;
        ISSN:<span class="NLM_cas:issn">2076-3921</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">We investigated the contributing role of the histone deacetylase 6 (HDAC6) to the early stages of diabetic retinopathy (DR).  Furthermore, we examd. the mechanism of action of HDAC6 in human retinal endothelial cells (HuREC) exposed to glucidic stress.  Streptozotocin-induced diabetic rats (STZ-rats), a rat model of type 1 diabetes, were used as model of DR.  HDAC6 expression and activity were increased in human diabetic postmortem donors and STZ-rat retinas and were augmented in HuREC exposed to glucidic stress (25 mM glucose).  Administration of the HDAC6 specific inhibitor Tubastatin A (TS) (10 mg/kg) prevented retinal microvascular hyperpermeability and up-regulation of inflammatory markers.  Furthermore, in STZ-rats, TS decreased the levels of senescence markers and rescued the expression and activity of the histone deacetylase sirtuin 1 (SIRT1), while downregulating the levels of free radicals and of the redox stress markers 4-hydroxynonenal (4-HNE) and nitrotyrosine (NT).  The antioxidant effects of TS, consequent to HDAC6 inhibition, were assocd. with preservation of Nrf2-dependent gene expression and up-regulation of thioredoxin-1 activity.  In summary, our data implicate HDAC6 activation in mediating hyperglycemia-induced retinal oxidative/nitrative stress leading to retinal microangiopathy and, potentially, DR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB9dSjvoMARLVg90H21EOLACvtfcHk0ljjvkPt8KCQtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Ciu73P&md5=471f95e0abc1eba63a5316b49117caf6</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.3390%2Fantiox9070599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fantiox9070599%26sid%3Dliteratum%253Aachs%26aulast%3DAbouhish%26aufirst%3DH.%26aulast%3DThounaojam%26aufirst%3DM.%2BC.%26aulast%3DJadeja%26aufirst%3DR.%2BN.%26aulast%3DGutsaeva%26aufirst%3DD.%2BR.%26aulast%3DPowell%26aufirst%3DF.%2BL.%26aulast%3DKhriza%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DP.%2BM.%26aulast%3DBartoli%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520HDAC6%2520Attenuates%2520Diabetes-Induced%2520Retinal%2520Redox%2520Imbalance%2520and%2520Microangiopathy%26jtitle%3DAntioxidants%26date%3D2020%26volume%3D9%26spage%3D599%26doi%3D10.3390%2Fantiox9070599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byeon, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkowitz, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine gamma-lyase protein degradation</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">104281</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2019.104281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.phrs.2019.104281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31125601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKisr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2019&pages=104281&author=Z.+Chiauthor=H.+E.+Byeonauthor=E.+Seoauthor=Q.+T.+Nguyenauthor=W.+Leeauthor=Y.+Jeongauthor=J.+Choiauthor=D.+Pandeyauthor=D.+E.+Berkowitzauthor=J.+H.+Kimauthor=S.+Y.+Lee&title=Histone+deacetylase+6+inhibitor+tubastatin+A+attenuates+angiotensin+II-induced+hypertension+by+preventing+cystathionine+gamma-lyase+protein+degradation&doi=10.1016%2Fj.phrs.2019.104281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation</span></div><div class="casAuthors">Chi, Zhexi; Byeon, Hye-Eun; Seo, Eunjeong; Nguyen, Quynh-Anh T.; Lee, Wonbeom; Jeong, Yunyong; Choi, Juyong; Pandey, Deepesh; Berkowitz, Dan E.; Kim, Jae Hyung; Lee, Sang Yoon</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104281</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cystathionine γ-lyase (CSEγ) is a hydrogen sulfide (H2S)-producing enzyme.  Endothelial H2S prodn. can mediate vasodilatory effects, contributing to the alleviation of hypertension (high blood pressure).  Recent studies have suggested a role of histone deacetylase 6 (HDAC6) in hypertension, although its underlying mechanisms are poorly understood.  Here, we addressed the potential regulation of CSEγ by HDAC6 in angiotensin II (AngII)-induced hypertension and its mol. details focusing on CSEγ posttranslational modification.  Treatment of mice with a selective HDAC6 inhibitor tubastatin A (TubA) alleviated high blood pressure and vasoconstriction induced by AngII.  Cotreatment of the aorta and human aortic endothelial cells with TubA recovered AngII-mediated decreased H2S levels.  AngII treatment upregulated HDAC6 mRNA and protein expression, but conversely downregulated CSEγ protein.  Notably, potent HDAC6 inhibitors and HDAC6 siRNA as well as a proteasomal inhibitor increased CSEγ protein levels and blocked the downregulatory effect of AngII on CSEγ.  In contrast, other HDAC isoforms-specific inhibitors and siRNAs did not show such blocking effects.  Transfected CSEγ protein levels were also reciprocally regulated by AngII and TubA, and were reduced by wild-type, but not by deacetylase-deficient, HDAC6.  Moreover, TubA significantly increased both protein stability and K73 acetylation level of CSEγ.  Consistent with these results, AngII induced CSEγ ubiquitination and degrdn., which was inhibited by TubA.  Our results indicate that AngII promoted HDAC6-dependent deacetylation of CSEγ at K73 residue, leading to its ubiquitin-mediated proteolysis, which underlies AngII-induced hypertension.  Overall, this study suggests that upregulation of CSEγ and H2S through HDAC6 inhibition may be considered as a valid strategy for preventing the progression of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohIA6gZf-iXbVg90H21EOLACvtfcHk0ljjvkPt8KCQtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKisr7P&md5=6945509e82de1423f901b2f36348526e</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2019.104281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2019.104281%26sid%3Dliteratum%253Aachs%26aulast%3DChi%26aufirst%3DZ.%26aulast%3DByeon%26aufirst%3DH.%2BE.%26aulast%3DSeo%26aufirst%3DE.%26aulast%3DNguyen%26aufirst%3DQ.%2BT.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DPandey%26aufirst%3DD.%26aulast%3DBerkowitz%26aufirst%3DD.%2BE.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DS.%2BY.%26atitle%3DHistone%2520deacetylase%25206%2520inhibitor%2520tubastatin%2520A%2520attenuates%2520angiotensin%2520II-induced%2520hypertension%2520by%2520preventing%2520cystathionine%2520gamma-lyase%2520protein%2520degradation%26jtitle%3DPharmacol.%2520Res.%26date%3D2019%26volume%3D146%26spage%3D104281%26doi%3D10.1016%2Fj.phrs.2019.104281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hour, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. W.</span></span> <span> </span><span class="NLM_article-title">Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">954</span>, <span class="refDoi"> DOI: 10.3390/ijms18050954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3390%2Fijms18050954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGjsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=954&author=C.+Y.+Luauthor=Y.+C.+Changauthor=C.+H.+Huaauthor=C.+Chuangauthor=S.+H.+Huangauthor=S.+H.+Kungauthor=M.+J.+Hourauthor=C.+W.+Lin&title=Tubacin%2C+an+HDAC6+Selective+Inhibitor%2C+Reduces+the+Replication+of+the+Japanese+Encephalitis+Virus+via+the+Decrease+of+Viral+RNA+Synthesis&doi=10.3390%2Fijms18050954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Tubacin, an HDAC6 selective inhibitor, reduces the replication of the Japanese encephalitis virus via the decrease of viral RNA synthesis</span></div><div class="casAuthors">Lu, Chien-Yi; Chang, Yi-Chih; Hua, Chun-Hung; Chuang, Chieh; Huang, Su-Hua; Kung, Szu-Hao; Hour, Mann-Jen; Lin, Cheng-Wen</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">954/1-954/14</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Japanese encephalitis virus (JEV), a neurotropic flavivirus, annually causes over 30,000 Japanese Encephalitis (JE) cases in East and Southeast Asia.  Histone deacetylases (HDACs) modulate lysine acetylation of histones and non-histone proteins, regulating many processes including inflammation and antiviral immune response.  This study investigated antiviral activity of pan- and selective-HDAC inhibitors as host-targeting agents against JEV.  Among HDAC inhibitors, selective HDAC6 inhibitors (tubastatin-A (TBSA) and tubacin) concn.-dependently inhibited JEV-induced cytopathic effect and apoptosis, as well as reduced virus yield in human cerebellar medulloblastoma cells.  The 50% inhibitory concn. (IC50) values of virus yield was 0.26 μM for tubacin and 1.75 M for TBSA, resp.  Tubacin (IC50 of 1.52 μM), but not TBSA, meaningfully blocked the prodn. of intracellular infectious virus particles.  In time-of-addn. assays, the greatest potency of antiviral activity was obsd. in the mode of pre-treatment with tubacin (IC50 of 1.89 μM) compared to simultaneous (IC50 of 4.88 μM) and post-treatment (IC50 of 2.05 μM) modes.  Interestingly, tubacin induced the hyperacetylation of a HDAC6 substrate Hsp90 and reduced the interaction of Hsp90 with JEV NS5 protein.  Novobiocin, an Hsp90 inhibitor, diminished the NS5 protein amt. and virus replication in JEV-infected cells.  Meantime, tubacin suppressed the NS5 expression and antisense RNA genome synthesis in infected cells.  Tubacin-induced Hsp90 hyperacetylation was suggested to influence the NS5 activity in JEV replication.  Therefore, tubacin had a high potential of a host-targeting agent against JEV, exhibiting preventive and therapeutic activities against JEV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxhk2RVCeLqrVg90H21EOLACvtfcHk0ljquFZ3rfw5IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGjsrbP&md5=d3a7e0f226b6f8e157780664d0f8aecb</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.3390%2Fijms18050954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18050954%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%2BY.%26aulast%3DChang%26aufirst%3DY.%2BC.%26aulast%3DHua%26aufirst%3DC.%2BH.%26aulast%3DChuang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%2BH.%26aulast%3DKung%26aufirst%3DS.%2BH.%26aulast%3DHour%26aufirst%3DM.%2BJ.%26aulast%3DLin%26aufirst%3DC.%2BW.%26atitle%3DTubacin%252C%2520an%2520HDAC6%2520Selective%2520Inhibitor%252C%2520Reduces%2520the%2520Replication%2520of%2520the%2520Japanese%2520Encephalitis%2520Virus%2520via%2520the%2520Decrease%2520of%2520Viral%2520RNA%2520Synthesis%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D954%26doi%3D10.3390%2Fijms18050954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span> <span> </span><span class="NLM_article-title">Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">6623</span>– <span class="NLM_lpage">6632</span>, <span class="refDoi"> DOI: 10.1002/jcb.26841</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fjcb.26841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29665050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnslSgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2018&pages=6623-6632&author=H.+Taoauthor=Y.+Y.+Chenauthor=Z.+W.+Sunauthor=H.+L.+Chenauthor=M.+Chen&title=Silence+of+HDAC6+suppressed+esophageal+squamous+cell+carcinoma+proliferation+and+migration+by+disrupting+chaperone+function+of+HSP90&doi=10.1002%2Fjcb.26841"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90</span></div><div class="casAuthors">Tao, Hua; Chen, Yuan-Yuan; Sun, Zong-Wen; Chen, Hua-Lin; Chen, Ming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">6623-6632</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Esophageal carcinoma is aggressive in nature and its prognosis is largely dependent on the degree of invasion.  Histone deacetylase 6 (HDAC6), as the most unique member of HDACs family, has the pos. activity to promote initiation and progression of various cancers via targeting multiple non-histone proteins in cytoplasm.  In this study, we found that HDAC6 was over-expressed in three esophageal cancer cell lines (KYSE140, KYSE170, KYSE180) when compared to non-carcinoma esophageal epithelial cell HEEC-1.  Then two HDAC6 specific siRNAs and HDAC6 inhibitor tubastatin A greatly suppressed KYSE140 and KYSE180 cells proliferation and migration, and the inhibition of cell motility was accompanied by elevated acetylation of α-tubulin, a target of HDAC6.  Consistently, the microtubulin skeleton was stabilized after HDAC6 knockdown or inhibition.  In addn., acetylation status of HSP90, another HDAC6 target, was also increased towards HDAC6 knockdown or inhibition by co-immunopptn. assay.  Besides, co-treatment of HSP90 inhibitor (PU-H71) and HDAC6 inhibitor (tubastatin A) induced a stronger cell migration inhibition compared to administration of either drug alone.  Furthermore, cell proliferation of KYSE140 and KYSE180 were also compromised in response to combination of HDAC6 and HSP90 inhibitors.  Addnl., co-administration of HSP90 inhibitor and HDAC6 inhibitor strongly inhibited tumor growth in vivo.  Taken together, our results indicated that HDAC6 is a promising target by inhibiting HSP90 function in ESCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_6U1lcLK5w7Vg90H21EOLACvtfcHk0ljquFZ3rfw5IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnslSgtLo%253D&md5=d0e49518dd2059cc349ca0912a82f9c0</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1002%2Fjcb.26841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.26841%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%2BY.%26aulast%3DSun%26aufirst%3DZ.%2BW.%26aulast%3DChen%26aufirst%3DH.%2BL.%26aulast%3DChen%26aufirst%3DM.%26atitle%3DSilence%2520of%2520HDAC6%2520suppressed%2520esophageal%2520squamous%2520cell%2520carcinoma%2520proliferation%2520and%2520migration%2520by%2520disrupting%2520chaperone%2520function%2520of%2520HSP90%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2018%26volume%3D119%26spage%3D6623%26epage%3D6632%26doi%3D10.1002%2Fjcb.26841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urdiciain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erausquin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melendez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idoate, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castresana, J. S.</span></span> <span> </span><span class="NLM_article-title">Tubastatin A, an inhibitor of HDAC6, enhances temozolomideinduced apoptosis and reverses the malignant phenotype of glioblastoma cells</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1808</span>, <span class="refDoi"> DOI: 10.3892/ijo.2019.4739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3892%2Fijo.2019.4739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30864703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlCgtbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2019&pages=1797-1808&author=A.+Urdiciainauthor=E.+Erausquinauthor=B.+Melendezauthor=J.+A.+Reyauthor=M.+A.+Idoateauthor=J.+S.+Castresana&title=Tubastatin+A%2C+an+inhibitor+of+HDAC6%2C+enhances+temozolomideinduced+apoptosis+and+reverses+the+malignant+phenotype+of+glioblastoma+cells&doi=10.3892%2Fijo.2019.4739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Tubastatin A, an inhibitor of HDAC6, enhances temozolomide-induced apoptosis and reverses the malignant phenotype of glioblastoma cells</span></div><div class="casAuthors">Urdiciain, Alejandro; Erausquin, Elena; Melendez, Barbara; Rey, Juan A.; Idoate, Miguel A.; Castresana, Javier S.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1797-1808</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Glioblastoma or grade IV astrocytoma is the most common and lethal form of glioma.  Current glioblastoma treatment strategies use surgery followed by chemotherapy with temozolomide.  Despite this, numerous glioblastoma cases develop resistance to temozolomide treatments, resulting in a poor prognosis for the patients.  Novel approaches are being investigated, including the inhibition of histone deacetylase 6 (HDAC6), an enzyme that deacetylates α-tubulin, and whose overexpression in glioblastoma is assocd. with the loss of primary cilia.  The aim of the present study was to treat glioblastoma cells with a selective HDAC6 inhibitor, tubastatin A, to det. if the malignant phenotype may be reverted.  The results demonstrated a notable increase in acetylated α-tubulin levels in treated cells, which assocd. with downregulation of the sonic hedgehog pathway, and may hypothetically promote ciliogenesis in those cells.  Treatment with tubastatin A also reduced glioblastoma clonogenicity and migration capacities, and accelerated temozolomide-induced apoptosis.  Finally, HDAC6 inhibition decreased the expression of mesenchymal markers, contributing to reverse epithelial-mesenchymal transition in glioblastoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo35bGhqcuVxrVg90H21EOLACvtfcHk0ljDTXkUfjXLxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlCgtbvP&md5=d115db089f2048f2e360f99c738eec01</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.3892%2Fijo.2019.4739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2019.4739%26sid%3Dliteratum%253Aachs%26aulast%3DUrdiciain%26aufirst%3DA.%26aulast%3DErausquin%26aufirst%3DE.%26aulast%3DMelendez%26aufirst%3DB.%26aulast%3DRey%26aufirst%3DJ.%2BA.%26aulast%3DIdoate%26aufirst%3DM.%2BA.%26aulast%3DCastresana%26aufirst%3DJ.%2BS.%26atitle%3DTubastatin%2520A%252C%2520an%2520inhibitor%2520of%2520HDAC6%252C%2520enhances%2520temozolomideinduced%2520apoptosis%2520and%2520reverses%2520the%2520malignant%2520phenotype%2520of%2520glioblastoma%2520cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2019%26volume%3D54%26spage%3D1797%26epage%3D1808%26doi%3D10.3892%2Fijo.2019.4739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geraldy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steimbach, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogueira, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunkel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. K.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4426</span>– <span class="NLM_lpage">4443</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01936</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01936" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvFSjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4426-4443&author=M.+Geraldyauthor=M.+Morgenauthor=P.+Sehrauthor=R.+R.+Steimbachauthor=D.+Moiauthor=J.+Ridingerauthor=I.+Oehmeauthor=O.+Wittauthor=M.+Malzauthor=M.+S.+Nogueiraauthor=O.+Kochauthor=N.+Gunkelauthor=A.+K.+Miller&title=Selective+Inhibition+of+Histone+Deacetylase+10%3A+Hydrogen+Bonding+to+the+Gatekeeper+Residue+is+Implicated&doi=10.1021%2Facs.jmedchem.8b01936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated</span></div><div class="casAuthors">Geraldy, Magalie; Morgen, Michael; Sehr, Peter; Steimbach, Raphael R.; Moi, Davide; Ridinger, Johannes; Oehme, Ina; Witt, Olaf; Malz, Mona; Nogueira, Mauro S.; Koch, Oliver; Gunkel, Nikolas; Miller, Aubry K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4426-4443</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of isoenzyme-selective histone deacetylase (HDAC) inhibitors is crit. for understanding the biol. functions of individual HDACs and for validating HDACs as drug targets.  The isoenzyme HDAC10 contributes to chemotherapy resistance and has recently been described to be a polyamine deacetylase, but no studies toward selective HDAC10 inhibitors have been published.  Using two complementary assays, the authors found tubastatin A, an HDAC6 inhibitor, to potently bind HDAC10.  The authors synthesized tubastatin A derivs. and found that a basic amine in the cap group was required for strong HDAC10 binding.  HDAC10 inhibitors mimicked knockdown by causing dose-dependent accumulation of acidic vesicles in a neuroblastoma cell line.  Furthermore, docking into human HDAC10 homol. models indicated that a hydrogen-bond between a cap group nitrogen and the gatekeeper residue Glu272 was responsible for potent HDAC10 binding.  Taken together, the authors' data provide an optimal platform for the development of HDAC10-selective inhibitors, as exemplified with the tubastatin A scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl1kc8D1boarVg90H21EOLACvtfcHk0ljDTXkUfjXLxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvFSjsb8%253D&md5=9c8fbb8ac46ca0db29df3848cb5e9b50</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01936%26sid%3Dliteratum%253Aachs%26aulast%3DGeraldy%26aufirst%3DM.%26aulast%3DMorgen%26aufirst%3DM.%26aulast%3DSehr%26aufirst%3DP.%26aulast%3DSteimbach%26aufirst%3DR.%2BR.%26aulast%3DMoi%26aufirst%3DD.%26aulast%3DRidinger%26aufirst%3DJ.%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DMalz%26aufirst%3DM.%26aulast%3DNogueira%26aufirst%3DM.%2BS.%26aulast%3DKoch%26aufirst%3DO.%26aulast%3DGunkel%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DA.%2BK.%26atitle%3DSelective%2520Inhibition%2520of%2520Histone%2520Deacetylase%252010%253A%2520Hydrogen%2520Bonding%2520to%2520the%2520Gatekeeper%2520Residue%2520is%2520Implicated%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4426%26epage%3D4443%26doi%3D10.1021%2Facs.jmedchem.8b01936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stangl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunstein, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongratz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striegl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenei-Lanzl, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dove, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span> <span> </span><span class="NLM_article-title">Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3454</span>– <span class="NLM_lpage">3477</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01593</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01593" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtFCnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3454-3477&author=A.+Sellmerauthor=H.+Stanglauthor=M.+Beyerauthor=E.+Grunsteinauthor=M.+Leonhardtauthor=H.+Pongratzauthor=E.+Eichhornauthor=S.+Elzauthor=B.+Strieglauthor=Z.+Jenei-Lanzlauthor=S.+Doveauthor=R.+H.+Straubauthor=O.+H.+Kramerauthor=S.+Mahboobi&title=Marbostat-100+Defines+a+New+Class+of+Potent+and+Selective+Antiinflammatory+and+Antirheumatic+Histone+Deacetylase+6+Inhibitors&doi=10.1021%2Facs.jmedchem.7b01593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors</span></div><div class="casAuthors">Sellmer, Andreas; Stangl, Hubert; Beyer, Mandy; Gruenstein, Elisabeth; Leonhardt, Michel; Pongratz, Herwig; Eichhorn, Emerich; Elz, Sigurd; Striegl, Birgit; Jenei-Lanzl, Zsuzsa; Dove, Stefan; Straub, Rainer H.; Kraemer, Oliver H.; Mahboobi, Siavosh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3454-3477</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epigenetic modifiers of the histone deacetylase (HDAC) family contribute to autoimmunity, cancer, HIV infection, inflammation, and neurodegeneration.  Hence, histone deacetylase inhibitors (HDACi), which alter protein acetylation, gene expression patterns, and cell fate decisions, represent promising new drugs for the therapy of these diseases.  Whereas pan-HDACi inhibit all 11 Zn2+-dependent histone deacetylases (HDACs) and cause a broad spectrum of side effects, specific inhibitors of histone deacetylase 6 (HDAC6i) are supposed to have less side effects.  The authors present the synthesis and biol. evaluation of Marbostats, novel HDAC6i that contain the hydroxamic acid moiety linked to tetrahydro-β-carboline derivs.  The lead compd. Marbostat-100 is a more potent and more selective HDAC6i than previously established well-characterized compds. in vitro as well as in cells.  Moreover, Marbostat-100 is well tolerated by mice and effective against collagen type II induced arthritis.  Thus, Marbostat-100 represents a most selective known HDAC6i and the possibility for clin. evaluation of a HDAC isoform-specific drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqixUQJJP-7bVg90H21EOLACvtfcHk0ljDTXkUfjXLxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtFCnsbg%253D&md5=0f6c62f03f50501728d43fef66d0d64b</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01593%26sid%3Dliteratum%253Aachs%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DStangl%26aufirst%3DH.%26aulast%3DBeyer%26aufirst%3DM.%26aulast%3DGrunstein%26aufirst%3DE.%26aulast%3DLeonhardt%26aufirst%3DM.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DElz%26aufirst%3DS.%26aulast%3DStriegl%26aufirst%3DB.%26aulast%3DJenei-Lanzl%26aufirst%3DZ.%26aulast%3DDove%26aufirst%3DS.%26aulast%3DStraub%26aufirst%3DR.%2BH.%26aulast%3DKramer%26aufirst%3DO.%2BH.%26aulast%3DMahboobi%26aufirst%3DS.%26atitle%3DMarbostat-100%2520Defines%2520a%2520New%2520Class%2520of%2520Potent%2520and%2520Selective%2520Antiinflammatory%2520and%2520Antirheumatic%2520Histone%2520Deacetylase%25206%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3454%26epage%3D3477%26doi%3D10.1021%2Facs.jmedchem.7b01593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leonhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dove, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span> <span> </span><span class="NLM_article-title">Design and biological evaluation of tetrahydro-beta-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.04.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2018.04.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29738953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt1agtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2018&pages=329-357&author=M.+Leonhardtauthor=A.+Sellmerauthor=O.+H.+Kramerauthor=S.+Doveauthor=S.+Elzauthor=B.+Krausauthor=M.+Beyerauthor=S.+Mahboobi&title=Design+and+biological+evaluation+of+tetrahydro-beta-carboline+derivatives+as+highly+potent+histone+deacetylase+6+%28HDAC6%29+inhibitors&doi=10.1016%2Fj.ejmech.2018.04.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors</span></div><div class="casAuthors">Leonhardt, Michel; Sellmer, Andreas; Kraemer, Oliver H.; Dove, Stefan; Elz, Sigurd; Kraus, Birgit; Beyer, Mandy; Mahboobi, Siavosh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">329-357</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Various diseases are related to epigenetic modifications.  Histone deacetylases (HDACs) and histone acetyltransferases (HATs) det. the pattern of histone acetylation, and thus are involved in the regulation of gene expression.  First generation histone deacetylase inhibitors (HDACi) are unselective, hinder all different kinds of zinc dependent HDACs and addnl. cause several side effects.  Subsequently, selective HDACi are gaining more and more interest.  Esp., selective histone deacetylase 6 inhibitors (HDAC6i) are supposed to be less toxic.  Here the authors present a successful optimization study of tubastatin A, the synthesis and biol. evaluation of new inhibitors based on hydroxamic acids linked to various tetrahydro-β-carboline derivs.  The potency of the authors' selective HDAC6 inhibitors, exhibiting IC50 values in a range of 1-10 nM towards HDAC6, was evaluated with the help of a recombinant human HDAC6 enzyme assay.  Selectivity was proofed in cellular assays by the hyperacetylation of surrogate parameter α-tubulin in the absence of acetylated histone H3 analyzed by Western Blot.  The authors show that all synthesized compds., with varies modifications of the rigid cap group, were selective and potent HDAC6 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO3jAwqO8N0LVg90H21EOLACvtfcHk0ljGY7sqZwpuVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt1agtbY%253D&md5=668b7ae179e680a0ae7116589e315cb5</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.04.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.04.046%26sid%3Dliteratum%253Aachs%26aulast%3DLeonhardt%26aufirst%3DM.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DKramer%26aufirst%3DO.%2BH.%26aulast%3DDove%26aufirst%3DS.%26aulast%3DElz%26aufirst%3DS.%26aulast%3DKraus%26aufirst%3DB.%26aulast%3DBeyer%26aufirst%3DM.%26aulast%3DMahboobi%26aufirst%3DS.%26atitle%3DDesign%2520and%2520biological%2520evaluation%2520of%2520tetrahydro-beta-carboline%2520derivatives%2520as%2520highly%2520potent%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D152%26spage%3D329%26epage%3D357%26doi%3D10.1016%2Fj.ejmech.2018.04.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieger, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ressing, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borkhardt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span> <span> </span><span class="NLM_article-title">Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">10299</span>– <span class="NLM_lpage">10309</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWrur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10299-10309&author=S.+Bhatiaauthor=V.+Kriegerauthor=M.+Grollauthor=J.+D.+Oskoauthor=N.+Ressingauthor=H.+Ahlertauthor=A.+Borkhardtauthor=T.+Kurzauthor=D.+W.+Christiansonauthor=J.+Hauerauthor=F.+K.+Hansen&title=Discovery+of+the+First-in-Class+Dual+Histone+Deacetylase-Proteasome+Inhibitor&doi=10.1021%2Facs.jmedchem.8b01487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor</span></div><div class="casAuthors">Bhatia, Sanil; Krieger, Viktoria; Groll, Michael; Osko, Jeremy D.; Ressing, Nina; Ahlert, Heinz; Borkhardt, Arndt; Kurz, Thomas; Christianson, David W.; Hauer, Julia; Hansen, Finn K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10299-10309</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual- or multitarget drugs have emerged as a promising alternative to combination therapies.  Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase (HDAC) inhibitors due to the simultaneous blockage of the ubiquitin degrdn. and aggresome pathways.  Here, the authors present the design, synthesis, binding modes, and anticancer properties of RTS-V5 as the first-in-class dual HDAC-proteasome ligand.  The inhibition of both targets was confirmed by biochem. and cellular assays as well as x-ray crystal structures of the 20S proteasome and HDAC6 complexed with RTS-V5.  Cytotoxicity assays with leukemia and multiple myeloma cell lines as well as therapy refractory primary patient-derived leukemia cells demonstrated that RTS-V5 possesses potent and selective anticancer activity.  The results will thus guide the structure-based optimization of dual HDAC-proteasome inhibitors for the treatment of hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwJMqcDlzXA7Vg90H21EOLACvtfcHk0ljGY7sqZwpuVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWrur7K&md5=7d47e664bd77ac1bc5ebd39ea6eed02a</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01487%26sid%3Dliteratum%253Aachs%26aulast%3DBhatia%26aufirst%3DS.%26aulast%3DKrieger%26aufirst%3DV.%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DRessing%26aufirst%3DN.%26aulast%3DAhlert%26aufirst%3DH.%26aulast%3DBorkhardt%26aufirst%3DA.%26aulast%3DKurz%26aufirst%3DT.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DHauer%26aufirst%3DJ.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26atitle%3DDiscovery%2520of%2520the%2520First-in-Class%2520Dual%2520Histone%2520Deacetylase-Proteasome%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D10299%26epage%3D10309%26doi%3D10.1021%2Facs.jmedchem.8b01487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reßing, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnichsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schliehe-Diecks, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerhut, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borkhardt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D.. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span> <span> </span><span class="NLM_article-title">Multicomponent synthesis, binding mode and structure-activity relationships of selective histone deacetylase 6 (HDAC6) inhibitors with bifurcated capping groups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10339</span>– <span class="NLM_lpage">10351</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01888</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01888" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Srsr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10339-10351&author=N.+Re%C3%9Fingauthor=M.+Sonnichsenauthor=J.+D.+Oskoauthor=A.+Scholerauthor=J.+Schliehe-Diecksauthor=A.+Skerhutauthor=A.+Borkhardtauthor=J.+Hauerauthor=M.+U.+Kassackauthor=D..+W.+Christiansonauthor=S.+Bhatiaauthor=F.+K.+Hansen&title=Multicomponent+synthesis%2C+binding+mode+and+structure-activity+relationships+of+selective+histone+deacetylase+6+%28HDAC6%29+inhibitors+with+bifurcated+capping+groups&doi=10.1021%2Facs.jmedchem.9b01888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Multicomponent synthesis, binding mode and structure-activity relationships of selective histone deacetylase 6 (HDAC6) inhibitors with bifurcated capping groups</span></div><div class="casAuthors">Ressing, Nina; Soennichsen, Melf; Osko, Jeremy D.; Schoeler, Andrea; Schliehe-Diecks, Julian; Skerhut, Alexander; Borkhardt, Arndt; Hauer, Julia; Kassack, Matthias U.; Christianson, David. W.; Bhatia, Sanil; Hansen, Finn K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10339-10351</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multicomponent synthesis and structure-activity relationships of a series of tetrazole-based HDAC6 inhibitors was reported.  Hit compd. NR-160 was discovered by investigating the inhibition of recombinant HDAC enzymes and protein acetylation.  A co-crystal structure of HDAC6 complexed with NR-160 disclosed that the steric complementarity of the bifurcated capping group of NR-160 to the L1 and L2 loop pockets may be responsible for its HDAC6-selective inhibition.  NR-160 displayed only low cytotoxicity as single-agent against leukemia cell lines, it augmented the apoptosis induction of the proteasome inhibitor bortezomib in combination expts. significantly.  Furthermore, a combinatorial high throughput drug screen revealed significantly enhanced cytotoxicity when NR-160 was used in combination with epirubicin and daunorubicin.  The synergistic effect in combination with bortezomib and anthracyclines highlights NR-160's potential in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokiwDPM_2Xf7Vg90H21EOLACvtfcHk0ljGY7sqZwpuVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Srsr7P&md5=a8c3f9c5b70228e97bd147bc3e82a0f3</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01888%26sid%3Dliteratum%253Aachs%26aulast%3DRe%25C3%259Fing%26aufirst%3DN.%26aulast%3DSonnichsen%26aufirst%3DM.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DScholer%26aufirst%3DA.%26aulast%3DSchliehe-Diecks%26aufirst%3DJ.%26aulast%3DSkerhut%26aufirst%3DA.%26aulast%3DBorkhardt%26aufirst%3DA.%26aulast%3DHauer%26aufirst%3DJ.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DChristianson%26aufirst%3DD..%2BW.%26aulast%3DBhatia%26aufirst%3DS.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26atitle%3DMulticomponent%2520synthesis%252C%2520binding%2520mode%2520and%2520structure-activity%2520relationships%2520of%2520selective%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529%2520inhibitors%2520with%2520bifurcated%2520capping%2520groups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10339%26epage%3D10351%26doi%3D10.1021%2Facs.jmedchem.9b01888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adejare, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span> <span> </span><span class="NLM_article-title">Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1369</span>– <span class="NLM_lpage">1382</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S124977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.2147%2FDDDT.S124977" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=28496307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKns7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=1369-1382&author=Y.+Wangauthor=J.+Wallachauthor=S.+Duaneauthor=Y.+Wangauthor=J.+Wuauthor=J.+Wangauthor=A.+Adejareauthor=H.+Ma&title=Developing+selective+histone+deacetylases+%28HDACs%29+inhibitors+through+ebselen+and+analogs&doi=10.2147%2FDDDT.S124977"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs</span></div><div class="casAuthors">Wang, Yuren; Wallach, Jason; Duane, Stephanie; Wang, Yuan; Wu, Jianghong; Wang, Jeffrey; Adejare, Adeboye; Ma, Haiching</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1369-1382</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are key regulators of gene expression in cells and have been investigated as important therapeutic targets for cancer and other diseases.  Different subtypes of HDACs appear to play disparate roles in the cells and are assocd. with specific diseases.  Therefore, substantial effort has been made to develop subtype-selective HDAC inhibitors.  In an effort to discover existing scaffolds with HDAC inhibitory activity, we screened a drug library approved by the US Food and Drug Administration and a National Institutes of Health Clin. Collection compd. library in HDAC enzymic assays.  Ebselen, a clin. safe compd., was identified as a weak inhibitor of several HDACs, including HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9 with half maximal inhibitory concns. approx. single digit of μM.  Two ebselen analogs, ebselen oxide and ebsulfur (a diselenide analog of ebselen), also inhibited these HDACs, however with improved potencies on HDAC8.  Benzisothiazol, the core structure of ebsulfur, specifically inhibited HDAC6 at a single digit of μM but had no inhibition on other HDACs.  Further efforts on structure-activity relationship based on the core structure of ebsulfur led to the discovery of a novel class of potent and selective HDAC6 inhibitors with RBC-2008 as the lead compd. with single-digit nM potency.  This class of histone deacetylase inhibitor features a novel pharmacophore with an ebsulfur scaffold selectively targeting HDAC6.  Consistent with its inhibition on HDAC6, RBC-2008 significantly increased the acetylation levels of α-tubulin in PC-3 cells.  Furthermore, treatment with these compds. led to cell death of multiple tumor cell lines in a dose-dependent manner.  These results demonstrated that ebselen and ebsulfur analogs are inhibitors of HDACs, supporting further preclin. development of this class of compds. for potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTSO9qayhR7rVg90H21EOLACvtfcHk0lj7VJ5B-ZimXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKns7rM&md5=7c71fca15cacf6026275682e886245b2</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S124977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S124977%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWallach%26aufirst%3DJ.%26aulast%3DDuane%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAdejare%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DH.%26atitle%3DDeveloping%2520selective%2520histone%2520deacetylases%2520%2528HDACs%2529%2520inhibitors%2520through%2520ebselen%2520and%2520analogs%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D1369%26epage%3D1382%26doi%3D10.2147%2FDDDT.S124977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer’s disease</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5718</span>– <span class="NLM_lpage">5729</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmc.2018.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30385227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVentL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=5718-5729&author=J.+Huauthor=B.+Anauthor=T.+Panauthor=Z.+Liauthor=L.+Huangauthor=X.+Li&title=Design%2C+synthesis%2C+and+biological+evaluation+of+histone+deacetylase+inhibitors+possessing+glutathione+peroxidase-like+and+antioxidant+activities+against+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.bmc.2018.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease</span></div><div class="casAuthors">Hu, Jinhui; An, Baijiao; Pan, Tingting; Li, Zhengcunxiao; Huang, Ling; Li, Xingshu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5718-5729</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of hybrids contg. the pharmacophores of the histone deacetylase (HDAC) inhibitor, SAHA, and the antioxidant ebselen were designed and synthesized as multi-target-directed ligands against Alzheimer's disease.  An in vitro assay indicated that some of these mols. exhibit potent HDAC inhibitory activity and ebselen-related pharmacol. effects.  Specifically, the optimal compd. 7f was found to be a potent HDAC inhibitor (IC50 = 0.037 μM), possessing rapid hydrogen peroxide scavenging activity and glutathione peroxidase-like activity (ν0 = 150.0 μM min-1) and good free oxygen radical absorbance capacity (value of ORAC: 2.2).  Furthermore, compd. 7f showed significant protective effects against damage induced by H2O2 and the ability to prevent ROS accumulation in PC12 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv2EKWVVijlLVg90H21EOLACvtfcHk0lj7VJ5B-ZimXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVentL%252FK&md5=b9a5f6059db2b4c611f9a050e2b54d6f</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DAn%26aufirst%3DB.%26aulast%3DPan%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520histone%2520deacetylase%2520inhibitors%2520possessing%2520glutathione%2520peroxidase-like%2520and%2520antioxidant%2520activities%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D5718%26epage%3D5729%26doi%3D10.1016%2Fj.bmc.2018.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, Y. H.</span></span> <span> </span><span class="NLM_article-title">Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">6213</span>, <span class="refDoi"> DOI: 10.3390/ijms20246213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3390%2Fijms20246213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslChtb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=6213&author=C.+Sharmaauthor=Y.+J.+Ohauthor=B.+Parkauthor=S.+Leeauthor=C.+H.+Jeongauthor=S.+Leeauthor=J.+H.+Seoauthor=Y.+H.+Seo&title=Development+of+Thiazolidinedione-Based+HDAC6+Inhibitors+to+Overcome+Methamphetamine+Addiction&doi=10.3390%2Fijms20246213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Development of thiazolidinedione-based HDAC6 inhibitors to overcome methamphetamine addiction</span></div><div class="casAuthors">Sharma, Chiranjeev; Oh, Yong Jin; Park, Byoungduck; Lee, Sooyeun; Jeong, Chul-Ho; Lee, Sangkil; Seo, Ji Hae; Seo, Young Ho</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6213</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Thiazolidinedione is a five-membered heterocycle that is widely used in drug discovery endeavors.  In this study, we report the design, synthesis, and biol. evaluation of a series of thiazolidinedione-based HDAC6 inhibitors.  In particular, compd. 6b exerts an excellent inhibitory activity against HDAC6 with an IC50 value of 21 nM, displaying a good HDAC6 selectivity over HDAC1.  Compd. 6b dose-dependently induces the acetylation level of alpha-tubulin via inhibition of HDAC6 in human neuroblastoma SH-SY5Y cell line.  Moreover, compd. 6b efficiently reverses methamphetamine-induced morphol. changes of SH-SY5Y cells via regulating acetylation landscape of α-tubulin.  Collectively, compd. 6b represents a novel HDAC6-isoform selective inhibitor and demonstrates promising therapeutic potential for the treatment of methamphetamine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM-EVD1Rc2abVg90H21EOLACvtfcHk0lj7VJ5B-ZimXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslChtb7I&md5=372dcca52fe0cb3946e1b40c899f968a</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.3390%2Fijms20246213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20246213%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DC.%26aulast%3DOh%26aufirst%3DY.%2BJ.%26aulast%3DPark%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DJeong%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26aulast%3DSeo%26aufirst%3DY.%2BH.%26atitle%3DDevelopment%2520of%2520Thiazolidinedione-Based%2520HDAC6%2520Inhibitors%2520to%2520Overcome%2520Methamphetamine%2520Addiction%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D6213%26doi%3D10.3390%2Fijms20246213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1122</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00084</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlamsLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1122-1127&author=T.+Liangauthor=X.+Houauthor=Y.+Zhouauthor=X.+Yangauthor=H.+Fang&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+2%2C4-Imidazolinedione+Derivatives+as+HDAC6+Isoform-Selective+Inhibitors&doi=10.1021%2Facsmedchemlett.9b00084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors</span></div><div class="casAuthors">Liang, Tao; Hou, Xuben; Zhou, Yi; Yang, Xinying; Fang, Hao</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1122-1127</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) has emerged as a promising drug target for various human diseases, including diverse neurodegenerative diseases and cancer.  Herein, a series of 2,4-imidazolinedione derivs. as HDAC6 isoform-selective inhibitors based on structure-based drug design, is reported.  Most target compds. exhibit good profiles in a preliminary screening concerning HDAC6 inhibitory activities.  Moreover, the most active compd. I increases the acetylation level of α-tubulin with little effect on the acetylation of histone H3.  Further biol. evaluation suggested that potent compd. I, which possesses good antiproliferative activity, could induce apoptosis in HL-60 cell by activating caspase 3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbKZDLzBq-JLVg90H21EOLACvtfcHk0lhtri6vaVM9kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlamsLzL&md5=e97c451e0cb8a770ef36775c4c00f14b</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00084%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%25202%252C4-Imidazolinedione%2520Derivatives%2520as%2520HDAC6%2520Isoform-Selective%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1122%26epage%3D1127%26doi%3D10.1021%2Facsmedchemlett.9b00084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Arias, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miguel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Gonzalez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estella-Hermoso de Mendoza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espelosin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda-Lucena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span> <span> </span><span class="NLM_article-title">Multitarget Approach for the Treatment of Alzheimer’s Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4076</span>– <span class="NLM_lpage">4101</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.9b00303</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.9b00303" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1egu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=4076-4101&author=O.+Rabalauthor=J.+A.+Sanchez-Ariasauthor=M.+Cuadrado-Tejedorauthor=I.+de+Miguelauthor=M.+Perez-Gonzalezauthor=C.+Garcia-Barrosoauthor=A.+Ugarteauthor=A.+Estella-Hermoso+de+Mendozaauthor=E.+Saezauthor=M.+Espelosinauthor=S.+Ursuaauthor=H.+Tanauthor=W.+Wuauthor=M.+Xuauthor=A.+Pineda-Lucenaauthor=A.+Garcia-Ostaauthor=J.+Oyarzabal&title=Multitarget+Approach+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease%3A+Inhibition+of+Phosphodiesterase+9+%28PDE9%29+and+Histone+Deacetylases+%28HDACs%29+Covering+Diverse+Selectivity+Profiles&doi=10.1021%2Facschemneuro.9b00303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles</span></div><div class="casAuthors">Rabal, Obdulia; Sanchez-Arias, Juan A.; Cuadrado-Tejedor, Mar; de Miguel, Irene; Perez-Gonzalez, Marta; Garcia-Barroso, Carolina; Ugarte, Ana; Estella-Hermoso de Mendoza, Ander; Saez, Elena; Espelosin, Maria; Ursua, Susana; Tan, Haizhong; Wu, Wei; Xu, Musheng; Pineda-Lucena, Antonio; Garcia-Osta, Ana; Oyarzabal, Julen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4076-4101</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here, we present a series of dual-target phosphodiesterase 9 (PDE9) and histone deacetylase (HDAC) inhibitors devised as pharmacol. tool compds. for assessing the implications of these two targets in Alzheimer's disease (AD).  These novel inhibitors were designed taking into account the key pharmacophoric features of known selective PDE9 inhibitors as well as privileged chem. structures, bearing zinc binding groups (hydroxamic acids and ortho-amino anilides) that hit HDAC targets.  These substituents were selected according to rational criteria and previous knowledge from our group to explore diverse HDAC selectivity profiles (pan-HDAC, HDAC6 selective, and class I selective) that were confirmed in biochem. screens.  Their functional response in inducing acetylation of histone and tubulin and phosphorylation of cAMP response element binding (CREB) was measured as a requisite for further progression into complete in vitro absorption, distribution, metab. and excretion (ADME) and in vivo brain penetration profiling.  Compd. 31b, a selective HDAC6 inhibitor with acceptable brain permeability, was chosen for assessing in vivo efficacy of these first-in-class inhibitors, as well as studying their mode of action (MoA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9GkgLW75qELVg90H21EOLACvtfcHk0lhtri6vaVM9kQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1egu7rF&md5=be57148d4b99a7e517c51142a1908fb8</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.9b00303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.9b00303%26sid%3Dliteratum%253Aachs%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DSanchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3Dde%2BMiguel%26aufirst%3DI.%26aulast%3DPerez-Gonzalez%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DEstella-Hermoso%2Bde%2BMendoza%26aufirst%3DA.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DEspelosin%26aufirst%3DM.%26aulast%3DUrsua%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DPineda-Lucena%26aufirst%3DA.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26aulast%3DOyarzabal%26aufirst%3DJ.%26atitle%3DMultitarget%2520Approach%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Inhibition%2520of%2520Phosphodiesterase%25209%2520%2528PDE9%2529%2520and%2520Histone%2520Deacetylases%2520%2528HDACs%2529%2520Covering%2520Diverse%2520Selectivity%2520Profiles%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D4076%26epage%3D4101%26doi%3D10.1021%2Facschemneuro.9b00303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danchik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilha, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharbanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, G.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4256</span>– <span class="NLM_lpage">4292</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslCgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4256-4292&author=A.+Thakurauthor=G.+J.+Tawaauthor=M.+J.+Hendersonauthor=C.+Danchikauthor=S.+Liuauthor=P.+Shahauthor=A.+Q.+Wangauthor=G.+Dunnauthor=M.+Kabirauthor=E.+C.+Padilhaauthor=X.+Xuauthor=A.+Simeonovauthor=S.+Kharbandaauthor=R.+Stoneauthor=G.+Grewal&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Quinazolin-4-one-Based+Hydroxamic+Acids+as+Dual+PI3K%2FHDAC+Inhibitors&doi=10.1021%2Facs.jmedchem.0c00193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors</span></div><div class="casAuthors">Thakur, Ashish; Tawa, Gregory J.; Henderson, Mark J.; Danchik, Carina; Liu, Suiyang; Shah, Pranav; Wang, Amy Q.; Dunn, Garrett; Kabir, Md.; Padilha, Elias C.; Xu, Xin; Simeonov, Anton; Kharbanda, Surender; Stone, Richard; Grewal, Gurmit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4256-4292</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of quinazolin-4-one based hydroxamic acids was rationally designed and synthesized as novel dual PI3K/HDAC inhibitors by incorporating an HDAC pharmacophore into a PI3K inhibitor (Idelalisib) via an optimized linker.  Several of these dual inhibitors were highly potent (IC50 < 10 nM) and selective against PI3Kγ, δ and HDAC6 enzymes and exhibited good antiproliferative activity against multiple cancer cell lines.  The lead compd. 48c, induced necrosis in several mutant and FLT3-resistant AML cell lines and primary blasts from AML patients, while showing no cytotoxicity against normal PBMCs, NIH3T3, and HEK293 cells.  Target engagement of PI3Kδ and HDAC6 by 48c was demonstrated in MV411 cells using the cellular thermal shift assay (CETSA).  Compd. 48c showed good pharmacokinetics properties in mice via i.p. administration and provides a means to examine the biol. effects of inhibiting these two important enzymes with a single mol., either in vitro or in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWWMm2AttIWLVg90H21EOLACvtfcHk0lixBpKl-y75vw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslCgsrg%253D&md5=75f1696a5d5826a46380a85e2a115b59</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00193%26sid%3Dliteratum%253Aachs%26aulast%3DThakur%26aufirst%3DA.%26aulast%3DTawa%26aufirst%3DG.%2BJ.%26aulast%3DHenderson%26aufirst%3DM.%2BJ.%26aulast%3DDanchik%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DA.%2BQ.%26aulast%3DDunn%26aufirst%3DG.%26aulast%3DKabir%26aufirst%3DM.%26aulast%3DPadilha%26aufirst%3DE.%2BC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DKharbanda%26aufirst%3DS.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DGrewal%26aufirst%3DG.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Quinazolin-4-one-Based%2520Hydroxamic%2520Acids%2520as%2520Dual%2520PI3K%252FHDAC%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4256%26epage%3D4292%26doi%3D10.1021%2Facs.jmedchem.0c00193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Relitti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraswati, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtkunz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccoccia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruberti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulivieri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamponi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span> <span> </span><span class="NLM_article-title">Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">112998</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112998</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2020.112998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=33199154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3s3ls1ygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=112998&author=N.+Relittiauthor=A.+P.+Saraswatiauthor=G.+Chemiauthor=M.+Brindisiauthor=S.+Brogiauthor=D.+Herpauthor=K.+Schmidtkunzauthor=F.+Saccocciaauthor=G.+Rubertiauthor=C.+Ulivieriauthor=F.+Vanniauthor=F.+Sarnoauthor=L.+Altucciauthor=S.+Lamponiauthor=M.+Jungauthor=S.+Gemmaauthor=S.+Butiniauthor=G.+Campiani&title=Novel+quinolone-based+potent+and+selective+HDAC6+inhibitors%3A+Synthesis%2C+molecular+modeling+studies+and+biological+investigation&doi=10.1016%2Fj.ejmech.2020.112998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation</span></div><div class="casAuthors">Relitti Nicola; Saraswati A Prasanth; Chemi Giulia; Brindisi Margherita; Lamponi Stefania; Gemma Sandra; Butini Stefania; Brogi Simone; Herp Daniel; Schmidtkunz Karin; Jung Manfred; Saccoccia Fulvio; Ruberti Giovina; Ulivieri Cristina; Vanni Francesca; Sarno Federica; Altucci Lucia; Campiani Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">European journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112998</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In this work we describe the synthesis of potent and selective quinolone-based histone deacetylase 6 (HDAC6) inhibitors.  The quinolone moiety has been exploited as an innovative bioactive cap-group for HDAC6 inhibition; its synthesis was achieved by applying a multicomponent reaction.  The optimization of potency and selectivity of these products was performed by employing computational studies which led to the discovery of the diethylaminomethyl derivatives 7g and 7k as the most promising hit molecules.  These compounds were investigated in cellular studies to evaluate their anticancer effect against colon (HCT-116) and histiocytic lymphoma (U9347) cancer cells, showing good to excellent potency, leading to tumor cell death by apoptosis induction.  The small molecules 7a, 7g and 7k were able to strongly inhibit the cytoplasmic and slightly the nuclear HDAC enzymes, increasing the acetylation of tubulin and of the lysine 9 and 14 of histone 3, respectively.  Compound 7g was also able to increase Hsp90 acetylation levels in HCT-116 cells, thus further supporting its HDAC6 inhibitory profile.  Cytotoxicity and mutagenicity assays of these molecules showed a safe profile; moreover, the HPLC analysis of compound 7k revealed good solubility and stability profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwT9brH_VNAP_I8Jvzw4xCfW6udTcc2eYAa4Em5_T2nLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s3ls1ygsg%253D%253D&md5=e96c6ae6db6fd3f724e8bd24c031a250</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112998%26sid%3Dliteratum%253Aachs%26aulast%3DRelitti%26aufirst%3DN.%26aulast%3DSaraswati%26aufirst%3DA.%2BP.%26aulast%3DChemi%26aufirst%3DG.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DHerp%26aufirst%3DD.%26aulast%3DSchmidtkunz%26aufirst%3DK.%26aulast%3DSaccoccia%26aufirst%3DF.%26aulast%3DRuberti%26aufirst%3DG.%26aulast%3DUlivieri%26aufirst%3DC.%26aulast%3DVanni%26aufirst%3DF.%26aulast%3DSarno%26aufirst%3DF.%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DLamponi%26aufirst%3DS.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26atitle%3DNovel%2520quinolone-based%2520potent%2520and%2520selective%2520HDAC6%2520inhibitors%253A%2520Synthesis%252C%2520molecular%2520modeling%2520studies%2520and%2520biological%2520investigation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26spage%3D112998%26doi%3D10.1016%2Fj.ejmech.2020.112998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fcmdc.201500486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=26603496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvV2jsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=15-21&author=S.+Shenauthor=A.+P.+Kozikowski&title=Why+Hydroxamates+May+Not+Be+the+Best+Histone+Deacetylase+Inhibitors%2D%2DWhat+Some+May+Have+Forgotten+or+Would+Rather+Forget%3F&doi=10.1002%2Fcmdc.201500486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors-What Some May Have Forgotten or Would Rather Forget?</span></div><div class="casAuthors">Shen, Sida; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-21</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Hydroxamate-based histone deacetylase inhibitors (HDACIs) have been approved as therapeutic agents by the US Food and Drug Administration for use in oncol. applications.  While the potential utility of such HDACIs in other areas of medicinal chem. is tremendous, there are significant concerns that "pan-HDAC inhibitors" may be too broadly acting and/or toxic for clin. use beyond oncol.  In addn. to the isoenzyme selectivity challenge, the potential mutagenicity of hydroxamate-contg. HDAC inhibitors represents a major hindrance in their application to other therapeutic areas.  Herein the authors report on the mutagenicity of known hydroxamates, discuss the mechanisms responsible for their genotoxicity, and review some of the current alternatives to hydroxamates.  The authors conclude that the hydroxamate group, while providing high-potency HDACIs, is not necessarily the best zinc-binding group for HDACI drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplftHMFVoN6rVg90H21EOLACvtfcHk0lif1UFRc-tv7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvV2jsrbL&md5=5183d2c0a4c86fe67bea480a66bc5dc6</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500486%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DWhy%2520Hydroxamates%2520May%2520Not%2520Be%2520the%2520Best%2520Histone%2520Deacetylase%2520Inhibitors--What%2520Some%2520May%2520Have%2520Forgotten%2520or%2520Would%2520Rather%2520Forget%253F%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D15%26epage%3D21%26doi%3D10.1002%2Fcmdc.201500486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steimbach, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span> <span> </span><span class="NLM_article-title">Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">111950</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2019.111950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31865013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVeqtLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2020&pages=111950&author=X.+Chenauthor=X.+Chenauthor=R.+R.+Steimbachauthor=T.+Wuauthor=H.+Liauthor=W.+Danauthor=P.+Shiauthor=C.+Caoauthor=D.+Liauthor=A.+K.+Millerauthor=Z.+Qiuauthor=J.+Gaoauthor=Y.+Zhu&title=Novel+2%2C+5-diketopiperazine+derivatives+as+potent+selective+histone+deacetylase+6+inhibitors%3A+Rational+design%2C+synthesis+and+antiproliferative+activity&doi=10.1016%2Fj.ejmech.2019.111950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity</span></div><div class="casAuthors">Chen, Xin; Chen, Xinyang; Steimbach, Raphael R.; Wu, Tong; Li, Hongmei; Dan, Wenjia; Shi, Peidong; Cao, Chenyu; Li, Ding; Miller, Aubry K.; Qiu, Zhixia; Gao, Jinming; Zhu, Yong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111950</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) has gained popular attention for its wide participation in various patNovel 2, 5-diketopiperazine derivs. as potent selective histone deacetylase 6 inhibitors: Rational desighol. process recently.  In this paper, a series of novel derivs. contg. 2, 5-diketopiperazine (DKP) skeleton were developed as potent selective HDAC6 inhibitors (sHDAC6is).  Most of these compds. exhibited low nanomolar IC50 values toward HDAC6, and the best compd. was 21b (IC50 = 0.73 nM) which had 144-10941-fold selectivity over other HDAC isoforms.  Western blot assay further validated these compds. to be sHDAC6is.  Mol. simulation of 21b was conducted to rationalize the high binding affinity for HDAC6.  In the cytotoxicity expt., 18a, 18b and 18d gave superior or comparable influence on the growth of two multiple myeloma cells U266 and RPMI-8226 compared to ACY-1215.  Moreover, the combination of 18a and adriamycin showed synergistic effect against non-small cell lung cancer cell A549. 18a and 18b also demonstrated appropriate drug metab. in human liver microsome (HLM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxkduBDp5v4bVg90H21EOLACvtfcHk0lif1UFRc-tv7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVeqtLfJ&md5=d662060f4aee956b065d0e24a534fe1e</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111950%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSteimbach%26aufirst%3DR.%2BR.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DDan%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DP.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DA.%2BK.%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DY.%26atitle%3DNovel%25202%252C%25205-diketopiperazine%2520derivatives%2520as%2520potent%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%253A%2520Rational%2520design%252C%2520synthesis%2520and%2520antiproliferative%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D187%26spage%3D111950%26doi%3D10.1016%2Fj.ejmech.2019.111950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, J. W.</span></span> <span> </span><span class="NLM_article-title">Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">857</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01590</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01590" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKrtr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=857-874&author=C.+W.+Yuauthor=P.+Y.+Hungauthor=H.+T.+Yangauthor=Y.+H.+Hoauthor=H.+Y.+Laiauthor=Y.+S.+Chengauthor=J.+W.+Chern&title=Quinazolin-2%2C4-dione-Based+Hydroxamic+Acids+as+Selective+Histone+Deacetylase-6+Inhibitors+for+Treatment+of+Non-Small+Cell+Lung+Cancer&doi=10.1021%2Facs.jmedchem.8b01590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Yu, Chao-Wu; Hung, Pei-Yun; Yang, Hui-Ting; Ho, Yi-Hsun; Lai, Hsing-Yi; Cheng, Yi-Sheng; Chern, Ji-Wang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">857-874</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We designed and synthesized quinazolin-2,4-dione-based hydroxamic acids to serve as selective competitive inhibitors of histone deacetylase-6 (HDAC6).  The most potent and selective compd., I (IC50, 4 nM, HDAC6; IC50 > 10 μM, HDAC1), substantially increased acetylation of α-tubulin instead of histones in the lung cancer cell line, LL2.  Paclitaxel in combination with I had a synergistic anticancer effect on redn. of programmed death-ligand 1 expression in LL/2 cells.  When given orally, I was mainly found to locate in the liver and lungs, at a concn. 18- to 70-fold greater, resp., than in plasma.  As an orally active HDAC6 inhibitor, I (20 mg/kg), potentiated paclitaxel antitumor activity (percentage tumor growth inhibition, 67.5%) in a xenograft syngeneic non-small cell lung cancer mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIz_AQ5jytrrVg90H21EOLACvtfcHk0lif1UFRc-tv7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKrtr%252FF&md5=eaee2fc7b612a60eac2469eeb8afdc49</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01590%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DC.%2BW.%26aulast%3DHung%26aufirst%3DP.%2BY.%26aulast%3DYang%26aufirst%3DH.%2BT.%26aulast%3DHo%26aufirst%3DY.%2BH.%26aulast%3DLai%26aufirst%3DH.%2BY.%26aulast%3DCheng%26aufirst%3DY.%2BS.%26aulast%3DChern%26aufirst%3DJ.%2BW.%26atitle%3DQuinazolin-2%252C4-dione-Based%2520Hydroxamic%2520Acids%2520as%2520Selective%2520Histone%2520Deacetylase-6%2520Inhibitors%2520for%2520Treatment%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D857%26epage%3D874%26doi%3D10.1021%2Facs.jmedchem.8b01590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsin, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, J. W.</span></span> <span> </span><span class="NLM_article-title">High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2019.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bcp.2019.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30885763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1eitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2019&pages=458-471&author=J.+R.+Liuauthor=C.+W.+Yuauthor=P.+Y.+Hungauthor=L.+W.+Hsinauthor=J.+W.+Chern&title=High-selective+HDAC6+inhibitor+promotes+HDAC6+degradation+following+autophagy+modulation+and+enhanced+antitumor+immunity+in+glioblastoma&doi=10.1016%2Fj.bcp.2019.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma</span></div><div class="casAuthors">Liu, Jia-Rong; Yu, Chao-Wu; Hung, Pei-Yun; Hsin, Ling-Wei; Chern, Ji-Wang</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">458-471</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Glioblastoma is the most fatal type of primary brain cancer, and current treatments for glioblastoma are insufficient.  HDAC6 is overexpressed in glioblastoma, and siRNA-mediated knockdown of HDAC6 inhibits glioma cell proliferation.  Herein, we report a high-selective HDAC6 inhibitor, J22352, which has PROTAC (proteolysis-targeting chimeras)-like property resulted in both p62 accumulation and proteasomal degrdn., leading to proteolysis of aberrantly overexpressed HDAC6 in glioblastoma.  The consequences of decreased HDAC6 expression in response to J22352 decreased cell migration, increased autophagic cancer cell death and significant tumor growth inhibition.  Notably, J22352 reduced the immunosuppressive activity of PD-L1, leading to the restoration of host anti-tumor activity.  These results demonstrate that J22352 promotes HDAC6 degrdn. and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma.  Therefore, this highly selective HDAC6 inhibitor can be considered a potential therapeutic for the treatment of glioblastoma and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4CvL8Dho7i7Vg90H21EOLACvtfcHk0lguQR2vfCIv2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1eitbg%253D&md5=5fcf3fe4d0236e802e93a8043af27213</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2019.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2019.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BR.%26aulast%3DYu%26aufirst%3DC.%2BW.%26aulast%3DHung%26aufirst%3DP.%2BY.%26aulast%3DHsin%26aufirst%3DL.%2BW.%26aulast%3DChern%26aufirst%3DJ.%2BW.%26atitle%3DHigh-selective%2520HDAC6%2520inhibitor%2520promotes%2520HDAC6%2520degradation%2520following%2520autophagy%2520modulation%2520and%2520enhanced%2520antitumor%2520immunity%2520in%2520glioblastoma%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2019%26volume%3D163%26spage%3D458%26epage%3D471%26doi%3D10.1016%2Fj.bcp.2019.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. W.</span></span> <span> </span><span class="NLM_article-title">A highly HDAC6-selective inhibitor acts as a fluorescent probe</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">7820</span>– <span class="NLM_lpage">7832</span>, <span class="refDoi"> DOI: 10.1039/C8OB00966J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1039%2FC8OB00966J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30168823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFOqtrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=7820-7832&author=Y.+H.+Hoauthor=K.+J.+Wangauthor=P.+Y.+Hungauthor=Y.+S.+Chengauthor=J.+R.+Liuauthor=S.+T.+Fungauthor=P.+H.+Liangauthor=J.+W.+Chernauthor=C.+W.+Yu&title=A+highly+HDAC6-selective+inhibitor+acts+as+a+fluorescent+probe&doi=10.1039%2FC8OB00966J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">A highly HDAC6-selective inhibitor acts as a fluorescent probe</span></div><div class="casAuthors">Ho, Yi-Hsun; Wang, Kuang-Jui; Hung, Pei-Yun; Cheng, Yi-Sheng; Liu, Jia-Rong; Fung, Sheang-Tze; Liang, Pi-Hui; Chern, Ji-Wang; Yu, Chao-Wu</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">7820-7832</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">HDAC6 receives great attention because of its therapeutic potential for the treatment of various diseases.  Selective fluorescence imaging for HDAC6 is important for its pathol. and biol. studies.  However, specific detection of HDAC6 by using a fluorescent small mol. probe remains a great challenge.  Herein, a series of fluorescent HDAC6-selective inhibitors incorporating a naphthalimide skeleton were designed and synthesized.  A structure-activity relationship study identified that compd. JW-1 had the greatest inhibitory activity and superior specificity against HDAC6.  JW-1 could substantially increase α-tubulin acetylation and was active against a panel of six cancer cell lines.  Photophys. characterization and cellular imaging of MDA-MB-231 cells demonstrated that JW-1 is a highly fluorescent, cell penetrable, small-mol. inhibitor of HDAC6 that can be used for the detection of HDAC6 in complex cellular environments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOU3VXU8SZybVg90H21EOLACvtfcHk0lguQR2vfCIv2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFOqtrrM&md5=212d645f0245b2f092b3d75f4a10f38a</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1039%2FC8OB00966J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8OB00966J%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DY.%2BH.%26aulast%3DWang%26aufirst%3DK.%2BJ.%26aulast%3DHung%26aufirst%3DP.%2BY.%26aulast%3DCheng%26aufirst%3DY.%2BS.%26aulast%3DLiu%26aufirst%3DJ.%2BR.%26aulast%3DFung%26aufirst%3DS.%2BT.%26aulast%3DLiang%26aufirst%3DP.%2BH.%26aulast%3DChern%26aufirst%3DJ.%2BW.%26aulast%3DYu%26aufirst%3DC.%2BW.%26atitle%3DA%2520highly%2520HDAC6-selective%2520inhibitor%2520acts%2520as%2520a%2520fluorescent%2520probe%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2018%26volume%3D16%26spage%3D7820%26epage%3D7832%26doi%3D10.1039%2FC8OB00966J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szarics, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den
Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jope, R. S.</span></span> <span> </span><span class="NLM_article-title">Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1679</span>– <span class="NLM_lpage">1695</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00600</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00600" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitl2jtb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1679-1695&author=A.+P.+Kozikowskiauthor=S.+Shenauthor=M.+Pardoauthor=M.+T.+Tavaresauthor=D.+Szaricsauthor=V.+Benoyauthor=C.+A.+Zimprichauthor=Z.+Kutilauthor=G.+Zhangauthor=C.+Barinkaauthor=M.+B.+Robersauthor=L.+Van+Den%0ABoschauthor=J.+H.+Eubanksauthor=R.+S.+Jope&title=Brain+Penetrable+Histone+Deacetylase+6+Inhibitor+SW-100+Ameliorates+Memory+and+Learning+Impairments+in+a+Mouse+Model+of+Fragile+X+Syndrome&doi=10.1021%2Facschemneuro.8b00600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome</span></div><div class="casAuthors">Kozikowski, Alan P.; Shen, Sida; Pardo, Marta; Tavares, Mauricio T.; Szarics, Dora; Benoy, Veronick; Zimprich, Chad A.; Kutil, Zsofia; Zhang, Guiping; Barinka, Cyril; Robers, Matthew B.; Van Den Bosch, Ludo; Eubanks, James H.; Jope, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1679-1695</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Disease-modifying therapies are needed for Fragile X Syndrome (FXS), as at present there are no effective treatments or cures.  Herein, we report on a tetrahydroquinoline-based selective histone deacetylase 6 (HDAC6) inhibitor SW-100, its pharmacol. and ADMET properties, and its ability to improve upon memory performance in a mouse model of FXS, Fmr1-/- mice.  This small mol. demonstrates good brain penetrance, low-nanomolar potency for the inhibition of HDAC6 (IC50 = 2.3 nM), with at least a thousand-fold selectivity over all other class I, II, and IV HDAC isoforms.  Moreover, through its inhibition of the α-tubulin deacetylase domain of HDAC6 (CD2), in cells SW-100 upregulates α-tubulin acetylation with no effect on histone acetylation and selectively restores the impaired acetylated α-tubulin levels in the hippocampus of Fmr1-/- mice.  Lastly, SW-100 ameliorates several memory and learning impairments in Fmr1-/- mice, thus modeling the intellectual deficiencies assocd. with FXS, and hence providing a strong rationale for pursuing HDAC6-based therapies for the treatment of this rare disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphc-8bfGiZh7Vg90H21EOLACvtfcHk0lguQR2vfCIv2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitl2jtb3E&md5=b1e70a1a45522720d481985b3a4339f3</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00600%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DPardo%26aufirst%3DM.%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DSzarics%26aufirst%3DD.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DEubanks%26aufirst%3DJ.%2BH.%26aulast%3DJope%26aufirst%3DR.%2BS.%26atitle%3DBrain%2520Penetrable%2520Histone%2520Deacetylase%25206%2520Inhibitor%2520SW-100%2520Ameliorates%2520Memory%2520and%2520Learning%2520Impairments%2520in%2520a%2520Mouse%2520Model%2520of%2520Fragile%2520X%2520Syndrome%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D1679%26epage%3D1695%26doi%3D10.1021%2Facschemneuro.8b00600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Picci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinnon, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swift, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusky, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibition promotes alpha-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>328</i></span>,  <span class="NLM_fpage">113281</span>, <span class="refDoi"> DOI: 10.1016/j.expneurol.2020.113281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.expneurol.2020.113281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32147437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvF2juro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=2020&pages=113281&author=C.+Picciauthor=V.+S.+C.+Wongauthor=C.+J.+Costaauthor=M.+C.+McKinnonauthor=D.+C.+Goldbergauthor=M.+Swiftauthor=N.+M.+Alamauthor=G.+T.+Pruskyauthor=S.+Shenauthor=A.+P.+Kozikowskiauthor=D.+E.+Willisauthor=B.+Langley&title=HDAC6+inhibition+promotes+alpha-tubulin+acetylation+and+ameliorates+CMT2A+peripheral+neuropathy+in+mice&doi=10.1016%2Fj.expneurol.2020.113281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice</span></div><div class="casAuthors">Picci, Cristina; Wong, Victor S. C.; Costa, Christopher J.; McKinnon, Marion C.; Goldberg, David C.; Swift, Michelle; Alam, Nazia M.; Prusky, Glen T.; Shen, Sida; Kozikowski, Alan P.; Willis, Dianna E.; Langley, Brett</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113281</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Charcot-Marie-Tooth type 2A (CMT2A) peripheral neuropathy, the most common axonal form of CMT, is caused by dominantly inherited point mutations in the Mitofusin 2 (Mfn2) gene.  It is characterized by progressive length-dependent degeneration of motor and sensory nerves with corresponding clin. features of motor and sensory impairment.  There is no cure for CMT, and therapeutic approaches are limited to phys. therapy, orthopedic devices, surgery, and analgesics.  In this study we focus on histone deacetylase 6 (HDAC6) as a therapeutic target in a mouse model of mutant MFN2 (MFN2R94Q)-induced CMT2A.  We report that these mice display progressive motor and sensory dysfunction as well as a significant decrease in α-tubulin acetylation in distal segments of long peripheral nerves.  Treatment with a new, highly selective HDAC6 inhibitor, SW-100, was able to restore α-tubulin acetylation and ameliorate motor and sensory dysfunction when given either prior to or after the onset of symptoms.  To confirm HDAC6 is the target for ameliorating the CMT2A phenotype, we show that genetic deletion of Hdac6 in CMT2A mice prevents the development of motor and sensory dysfunction.  Our findings suggest α-tubulin acetylation defects in distal parts of nerves as a pathogenic mechanism and HDAC6 as a therapeutic target for CMT2A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLIL7Cazwz7rVg90H21EOLACvtfcHk0ljwI6VQHXMxyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvF2juro%253D&md5=c8b6b6c12c5b341a6ab773ff7ecbd300</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2020.113281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2020.113281%26sid%3Dliteratum%253Aachs%26aulast%3DPicci%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DV.%2BS.%2BC.%26aulast%3DCosta%26aufirst%3DC.%2BJ.%26aulast%3DMcKinnon%26aufirst%3DM.%2BC.%26aulast%3DGoldberg%26aufirst%3DD.%2BC.%26aulast%3DSwift%26aufirst%3DM.%26aulast%3DAlam%26aufirst%3DN.%2BM.%26aulast%3DPrusky%26aufirst%3DG.%2BT.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DWillis%26aufirst%3DD.%2BE.%26aulast%3DLangley%26aufirst%3DB.%26atitle%3DHDAC6%2520inhibition%2520promotes%2520alpha-tubulin%2520acetylation%2520and%2520ameliorates%2520CMT2A%2520peripheral%2520neuropathy%2520in%2520mice%26jtitle%3DExp.%2520Neurol.%26date%3D2020%26volume%3D328%26spage%3D113281%26doi%3D10.1016%2Fj.expneurol.2020.113281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01404</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01404" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXksVKiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=905-917&author=H.+Y.+Leeauthor=K.+Nepaliauthor=F.+I.+Huangauthor=C.+Y.+Changauthor=M.+J.+Laiauthor=Y.+H.+Liauthor=H.+L.+Huangauthor=C.+R.+Yangauthor=J.+P.+Liou&title=%28N-Hydroxycarbonylbenylamino%29quinolines+as+Selective+Histone+Deacetylase+6+Inhibitors+Suppress+Growth+of+Multiple+Myeloma+in+Vitro+and+in+Vivo&doi=10.1021%2Facs.jmedchem.7b01404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">(N-Hydroxycarbonylbenzylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo</span></div><div class="casAuthors">Lee, Hsueh-Yun; Nepali, Kunal; Huang, Fang-I.; Chang, Chih-Yi; Lai, Mei-Jung; Li, Yu-Hsuan; Huang, Hsiang-Ling; Yang, Chia-Ron; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">905-917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of bicyclic arylamino/heteroarylamino hydroxamic acids (7-31) have been examd. as novel histone deacetylase 6 (HDAC6) inhibitors.  One compd. (13, N-hydroxy-4-((quinolin-8-ylamino)methyl)benzamide) exhibits remarkable inhibitory activity of HDAC6 with an IC50 value of 0.29 nM, which is 4000-43,000 times more selective over other HDAC isoforms.  Compd. 13 was shown to have antiproliferative activity against human multiple myeloma RPMI 8226, U266, and NCI-H929 cells with no effect on normal bone marrow cells.  Compd. 13, as a single drug, suppresses the growth of tumors by a %TGI factor of 60.4% in human multiple myeloma RPMI 8226 xenograft models and, in combination with bortezomib, shows significant in vivo antitumor activity (%TGI = 86.2%).  Compd. 13 also demonstrates good human hepatocytic stability and high permeability, without any effect on mutagenicity and cytotoxicity.  Thus, compd. 13 is a potent HDAC6 inhibitor that could be developed for the treatment of multiple myeloma in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRGAacR3ID_LVg90H21EOLACvtfcHk0ljwI6VQHXMxyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXksVKiuw%253D%253D&md5=4e76a60f13c7414ba7cf871aa0193b14</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01404%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DF.%2BI.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BH.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DYang%26aufirst%3DC.%2BR.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3D%2528N-Hydroxycarbonylbenylamino%2529quinolines%2520as%2520Selective%2520Histone%2520Deacetylase%25206%2520Inhibitors%2520Suppress%2520Growth%2520of%2520Multiple%2520Myeloma%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D905%26epage%3D917%26doi%3D10.1021%2Facs.jmedchem.7b01404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. R.</span></span> <span> </span><span class="NLM_article-title">The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">655</span>, <span class="refDoi"> DOI: 10.1038/s41419-018-0688-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fs41419-018-0688-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29844403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BC1MbhsFejtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=655&author=S.+J.+Fanauthor=F.+I.+Huangauthor=J.+P.+Liouauthor=C.+R.+Yang&title=The+novel+histone+de+acetylase+6+inhibitor%2C+MPT0G211%2C+ameliorates+tau+phosphorylation+and+cognitive+deficits+in+an+Alzheimer%E2%80%99s+disease+model&doi=10.1038%2Fs41419-018-0688-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model</span></div><div class="casAuthors">Fan Sheng-Jun; Huang Fang-I; Yang Chia-Ron; Liou Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">655</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's disease (AD) is a dreadful neurodegenerative disease that leads to severe impairment of cognitive function, leading to a drastic decline in the quality of life.  The primary pathological features of AD include senile plaques (SPs) and intracellular neurofibrillary tangles (NFTs), comprising aggregated amyloid β (Aβ) and hyperphosphorylated tau protein, respectively, in the hippocampus of AD patients.  Histone deacetylase 6 (HDAC6) is a key enzyme in this neurodegenerative disease, in particular, as it relates to tau hyperphosphorylation.  This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model.  Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs.  This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins.  In addition, a significant increase of phospho-glycogen synthase kinase-3β (phospho-GSK3β) on Ser9 (the inactive form) through Akt phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment.  In AD in vivo models, MPT0G211 appeared to ameliorate learning and memory impairment in animals.  Furthermore, MPT0G211 treatment reduced the amount of phosphorylated tau in the hippocampal CA1 region.  In summary, MPT0G211 treatment appears to be a promising strategy for improving the AD phenotypes, including tau hyperphosphorylation and aggregation, neurodegeneration, and learning and memory impairment, making it a valuable agent for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThODJPxWFHy0EgZCMqtRBifW6udTcc2eY7OiSnlLqlXLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbhsFejtQ%253D%253D&md5=5b9b227e4df99bd8150004e7342c214c</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1038%2Fs41419-018-0688-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-018-0688-5%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DS.%2BJ.%26aulast%3DHuang%26aufirst%3DF.%2BI.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DYang%26aufirst%3DC.%2BR.%26atitle%3DThe%2520novel%2520histone%2520de%2520acetylase%25206%2520inhibitor%252C%2520MPT0G211%252C%2520ameliorates%2520tau%2520phosphorylation%2520and%2520cognitive%2520deficits%2520in%2520an%2520Alzheimer%25E2%2580%2599s%2520disease%2520model%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2018%26volume%3D9%26spage%3D655%26doi%3D10.1038%2Fs41419-018-0688-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. R.</span></span> <span> </span><span class="NLM_article-title">Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1866</i></span>,  <span class="NLM_fpage">992</span>– <span class="NLM_lpage">1003</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2019.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bbamcr.2019.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30867138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVWgsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1866&publication_year=2019&pages=992-1003&author=Y.+L.+Hsiehauthor=H.+J.+Tuauthor=S.+L.+Panauthor=J.+P.+Liouauthor=C.+R.+Yang&title=Anti-metastatic+activity+of+MPT0G211%2C+a+novel+HDAC6+inhibitor%2C+in+human+breast+cancer+cells+in+vitro+and+in+vivo&doi=10.1016%2Fj.bbamcr.2019.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo</span></div><div class="casAuthors">Hsieh, Yi-Ling; Tu, Huang-Ju; Pan, Shiow-Lin; Liou, Jing-Ping; Yang, Chia-Ron</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1866</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">992-1003</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is assocd. with an increased risk of metastasis and a poor prognosis.  The invasive ability of TNBC relies on actin reorganization and is regulated by histone deacetylase 6 (HDAC6).  The present study aimed to examine the effect of MPT0G211, a novel HDAC6 inhibitor, on cell migration and microtubule assocn. in both in vitro and in vivo models of TNBC.  Here MPT0G211 more selectively and potently targeted and inhibited HDAC6, compared with tubastatin A, another selective HDAC6 inhibitor.  In vitro, MPT0G211 decreased the migration of the TNBC cell line MDA-MB-231, particularly when administered together with paclitaxel, and increased heat shock protein 90 (Hsp90) acetylation, leading to the dissocn. of Hsp90 from aurora-A and proteasomal degrdn.  Furthermore, MPT0G211 significantly disrupted F-actin polymn. by increasing cortactin acetylation and downregulating slingshot protein phosphatase 1 (SSH1) and active cofilin expression.  In vivo, MPT0G211 treatment significantly ameliorated TNBC metastasis.  In conclusion, our results demonstrate that MPT0G211 reduces TNBC cell motility by promoting cortactin acetylation and aurora-A degrdn., and inhibiting the cofilin-F-actin pathway via HDAC6 activity attenuation.  MPT0G211 therefore demonstrates therapeutic potential for invasive TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW5PmBHL4-8LVg90H21EOLACvtfcHk0lgwrfIW4upkWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVWgsrc%253D&md5=9bb277696b5badb7e95c09754cf3306c</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2019.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2019.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DHsieh%26aufirst%3DY.%2BL.%26aulast%3DTu%26aufirst%3DH.%2BJ.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DYang%26aufirst%3DC.%2BR.%26atitle%3DAnti-metastatic%2520activity%2520of%2520MPT0G211%252C%2520a%2520novel%2520HDAC6%2520inhibitor%252C%2520in%2520human%2520breast%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2019%26volume%3D1866%26spage%3D992%26epage%3D1003%26doi%3D10.1016%2Fj.bbamcr.2019.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">112193</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2020.112193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32151835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFels70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2020&pages=112193&author=H.+J.+Tsengauthor=M.+H.+Linauthor=Y.+J.+Shiaoauthor=Y.+C.+Yangauthor=J.+C.+Chuauthor=C.+Y.+Chenauthor=Y.+Y.+Chenauthor=T.+E.+Linauthor=C.+J.+Suauthor=S.+L.+Panauthor=L.+C.+Chenauthor=C.+Y.+Wangauthor=K.+C.+Hsuauthor=W.+J.+Huang&title=Synthesis+and+biological+evaluation+of+acridine-based+histone+deacetylase+inhibitors+as+multitarget+agents+against+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2020.112193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease</span></div><div class="casAuthors">Tseng, Hui-Ju; Lin, Mei-Hsiang; Shiao, Young-Ji; Yang, Ying-Chen; Chu, Jung-Chun; Chen, Chun-Yung; Chen, Yi-Ying; Lin, Tony Eight; Su, Chih-Jou; Pan, Shiow-Lin; Chen, Liang-Chieh; Wang, Chen-Yu; Hsu, Kai-Cheng; Huang, Wei-Jan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112193</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Multitarget agents simultaneously trigger mols. in functionally complementary pathways, and are therefore considered to have potential in effectively treating Alzheimer's disease (AD), which has a complex pathogenetic mechanism.  In this study, the HDAC inhibitor core is incorporated into the acetylcholine esterase (ACE) inhibitor acridine-derived moiety and resulted in compds. that exhibited higher class IIa HDAC (4, 5, 7, and 9)- and class IIb HDAC6-inhibiting activity when compared to the pan-HDAC inhibitor SAHA in clin. practice.  One of these compds., I, displayed greater selectivity toward HDAC6 than other isoform enzymes.  In contrast, the activity of compd. II was selective toward class IIa HDAC and HDAC6.  These two compds. exhibited strong activity against Aβ-aggregation as well as significantly disrupted Aβ-oligomer.  Addnl., I and II strongly inhibited AChE.  These exptl. findings demonstrate that the above two are HDAC-Aβ-aggregation-AChE inhibitors.  Notably, they can enhance neurite outgrowth, but with no significant neurotoxicity.  Further biol. evaluation revealed the various cellular effects of multitarget compds. I and II, which have the potential to treat AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqexIdMql7N8bVg90H21EOLACvtfcHk0lgwrfIW4upkWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFels70%253D&md5=f4dd58408b6092ade3b9183065014f33</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112193%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DH.%2BJ.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DShiao%26aufirst%3DY.%2BJ.%26aulast%3DYang%26aufirst%3DY.%2BC.%26aulast%3DChu%26aufirst%3DJ.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BY.%26aulast%3DLin%26aufirst%3DT.%2BE.%26aulast%3DSu%26aufirst%3DC.%2BJ.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DWang%26aufirst%3DC.%2BY.%26aulast%3DHsu%26aufirst%3DK.%2BC.%26aulast%3DHuang%26aufirst%3DW.%2BJ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520acridine-based%2520histone%2520deacetylase%2520inhibitors%2520as%2520multitarget%2520agents%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D192%26spage%3D112193%26doi%3D10.1016%2Fj.ejmech.2020.112193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vögerl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtkunz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracher, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1138</span>– <span class="NLM_lpage">1166</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01090</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01090" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3cjhs1Sltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1138-1166&author=K.+V%C3%B6gerlauthor=N.+Ongauthor=J.+Sengerauthor=D.+Herpauthor=K.+Schmidtkunzauthor=M.+Marekauthor=M.+M%C3%BCllerauthor=K.+Bartelauthor=T.+B.+Shaikauthor=N.+J.+Porterauthor=D.+Robaaauthor=D.+W.+Christiansonauthor=C.+Romierauthor=W.+Sipplauthor=M.+Jungauthor=F.+Bracher&title=Synthesis+and+Biological+Investigation+of+Phenothiazine-Based+Benzhydroxamic+Acids+as+Selective+Histone+Deacetylase+6+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors</span></div><div class="casAuthors">Vogerl Katharina; Ong Nghia; Muller Martin; Bartel Karin; Bracher Franz; Senger Johanna; Herp Daniel; Schmidtkunz Karin; Jung Manfred; Marek Martin; Shaik Tajith B; Romier Christophe; Porter Nicholas J; Christianson David W; Robaa Dina; Sippl Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1138-1166</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The phenothiazine system was identified as a favorable cap group for potent and selective histone deacetylase 6 (HDAC6) inhibitors.  Here, we report the preparation and systematic variation of phenothiazines and their analogues containing a benzhydroxamic acid moiety as the zinc-binding group.  We evaluated their ability to selectively inhibit HDAC6 by a recombinant HDAC enzyme assay, by determining the protein acetylation levels in cells by western blotting (tubulin vs histone acetylation), and by assessing their effects on various cancer cell lines.  Structure-activity relationship studies revealed that incorporation of a nitrogen atom into the phenothiazine framework results in increased potency and selectivity for HDAC6 (more than 500-fold selectivity relative to the inhibition of HDAC1, HDAC4, and HDAC8), as rationalized by molecular modeling and docking studies.  The binding mode was confirmed by co-crystallization of the potent azaphenothiazine inhibitor with catalytic domain 2 from Danio rerio HDAC6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkSJzGKNxKWK69lAbTj9rGfW6udTcc2eYIcsIKUjACYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjhs1Sltw%253D%253D&md5=9d72da7b8f4bb63cd05ccc5f907d2dca</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01090%26sid%3Dliteratum%253Aachs%26aulast%3DV%25C3%25B6gerl%26aufirst%3DK.%26aulast%3DOng%26aufirst%3DN.%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DHerp%26aufirst%3DD.%26aulast%3DSchmidtkunz%26aufirst%3DK.%26aulast%3DMarek%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%26aulast%3DBartel%26aufirst%3DK.%26aulast%3DShaik%26aufirst%3DT.%2BB.%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DRobaa%26aufirst%3DD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DBracher%26aufirst%3DF.%26atitle%3DSynthesis%2520and%2520Biological%2520Investigation%2520of%2520Phenothiazine-Based%2520Benzhydroxamic%2520Acids%2520as%2520Selective%2520Histone%2520Deacetylase%25206%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1138%26epage%3D1166%26doi%3D10.1021%2Facs.jmedchem.8b01090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackwitz, M. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamacher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span> <span> </span><span class="NLM_article-title">Multicomponent Synthesis and Binding Mode of Imidazo[1,2- a]pyridine-Capped Selective HDAC6 Inhibitors</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3255</span>– <span class="NLM_lpage">3258</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.8b01118</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.8b01118" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVCnsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=3255-3258&author=M.+K.+W.+Mackwitzauthor=A.+Hamacherauthor=J.+D.+Oskoauthor=J.+Heldauthor=A.+Scholerauthor=D.+W.+Christiansonauthor=M.+U.+Kassackauthor=F.+K.+Hansen&title=Multicomponent+Synthesis+and+Binding+Mode+of+Imidazo%5B1%2C2-+a%5Dpyridine-Capped+Selective+HDAC6+Inhibitors&doi=10.1021%2Facs.orglett.8b01118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Multicomponent Synthesis and Binding Mode of Imidazo[1,2-a]pyridine-Capped Selective HDAC6 Inhibitors</span></div><div class="casAuthors">Mackwitz, Marcel K. W.; Hamacher, Alexandra; Osko, Jeremy D.; Held, Jana; Schoeler, Andrea; Christianson, David W.; Kassack, Matthias U.; Hansen, Finn K.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3255-3258</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The multicomponent synthesis of a mini-library of histone deacetylase inhibitors with imidazo[1,2-a]pyridine-based cap groups is presented.  The biol. evaluation led to the discovery of the hit compd. MAIP-032 as a selective HDAC6 inhibitor with promising anticancer activity.  The X-ray structure of catalytic domain 2 from Danio rerio HDAC6 complexed with MAIP-032 revealed a monodentate zinc-binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4rI48LyncTrVg90H21EOLACvtfcHk0liYt06O_LVEog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVCnsbw%253D&md5=0c53331fabd83781717e0678a56dab7e</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.8b01118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.8b01118%26sid%3Dliteratum%253Aachs%26aulast%3DMackwitz%26aufirst%3DM.%2BK.%2BW.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DHeld%26aufirst%3DJ.%26aulast%3DScholer%26aufirst%3DA.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26atitle%3DMulticomponent%2520Synthesis%2520and%2520Binding%2520Mode%2520of%2520Imidazo%255B1%252C2-%2520a%255Dpyridine-Capped%2520Selective%2520HDAC6%2520Inhibitors%26jtitle%3DOrg.%2520Lett.%26date%3D2018%26volume%3D20%26spage%3D3255%26epage%3D3258%26doi%3D10.1021%2Facs.orglett.8b01118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cucinella, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamponi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iside, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebbioso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span> <span> </span><span class="NLM_article-title">Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.07.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2018.07.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30092367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOntbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=127-138&author=M.+Brindisiauthor=J.+Sengerauthor=C.+Cavellaauthor=A.+Grilloauthor=G.+Chemiauthor=S.+Gemmaauthor=D.+M.+Cucinellaauthor=S.+Lamponiauthor=F.+Sarnoauthor=C.+Isideauthor=A.+Nebbiosoauthor=E.+Novellinoauthor=T.+B.+Shaikauthor=C.+Romierauthor=D.+Herpauthor=M.+Jungauthor=S.+Butiniauthor=G.+Campianiauthor=L.+Altucciauthor=S.+Brogi&title=Novel+spiroindoline+HDAC+inhibitors%3A+Synthesis%2C+molecular+modelling+and+biological+studies&doi=10.1016%2Fj.ejmech.2018.07.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies</span></div><div class="casAuthors">Brindisi, Margherita; Senger, Johanna; Cavella, Caterina; Grillo, Alessandro; Chemi, Giulia; Gemma, Sandra; Cucinella, Dora Mariagrazia; Lamponi, Stefania; Sarno, Federica; Iside, Concetta; Nebbioso, Angela; Novellino, Ettore; Shaik, Tajith Baba; Romier, Christophe; Herp, Daniel; Jung, Manfred; Butini, Stefania; Campiani, Giuseppe; Altucci, Lucia; Brogi, Simone</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-138</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Spiroindolinylmethyl arylhydroxamates such as I (R = t-BuOCO, Me, MeCO, t-BuCO) were prepd. as selective inhibitors of histone deacetylase 6 (HDAC6) for potential use as antitumor agents.  The spiroindolinylmethyl arylhydroxamates were prepd. using a one-pot Fischer indole synthesis of cyclohexane- or piperidinecarboxaldehydes and phenylhydrazine followed by indolenine redn. and reductive amination with formylarylcarboxylates as the key step.  The inhibition of HDAC1 and HDAC6 by the spiroindolinylmethyl arylhydroxamates was detd. and mol. docking calcns. of their binding to HDAC1 and HDAC6 performed; in addn., their calcd. lipophilicities, biol. permeabilities, polar mol. surface areas, and hERG inhibition were detd.  The inhibition of HDAC8 by I (R = t-BuOCO), its effect on metastasis and its toxicity to mouse fibroblasts, and the effect of I (R = t-BuOCO, t-BuCO) on HDAC acetylation in cells were detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBNiJdoIAsrVg90H21EOLACvtfcHk0liYt06O_LVEog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOntbnJ&md5=e12eadf2c73e321b1a733c1cbfdfc822</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.07.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.07.069%26sid%3Dliteratum%253Aachs%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DCavella%26aufirst%3DC.%26aulast%3DGrillo%26aufirst%3DA.%26aulast%3DChemi%26aufirst%3DG.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DCucinella%26aufirst%3DD.%2BM.%26aulast%3DLamponi%26aufirst%3DS.%26aulast%3DSarno%26aufirst%3DF.%26aulast%3DIside%26aufirst%3DC.%26aulast%3DNebbioso%26aufirst%3DA.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DShaik%26aufirst%3DT.%2BB.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DHerp%26aufirst%3DD.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DBrogi%26aufirst%3DS.%26atitle%3DNovel%2520spiroindoline%2520HDAC%2520inhibitors%253A%2520Synthesis%252C%2520molecular%2520modelling%2520and%2520biological%2520studies%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D127%26epage%3D138%26doi%3D10.1016%2Fj.ejmech.2018.07.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saraswati, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Relitti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federico, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkington, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamponi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghanim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zisterer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amet, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannon Barroeta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulivieri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Costanzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccoccia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruberti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span> <span> </span><span class="NLM_article-title">Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2268</span>– <span class="NLM_lpage">2276</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00395</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00395" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGrurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=2268-2276&author=A.+P.+Saraswatiauthor=N.+Relittiauthor=M.+Brindisiauthor=J.+D.+Oskoauthor=G.+Chemiauthor=S.+Federicoauthor=A.+Grilloauthor=S.+Brogiauthor=N.+H.+McCabeauthor=R.+C.+Turkingtonauthor=O.+Ibrahimauthor=J.+O%E2%80%99Sullivanauthor=S.+Lamponiauthor=M.+Ghanimauthor=V.+P.+Kellyauthor=D.+Zistererauthor=R.+Ametauthor=P.+Hannon+Barroetaauthor=F.+Vanniauthor=C.+Ulivieriauthor=D.+Herpauthor=F.+Sarnoauthor=A.+Di+Costanzoauthor=F.+Saccocciaauthor=G.+Rubertiauthor=M.+Jungauthor=L.+Altucciauthor=S.+Gemmaauthor=S.+Butiniauthor=D.+W.+Christiansonauthor=G.+Campiani&title=Spiroindoline-Capped+Selective+HDAC6+Inhibitors%3A+Design%2C+Synthesis%2C+Structural+Analysis%2C+and+Biological+Evaluation&doi=10.1021%2Facsmedchemlett.0c00395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation</span></div><div class="casAuthors">Saraswati, A. Prasanth; Relitti, Nicola; Brindisi, Margherita; Osko, Jeremy D.; Chemi, Giulia; Federico, Stefano; Grillo, Alessandro; Brogi, Simone; McCabe, Niamh H.; Turkington, Richard C.; Ibrahim, Ola; O'Sullivan, Jeffrey; Lamponi, Stefania; Ghanim, Magda; Kelly, Vincent P.; Zisterer, Daniela; Amet, Rebecca; Hannon Barroeta, Patricia; Vanni, Francesca; Ulivieri, Cristina; Herp, Daniel; Sarno, Federica; Di Costanzo, Antonella; Saccoccia, Fulvio; Ruberti, Giovina; Jung, Manfred; Altucci, Lucia; Gemma, Sandra; Butini, Stefania; Christianson, David W.; Campiani, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2268-2276</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACi) have emerged as promising therapeutics for the treatment of neurodegeneration, cancer, and rare disorders.  Herein, we report the development of a series of spiroindoline-based HDAC6 isoform-selective inhibitors based on the X-ray crystal studies of the hit 6a.  We identified compd. 6j as the most potent and selective hHDAC6 inhibitor of the series.  Biol. investigation of compds. 6b, 6h, and 6j demonstrated their antiproliferative activity against several cancer cell lines.  Western blotting studies indicated that they were able to increase tubulin acetylation, without significant variation in histone acetylation state, and induced PARP cleavage indicating their apoptotic potential at the mol. level. 6j induced HDAC6-dependent pSTAT3 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDjoa_t6NxLbVg90H21EOLACvtfcHk0lj9eIeiqBCCHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGrurrJ&md5=eb2bb9788f4a646180dce78cce7d8957</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00395%26sid%3Dliteratum%253Aachs%26aulast%3DSaraswati%26aufirst%3DA.%2BP.%26aulast%3DRelitti%26aufirst%3DN.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DChemi%26aufirst%3DG.%26aulast%3DFederico%26aufirst%3DS.%26aulast%3DGrillo%26aufirst%3DA.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DMcCabe%26aufirst%3DN.%2BH.%26aulast%3DTurkington%26aufirst%3DR.%2BC.%26aulast%3DIbrahim%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DJ.%26aulast%3DLamponi%26aufirst%3DS.%26aulast%3DGhanim%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DV.%2BP.%26aulast%3DZisterer%26aufirst%3DD.%26aulast%3DAmet%26aufirst%3DR.%26aulast%3DHannon%2BBarroeta%26aufirst%3DP.%26aulast%3DVanni%26aufirst%3DF.%26aulast%3DUlivieri%26aufirst%3DC.%26aulast%3DHerp%26aufirst%3DD.%26aulast%3DSarno%26aufirst%3DF.%26aulast%3DDi%2BCostanzo%26aufirst%3DA.%26aulast%3DSaccoccia%26aufirst%3DF.%26aulast%3DRuberti%26aufirst%3DG.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DCampiani%26aufirst%3DG.%26atitle%3DSpiroindoline-Capped%2520Selective%2520HDAC6%2520Inhibitors%253A%2520Design%252C%2520Synthesis%252C%2520Structural%2520Analysis%252C%2520and%2520Biological%2520Evaluation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D2268%26epage%3D2276%26doi%3D10.1021%2Facsmedchemlett.0c00395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deep, A.</span></span> <span> </span><span class="NLM_article-title">Thiazole-containing compounds as therapeutic targets for cancer therapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">112016</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.112016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2019.112016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31926469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCjtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2020&pages=112016&author=P.+C.+Sharmaauthor=K.+K.+Bansalauthor=A.+Sharmaauthor=D.+Sharmaauthor=A.+Deep&title=Thiazole-containing+compounds+as+therapeutic+targets+for+cancer+therapy&doi=10.1016%2Fj.ejmech.2019.112016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Thiazole-containing compounds as therapeutic targets for cancer therapy</span></div><div class="casAuthors">Sharma, Prabodh Chander; Bansal, Kushal Kumar; Sharma, Archana; Sharma, Diksha; Deep, Aakash</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112016</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  In the last few decades, considerable progress has been made in anticancer agents development, and several new anticancer agents of natural and synthetic origin have been produced.  Among heterocyclic compds., thiazole, a 5-membered unique heterocyclic motif contg. sulfur and nitrogen atoms, serves as an essential core scaffold in several medicinally important compds.  Thiazole nucleus is a fundamental part of some clin. applied anticancer drugs, such as dasatinib, dabrafenib, ixabepilone, patellamide A, and epothilone.  Recently, thiazole-contg. compds. have been successfully developed as possible inhibitors of several biol. targets, including enzyme-linked receptor(s) located on the cell membrane, (i.e., polymerase inhibitors) and the cell cycle (i.e., microtubular inhibitors).  Moreover, these compds. have been proven to exhibit high effectiveness, potent anticancer activity, and less toxicity.  This review presents current research on thiazoles and elucidates their biol. importance in anticancer drug discovery.  The findings may aid researchers in the rational design of more potent and bio-target specific anticancer drug mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopwqMNI9zt1rVg90H21EOLACvtfcHk0lj9eIeiqBCCHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCjtb4%253D&md5=100a7bbfe827f34164ab989e86699aa0</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.112016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.112016%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DP.%2BC.%26aulast%3DBansal%26aufirst%3DK.%2BK.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DD.%26aulast%3DDeep%26aufirst%3DA.%26atitle%3DThiazole-containing%2520compounds%2520as%2520therapeutic%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D188%26spage%3D112016%26doi%3D10.1016%2Fj.ejmech.2019.112016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhargava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahiya, L.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of oxazole scaffold: a patent review (2006–2017)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">812</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1526280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1080%2F13543776.2018.1526280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30239247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslymurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=783-812&author=R.+Kaurauthor=K.+Paltaauthor=M.+Kumarauthor=M.+Bhargavaauthor=L.+Dahiya&title=Therapeutic+potential+of+oxazole+scaffold%3A+a+patent+review+%282006%E2%80%932017%29&doi=10.1080%2F13543776.2018.1526280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of oxazole scaffold: a patent review (2006-2017)</span></div><div class="casAuthors">Kaur, Ramandeep; Palta, Kezia; Kumar, Manoj; Bhargava, Meha; Dahiya, Lalita</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">783-812</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Oxazoles are oxygen and nitrogen contg. five membered heterocyclic ring systems that are present in various anticancer, antimicrobial, antihyperglycemic, anti-inflammatory agents etc. of natural origin.  These pharmacol. active oxazole derivs. have attracted numerous researchers to explore this scaffold for the design and development of newer potential therapeutic agents.  A large no. of synthetic oxazole contg. mols. have been reported over the period that exhibited wide spectrum of pharmacol. profiles.  Some of them have shown promising therapeutic potential and have qualified for both preclin. and clin. evaluations.  In this review, the patents (published during 2006-2017) focusing on the biol. potential of oxazoles have been covered.  Therapeutic applications and various techniques/assays employed for the in vitro/in vivo evaluation of patented derivs. have been discussed majorly.  Chem. oxazole offers three positions for substitution.  These substituted oxazole derivs. of natural as well as synthetic origin have numerous pharmacol. applications including anticancer, anti-Alzheimers, anti-hyperglycemic, anti-inflammatory, antibacterial etc.  Their pharmacol. actions are mainly mediated through enzyme/receptor involved in the particular disease.  The flexible nature of this ligand for various mol. level targets (enzyme/receptor) make this heterocylce an attractive scaffold for development of effective and clin. relevant oxazole contg. therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQjVtEFDptT7Vg90H21EOLACvtfcHk0lgw8f5X70U8lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslymurnM&md5=eecd45cbc407acda93c90ad666025515</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1526280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1526280%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DR.%26aulast%3DPalta%26aufirst%3DK.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DBhargava%26aufirst%3DM.%26aulast%3DDahiya%26aufirst%3DL.%26atitle%3DTherapeutic%2520potential%2520of%2520oxazole%2520scaffold%253A%2520a%2520patent%2520review%2520%25282006%25E2%2580%25932017%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26spage%3D783%26epage%3D812%26doi%3D10.1080%2F13543776.2018.1526280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultheisz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzbich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtkunz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goskowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borchert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praetorius, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewald, N.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationship of Propargylamine-Based HDAC Inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2044</span>– <span class="NLM_lpage">2053</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700550</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fcmdc.201700550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29120081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BC1M7psVGnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=2044-2053&author=M.+Wunschauthor=J.+Sengerauthor=P.+Schultheiszauthor=S.+Schwarzbichauthor=K.+Schmidtkunzauthor=C.+Michalekauthor=M.+Klassauthor=S.+Goskowitzauthor=P.+Borchertauthor=L.+Praetoriusauthor=W.+Sipplauthor=M.+Jungauthor=N.+Sewald&title=Structure-Activity+Relationship+of+Propargylamine-Based+HDAC+Inhibitors&doi=10.1002%2Fcmdc.201700550"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship of Propargylamine-Based HDAC Inhibitors</span></div><div class="casAuthors">Wunsch Matthias; Schultheisz Philipp; Schwarzbich Sabrina; Michalek Carmela; Klass Michaela; Goskowitz Stefanie; Borchert Philipp; Sewald Norbert; Senger Johanna; Schmidtkunz Karin; Jung Manfred; Praetorius Lucas; Sippl Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2044-2053</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As histone deacetylases (HDACs) play an important role in the treatment of cancer, their selective inhibition has been the subject of various studies.  These continuous investigations have given rise to a large collection of pan- and selective HDAC inhibitors, containing diverse US Food and Drug Administration (FDA)-approved representatives.  In previous studies, a class of alkyne-based HDAC inhibitors was presented.  We modified this scaffold in two previously neglected regions and compared their cytotoxicity and affinity toward HDAC1, HDAC6, and HDAC8.  We were able to show that R-configured propargylamines contribute to increased selectivity for HDAC6.  Docking studies on available HDAC crystal structures were carried out to rationalize the observed selectivity of the compounds.  Substitution of the aromatic portion by a thiophene derivative results in high affinity and low cytotoxicity, indicating an improved drug tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpjuKsoe-S4v9pSBfyDvp7fW6udTcc2eaT17xJOsEUcbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7psVGnsA%253D%253D&md5=71967e607dac8d4a467f7da6bddf634d</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700550%26sid%3Dliteratum%253Aachs%26aulast%3DWunsch%26aufirst%3DM.%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DSchultheisz%26aufirst%3DP.%26aulast%3DSchwarzbich%26aufirst%3DS.%26aulast%3DSchmidtkunz%26aufirst%3DK.%26aulast%3DMichalek%26aufirst%3DC.%26aulast%3DKlass%26aufirst%3DM.%26aulast%3DGoskowitz%26aufirst%3DS.%26aulast%3DBorchert%26aufirst%3DP.%26aulast%3DPraetorius%26aufirst%3DL.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DSewald%26aufirst%3DN.%26atitle%3DStructure-Activity%2520Relationship%2520of%2520Propargylamine-Based%2520HDAC%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D2044%26epage%3D2053%26doi%3D10.1002%2Fcmdc.201700550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melesina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01493</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01493" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1545-1555&author=J.+Sengerauthor=J.+Melesinaauthor=M.+Marekauthor=C.+Romierauthor=I.+Oehmeauthor=O.+Wittauthor=W.+Sipplauthor=M.+Jung&title=Synthesis+and+Biological+Investigation+of+Oxazole+Hydroxamates+as+Highly+Selective+Histone+Deacetylase+6+%28HDAC6%29+Inhibitors&doi=10.1021%2Facs.jmedchem.5b01493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors</span></div><div class="casAuthors">Senger, Johanna; Melesina, Jelena; Marek, Martin; Romier, Christophe; Oehme, Ina; Witt, Olaf; Sippl, Wolfgang; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1545-1555</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) catalyzes the removal of an acetyl group from lysine residues of several non-histone proteins.  Herein, the prepn. of thiazole-, oxazole-, and oxadiazole-contg. biarylhydroxamic acids by a short synthetic procedure is reported.  They were identified as selective HDAC6 inhibitors by investigating the inhibition of recombinant HDAC enzymes and the protein acetylation in cells by Western blotting (tubulin vs histone acetylation).  The most active compds. exhibited nanomolar potency and high selectivity for HDAC6.  For example, an oxazole hydroxamate inhibits HDAC6 with an IC50 of 59 nM and has a selectivity index of >200 against HDAC1 and HDAC8.  This is the first report showing that the nature of a heterocycle directly connected to a zinc binding group (ZBG) can be used to modulate subtype selectivity and potency for HDAC6 inhibitors to such an extent.  Compds. I (R = Br or Ph) were found to have the bect activity/HDAC6 selectivity.  The high potency and selectivity of the oxazoles was rationalized by mol. modeling and docking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH3cCvoW67w7Vg90H21EOLACvtfcHk0lgw8f5X70U8lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rO&md5=19436b79e523ac3ad5a2a3fcec7c5493</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01493%26sid%3Dliteratum%253Aachs%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DMelesina%26aufirst%3DJ.%26aulast%3DMarek%26aufirst%3DM.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520Biological%2520Investigation%2520of%2520Oxazole%2520Hydroxamates%2520as%2520Highly%2520Selective%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1545%26epage%3D1555%26doi%3D10.1021%2Facs.jmedchem.5b01493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Arias, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miguel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Gonzalez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estella-Hermoso
de Mendoza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espelosin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haizhong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2018.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29549837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslaiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=506-524&author=O.+Rabalauthor=J.+A.+Sanchez-Ariasauthor=M.+Cuadrado-Tejedorauthor=I.+de+Miguelauthor=M.+Perez-Gonzalezauthor=C.+Garcia-Barrosoauthor=A.+Ugarteauthor=A.+Estella-Hermoso%0Ade+Mendozaauthor=E.+Saezauthor=M.+Espelosinauthor=S.+Ursuaauthor=T.+Haizhongauthor=W.+Weiauthor=X.+Mushengauthor=A.+Garcia-Ostaauthor=J.+Oyarzabal&title=Design%2C+synthesis%2C+biological+evaluation+and+in+vivo+testing+of+dual+phosphodiesterase+5+%28PDE5%29+and+histone+deacetylase+6+%28HDAC6%29-selective+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2018.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Rabal, Obdulia; Sanchez-Arias, Juan A.; Cuadrado-Tejedor, Mar; de Miguel, Irene; Perez-Gonzalez, Marta; Garcia-Barroso, Carolina; Ugarte, Ana; Estella-Hermoso de Mendoza, Ander; Saez, Elena; Espelosin, Maria; Ursua, Susana; Tan, Haizhong; Wu, Wei; Xu, Musheng; Garcia-Osta, Ana; Oyarzabal, Julen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">506-524</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The authors have identified chem. probes that act as dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors (>1 log unit difference vs. class I HDACs) to decipher the contribution of HDAC isoforms to the pos. impact of dual-acting PDE5 and HDAC inhibitors on mouse models of Alzheimer's disease (AD) and fine-tune this systems therapeutics approach.  Structure- and knowledge-based approaches led to the design of first-in-class mols. with the desired target compd. profile: dual PDE5 and HDAC6-selective inhibitors.  Compd. 44b (5-[[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]methyl]thiophene-2-carbohydroxamic acid), which fulfilled the biochem., functional and ADME-Tox profiling requirements and exhibited adequate pharmacokinetic properties, was selected as pharmacol. tool compd. and tested in a mouse model of AD (Tg2576) in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFqq9VoRla3bVg90H21EOLACvtfcHk0li6aRMKce_Z_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslaiur4%253D&md5=1ced6634343dd8c0913ea3e6be07ff91</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DSanchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3Dde%2BMiguel%26aufirst%3DI.%26aulast%3DPerez-Gonzalez%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DEstella-Hermoso%2Bde%2BMendoza%26aufirst%3DA.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DEspelosin%26aufirst%3DM.%26aulast%3DUrsua%26aufirst%3DS.%26aulast%3DHaizhong%26aufirst%3DT.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DMusheng%26aufirst%3DX.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26aulast%3DOyarzabal%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520biological%2520evaluation%2520and%2520in%2520vivo%2520testing%2520of%2520dual%2520phosphodiesterase%25205%2520%2528PDE5%2529%2520and%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529-selective%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D150%26spage%3D506%26epage%3D524%26doi%3D10.1016%2Fj.ejmech.2018.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span> <span> </span><span class="NLM_article-title">The recent progress of isoxazole in medicinal chemistry</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3065</span>– <span class="NLM_lpage">3075</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmc.2018.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29853341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVamtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=3065-3075&author=J.+Zhuauthor=J.+Moauthor=H.+Z.+Linauthor=Y.+Chenauthor=H.+P.+Sun&title=The+recent+progress+of+isoxazole+in+medicinal+chemistry&doi=10.1016%2Fj.bmc.2018.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">The recent progress of isoxazole in medicinal chemistry</span></div><div class="casAuthors">Zhu, Jie; Mo, Jun; Lin, Hong-zhi; Chen, Yao; Sun, Hao-peng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3065-3075</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Isoxazole compds. exhibit a wide spectrum of targets and broad biol. activities.  Developing compds. with heterocycle rings has been one of the trends.  The integration of isoxazole ring can offer improved phys.-chem. properties.  Because of the unique profiles, isoxazole ring becomes a popular moiety in compds. design.  In this review article, the major focus has been paid to the applications of isoxazole compds. in treating multiple diseases, including anticancer, antimicrobial, anti-inflammatory, etc.  Strategies for compds. design for preclin., clin., and FDA approved drugs were discussed.  Also, the emphasis has been addressed to the future perspectives and trend for the application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_Igl9jCgG1rVg90H21EOLACvtfcHk0li6aRMKce_Z_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVamtLnL&md5=f2cf06eed32e8655baa76d35b41ef6a1</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DH.%2BZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.%2BP.%26atitle%3DThe%2520recent%2520progress%2520of%2520isoxazole%2520in%2520medicinal%2520chemistry%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D3065%26epage%3D3075%26doi%3D10.1016%2Fj.bmc.2018.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaisina, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tueckmantel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugolkov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskyi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fcmdc.201500456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=26592932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVyhtLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=81-92&author=I.+N.+Gaisinaauthor=W.+Tueckmantelauthor=A.+Ugolkovauthor=S.+Shenauthor=J.+Hoffenauthor=O.+Dubrovskyiauthor=A.+Mazarauthor=R.+A.+Schoonauthor=D.+Billadeauauthor=A.+P.+Kozikowski&title=Identification+of+HDAC6-Selective+Inhibitors+of+Low+Cancer+Cell+Cytotoxicity&doi=10.1002%2Fcmdc.201500456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity</span></div><div class="casAuthors">Gaisina, Irina N.; Tueckmantel, Werner; Ugolkov, Andrey; Shen, Sida; Hoffen, Jessica; Dubrovskyi, Oleksii; Mazar, Andrew; Schoon, Renee A.; Billadeau, Daniel; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-92</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The histone deacetylases (HDACs) occur in 11 different isoforms, and these enzymes regulate the activity of a large no. of proteins involved in cancer initiation and progression.  The discovery of isoform-selective HDAC inhibitors (HDACIs) is desirable, as it is likely that such compds. would avoid some of the undesirable side effects found with the first-generation inhibitors.  A series of HDACIs previously reported by the authors were found to display some selectivity for HDAC6 and to induce cell-cycle arrest and apoptosis in pancreatic cancer cells.  In the present work, the authors show that structural modification of these isoxazole-based inhibitors leads to high potency and selectivity for HDAC6 over HDAC1-3 and HDAC10, while unexpectedly abolishing their ability to block cell growth.  Three inhibitors with lower HDAC6 selectivity inhibit the growth of cell lines BxPC3 and L3.6pl, and they only induce apoptosis in L3.6pl cells.  The authors conclude that HDAC6 inhibition alone is insufficient for disruption of cell growth, and that some degree of class 1 HDAC inhibition is required.  Moreover, the highly selective HDAC6Is reported herein that are weakly cytotoxic may find use in cancer immune system reactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8NrQruF5oObVg90H21EOLACvtfcHk0li6aRMKce_Z_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVyhtLnI&md5=2c241c869dfcdd2863cee7aec9c2e898</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500456%26sid%3Dliteratum%253Aachs%26aulast%3DGaisina%26aufirst%3DI.%2BN.%26aulast%3DTueckmantel%26aufirst%3DW.%26aulast%3DUgolkov%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DHoffen%26aufirst%3DJ.%26aulast%3DDubrovskyi%26aufirst%3DO.%26aulast%3DMazar%26aufirst%3DA.%26aulast%3DSchoon%26aufirst%3DR.%2BA.%26aulast%3DBilladeau%26aufirst%3DD.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DIdentification%2520of%2520HDAC6-Selective%2520Inhibitors%2520of%2520Low%2520Cancer%2520Cell%2520Cytotoxicity%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D81%26epage%3D92%26doi%3D10.1002%2Fcmdc.201500456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustinova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlicek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noonepalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8557</span>– <span class="NLM_lpage">8577</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00946</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00946" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8557-8577&author=S.+Shenauthor=M.+Hadleyauthor=K.+Ustinovaauthor=J.+Pavlicekauthor=T.+Knoxauthor=S.+Noonepalleauthor=M.+T.+Tavaresauthor=C.+A.+Zimprichauthor=G.+Zhangauthor=M.+B.+Robersauthor=C.+Barinkaauthor=A.+P.+Kozikowskiauthor=A.+Villagra&title=Discovery+of+a+New+Isoxazole-3-hydroxamate-Based+Histone+Deacetylase+6+Inhibitor+SS-208+with+Antitumor+Activity+in+Syngeneic+Melanoma+Mouse+Models&doi=10.1021%2Facs.jmedchem.9b00946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models</span></div><div class="casAuthors">Shen, Sida; Hadley, Melissa; Ustinova, Kseniya; Pavlicek, Jiri; Knox, Tessa; Noonepalle, Satish; Tavares, Mauricio T.; Zimprich, Chad A.; Zhang, Guiping; Robers, Matthew B.; Barinka, Cyril; Kozikowski, Alan P.; Villagra, Alejandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8557-8577</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Isoxazole is a five-membered heterocycle that is widely used in drug discovery endeavors.  Here, the authors report the design, synthesis, and structural and biol. characterization of SS-208, a novel HDAC6-selective inhibitor contg. the isoxazole-3-hydroxamate moiety as a zinc-binding group as well as a hydrophobic linker.  A crystal structure of the Danio rerio HDAC6/SS-208 complex reveals a bidentate coordination of the active-site zinc ion that differs from the preferred monodentate coordination obsd. for HDAC6 complexes with phenylhydroxamate-based inhibitors.  While SS-208 has minimal effects on the viability of murine SM1 melanoma cells in vitro, it significantly reduced in vivo tumor growth in a murine SM1 syngeneic melanoma mouse model.  These findings suggest that the antitumor activity of SS-208 is mainly mediated by immune-related antitumor activity as evidenced by the increased infiltration of CD8+ and NK+ T cells and the enhanced ratio of M1 and M2 macrophages in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUagVGHIiRHbVg90H21EOLACvtfcHk0ljKgSstwDJHLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbzI&md5=53b4c45ce582d8752869430407d44649</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00946%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DUstinova%26aufirst%3DK.%26aulast%3DPavlicek%26aufirst%3DJ.%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DNoonepalle%26aufirst%3DS.%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520New%2520Isoxazole-3-hydroxamate-Based%2520Histone%2520Deacetylase%25206%2520Inhibitor%2520SS-208%2520with%2520Antitumor%2520Activity%2520in%2520Syngeneic%2520Melanoma%2520Mouse%2520Models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8557%26epage%3D8577%26doi%3D10.1021%2Facs.jmedchem.9b00946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6056</span>– <span class="NLM_lpage">6074</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6056-6074&author=Y.+Huangauthor=G.+Dongauthor=H.+Liauthor=N.+Liuauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+Janus+Kinase+2+%28JAK2%29+and+Histone+Deacetylase+%28HDAC%29+Dual+Inhibitors+as+a+Novel+Strategy+for+the+Combinational+Treatment+of+Leukemia+and+Invasive+Fungal+Infections&doi=10.1021%2Facs.jmedchem.8b00393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections</span></div><div class="casAuthors">Huang, Yahui; Dong, Guoqiang; Li, Huanqiu; Liu, Na; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6056-6074</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin., leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens.  Herein, a novel therapeutic strategy was developed in which a small mol. can simultaneously treat leukemia and invasive fungal infections (IFIs).  Novel Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors were identified to possess potent anti-proliferative activity toward hematol. cell lines and excellent synergistic effects with fluconazole to treat resistant Candida albicans infections.  In particular, compd. I, a highly active and selective JAK2/HDAC6 dual inhibitor, showed excellent in vivo antitumor efficacy in several acute myeloid leukemia (AML) models and synergized with fluconazole for the treatment of resistant C. albicans infections.  This study highlights the therapeutic potential of JAK2/HDAC dual inhibitors in treating AML and IFIs and provides an efficient strategy for multitargeting drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_ii7EQG1qLVg90H21EOLACvtfcHk0ljKgSstwDJHLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN&md5=ba7cf74761120f0526ab520196e3dded</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Janus%2520Kinase%25202%2520%2528JAK2%2529%2520and%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Dual%2520Inhibitors%2520as%2520a%2520Novel%2520Strategy%2520for%2520the%2520Combinational%2520Treatment%2520of%2520Leukemia%2520and%2520Invasive%2520Fungal%2520Infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6056%26epage%3D6074%26doi%3D10.1021%2Facs.jmedchem.8b00393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 2-quinolineacrylamides</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115250</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.115250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmc.2019.115250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31924504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3MbovVSnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115250&author=S.+W.+Wangauthor=M.+H.+Linauthor=F.+C.+Hsuauthor=M.+C.+Chenauthor=J.+P.+Liouauthor=Y.+T.+Liuauthor=S.+S.+Chenauthor=H.+Y.+Lee&title=Synthesis+and+biological+evaluation+of+2-quinolineacrylamides&doi=10.1016%2Fj.bmc.2019.115250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 2-quinolineacrylamides</span></div><div class="casAuthors">Wang Shih-Wei; Lin Mei-Hsiang; Hsu Fu-Chun; Liou Jing-Ping; Liu Yi-Ting; Chen Mei-Chuan; Chen Shiou-Sheng; Lee Hsueh-Yun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">115250</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A series of C6-substituted N-hydroxy-2-quinolineacrylamides (3-15), with four types of bridging groups have been synthesized.  Most of these compounds exhibit antiproliferative activity against A549 and HCT116 cells and Western blot analysis revealed that they are able to inhibit HDAC.  Measurement of the HDAC isoform activity of ether-containing compounds showed that compound 9 has distinct HDAC6 selectivity, more than 300-fold over other isoforms.  This paper describes the development of 6-aryloxy-N-hydroxy-2-quinolineacrylamides as potential HDAC6 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgYp6bSmGsmWLFM_lbR1VmfW6udTcc2eZQK7Zr_rvE77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbovVSnsQ%253D%253D&md5=b74f14db94cc7db32ee7c8c80d3b863f</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.115250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.115250%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%2BW.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DHsu%26aufirst%3DF.%2BC.%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DChen%26aufirst%3DS.%2BS.%26aulast%3DLee%26aufirst%3DH.%2BY.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25202-quinolineacrylamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115250%26doi%3D10.1016%2Fj.bmc.2019.115250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1301</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1yjtLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1301-1305&author=N.+J.+Porterauthor=S.+Shenauthor=C.+Barinkaauthor=A.+P.+Kozikowskiauthor=D.+W.+Christianson&title=Molecular+Basis+for+the+Selective+Inhibition+of+Histone+Deacetylase+6+by+a+Mercaptoacetamide+Inhibitor&doi=10.1021%2Facsmedchemlett.8b00487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor</span></div><div class="casAuthors">Porter, Nicholas J.; Shen, Sida; Barinka, Cyril; Kozikowski, Alan P.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1301-1305</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mercaptoacetamide histone deacetylase inhibitors are neuroprotective agents that do not exhibit the genotoxicity assocd. with more commonly used hydroxamate inhibitors.  Here, the authors present the crystal structure of a selective mercaptoacetamide complexed with the C-terminal catalytic domain of HDAC6.  When compared with the structure of a mercaptoacetamide bound to the class I isoenzyme HDAC8, different interactions are obsd. with the conserved tandem histidine pair in the active site.  These differences likely contribute to the selectivity for inhibition of HDAC6, an important target for cancer chemotherapy and the treatment of neurodegenerative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMteS3uqOlwrVg90H21EOLACvtfcHk0lhSE8nj0v8A3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1yjtLfP&md5=aa88b205bd6c1ddfa084be1772a06f89</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00487%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DMolecular%2520Basis%2520for%2520the%2520Selective%2520Inhibition%2520of%2520Histone%2520Deacetylase%25206%2520by%2520a%2520Mercaptoacetamide%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D1301%26epage%3D1305%26doi%3D10.1021%2Facsmedchemlett.8b00487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">515</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVaqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=510-515&author=W.+Lvauthor=G.+Zhangauthor=C.+Barinkaauthor=J.+H.+Eubanksauthor=A.+P.+Kozikowski&title=Design+and+Synthesis+of+Mercaptoacetamides+as+Potent%2C+Selective%2C+and+Brain+Permeable+Histone+Deacetylase+6+Inhibitors&doi=10.1021%2Facsmedchemlett.7b00012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors</span></div><div class="casAuthors">Lv, Wei; Zhang, Guangming; Barinka, Cyril; Eubanks, James H.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">510-515</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of non-hydroxamate HDAC6 inhibitors were prepd. in our effort to develop potent and selective compds. for possible use in Central Nervous System (CNS) disorders, thus obviating the genotoxicity often assocd. with the hydroxamates.  Halogens are incorporated in the cap groups of the designed mercaptoacetamides in order to increase brain accessibility.  The indole analog and quinoline analog displayed potent HDAC6 inhibitory activity (IC50 11 nM and 2.8 nM) and excellent selectivity against HDAC1.  Both compds., together with their ester prodrug and disulfide prodrugs were found to be effective in promoting tubulin acetylation in HEK cells.  The disulfide prodrugs also released a stable concn. of the indole and quinoline analogs upon microsomal incubation.  Administration of disulfide prodrugs in vivo was found to trigger an increase of tubulin acetylation in mouse cortex.  These results suggest that further exploration of these com-pounds for the treatment of CNS disorders is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4LBQBS-jHCrVg90H21EOLACvtfcHk0lhSE8nj0v8A3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVaqtb8%253D&md5=f7709c8f4c339737da3201149afe0f82</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00012%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DEubanks%26aufirst%3DJ.%2BH.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Mercaptoacetamides%2520as%2520Potent%252C%2520Selective%252C%2520and%2520Brain%2520Permeable%2520Histone%2520Deacetylase%25206%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D510%26epage%3D515%26doi%3D10.1021%2Facsmedchemlett.7b00012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Design of Dual Inhibitors of Histone Deacetylase 6 and Heat Shock Protein 90</span>. <i>ACS omega</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">11473</span>– <span class="NLM_lpage">11480</span>, <span class="refDoi"> DOI: 10.1021/acsomega.0c00559</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.0c00559" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovVyntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=11473-11480&author=L.+Pinziauthor=R.+Benedettiauthor=L.+Altucciauthor=G.+Rastelli&title=Design+of+Dual+Inhibitors+of+Histone+Deacetylase+6+and+Heat+Shock+Protein+90&doi=10.1021%2Facsomega.0c00559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Dual Inhibitors of Histone Deacetylase 6 and Heat Shock Protein 90</span></div><div class="casAuthors">Pinzi, Luca; Benedetti, Rosaria; Altucci, Lucia; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">11473-11480</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) and heat shock protein 90 (Hsp90) are widely investigated anticancer drug targets.  Importantly, several lines of evidence indicate that their regulation and activity are intimately linked, and that their combined inhibition may lead to impressive therapeutic benefits.  In this study, we developed and applied an integrated computational strategy to design dual inhibitors of HDAC6 and Hsp90.  Although the two targets share very little homol., an integrated ligand-based and structure-based virtual screening approach indicated a subset of compds. possessing the key structural requirements for binding at both targets.  In vitro tests demonstrated that some of the selected candidates are able to selectively inhibit HDAC6 over HDAC1, to increase the acetylation levels of tubulin on cell assays and to reduce cell proliferation.  The discovered compds. represent valuable starting points for further hit optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaKvpHIkSRTbVg90H21EOLACvtfcHk0ljZS2oOedA-9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovVyntbY%253D&md5=a615fa649778b667d748b5905045bf19</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Facsomega.0c00559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.0c00559%26sid%3Dliteratum%253Aachs%26aulast%3DPinzi%26aufirst%3DL.%26aulast%3DBenedetti%26aufirst%3DR.%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DDesign%2520of%2520Dual%2520Inhibitors%2520of%2520Histone%2520Deacetylase%25206%2520and%2520Heat%2520Shock%2520Protein%252090%26jtitle%3DACS%2520omega%26date%3D2020%26volume%3D5%26spage%3D11473%26epage%3D11480%26doi%3D10.1021%2Facsomega.0c00559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madauss, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlhaus, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, Q. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trocha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baloglu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trump, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray-Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravorty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mander, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruidenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turunen, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, M. A.</span></span> <span> </span><span class="NLM_article-title">Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fnchembio.1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=23524983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=319-325&author=M.+Loberaauthor=K.+P.+Madaussauthor=D.+T.+Pohlhausauthor=Q.+G.+Wrightauthor=M.+Trochaauthor=D.+R.+Schmidtauthor=E.+Balogluauthor=R.+P.+Trumpauthor=M.+S.+Headauthor=G.+A.+Hofmannauthor=M.+Murray-Thompsonauthor=B.+Schwartzauthor=S.+Chakravortyauthor=Z.+Wuauthor=P.+K.+Manderauthor=L.+Kruidenierauthor=R.+A.+Reidauthor=W.+Burkhartauthor=B.+J.+Turunenauthor=J.+X.+Rongauthor=C.+Wagnerauthor=M.+B.+Moyerauthor=C.+Wellsauthor=X.+Hongauthor=J.+T.+Mooreauthor=J.+D.+Williamsauthor=D.+Solerauthor=S.+Ghoshauthor=M.+A.+Nolan&title=Selective+class+IIa+histone+deacetylase+inhibition+via+a+nonchelating+zinc-binding+group&doi=10.1038%2Fnchembio.1223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group</span></div><div class="casAuthors">Lobera, Mercedes; Madauss, Kevin P.; Pohlhaus, Denise T.; Wright, Quentin G.; Trocha, Mark; Schmidt, Darby R.; Baloglu, Erkan; Trump, Ryan P.; Head, Martha S.; Hofmann, Glenn A.; Murray-Thompson, Monique; Schwartz, Benjamin; Chakravorty, Subhas; Wu, Zining; Mander, Palwinder K.; Kruidenier, Laurens; Reid, Robert A.; Burkhart, William; Turunen, Brandon J.; Rong, James X.; Wagner, Craig; Moyer, Mary B.; Wells, Carrow; Hong, Xuan; Moore, John T.; Williams, Jon D.; Soler, Dulce; Ghosh, Shomir; Nolan, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">319-325</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In contrast to studies on class I histone deacetylase (HDAC) inhibitors, the elucidation of the mol. mechanisms and therapeutic potential of class IIa HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) is impaired by the lack of potent and selective chem. probes.  Here we report the discovery of inhibitors that fill this void with an unprecedented metal-binding group, trifluoromethyloxadiazole (TFMO), which circumvents the selectivity and pharmacol. liabilities of hydroxamates.  We confirm direct metal binding of the TFMO through crystallog. approaches and use chemoproteomics to demonstrate the superior selectivity of the TFMO series relative to a hydroxamate-substituted analog.  We further apply these tool compds. to reveal gene regulation dependent on the catalytic active site of class IIa HDACs.  The discovery of these inhibitors challenges the design process for targeting metalloenzymes through a chelating metal-binding group and suggests therapeutic potential for class IIa HDAC enzyme blockers distinct in mechanism and application compared to current HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpglr3JvlNjhbVg90H21EOLACvtfcHk0ljZS2oOedA-9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D&md5=f15a4565213d7a0ec5dc0a0b6032b9ab</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1223%26sid%3Dliteratum%253Aachs%26aulast%3DLobera%26aufirst%3DM.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DPohlhaus%26aufirst%3DD.%2BT.%26aulast%3DWright%26aufirst%3DQ.%2BG.%26aulast%3DTrocha%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DD.%2BR.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DTrump%26aufirst%3DR.%2BP.%26aulast%3DHead%26aufirst%3DM.%2BS.%26aulast%3DHofmann%26aufirst%3DG.%2BA.%26aulast%3DMurray-Thompson%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DChakravorty%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DMander%26aufirst%3DP.%2BK.%26aulast%3DKruidenier%26aufirst%3DL.%26aulast%3DReid%26aufirst%3DR.%2BA.%26aulast%3DBurkhart%26aufirst%3DW.%26aulast%3DTurunen%26aufirst%3DB.%2BJ.%26aulast%3DRong%26aufirst%3DJ.%2BX.%26aulast%3DWagner%26aufirst%3DC.%26aulast%3DMoyer%26aufirst%3DM.%2BB.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DHong%26aufirst%3DX.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26aulast%3DWilliams%26aufirst%3DJ.%2BD.%26aulast%3DSoler%26aufirst%3DD.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DNolan%26aufirst%3DM.%2BA.%26atitle%3DSelective%2520class%2520IIa%2520histone%2520deacetylase%2520inhibition%2520via%2520a%2520nonchelating%2520zinc-binding%2520group%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D319%26epage%3D325%26doi%3D10.1038%2Fnchembio.1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. P.</span></span> <span> </span><span class="NLM_article-title">Evaluation of WO2017018805:1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1508451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1080%2F13543776.2018.1508451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30073889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGrtr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=647-651&author=Y.+Y.+Liangauthor=C.+M.+Zhangauthor=Z.+P.+Liu&title=Evaluation+of+WO2017018805%3A1%2C3%2C4-oxadiazole+sulfamide+derivatives+as+selective+HDAC6+inhibitors&doi=10.1080%2F13543776.2018.1508451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors</span></div><div class="casAuthors">Liang, Yuan-Yuan; Zhang, Cheng-Mei; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">647-651</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">There are great potential in the development of selective HDAC6 inhibitors for the treatment of infectious diseases, neoplasms, endocrine diseases, and other diseases assocd. with HDAC6 activity.  The application claims 1,3,4-oxadiazole sulfamide derivs. as selective HDAC6 inhibitors for the treatment of infectious diseases, neoplasms, endocrine, nutritional, and metabolic diseases; mental and behavioral disorders; neurol. diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and s.c. tissue; disease of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.  Many of the exemplified compds. showed nanomole potency against HDAC6 and were more than 5000-fold selectivity for HDAC6 over HDAC1.  These 1,3,4-oxadiazole sulfamide derivs. have a unique zinc-binding group (ZBG) that provide good leads for the discovery of potent selective HDAC6 inhibitors for the treatment of a variety of diseases assocd. with HDAC6 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprQFwE60NVurVg90H21EOLACvtfcHk0ljZS2oOedA-9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGrtr3M&md5=846dc4375f614a5b1fca386c74c21d37</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1508451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1508451%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.%2BY.%26aulast%3DZhang%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DZ.%2BP.%26atitle%3DEvaluation%2520of%2520WO2017018805%253A1%252C3%252C4-oxadiazole%2520sulfamide%2520derivatives%2520as%2520selective%2520HDAC6%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26spage%3D647%26epage%3D651%26doi%3D10.1080%2F13543776.2018.1508451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0lhdGugwwlvMoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span> <span> </span><span class="NLM_article-title">PROTACs: A novel strategy for cancer therapy</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2020.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.semcancer.2020.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32058059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjvFynur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2020&pages=171-179&author=J.+Liuauthor=J.+Maauthor=Y.+Liuauthor=J.+Xiaauthor=Y.+Liauthor=Z.+P.+Wangauthor=W.+Wei&title=PROTACs%3A+A+novel+strategy+for+cancer+therapy&doi=10.1016%2Fj.semcancer.2020.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs: A novel strategy for cancer therapy</span></div><div class="casAuthors">Liu, Jing; Ma, Jia; Liu, Yi; Xia, Jun; Li, Yuyun; Wang, Z. Peter; Wei, Wenyi</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">Part_2</span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  However, most intracellular proteins lack of active sites or antigens where SMIs or mAbs bind with, and are called as non-druggable targets for a long time.  From the first year of this century, PROteolysis-TArgeting Chimeras (PROTACs) has emerged to be a promising approach for proteins, including those non-druggable ones, such as transcriptional factors and scaffold proteins.  The first generation of peptide-based PROTACs adopts β-TrCP and VHL as E3 ligases, but the cellular permeability and chem. stability issues restrict their clin. application.  The second generation of small mol.-based PROTACs adopts MDM2, VHL, IAPs and Cereblon as E3 ligases have been tensely studied.  To date, the targets of PROTACs including those overexpressed oncogenic proteins such as ER, AR and BRDs, disease-relevant fusion proteins such as NPM/EML4-ALK and BCR-ABL, cancer-driven mutant proteins such as EGFR, kinases such as CDKs and RTKs.  The major disadvantage of PROTACs is the noncancer specificity and relative higher toxicity, due to its catalytic role.  To overcome this, we and other have recently developed several similar light-controllable PROTACs, termed as the third generation controllable PROTACs.  The degrdn. of targets by those PROTACs can be triggered by UVA or visible light, providing a tool box for further PROTACs design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYKjhYqcuOobVg90H21EOLACvtfcHk0lhdGugwwlvMoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjvFynur8%253D&md5=857bf22e06e986d57ad70fdd4a518953</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2020.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2020.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%2BP.%26aulast%3DWei%26aufirst%3DW.%26atitle%3DPROTACs%253A%2520A%2520novel%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2020%26volume%3D67%26spage%3D171%26epage%3D179%26doi%3D10.1016%2Fj.semcancer.2020.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation by PROTACs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.pharmthera.2017.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=28223226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=138-144&author=T.+K.+Neklesaauthor=J.+D.+Winklerauthor=C.+M.+Crews&title=Targeted+protein+degradation+by+PROTACs&doi=10.1016%2Fj.pharmthera.2017.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation by PROTACs</span></div><div class="casAuthors">Neklesa, Taavi K.; Winkler, James D.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-144</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeted protein degrdn. using the PROTAC technol. is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein.  PROTAC mols. are bifunctional small mols. that simultaneously bind a target protein and an E3-ubiquitin ligase, thus causing ubiquitination and degrdn. of the target protein by the proteasome.  Like small mols., PROTAC mols. possess good tissue distribution and the ability to target intracellular proteins.  Herein, we highlight the advantages of protein degrdn. using PROTACs, and provide specific examples where degrdn. offers therapeutic benefit over classical enzyme inhibition.  Foremost, PROTACs can degrade proteins regardless of their function.  This includes the currently "undruggable" proteome, which comprises approx. 85% of all human proteins.  Other beneficial aspects of protein degrdn. include the ability to target overexpressed and mutated proteins, as well as the potential to demonstrate prolonged pharmacodynamics effect beyond drug exposure.  Lastly, due to their catalytic nature and the pre-requisite ubiquitination step, an exquisitely potent mols. with a high degree of degrdn. selectivity can be designed.  Impressive preclin. in vitro and in vivo PROTAC data have been published, and these data have propelled the development of clin. viable PROTACs.  With the mol. wt. falling in the 700-1000 Da range, the delivery and bioavailability of PROTACs remain the largest hurdles on the way to the clinic.  Solving these issues and demonstrating proof of concept clin. data will be the focus of many labs over the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RSLWYqqBMrVg90H21EOLACvtfcHk0lhdGugwwlvMoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D&md5=08a74402a274a13c8c484cd68167a5a1</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%2520by%2520PROTACs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D174%26spage%3D138%26epage%3D144%26doi%3D10.1016%2Fj.pharmthera.2017.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00046</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltValtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=575-581&author=K.+Yangauthor=H.+Wuauthor=Z.+Zhangauthor=E.+D.+Leistenauthor=X.+Nieauthor=B.+Liuauthor=Z.+Wenauthor=J.+Zhangauthor=M.+D.+Cunninghamauthor=W.+Tang&title=Development+of+Selective+Histone+Deacetylase+6+%28HDAC6%29+Degraders+Recruiting+Von+Hippel-Lindau+%28VHL%29+E3+Ubiquitin+Ligase&doi=10.1021%2Facsmedchemlett.0c00046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Development of selective histone deacetylase 6 (HDAC6) degraders recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase</span></div><div class="casAuthors">Yang, Ka; Wu, Hao; Zhang, Zhongrui; Leisten, Eric D.; Nie, Xueqing; Liu, Binkai; Wen, Zhi; Zhang, Jing; Cunningham, Michael D.; Tang, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">575-581</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is involved in multiple cellular processes such as aggresome formation, protein stability, and cell motility.  Numerous HDAC6-selective inhibitors have been developed as cellular chem. tools to elucidate the function of HDAC6.  Since HDAC6 has multiple domains that cannot be studied by HDAC6-selective inhibitors, CRISPR-CAS9 and siRNA/shRNA have been employed to elucidate the nonenzymic functions of HDAC6.  However, these genetic methods have many limitations.  Proteolysis targeting chimera (PROTAC) is an emerging technol. for the development of small mols. that can quickly remove the entire protein in cells.  We previously developed multifunctional HDAC6 degraders that can recruit cereblon (CRBN) E3 ubiquitin ligase.  These HDAC6 degraders can degrade not only HDAC6 but also neo-substrates of CRBN.  They are excellent candidates for the development of anticancer therapeutics, but the multifunctional nature of the CRBN-based HDAC6 degraders has limited their utility as specific chem. probes for the study of HDAC6-related cellular pathways.  Herein we report the development of the first cell-permeable HDAC6-selective degraders employing Von Hippel-Lindau (VHL) E3 ubiquitin ligase, which does not have any known neo-substrates.  The DC50's of the most potent compd. 3j are 7.1 nM and 4.3 nM in human MM1S and mouse 4935 cell lines, resp.  The Dmax's of 3j in these two cell lines are 90% and 57%, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5wocEPQJIsLVg90H21EOLACvtfcHk0ljckrAiNebVjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltValtr8%253D&md5=262e34a4a9376e31fed2d031cc04cb92</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00046%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLeisten%26aufirst%3DE.%2BD.%26aulast%3DNie%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DM.%2BD.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520Selective%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529%2520Degraders%2520Recruiting%2520Von%2520Hippel-Lindau%2520%2528VHL%2529%2520E3%2520Ubiquitin%2520Ligase%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D575%26epage%3D581%26doi%3D10.1021%2Facsmedchemlett.0c00046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, X.</span></span> <span> </span><span class="NLM_article-title">Hydroxamic acid hybrids as the potential anticancer agents: An Overview</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">112679</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2020.112679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32791404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsF2qtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2020&pages=112679&author=W.+Liuauthor=Y.+Liangauthor=X.+Si&title=Hydroxamic+acid+hybrids+as+the+potential+anticancer+agents%3A+An+Overview&doi=10.1016%2Fj.ejmech.2020.112679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxamic acid hybrids as the potential anticancer agents: An Overview</span></div><div class="casAuthors">Liu, Wenhua; Liang, Yuchen; Si, Xiaoyong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112679</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Hydroxamic acid derivs. are potential histone deacetylase inhibitors, and several hydroxamic acid-based histone deacetylase inhibitors have already been used clin. as potent anticancer agents, so hydroxamic acid derivs. are useful scaffolds for the development of novel anticancer agents.  Hybridization of hydroxamic acid moiety with other anticancer pharmacophores can overcome drug resistance and improve the specificity, so rational design of hydroxamic acid hybrids may provide valuable therapeutic interventions for the treatment of cancers.  The purpose of the present review article is to update the current developments in hydroxamic acid hybrids with an emphasis on anticancer activity, structure-activity relationships, and mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE_wMu67SxuLVg90H21EOLACvtfcHk0ljckrAiNebVjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsF2qtL%252FE&md5=68cf1d971d0762edd53e1a549c9ad308</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112679%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DSi%26aufirst%3DX.%26atitle%3DHydroxamic%2520acid%2520hybrids%2520as%2520the%2520potential%2520anticancer%2520agents%253A%2520An%2520Overview%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D205%26spage%3D112679%26doi%3D10.1016%2Fj.ejmech.2020.112679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galloway, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colevas, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saba, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtness, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span> <span> </span><span class="NLM_article-title">A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1566</span>– <span class="NLM_lpage">1573</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1158%2F1078-0432.CCR-14-2820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=25573383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVahs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1566-1573&author=T.+J.+Gallowayauthor=L.+J.+Wirthauthor=A.+D.+Colevasauthor=J.+Gilbertauthor=J.+E.+Baumanauthor=N.+F.+Sabaauthor=D.+Rabenauthor=R.+Mehraauthor=A.+W.+Maauthor=R.+Atoyanauthor=J.+Wangauthor=B.+Burtnessauthor=A.+Jimeno&title=A+Phase+I+Study+of+CUDC-101%2C+a+Multitarget+Inhibitor+of+HDACs%2C+EGFR%2C+and+HER2%2C+in+Combination+with+Chemoradiation+in+Patients+with+Head+and+Neck+Squamous+Cell+Carcinoma&doi=10.1158%2F1078-0432.CCR-14-2820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma</span></div><div class="casAuthors">Galloway, Thomas J.; Wirth, Lori J.; Colevas, Alexander D.; Gilbert, Jill; Bauman, Julie E.; Saba, Nabil F.; Raben, David; Mehra, Ranee; Ma, Anna W.; Atoyan, Ruzanna; Wang, Jing; Burtness, Barbara; Jimeno, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1566-1573</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CUDC-101 is a small mol. that simultaneously inhibits the epidermal growth factor receptor (EGFR), human growth factor receptor 2 (HER2), and histone deacetylase (HDAC) with preclin. activity in head and neck squamous cell cancer (HNSCC).  The primary objective of this investigation is to det. the max. tolerated dose (MTD) of CUDC-101 with cisplatin-radiotherapy in the treatment of HNSCC.  CUDC-101 monotherapy was administered i.v. three times weekly (Monday, Wednesday, Friday) for a one-week run-in, then continued with concurrent cisplatin (100 mg/m2 every 3 wk) and external beam radiation (70 Gy to gross disease) over 7 wk.  Twelve patients with intermediate or high-risk HNSCC enrolled.  Eleven were p16INKa (p16)-neg.  The MTD of CUDC-101-based combination therapy was established at 275 mg/m2/dose.  Five patients discontinued CUDC-101 due to an adverse event (AE); only one was considered a dose-limiting toxicity (DLT), at the MTD.  Pharmacokinetic evaluation suggested low accumulation with this dosing regimen.  HDAC inhibition was demonstrated by pharmacodynamic analyses in peripheral blood mononuclear cells (PBMC), tumor biopsies, and paired skin biopsies.  Paired tumor biopsies demonstrated a trend of EGFR inhibition.  At 1.5 years of median follow-up, there has been one recurrence and two patient deaths (neither attributed to CUDC-101).  The remaining nine patients are free of progression.  CUDC-101, cisplatin, and radiation were feasible in intermediate-/high-risk patients with HNSCC, with no unexpected patterns of AE.  Although the MTD was identified, a high rate of DLT-independent discontinuation of CUDC-101 suggests a need for alternate schedules or routes of administration.  Clin Cancer Res; 21(7); 1566-73. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRDbfIvcyF87Vg90H21EOLACvtfcHk0ljckrAiNebVjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVahs7o%253D&md5=dd6b5663ffbf995b5def843a8b8b7556</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2820%26sid%3Dliteratum%253Aachs%26aulast%3DGalloway%26aufirst%3DT.%2BJ.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DColevas%26aufirst%3DA.%2BD.%26aulast%3DGilbert%26aufirst%3DJ.%26aulast%3DBauman%26aufirst%3DJ.%2BE.%26aulast%3DSaba%26aufirst%3DN.%2BF.%26aulast%3DRaben%26aufirst%3DD.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBurtness%26aufirst%3DB.%26aulast%3DJimeno%26aufirst%3DA.%26atitle%3DA%2520Phase%2520I%2520Study%2520of%2520CUDC-101%252C%2520a%2520Multitarget%2520Inhibitor%2520of%2520HDACs%252C%2520EGFR%252C%2520and%2520HER2%252C%2520in%2520Combination%2520with%2520Chemoradiation%2520in%2520Patients%2520with%2520Head%2520and%2520Neck%2520Squamous%2520Cell%2520Carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1566%26epage%3D1573%26doi%3D10.1158%2F1078-0432.CCR-14-2820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerecitano, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelapu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, Y.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(15)00584-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2FS1470-2045%2815%2900584-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27049457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=622-631&author=A.+Younesauthor=J.+G.+Berdejaauthor=M.+R.+Patelauthor=I.+Flinnauthor=J.+F.+Gerecitanoauthor=S.+S.+Neelapuauthor=K.+R.+Kellyauthor=A.+R.+Copelandauthor=A.+Akinsauthor=M.+S.+Clancyauthor=L.+Gongauthor=J.+Wangauthor=A.+Maauthor=J.+L.+Vinerauthor=Y.+Oki&title=Safety%2C+tolerability%2C+and+preliminary+activity+of+CUDC-907%2C+a+first-in-class%2C+oral%2C+dual+inhibitor+of+HDAC+and+PI3K%2C+in+patients+with+relapsed+or+refractory+lymphoma+or+multiple+myeloma%3A+an+open-label%2C+dose-escalation%2C+phase+1+trial&doi=10.1016%2FS1470-2045%2815%2900584-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span></div><div class="casAuthors">Younes, Anas; Berdeja, Jesus G.; Patel, Manish R.; Flinn, Ian; Gerecitano, John F.; Neelapu, Sattva S.; Kelly, Kevin R.; Copeland, Amanda R.; Akins, Amy; Clancy, Myles S.; Gong, Lucy; Wang, Jing; Ma, Anna; Viner, Jaye L.; Oki, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">622-631</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited.  CUDC-907 is an oral, first-in-class, small mol. that is designed to inhibit both histone deacetylase (HDAC) and PI3K enzymes, which are members of common oncogenic pathways in haematol. malignancies.  We aimed to assess overall safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymphoma and multiple myeloma.  This open-label, first-in-man, phase 1 trial recruited adult patients (aged ≥18 years) with lymphoma or multiple myeloma who were refractory to or had relapsed after two or more previous regimens, from four US cancer centers.  CUDC-907 was orally administered in a std. 3 + 3 dose-escalation design at four different dosing schedules, to which participants were sequentially assigned as follows: once daily, intermittently (twice or three times weekly; simultaneous enrolment), and daily for 5 days followed by a 2-day break (5/2), in 21-day cycles.  Dosing started at 30 mg for the once-daily schedule and 60 mg for other schedules, escalating in 30 mg increments.  Patients continued to receive CUDC-907 until disease progression or until other treatment discontinuation criteria were met.  The primary objective was to det. the max. tolerated dose (MTD) and recommended phase 2 dose, assessed in patients who received at least 66% of cycle 1 doses without modification and those who had a dose-limiting toxicity (DLT) in cycle 1 irresp. of dose modification.  We assessed safety in all patients who received at least one dose of study drug.  This ongoing trial is registered at ClinicalTrials.gov, no. NCT01742988.  Between Jan 23, 2013, and July 27, 2015, we enrolled 44 patients, of whom ten were sequentially assigned to CUDC-907 once-daily (MTD 60 mg), 12 to twice-weekly (MTD 150 mg), 15 to three-times-weekly (MTD 150 mg), and seven to the 5/2 dosing schedule (MTD 60 mg). 37 (84%) patients had discontinued study drug as a result of progressive disease or clin. signs of progressive disease at the data cutoff.  Four DLTs occurred in three of 40 DLT-evaluable patients (diarrhoea and hyperglycemia in one patient on 60 mg once daily, hyperglycemia in one patient on 150 mg twice weekly, and diarrhoea in one patient on 150 mg three times weekly); no DLTs were reported in patients on the 5/2 schedule.  Grade 3 or worse adverse events occurred in 19 (43%) of 44 patients, the most common of which were thrombocytopenia (in nine [20%] of 44 patients), neutropenia (three [7%]), and hyperglycemia (three [7%]). 11 (25%) of 44 patients had serious adverse events, three of which were regarded as treatment related (epistaxis and the DLTs of diarrhoea and hyperglycemia).  Adverse events led to dose redns. in six (14%) patients and treatment discontinuation in seven (16%).  Five (14%) of 37 response-evaluable patients achieved an objective response (two complete responses and three partial responses).  All five responses occurred in the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; n=9), and three occurred in those with transformed follicular lymphoma DLBCL (n=5). 21 (57%) of 37 response-evaluable patients had stable disease, including those with DLBCL, Hodgkin's lymphoma, and multiple myeloma.  On the basis of these findings, we selected CUDC-907 60 mg on the 5/2 dosing schedule as the recommended phase 2 dose.  The safety and tolerability profile of CUDC-907 and the promising preliminary evidence of response support continued development of CUDC-907 at the 60 mg 5/2 dosing schedule, alone and in combination with other therapies.  A dose-expansion trial of this dose in patients with refractory and relapsed DLBCL in particular, is ongoing.  Curis, Inc, and the Leukemia and Lymphoma Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFEt7vSuwM7Vg90H21EOLACvtfcHk0ljQvn6lDiZQ_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D&md5=b759c77ac239b6ae0052d30c9bea3221</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900584-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900584-7%26sid%3Dliteratum%253Aachs%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DCopeland%26aufirst%3DA.%2BR.%26aulast%3DAkins%26aufirst%3DA.%26aulast%3DClancy%26aufirst%3DM.%2BS.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DOki%26aufirst%3DY.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520preliminary%2520activity%2520of%2520CUDC-907%252C%2520a%2520first-in-class%252C%2520oral%252C%2520dual%2520inhibitor%2520of%2520HDAC%2520and%2520PI3K%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520lymphoma%2520or%2520multiple%2520myeloma%253A%2520an%2520open-label%252C%2520dose-escalation%252C%2520phase%25201%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D622%26epage%3D631%26doi%3D10.1016%2FS1470-2045%2815%2900584-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zylla, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhardwaj, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miskimins, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Puente, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnimpieba, E. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messerli, S. M.</span></span> <span> </span><span class="NLM_article-title">Analysis of Dual Class I Histone Deacetylase and Lysine Demethylase Inhibitor Domatinostat (4SC-202) on Growth and Cellular and Genomic Landscape of Atypical Teratoid/Rhabdoid</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">756</span>, <span class="refDoi"> DOI: 10.3390/cancers12030756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3390%2Fcancers12030756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVShtr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=756&author=M.+M.+Hoffmanauthor=J.+S.+Zyllaauthor=S.+Bhattacharyaauthor=K.+Calarauthor=T.+W.+Hartmanauthor=R.+D.+Bhardwajauthor=W.+K.+Miskiminsauthor=P.+de+la+Puenteauthor=E.+Z.+Gnimpiebaauthor=S.+M.+Messerli&title=Analysis+of+Dual+Class+I+Histone+Deacetylase+and+Lysine+Demethylase+Inhibitor+Domatinostat+%284SC-202%29+on+Growth+and+Cellular+and+Genomic+Landscape+of+Atypical+Teratoid%2FRhabdoid&doi=10.3390%2Fcancers12030756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of dual class I histone deacetylase and lysine demethylase inhibitor domatinostat (4SC-202) on growth and cellular and genomic landscape of atypical teratoid/rhabdoid</span></div><div class="casAuthors">Hoffman, Mariah M.; Zylla, Jessica S.; Bhattacharya, Somshuvra; Calar, Kristin; Hartman, Timothy W.; Bhardwaj, Ratan D.; Miskimins, W. Keith; de la Puente, Pilar; Gnimpieba, Etienne Z.; Messerli, Shanta M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">756</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Central nervous system atypical teratoid/rhabdoid tumors (ATRTs) are rare and aggressive tumors with a very poor prognosis.  Current treatments for ATRT include resection of the tumor, followed by systemic chemotherapy and radiation therapy, which have toxic side effects for young children.  Gene expression analyses of human ATRTs and normal brain samples indicate that ATRTs have aberrant expression of epigenetic markers including class I histone deacetylases (HDAC's) and lysine demethylase (LSD1).  Here, we investigate the effect of a small mol. epigenetic modulator known as Domatinostat (4SC-202), which inhibits both class I HDAC's and Lysine Demethylase (LSD1), on ATRT cell survival and single cell heterogeneity.  Our findings suggest that 4SC-202 is both cytotoxic and cytostatic to ATRT in 2D and 3D scaffold cell culture models and may target cancer stem cells.  Single-cell RNA sequencing data from ATRT-06 spheroids treated with 4SC-202 have a reduced population of cells overexpressing stem cell-related genes, including SOX2.  Flow cytometry and immunofluorescence on 3D ATRT-06 scaffold models support these results suggesting that 4SC-202 reduces expression of cancer stem cell markers SOX2, CD133, and FOXM1.  Drug-induced changes to the systems biol. landscape are also explored by multi-omics enrichment analyses.  In summary, our data indicate that 4SC-202 has both cytotoxic and cytostatic effects on ATRT, targets specific cell sub-populations, including those with cancer stem-like features, and is an important potential cancer therapeutic to be investigated in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ0LyYtW0QabVg90H21EOLACvtfcHk0ljQvn6lDiZQ_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVShtr3M&md5=26d4293a3e4025eda9745e8099460f26</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.3390%2Fcancers12030756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12030756%26sid%3Dliteratum%253Aachs%26aulast%3DHoffman%26aufirst%3DM.%2BM.%26aulast%3DZylla%26aufirst%3DJ.%2BS.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DCalar%26aufirst%3DK.%26aulast%3DHartman%26aufirst%3DT.%2BW.%26aulast%3DBhardwaj%26aufirst%3DR.%2BD.%26aulast%3DMiskimins%26aufirst%3DW.%2BK.%26aulast%3Dde%2Bla%2BPuente%26aufirst%3DP.%26aulast%3DGnimpieba%26aufirst%3DE.%2BZ.%26aulast%3DMesserli%26aufirst%3DS.%2BM.%26atitle%3DAnalysis%2520of%2520Dual%2520Class%2520I%2520Histone%2520Deacetylase%2520and%2520Lysine%2520Demethylase%2520Inhibitor%2520Domatinostat%2520%25284SC-202%2529%2520on%2520Growth%2520and%2520Cellular%2520and%2520Genomic%2520Landscape%2520of%2520Atypical%2520Teratoid%252FRhabdoid%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D756%26doi%3D10.3390%2Fcancers12030756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">Developing potent PROTACs tools for selective degradation of HDAC6 protein</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">609</span>, <span class="refDoi"> DOI: 10.1007/s13238-018-0602-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs13238-018-0602-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30603959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVCktLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=606-609&author=Z.+Anauthor=W.+Lvauthor=S.+Suauthor=W.+Wuauthor=Y.+Rao&title=Developing+potent+PROTACs+tools+for+selective+degradation+of+HDAC6+protein&doi=10.1007%2Fs13238-018-0602-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Developing potent PROTACs tools for selective degradation of HDAC6 protein</span></div><div class="casAuthors">An, Zixuan; Lv, Wenxing; Su, Shang; Wu, Wei; Rao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">606-609</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">The present article describes about developing potent PROTACs tools for selective degrdn. of HDAC6 protein.  To evaluate the degrdn. capability of our PROTACs for HDAC6 protein, analyzed the cellular levels of HDAC6 in HeLa cells by Western blot after incubation with four different PROTACs.  It was found that all PROTACs can effectively induce HDAC6 degrdn. after 24 h.  Among them, NP8 was the most potent degrader which can significantly reduce the HDAC6 protein level at 100 nmol/L.  Then went on to evaluate the degrdn. potential of NP8 in a panel of cell lines from different origin.  NP8 consistently induced significant degrdn. of HDAC6 in all the cell lines we tested, while the multiple myeloma cell line MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0CReXjWgVRbVg90H21EOLACvtfcHk0ljQvn6lDiZQ_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVCktLjL&md5=f3c3a4afb585f9d09b753b005d5b6428</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1007%2Fs13238-018-0602-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-018-0602-z%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DZ.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DDeveloping%2520potent%2520PROTACs%2520tools%2520for%2520selective%2520degradation%2520of%2520HDAC6%2520protein%26jtitle%3DProtein%2520Cell%26date%3D2019%26volume%3D10%26spage%3D606%26epage%3D609%26doi%3D10.1007%2Fs13238-018-0602-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 5 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tao  Liang</span>, <span class="hlFld-ContribAuthor ">Junxin  Xue</span>, <span class="hlFld-ContribAuthor ">Zefu  Yao</span>, <span class="hlFld-ContribAuthor ">Yang  Ye</span>, <span class="hlFld-ContribAuthor ">Xinying  Yang</span>, <span class="hlFld-ContribAuthor ">Xuben  Hou</span>, <span class="hlFld-ContribAuthor ">Hao  Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113526. <a href="https://doi.org/10.1016/j.ejmech.2021.113526" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113526</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113526&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113526%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B3%25252C%252B4-disubstituted-imidazolidine-2%25252C%252B5-dione%252Bderivatives%252Bas%252BHDAC6%252Bselective%252Binhibitors%26aulast%3DLiang%26aufirst%3DTao%26date%3D2021%26volume%3D221%26spage%3D113526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingming  Zhang</span>, <span class="hlFld-ContribAuthor ">Wei  Wei</span>, <span class="hlFld-ContribAuthor ">Chengjun  Peng</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>, <span class="hlFld-ContribAuthor ">Xiao  He</span>, <span class="hlFld-ContribAuthor ">Heng  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingkang  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel pyrazolopyrimidine derivatives as potent mTOR/HDAC bi-functional inhibitors via pharmacophore-merging strategy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>49 </em>, 128286. <a href="https://doi.org/10.1016/j.bmcl.2021.128286" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128286</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128286%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bnovel%252Bpyrazolopyrimidine%252Bderivatives%252Bas%252Bpotent%252BmTOR%25252FHDAC%252Bbi-functional%252Binhibitors%252Bvia%252Bpharmacophore-merging%252Bstrategy%26aulast%3DZhang%26aufirst%3DMingming%26date%3D2021%26volume%3D49%26spage%3D128286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takashi  Kurohara</span>, <span class="hlFld-ContribAuthor ">Keita  Tanaka</span>, <span class="hlFld-ContribAuthor ">Daisuke  Takahashi</span>, <span class="hlFld-ContribAuthor ">Satoshi  Ueda</span>, <span class="hlFld-ContribAuthor ">Yasunobu  Yamashita</span>, <span class="hlFld-ContribAuthor ">Yuri  Takada</span>, <span class="hlFld-ContribAuthor ">Hirokazu  Takeshima</span>, <span class="hlFld-ContribAuthor ">Shengwang  Yu</span>, <span class="hlFld-ContribAuthor ">Yukihiro  Itoh</span>, <span class="hlFld-ContribAuthor ">Koji  Hase</span>, <span class="hlFld-ContribAuthor ">Takayoshi  Suzuki</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Novel Histone Deacetylase 6‐Selective Inhibitors Bearing 3,3,3‐Trifluorolactic Amide (TFLAM) Motif as a Zinc Binding Group. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2021,</strong> <em>118 </em><a href="https://doi.org/10.1002/cbic.202100255" title="DOI URL">https://doi.org/10.1002/cbic.202100255</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.202100255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.202100255%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DIdentification%252Bof%252BNovel%252BHistone%252BDeacetylase%252B6%2525E2%252580%252590Selective%252BInhibitors%252BBearing%252B3%25252C3%25252C3%2525E2%252580%252590Trifluorolactic%252BAmide%252B%252528TFLAM%252529%252BMotif%252Bas%252Ba%252BZinc%252BBinding%252BGroup%26aulast%3DKurohara%26aufirst%3DTakashi%26date%3D2021%26date%3D2021%26volume%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maurício  T Tavares</span>, <span class="hlFld-ContribAuthor ">Sida  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Recent innovative advances in the discovery of selective HDAC6 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2021,</strong> <em>13 </em>
                                    (12)
                                     , 1017-1019. <a href="https://doi.org/10.4155/fmc-2021-0040" title="DOI URL">https://doi.org/10.4155/fmc-2021-0040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2021-0040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2021-0040%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Binnovative%252Badvances%252Bin%252Bthe%252Bdiscovery%252Bof%252Bselective%252BHDAC6%252Binhibitors%26aulast%3DT%25C2%25A0Tavares%26aufirst%3DMaur%25C3%25ADcio%26date%3D2021%26volume%3D13%26issue%3D12%26spage%3D1017%26epage%3D1019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin-Hui  Zhang</span>, <span class="hlFld-ContribAuthor ">Hui-Qin  Kang</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Tao</span>, <span class="hlFld-ContribAuthor ">Yi-Han  Li</span>, <span class="hlFld-ContribAuthor ">Jun-Ru  Zhao</span>, <span class="hlFld-ContribAuthor ">Ya-Gao</span>, <span class="hlFld-ContribAuthor ">Li-Ying  Ma</span>, <span class="hlFld-ContribAuthor ">Hong-Min  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>218 </em>, 113392. <a href="https://doi.org/10.1016/j.ejmech.2021.113392" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113392%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIdentification%252Bof%252Bnovel%252B1%25252C3-diaryl-1%25252C2%25252C4-triazole-capped%252Bhistone%252Bdeacetylase%252B6%252Binhibitors%252Bwith%252Bpotential%252Banti-gastric%252Bcancer%252Bactivity%26aulast%3DZhang%26aufirst%3DXin-Hui%26date%3D2021%26volume%3D218%26spage%3D113392" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0031.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) The reversible lysine acetylation and deacetylation processes are catalyzed by HATs and HDACs, respectively. (b) Currently approved HDACis for cancer treatment in clinical practice (chidamide was approved in China) and their representative pharmacophore model: cap, linker, and zinc-binding group (ZBG).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (a) The architecture of HDAC6 functional domains and cartoon representation of the CD1–CD2 crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G0J">5G0J</a>). The CD1 and CD2 domains are in cyan and dark red, respectively, while the interdomain linker is green. The catalytic pockets are indicated in red boxes.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> (b) Molecular surface of HDAC6 CD1 (upper blue one) and CD2 (lower gray one). Residues K330 and L712 differ between the catalytic domains, giving rise to different contours at the mouth of the active site. Reprinted with permission from ref <a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (a) Coordination model of trichostatin A (TSA) hydroxamic acid group bound with the Zn<sub>2</sub><sup>+</sup> ion of histone deacetylase-like protein (HDLP) exhibited a typical O,O′-bidentate fashion. (b) Representation of the bidentate (left) and monodentate (right) zinc-binding models observed in the coordination complex of HDAC6 with hydroxamate HDAC inhibitors. Reproduced with permission from <i>Proceedings of the National Academy of Sciences of the United States of America</i>, Porter, N. J.; Mahendran, A.; Breslow, R.; Christianson, D. W., Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors, 2017, 114, 13459−13464.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (a) The structure and HDAC inhibition data of ricolinostat (ACY-1215, <b>6</b>) are shown accordingly. (b) The X-ray crystal structure of zebrafish HDAC6 CD2 in complex with ACY-1215 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGL">5WGL</a>). Simulated annealing omit map (green, contoured at 2.5σ) for ACY-1215 bound to HDAC6 (monomer A). Two conformations for the capping group are shown with different shades of purple, the darker of which indicates the sole conformation observed in monomer B. The Zn<sub>2</sub><sup>+</sup> ion is shown as a large gray sphere, and water molecules are shown as smaller red spheres. Metal coordination and hydrogen bond interactions are indicated by solid and dashed black lines, respectively. The snapshot displayed the hydroxamate moiety of ACY-1215 coordinated to Zn<sub>2</sub><sup>+</sup> ion in an typical O,O′-bidentate fashion. Reproduced with permission from <i>Proceedings of the National Academy of Sciences of the United States of America</i>, Porter, N. J.; Mahendran, A.; Breslow, R.; Christianson, D. W., Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors, 2017, 114, 13459−13464.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures and HDAC inhibition data of citarinostat (ACY-241, <b>7</b>) and WT161(<b>8</b>) are shown accordingly (upper). Molecular dynamic (MD) simulations display the interaction diagram for WT161 bound to HDAC6 (lower). Reproduced with permission from <i>Proceedings of the National Academy of Sciences of the United States of America</i>, Hideshima, T.; Qi, J.; Paranal, R. M.; Tang, W.; Greenberg, E.; West, N.; Colling, M. E.; Estiu, G.; Mazitschek, R.; Perry, J. A.; Ohguchi, H.; Cottini, F.; Mimura, N.; Gorgun, G.; Tai, Y. T.; Richardson, P. G.; Carrasco, R. D.; Wiest, O.; Schreiber, S. L.; Anderson, K. C.; Bradner, J. E., Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma, 2016, 113, 13162−13167.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Structures and HDAC inhibition data of CAY10603 (left). CAY10603 docked into the binding site of HDAC6 homology model (right). Reprinted with permission from ref <a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a>. Copyright 2008, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structure, HDAC inhibition data, and key SARs of HDAC6 inhibitors bearing linear phenyl-derived capping groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (a) Structure and HDAC inhibition of compounds <b>16</b> and <b>17</b> bearing HSP90 inhibitors-derived capping groups. (b) Isoform structural differences lead to HDAC6 selectivity of <b>17</b>. The docked pose of <b>17</b> (yellow) in HDA6 (blue) are superimposed with HDAC1 (green) and HDAC3 (purple) (up). The surface model of <b>17</b> docked in HDAC6 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU">5EDU</a>), HDAC1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ICN">5ICN</a>), and HDAC3 ((PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69">4A69</a>). A specific pocket for the capping group is observed in HDAC6 (lower). Reprinted with permission from <i>European Journal of Medicinal Chemistry</i> (ref <a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a>). Copyright 2020, Elsevier.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Sturcture and HDAC inhibition of HDAC6 inhibitors bearing JAK inhibitor-derived capping groups. Docking models displayed the <b>19</b> bound to HDAC6 homology model (derived from the crystal structure of HDAC4, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQW">2VQW</a>), HDAC1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>), and JAK2 <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2B7A">2B7A</a>). A pocket unique to HDAC6 was formed by P748 and L749, marked by a red box. The hydroxamic acid linker of <b>19</b> is positioned in the solvent exposed channel of JAK2, marked by a orange box. Reprinted with permission from ref <a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a>. Copyright 2016, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Structures and HDAC inhibition of HDAC6 inhibitors bearing Topo II (<b>26</b>), ER (<b>28</b>), Bcl-2 (<b>30</b>), and BD2 (<b>32</b>) inhibitor-derived capping groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. (a) Structure and HDAC inhibition of HPOB (<b>33</b>) and crystal structure of the HPOB–HDAC6 CD2 complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EF7">5EF7</a>). (b) Structure and HDAC inhibition of HPB (<b>34</b>) and crystal structure of the HPB–HDAC6 CD2 complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEM">5EEM</a>). Reproduced with permission from <i>Proceedings of the National Academy of Sciences of the United States of America</i>, Porter, N. J.; Mahendran, A.; Breslow, R.; Christianson, D. W., Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors, 2017, 114, 13459−13464.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Structure and HDAC inhibition of NextA and its derivatives. (a) Compound <b>36</b> docked into HDAC6 CD2 (PBD code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G0I">5G0I</a>) and an additional hydrogen bonding interaction was observed between indazole NH group and the carbonyl group of Ala641. Reprinted with permission from ref <a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a>. Copyright 2017, American Chemical Society. (b) Crystal structure of Suprastat–HDAC6 CD2 complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TCY">6TCY</a>). Newly introduced polar/ionic contacts between the aminomethyl and hydroxylbutyl groups of Suprastat and D460 and N530, respectively. (c) Molecular dynamics (MD) simulations showed H-bonding interaction between Suprastat and S531. Reprinted with permission from ref <a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a>. Copyright 2020, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Sturcture and HDAC inhibition of TubA, and X-ray crystal structure of TubA complexed with HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6THV">6THV</a>). (a) Detailed view of the residues delineating the active site and the substrate tunnel: the catalytic Zn<sub>2</sub><sup>+</sup> ion and water molecules are shown as orange and red spheres, respectively. (b) Detailed view of monodentate binding model. (c) Interactions between the carboline-based capping group and the “L1-loop pocket” of HDAC6 established by H463, P464, F583, and L712 side chains (colored blue). The surface of HDAC6 is shown in a semitransparent surface representation. Reprinted with permission from ref <a onclick="showRef(event, 'ref135'); return false;" href="javascript:void(0);" class="ref ref135">(135)</a>. Copyright 2020, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Structures and HDAC inhibition of TubA derivatives. (<i>R</i>)-Marbostat-100 (gray) and (<i>S</i>)-Marbostat-100 (yellow) docked into HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WEK">5WEK</a>). The binding site is represented by the lipophilic potential mapped onto a MOLCAD Connolly surface (hydrophobic areas, brown; polar areas, green and blue). Reprinted with permission from ref <a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a>. Copyright 2020, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. (a) Structure of the HDAC6 CD2 complex with RTS-V5 bearing a bifurcated capping group (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CW8">6CW8</a>). Molecular surface of the active site illustrates the L1 and L2 pockets.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> (b) The structure and HDAC inhibition of RTS-V5 and crystal structure with HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CW8">6CW8</a>).<a onclick="showRef(event, 'ref149'); return false;" href="javascript:void(0);" class="ref ref149">(149)</a> (c) The structure and HDAC inhibition of NR-160 and crystal structure with HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PYE">6PYE</a>). Reproduced with permission from refs <a onclick="showRef(event, 'ref43 ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref43 ref149 ref150">(43,149,and150)</a>. Copyright 2020, 2018, 2020, American Chemical Society, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. Structure and HDAC inhibition of HDAC6 inhibitors bearing heterocyclic ketone-derived capping groups. Docking model displayed lead compound <b>47</b> docked into HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU">5EDU</a>). Pocket analysis of HDAC6 was performed using <i>AlphaSpace</i>, and hydrophobic regions were colored, respectively. Reproduced with permission from ref <a onclick="showRef(event, 'ref154'); return false;" href="javascript:void(0);" class="ref ref154">(154)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Structure and HDAC inhibition of HDAC6 inhibitors bearing heterocyclic ketone-derived capping groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. (a) Binding interactions of SW-100 (orange) within HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G0I">5G0I</a>). (b) Surface pose of SW-100 (orange) within HDAC6 CD2. (c) Surface pose of TubA (cyan) within HDAC6 CD2. Hydrophobic interaction areas are colored yellow, and polar are colored green. Reprinted with permission from ref <a onclick="showRef(event, 'ref163'); return false;" href="javascript:void(0);" class="ref ref163">(163)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Structure and HDAC inhibition of HDAC6 inhibitors bearing benzo heterocyclic-derived capping groups.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. Structure and HDAC inhibition of compound <b>60</b>, and X-ray crystal structure of the <b>60</b> complex with zebrafish HDAC6 CD2 (2.50 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CGP">6CGP</a>). Reprinted with permission from ref <a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a>. Copyright 2018, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. HDAC6 inhibitors employing spiroindoline-derived capping groups. (a) X-ray crystal structure of the <b>62</b> complex with zebrafish HDAC6 CD2 complex (2.09 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V7A">6V7A</a>). (b) Dock pose of <b>63</b> into human HDAC1 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX">4BKX</a>). (c) Dock pose of <b>63</b> into human HDAC6 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU">5EDU</a>). Reprinted with permission from ref <a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a>. Copyright 2020, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. Angle of the rigid five-membered heteroaryl-based linkers to ZBG differ from that of phenyl-based linkers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. HDAC6 inhibitors employing five-membered heteroaryl-based linkers. (a) Molecular surface of the HDAC6 binding pocket. The orientations of two docked inhibitors, <b>65</b> (cyan) and <b>66</b> (orange), are shown. Reproduced with permission from ref <a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a>. Copyright 2016, American Chemical Society. (b) Polder omit map of the zebrafish HDAC6 CD2–<b>65</b> complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q0Z">6Q0Z</a>). Reprinted with permission from ref <a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a>. Copyright 2020, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Structures and HDAC inhibition of HDAC6 inhibitors bearing thiophene-containing linkers, which were obtained based on linker replacement strategy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Structures and HDAC inhibition of HDAC6 inhibitors bearing isoxazole-containing linkers. Crystal structure of <b>72</b> complex with zebrafish HDAC CD2 (1.15 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEM">5EEM</a>). (a) Detailed view of the substrate tunnel of HDAC6 in the complex with <b>72</b>. (b) Interactions between the dichlorophenyl-based capping group of <b>72</b> and the “L1-loop pocket” formed by side chains of H463, P464, F583, and L712 (colored blue). Reprinted with permission from ref <a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a>. Copyright 2019, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Structures and HDAC inhibition of HDAC6 inhibitors bearing alkenyl-based linkers. Crystal structures of resminostat (<b>73</b>), a HDAC1/3/6 inhibitor, complexed with zebrafish HDAC6 CD1 (1.58 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UOB">6UOB</a>) (a)<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and CD2 (2.30 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PZR">6PZR</a>) (b).<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Reprinted with permission from refs <a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> and <a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a>. Copyright 2019 and 2020, American Chemical Society, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Structures and HDAC inhibition of HDAC6 inhibitors bearing mercaptoacetamide-based ZBG. (a) The mechanism for the Lossen rearrangement as potentially catalyzed by the Zn<sup>2+</sup> ion in the HDAC active site. (b) Crystal structure of <b>76</b> complexed with zebrafish HDAC6 CD2 (1.85 Å, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MR5">6MR5</a>). (c) Schematic representation of active site interactions for <b>76</b> bound to HDAC6 CD2. Reprinted with permission from ref <a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a>. Copyright 2018, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Structures and HDAC inhibition of HDAC6 inhibitors bearing trifluoromethyloxadiazolyl-based ZBGs. Predicted docking poses of <b>78</b> in HDAC6 CD2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU">5EDU</a>).<a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a> Reproduced with permission from ref <a onclick="showRef(event, 'ref185'); return false;" href="javascript:void(0);" class="ref ref185">(185)</a>. Copyright 2020, American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/medium/jm0c01782_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Selective HDAC6 inhibitors-derived PROTACs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-3/acs.jmedchem.0c01782/20210204/images/large/jm0c01782_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01782&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i37">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11572" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11572" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 196 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bird, A.</span></span> <span> </span><span class="NLM_article-title">Perceptions of epigenetics</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>447</i></span>,  <span class="NLM_fpage">396</span>– <span class="NLM_lpage">398</span>, <span class="refDoi"> DOI: 10.1038/nature05913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fnature05913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=17522671" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsFOgsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=447&publication_year=2007&pages=396-398&author=A.+Bird&title=Perceptions+of+epigenetics&doi=10.1038%2Fnature05913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Perceptions of epigenetics</span></div><div class="casAuthors">Bird, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">447</span>
        (<span class="NLM_cas:issue">7143</span>),
    <span class="NLM_cas:pages">396-398</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Geneticists study the gene; however, for epigeneticists, there is no obvious 'epigene'.  Nevertheless, during the past year, more than 2,500 articles, numerous scientific meetings and a new journal were devoted to the subject of epigenetics.  It encompasses some of the most exciting contemporary biol. and is portrayed by the popular press as a revolutionary new science - an antidote to the idea that we are hard-wired by our genes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouKz8gQlpQmrVg90H21EOLACvtfcHk0lhYa9zoCKEDlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsFOgsrk%253D&md5=c1e6a0f02ee7a50f2befdc19b9df4489</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnature05913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature05913%26sid%3Dliteratum%253Aachs%26aulast%3DBird%26aufirst%3DA.%26atitle%3DPerceptions%2520of%2520epigenetics%26jtitle%3DNature%26date%3D2007%26volume%3D447%26spage%3D396%26epage%3D398%26doi%3D10.1038%2Fnature05913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. S.</span></span> <span> </span><span class="NLM_article-title">Reversing the ‘irreversible’</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>450</i></span>,  <span class="NLM_fpage">357</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1038/450357a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2F450357a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=18004369" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlajs7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=450&publication_year=2007&pages=357-359&author=R.+S.+Jones&title=Reversing+the+%E2%80%98irreversible%E2%80%99&doi=10.1038%2F450357a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Reversing the 'irreversible'</span></div><div class="casAuthors">Jones, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">450</span>
        (<span class="NLM_cas:issue">7168</span>),
    <span class="NLM_cas:pages">357, 359</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">"Do not speak-unless it improves on silence" is generally wise advice, and is even vital for a subset of essential genes.  New studies describe how, when appropriate, the silence of these genes is broken.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0akFH73x-F7Vg90H21EOLACvtfcHk0lhyHXwBfz9Hlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlajs7zP&md5=9c399b3e0d25bd9383cdbc59ae2bed2b</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F450357a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F450357a%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DR.%2BS.%26atitle%3DReversing%2520the%2520%25E2%2580%2598irreversible%25E2%2580%2599%26jtitle%3DNature%26date%3D2007%26volume%3D450%26spage%3D357%26epage%3D359%26doi%3D10.1038%2F450357a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Law, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobsen, S. E.</span></span> <span> </span><span class="NLM_article-title">Dynamic DNA Methylation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>323</i></span>,  <span class="NLM_fpage">1568</span>– <span class="NLM_lpage">1569</span>, <span class="refDoi"> DOI: 10.1126/science.1172782</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1126%2Fscience.1172782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=19299607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjvVSntbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=323&publication_year=2009&pages=1568-1569&author=J.+A.+Lawauthor=S.+E.+Jacobsen&title=Dynamic+DNA+Methylation&doi=10.1126%2Fscience.1172782"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic DNA Methylation</span></div><div class="casAuthors">Law, Julie A.; Jacobsen, Steven E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">323</span>
        (<span class="NLM_cas:issue">5921</span>),
    <span class="NLM_cas:pages">1568-1569</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">A review.  The methylation of DNA during plant development is a much more dynamic process than previously assumed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe8eERMvq7t7Vg90H21EOLACvtfcHk0lhyHXwBfz9Hlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjvVSntbo%253D&md5=9b1a650b9ea40d450905d39b5ba4b99b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1172782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1172782%26sid%3Dliteratum%253Aachs%26aulast%3DLaw%26aufirst%3DJ.%2BA.%26aulast%3DJacobsen%26aufirst%3DS.%2BE.%26atitle%3DDynamic%2520DNA%2520Methylation%26jtitle%3DScience%26date%3D2009%26volume%3D323%26spage%3D1568%26epage%3D1569%26doi%3D10.1126%2Fscience.1172782" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kouzarides, T.</span></span> <span> </span><span class="NLM_article-title">Chromatin modifications and their function</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.cell.2007.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=17320507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis12ju7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2007&pages=693-705&author=T.+Kouzarides&title=Chromatin+modifications+and+their+function&doi=10.1016%2Fj.cell.2007.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Chromatin modifications and their function</span></div><div class="casAuthors">Kouzarides, Tony</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">693-705</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The surface of nucleosomes is studded with a multiplicity of modifications.  At least eight different classes have been characterized to date and many different sites have been identified for each class.  Operationally, modifications function either by disrupting chromatin contacts or by affecting the recruitment of nonhistone proteins to chromatin.  Their presence on histones can dictate the higher-order chromatin structure in which DNA is packaged and can orchestrate the ordered recruitment of enzyme complexes to manipulate DNA.  In this way, histone modifications have the potential to influence many fundamental biol. processes, some of which may be epigenetically inherited.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAH9AX2dGicbVg90H21EOLACvtfcHk0lhyHXwBfz9Hlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis12ju7Y%253D&md5=c5995fe68fd9473f4268d59c01d3b9de</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DKouzarides%26aufirst%3DT.%26atitle%3DChromatin%2520modifications%2520and%2520their%2520function%26jtitle%3DCell%26date%3D2007%26volume%3D128%26spage%3D693%26epage%3D705%26doi%3D10.1016%2Fj.cell.2007.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allis, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernstein, E.</span></span> <span> </span><span class="NLM_article-title">Epigenetics: a landscape takes shape</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">635</span>– <span class="NLM_lpage">638</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2007.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.cell.2007.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=17320500" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis12ju74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2007&pages=635-638&author=A.+D.+Goldbergauthor=C.+D.+Allisauthor=E.+Bernstein&title=Epigenetics%3A+a+landscape+takes+shape&doi=10.1016%2Fj.cell.2007.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Epigenetics: a landscape takes shape</span></div><div class="casAuthors">Goldberg, Aaron D.; Allis, C. David; Bernstein, Emily</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">635-638</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Epigenetics has recently evolved from a collection of diverse phenomena to a defined and far-reaching field of study.  In this Essay, we examine the epistemol. of epigenetics, provide a brief overview of underlying mol. mechanisms, and suggest future challenges for the field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgnXp5dGbNGbVg90H21EOLACvtfcHk0lhyHXwBfz9Hlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis12ju74%253D&md5=ba84473b843a82b90a33bba8adb167eb</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DGoldberg%26aufirst%3DA.%2BD.%26aulast%3DAllis%26aufirst%3DC.%2BD.%26aulast%3DBernstein%26aufirst%3DE.%26atitle%3DEpigenetics%253A%2520a%2520landscape%2520takes%2520shape%26jtitle%3DCell%26date%3D2007%26volume%3D128%26spage%3D635%26epage%3D638%26doi%3D10.1016%2Fj.cell.2007.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirota, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyoshi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kugou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, K.</span></span> <span> </span><span class="NLM_article-title">Stepwise chromatin remodelling by a cascade of transcription initiation of non-coding RNAs</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>456</i></span>,  <span class="NLM_fpage">130</span>, <span class="refDoi"> DOI: 10.1038/nature07348</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fnature07348" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=18820678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlCjt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=456&publication_year=2008&pages=130&author=K.+Hirotaauthor=T.+Miyoshiauthor=K.+Kugouauthor=C.+S.+Hoffmanauthor=T.+Shibataauthor=K.+Ohta&title=Stepwise+chromatin+remodelling+by+a+cascade+of+transcription+initiation+of+non-coding+RNAs&doi=10.1038%2Fnature07348"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Stepwise chromatin remodelling by a cascade of transcription initiation of non-coding RNAs</span></div><div class="casAuthors">Hirota, Kouji; Miyoshi, Tomoichiro; Kugou, Kazuto; Hoffman, Charles S.; Shibata, Takehiko; Ohta, Kunihiro</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">456</span>
        (<span class="NLM_cas:issue">7218</span>),
    <span class="NLM_cas:pages">130-134</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Recent transcriptome analyses using high-d. tiling arrays and data from large-scale analyses of full-length complementary DNA libraries by the FANTOM3 consortium demonstrate that many transcripts are non-coding RNAs (ncRNAs).  These transcriptome analyses indicate that many of the non-coding regions, previously thought to be functionally inert, are actually transcriptionally active regions with various features.  Furthermore, most relatively large (∼several kilobases) polyadenylated mRNA transcripts are transcribed from regions harboring little coding potential.  However, the function of such ncRNAs is mostly unknown and has been a matter of debate.  Here the authors show that RNA polymerase II (RNAPII) transcription of ncRNAs is required for chromatin remodelling at the fission yeast Schizosaccharomyces pombe fbp1+ locus during transcriptional activation.  The chromatin at fbp1+ is progressively converted to an open configuration, as several species of ncRNAs are transcribed through fbp1+.  This is coupled with the translocation of RNAPII through the region upstream of the eventual fbp1+ transcriptional start site.  Insertion of a transcription terminator into this upstream region abolishes both the cascade of transcription of ncRNAs and the progressive chromatin alteration.  These results demonstrate that transcription through the promoter region is required to make DNA sequences accessible to transcriptional activators and to RNAPII.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo77Z6NGnfNgLVg90H21EOLACvtfcHk0liZkfrS0vdlHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlCjt7%252FM&md5=498cb1b8314bd97c4bdc276f7b6639f6</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnature07348&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature07348%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DK.%26aulast%3DMiyoshi%26aufirst%3DT.%26aulast%3DKugou%26aufirst%3DK.%26aulast%3DHoffman%26aufirst%3DC.%2BS.%26aulast%3DShibata%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DK.%26atitle%3DStepwise%2520chromatin%2520remodelling%2520by%2520a%2520cascade%2520of%2520transcription%2520initiation%2520of%2520non-coding%2520RNAs%26jtitle%3DNature%26date%3D2008%26volume%3D456%26spage%3D130%26doi%3D10.1038%2Fnature07348" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hancock, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, K. L.</span></span> <span> </span><span class="NLM_article-title">Regulation of cellular metabolism by protein lysine acetylation</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>327</i></span>,  <span class="NLM_fpage">1000</span>– <span class="NLM_lpage">1004</span>, <span class="refDoi"> DOI: 10.1126/science.1179689</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1126%2Fscience.1179689" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=20167786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitVSjtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2010&pages=1000-1004&author=S.+Zhaoauthor=W.+Xuauthor=W.+Jiangauthor=W.+Yuauthor=Y.+Linauthor=T.+Zhangauthor=J.+Yaoauthor=L.+Zhouauthor=Y.+Zengauthor=H.+Liauthor=Y.+Liauthor=J.+Shiauthor=W.+Anauthor=S.+M.+Hancockauthor=F.+Heauthor=L.+Qinauthor=J.+Chinauthor=P.+Yangauthor=X.+Chenauthor=Q.+Leiauthor=Y.+Xiongauthor=K.+L.+Guan&title=Regulation+of+cellular+metabolism+by+protein+lysine+acetylation&doi=10.1126%2Fscience.1179689"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of cellular metabolism by protein lysine acetylation</span></div><div class="casAuthors">Zhao, Shimin; Xu, Wei; Jiang, Wenqing; Yu, Wei; Lin, Yan; Zhang, Tengfei; Yao, Jun; Zhou, Li; Zeng, Yaxue; Li, Hong; Li, Yixue; Shi, Jiong; An, Wenlin; Hancock, Susan M.; He, Fuchu; Qin, Lunxiu; Chin, Jason; Yang, Pengyuan; Chen, Xian; Lei, Qunying; Xiong, Yue; Guan, Kun-Liang</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">5968</span>),
    <span class="NLM_cas:pages">1000-1004</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Protein Lys acetylation has emerged as a key post-translational modification in cellular regulation, in particular through the modification of histones and nuclear transcription regulators.  Here, the authors show that acetylation of Lys residues is a prevalent modification in enzymes that catalyze intermediate metab.  Virtually every enzyme in glycolysis, gluconeogenesis, the tricarboxylic acid (TCA) cycle, the urea cycle, fatty acid metab., and glycogen metab. was found to be acetylated in human liver tissue.  The concn. of metabolic fuels, such as glucose, amino acids, and fatty acids, influenced the acetylation status of metabolic enzymes.  Acetylation activated enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in fatty acid oxidn. and malate dehydrogenase in the TCA cycle, inhibited argininosuccinate lyase in the urea cycle, and destabilized phosphoenolpyruvate carboxykinase in gluconeogenesis.  Thus, this study revealed that acetylation plays a major role in metabolic regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbdnDsuudXV7Vg90H21EOLACvtfcHk0liZkfrS0vdlHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitVSjtbo%253D&md5=d2c3c897077b9285842a7c55e8f8737e</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1126%2Fscience.1179689&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1179689%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DZeng%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DAn%26aufirst%3DW.%26aulast%3DHancock%26aufirst%3DS.%2BM.%26aulast%3DHe%26aufirst%3DF.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DChin%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DLei%26aufirst%3DQ.%26aulast%3DXiong%26aufirst%3DY.%26aulast%3DGuan%26aufirst%3DK.%2BL.%26atitle%3DRegulation%2520of%2520cellular%2520metabolism%2520by%2520protein%2520lysine%2520acetylation%26jtitle%3DScience%26date%3D2010%26volume%3D327%26spage%3D1000%26epage%3D1004%26doi%3D10.1126%2Fscience.1179689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furumai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Komatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishino, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horinouchi, S.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase as a New Target for Cancer Chemotherapy</span>. <i>Cancer Chemother. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1007/s002800100300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs002800100300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=11587361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD3MXot1Gisb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2001&pages=20-26&author=M.+Yoshidaauthor=R.+Furumaiauthor=M.+Nishiyamaauthor=Y.+Komatsuauthor=N.+Nishinoauthor=S.+Horinouchi&title=Histone+Deacetylase+as+a+New+Target+for+Cancer+Chemotherapy&doi=10.1007%2Fs002800100300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase as a new target for cancer chemotherapy</span></div><div class="casAuthors">Yoshida, Minoru; Furumai, Ryohei; Nishiyama, Makoto; Komatsu, Yasuhiko; Nishino, Norikazu; Horinouchi, Sueharu</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">S20-S26</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">A review.  Trichostatin A (TSA) and trapoxin (TPX), inhibitors of the eukaryotic cell cycle and inducers of morphol. reversion of transformed cells, inhibit histone deacetylase (HDAC) at nanomolar concns.  Recently, FK228 (also known as FR901228 and depsipeptide) and MS-275, antitumor agents structurally unrelated to TSA, have been shown to be potent HDAC inhibitors.  These inhibitors activate the expression of p21Waf1 in a p53-independent manner.  Changes in the expression of regulators of the cell cycle, differentiation, and apoptosis with increased histone acetylation may be responsible for the cell cycle arrest and antitumor activity of HDAC inhibitors.  TSA has been suggested to block the catalytic reaction by chelating a zinc ion in the active site pocket through its hydroxamic acid group.  On the other hand, an epoxyketone has been suggested to be the functional group of TPX capable of alkylating the enzyme.  We synthesized a novel TPX analog contg. a hydroxamic acid instead of the epoxyketone.  The hybrid compd., called cyclic hydroxamic-acid-contg. peptide 1 (CHAP1) inhibited HDAC at low nanomolar concns.  The HDAC1 inhibition by CHAP1 was reversible, as is that by TSA, in contrast to irreversible inhibition by TPX.  Interestingly, HDAC6, but not HDAC1 or HDAC4, was resistant to TPX and CHAP1, while TSA inhibited these HDACs to a similar degree.  CHAP31, the strongest HDAC inhibitor obtained from a variety of CHAP derivs., exhibited antitumor activity in BDF1 mice bearing B16/BL6 tumor cells.  These results suggest that CHAP31 is promising as a novel therapeutic agent for cancer treatment, and that CHAP may serve as a basis for new HDAC inhibitors and be useful for combinatorial synthesis and high-throughput screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5hFVbRKsj-7Vg90H21EOLACvtfcHk0liZkfrS0vdlHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXot1Gisb4%253D&md5=e99fb4ca4f204f861bcda050bdd88c16</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1007%2Fs002800100300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs002800100300%26sid%3Dliteratum%253Aachs%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DFurumai%26aufirst%3DR.%26aulast%3DNishiyama%26aufirst%3DM.%26aulast%3DKomatsu%26aufirst%3DY.%26aulast%3DNishino%26aufirst%3DN.%26aulast%3DHorinouchi%26aufirst%3DS.%26atitle%3DHistone%2520Deacetylase%2520as%2520a%2520New%2520Target%2520for%2520Cancer%2520Chemotherapy%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2001%26volume%3D48%26spage%3D20%26epage%3D26%26doi%3D10.1007%2Fs002800100300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shakespear, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halili, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, M. J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases as regulators of inflammation and immunity</span>. <i>Trends Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1016/j.it.2011.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.it.2011.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=21570914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFagt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=335-343&author=M.+R.+Shakespearauthor=M.+A.+Haliliauthor=K.+M.+Irvineauthor=D.+P.+Fairlieauthor=M.+J.+Sweet&title=Histone+deacetylases+as+regulators+of+inflammation+and+immunity&doi=10.1016%2Fj.it.2011.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases as regulators of inflammation and immunity</span></div><div class="casAuthors">Shakespear, Melanie R.; Halili, Maria A.; Irvine, Katharine M.; Fairlie, David P.; Sweet, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">335-343</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) remove an acetyl group from lysine residues of target proteins to regulate cellular processes.  Small-mol. inhibitors of HDACs cause cellular growth arrest, differentiation and/or apoptosis, and some are used clin. as anticancer drugs.  In animal models, HDAC inhibitors are therapeutic for several inflammatory diseases, but exacerbate atherosclerosis and compromise host defense.  Loss of HDAC function has also been linked to chronic lung diseases in humans.  These contrasting effects might reflect distinct roles for individual HDACs in immune responses.  Here, we review the current understanding of innate and adaptive immune pathways that are regulated by classical HDAC enzymes.  The objective is to provide a rationale for targeting (or not targeting) individual HDAC enzymes with inhibitors for future immune-related applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMfUdRVPPTGrVg90H21EOLACvtfcHk0ljq6UquXGiaqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFagt7s%253D&md5=b99eac5fe3487afc612c501162a51fca</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2011.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2011.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DShakespear%26aufirst%3DM.%2BR.%26aulast%3DHalili%26aufirst%3DM.%2BA.%26aulast%3DIrvine%26aufirst%3DK.%2BM.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26aulast%3DSweet%26aufirst%3DM.%2BJ.%26atitle%3DHistone%2520deacetylases%2520as%2520regulators%2520of%2520inflammation%2520and%2520immunity%26jtitle%3DTrends%2520Immunol.%26date%3D2011%26volume%3D32%26spage%3D335%26epage%3D343%26doi%3D10.1016%2Fj.it.2011.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bagchi, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weeks, K. L.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylases in cardiovascular and metabolic diseases</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2019.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.yjmcc.2019.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30978343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsVequ74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2019&pages=151-159&author=R.+A.+Bagchiauthor=K.+L.+Weeks&title=Histone+deacetylases+in+cardiovascular+and+metabolic+diseases&doi=10.1016%2Fj.yjmcc.2019.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases in cardiovascular and metabolic diseases</span></div><div class="casAuthors">Bagchi, Rushita A.; Weeks, Kate L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-159</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) regulate gene transcription by catalyzing the removal of acetyl groups from key lysine residues in nucleosomal histones and via the recruitment of other epigenetic regulators to DNA promoter/enhancer regions.  Over the past two decades, HDACs have been implicated in multiple processes pertinent to cardiovascular and metabolic diseases, including cardiac hypertrophy and remodeling, fibrosis, calcium handling, inflammation and energy metab.  The development of small mol. HDAC inhibitors and genetically modified loss- and gain-of-function mouse models has allowed interrogation of the roles of specific HDAC isoforms in these processes.  Isoform-selective HDAC inhibitors may prove to be powerful therapeutic agents for the treatment of cardiovascular diseases, obesity and diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwzAygsk0c0bVg90H21EOLACvtfcHk0ljq6UquXGiaqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsVequ74%253D&md5=e023d2e22d069b9e69f6e6457d15005e</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2019.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2019.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DBagchi%26aufirst%3DR.%2BA.%26aulast%3DWeeks%26aufirst%3DK.%2BL.%26atitle%3DHistone%2520deacetylases%2520in%2520cardiovascular%2520and%2520metabolic%2520diseases%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2019%26volume%3D130%26spage%3D151%26epage%3D159%26doi%3D10.1016%2Fj.yjmcc.2019.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, A. H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, A.</span></span> <span> </span><span class="NLM_article-title">Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">12460</span>– <span class="NLM_lpage">12484</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00830</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00830" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSisrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=12460-12484&author=T.+C.+S.+Hoauthor=A.+H.+Y.+Chanauthor=A.+Ganesan&title=Thirty+Years+of+HDAC+Inhibitors%3A+2020+Insight+and+Hindsight&doi=10.1021%2Facs.jmedchem.0c00830"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight</span></div><div class="casAuthors">Ho, Terence C. S.; Chan, Alex H. Y.; Ganesan, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">12460-12484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  It is now 30 years since the first report of a potent zinc-dependent histone deacetylase (HDAC) inhibitor appeared.  Since then, five HDAC inhibitors have received regulatory approval for cancer chemotherapy while many others are in clin. development for oncol. as well as other therapeutic indications.  This Perspective reviews the biol. and medicinal chem. advances over the past 3 decades with an emphasis on the design of selective inhibitors that discriminate between the 11 human HDAC isoforms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrES4d2gbkB17Vg90H21EOLACvtfcHk0ljq6UquXGiaqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSisrzP&md5=1deb2ad5787797a9ee98dcf7bdade52c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00830&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00830%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DT.%2BC.%2BS.%26aulast%3DChan%26aufirst%3DA.%2BH.%2BY.%26aulast%3DGanesan%26aufirst%3DA.%26atitle%3DThirty%2520Years%2520of%2520HDAC%2520Inhibitors%253A%25202020%2520Insight%2520and%2520Hindsight%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D12460%26epage%3D12484%26doi%3D10.1021%2Facs.jmedchem.0c00830" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marmorstein, R.</span></span> <span> </span><span class="NLM_article-title">Structural basis for sirtuin activity and inhibition</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">42428</span>– <span class="NLM_lpage">42435</span>, <span class="refDoi"> DOI: 10.1074/jbc.R112.372300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1074%2Fjbc.R112.372300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=23086949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVeksb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=42428-42435&author=H.+Yuanauthor=R.+Marmorstein&title=Structural+basis+for+sirtuin+activity+and+inhibition&doi=10.1074%2Fjbc.R112.372300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for Sirtuin Activity and Inhibition</span></div><div class="casAuthors">Yuan, Hua; Marmorstein, Ronen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">42428-42435</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  Sir2 proteins, or sirtuins, are a family of enzymes that catalyze NAD+-dependent deacetylation reactions and can also process ribosyltransferase, demalonylase, and desuccinylase activities.  More than 40 crystal structures of sirtuins have been detd., alone or in various liganded forms.  These high-resoln. architectural details lay the foundation for understanding the mol. mechanisms of catalysis, regulation, substrate specificity, and inhibition of sirtuins.  In this minireview, we summarize these structural features and discuss their implications for understanding sirtuin function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreG2RWpBd2ILVg90H21EOLACvtfcHk0lhlW9nygpgOjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVeksb%252FM&md5=c20a154f55db917407f1a1b58edf95fd</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1074%2Fjbc.R112.372300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.R112.372300%26sid%3Dliteratum%253Aachs%26aulast%3DYuan%26aufirst%3DH.%26aulast%3DMarmorstein%26aufirst%3DR.%26atitle%3DStructural%2520basis%2520for%2520sirtuin%2520activity%2520and%2520inhibition%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D42428%26epage%3D42435%26doi%3D10.1074%2Fjbc.R112.372300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. S.</span></span> <span> </span><span class="NLM_article-title">Targeting histone deacetylase in cancer therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1002/med.20056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fmed.20056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=16450343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFaltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=397-413&author=H.+Y.+Linauthor=C.+S.+Chenauthor=S.+P.+Linauthor=J.+R.+Wengauthor=C.+S.+Chen&title=Targeting+histone+deacetylase+in+cancer+therapy&doi=10.1002%2Fmed.20056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylase in cancer therapy</span></div><div class="casAuthors">Lin, Hsiang-Yu; Chen, Chang-Shi; Lin, Shuan-Pei; Weng, Jing-Ru; Chen, Ching-Shih</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">397-413</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) is recognized as one of the promising targets for cancer treatment as many HDAC inhibitors have entered clin. trials for both solid and liq. tumors.  Nevertheless, the mechanisms underlying the antiproliferative effects of HDAC inhibitors remain elusive.  Although they have been shown to regulate the transcription of a defined set of genes through chromatin remodeling, increasing evidence suggests that modifications of the epigenetic histone code may not be the primary mechanism for HDAC inhibitor-mediated growth inhibition and apoptosis in cancer cells.  While histones still represent a primary target for the physiol. function of HDACs, the antitumor effect of HDAC inhibitors might also be attributed to transcription-independent mechanisms by modulating the acetylation status of a series of nonhistone targets.  Also noteworthy is the effect of HDAC inhibitors on Akt downregulation through the alteration of protein phosphatase 1 (PP1) complex formation.  To provide an overview of the use of HDAC inhibitors in cancer treatment, this review addresses the following subjects: (1) the physiol. relevance of HDAC-mediated acetylation of histone and nonhistone substrates, (2) the chem. biol. of HDACs and development of a novel class of HDAC inhibitors, and (3) the protein acetylation-independent effect of HDAC inhibitors on the activation status of signaling kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsa6h2NkYnN7Vg90H21EOLACvtfcHk0lhlW9nygpgOjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFaltrc%253D&md5=4d663196ac8258cd0e079b47761f3128</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fmed.20056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20056%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%2BY.%26aulast%3DChen%26aufirst%3DC.%2BS.%26aulast%3DLin%26aufirst%3DS.%2BP.%26aulast%3DWeng%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DC.%2BS.%26atitle%3DTargeting%2520histone%2520deacetylase%2520in%2520cancer%2520therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2006%26volume%3D26%26spage%3D397%26epage%3D413%26doi%3D10.1002%2Fmed.20056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span> <span> </span><span class="NLM_article-title">Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China</span>. <i>Intractable Rare Dis. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.5582/irdr.2016.01024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.5582%2Firdr.2016.01024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27672541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BC2svkt1Cnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=185-191&author=X.+Luauthor=Z.+Ningauthor=Z.+Liauthor=H.+Caoauthor=X.+Wang&title=Development+of+chidamide+for+peripheral+T-cell+lymphoma%2C+the+first+orphan+drug+approved+in+China&doi=10.5582%2Firdr.2016.01024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China</span></div><div class="casAuthors">Lu Xianping; Ning Zhiqiang; Li Zhibin; Cao Haixiang; Wang Xinhao</div><div class="citationInfo"><span class="NLM_cas:title">Intractable & rare diseases research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">185-91</span>
        ISSN:<span class="NLM_cas:issn">2186-3644</span>.
    </div><div class="casAbstract">Peripheral T-cell lymphoma (PTCL) is a set of rare and highly heterogeneous group of mature T- and NK-cell neoplasms associated with poor outcomes and lack of standard and effective therapies.  The total number of newly diagnosed cases of PTCL yearly in China is estimated about 50,000.  Chidamide (CS055) is a novel and orally active benzamide class of histone deacetylase (HDAC) inhibitor that selectively inhibits activity of HDAC1, 2, 3 and 10, the enzymes that are involved and play an important role in tumor initiation and development in both tumor cells and their surrounding micro-environment.  Functioning as a genuine epigenetic modulator, chidamide induces growth arrest and apoptosis in tumor cells and enhances cellular antitumor immunity.  Based on the overall results from preclinical and phase I clinical studies, exploratory and pivotal phase II trials of chidamide for relapsed or refractory PTCL were conducted from March 2009 to May 2012, and the results led to CFDA approval of chidamide for the indication in December 2014, being the first approved orphan drug according to the research & development approach of orphan drugs in China, as well as the first orally active drug for PTCL in China and worldwide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSsI-YolguuyLP3FVUi_gf8fW6udTcc2eY8tN7jQflo-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2svkt1Cnsg%253D%253D&md5=5c1f310ea15bb4a706f54d5fdc55c7d5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.5582%2Firdr.2016.01024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.5582%252Firdr.2016.01024%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DX.%26aulast%3DNing%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DCao%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDevelopment%2520of%2520chidamide%2520for%2520peripheral%2520T-cell%2520lymphoma%252C%2520the%2520first%2520orphan%2520drug%2520approved%2520in%2520China%26jtitle%3DIntractable%2520Rare%2520Dis.%2520Res.%26date%3D2016%26volume%3D5%26spage%3D185%26epage%3D191%26doi%3D10.5582%2Firdr.2016.01024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duvic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talpur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazarika, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiao, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ricker, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, S. R.</span></span> <span> </span><span class="NLM_article-title">Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1182/blood-2006-06-025999</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1182%2Fblood-2006-06-025999" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=16960145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivVyrt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2007&pages=31-39&author=M.+Duvicauthor=R.+Talpurauthor=X.+Niauthor=C.+Zhangauthor=P.+Hazarikaauthor=C.+Kellyauthor=J.+H.+Chiaoauthor=J.+F.+Reillyauthor=J.+L.+Rickerauthor=V.+M.+Richonauthor=S.+R.+Frankel&title=Phase+2+trial+of+oral+vorinostat+%28suberoylanilide+hydroxamic+acid%2C+SAHA%29+for+refractory+cutaneous+T-cell+lymphoma+%28CTCL%29&doi=10.1182%2Fblood-2006-06-025999"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)</span></div><div class="casAuthors">Duvic, Madeleine; Talpur, Rakshandra; Ni, Xiao; Zhang, Chunlei; Hazarika, Parul; Kelly, Cecilia; Chiao, Judy H.; Reilly, John F.; Ricker, Justin L.; Richon, Victoria M.; Frankel, Stanley R.</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-39</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The activity and safety of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) were evaluated in patients with refractory cutaneous T-cell lymphoma (CTCL).  Group 1 received vorinostat 400 mg daily, group 2 received vorinostat 300 mg twice daily for 3 days with 4 days rest, and group 3 received vorinostat 300 mg twice daily for 14 days with 7 days rest followed by 200 mg twice daily.  Treatment continued until disease progression or intolerable toxicity.  The primary objective was to det. the complete and partial response (PR) rate.  Time to response (TTR), time to progressive disease (TTP), response duration (DOR), pruritus relief, and safety were detd.  Thirty-three patients who had received a median of 5 prior therapies were enrolled.  Eight patients achieved a PR, including 7 with advanced disease and 4 with Sezary syndrome.  The median TTR, DOR, and TTP for responders were 11.9, 15.1, and 30.2 wk, resp.  Fourteen of 31 evaluable patients had pruritus relief.  The most common drug-related AEs were fatigue, thrombocytopenia, diarrhea, and nausea.  The most common grade 3 or 4 drug-related AEs were thrombocytopenia and dehydration.  Vorinostat demonstrated activity in heavily pretreated patients with CTCL.  The 400 mg daily regimen had the most favorable safety profile and is being further evaluated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo80_rNvPEEgLVg90H21EOLACvtfcHk0lhDgXttzs_hOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivVyrt7g%253D&md5=b4c8b3c20213eaf692bd9b44266d045f</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1182%2Fblood-2006-06-025999&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2006-06-025999%26sid%3Dliteratum%253Aachs%26aulast%3DDuvic%26aufirst%3DM.%26aulast%3DTalpur%26aufirst%3DR.%26aulast%3DNi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHazarika%26aufirst%3DP.%26aulast%3DKelly%26aufirst%3DC.%26aulast%3DChiao%26aufirst%3DJ.%2BH.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DRicker%26aufirst%3DJ.%2BL.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DFrankel%26aufirst%3DS.%2BR.%26atitle%3DPhase%25202%2520trial%2520of%2520oral%2520vorinostat%2520%2528suberoylanilide%2520hydroxamic%2520acid%252C%2520SAHA%2529%2520for%2520refractory%2520cutaneous%2520T-cell%2520lymphoma%2520%2528CTCL%2529%26jtitle%3DBlood%26date%3D2007%26volume%3D109%26spage%3D31%26epage%3D39%26doi%3D10.1182%2Fblood-2006-06-025999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">DeAngelo, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesa, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiskus, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tefferi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wadleigh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritchie, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Begna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ondovik, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhalla, K. N.</span></span> <span> </span><span class="NLM_article-title">Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis</span>. <i>Br. J. Haematol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">326</span>– <span class="NLM_lpage">335</span>, <span class="refDoi"> DOI: 10.1111/bjh.12384</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1111%2Fbjh.12384" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=23701016" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2013&pages=326-335&author=D.+J.+DeAngeloauthor=R.+A.+Mesaauthor=W.+Fiskusauthor=A.+Tefferiauthor=C.+Paleyauthor=M.+Wadleighauthor=E.+K.+Ritchieauthor=D.+S.+Snyderauthor=K.+Begnaauthor=S.+Gangulyauthor=M.+S.+Ondovikauthor=J.+Rineauthor=K.+N.+Bhalla&title=Phase+II+trial+of+panobinostat%2C+an+oral+pan-deacetylase+inhibitor+in+patients+with+primary+myelofibrosis%2C+post-essential+thrombocythaemia%2C+and+post-polycythaemia+vera+myelofibrosis&doi=10.1111%2Fbjh.12384"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis</span></div><div class="casAuthors">DeAngelo, Daniel J.; Mesa, Ruben A.; Fiskus, Warren; Tefferi, Ayalew; Paley, Carole; Wadleigh, Martha; Ritchie, Ellen K.; Snyder, David S.; Begna, Kebede; Ganguly, Siddhartha; Ondovik, Michael S.; Rine, Jessica; Bhalla, Kapil N.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Haematology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">326-335</span>CODEN:
                <span class="NLM_cas:coden">BJHEAL</span>;
        ISSN:<span class="NLM_cas:issn">0007-1048</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Myelofibrosis (MF) is a Philadelphia chromosome-neg. stem cell myeloproliferative neoplasm (MPN) assocd. with cytopenias, splenomegaly, constitutional symptoms, and poor prognosis.  MF patients commonly express JAK2V617F mutation and activation of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signalling.  Agents targeting the JAK/STAT pathway have demonstrated efficacy in patients with MF.  This study evaluated panobinostat, a pan-deacetylase inhibitor that depletes JAK2 V617F levels and JAK/STAT signalling in MPN cells, in patients with primary MF, post-essential thrombocythemia MF, and post-polycythemia vera MF.  Patients received panobinostat 40 mg administered three times per wk.  Dose redns. were permitted for toxicities.  The primary endpoint was response rate at 6 mo using International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) consensus criteria.  Analyses of peripheral blood cells from treated patients revealed that panobinostat inhibited JAK/STAT signalling, decreased inflammatory cytokine levels, and decreased JAK2V617F allelic burden.  However, panobinostat was poorly tolerated at the dose and schedule evaluated, and only 16 of 35 patients completed ≥2 cycles of treatment.  One patient (3%) achieved an IWG-MRT response.  Common adverse events were thrombocytopenia (71·4%) and diarrhoea (80·0%).  Although mol. correlative analyses suggested that panobinostat inhibits key intracellular targets, limited clin. activity was obsd. because of poor tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotDmgamqFK27Vg90H21EOLACvtfcHk0lhDgXttzs_hOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFSrtLnM&md5=584d6afad24b34f916f2120247c2a246</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fbjh.12384&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbjh.12384%26sid%3Dliteratum%253Aachs%26aulast%3DDeAngelo%26aufirst%3DD.%2BJ.%26aulast%3DMesa%26aufirst%3DR.%2BA.%26aulast%3DFiskus%26aufirst%3DW.%26aulast%3DTefferi%26aufirst%3DA.%26aulast%3DPaley%26aufirst%3DC.%26aulast%3DWadleigh%26aufirst%3DM.%26aulast%3DRitchie%26aufirst%3DE.%2BK.%26aulast%3DSnyder%26aufirst%3DD.%2BS.%26aulast%3DBegna%26aufirst%3DK.%26aulast%3DGanguly%26aufirst%3DS.%26aulast%3DOndovik%26aufirst%3DM.%2BS.%26aulast%3DRine%26aufirst%3DJ.%26aulast%3DBhalla%26aufirst%3DK.%2BN.%26atitle%3DPhase%2520II%2520trial%2520of%2520panobinostat%252C%2520an%2520oral%2520pan-deacetylase%2520inhibitor%2520in%2520patients%2520with%2520primary%2520myelofibrosis%252C%2520post-essential%2520thrombocythaemia%252C%2520and%2520post-polycythaemia%2520vera%2520myelofibrosis%26jtitle%3DBr.%2520J.%2520Haematol.%26date%3D2013%26volume%3D162%26spage%3D326%26epage%3D335%26doi%3D10.1111%2Fbjh.12384" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roche, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, P.</span></span> <span> </span><span class="NLM_article-title">Inside HDACs with more selective HDAC inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>121</i></span>,  <span class="NLM_fpage">451</span>– <span class="NLM_lpage">483</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.05.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2016.05.047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27318122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVWns7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=121&publication_year=2016&pages=451-483&author=J.+Rocheauthor=P.+Bertrand&title=Inside+HDACs+with+more+selective+HDAC+inhibitors&doi=10.1016%2Fj.ejmech.2016.05.047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inside HDACs with more selective HDAC inhibitors</span></div><div class="casAuthors">Roche, Joelle; Bertrand, Philippe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">121</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">451-483</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Inhibitors of histone deacetylases (HDACs) are nowadays part of the therapeutic arsenal mainly against cancers, with four compds. approved by the Food and Drug Administration.  During the last five years, several groups have made continuous efforts to improve this class of compds., designing more selective compds. or compds. with multiple capacities.  After a survey of the HDAC biol. and structures, this review summarizes the results of the chemists working in this field, and highlights when possible the behavior of the mols. inside their targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHO5YBuaN7c7Vg90H21EOLACvtfcHk0lhDgXttzs_hOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVWns7%252FI&md5=3bbd062c1fb8a402c039e20bacd4af14</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.05.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.05.047%26sid%3Dliteratum%253Aachs%26aulast%3DRoche%26aufirst%3DJ.%26aulast%3DBertrand%26aufirst%3DP.%26atitle%3DInside%2520HDACs%2520with%2520more%2520selective%2520HDAC%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D121%26spage%3D451%26epage%3D483%26doi%3D10.1016%2Fj.ejmech.2016.05.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grozinger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassig, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span> <span> </span><span class="NLM_article-title">Three proteins define a class of human histone deacetylases related to yeast Hda1p</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">4868</span>– <span class="NLM_lpage">4873</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.9.4868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1073%2Fpnas.96.9.4868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10220385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADyaK1MXjtVKms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=4868-4873&author=C.+M.+Grozingerauthor=C.+A.+Hassigauthor=S.+L.+Schreiber&title=Three+proteins+define+a+class+of+human+histone+deacetylases+related+to+yeast+Hda1p&doi=10.1073%2Fpnas.96.9.4868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Three proteins define a class of human histone deacetylases related to yeast Hda1p</span></div><div class="casAuthors">Grozinger, Christina M.; Hassig, Christian A.; Schreiber, Stuart L.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4868-4873</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Gene expression is in part controlled by chromatin remodeling factors and the acetylation state of nucleosomal histones.  The latter process is regulated by histone acetyltransferases and histone deacetylases (HDACs).  Previously, three human and five yeast HDAC enzymes had been identified.  These can be categorized into two classes: the first class represented by yeast Rpd3-like proteins and the second by yeast Hda1-like proteins.  Human HDAC1, HDAC2, and HDAC3 proteins are members of the first class, whereas no class II human HDAC proteins had been identified.  The amino acid sequence of Hda1p was used to search the GenBank/expressed sequence tag databases to identify partial sequences from three putative class II human HDAC proteins.  The corresponding full-length cDNAs were cloned and defined as HDAC4, HDAC5, and HDAC6.  These proteins possess certain features present in the conserved catalytic domains of class I human HDACs, but also contain addnl. sequence domains.  Interestingly, HDAC6 contains an internal duplication of two catalytic domains, which appear to function independently of each other.  These class II HDAC proteins have differential mRNA expression in human tissues and possess in vitro HDAC activity that is inhibited by trichostatin A.  Coimmunopptn. expts. indicate that these HDAC proteins are not components of the previously identified HDAC1 and HDAC2 NRD and mSin3A complexes.  However, HDAC4 and HDAC5 assoc. with HDAC3 in vivo.  This finding suggests that the human class II HDAC enzymes may function in cellular processes distinct from those of HDAC1 and HDAC2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcejIcOOdQtrVg90H21EOLACvtfcHk0lgQRbe-ADjf2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtVKms7s%253D&md5=923a1617e1ed850f39fb5247e6baf14f</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.9.4868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.9.4868%26sid%3Dliteratum%253Aachs%26aulast%3DGrozinger%26aufirst%3DC.%2BM.%26aulast%3DHassig%26aufirst%3DC.%2BA.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26atitle%3DThree%2520proteins%2520define%2520a%2520class%2520of%2520human%2520histone%2520deacetylases%2520related%2520to%2520yeast%2520Hda1p%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D4868%26epage%3D4873%26doi%3D10.1073%2Fpnas.96.9.4868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ouyang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravichandran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacKenzie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhe-Paganon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, R. G.</span></span> <span> </span><span class="NLM_article-title">Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>287</i></span>,  <span class="NLM_fpage">2317</span>– <span class="NLM_lpage">2327</span>, <span class="refDoi"> DOI: 10.1074/jbc.M111.273730</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1074%2Fjbc.M111.273730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=22069321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC38XpslKqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=287&publication_year=2012&pages=2317-2327&author=H.+Ouyangauthor=Y.+O.+Aliauthor=M.+Ravichandranauthor=A.+Dongauthor=W.+Qiuauthor=F.+MacKenzieauthor=S.+Dhe-Paganonauthor=C.+H.+Arrowsmithauthor=R.+G.+Zhai&title=Protein+aggregates+are+recruited+to+aggresome+by+histone+deacetylase+6+via+unanchored+ubiquitin+C+termini&doi=10.1074%2Fjbc.M111.273730"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Aggregates Are Recruited to Aggresome by Histone Deacetylase 6 via Unanchored Ubiquitin C Termini</span></div><div class="casAuthors">Ouyang, Hui; Ali, Yousuf O.; Ravichandran, Mani; Dong, Aiping; Qiu, Wei; MacKenzie, Farrell; Dhe-Paganon, Sirano; Arrowsmith, Cheryl H.; Zhai, R. Grace</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">287</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2317-2327</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The aggresome pathway is activated when proteasomal clearance of misfolded proteins is hindered.  Misfolded polyubiquitinated protein aggregates are recruited and transported to the aggresome via the microtubule network by a protein complex consisting of histone deacetylase 6 (HDAC6) and the dynein motor complex.  The current model suggests that HDAC6 recognizes protein aggregates by binding directly to polyubiquitinated proteins.  Here, we show that there are substantial amts. of unanchored ubiquitin in protein aggregates with solvent-accessible C termini.  The ubiquitin-binding domain (ZnF-UBP) of HDAC6 binds exclusively to the unanchored C-terminal diglycine motif of ubiquitin instead of conjugated polyubiquitin.  The unanchored ubiquitin C termini in the aggregates are generated in situ by aggregate-assocd. deubiquitinase ataxin-3.  These results provide structural and mechanistic bases for the role of HDAC6 in aggresome formation and further suggest a novel ubiquitin-mediated signaling pathway, where the exposure of ubiquitin C termini within protein aggregates enables HDAC6 recognition and transport to the aggresome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4RKfc994fbbVg90H21EOLACvtfcHk0lgQRbe-ADjf2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpslKqsQ%253D%253D&md5=1ee8c5479d3936c2da903f023ba9f091</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M111.273730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M111.273730%26sid%3Dliteratum%253Aachs%26aulast%3DOuyang%26aufirst%3DH.%26aulast%3DAli%26aufirst%3DY.%2BO.%26aulast%3DRavichandran%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DA.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DMacKenzie%26aufirst%3DF.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26aulast%3DZhai%26aufirst%3DR.%2BG.%26atitle%3DProtein%2520aggregates%2520are%2520recruited%2520to%2520aggresome%2520by%2520histone%2520deacetylase%25206%2520via%2520unanchored%2520ubiquitin%2520C%2520termini%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2012%26volume%3D287%26spage%3D2317%26epage%3D2327%26doi%3D10.1074%2Fjbc.M111.273730" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubbert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guardiola, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawaguchi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nixon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T. P.</span></span> <span> </span><span class="NLM_article-title">HDAC6 is a microtubule-associated deacetylase</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>417</i></span>,  <span class="NLM_fpage">455</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1038/417455a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2F417455a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=12024216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=455-458&author=C.+Hubbertauthor=A.+Guardiolaauthor=R.+Shaoauthor=Y.+Kawaguchiauthor=A.+Itoauthor=A.+Nixonauthor=M.+Yoshidaauthor=X.+F.+Wangauthor=T.+P.+Yao&title=HDAC6+is+a+microtubule-associated+deacetylase&doi=10.1038%2F417455a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 is a microtubule-associated deacetylase</span></div><div class="casAuthors">Hubbert, Charlotte; Guardiola, Amaris; Shao, Rong; Kawaguchi, Yoshiharu; Ito, Akihiro; Nixon, Andrew; Yoshida, Minoru; Wang, Xiao-Fan; Yao, Tso-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6887</span>),
    <span class="NLM_cas:pages">455-458</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Reversible acetylation of α-tubulin has been implicated in regulating microtubule stability and function.  The distribution of acetylated α-tubulin is tightly controlled and stereotypic.  Acetylated α-tubulin is most abundant in stable microtubules but is absent from dynamic cellular structures such as neuronal growth cones and the leading edges of fibroblasts.  However, the enzymes responsible for regulating tubulin acetylation and deacetylation are not known.  Here we report that a member of the histone deacetylase family, HDAC6, functions as a tubulin deacetylase.  HDAC6 is localized exclusively in the cytoplasm, where it assocs. with microtubules and localizes with the microtubule motor complex contg. p150glued.  In vivo, the overexpression of HDAC6 leads to a global deacetylation of α-tubulin, whereas a decrease in HDAC6 increases α-tubulin acetylation.  In vitro, purified HDAC6 potently deacetylates α-tubulin in assembled microtubules.  Furthermore, overexpression of HDAC6 promotes chemotactic cell movement, supporting the idea that HDAC6-mediated deacetylation regulates microtubule-dependent cell motility.  Our results show that HDAC6 is the tubulin deacetylase, and provide evidence that reversible acetylation regulates important biol. processes beyond histone metab. and gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp76Er3MrWtO7Vg90H21EOLACvtfcHk0lgQRbe-ADjf2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvVersr4%253D&md5=f18cbb0af388925c606e822358ba3da6</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2F417455a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F417455a%26sid%3Dliteratum%253Aachs%26aulast%3DHubbert%26aufirst%3DC.%26aulast%3DGuardiola%26aufirst%3DA.%26aulast%3DShao%26aufirst%3DR.%26aulast%3DKawaguchi%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DA.%26aulast%3DNixon%26aufirst%3DA.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%2BF.%26aulast%3DYao%26aufirst%3DT.%2BP.%26atitle%3DHDAC6%2520is%2520a%2520microtubule-associated%2520deacetylase%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D455%26epage%3D458%26doi%3D10.1038%2F417455a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cook, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlomagno, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendron, T. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunmore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeTure, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petrucelli, L.</span></span> <span> </span><span class="NLM_article-title">Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance</span>. <i>Hum. Mol. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">116</span>, <span class="refDoi"> DOI: 10.1093/hmg/ddt402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1093%2Fhmg%2Fddt402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=23962722" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFegsL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=104-116&author=C.+Cookauthor=Y.+Carlomagnoauthor=T.+F.+Gendronauthor=J.+Dunmoreauthor=K.+Scheffelauthor=C.+Stetlerauthor=M.+Davisauthor=D.+Dicksonauthor=M.+Jarpeauthor=M.+DeTureauthor=L.+Petrucelli&title=Acetylation+of+the+KXGS+motifs+in+tau+is+a+critical+determinant+in+modulation+of+tau+aggregation+and+clearance&doi=10.1093%2Fhmg%2Fddt402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance</span></div><div class="casAuthors">Cook, Casey; Carlomagno, Yari; Gendron, Tania F.; Dunmore, Judy; Scheffel, Kristyn; Stetler, Caroline; Davis, Mary; Dickson, Dennis; Jarpe, Matthew; DeTure, Michael; Petrucelli, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Human Molecular Genetics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-116</span>CODEN:
                <span class="NLM_cas:coden">HMGEE5</span>;
        ISSN:<span class="NLM_cas:issn">0964-6906</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The accumulation of hyperphosphorylated tau in neurofibrillary tangles (NFTs) is a neuropathol. hallmark of tauopathies, including Alzheimer's disease (AD) and chronic traumatic encephalopathy, but effective therapies directly targeting the tau protein are currently lacking.  Herein, the authors describe a novel mechanism in which the acetylation of tau on KXGS motifs inhibits phosphorylation on this same motif, and also prevents tau aggregation.  Using a site-specific antibody to detect acetylation of KXGS motifs, the authors demonstrate that these sites are hypoacetylated in patients with AD, as well as a mouse model of tauopathy, suggesting that loss of acetylation on KXGS motifs renders tau vulnerable to pathogenic insults.  Furthermore, the authors identify histone deacetylase 6 (HDAC6) as the enzyme responsible for the deacetylation of these residues, and provide proof of concept that acute treatment with a selective and blood-brain barrier-permeable HDAC6 inhibitor enhances acetylation and decreases phosphorylation on tau's KXGS motifs in vivo.  As such, the authors have uncovered a novel therapeutic pathway that can be manipulated to block the formation of pathogenic tau species in disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSzT8uddBwVLVg90H21EOLACvtfcHk0ljh8Zz18f3coA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFegsL3P&md5=fea73049a2ab19c87f56b174d66691cf</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1093%2Fhmg%2Fddt402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fhmg%252Fddt402%26sid%3Dliteratum%253Aachs%26aulast%3DCook%26aufirst%3DC.%26aulast%3DCarlomagno%26aufirst%3DY.%26aulast%3DGendron%26aufirst%3DT.%2BF.%26aulast%3DDunmore%26aufirst%3DJ.%26aulast%3DScheffel%26aufirst%3DK.%26aulast%3DStetler%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DM.%26aulast%3DDickson%26aufirst%3DD.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3DDeTure%26aufirst%3DM.%26aulast%3DPetrucelli%26aufirst%3DL.%26atitle%3DAcetylation%2520of%2520the%2520KXGS%2520motifs%2520in%2520tau%2520is%2520a%2520critical%2520determinant%2520in%2520modulation%2520of%2520tau%2520aggregation%2520and%2520clearance%26jtitle%3DHum.%2520Mol.%2520Genet.%26date%3D2014%26volume%3D23%26spage%3D104%26epage%3D116%26doi%3D10.1093%2Fhmg%2Fddt402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salas-Burgos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koomen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olashaw, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parsons, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dent, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">HDAC6 modulates cell motility by altering the acetylation level of cortactin</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2007.05.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.molcel.2007.05.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=17643370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFamtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2007&pages=197-213&author=X.+Zhangauthor=Z.+Yuanauthor=Y.+Zhangauthor=S.+Yongauthor=A.+Salas-Burgosauthor=J.+Koomenauthor=N.+Olashawauthor=J.+T.+Parsonsauthor=X.+J.+Yangauthor=S.+R.+Dentauthor=T.+P.+Yaoauthor=W.+S.+Laneauthor=E.+Seto&title=HDAC6+modulates+cell+motility+by+altering+the+acetylation+level+of+cortactin&doi=10.1016%2Fj.molcel.2007.05.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 modulates cell motility by altering the acetylation level of cortactin</span></div><div class="casAuthors">Zhang, Xiaohong; Yuan, Zhigang; Zhang, Yingtao; Yong, Sarah; Salas-Burgos, Alexis; Koomen, John; Olashaw, Nancy; Parsons, J. Thomas; Yang, Xiang-Jiao; Dent, Sharon R.; Yao, Tso-Pang; Lane, William S.; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">197-213</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is a tubulin-specific deacetylase that regulates microtubule-dependent cell movement.  In this study, we identify the F-actin-binding protein cortactin as a HDAC6 substrate.  We demonstrate that HDAC6 binds cortactin and that overexpression of HDAC6 leads to hypoacetylation of cortactin, whereas inhibition of HDAC6 activity leads to cortactin hyperacetylation.  HDAC6 alters the ability of cortactin to bind F-actin by modulating a "charge patch" in its repeat region.  Introduction of charge-preserving or charge-neutralizing mutations in this cortactin repeat region correlates with the gain or loss of F-actin binding ability, resp.  Cells expressing a charge-neutralizing cortactin mutant were less motile than control cells or cells expressing a charge-preserving mutant.  These findings suggest that, in addn. to its role in microtubule-dependent cell motility, HDAC6 influences actin-dependent cell motility by altering the acetylation status of cortactin, which, in turn, changes the F-actin binding activity of cortactin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQSM-mAzzZOrVg90H21EOLACvtfcHk0ljh8Zz18f3coA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFamtLg%253D&md5=752a0203b7cde321c9c5de07fba79ca7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2007.05.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2007.05.033%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYong%26aufirst%3DS.%26aulast%3DSalas-Burgos%26aufirst%3DA.%26aulast%3DKoomen%26aufirst%3DJ.%26aulast%3DOlashaw%26aufirst%3DN.%26aulast%3DParsons%26aufirst%3DJ.%2BT.%26aulast%3DYang%26aufirst%3DX.%2BJ.%26aulast%3DDent%26aufirst%3DS.%2BR.%26aulast%3DYao%26aufirst%3DT.%2BP.%26aulast%3DLane%26aufirst%3DW.%2BS.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DHDAC6%2520modulates%2520cell%2520motility%2520by%2520altering%2520the%2520acetylation%2520level%2520of%2520cortactin%26jtitle%3DMol.%2520Cell%26date%3D2007%26volume%3D27%26spage%3D197%26epage%3D213%26doi%3D10.1016%2Fj.molcel.2007.05.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kovacs, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaillard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicchitta, C. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toft, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, T. P.</span></span> <span> </span><span class="NLM_article-title">HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">601</span>– <span class="NLM_lpage">607</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2005.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.molcel.2005.04.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=15916966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltFOksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2005&pages=601-607&author=J.+J.+Kovacsauthor=P.+J.+Murphyauthor=S.+Gaillardauthor=X.+Zhaoauthor=J.+T.+Wuauthor=C.+V.+Nicchittaauthor=M.+Yoshidaauthor=D.+O.+Toftauthor=W.+B.+Prattauthor=T.+P.+Yao&title=HDAC6+regulates+Hsp90+acetylation+and+chaperone-dependent+activation+of+glucocorticoid+receptor&doi=10.1016%2Fj.molcel.2005.04.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor</span></div><div class="casAuthors">Kovacs, Jeffrey J.; Murphy, Patrick J. M.; Gaillard, Stephanie; Zhao, Xuan; Wu, June-Tai; Nicchitta, Christopher V.; Yoshida, Minoru; Toft, David O.; Pratt, William B.; Yao, Tso-Pang</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">601-607</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mol. chaperone heat shock protein 90 (Hsp90) and its accessory cochaperones function by facilitating the structural maturation and complex assembly of client proteins, including steroid hormone receptors and selected kinases.  By promoting the activity and stability of these signaling proteins, Hsp90 has emerged as a crit. modulator in cell signaling.  Here, we present evidence that Hsp90 chaperone activity is regulated by reversible acetylation and controlled by the deacetylase HDAC6.  We show that HDAC6 functions as an Hsp90 deacetylase.  Inactivation of HDAC6 leads to Hsp90 hyperacetylation, its dissocn. from an essential cochaperone, p23, and a loss of chaperone activity.  In HDAC6-deficient cells, Hsp90-dependent maturation of the glucocorticoid receptor (GR) is compromised, resulting in GR defective in ligand binding, nuclear translocation, and transcriptional activation.  Our results identify Hsp90 as a target of HDAC6 and suggest reversible acetylation as a unique mechanism that regulates Hsp90 chaperone complex activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6rzQe2Zsw_7Vg90H21EOLACvtfcHk0ljh8Zz18f3coA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltFOksb4%253D&md5=338a8456c56a74d82ad3d28cbccae33f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2005.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2005.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DKovacs%26aufirst%3DJ.%2BJ.%26aulast%3DMurphy%26aufirst%3DP.%2BJ.%26aulast%3DGaillard%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DJ.%2BT.%26aulast%3DNicchitta%26aufirst%3DC.%2BV.%26aulast%3DYoshida%26aufirst%3DM.%26aulast%3DToft%26aufirst%3DD.%2BO.%26aulast%3DPratt%26aufirst%3DW.%2BB.%26aulast%3DYao%26aufirst%3DT.%2BP.%26atitle%3DHDAC6%2520regulates%2520Hsp90%2520acetylation%2520and%2520chaperone-dependent%2520activation%2520of%2520glucocorticoid%2520receptor%26jtitle%3DMol.%2520Cell%26date%3D2005%26volume%3D18%26spage%3D601%26epage%3D607%26doi%3D10.1016%2Fj.molcel.2005.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parmigiani, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venta-Perez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erdjument-Bromage, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaneva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tempst, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">9633</span>– <span class="NLM_lpage">9638</span>, <span class="refDoi"> DOI: 10.1073/pnas.0803749105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1073%2Fpnas.0803749105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=18606987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovVOjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=9633-9638&author=R.+B.+Parmigianiauthor=W.+S.+Xuauthor=G.+Venta-Perezauthor=H.+Erdjument-Bromageauthor=M.+Yanevaauthor=P.+Tempstauthor=P.+A.+Marks&title=HDAC6+is+a+specific+deacetylase+of+peroxiredoxins+and+is+involved+in+redox+regulation&doi=10.1073%2Fpnas.0803749105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation</span></div><div class="casAuthors">Parmigiani, R. B.; Xu, W. S.; Venta-Perez, G.; Erdjumen-Bromage, H.; Yaneva, M.; Tempst, P.; Marks, P. A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">9633-9638</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Eighteen histone deacetylases (HDACs) are present in humans, categorized into 2 groups: (1) Zn-dependent enzymes (HDAC1-11) and (2) NAD-dependent enzymes (sirtuins 1-7).  Among Zn-dependent HDACs, HDAC6 is unique.  It has a cytoplasmic localization, 2 catalytic sites, a ubiquitin-binding site, and it selectively deacetylates α-tubulin and Hsp90.  Here, the authors report the discovery that the redox regulatory proteins, peroxiredoxins (Prxs) I and II are specific targets of HDAC6 in human prostate cancer cells.  Prxs are antioxidant enzymes whose main function is H2O2 redn.  Prxs are elevated in many cancers and neurodegenerative diseases.  The acetylated form of Prx accumulates in the absence of an active HDAC6.  Acetylation of Prx increases its reducing activity, its resistance to superoxidn., and its resistance to transition to high-mol.-wt. complexes.  Thus, HDAC6 and Prxs are targets for modulating intracellular redox status in therapeutic strategies for disorders as disparate as cancers and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPhHinn-zsRbVg90H21EOLACvtfcHk0lhLOowA1_Bntg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovVOjt7g%253D&md5=205d33a2f6c154d83b1d1cee59d29108</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0803749105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0803749105%26sid%3Dliteratum%253Aachs%26aulast%3DParmigiani%26aufirst%3DR.%2BB.%26aulast%3DXu%26aufirst%3DW.%2BS.%26aulast%3DVenta-Perez%26aufirst%3DG.%26aulast%3DErdjument-Bromage%26aufirst%3DH.%26aulast%3DYaneva%26aufirst%3DM.%26aulast%3DTempst%26aufirst%3DP.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DHDAC6%2520is%2520a%2520specific%2520deacetylase%2520of%2520peroxiredoxins%2520and%2520is%2520involved%2520in%2520redox%2520regulation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D9633%26epage%3D9638%26doi%3D10.1073%2Fpnas.0803749105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aldana-Masangkay, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, K. M.</span></span> <span> </span><span class="NLM_article-title">The Role of HDAC6 in Cancer</span>. <i>J. Biomed. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2011</i></span>,  <span class="NLM_fpage">875824</span>, <span class="refDoi"> DOI: 10.1155/2011/875824</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1155%2F2011%2F875824" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=21076528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BC3cbmvFKnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=875824&author=G.+I.+Aldana-Masangkayauthor=K.+M.+Sakamoto&title=The+Role+of+HDAC6+in+Cancer&doi=10.1155%2F2011%2F875824"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The role of HDAC6 in cancer</span></div><div class="casAuthors">Aldana-Masangkay Grace I; Sakamoto Kathleen M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomedicine & biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">875824</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylase 6 (HDAC6), a member of the HDAC family whose major substrate is α-tubulin, has become a target for drug development to treat cancer due to its major contribution in oncogenic cell transformation.  Overexpression of HDAC6 correlates with tumorigenesis and improved survival; therefore, HDAC6 may be used as a marker for prognosis.  Previous work demonstrated that in multiple myeloma cells, inhibition of HDAC6 results in apoptosis.  Furthermore, HDAC6 is required for the activation of heat-shock factor 1 (HSF1), an activator of heat-shock protein encoding genes (HSPs) and CYLD, a cylindromatosis tumor suppressor gene.  HDAC6 contributes to cancer metastasis since its upregulation increases cell motility in breast cancer MCF-7 cells and its interaction with cortactin regulates motility.  HDAC6 also affects transcription and translation by regulating the heat-shock protein 90 (Hsp90) and stress granules (SGs), respectively.  This review will discuss the role of HDAC6 in the pathogenesis and treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIuDxliM3SH5QHPYJuLg8TfW6udTcc2eZ_ZdcIM5pSILntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cbmvFKnsA%253D%253D&md5=8be7e0edb941ebf8b761778c99ad4c57</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1155%2F2011%2F875824&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F875824%26sid%3Dliteratum%253Aachs%26aulast%3DAldana-Masangkay%26aufirst%3DG.%2BI.%26aulast%3DSakamoto%26aufirst%3DK.%2BM.%26atitle%3DThe%2520Role%2520of%2520HDAC6%2520in%2520Cancer%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2011%26volume%3D2011%26spage%3D875824%26doi%3D10.1155%2F2011%2F875824" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seidel, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnekenburger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dicato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diederich, M.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 in health and disease</span>. <i>Epigenomics</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">103</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.2217/epi.14.69</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.2217%2Fepi.14.69" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=25687470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXislGisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2015&pages=103-118&author=C.+Seidelauthor=M.+Schnekenburgerauthor=M.+Dicatoauthor=M.+Diederich&title=Histone+deacetylase+6+in+health+and+disease&doi=10.2217%2Fepi.14.69"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 in health and disease</span></div><div class="casAuthors">Seidel, Carole; Schnekenburger, Michael; Dicato, Mario; Diederich, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Epigenomics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">103-118</span>CODEN:
                <span class="NLM_cas:coden">EPIGC7</span>;
        ISSN:<span class="NLM_cas:issn">1750-192X</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC)6 is a member of the class IIb HDAC family.  This enzyme is zinc-dependent and mainly localized in the cytoplasm.  HDAC6 is a unique isoenzyme with two functional catalytic domains and specific physiol. roles.  Indeed, HDAC6 deacetylates various substrates including α-tubulin and HSP90α, and is involved in protein trafficking and degrdn., cell shape and migration.  Consequently, deregulation of HDAC6 activity was assocd. to a variety of diseases including cancer, neurodegenerative diseases and pathol. autoimmune response.  Therefore, HDAC6 represents an interesting potential therapeutic target.  In this review, we discuss structural features of this histone deacetylase, regulation of its expression and activity, biol. functions, implication in human disease initiation and progression.  Finally will describe novel and selective HDAC6 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0ng4pDM6Ob7Vg90H21EOLACvtfcHk0lhLOowA1_Bntg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXislGisbY%253D&md5=21a22233741335632ae499640d799f8d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2217%2Fepi.14.69&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Fepi.14.69%26sid%3Dliteratum%253Aachs%26aulast%3DSeidel%26aufirst%3DC.%26aulast%3DSchnekenburger%26aufirst%3DM.%26aulast%3DDicato%26aufirst%3DM.%26aulast%3DDiederich%26aufirst%3DM.%26atitle%3DHistone%2520deacetylase%25206%2520in%2520health%2520and%2520disease%26jtitle%3DEpigenomics%26date%3D2015%26volume%3D7%26spage%3D103%26epage%3D118%26doi%3D10.2217%2Fepi.14.69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 in cancer</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">111</span>, <span class="refDoi"> DOI: 10.1186/s13045-018-0654-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1186%2Fs13045-018-0654-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30176876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=111&author=T.+Liauthor=C.+Zhangauthor=S.+Hassanauthor=X.+Liuauthor=F.+Songauthor=K.+Chenauthor=W.+Zhangauthor=J.+Yang&title=Histone+deacetylase+6+in+cancer&doi=10.1186%2Fs13045-018-0654-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 in cancer</span></div><div class="casAuthors">Li, Ting; Zhang, Chao; Hassan, Shafat; Liu, Xinyue; Song, Fengju; Chen, Kexin; Zhang, Wei; Yang, Jilong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111/1-111/10</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription.  Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone substrates, such as a-tubulin, cortactin, and heat shock protein 90 (HSP90), to regulate cell proliferation, metastasis, invasion, and mitosis in tumors.  Furthermore, HDAC6 also upregulates several crit. factors in the immune system, such as program death receptor-1 (PD-1) and program death receptor ligand-1 (PD-L1) receptor, which are the main targets for cancer immunotherapy.  Several selective HDAC6 inhibitors are currently in clin. trials for cancer treatment and bring hope for patients with malignant tumors.  A fuller understanding of HDAC6 as a crit. regulator of many cellular pathways will help further the development of targeted anti-HDAC6 therapies.  Here, we review the unique features of HDAC6 and its role in cancer, which make HDAC6 an appealing drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv-ZU431-gtrVg90H21EOLACvtfcHk0lhQESARH5-nsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVyqsbs%253D&md5=eb9bc73343a7ee078124b017ee00b636</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1186%2Fs13045-018-0654-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-018-0654-9%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DHassan%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DHistone%2520deacetylase%25206%2520in%2520cancer%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D111%26doi%3D10.1186%2Fs13045-018-0654-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Auzmendi-Iriarte, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saenz-Antoñanzas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikelez-Alonso, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco-Garcia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tellaetxe-Abete, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrie, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortajarena, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matheu, A.</span></span> <span> </span><span class="NLM_article-title">Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">417</span>, <span class="refDoi"> DOI: 10.1038/s41419-020-2586-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fs41419-020-2586-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32488056" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFemt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=417&author=J.+Auzmendi-Iriarteauthor=A.+Saenz-Anto%C3%B1anzasauthor=I.+Mikelez-Alonsoauthor=E.+Carrasco-Garciaauthor=M.+Tellaetxe-Abeteauthor=C.+H.+Lawrieauthor=N.+Sampronauthor=A.+L.+Cortajarenaauthor=A.+Matheu&title=Characterization+of+a+new+small-molecule+inhibitor+of+HDAC6+in+glioblastoma&doi=10.1038%2Fs41419-020-2586-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma</span></div><div class="casAuthors">Auzmendi-Iriarte, Jaione; Saenz-Antonanzas, Ander; Mikelez-Alonso, Idoia; Carrasco-Garcia, Estefania; Tellaetxe-Abete, Maitena; Lawrie, Charles H.; Sampron, Nicolas; Cortajarena, Aitziber L.; Matheu, Ander</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">417</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Histone deacetylase 6 (HDAC6) is an epigenetic modifier that is an attractive pharmacol. target in cancer.  In this work, we show that HDAC6 is elevated in glioblastoma, the most malignant and common brain tumor in adults, in which its high levels correlate with poor patient survival and is more abundant in glioma stem cell subpopulation.  Moreover, we identified a new small-mol. inhibitor of HDAC6, which presents strong sensitivity for HDAC6 inhibition and exerts high cytotoxic activity, alone or in combination with temozolomide.  It is also able to significantly reduce tumor growth in vivo.  Transcriptomic anal. of patient-derived glioma stem cells revealed an increase in cell differentiation and cell death pathways, as well as a decrease in cell-cycle activity and cell division by the treatment with the compd.  Finally, the comparison with a pan-HDAC inhibitor, Vorinostat (SAHA), or HDAC6-specific inhibitor, Tubastatin A, showed higher target specificity and antitumor activity of the new HDAC6 inhibitor.  In conclusion, our data reveal the efficacy of a novel HDAC6 inhibitor in glioblastoma preclin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp53nM_XMZC7LVg90H21EOLACvtfcHk0lhQESARH5-nsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFemt7%252FM&md5=fd4fad040bffea9191e1a00e9268a3b5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fs41419-020-2586-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-020-2586-x%26sid%3Dliteratum%253Aachs%26aulast%3DAuzmendi-Iriarte%26aufirst%3DJ.%26aulast%3DSaenz-Anto%25C3%25B1anzas%26aufirst%3DA.%26aulast%3DMikelez-Alonso%26aufirst%3DI.%26aulast%3DCarrasco-Garcia%26aufirst%3DE.%26aulast%3DTellaetxe-Abete%26aufirst%3DM.%26aulast%3DLawrie%26aufirst%3DC.%2BH.%26aulast%3DSampron%26aufirst%3DN.%26aulast%3DCortajarena%26aufirst%3DA.%2BL.%26aulast%3DMatheu%26aufirst%3DA.%26atitle%3DCharacterization%2520of%2520a%2520new%2520small-molecule%2520inhibitor%2520of%2520HDAC6%2520in%2520glioblastoma%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2020%26volume%3D11%26spage%3D417%26doi%3D10.1038%2Fs41419-020-2586-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rossaert, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bosch, L.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>1733</i></span>,  <span class="NLM_fpage">146692</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2020.146692</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.brainres.2020.146692" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32006555" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjsVOksbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1733&publication_year=2020&pages=146692&author=E.+Rossaertauthor=L.+Van+Den+Bosch&title=HDAC6+inhibitors%3A+Translating+genetic+and+molecular+insights+into+a+therapy+for+axonal+CMT&doi=10.1016%2Fj.brainres.2020.146692"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT</span></div><div class="casAuthors">Rossaert, Elisabeth; Van Den Bosch, Ludo</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">1733</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">146692</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase 6 (HDAC6) plays a central role in various processes that are key for neuronal survival.  In this review, we summarize the current evidence related to disease pathways in the axonal form of Charcot-Marie-Tooth disease (CMT) and highlight the role of HDAC6 in these pathways.  We hypothesize that HDAC6 might in fact actively contribute to the pathogenesis of certain forms of axonal CMT.  HDAC6 plays a deacetylase activity-dependent, neg. role in axonal transport and axonal regeneration, which are both processes implicated in axonal CMT.  On the other hand, HDAC6 coordinates a protective response during elimination of toxic misfolded proteins, but this is mostly mediated independent of its deacetylase activity.  The current mechanistic insights on these functions of HDAC6 in axonal CMT, along with the selective druggability against its deacetylase activity, make the targeting of HDAC6 particularly attractive.  We elaborate on the preclin. studies that demonstrated beneficial effects of HDAC6 inhibitors in axonal CMT models and outline possible modes of action.  Overall, this overview ultimately provides a rationale for the use of small-mol. HDAC6 inhibitors as a therapeutic strategy for this devastating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLQPvMw55ppbVg90H21EOLACvtfcHk0lhQESARH5-nsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjsVOksbw%253D&md5=3005fe78c94cf2a719d6e031573320c5</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2020.146692&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2020.146692%26sid%3Dliteratum%253Aachs%26aulast%3DRossaert%26aufirst%3DE.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26atitle%3DHDAC6%2520inhibitors%253A%2520Translating%2520genetic%2520and%2520molecular%2520insights%2520into%2520a%2520therapy%2520for%2520axonal%2520CMT%26jtitle%3DBrain%2520Res.%26date%3D2020%26volume%3D1733%26spage%3D146692%26doi%3D10.1016%2Fj.brainres.2020.146692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraswati, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span> <span> </span><span class="NLM_article-title">Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">23</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00924</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00924" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=23-39&author=M.+Brindisiauthor=A.+P.+Saraswatiauthor=S.+Brogiauthor=S.+Gemmaauthor=S.+Butiniauthor=G.+Campiani&title=Old+but+Gold%3A+Tracking+the+New+Guise+of+Histone+Deacetylase+6+%28HDAC6%29+Enzyme+as+a+Biomarker+and+Therapeutic+Target+in+Rare+Diseases&doi=10.1021%2Facs.jmedchem.9b00924"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Old but Gold: Tracking the New Guise of Histone Deacetylase 6 (HDAC6) Enzyme as a Biomarker and Therapeutic Target in Rare Diseases</span></div><div class="casAuthors">Brindisi, Margherita; Saraswati, A. Prasanth; Brogi, Simone; Gemma, Sandra; Butini, Stefania; Campiani, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">23-39</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Epigenetic regulation orchestrates many cellular processes and greatly influences key disease mechanisms.  Histone deacetylase (HDAC) enzymes play a crucial role either as biomarkers or therapeutic targets owing to their involvement in specific pathophysiol. pathways.  Beyond their well-characterized role as histone modifiers, HDACs also interact with several non-histone substrates and their increased expression has been highlighted in specific diseases.  HDAC6 isoform, due to its unique cytoplasmic localization, modulates the acetylation status of tubulin, HSP90, TGF-β and peroxiredoxins.  HDAC6 also exerts non-catalytic activities, through its interaction with ubiquitin.  Both catalytic and non-catalytic functions of HDACs are being actively studied in the field of specific rare disorders, beyond the well-established role in carcinogenesis.  This perspective outlines the application of HDAC(6) inhibitors in rare diseases, such as Rett syndrome, inherited retinal disorders, idiopathic pulmonary fibrosis and Charcot-Marie-Tooth disease, highlighting their therapeutic potential as innovative and targeted disease-modifying agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-kzJmRToypbVg90H21EOLACvtfcHk0lhpp34Uqo0aXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbrK&md5=688368246471313ed025f0c230167052</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00924&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00924%26sid%3Dliteratum%253Aachs%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DSaraswati%26aufirst%3DA.%2BP.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26atitle%3DOld%2520but%2520Gold%253A%2520Tracking%2520the%2520New%2520Guise%2520of%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529%2520Enzyme%2520as%2520a%2520Biomarker%2520and%2520Therapeutic%2520Target%2520in%2520Rare%2520Diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D23%26epage%3D39%26doi%3D10.1021%2Facs.jmedchem.9b00924" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span> <span> </span><span class="NLM_article-title">Structure, Functions and Selective Inhibitors of HDAC6</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2429</span>– <span class="NLM_lpage">2447</span>, <span class="refDoi"> DOI: 10.2174/1568026619666181129141822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.2174%2F1568026619666181129141822" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=2429-2447&author=T.+Liangauthor=H.+Fang&title=Structure%2C+Functions+and+Selective+Inhibitors+of+HDAC6&doi=10.2174%2F1568026619666181129141822"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.2174%2F1568026619666181129141822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666181129141822%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DT.%26aulast%3DFang%26aufirst%3DH.%26atitle%3DStructure%252C%2520Functions%2520and%2520Selective%2520Inhibitors%2520of%2520HDAC6%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D18%26spage%3D2429%26epage%3D2447%26doi%3D10.2174%2F1568026619666181129141822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014–2019)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1708901</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1080%2F13543776.2019.1708901" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31865813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVKnsb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=121-136&author=S.+Shenauthor=A.+P.+Kozikowski&title=A+patent+review+of+histone+deacetylase+6+inhibitors+in+neurodegenerative+diseases+%282014%E2%80%932019%29&doi=10.1080%2F13543776.2019.1708901"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019)</span></div><div class="casAuthors">Shen, Sida; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-136</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase 6 (HDAC6) is unique in comparison with other zinc-dependent HDAC family members.  An increasing amt. of evidence from clin. and preclin. research demonstrates the potential of HDAC6 inhibition as an effective therapeutic approach for the treatment of cancer, autoimmune diseases, as well as neurol. disorders.  The recently disclosed crystal structures of HDAC6-ligand complexes offer further means for achieving pharmacophore refinement, thus further accelerating the pace of HDAC6 inhibitor discovery in the last few years.: This review summarizes the latest clin. status of HDAC6 inhibitors, discusses pharmacol. applications of selective HDAC6 inhibitors in neurodegenerative diseases, and describes the patent applications dealing with HDAC6 inhibitors from 2014-2019 that have not been reported in research articles.: Phenylhydroxamate has proven a very useful scaffold in the discovery of potent and selective HDAC6 inhibitors.  However, weaknesses of the hydroxamate function such as metabolic instability and mutagenic potential limit its application in the neurol. field, where long-term administration is required.  The recent invention of oxadiazole-based ligands by pharmaceutical companies may provide a new opportunity to optimize the druglike properties of HDAC6 inhibitors for the treatment of neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCWThC7SH8r7Vg90H21EOLACvtfcHk0lhpp34Uqo0aXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVKnsb3J&md5=926d00ce3a0153953eb2f933599500b9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1708901&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1708901%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DA%2520patent%2520review%2520of%2520histone%2520deacetylase%25206%2520inhibitors%2520in%2520neurodegenerative%2520diseases%2520%25282014%25E2%2580%25932019%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2020%26volume%3D30%26spage%3D121%26epage%3D136%26doi%3D10.1080%2F13543776.2019.1708901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bae, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. i.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youn, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y. W.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis</span>. <i>Arthritis Res. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">176</span>, <span class="refDoi"> DOI: 10.1186/s13075-020-02258-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1186%2Fs13075-020-02258-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32711562" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVyltrvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2020&pages=176&author=J.+K.+Parkauthor=Y.+J.+Jangauthor=B.+R.+Ohauthor=J.+Shinauthor=D.+Baeauthor=N.+Haauthor=Y.+i.+Choiauthor=G.+S.+Younauthor=J.+Parkauthor=E.+Y.+Leeauthor=E.+B.+Leeauthor=Y.+W.+Song&title=Therapeutic+potential+of+CKD-506%2C+a+novel+selective+histone+deacetylase+6+inhibitor%2C+in+a+murine+model+of+rheumatoid+arthritis&doi=10.1186%2Fs13075-020-02258-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis</span></div><div class="casAuthors">Park, Jin Kyun; Jang, Yu Jin; Oh, Bo Ram; Shin, Jieun; Bae, Daekwon; Ha, Nina; Choi, Young il; Youn, Gi Soo; Park, Jinseu; Lee, Eun Young; Lee, Eun Bong; Song, Yeong Wook</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis Research & Therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">176</span>CODEN:
                <span class="NLM_cas:coden">ARTRCV</span>;
        ISSN:<span class="NLM_cas:issn">1478-6362</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) 6 promotes inflammation.  We investigated the anti-arthritic effects of CKD-506, a novel HDAC6 inhibitor, in vitro and in a murine model of arthritis as a novel treatment option for rheumatoid arthritis (RA).  HDAC6 was overexpressed in mouse peritoneal macrophages and RAW 264.7 cells, and the effects of a HDAC6 inhibitor CKD-506 on cytokine prodn. and activity of NF-κB and AP-1 signaling were examd.  Peripheral blood mononuclear cells (PBMCs) from RA patients and fibroblast-like synoviocytes (FLS) were activated in the presence of CKD-506.  Next, regulatory T cells (Tregs) were induced from RA patients and co-cultured with healthy effector T cells (Teffs) and cell proliferation was analyzed by flow cytometry.  Finally, the effects of the inhibitor on the severity of arthritis were assessed in a murine model of adjuvant-induced arthritis (AIA).  Overexpression of HDAC6 induced macrophages to produce TNF-α and IL-6.  The inhibitory effect of CKD-506 was mediated via blockade of NF-κB and AP-1 activation.  HDAC6 inhibition reduced TNF-α and IL-6 prodn. by activated RA PBMCs.  CKD-506 inhibited prodn. of MMP-1, MMP-3, IL-6, and IL-8 by activated FLS.  In addn., CKD-506 inhibited proliferation of Teffs directly and indirectly by improving iTreg function.  In AIA rats, oral CKD-506 improved clin. arthritis in a dose-dependent manner.  A combination of sub-therapeutic CKD-506 and methotrexate exerted a synergistic effect.  The novel HDAC6 inhibitor CKD-506 suppresses inflammatory responses by monocytes/macrophages, improves Treg function, and ameliorates arthritis severity in a murine model of RA.  Thus, CKD-506 might be a novel and effective treatment option for RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphLzwIQN7AvbVg90H21EOLACvtfcHk0lhpp34Uqo0aXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVyltrvF&md5=3377bfe25a6d2b7218aa1cc98c3fa3b1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1186%2Fs13075-020-02258-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13075-020-02258-0%26sid%3Dliteratum%253Aachs%26aulast%3DPark%26aufirst%3DJ.%2BK.%26aulast%3DJang%26aufirst%3DY.%2BJ.%26aulast%3DOh%26aufirst%3DB.%2BR.%26aulast%3DShin%26aufirst%3DJ.%26aulast%3DBae%26aufirst%3DD.%26aulast%3DHa%26aufirst%3DN.%26aulast%3DChoi%26aufirst%3DY.%2Bi.%26aulast%3DYoun%26aufirst%3DG.%2BS.%26aulast%3DPark%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BY.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DSong%26aufirst%3DY.%2BW.%26atitle%3DTherapeutic%2520potential%2520of%2520CKD-506%252C%2520a%2520novel%2520selective%2520histone%2520deacetylase%25206%2520inhibitor%252C%2520in%2520a%2520murine%2520model%2520of%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2020%26volume%3D22%26spage%3D176%26doi%3D10.1186%2Fs13075-020-02258-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span> <span> </span><span class="NLM_article-title">Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>208</i></span>,  <span class="NLM_fpage">112831</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2020.112831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32961382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFWmsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=208&publication_year=2020&pages=112831&author=X.+Pengauthor=Z.+Sunauthor=P.+Kuangauthor=J.+Chen&title=Recent+progress+on+HDAC+inhibitors+with+dual+targeting+capabilities+for+cancer+treatment&doi=10.1016%2Fj.ejmech.2020.112831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment</span></div><div class="casAuthors">Peng, Xiaopeng; Sun, Zhiqiang; Kuang, Peihua; Chen, Jianjun</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">208</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112831</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a class of enzymes that remove acetyl from the ε-N-acetyl lysine of histones, allowing histones to wrap DNA more tightly.  HDACs play an essential role in many biol. processes such as gene regulation, transcription, cell proliferation, angiogenesis, migration, differentiation and metastasis.  As a result, HDACs represent an excellent target for anti-cancer drug discovery.  The search for histone deacetylase inhibitors (HDACis) has been intensified in the last decade with numerous HDACis being discovered, and some of them have reached the market.  However, currently available HDACis are mostly non-isoform selective and suffer from several drawbacks such as limited efficacy, drug resistance, and toxicities.  Therefore, isoform-selective HDACis and HDACis with dual targeting capabilities have attracted much attention from academia to industry in the past 5 years, and great advances have been achieved in this area.  In this paper, we summarize recent progress on HDACis with dual targeting capabilities and their potential application to cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTHs5GEjS8RbVg90H21EOLACvtfcHk0li-XeKOfY3UQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFWmsbvM&md5=d6f340dc0222b3f22a702c963cb1728b</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112831%26sid%3Dliteratum%253Aachs%26aulast%3DPeng%26aufirst%3DX.%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DKuang%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DJ.%26atitle%3DRecent%2520progress%2520on%2520HDAC%2520inhibitors%2520with%2520dual%2520targeting%2520capabilities%2520for%2520cancer%2520treatment%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D208%26spage%3D112831%26doi%3D10.1016%2Fj.ejmech.2020.112831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Woan, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lienlaf, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Villaroel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrios, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahakian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canales, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marante, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smalley, K. S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla-Ibarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Celis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1447</span>– <span class="NLM_lpage">1457</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2015.04.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.molonc.2015.04.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=25957812" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnsF2gtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2015&pages=1447-1457&author=K.+V.+Woanauthor=M.+Lienlafauthor=P.+Perez-Villaroelauthor=C.+Leeauthor=F.+Chengauthor=T.+Knoxauthor=D.+M.+Woodsauthor=K.+Barriosauthor=J.+Powersauthor=E.+Sahakianauthor=H.+W.+Wangauthor=J.+Canalesauthor=D.+Maranteauthor=K.+S.+M.+Smalleyauthor=J.+Bergmanauthor=E.+Setoauthor=A.+Kozikowskiauthor=J.+Pinilla-Ibarzauthor=A.+Sarnaikauthor=E.+Celisauthor=J.+Weberauthor=E.+M.+Sotomayorauthor=A.+Villagra&title=Targeting+histone+deacetylase+6+mediates+a+dual+anti-melanoma+effect%3A+Enhanced+antitumor+immunity+and+impaired+cell+proliferation&doi=10.1016%2Fj.molonc.2015.04.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation</span></div><div class="casAuthors">Woan, K. V.; Lienlaf, M.; Perez-Villaroel, P.; Lee, C.; Cheng, F.; Knox, T.; Woods, D. M.; Barrios, K.; Powers, J.; Sahakian, E.; Wang, H. W.; Canales, J.; Marante, D.; Smalley, K. S. M.; Bergman, J.; Seto, E.; Kozikowski, A.; Pinilla-Ibarz, J.; Sarnaik, A.; Celis, E.; Weber, J.; Sotomayor, E. M.; Villagra, A.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1447-1457</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The median survival for metastatic melanoma is in the realm of 8-16 mo and there are few therapies that offer significant improvement in overall survival.  One of the recent advances in cancer treatment focuses on epigenetic modifiers to alter the survivability and immunogenicity of cancer cells.  Our group and others have previously demonstrated that pan-HDAC inhibitors induce apoptosis, cell cycle arrest and changes in the immunogenicity of melanoma cells.  Here we interrogated specific HDACs which may be responsible for this effect.  We found that both genetic abrogation and pharmacol. inhibition of HDAC6 decreases in vitro proliferation and induces G1 arrest of melanoma cell lines without inducing apoptosis.  Moreover, targeting this mol. led to an important upregulation in the expression of tumor assocd. antigens and MHC class I, suggesting a potential improvement in the immunogenicity of these cells.  Of note, this anti-melanoma activity was operative regardless of mutational status of the cells.  These effects translated into a pronounced delay of in vivo melanoma tumor growth which was, at least in part, dependent on intact immunity as evidenced by the restoration of tumor growth after CD4+ and CD8+ depletion.  Given our findings, we provide the initial rationale for the further development of selective HDAC6 inhibitors as potential therapeutic anti-melanoma agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDIQ5LKbZF8bVg90H21EOLACvtfcHk0li-XeKOfY3UQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnsF2gtLw%253D&md5=7534df9db01f52a71f97f0e112db37cc</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2015.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2015.04.002%26sid%3Dliteratum%253Aachs%26aulast%3DWoan%26aufirst%3DK.%2BV.%26aulast%3DLienlaf%26aufirst%3DM.%26aulast%3DPerez-Villaroel%26aufirst%3DP.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DWoods%26aufirst%3DD.%2BM.%26aulast%3DBarrios%26aufirst%3DK.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DSahakian%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DH.%2BW.%26aulast%3DCanales%26aufirst%3DJ.%26aulast%3DMarante%26aufirst%3DD.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DBergman%26aufirst%3DJ.%26aulast%3DSeto%26aufirst%3DE.%26aulast%3DKozikowski%26aufirst%3DA.%26aulast%3DPinilla-Ibarz%26aufirst%3DJ.%26aulast%3DSarnaik%26aufirst%3DA.%26aulast%3DCelis%26aufirst%3DE.%26aulast%3DWeber%26aufirst%3DJ.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DTargeting%2520histone%2520deacetylase%25206%2520mediates%2520a%2520dual%2520anti-melanoma%2520effect%253A%2520Enhanced%2520antitumor%2520immunity%2520and%2520impaired%2520cell%2520proliferation%26jtitle%3DMol.%2520Oncol.%26date%3D2015%26volume%3D9%26spage%3D1447%26epage%3D1457%26doi%3D10.1016%2Fj.molonc.2015.04.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustinova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlicek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noonepalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bařinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8557</span>– <span class="NLM_lpage">8577</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00946</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00946" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8557-8577&author=S.+Shenauthor=M.+Hadleyauthor=K.+Ustinovaauthor=J.+Pavlicekauthor=T.+Knoxauthor=S.+Noonepalleauthor=M.+T.+Tavaresauthor=C.+A.+Zimprichauthor=G.+Zhangauthor=M.+B.+Robersauthor=C.+Ba%C5%99inkaauthor=A.+P.+Kozikowskiauthor=A.+Villagra&title=Discovery+of+a+New+Isoxazole-3-hydroxamate-Based+Histone+Deacetylase+6+Inhibitor+SS-208+with+Antitumor+Activity+in+Syngeneic+Melanoma+Mouse+Models&doi=10.1021%2Facs.jmedchem.9b00946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models</span></div><div class="casAuthors">Shen, Sida; Hadley, Melissa; Ustinova, Kseniya; Pavlicek, Jiri; Knox, Tessa; Noonepalle, Satish; Tavares, Mauricio T.; Zimprich, Chad A.; Zhang, Guiping; Robers, Matthew B.; Barinka, Cyril; Kozikowski, Alan P.; Villagra, Alejandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8557-8577</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Isoxazole is a five-membered heterocycle that is widely used in drug discovery endeavors.  Here, the authors report the design, synthesis, and structural and biol. characterization of SS-208, a novel HDAC6-selective inhibitor contg. the isoxazole-3-hydroxamate moiety as a zinc-binding group as well as a hydrophobic linker.  A crystal structure of the Danio rerio HDAC6/SS-208 complex reveals a bidentate coordination of the active-site zinc ion that differs from the preferred monodentate coordination obsd. for HDAC6 complexes with phenylhydroxamate-based inhibitors.  While SS-208 has minimal effects on the viability of murine SM1 melanoma cells in vitro, it significantly reduced in vivo tumor growth in a murine SM1 syngeneic melanoma mouse model.  These findings suggest that the antitumor activity of SS-208 is mainly mediated by immune-related antitumor activity as evidenced by the increased infiltration of CD8+ and NK+ T cells and the enhanced ratio of M1 and M2 macrophages in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUagVGHIiRHbVg90H21EOLACvtfcHk0li-XeKOfY3UQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbzI&md5=53b4c45ce582d8752869430407d44649</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00946%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DUstinova%26aufirst%3DK.%26aulast%3DPavlicek%26aufirst%3DJ.%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DNoonepalle%26aufirst%3DS.%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DBa%25C5%2599inka%26aufirst%3DC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520New%2520Isoxazole-3-hydroxamate-Based%2520Histone%2520Deacetylase%25206%2520Inhibitor%2520SS-208%2520with%2520Antitumor%2520Activity%2520in%2520Syngeneic%2520Melanoma%2520Mouse%2520Models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8557%26epage%3D8577%26doi%3D10.1021%2Facs.jmedchem.9b00946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Development of the first small molecule histone deacetylase 6 (HDAC6) degraders</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2493</span>– <span class="NLM_lpage">2497</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.05.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmcl.2018.05.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29871848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2493-2497&author=K.+Yangauthor=Y.+Songauthor=H.+Xieauthor=H.+Wuauthor=Y.+T.+Wuauthor=E.+D.+Leistenauthor=W.+Tang&title=Development+of+the+first+small+molecule+histone+deacetylase+6+%28HDAC6%29+degraders&doi=10.1016%2Fj.bmcl.2018.05.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Development of the first small molecule histone deacetylase 6 (HDAC6) degraders</span></div><div class="casAuthors">Yang, Ka; Song, Yanling; Xie, Haibo; Wu, Hao; Wu, Yi-Ting; Leisten, Eric D.; Tang, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2493-2497</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) decrease the acetylation level of histones and other non-histone proteins.  Over expression of HDACs have been obsd. in cancers and other diseases.  Targeted protein degrdn. by "hijacking" the natural ubiquitin-proteasome-system (UPS) recently emerged as a novel technol. to "knock-out" endogenous disease-causing proteins.  The authors applied this strategy to the development of the first small mol. degraders for zinc-dependent HDACs by conjugating non-selective HDAC inhibitors with E3 ubiquitin ligase ligands.  Through cell-based assays, the authors discovered novel bifunctional mols. (dHDAC6) that could selectively degrade HDAC6.  Further mechanistic studies indicated that HDAC6 was selectively removed by the UPS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp9t1stJ7Qkf7Vg90H21EOLACvtfcHk0lhH-t0jf_JUaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVOlsrfF&md5=20be52b05a327184f824ccf9cf88333f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.05.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.05.057%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DK.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DY.%2BT.%26aulast%3DLeisten%26aufirst%3DE.%2BD.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520the%2520first%2520small%2520molecule%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529%2520degraders%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2493%26epage%3D2497%26doi%3D10.1016%2Fj.bmcl.2018.05.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">Developing potent PROTACs tools for selective degradation of HDAC6 protein</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">609</span>, <span class="refDoi"> DOI: 10.1007/s13238-018-0602-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs13238-018-0602-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30603959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVCktLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=606-609&author=Z.+Anauthor=W.+Lvauthor=S.+Suauthor=W.+Wuauthor=Y.+Rao&title=Developing+potent+PROTACs+tools+for+selective+degradation+of+HDAC6+protein&doi=10.1007%2Fs13238-018-0602-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Developing potent PROTACs tools for selective degradation of HDAC6 protein</span></div><div class="casAuthors">An, Zixuan; Lv, Wenxing; Su, Shang; Wu, Wei; Rao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">606-609</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">The present article describes about developing potent PROTACs tools for selective degrdn. of HDAC6 protein.  To evaluate the degrdn. capability of our PROTACs for HDAC6 protein, analyzed the cellular levels of HDAC6 in HeLa cells by Western blot after incubation with four different PROTACs.  It was found that all PROTACs can effectively induce HDAC6 degrdn. after 24 h.  Among them, NP8 was the most potent degrader which can significantly reduce the HDAC6 protein level at 100 nmol/L.  Then went on to evaluate the degrdn. potential of NP8 in a panel of cell lines from different origin.  NP8 consistently induced significant degrdn. of HDAC6 in all the cell lines we tested, while the multiple myeloma cell line MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0CReXjWgVRbVg90H21EOLACvtfcHk0lhH-t0jf_JUaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVCktLjL&md5=f3c3a4afb585f9d09b753b005d5b6428</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1007%2Fs13238-018-0602-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-018-0602-z%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DZ.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DDeveloping%2520potent%2520PROTACs%2520tools%2520for%2520selective%2520degradation%2520of%2520HDAC6%2520protein%26jtitle%3DProtein%2520Cell%26date%3D2019%26volume%3D10%26spage%3D606%26epage%3D609%26doi%3D10.1007%2Fs13238-018-0602-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 structure and molecular basis of catalysis and inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">741</span>– <span class="NLM_lpage">747</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fnchembio.2134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27454933" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=741-747&author=Y.+Haiauthor=D.+W.+Christianson&title=Histone+deacetylase+6+structure+and+molecular+basis+of+catalysis+and+inhibition&doi=10.1038%2Fnchembio.2134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 structure and molecular basis of catalysis and inhibition</span></div><div class="casAuthors">Hai, Yang; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">741-747</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is a crit. target for drug design because of its role in oncogenic transformation and cancer metastasis, and is unique among all histone deacetylases in that it contains tandem catalytic domains designated CD1 and CD2.  We now report the crystal structures of CD2 from Homo sapiens HDAC6 and of CD1 and CD2 from Danio rerio HDAC6.  We correlated these structures with activity measurements using 13 different substrates.  The catalytic activity of CD2 from both species exhibited broad substrate specificity, whereas that of CD1 was highly specific for substrates bearing C-terminal acetyllysine residues.  Crystal structures of substrate complexes yielded unprecedented snapshots of the catalytic mechanism.  Addnl., crystal structures of complexes with eight different inhibitors, including belinostat and panobinostat (currently used in cancer chemotherapy), the macrocyclic tetrapeptide HC toxin, and the HDAC6-specific inhibitor N-hydroxy-4-(2-((2-hydroxyethyl)(phenyl)amino)-2-oxoethyl)benzamide, revealed surprising new insight regarding changes in Zn2+ coordination and isoenzyme-specific inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqCfziGBHBRLVg90H21EOLACvtfcHk0lhH-t0jf_JUaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rJ&md5=e167bc6f66e00923da4f2bced2b306b9</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2134%26sid%3Dliteratum%253Aachs%26aulast%3DHai%26aufirst%3DY.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DHistone%2520deacetylase%25206%2520structure%2520and%2520molecular%2520basis%2520of%2520catalysis%2520and%2520inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D741%26epage%3D747%26doi%3D10.1038%2Fnchembio.2134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keusch, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melancon, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helquist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gut, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthias, P.</span></span> <span> </span><span class="NLM_article-title">Structural insights into HDAC6 tubulin deacetylation and its selective inhibition</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">748</span>– <span class="NLM_lpage">754</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fnchembio.2140" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27454931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=748-754&author=Y.+Miyakeauthor=J.+J.+Keuschauthor=L.+Wangauthor=M.+Saitoauthor=D.+Hessauthor=X.+Wangauthor=B.+J.+Melanconauthor=P.+Helquistauthor=H.+Gutauthor=P.+Matthias&title=Structural+insights+into+HDAC6+tubulin+deacetylation+and+its+selective+inhibition&doi=10.1038%2Fnchembio.2140"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into HDAC6 tubulin deacetylation and its selective inhibition</span></div><div class="casAuthors">Miyake, Yasuyuki; Keusch, Jeremy J.; Wang, Longlong; Saito, Makoto; Hess, Daniel; Wang, Xiaoning; Melancon, Bruce J.; Helquist, Paul; Gut, Heinz; Matthias, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">748-754</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The authors report crystal structures of zebrafish histone deacetylase 6 (HDAC6) catalytic domains in tandem or as single domains in complex with the (R) and (S) enantiomers of trichostatin A (TSA) or with the HDAC6-specific inhibitor, nexturastat A.  The tandem domains formed, together with the inter-domain linker, an ellipsoid-shaped complex with pseudo-twofold symmetry.  The authors identified important active site differences between both catalytic domains and revealed the binding mode of HDAC6 selective inhibitors.  HDAC inhibition assays with (R)- and (S)-TSA showed that (R)-TSA was a broad-range inhibitor, whereas (S)-TSA had moderate selectivity for HDAC6.  The authors identified a uniquely positioned α-helix and a flexible Trp residue in the loop joining α-helixes H20 to H21 as crit. for deacetylation of the physiol. substrate, tubulin.  Using single-mol. measurements and biochem. assays, the authors demonstrated that HDAC6 catalytic domain 2 deacetylated α-tubulin Lys-40 in the lumen of microtubules, but that its preferred substrate was unpolymd. tubulin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpERJRurS1cC7Vg90H21EOLACvtfcHk0liGGyu6_Ui6RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Kmu7rM&md5=4abe529ab89615df33f54350a1a8c69a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2140%26sid%3Dliteratum%253Aachs%26aulast%3DMiyake%26aufirst%3DY.%26aulast%3DKeusch%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DSaito%26aufirst%3DM.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMelancon%26aufirst%3DB.%2BJ.%26aulast%3DHelquist%26aufirst%3DP.%26aulast%3DGut%26aufirst%3DH.%26aulast%3DMatthias%26aufirst%3DP.%26atitle%3DStructural%2520insights%2520into%2520HDAC6%2520tubulin%2520deacetylation%2520and%2520its%2520selective%2520inhibition%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26spage%3D748%26epage%3D754%26doi%3D10.1038%2Fnchembio.2140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4912</span>– <span class="NLM_lpage">4924</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.9b00934</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.9b00934" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit1Snsb3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2019&pages=4912-4924&author=J.+D.+Oskoauthor=D.+W.+Christianson&title=Structural+Basis+of+Catalysis+and+Inhibition+of+HDAC6+CD1%2C+the+Enigmatic+Catalytic+Domain+of+Histone+Deacetylase+6&doi=10.1021%2Facs.biochem.9b00934"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6</span></div><div class="casAuthors">Osko, Jeremy D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">4912-4924</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is emerging as a target for inhibition in therapeutic strategies aimed at treating cancer, neurodegenerative disease, and other disorders.  Among the metal-dependent HDAC isoenzymes, HDAC6 is unique in that it contains two catalytic domains, CD1 and CD2.  CD2 is a tubulin deacetylase and a tau deacetylase, and the development of HDAC6-selective inhibitors has focused exclusively on this domain.  In contrast, there is a dearth of structural and functional information regarding CD1, which exhibits much narrower substrate specificity in comparison with CD2.  As the first step in addressing the CD1 information gap, we now present X-ray crystal structures of seven inhibitor complexes with wild-type, Y363F, and K330L HDAC6 CD1.  These structures broaden our understanding of mol. features important for catalysis and inhibitor binding.  The active site of HDAC6 CD1 is wider than that of CD2, which is unexpected in view of the narrow substrate specificity of CD1.  Amino acid substitutions between HDAC6 CD1 and CD2, as well as conformational differences in conserved residues, define striking differences in active site contours.  Catalytic activity measurements with HDAC6 CD1 confirm the preference for peptide substrates contg. C-terminal acetyllysine residues.  However, these measurements also show that CD1 exhibits weak activity for peptide substrates bearing certain small amino acids on the carboxyl side of the scissile acetyllysine residue.  Taken together, these results establish a foundation for understanding the structural basis of HDAC6 CD1 catalysis and inhibition, pointing to possible avenues for the development of HDAC6 CD1-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk6bd_6kU9erVg90H21EOLACvtfcHk0liGGyu6_Ui6RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit1Snsb3P&md5=4bebfc15825270bceeb7b87ca61c0f10</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.9b00934&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.9b00934%26sid%3Dliteratum%253Aachs%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructural%2520Basis%2520of%2520Catalysis%2520and%2520Inhibition%2520of%2520HDAC6%2520CD1%252C%2520the%2520Enigmatic%2520Catalytic%2520Domain%2520of%2520Histone%2520Deacetylase%25206%26jtitle%3DBiochemistry%26date%3D2019%26volume%3D58%26spage%3D4912%26epage%3D4924%26doi%3D10.1021%2Facs.biochem.9b00934" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">13459</span>– <span class="NLM_lpage">13464</span>, <span class="refDoi"> DOI: 10.1073/pnas.1718823114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1073%2Fpnas.1718823114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29203661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFWgsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=13459-13464&author=N.+J.+Porterauthor=A.+Mahendranauthor=R.+Breslowauthor=D.+W.+Christianson&title=Unusual+zinc-binding+mode+of+HDAC6-selective+hydroxamate+inhibitors&doi=10.1073%2Fpnas.1718823114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors</span></div><div class="casAuthors">Porter, Nicholas J.; Mahendran, Adaickapillai; Breslow, Ronald; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">51</span>),
    <span class="NLM_cas:pages">13459-13464</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) regulate myriad cellular processes by catalyzing the hydrolysis of acetyl-L-lysine residues in histone and nonhistone proteins.  The Zn2+-dependent class IIb enzyme HDAC6 regulates microtubule function by deacetylating α-tubulin, which suppresses microtubule dynamics and leads to cell cycle arrest and apoptosis.  Accordingly, HDAC6 is a target for the development of selective inhibitors that might be useful in new therapeutic approaches for the treatment of cancer, neurodegenerative diseases, and other disorders.  Here, we present high-resoln. structures of catalytic domain 2 from Danio rerio HDAC6 (henceforth simply "HDAC6") complexed with compds. that selectively inhibit HDAC6 while maintaining nanomolar inhibitory potency: N-hydroxy-4-((N(2-hydroxyethyl)-2-phenylacetamido)methyl)-benzamide (HPB), ACY-1215 (Ricolinostat), and ACY-1083.  These structures reveal that an unusual monodentate Zn2+ coordination mode is exploited by sterically bulky HDAC6-selective phenylhydroxamate inhibitors.  We addnl. report the ultrahigh-resoln. structure of the HDAC6-trichostatin A complex, which reveals two Zn2+-binding conformers for the inhibitor: a major conformer (70%) with canonical bidentate hydroxamate-Zn2+ coordination geometry and a minor conformer (30%) with monodentate hydroxamate-Zn2+ coordination geometry, reflecting a free energy difference of only 0.5 kcal/mol.  The minor conformer is not visible in lower resoln. structure detns.  Structural comparisons of HDAC6-inhibitor complexes with class I HDACs suggest active site features that contribute to the isoenzyme selectivity obsd. in biochem. assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0oUH1X_04p7Vg90H21EOLACvtfcHk0liGGyu6_Ui6RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFWgsrbI&md5=07180756239eac4891642cf59a2e6992</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1718823114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1718823114%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DMahendran%26aufirst%3DA.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DUnusual%2520zinc-binding%2520mode%2520of%2520HDAC6-selective%2520hydroxamate%2520inhibitors%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D13459%26epage%3D13464%26doi%3D10.1073%2Fpnas.1718823114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayana
Reddy, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rokka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salvino, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01540</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01540" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12jsr3N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=295-308&author=J.+D.+Oskoauthor=N.+J.+Porterauthor=P.+A.+Narayana%0AReddyauthor=Y.+C.+Xiaoauthor=J.+Rokkaauthor=M.+Jungauthor=J.+M.+Hookerauthor=J.+M.+Salvinoauthor=D.+W.+Christianson&title=Exploring+Structural+Determinants+of+Inhibitor+Affinity+and+Selectivity+in+Complexes+with+Histone+Deacetylase+6&doi=10.1021%2Facs.jmedchem.9b01540"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6</span></div><div class="casAuthors">Osko, Jeremy D.; Porter, Nicholas J.; Narayana Reddy, Poli Adi; Xiao, You-Cai; Rokka, Johanna; Jung, Manfred; Hooker, Jacob M.; Salvino, Joseph M.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">295-308</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibition of histone deacetylase 6 (HDAC6) has emerged as a promising therapeutic strategy for the treatment of cancer, chemotherapy-induced peripheral neuropathy, and neurodegenerative disease.  The recent X-ray crystal structure detn. of HDAC6 enables an understanding of structural features directing affinity and selectivity in the active site.  Here, we present the X-ray crystal structures of five HDAC6-inhibitor complexes that illuminate key mol. features of the inhibitor linker and capping groups that facilitate and differentiate binding to HDAC6.  In particular, arom. and heteroarom. linkers nestle within an arom. cleft defined by F583 and F643, and different arom. linkers direct the capping group toward shallow pockets defined by the L1 loop, the L2 loop, or somewhere in between these pockets.  These results expand our understanding of factors contributing to the selective inhibition of HDAC6, particularly regarding interactions that can be targeted in the region of the L2 pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBosfiCC-DubVg90H21EOLACvtfcHk0lj7BavN0sXU4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit12jsr3N&md5=0ebd3729b8a0ed03629c4ecca475b02e</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01540%26sid%3Dliteratum%253Aachs%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DNarayana%2BReddy%26aufirst%3DP.%2BA.%26aulast%3DXiao%26aufirst%3DY.%2BC.%26aulast%3DRokka%26aufirst%3DJ.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DHooker%26aufirst%3DJ.%2BM.%26aulast%3DSalvino%26aufirst%3DJ.%2BM.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DExploring%2520Structural%2520Determinants%2520of%2520Inhibitor%2520Affinity%2520and%2520Selectivity%2520in%2520Complexes%2520with%2520Histone%2520Deacetylase%25206%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D295%26epage%3D308%26doi%3D10.1021%2Facs.jmedchem.9b01540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127023</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmcl.2020.127023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32067866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFGqs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127023&author=J.+D.+Oskoauthor=D.+W.+Christianson&title=Structural+determinants+of+affinity+and+selectivity+in+the+binding+of+inhibitors+to+histone+deacetylase+6&doi=10.1016%2Fj.bmcl.2020.127023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6</span></div><div class="casAuthors">Osko, Jeremy D.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">127023</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review. Digest.  Histone deacetylase 6 (HDAC6) is assocd. with multiple neurol. disorders as well as aggressive cancers, making its selective inhibition highly desirable for therapeutic purposes.  The basic mol. design of an effective HDAC6 inhibitor consists of a zinc-binding group, a linker, and a capping group capable of making interactions at the mouth of the active site.  To date, more than 50 high-resoln. X-ray crystal structures of HDAC6-inhibitor complexes have been reported, many of which reveal intermol. interactions that contribute to isoenzyme affinity and selectivity.  Here, we review the key features of HDAC6 inhibitor design illuminated by these structural studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEHMdvmF9TPLVg90H21EOLACvtfcHk0lj7BavN0sXU4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFGqs70%253D&md5=df46fa5e4720d8340d728e6269dadb90</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127023%26sid%3Dliteratum%253Aachs%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DStructural%2520determinants%2520of%2520affinity%2520and%2520selectivity%2520in%2520the%2520binding%2520of%2520inhibitors%2520to%2520histone%2520deacetylase%25206%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127023%26doi%3D10.1016%2Fj.bmcl.2020.127023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span> <span> </span><span class="NLM_article-title">Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">112887</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112887</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2020.112887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=33035922" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOqsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2021&pages=112887&author=M.+T.+Tavaresauthor=A.+P.+Kozikowskiauthor=S.+Shen&title=Mercaptoacetamide%3A+A+promising+zinc-binding+group+for+the+discovery+of+selective+histone+deacetylase+6+inhibitors&doi=10.1016%2Fj.ejmech.2020.112887"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Mercaptoacetamide: A promising zinc-binding group for the discovery of selective histone deacetylase 6 inhibitors</span></div><div class="casAuthors">Tavares, Mauricio T.; Kozikowski, Alan P.; Shen, Sida</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112887</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is a zinc-dependent HDAC that mainly modulates the acetylation status of non-histone substrates, such as α-tubulin and heat shock protein 90 (HSP90).  The activity of HDAC6 plays a crit. role in cell proliferation, protein trafficking and degrdn., cell shape, migration, as well as regulation of immunomodulatory factors.  For this reason, HDAC6 influences the progress of cancers, neurodegenerative disorders, and autoimmune responses.  In the last few years, the discovery of selective HDAC6 inhibitors (HDAC6is) has become an attractive research area as five HDAC6is are being investigated in phase I/II clin. trials.  However, the hydroxamic acid functional group still represents the predominant zinc-binding group (ZBG), that often suffers from poor pharmacokinetics and mutagenic potential, thus impairing the application of hydroxamate-based HDAC6is for long-term therapies.  On the other hand, mercaptoacetamide (MCA)-based HDAC6is comprise a class of compds. that, in some cases, display nanomolar HDAC6 potency and a thousand-fold selectivity over class I HDAC isoenzymes.  Moreover, MCA-based HDAC6is lack the mutagenicity assocd. with the hydroxamate function and display pharmacol. effects, demonstrating the potential of this particular ZBG to improve upon the drug-like properties of HDAC6is.  Herein, we summarize for the first time the structure-activity relationships (SARs) of MCA-based HDAC6is, discuss their HDAC6 selectivity at the mol. level using inhibitor-HDAC co-crystal structures, and further provide our perspective regarding their drug metab., pharmacokinetics, and pharmacol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxMKQVo-QIlrVg90H21EOLACvtfcHk0lj7BavN0sXU4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOqsbfJ&md5=54ac6badbc1575a7295a84db3934d6f3</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112887%26sid%3Dliteratum%253Aachs%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DShen%26aufirst%3DS.%26atitle%3DMercaptoacetamide%253A%2520A%2520promising%2520zinc-binding%2520group%2520for%2520the%2520discovery%2520of%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D209%26spage%3D112887%26doi%3D10.1016%2Fj.ejmech.2020.112887" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, R. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. P.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the discovery of potent and selective HDAC6 inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>143</i></span>,  <span class="NLM_fpage">1406</span>– <span class="NLM_lpage">1418</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.10.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2017.10.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29133060" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsl2ntbrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=143&publication_year=2018&pages=1406-1418&author=X.+X.+Wangauthor=R.+Z.+Wanauthor=Z.+P.+Liu&title=Recent+advances+in+the+discovery+of+potent+and+selective+HDAC6+inhibitors&doi=10.1016%2Fj.ejmech.2017.10.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the discovery of potent and selective HDAC6 inhibitors</span></div><div class="casAuthors">Wang, Xiu-Xiu; Wan, Ren-Zhong; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">143</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1406-1418</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase HDAC6, a member of the class IIb HDAC family, is unique among HDAC enzymes in having two active catalytic domains, and has unique physiol. function.  In addn. to the modification of histone, HDAC6 targets specific substrates including α-tubulin and HSP90, and are involved in protein trafficking and degrdn., cell shape and migration.  Selective HDAC6 inhibitors are an emerging class of pharmaceuticals due to the involvement of HDAC6 in different pathways related to neurodegenerative diseases, cancer, and immunol.  Therefore, extensive investigations have been made in the discovery of selective HDAC6 inhibitors.  Based on their different zinc binding groups (ZBGs), in this review, HDAC6 inhibitors are grouped as hydroxamic acids, a sulfur contg. ZBG based derivs. and other ZBG-derived compds., and their enzymic inhibitory activity, selectivity and other biol. activities are introduced and summarized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdsNBEWGhpCrVg90H21EOLACvtfcHk0lgDhc-J1Hxx4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsl2ntbrM&md5=f24fea971dbed247e1bb2568f85d1703</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.10.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.10.040%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%2BX.%26aulast%3DWan%26aufirst%3DR.%2BZ.%26aulast%3DLiu%26aufirst%3DZ.%2BP.%26atitle%3DRecent%2520advances%2520in%2520the%2520discovery%2520of%2520potent%2520and%2520selective%2520HDAC6%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D143%26spage%3D1406%26epage%3D1418%26doi%3D10.1016%2Fj.ejmech.2017.10.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Codd, R.</span></span> <span> </span><span class="NLM_article-title">Traversing the coordination chemistry and chemical biology of hydroxamic acids</span>. <i>Coord. Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>252</i></span>,  <span class="NLM_fpage">1387</span>– <span class="NLM_lpage">1408</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2007.08.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ccr.2007.08.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvFyntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=252&publication_year=2008&pages=1387-1408&author=R.+Codd&title=Traversing+the+coordination+chemistry+and+chemical+biology+of+hydroxamic+acids&doi=10.1016%2Fj.ccr.2007.08.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Traversing the coordination chemistry and chemical biology of hydroxamic acids</span></div><div class="casAuthors">Codd, Rachel</div><div class="citationInfo"><span class="NLM_cas:title">Coordination Chemistry Reviews</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">252</span>
        (<span class="NLM_cas:issue">12-14</span>),
    <span class="NLM_cas:pages">1387-1408</span>CODEN:
                <span class="NLM_cas:coden">CCHRAM</span>;
        ISSN:<span class="NLM_cas:issn">0010-8545</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Hydroxamic acids, R CC(O)N(R N)OH (R C = alkyl/aryl; R N = alkyl/aryl or H), coordinate a wide variety of transition metal ions predominantly as the monoanionic hydroxamato or dianionic (R N = H) hydroximato O,O'-bidentate chelate.  Anal. of x-ray crystallog. data from 25 hydroxamato and 17 hydroximato mononuclear non-oxo-contg. complexes with bidentate O,O'-coordination from monohydroxamic acids shows a strong (R ≥ 0.92) pos. correlation between the metal ion radius and the M-OC or M-ON bond lengths; in almost all complexes, M-OC > M-ON.  A map of bond lengths in the second coordination sphere (C-N, C-O, N-O), compared to the corresponding bond lengths in free hydroxamic acids, provides insight into the dominant resonance structures of the coordinated ligands.  The diverse coordination chem. of hydroxamic acids is reflected in the groups of complexes which have been characterized by x-ray crystallog.: homo- and hetero-metallic complexes of higher nuclearity, metallacrowns, and Pt(II) and Pd(II) complexes, which show non-O,O'-type coordination modes.  The coordination chem. of hydroxamic acids is relevant in the context of chem. biol. since these bioligands: (i) coordinate metal sites in the Ni(II)-contg. metalloprotein, urease, and the Zn(II)-contg. metalloproteins, matrix metalloproteases (MMPs), carbonic anhydrase and tumor necrosis factor-α converting enzyme (TACE); and (ii) feature as the Fe(III)-binding functional groups in bacterially derived Fe(III) sequestration mols. called siderophores.  Each of (i) and (ii) couples into aspects of human medicine, in terms of hydroxamic acid-based inhibition of MMPs and related enzymes and the treatment of Fe(III) overload disease, which is currently treated using the mesylate salt of desferrioxamine B (DFOB), a linear trihydroxamic acid originally sourced from the soil bacterium, Streptomyces pilosus.  The x-ray crystal structure of Fe(III)-loaded DFOB (ferrioxamine B: FOB) bound to the iron-siderophore periplasmic transport protein from Escherichia coli (FhuD) shows that FOB adopts a chiral and geometric form in the binary FOB-FhuD complex that is distinct from that obsd. in free FOB.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLPR-i9AgPHLVg90H21EOLACvtfcHk0lgDhc-J1Hxx4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvFyntrg%253D&md5=1f9db151c02645e39493beae339adbcb</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2007.08.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2007.08.001%26sid%3Dliteratum%253Aachs%26aulast%3DCodd%26aufirst%3DR.%26atitle%3DTraversing%2520the%2520coordination%2520chemistry%2520and%2520chemical%2520biology%2520of%2520hydroxamic%2520acids%26jtitle%3DCoord.%2520Chem.%2520Rev.%26date%3D2008%26volume%3D252%26spage%3D1387%26epage%3D1408%26doi%3D10.1016%2Fj.ccr.2007.08.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marmion, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, K. B.</span></span> <span> </span><span class="NLM_article-title">Hydroxamic Acids - An Intriguing Family of Enzyme Inhibitors and Biomedical Ligands</span>. <i>Eur. J. Inorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>2004</i></span>,  <span class="NLM_fpage">3003</span>– <span class="NLM_lpage">3016</span>, <span class="refDoi"> DOI: 10.1002/ejic.200400221</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fejic.200400221" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2004&publication_year=2004&pages=3003-3016&author=C.+J.+Marmionauthor=D.+Griffithauthor=K.+B.+Nolan&title=Hydroxamic+Acids+-+An+Intriguing+Family+of+Enzyme+Inhibitors+and+Biomedical+Ligands&doi=10.1002%2Fejic.200400221"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1002%2Fejic.200400221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejic.200400221%26sid%3Dliteratum%253Aachs%26aulast%3DMarmion%26aufirst%3DC.%2BJ.%26aulast%3DGriffith%26aufirst%3DD.%26aulast%3DNolan%26aufirst%3DK.%2BB.%26atitle%3DHydroxamic%2520Acids%2520-%2520An%2520Intriguing%2520Family%2520of%2520Enzyme%2520Inhibitors%2520and%2520Biomedical%2520Ligands%26jtitle%3DEur.%2520J.%2520Inorg.%2520Chem.%26date%3D2004%26volume%3D2004%26spage%3D3003%26epage%3D3016%26doi%3D10.1002%2Fejic.200400221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pikul, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almstead, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natchus, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anastasio, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhail, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snider, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taiwo, Y. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunaway, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowty, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mieling, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janusz, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang-Weigand, S.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Piperazine-Based Matrix Metalloproteinase Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1021/jm990366q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990366q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD3cXksVSluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=369-380&author=M.+Chengauthor=B.+Deauthor=S.+Pikulauthor=N.+G.+Almsteadauthor=M.+G.+Natchusauthor=M.+V.+Anastasioauthor=S.+J.+McPhailauthor=C.+E.+Sniderauthor=Y.+O.+Taiwoauthor=L.+Chenauthor=C.+M.+Dunawayauthor=F.+Guauthor=M.+E.+Dowtyauthor=G.+E.+Mielingauthor=M.+J.+Januszauthor=S.+Wang-Weigand&title=Design+and+Synthesis+of+Piperazine-Based+Matrix+Metalloproteinase+Inhibitors&doi=10.1021%2Fjm990366q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Piperazine-Based Matrix Metalloproteinase Inhibitors</span></div><div class="casAuthors">Cheng, Menyan; De, Biswanath; Pikul, Stanislaw; Almstead, Neil G.; Natchus, Michael G.; Anastasio, Melanie V.; McPhail, Sara J.; Snider, Catherine E.; Taiwo, Yetunde O.; Chen, Longyin; Dunaway, C. Michelle; Gu, Fei; Dowty, Martin E.; Mieling, Glen E.; Janusz, Michael J.; Wang-Weigand, Sherry</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">43</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">369-380</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new generation of cyclic matrix metalloproteinase (MMP) inhibitors derived from dl-piperazinecarboxylic acid was described.  The design involves: incorporation of hydroxamic acid as the bidentate chelating agent for catalytic Zn2+, placement of a sulfonamide group at the 1N-position of the piperazine ring to fill the S1' pocket of the enzyme, and finally attachment of diverse functional groups at the 4N-position to optimize potency and peroral absorption.  A unique combination of all three elements produced 3-[(hydroxyamino)carbonyl]-4-[(4-methoxyphenyl)sulfonyl]-1-piperazinecarboxylic acid phenylmethyl ester with high affinity for MMP-1, MMP-3, MMP-9, and MMP-13 (24, 18, 1.9, and 1.3 nM, resp.).  X-ray crystallog. data obtained for MMP-3 co-crystd. with 3-[(hydroxyamino)carbonyl]-4-[(4-methoxyphenyl)sulfonyl]-1-piperazinecarboxylic acid phenylmethyl ester gave detailed information on key binding interactions defining an overall scaffold geometry for piperazine-based MMP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9QAn3BVmNX7Vg90H21EOLACvtfcHk0lgDhc-J1Hxx4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXksVSluw%253D%253D&md5=471d82becec78b52f34b755a9ad7484c</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1021%2Fjm990366q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990366q%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DM.%26aulast%3DDe%26aufirst%3DB.%26aulast%3DPikul%26aufirst%3DS.%26aulast%3DAlmstead%26aufirst%3DN.%2BG.%26aulast%3DNatchus%26aufirst%3DM.%2BG.%26aulast%3DAnastasio%26aufirst%3DM.%2BV.%26aulast%3DMcPhail%26aufirst%3DS.%2BJ.%26aulast%3DSnider%26aufirst%3DC.%2BE.%26aulast%3DTaiwo%26aufirst%3DY.%2BO.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDunaway%26aufirst%3DC.%2BM.%26aulast%3DGu%26aufirst%3DF.%26aulast%3DDowty%26aufirst%3DM.%2BE.%26aulast%3DMieling%26aufirst%3DG.%2BE.%26aulast%3DJanusz%26aufirst%3DM.%2BJ.%26aulast%3DWang-Weigand%26aufirst%3DS.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Piperazine-Based%2520Matrix%2520Metalloproteinase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D369%26epage%3D380%26doi%3D10.1021%2Fjm990366q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of novel benzofuroxan-based pyrrolidine hydroxamates as matrix metalloproteinase inhibitors with nitric oxide releasing activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">4363</span>– <span class="NLM_lpage">4374</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.06.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmc.2018.06.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30093347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGitrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=4363-4374&author=H.+Zhangauthor=X.+Wangauthor=J.+Maoauthor=Y.+Huangauthor=W.+Xuauthor=Y.+Duanauthor=J.+Zhang&title=Synthesis+and+biological+evaluation+of+novel+benzofuroxan-based+pyrrolidine+hydroxamates+as+matrix+metalloproteinase+inhibitors+with+nitric+oxide+releasing+activity&doi=10.1016%2Fj.bmc.2018.06.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of novel benzofuroxan-based pyrrolidine hydroxamates as matrix metalloproteinase inhibitors with nitric oxide releasing activity</span></div><div class="casAuthors">Zhang, Hao; Wang, Xuejian; Mao, Jing; Huang, Yongxue; Xu, Wenfang; Duan, Yu; Zhang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4363-4374</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">On the basis of the strategy of "multifunctional drugs", a series of novel matrix metalloproteinase inhibitors (MMPIs) contg. benzofuroxan scaffold as a nitric oxide donor were designed, synthesized and evaluated.  All synthesized compds., esp. 16a (5-(6)-(((3S,5S)-5-(hydroxycarbamoyl)-1-((4-phenoxyphenyl)sulfonyl)pyrrolidin-3-yl)carbamoyl)benzo[c][1,2,5]oxadiazole 1-oxide), exhibited potent MMP-2,-9 inhibitory activities, anti-proliferative activities and could produce high levels of NO in Hela cells.  They were also evaluated for both of their anti-invasion and anti-angiogenesis effects.  Furthermore, compared with LY52, 16a demonstrated competitive antitumor activity in vivo.  These hybrid NO-MMPIs might offer suitable scaffolds to develop valuable MMP inhibitors for the further discovery of novel anti-cancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCsBjuGxdEzLVg90H21EOLACvtfcHk0lhrb6Oomv1zYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGitrzJ&md5=cdf427e8768cdfe55f5c314ea0e6e229</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.06.023%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DMao%26aufirst%3DJ.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DDuan%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520novel%2520benzofuroxan-based%2520pyrrolidine%2520hydroxamates%2520as%2520matrix%2520metalloproteinase%2520inhibitors%2520with%2520nitric%2520oxide%2520releasing%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D4363%26epage%3D4374%26doi%3D10.1016%2Fj.bmc.2018.06.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vannini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Filocamo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casavola, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunetti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renzoni, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarty, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paolini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallinari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinkuhler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marco, S.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">15064</span>– <span class="NLM_lpage">15069</span>, <span class="refDoi"> DOI: 10.1073/pnas.0404603101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1073%2Fpnas.0404603101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=15477595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVShurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=15064-15069&author=A.+Vanniniauthor=C.+Volpariauthor=G.+Filocamoauthor=E.+C.+Casavolaauthor=M.+Brunettiauthor=D.+Renzoniauthor=P.+Chakravartyauthor=C.+Paoliniauthor=R.+De+Francescoauthor=P.+Gallinariauthor=C.+Steinkuhlerauthor=S.+Di+Marco&title=Crystal+structure+of+a+eukaryotic+zinc-dependent+histone+deacetylase%2C+human+HDAC8%2C+complexed+with+a+hydroxamic+acid+inhibitor&doi=10.1073%2Fpnas.0404603101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor</span></div><div class="casAuthors">Vannini, Alessandro; Volpari, Cinzia; Filocamo, Gessica; Casavola, Elena Caroli; Brunetti, Mirko; Renzoni, Debora; Chakravarty, Prasun; Paolini, Chantal; De Francesco, Raffaele; Gallinari, Paola; Steinkuehler, Christian; Di Marco, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">15064-15069</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a family of enzymes involved in the regulation of gene expression, DNA repair, and stress response.  These processes often are altered in tumors, and HDAC inhibitors have had pronounced antitumor activity with promising results in clin. trials.  Here, we report the crystal structure of human HDAC8 in complex with a hydroxamic acid inhibitor.  Such a structure of a eukaryotic zinc-dependent HDAC has not be described previously.  Similar to bacterial HDAC-like protein, HDAC8 folds in a single α/β domain.  The inhibitor and the zinc-binding sites are similar in both proteins.  However, significant differences are obsd. in the length and structure of the loops surrounding the active site, including the presence of two potassium ions in HDAC8 structure, one of which interacts with key catalytic residues.  CD data suggest a direct role of potassium in the fold stabilization of HDAC8.  Knockdown of HDAC8 by RNA interference inhibits growth of human lung, colon, and cervical cancer cell lines, highlighting the importance of this HDAC subtype for tumor cell proliferation.  Our findings open the way for the design and development of selective inhibitors of HDAC8 as possible antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqs_auq2Wf8RLVg90H21EOLACvtfcHk0lhrb6Oomv1zYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVShurY%253D&md5=86bf33830743d2169514f686b7a30ed8</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0404603101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0404603101%26sid%3Dliteratum%253Aachs%26aulast%3DVannini%26aufirst%3DA.%26aulast%3DVolpari%26aufirst%3DC.%26aulast%3DFilocamo%26aufirst%3DG.%26aulast%3DCasavola%26aufirst%3DE.%2BC.%26aulast%3DBrunetti%26aufirst%3DM.%26aulast%3DRenzoni%26aufirst%3DD.%26aulast%3DChakravarty%26aufirst%3DP.%26aulast%3DPaolini%26aufirst%3DC.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DGallinari%26aufirst%3DP.%26aulast%3DSteinkuhler%26aufirst%3DC.%26aulast%3DDi%2BMarco%26aufirst%3DS.%26atitle%3DCrystal%2520structure%2520of%2520a%2520eukaryotic%2520zinc-dependent%2520histone%2520deacetylase%252C%2520human%2520HDAC8%252C%2520complexed%2520with%2520a%2520hydroxamic%2520acid%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D15064%26epage%3D15069%26doi%3D10.1073%2Fpnas.0404603101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finnin, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Donigian, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richon, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rifkind, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">Structures of a histone deacetylase homologue bound to theTSA and SAHA inhibitoors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>401</i></span>,  <span class="NLM_fpage">188</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1038/43710</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2F43710" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10490031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=401&publication_year=1999&pages=188-193&author=M.+S.+Finninauthor=J.+R.+Donigianauthor=A.+Cohenauthor=V.+M.+Richonauthor=R.+A.+Rifkindauthor=P.+A.+Marksauthor=R.+Breslowauthor=N.+P.+Pavletich&title=Structures+of+a+histone+deacetylase+homologue+bound+to+theTSA+and+SAHA+inhibitoors&doi=10.1038%2F43710"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors</span></div><div class="casAuthors">Finnin, Michael S.; Donigian, Jill R.; Cohen, Alona; Richon, Victoria M.; Rifkind, Richard A.; Marks, Paul A.; Breslow, Ronald; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">401</span>
        (<span class="NLM_cas:issue">6749</span>),
    <span class="NLM_cas:pages">188-193</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) mediate changes in nucleosome conformation and are important in the regulation of gene expression.  HDACs are involved in cell-cycle progression and differentiation, and their deregulation is assocd. with several cancers.  HDAC inhibitors, such as trichostatin A (TSA) and suberoylanilide hydroxamic acid (SAHA), have anti-tumor effects, as they can inhibit cell growth, induce terminal differentiation and prevent the formation of tumors in mice models, and they are effective in the treatment of promyelocytic leukemia.  Here we describe the structure of the histone deacetylase catalytic core, as revealed by the crystal structure of a homolog from the hyperthermophilic bacterium Aquifex aeolicus, that shares 35.2% identity with human HDAC1 over 375 residues, deacetylates histones in vitro and is inhibited by TSA and SAHA.  The deacetylase, deacetylase-TSA and deacetylase-SAHA structures reveal an active site consisting of a tubular pocket, a zinc-binding site and two Asp-His charge-relay systems, and establish the mechanism of HDAC inhibition.  The residues that make up the active site and contact the inhibitors are conserved across the HDAC family.  These structures also suggest a mechanism for the deacetylation reaction and provide a framework for the further development of HDAC inhibitors as antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrG0lsZMMo37Vg90H21EOLACvtfcHk0lgeLkOPZX7vxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXlvFKgtrc%253D&md5=29bbc6d3ba9a9d2a8c330349ae8199a8</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2F43710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F43710%26sid%3Dliteratum%253Aachs%26aulast%3DFinnin%26aufirst%3DM.%2BS.%26aulast%3DDonigian%26aufirst%3DJ.%2BR.%26aulast%3DCohen%26aufirst%3DA.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DRifkind%26aufirst%3DR.%2BA.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DStructures%2520of%2520a%2520histone%2520deacetylase%2520homologue%2520bound%2520to%2520theTSA%2520and%2520SAHA%2520inhibitoors%26jtitle%3DNature%26date%3D1999%26volume%3D401%26spage%3D188%26epage%3D193%26doi%3D10.1038%2F43710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogier, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirstea, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scullen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canavese, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raje, N.</span></span> <span> </span><span class="NLM_article-title">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">2579</span>– <span class="NLM_lpage">2589</span>, <span class="refDoi"> DOI: 10.1182/blood-2011-10-387365</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1182%2Fblood-2011-10-387365" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=22262760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2012&pages=2579-2589&author=L.+Santoauthor=T.+Hideshimaauthor=A.+L.+Kungauthor=J.-C.+Tsengauthor=D.+Tamangauthor=M.+Yangauthor=M.+Jarpeauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=W.+C.+Ogierauthor=D.+Cirsteaauthor=S.+Rodigauthor=H.+Edaauthor=T.+Scullenauthor=M.+Canaveseauthor=J.+Bradnerauthor=K.+C.+Andersonauthor=S.+S.+Jonesauthor=N.+Raje&title=Preclinical+activity%2C+pharmacodynamic%2C+and+pharmacokinetic+properties+of+a+selective+HDAC6+inhibitor%2C+ACY-1215%2C+in+combination+with+bortezomib+in+multiple+myeloma&doi=10.1182%2Fblood-2011-10-387365"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma</span></div><div class="casAuthors">Santo, Loredana; Hideshima, Teru; Kung, Andrew L.; Tseng, Jen-Chieh; Tamang, David; Yang, Min; Jarpe, Matthew; van Duzer, John H.; Mazitschek, Ralph; Ogier, Walter C.; Cirstea, Diana; Rodig, Scott; Eda, Homare; Scullen, Tyler; Canavese, Miriam; Bradner, James; Anderson, Kenneth C.; Jones, Simon S.; Raje, Noopur</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2579-2589</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) enzymic activity has been linked to the transcription of DNA in cancers including multiple myeloma (MM).  Therefore, HDAC inhibitors used alone and in combination are being actively studied as novel therapies in MM.  In the present study, we investigated the preclin. activity of ACY-1215, an HDAC6-selective inhibitor, alone and in combination with bortezomib in MM.  Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase.  In vivo, the anti-MM activity of ACY-1215 in combination with bortezomib was confirmed using 2 different xenograft SCID mouse models: human MM injected s.c. (the plasmacytoma model) and luciferase-expressing human MM injected i.v. (the disseminated MM model).  Tumor growth was significantly delayed and overall survival was significantly prolonged in animals treated with the combination therapy.  Pharmacokinetic data showed peak plasma levels of ACY-1215 at 4 h after treatment coincident with an increase in acetylated α-tubulin, a marker of HDAC6 inhibition, by immunohistochem. and Western blot anal.  These studies provide preclin. rationale for acetylated α-tubulin use as a pharmacodynamic biomarker in future clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoelmsk1wo_LVg90H21EOLACvtfcHk0lgeLkOPZX7vxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XltVOntb4%253D&md5=094298bdd3d5b91c7060d8b294857846</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1182%2Fblood-2011-10-387365&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2011-10-387365%26sid%3Dliteratum%253Aachs%26aulast%3DSanto%26aufirst%3DL.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DTseng%26aufirst%3DJ.-C.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DOgier%26aufirst%3DW.%2BC.%26aulast%3DCirstea%26aufirst%3DD.%26aulast%3DRodig%26aufirst%3DS.%26aulast%3DEda%26aufirst%3DH.%26aulast%3DScullen%26aufirst%3DT.%26aulast%3DCanavese%26aufirst%3DM.%26aulast%3DBradner%26aufirst%3DJ.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DRaje%26aufirst%3DN.%26atitle%3DPreclinical%2520activity%252C%2520pharmacodynamic%252C%2520and%2520pharmacokinetic%2520properties%2520of%2520a%2520selective%2520HDAC6%2520inhibitor%252C%2520ACY-1215%252C%2520in%2520combination%2520with%2520bortezomib%2520in%2520multiple%2520myeloma%26jtitle%3DBlood%26date%3D2012%26volume%3D119%26spage%3D2579%26epage%3D2589%26doi%3D10.1182%2Fblood-2011-10-387365" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeciga-Pinto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Duzer, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span> <span> </span><span class="NLM_article-title">Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2694</span>– <span class="NLM_lpage">2707</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.13738</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.18632%2Foncotarget.13738" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27926524" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BC2sjksVSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=2694-2707&author=P.+Huangauthor=I.+Almeciga-Pintoauthor=M.+Jarpeauthor=J.+H.+van+Duzerauthor=R.+Mazitschekauthor=M.+Yangauthor=S.+S.+Jonesauthor=S.+N.+Quayle&title=Selective+HDAC+inhibition+by+ACY-241+enhances+the+activity+of+paclitaxel+in+solid+tumor+models&doi=10.18632%2Foncotarget.13738"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models</span></div><div class="casAuthors">Huang Pengyu; Almeciga-Pinto Ingrid; Jarpe Matthew; van Duzer John H; Yang Min; Jones Simon S; Quayle Steven N; Mazitschek Ralph</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">2694-2707</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">ACY-241 is a novel, orally available and selective histone deacetylase (HDAC) 6 inhibitor in Phase 1b clinical development in multiple myeloma (NCT 02400242).  Like the structurally related drug ACY-1215 (ricolinostat), ACY-241 has the potential for a substantially reduced side effect profile versus current nonselective HDAC inhibitor drug candidates due to reduced potency against Class I HDACs while retaining the potential for anticancer effectiveness.  We now show that combination treatment of xenograft models with paclitaxel and either ricolinostat or ACY-241 significantly suppresses solid tumor growth.  In cell lines from multiple solid tumor lineages, combination treatment with ACY-241 and paclitaxel enhanced inhibition of proliferation and increased cell death relative to either single agent alone.  Combination treatment with ACY-241 and paclitaxel also resulted in more frequent occurrence of mitotic cells with abnormal multipolar spindles and aberrant mitoses, consistent with the observed increase of aneuploid cells.  At the molecular level, multipolar mitotic spindle formation was observed to be NuMA-dependent and γ-tubulin independent, suggesting that treatment-induced multipolar spindle formation does not depend on centrosomal amplification.  The significantly enhanced efficacy of ACY-241 plus paclitaxel observed here, in addition to the anticipated superior safety profile of a selective HDAC6 inhibitor versus pan-HDAC inhibitors, provides a strong rationale for clinical development of this combination in patients with advanced solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFLMaYGUFFIBfKb6ELK8t0fW6udTcc2eaeQj4kFSt7MLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2sjksVSmuw%253D%253D&md5=b8a516375b03fc65536598ab9c0e4a21</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.13738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.13738%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DP.%26aulast%3DAlmeciga-Pinto%26aufirst%3DI.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3Dvan%2BDuzer%26aufirst%3DJ.%2BH.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26atitle%3DSelective%2520HDAC%2520inhibition%2520by%2520ACY-241%2520enhances%2520the%2520activity%2520of%2520paclitaxel%2520in%2520solid%2520tumor%2520models%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D2694%26epage%3D2707%26doi%3D10.18632%2Foncotarget.13738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span> <span> </span><span class="NLM_article-title">Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">817</span>, <span class="refDoi"> DOI: 10.1038/s41419-018-0788-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fs41419-018-0788-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30050135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3c7itlKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=817&author=J.+Caoauthor=W.+Lvauthor=L.+Wangauthor=J.+Xuauthor=P.+Yuanauthor=S.+Huangauthor=Z.+Heauthor=J.+Hu&title=Ricolinostat+%28ACY-1215%29+suppresses+proliferation+and+promotes+apoptosis+in+esophageal+squamous+cell+carcinoma+via+miR-30d%2FPI3K%2FAKT%2FmTOR+and+ERK+pathways&doi=10.1038%2Fs41419-018-0788-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways</span></div><div class="casAuthors">Cao Jinlin; Lv Wang; Wang Luming; Xu Jinming; Yuan Ping; Huang Sha; He Zhehao; Hu Jian</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">817</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Ricolinostat (ACY-1215), a first-in-class selective HDAC6 inhibitor, exhibits antitumor effects alone or in combination with other drugs in various cancers.  However, its efficacy in esophageal cancer remains unclear.  In this study, we found that the high expression of HDAC6 was associated with poor prognosis in esophageal squamous cell carcinoma (ESCC) tissues.  Then, we identified that ACY-1215 significantly inhibited cellular proliferation in ESCC, and caused G2/M phase arrest and apoptosis.  We further demonstrated that ACY-1215 treatment reduced the expression of PI3K, P-AKT, P-mTOR, and P-ERK1/2 and increased that of Ac-H3K9 and Ac-H4K8.  In addition, using miRNA microarray and bioinformatics analysis, we detected that ACY-1215 promoted miR-30d expression, and PI3K regulatory subunit 2 (PIK3R2) was a direct target of miR-30d.  Anti-miR-30d partially rescued the G2/M phase arrest and apoptosis caused by ACY-1215 treatment.  The reductions in PI3K, P-AKT, and P-mTOR expression were also partially reversed by miR-30d inhibitor.  Furthermore, the effects of ACY-1215 inhibited ESCC proliferation were validated in a mouse xenograft model in vivo.  In conclusion, our study showed that ACY-1215 suppressed proliferation and promoted apoptosis in ESCC via miR-30d/PI3K/AKT/mTOR and ERK pathways and that ACY-1215 may be a promising antitumor agent in ESCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSIrxW4JKD57hwLZxei1HN8fW6udTcc2eYPYx2wevC4bLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c7itlKktw%253D%253D&md5=574b62b346c61c362303e49c7c1311d5</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fs41419-018-0788-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-018-0788-2%26sid%3Dliteratum%253Aachs%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DP.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHe%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DJ.%26atitle%3DRicolinostat%2520%2528ACY-1215%2529%2520suppresses%2520proliferation%2520and%2520promotes%2520apoptosis%2520in%2520esophageal%2520squamous%2520cell%2520carcinoma%2520via%2520miR-30d%252FPI3K%252FAKT%252FmTOR%2520and%2520ERK%2520pathways%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2018%26volume%3D9%26spage%3D817%26doi%3D10.1038%2Fs41419-018-0788-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, Z.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">234</span>, <span class="refDoi"> DOI: 10.1111/jnc.14849</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1111%2Fjnc.14849" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31390677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1aqsb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2020&pages=221-234&author=Z.+Huangauthor=Y.+Xiaauthor=K.+Huauthor=S.+Zengauthor=L.+Wuauthor=S.+Liuauthor=C.+Zhiauthor=M.+Laiauthor=D.+Chenauthor=L.+Xieauthor=Z.+Yuan&title=Histone+deacetylase+6+promotes+growth+of+glioblastoma+through+the+MKK7%2FJNK%2Fc-Jun+signaling+pathway&doi=10.1111%2Fjnc.14849"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 promotes growth of glioblastoma through the MKK7/JNK/c-Jun signaling pathway</span></div><div class="casAuthors">Huang, Ziyan; Xia, Yong; Hu, Kunhua; Zeng, Shulian; Wu, Liqiang; Liu, Sisi; Zhi, Cheng; Lai, Miaoling; Chen, Danmin; Xie, Longchang; Yuan, Zhongmin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">221-234</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) activity contributes to the malignant proliferation, invasion, and migration of glioma cells (GCs), but the mol. mechanisms underlying the processes remains elusive.  Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth.  Further investigation showed that these effects resulted from HDAC6 inhibitor-induced suppression of MAPK kinase 7 (MKK7), which was identified to be crit. for JNK activation and exerts the oncogenic roles in GCs.  Selectively silencing HDAC6 by siRNAs had the same responses, whereas transient transfections expressing HDAC6 promoted MKK7 expression.  Interestingly, by performing Q-PCR, HDAC6 inhibition did not cause a down-regulation of MKK7 mRNA level, whereas the suppressive effects on MKK7 protein can be efficiently blocked by the proteasomal inhibitor MG132.  As a further test, elevating MKK7-JNK activity was sufficient to rescue HDAC6 inhibitor-mediated-suppressive effects on c-Jun activation and the malignant features.  The suppression of both MKK7 expression and JNK/c-Jun activities was involved in the tumor-growth inhibitory effects induced by CAY10603 in U87-xenograft mice.  Collectively, our findings provide new insights into the mol. mechanism of glioma malignancy regarding HDAC6 in the selective regulation of MKK7 expression and JNK/c-Jun activity.  MKK7 protein stability critically depends on HDAC6 activity, and inhibition of HDAC6 probably presents a potential strategy for suppressing the oncogenic roles of MKK7/JNK/c-Jun axis in GCs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoV6ciEffisZrVg90H21EOLACvtfcHk0lho2WM1lrtJBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1aqsb%252FJ&md5=239541d1b4051ddaa1a5b7aa42d109d3</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1111%2Fjnc.14849&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.14849%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DXia%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DK.%26aulast%3DZeng%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DZhi%26aufirst%3DC.%26aulast%3DLai%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DXie%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DZ.%26atitle%3DHistone%2520deacetylase%25206%2520promotes%2520growth%2520of%2520glioblastoma%2520through%2520the%2520MKK7%252FJNK%252Fc-Jun%2520signaling%2520pathway%26jtitle%3DJ.%2520Neurochem.%26date%3D2020%26volume%3D152%26spage%3D221%26epage%3D234%26doi%3D10.1111%2Fjnc.14849" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adeegbe, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lizotte, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamihara, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almonte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dries, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Warner-Hatten, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrillon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poudel-Neupane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guerriero, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awad, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span> <span> </span><span class="NLM_article-title">Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">852</span>– <span class="NLM_lpage">867</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-16-1020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1158%2F2159-8290.CD-16-1020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=28408401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1GgsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=852-867&author=D.+O.+Adeegbeauthor=Y.+Liuauthor=P.+H.+Lizotteauthor=Y.+Kamiharaauthor=A.+R.+Arefauthor=C.+Almonteauthor=R.+Driesauthor=Y.+Liauthor=S.+Liuauthor=X.+Wangauthor=T.+Warner-Hattenauthor=J.+Castrillonauthor=G.+C.+Yuanauthor=N.+Poudel-Neupaneauthor=H.+Zhangauthor=J.+L.+Guerrieroauthor=S.+Hanauthor=M.+M.+Awadauthor=D.+A.+Barbieauthor=J.+Ritzauthor=S.+S.+Jonesauthor=P.+S.+Hammermanauthor=J.+Bradnerauthor=S.+N.+Quayleauthor=K.+K.+Wong&title=Synergistic+Immunostimulatory+Effects+and+Therapeutic+Benefit+of+Combined+Histone+Deacetylase+and+Bromodomain+Inhibition+in+Non-Small+Cell+Lung+Cancer&doi=10.1158%2F2159-8290.CD-16-1020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Adeegbe, Dennis O.; Liu, Yan; Lizotte, Patrick H.; Kamihara, Yusuke; Aref, Amir R.; Almonte, Christina; Dries, Ruben; Li, Yuyang; Liu, Shengwu; Wang, Xiaoen; Warner-Hatten, Tiquella; Castrillon, Jessica; Yuan, Guo-Cheng; Poudel-Neupane, Neermala; Zhang, Haikuo; Guerriero, Jennifer L.; Han, Shiwei; Awad, Mark M.; Barbie, David A.; Ritz, Jerome; Jones, Simon S.; Hammerman, Peter S.; Bradner, James; Quayle, Steven N.; Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">852-867</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Effective therapies for non-small cell lung cancer (NSCLC) remain challenging despite an increasingly comprehensive understanding of somatically altered oncogenic pathways.  It is now clear that therapeutic agents with potential to impact the tumor immune microenvironment potentiate immune-orchestrated therapeutic benefit.  Herein, we evaluated the immunoregulatory properties of histone deacetylase (HDAC) and bromodomain inhibitors, two classes of drugs that modulate the epigenome, with a focus on key cell subsets that are engaged in an immune response.  By evaluating human peripheral blood and NSCLC tumors, we show that the selective HDAC6 inhibitor ricolinostat promotes phenotypic changes that support enhanced T-cell activation and improved function of antigen-presenting cells.  The bromodomain inhibitor JQ1 attenuated CD4+FOXP3+ T regulatory cell suppressive function and synergized with ricolinostat to facilitate immune-mediated tumor growth arrest, leading to prolonged survival of mice with lung adenocarcinomas.  Collectively, our findings highlight the immunomodulatory effects of two epigenetic modifiers that, together, promote T cell-mediated antitumor immunity and demonstrate their therapeutic potential for treatment of NSCLC.  Significance: Selective inhibition of HDACs and bromodomain proteins modulates tumor-assocd. immune cells in a manner that favors improved T-cell function and reduced inhibitory cellular mechanisms.  These effects facilitated robust antitumor responses in tumor-bearing mice, demonstrating the therapeutic potential of combining these epigenetic modulators for the treatment of NSCLC.  Cancer Discov; 7(8); 852-67. ©2017 AACR.  This article is highlighted in the In This Issue feature, p.  783.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqcW56lDCg-LVg90H21EOLACvtfcHk0lho2WM1lrtJBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1GgsrrP&md5=abb4406e10448c960a621df6505177cf</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-16-1020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-16-1020%26sid%3Dliteratum%253Aachs%26aulast%3DAdeegbe%26aufirst%3DD.%2BO.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLizotte%26aufirst%3DP.%2BH.%26aulast%3DKamihara%26aufirst%3DY.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DAlmonte%26aufirst%3DC.%26aulast%3DDries%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DWarner-Hatten%26aufirst%3DT.%26aulast%3DCastrillon%26aufirst%3DJ.%26aulast%3DYuan%26aufirst%3DG.%2BC.%26aulast%3DPoudel-Neupane%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DGuerriero%26aufirst%3DJ.%2BL.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DAwad%26aufirst%3DM.%2BM.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DRitz%26aufirst%3DJ.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DBradner%26aufirst%3DJ.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DSynergistic%2520Immunostimulatory%2520Effects%2520and%2520Therapeutic%2520Benefit%2520of%2520Combined%2520Histone%2520Deacetylase%2520and%2520Bromodomain%2520Inhibition%2520in%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2017%26volume%3D7%26spage%3D852%26epage%3D867%26doi%3D10.1158%2F2159-8290.CD-16-1020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adeegbe, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinn, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dries, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buczkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span> <span> </span><span class="NLM_article-title">NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">3709</span>– <span class="NLM_lpage">3717</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-18-0161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1158%2F0008-5472.CAN-18-0161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29760044" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1altbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2018&pages=3709-3717&author=Y.+Liuauthor=Y.+Liauthor=S.+Liuauthor=D.+O.+Adeegbeauthor=C.+L.+Christensenauthor=M.+M.+Quinnauthor=R.+Driesauthor=S.+Hanauthor=K.+Buczkowskiauthor=X.+Wangauthor=T.+Chenauthor=P.+Gaoauthor=H.+Zhangauthor=F.+Liauthor=P.+S.+Hammermanauthor=J.+E.+Bradnerauthor=S.+N.+Quayleauthor=K.+K.+Wong&title=NK+Cells+Mediate+Synergistic+Antitumor+Effects+of+Combined+Inhibition+of+HDAC6+and+BET+in+a+SCLC+Preclinical+Model&doi=10.1158%2F0008-5472.CAN-18-0161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model</span></div><div class="casAuthors">Liu, Yan; Li, Yuyang; Liu, Shengwu; Adeegbe, Dennis O.; Christensen, Camilla L.; Quinn, Max M.; Dries, Ruben; Han, Shiwei; Buczkowski, Kevin; Wang, Xiaoen; Chen, Ting; Gao, Peng; Zhang, Hua; Li, Fei; Hammerman, Peter S.; Bradner, James E.; Quayle, Steven N.; Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3709-3717</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Small-cell lung cancer (SCLC) has the highest malignancy among all lung cancers, exhibiting aggressive growth and early metastasis to distant sites.  For 30 years, treatment options for SCLC have been limited to chemotherapy, warranting the need for more effective treatments.  Frequent inactivation of TP53 and RB1 as well as histone dysmodifications in SCLC suggest that transcriptional and epigenetic regulations play a major role in SCLC disease evolution.  Here we performed a synthetic lethal screen using the BET inhibitor JQ1 and an shRNA library targeting 550 epigenetic genes in treatment-refractory SCLC xenograft models and identified HDAC6 as a synthetic lethal target in combination with JQ1.  Combined treatment of human and mouse SCLC cell line-derived xenograft tumors with the HDAC6 inhibitor ricolinostat (ACY-1215) and JQ1 demonstrated significant inhibition of tumor growth; this effect was abolished upon depletion of NK cells, suggesting that these innate immune lymphoid cells play a role in SCLC tumor treatment response.  Collectively, these findings suggest a potential new treatment for recurrent SCLC.  Significance: These findings identify a novel therapeutic strategy for SCLC using a combination of HDAC6 and BET inhibitors.  Cancer Res; 78(13); 3709-17. 2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiaTtuegpOv7Vg90H21EOLACvtfcHk0lhYhmTuIp7F9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1altbvP&md5=c254a1767c6ade0a7db7641ba7ed10d5</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-18-0161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-18-0161%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DAdeegbe%26aufirst%3DD.%2BO.%26aulast%3DChristensen%26aufirst%3DC.%2BL.%26aulast%3DQuinn%26aufirst%3DM.%2BM.%26aulast%3DDries%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DS.%26aulast%3DBuczkowski%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DNK%2520Cells%2520Mediate%2520Synergistic%2520Antitumor%2520Effects%2520of%2520Combined%2520Inhibition%2520of%2520HDAC6%2520and%2520BET%2520in%2520a%2520SCLC%2520Preclinical%2520Model%26jtitle%3DCancer%2520Res.%26date%3D2018%26volume%3D78%26spage%3D3709%26epage%3D3717%26doi%3D10.1158%2F0008-5472.CAN-18-0161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S. H.</span></span> <span> </span><span class="NLM_article-title">The HDAC6 inhibitor ACY1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">844</span>– <span class="NLM_lpage">854</span>, <span class="refDoi"> DOI: 10.3892/ijo.2018.4405</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3892%2Fijo.2018.4405" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29749542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCru7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2018&pages=844-854&author=D.+H.+Leeauthor=H.+R.+Wonauthor=H.+W.+Ryuauthor=J.+M.+Hanauthor=S.+H.+Kwon&title=The+HDAC6+inhibitor+ACY1215+enhances+the+anticancer+activity+of+oxaliplatin+in+colorectal+cancer+cells&doi=10.3892%2Fijo.2018.4405"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">The HDAC6 inhibitor ACY-1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells</span></div><div class="casAuthors">Lee, Dong Hoon; Won, Hye-Rim; Ryu, Hyun-Wook; Han, Jung Min; Kwon, So Hee</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">844-854</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">ACY-1215, also known as ricolinostat, is a leading histone deacetylase 6 inhibitor, which is currently being tested in clin. trials for hematol. malignancies.  Previous studies have reported that ACY-1215 is not potent enough as a monotherapy for the treatment of colorectal cancer (CRC), which generally requires combination therapy for successful treatment.  Therefore, the present study aimed to det. whether the synergistic interaction detected between ACY-1215 and anticancer agents in hematol. cancers could occur in solid tumors.  The results of the present study indicated that ACY-1215 exerted a potent synergistic anti-proliferative effect when used in combination with anticancer agents in CRC cells.  The combination of ACY-1215 and oxaliplatin was more potent than either drug alone, as indicated by an increase in apoptotic cells and their effects on the apoptotic pathway; ACY-1215 and oxaliplatin cotreatment activated caspase-3 and poly (ADP ribose) polymerase, increased B-cell lymphoma (Bcl)-2 homologous antagonist/killer expression, and decreased Bcl-extra large protein, phosphorylated-extracellular signal-regulated kinase and phosphorylated-protein kinase B expression.  In addn., combined treatment of ACY-1215 and anticancer agents induced synergistic upregulation of programmed death-ligand 1.  These findings suggested that a therapeutic strategy that combines ACY-1215 and oxaliplatin warrants attention for the treatment of solid tumors, including CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodrgw5rTr-hLVg90H21EOLACvtfcHk0lhYhmTuIp7F9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCru7g%253D&md5=ca18c069afe82350383d92de6c962c19</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.3892%2Fijo.2018.4405&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2018.4405%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DWon%26aufirst%3DH.%2BR.%26aulast%3DRyu%26aufirst%3DH.%2BW.%26aulast%3DHan%26aufirst%3DJ.%2BM.%26aulast%3DKwon%26aufirst%3DS.%2BH.%26atitle%3DThe%2520HDAC6%2520inhibitor%2520ACY1215%2520enhances%2520the%2520anticancer%2520activity%2520of%2520oxaliplatin%2520in%2520colorectal%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2018%26volume%3D53%26spage%3D844%26epage%3D854%26doi%3D10.3892%2Fijo.2018.4405" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forsythe, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Refaat, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khawaja, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weir, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emam, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkamp, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovici, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jithesh, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labonte, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, I. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Schaeybroeck, S.</span></span> <span> </span><span class="NLM_article-title">The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1280</span>– <span class="NLM_lpage">1290</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-0603</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1158%2F1535-7163.MCT-17-0603" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29483217" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsLzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1280-1290&author=N.+Forsytheauthor=A.+Refaatauthor=A.+Javadiauthor=H.+Khawajaauthor=J.+A.+Weirauthor=H.+Emamauthor=W.+L.+Allenauthor=F.+Burkampauthor=V.+Popoviciauthor=P.+V.+Jitheshauthor=C.+Isellaauthor=M.+J.+Labonteauthor=I.+G.+Millsauthor=P.+G.+Johnstonauthor=S.+Van+Schaeybroeck&title=The+Unfolded+Protein+Response%3A+A+Novel+Therapeutic+Target+for+Poor+Prognostic+BRAF+Mutant+Colorectal+Cancer&doi=10.1158%2F1535-7163.MCT-17-0603"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer</span></div><div class="casAuthors">Forsythe, Nicholas; Refaat, Alaa; Javadi, Arman; Khawaja, Hajrah; Weir, Jessica-Anne; Emam, Heba; Allen, Wendy L.; Burkamp, Frank; Popovici, Vlad; Jithesh, Puthen V.; Isella, Claudio; Labonte, Melissa J.; Mills, Ian G.; Johnston, Patrick G.; Van Schaeybroeck, Sandra</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1280-1290</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">BRAFV600E mutations occur in ∼10% of colorectal cancer cases, are assocd. with poor survival, and have limited responses to BRAF/MEK inhibition with or without EGFR inhibition.  There is an unmet need to understand the biol. of poor prognostic BRAFMT colorectal cancer.  We have used differential gene expression and pathway analyses of untreated stage II and stage III BRAFMT (discovery set: n = 31; validation set: n = 26) colorectal cancer, and an siRNA screen to characterize the biol. underpinning the BRAFMT subgroup with poorest outcome.  These analyses identified the unfolded protein response (UPR) as a novel and druggable pathway assocd. with the BRAFMT colorectal cancer subgroup with poorest outcome.  We also found that oncogenic BRAF drives endoplasmic reticulum (ER) stress and UPR pathway activation through MEK/ERK.  Furthermore, inhibition of GRP78, the master regulator of the UPR, using siRNA or small mol. inhibition, resulted in acute ER stress and apoptosis, in particular in BRAFMT colorectal cancer cells.  In addn., dual targeting of protein degrdn. using combined Carfilzomib (proteasome inhibitor) and ACY-1215 (HDAC6-selective inhibitor) treatment resulted in marked accumulation of protein aggregates, acute ER stress, apoptosis, and therapeutic efficacy in BRAFMT in vitro and xenograft models.  Mechanistically, we found that the apoptosis following combined Carfilzomib/ACY-1215 treatment is mediated through increased CHOP expression.  Taken together, our findings indicate that oncogenic BRAF induces chronic ER stress and that inducers of acute ER stress could be a novel treatment strategy for poor prognostic BRAFMT colorectal cancer.  Mol Cancer Ther; 17(6); 1280-90. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojEaeZfSfm6rVg90H21EOLACvtfcHk0lgIcfbXRFhsOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsLzN&md5=ae28640f42ca299afe9c6299b083d387</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-0603&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-0603%26sid%3Dliteratum%253Aachs%26aulast%3DForsythe%26aufirst%3DN.%26aulast%3DRefaat%26aufirst%3DA.%26aulast%3DJavadi%26aufirst%3DA.%26aulast%3DKhawaja%26aufirst%3DH.%26aulast%3DWeir%26aufirst%3DJ.%2BA.%26aulast%3DEmam%26aufirst%3DH.%26aulast%3DAllen%26aufirst%3DW.%2BL.%26aulast%3DBurkamp%26aufirst%3DF.%26aulast%3DPopovici%26aufirst%3DV.%26aulast%3DJithesh%26aufirst%3DP.%2BV.%26aulast%3DIsella%26aufirst%3DC.%26aulast%3DLabonte%26aufirst%3DM.%2BJ.%26aulast%3DMills%26aufirst%3DI.%2BG.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26aulast%3DVan%2BSchaeybroeck%26aufirst%3DS.%26atitle%3DThe%2520Unfolded%2520Protein%2520Response%253A%2520A%2520Novel%2520Therapeutic%2520Target%2520for%2520Poor%2520Prognostic%2520BRAF%2520Mutant%2520Colorectal%2520Cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D1280%26epage%3D1290%26doi%3D10.1158%2F1535-7163.MCT-17-0603" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan-Wasielewski, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulonis, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birrer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinopoulos, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. F.</span></span> <span> </span><span class="NLM_article-title">Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer</span>. <i>Gynecologic oncology reports</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">122</span>, <span class="refDoi"> DOI: 10.1016/j.gore.2019.07.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.gore.2019.07.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31467965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3MrjsVOltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=118-122&author=E.+K.+Leeauthor=Z.+Tan-Wasielewskiauthor=U.+A.+Matulonisauthor=M.+J.+Birrerauthor=A.+A.+Wrightauthor=N.+Horowitzauthor=P.+A.+Konstantinopoulosauthor=J.+Curtisauthor=J.+F.+Liu&title=Results+of+an+abbreviated+Phase+Ib+study+of+the+HDAC6+inhibitor+ricolinostat+and+paclitaxel+in+recurrent+ovarian%2C+fallopian+tube%2C+or+primary+peritoneal+cancer&doi=10.1016%2Fj.gore.2019.07.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer</span></div><div class="casAuthors">Lee Elizabeth K; Matulonis Ursula A; Wright Alexi A; Konstantinopoulos Panagiotis A; Liu Joyce F; Tan-Wasielewski Zhenying; Matulonis Ursula A; Wright Alexi A; Horowitz Neil; Konstantinopoulos Panagiotis A; Curtis Jennifer; Liu Joyce F; Birrer Michael J; Horowitz Neil</div><div class="citationInfo"><span class="NLM_cas:title">Gynecologic oncology reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">118-122</span>
        ISSN:<span class="NLM_cas:issn">2352-5789</span>.
    </div><div class="casAbstract">Peripheral neuropathy is a common side effect of chemotherapeutic agents that frequently necessitates dose-reduction, truncation of, or change in therapy.  HDAC6 inhibition has demonstrated preclinical efficacy in preventing and/or reversing chemotherapy-induced peripheral neuropathy and furthermore has demonstrated synergistic antitumor activity with various chemotherapies.  Here, we report the abbreviated results of a Phase Ib trial of ricolinostat, an HDAC6-specific inhibitor, in combination with paclitaxel, in the treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSZvz9w1O_ds2BAiYWy6n3SfW6udTcc2eZUFUGje6YAJ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrjsVOltg%253D%253D&md5=d3b9607e4cab2217a5f2c28c7fef4e32</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.gore.2019.07.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gore.2019.07.010%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DE.%2BK.%26aulast%3DTan-Wasielewski%26aufirst%3DZ.%26aulast%3DMatulonis%26aufirst%3DU.%2BA.%26aulast%3DBirrer%26aufirst%3DM.%2BJ.%26aulast%3DWright%26aufirst%3DA.%2BA.%26aulast%3DHorowitz%26aufirst%3DN.%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26aulast%3DCurtis%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26atitle%3DResults%2520of%2520an%2520abbreviated%2520Phase%2520Ib%2520study%2520of%2520the%2520HDAC6%2520inhibitor%2520ricolinostat%2520and%2520paclitaxel%2520in%2520recurrent%2520ovarian%252C%2520fallopian%2520tube%252C%2520or%2520primary%2520peritoneal%2520cancer%26jtitle%3DGynecologic%2520oncology%2520reports%26date%3D2019%26volume%3D29%26spage%3D118%26epage%3D122%26doi%3D10.1016%2Fj.gore.2019.07.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laschanzky, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphrey, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Enke, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shukla, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dasgupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brattain, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ly, Q. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, J. D.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1327</span>, <span class="refDoi"> DOI: 10.3390/cancers11091327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3390%2Fcancers11091327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXmtVWmsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=1327&author=R.+S.+Laschanzkyauthor=L.+E.+Humphreyauthor=J.+Maauthor=L.+M.+Smithauthor=T.+J.+Enkeauthor=S.+K.+Shuklaauthor=A.+Dasguptaauthor=P.+K.+Singhauthor=G.+M.+Howellauthor=M.+G.+Brattainauthor=Q.+P.+Lyauthor=A.+R.+Blackauthor=J.+D.+Black&title=Selective+Inhibition+of+Histone+Deacetylases+1%2F2%2F6+in+Combination+with+Gemcitabine%3A+A+Promising+Combination+for+Pancreatic+Cancer+Therapy&doi=10.3390%2Fcancers11091327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Selective inhibition of histone deacetylases 1/2/6 in combination with gemcitabine: a promising combination for pancreatic cancer therapy</span></div><div class="casAuthors">Laschanzky, Richard S.; Humphrey, Lisa E.; Ma, Jihyun; Smith, Lynette M.; Enke, Thomas J.; Shukla, Surendra K.; Dasgupta, Aneesha; Singh, Pankaj K.; Howell, Gillian M.; Brattain, Michael G.; Ly, Quan P.; Black, Adrian R.; Black, Jennifer D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1327</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of <10% due in part to a lack of effective therapies.  Pan-histone deacetylase (HDAC) inhibitors have shown preclin. efficacy against PDAC but have failed in the clinic due to toxicity.  Selective HDAC inhibitors may reduce toxicity while retaining therapeutic efficacy.  However, their use requires identification of the specific HDACs that mediate the therapeutic effects of HDAC inhibitors in PDAC.  We detd. that the HDAC1/2/3 inhibitor Mocetinostat synergizes with the HDAC4/5/6 inhibitor LMK-235 in a panel of PDAC cell lines.  Furthermore, while neither drug alone synergizes with gemcitabine, the combination of Mocetinostat, LMK-235, and gemcitabine showed strong synergy.  Using small interfering (si)RNA-mediated knockdown, this synergy was attributed to inhibition of HDACs 1, 2, and 6.  Pharmacol. inhibition of HDACs 1 and 2 with Romidepsin and HDAC6 with ACY-1215 also potently synergized with gemcitabine in a panel of PDAC cell lines, and this drug combination potentiated the antitumor effects of gemcitabine against PDAC xenografts in vivo.  Collectively, our data show that inhibition of multiple HDACs is required for therapeutic effects of HDAC inhibitors and support the development of novel strategies to inhibit HDACs 1, 2, and 6 for PDAC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof_zMSnNYGkrVg90H21EOLACvtfcHk0lgIcfbXRFhsOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXmtVWmsLo%253D&md5=dd724c10e07e94ffe21af163507fa7c9</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.3390%2Fcancers11091327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11091327%26sid%3Dliteratum%253Aachs%26aulast%3DLaschanzky%26aufirst%3DR.%2BS.%26aulast%3DHumphrey%26aufirst%3DL.%2BE.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DL.%2BM.%26aulast%3DEnke%26aufirst%3DT.%2BJ.%26aulast%3DShukla%26aufirst%3DS.%2BK.%26aulast%3DDasgupta%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DP.%2BK.%26aulast%3DHowell%26aufirst%3DG.%2BM.%26aulast%3DBrattain%26aufirst%3DM.%2BG.%26aulast%3DLy%26aufirst%3DQ.%2BP.%26aulast%3DBlack%26aufirst%3DA.%2BR.%26aulast%3DBlack%26aufirst%3DJ.%2BD.%26atitle%3DSelective%2520Inhibition%2520of%2520Histone%2520Deacetylases%25201%252F2%252F6%2520in%2520Combination%2520with%2520Gemcitabine%253A%2520A%2520Promising%2520Combination%2520for%2520Pancreatic%2520Cancer%2520Therapy%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26spage%3D1327%26doi%3D10.3390%2Fcancers11091327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yanda, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cebotaru, L.</span></span> <span> </span><span class="NLM_article-title">An inhibitor of histone deacetylase 6 activity, ACY-1215, reduces cAMP and cyst growth in polycystic kidney disease</span>. <i>American journal of physiology. Renal physiology</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>313</i></span>,  <span class="NLM_fpage">F997</span>– <span class="NLM_lpage">F1004</span>, <span class="refDoi"> DOI: 10.1152/ajprenal.00186.2017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1152%2Fajprenal.00186.2017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=28747357" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2017&pages=F997-F1004&author=M.+K.+Yandaauthor=Q.+Liuauthor=L.+Cebotaru&title=An+inhibitor+of+histone+deacetylase+6+activity%2C+ACY-1215%2C+reduces+cAMP+and+cyst+growth+in+polycystic+kidney+disease&doi=10.1152%2Fajprenal.00186.2017"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1152%2Fajprenal.00186.2017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajprenal.00186.2017%26sid%3Dliteratum%253Aachs%26aulast%3DYanda%26aufirst%3DM.%2BK.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DCebotaru%26aufirst%3DL.%26atitle%3DAn%2520inhibitor%2520of%2520histone%2520deacetylase%25206%2520activity%252C%2520ACY-1215%252C%2520reduces%2520cAMP%2520and%2520cyst%2520growth%2520in%2520polycystic%2520kidney%2520disease%26jtitle%3DAmerican%2520journal%2520of%2520physiology.%2520Renal%2520physiology%26date%3D2017%26volume%3D313%26spage%3DF997%26epage%3DF1004%26doi%3D10.1152%2Fajprenal.00186.2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lorenzo
Pisarello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masyuk, T. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gradilone, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masyuk, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LaRusso, N. F.</span></span> <span> </span><span class="NLM_article-title">Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">994</span>, <span class="refDoi"> DOI: 10.1016/j.ajpath.2017.12.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ajpath.2017.12.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29366679" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjsF2ntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2018&pages=981-994&author=M.+Lorenzo%0APisarelloauthor=T.+V.+Masyukauthor=S.+A.+Gradiloneauthor=A.+I.+Masyukauthor=J.+F.+Dingauthor=P.+Y.+Leeauthor=N.+F.+LaRusso&title=Combination+of+a+Histone+Deacetylase+6+Inhibitor+and+a+Somatostatin+Receptor+Agonist+Synergistically+Reduces+Hepatorenal+Cystogenesis+in+an+Animal+Model+of+Polycystic+Liver+Disease&doi=10.1016%2Fj.ajpath.2017.12.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease</span></div><div class="casAuthors">Lorenzo Pisarello, Maria; Masyuk, Tatyana V.; Gradilone, Sergio A.; Masyuk, Anatoliy I.; Ding, Jingyi F.; Lee, Pui-Yuen; La Russo, Nicholas F.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">981-994</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hepatic cystogenesis in polycystic liver disease (PLD) is assocd. with abnormalities in multiple cellular processes, including elevated cAMP and overexpression of histone deacetylase 6 (HDAC6).  Disease progression in polycystic kidney (PCK) rats (an animal model of PLD) is attenuated by inhibition of either cAMP prodn. or HDAC6.  Therefore, we hypothesized that concurrent targeting of HDAC6 and cAMP would synergistically reduce cyst growth.  Changes in hepatorenal cystogenesis were examd. in PCK rats treated with a pan-HDAC inhibitor, panobinostat; three specific HDAC6 inhibitors, ACY-1215, ACY-738, and ACY-241; and a combination of ACY-1215 and the somatostatin receptor analog, pasireotide.  We also assessed effects of ACY-1215 and pasireotide alone and in combination on cell proliferation, cAMP prodn., and expression of acetylated α-tubulin in vitro in cultured cholangiocytes and the length of primary cilia and the frequency of ciliated cholangiocytes in vivo in PCK rats.  Panobinostat and all three HDAC6 inhibitors decreased hepatorenal cystogenesis in PCK rats.  ACY-1215 was more effective than other HDAC inhibitors and was chosen for combinational treatment.  ACY-1215 + pasireotide combination synergistically reduced cyst growth and increased length of primary cilia in PCK rats.  In cultured cystic cholangiocytes, ACY-1215 + pasireotide combination concurrently decreased cell proliferation and inhibited cAMP levels.  These data suggest that the combination of drugs that inhibit HDAC6 and cAMP may be an effective therapy for PLD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQXU3e9EqT5bVg90H21EOLACvtfcHk0lh7zQTdMKYBHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjsF2ntbk%253D&md5=a2979ff3a1c3849bf372e89e22f43f49</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2017.12.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2017.12.016%26sid%3Dliteratum%253Aachs%26aulast%3DLorenzo%2BPisarello%26aufirst%3DM.%26aulast%3DMasyuk%26aufirst%3DT.%2BV.%26aulast%3DGradilone%26aufirst%3DS.%2BA.%26aulast%3DMasyuk%26aufirst%3DA.%2BI.%26aulast%3DDing%26aufirst%3DJ.%2BF.%26aulast%3DLee%26aufirst%3DP.%2BY.%26aulast%3DLaRusso%26aufirst%3DN.%2BF.%26atitle%3DCombination%2520of%2520a%2520Histone%2520Deacetylase%25206%2520Inhibitor%2520and%2520a%2520Somatostatin%2520Receptor%2520Agonist%2520Synergistically%2520Reduces%2520Hepatorenal%2520Cystogenesis%2520in%2520an%2520Animal%2520Model%2520of%2520Polycystic%2520Liver%2520Disease%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2018%26volume%3D188%26spage%3D981%26epage%3D994%26doi%3D10.1016%2Fj.ajpath.2017.12.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiao, F. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Z. J.</span></span> <span> </span><span class="NLM_article-title">Quantitative Proteomic Analysis Reveals the Sites Related to Acetylation and Mechanism of ACY-1215 in Acute Liver Failure Mice</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">653</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00653</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3389%2Ffphar.2019.00653" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31244662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkt12isLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=653&author=W.+B.+Zhangauthor=H.+Y.+Zhangauthor=Y.+Wangauthor=F.+Z.+Jiaoauthor=L.+W.+Wangauthor=Z.+J.+Gong&title=Quantitative+Proteomic+Analysis+Reveals+the+Sites+Related+to+Acetylation+and+Mechanism+of+ACY-1215+in+Acute+Liver+Failure+Mice&doi=10.3389%2Ffphar.2019.00653"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Quantitative proteomic analysis reveals the sites related to acetylation and mechanism of ACY-1215 in acute liver failure mice</span></div><div class="casAuthors">Zhang, Wen-bin; Zhang, Hai-yue; Wang, Yao; Jiao, Fang-zhou; Wang, Lu-Wen; Gong, Zuo-jiong</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">653</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">In this study, we aim to investigate whether ACY-1215 has inhibitory effects and mechanism on the necrosis of hepatocytes; moreover, the impact of ACY-1215 treatment on histone lysine acetylation still needs further elucidation.  Male C57/BL6 mice were divided into normal, model, and ACY-1215 groups.  ACY-1215 (25 mg/kg) and same amts. of saline were injected i.p. to the mice before the establishment of ALF model induced by lipopolysaccharide (LPS) (100μg/kg) combined with D-gal (400 mg/kg).  All animals were sacrificed after 24 h.  In this study, detection programs, including quant. proteomic anal., transmission electron microscopy (TEM) micrographs, pathol. staining, protein expression, the detection of reactive oxygen species (ROS) as well as glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) measurement.  The function of liver and the necrosis of hepatocytes in ALF mice were significantly normalized by ACY-1215 pretreatment.  The quant. proteomic anal. revealed that ACY-1215-restrained oxidative phosphorylation normalized the function respiratory electron-transport chain in the mitochondria.  Moreover, pretreatment of ACY- 1215 not only normalized the structure of mitochondria but also inhibited the generation of reactive oxygen species (ROS).  ACY-1215 was able to inhibit necrosis of hepatocytes in ALF mice through regulating the mitochondrial-mediated oxidative stress, and we identified the common sites related to acetylation level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHZr7krOIsW7Vg90H21EOLACvtfcHk0lh7zQTdMKYBHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkt12isLg%253D&md5=c3f7f5d38cd58f83a6b2e1ecde8816ca</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00653%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%2BB.%26aulast%3DZhang%26aufirst%3DH.%2BY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiao%26aufirst%3DF.%2BZ.%26aulast%3DWang%26aufirst%3DL.%2BW.%26aulast%3DGong%26aufirst%3DZ.%2BJ.%26atitle%3DQuantitative%2520Proteomic%2520Analysis%2520Reveals%2520the%2520Sites%2520Related%2520to%2520Acetylation%2520and%2520Mechanism%2520of%2520ACY-1215%2520in%2520Acute%2520Liver%2520Failure%2520Mice%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D653%26doi%3D10.3389%2Ffphar.2019.00653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span> <span> </span><span class="NLM_article-title">Protective Effects of ACY-1215 Against Chemotherapy-Related Cognitive Impairment and Brain Damage in Mice</span>. <i>Neurochem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>44</i></span>,  <span class="NLM_fpage">2460</span>– <span class="NLM_lpage">2469</span>, <span class="refDoi"> DOI: 10.1007/s11064-019-02882-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs11064-019-02882-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31571096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVOqu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2019&pages=2460-2469&author=D.+Wangauthor=B.+Wangauthor=Y.+Liuauthor=X.+Dongauthor=Y.+Suauthor=S.+Li&title=Protective+Effects+of+ACY-1215+Against+Chemotherapy-Related+Cognitive+Impairment+and+Brain+Damage+in+Mice&doi=10.1007%2Fs11064-019-02882-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Protective Effects of ACY-1215 Against Chemotherapy-Related Cognitive Impairment and Brain Damage in Mice</span></div><div class="casAuthors">Wang, Dongmei; Wang, Bei; Liu, Yumei; Dong, Xiaohui; Su, Yanwei; Li, Sanqiang</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemical Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2460-2469</span>CODEN:
                <span class="NLM_cas:coden">NEREDZ</span>;
        ISSN:<span class="NLM_cas:issn">0364-3190</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Chemotherapy-related cognitive impairment (CRCI) is a potential long-term side effect during cancer treatment.  There are currently no effective treatments for CRCI.  Redn. or inhibition of histone deacetylase 6 (HDAC6) has been considered a possible therapeutic strategy for cognitive deficits.  HDAC6 inhibition recently has been shown to reverse chemotherapy-induced peripheral neuropathy effectively.  In the present study, we examd. the effect of HDAC6 inhibitor ACY-1215 (Ricolinostat) on cisplatin-induced brain damage and cognitive deficits in mice.  Our results showed that ACY-1215 ameliorated behavioral deficits and dendritic spine loss and increased synaptic d. in cisplatin-treated mice.  Mechanistically, HDAC6 inhibitor ACY-1215 enhanced a-tubulin acetylation in the hippocampus of cisplatin-treated mice.  Furthermore, ACY-1215 recovered cisplatin-induced impaired mitochondrial transport and mitochondrial dysfunction in the hippocampus.  Our results suggest that inhibition of HDAC6 improves established cisplatin-induced cognitive deficits by the restoration of mitochondrial and synaptic impairments.  These results offer prospective approaches for CRCI, esp. because ACY1215 currently serves as an add-on cancer therapy during clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbB1UtHwvL37Vg90H21EOLACvtfcHk0lhk5dNNq1up_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVOqu7rN&md5=54b67a5f2b00ba3dfa32cdaca718a081</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1007%2Fs11064-019-02882-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11064-019-02882-6%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26atitle%3DProtective%2520Effects%2520of%2520ACY-1215%2520Against%2520Chemotherapy-Related%2520Cognitive%2520Impairment%2520and%2520Brain%2520Damage%2520in%2520Mice%26jtitle%3DNeurochem.%2520Res.%26date%3D2019%26volume%3D44%26spage%3D2460%26epage%3D2469%26doi%3D10.1007%2Fs11064-019-02882-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanden Berghe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarpe, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Damme, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robberecht, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den Bosch, L.</span></span> <span> </span><span class="NLM_article-title">Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">417</span>– <span class="NLM_lpage">428</span>, <span class="refDoi"> DOI: 10.1007/s13311-016-0501-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs13311-016-0501-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27957719" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XitV2ku7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=417-428&author=V.+Benoyauthor=P.+Vanden+Bergheauthor=M.+Jarpeauthor=P.+Van+Dammeauthor=W.+Robberechtauthor=L.+Van+Den+Bosch&title=Development+of+Improved+HDAC6+Inhibitors+as+Pharmacological+Therapy+for+Axonal+Charcot-Marie-Tooth+Disease&doi=10.1007%2Fs13311-016-0501-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease</span></div><div class="casAuthors">Benoy, Veronick; Vanden Berghe, Pieter; Jarpe, Matthew; Van Damme, Philip; Robberecht, Wim; Van Den Bosch, Ludo</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">417-428</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Recently, we identified histone deacetylase 6, which deacetylates α-tubulin, as a potential therapeutic target in axonal CMT.  Pharmacol. inhibition of the deacetylating function of HDAC6 reversed the motor and sensory deficits in a mouse model for mutant "small heat shock protein B1"-induced CMT2 at the behavioral and electrophysiol. level.  In order to translate this potential therapeutic strategy into a clin. application, small drug-like mols. that are potent and selective HDAC6 inhibitors are essential.  To screen for these, we developed a method that consisted of 3 distinct phases and that was based on the pathol. findings in the mutant HSPB1-induced CMT2 mouse model.  Three different inhibitors (ACY-738, ACY-775, and ACY-1215) were tested and demonstrated to be both potent and selective HDAC6 inhibitors.  Moreover, these inhibitors increased the innervation of the neuromuscular junctions in the gastrocnemius muscle and improved the motor and sensory nerve conduction, confirming that HDAC6 inhibition is a potential therapeutic strategy in CMT2.  Furthermore, ACY-1215 is an interesting lead mol. as it is currently tested in clin. trials for cancer.  Taken together, these results may speed up the translation of pharmacol. inhibition of HDAC6 into a therapy against CMT2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmJr47ap41l7Vg90H21EOLACvtfcHk0lhk5dNNq1up_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitV2ku7vO&md5=cb382132da19455955c1b432cf59aa5e</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1007%2Fs13311-016-0501-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-016-0501-z%26sid%3Dliteratum%253Aachs%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DVanden%2BBerghe%26aufirst%3DP.%26aulast%3DJarpe%26aufirst%3DM.%26aulast%3DVan%2BDamme%26aufirst%3DP.%26aulast%3DRobberecht%26aufirst%3DW.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520Improved%2520HDAC6%2520Inhibitors%2520as%2520Pharmacological%2520Therapy%2520for%2520Axonal%2520Charcot-Marie-Tooth%2520Disease%26jtitle%3DNeurotherapeutics%26date%3D2017%26volume%3D14%26spage%3D417%26epage%3D428%26doi%3D10.1007%2Fs13311-016-0501-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span> <span> </span><span class="NLM_article-title">ACY-1215 exhibits anti-inflammatory and chondroprotective effects in human osteoarthritis chondrocytes via inhibition of STAT3 and NF-kappaB signaling pathways</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2464</span>– <span class="NLM_lpage">2471</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2018.11.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.biopha.2018.11.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30551507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVWjs7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2019&pages=2464-2471&author=C.+Chengauthor=W.+Shanauthor=W.+Huangauthor=Z.+Dingauthor=G.+Cuiauthor=F.+Liuauthor=W.+Luauthor=J.+Xuauthor=W.+Heauthor=Z.+Yin&title=ACY-1215+exhibits+anti-inflammatory+and+chondroprotective+effects+in+human+osteoarthritis+chondrocytes+via+inhibition+of+STAT3+and+NF-kappaB+signaling+pathways&doi=10.1016%2Fj.biopha.2018.11.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">ACY-1215 exhibits anti-inflammatory and chondroprotective effects in human osteoarthritis chondrocytes via inhibition of STAT3 and NF-κB signaling pathways</span></div><div class="casAuthors">Cheng, Chao; Shan, Wenshan; Huang, Wei; Ding, Zhenfei; Cui, Guanjun; Liu, Fuen; Lu, Wei; Xu, Jiegou; He, Wei; Yin, Zongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2464-2471</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Cartilage degeneration is a basic pathol. feature of osteoarthritis (OA), and there is growing evidence that it is assocd. with inflammation.  ACY-1215, a selective HDAC6 inhibitor, has been reported to have anti-inflammatory effects.  Here, we investigated the anti-inflammatory and chondroprotective effects of ACY-1215 in IL-1β-stimulated human primary chondrocytes and C28/I2 cells.  The results suggested that ACY-1215 can markedly suppress the expression of inflammatory factors, including IL-1β and IL-6 in human primary chondrocytes and C28/I2 cells.  Furthermore, ACY-1215 exerts potent chondroprotection through the amelioration of cartilage degrdn. by inhibiting the expression of matrix-degrading proteases, including MMP-1 and MMP-13 in chondrocytes.  These effects may be related to ACY-1215 induced down-regulation of NF-κB and STAT3 pathways in OA chondrocytes.  Taken together, our results show that ACY-1215 may be a potential and promising therapeutic drug for the management of OA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9MqASkPCwb7Vg90H21EOLACvtfcHk0lhk5dNNq1up_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVWjs7jL&md5=7eec7657f80365a3f3605e67cc67f56e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2018.11.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2018.11.017%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DShan%26aufirst%3DW.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DDing%26aufirst%3DZ.%26aulast%3DCui%26aufirst%3DG.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DHe%26aufirst%3DW.%26aulast%3DYin%26aufirst%3DZ.%26atitle%3DACY-1215%2520exhibits%2520anti-inflammatory%2520and%2520chondroprotective%2520effects%2520in%2520human%2520osteoarthritis%2520chondrocytes%2520via%2520inhibition%2520of%2520STAT3%2520and%2520NF-kappaB%2520signaling%2520pathways%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2019%26volume%3D109%26spage%3D2464%26epage%3D2471%26doi%3D10.1016%2Fj.biopha.2018.11.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, Z.</span></span> <span> </span><span class="NLM_article-title">Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts</span>. <i>Biomed. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">109357</span>, <span class="refDoi"> DOI: 10.1016/j.biopha.2019.109357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.biopha.2019.109357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31548177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1arurbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2019&pages=109357&author=L.+Liauthor=F.+Liuauthor=W.+Huangauthor=J.+Wangauthor=Y.+Wanauthor=M.+Liauthor=Y.+Pangauthor=Z.+Yin&title=Ricolinostat+%28ACY-1215%29+inhibits+VEGF+expression+via+PI3K%2FAKT+pathway+and+promotes+apoptosis+in+osteoarthritic+osteoblasts&doi=10.1016%2Fj.biopha.2019.109357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Ricolinostat (ACY-1215) inhibits VEGF expression viaPI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts</span></div><div class="casAuthors">Li, Lei; Yin, Zongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicine & Pharmacotherapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">109357</span>CODEN:
                <span class="NLM_cas:coden">BIPHEX</span>;
        ISSN:<span class="NLM_cas:issn">0753-3322</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Osteoarthritis (OA) is involved in these pathophysiol. changes of articular cartilage, subchondral bone and synovium.  As a selective HDAC6 inhibitor, Ricolinostat (ACY-1215) has demonstrated chondroprotective effects in OA.  However, its efficacy remains unclear in subchondral bone.  In this study, we found that the mRNA and protein levels of HDAC6 were elevated in human OA osteoblasts in vitro.  PI3K/AKT signaling pathway was suppressed with downregulation of VEGF expression in osteoblasts after ACY-1215 treatment.  ACY-1215 promoted apoptosis of OA osteoblast in a concn.-dependent manner, and the expression of apoptosis-related proteins was also changed by activating caspase pathway.  Moreover, western blotting showed decreased expression of MMP9 and MMP13 in IL-1β-induced chondrocytes after co-culture with ACY-1215-stimulated osteoblasts.  These data of immunohistochem. and micro-CT from OA model mice also demonstrated the weak staining of MMPs in cartilage and prevention of aberrant subchondral bone formation after ACY-1215 injection.  Therefore, high expression of HDAC6 in osteoblasts also contributed to the OA progression, and our study provided a new evidence that HDAC6 inhibitor may be a potential therapeutic drug for OA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK4RIcdsW_A7Vg90H21EOLACvtfcHk0liZwRf7YFQ1Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1arurbM&md5=5fd57240090759e2dffe1ba17fd9fb84</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.biopha.2019.109357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biopha.2019.109357%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWan%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DPang%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DZ.%26atitle%3DRicolinostat%2520%2528ACY-1215%2529%2520inhibits%2520VEGF%2520expression%2520via%2520PI3K%252FAKT%2520pathway%2520and%2520promotes%2520apoptosis%2520in%2520osteoarthritic%2520osteoblasts%26jtitle%3DBiomed.%2520Pharmacother.%26date%3D2019%26volume%3D118%26spage%3D109357%26doi%3D10.1016%2Fj.biopha.2019.109357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pulya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amin, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adhikari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, B.</span></span> <span> </span><span class="NLM_article-title">HDAC6 as privileged target in drug discovery: A perspective</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">105274</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2020.105274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.phrs.2020.105274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=33171304" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFOrsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2021&pages=105274&author=S.+Pulyaauthor=S.+A.+Aminauthor=N.+Adhikariauthor=S.+Biswasauthor=T.+Jhaauthor=B.+Ghosh&title=HDAC6+as+privileged+target+in+drug+discovery%3A+A+perspective&doi=10.1016%2Fj.phrs.2020.105274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 as privileged target in drug discovery: A perspective</span></div><div class="casAuthors">Pulya, Sravani; Amin, Sk. Abdul; Adhikari, Nilanjan; Biswas, Swati; Jha, Tarun; Ghosh, Balaram</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">105274</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  HDAC6, a class IIB HDAC isoenzyme, stands unique in its structural and physiol. functions.  Besides histone modification, largely due to its cytoplasmic localization, HDAC6 also targets several non-histone proteins including Hsp90, α-tubulin, cortactin, HSF1, etc.  Thus, it is one of the key regulators of different physiol. and pathol. disease conditions.  HDAC6 is involved in different signaling pathways assocd. with several neurol. disorders, various cancers at early and advanced stage, rare diseases and immunol. conditions.  Therefore, targeting HDAC6 has been found to be effective for various therapeutic purposes in recent years.  Though several HDAC6 inhibitors (HDAC6is) have been developed till date, only two ACY-1215 (ricolinostat) and ACY-241 (citarinostat) are in the clin. trials.  Considering the recent crystal structure of HDAC6, novel HDAC6is of significant therapeutic value can be designed.  Notably, the canonical pharmacophore features of HDAC6is consist of a zinc binding group (ZBG), a linker function and a cap group.  Significant modifications of cap function may lead to achieve better selectivity of the inhibitors.  This review details the study about the structural biol. of HDAC6, the physiol. and pathol. role of HDAC6 in several disease states and the detailed structure-activity relationships (SARs) of the known HDAC6is.  This detailed review will provide key insights to design novel and highly effective HDAC6i in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwt5FbALiEZbVg90H21EOLACvtfcHk0liZwRf7YFQ1Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFOrsbzE&md5=78f2436f1aed4061650c812de9edb1ae</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2020.105274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2020.105274%26sid%3Dliteratum%253Aachs%26aulast%3DPulya%26aufirst%3DS.%26aulast%3DAmin%26aufirst%3DS.%2BA.%26aulast%3DAdhikari%26aufirst%3DN.%26aulast%3DBiswas%26aufirst%3DS.%26aulast%3DJha%26aufirst%3DT.%26aulast%3DGhosh%26aufirst%3DB.%26atitle%3DHDAC6%2520as%2520privileged%2520target%2520in%2520drug%2520discovery%253A%2520A%2520perspective%26jtitle%3DPharmacol.%2520Res.%26date%3D2021%26volume%3D163%26spage%3D105274%26doi%3D10.1016%2Fj.phrs.2020.105274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Guerrero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gotz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doose, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Gil, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nerreter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortum, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Simon, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einsele, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hudecek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danhof, S.</span></span> <span> </span><span class="NLM_article-title">Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">201</span>– <span class="NLM_lpage">214</span>, <span class="refDoi"> DOI: 10.1038/s41375-020-0840-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fs41375-020-0840-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32350373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXotlSkurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2021&pages=201-214&author=E.+Garcia-Guerreroauthor=R.+Gotzauthor=S.+Dooseauthor=M.+Sauerauthor=A.+Rodriguez-Gilauthor=T.+Nerreterauthor=K.+M.+Kortumauthor=J.+A.+Perez-Simonauthor=H.+Einseleauthor=M.+Hudecekauthor=S.+Danhof&title=Upregulation+of+CD38+expression+on+multiple+myeloma+cells+by+novel+HDAC6+inhibitors+is+a+class+effect+and+augments+the+efficacy+of+daratumumab&doi=10.1038%2Fs41375-020-0840-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab</span></div><div class="casAuthors">Garcia-Guerrero, Estefania; Gotz, Ralph; Doose, Soren; Sauer, Markus; Rodriguez-Gil, Alfonso; Nerreter, Thomas; Kortum, K. Martin; Perez-Simon, Jose A.; Einsele, Hermann; Hudecek, Michael; Danhof, Sophia</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">201-214</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Multiple myeloma (MM) is incurable, so there is a significant unmet need for effective therapy for patients with relapsed or refractory disease.  This situation has not changed despite the recent approval of the anti-CD38 antibody daratumumab, one of the most potent agents in MM treatment.  The efficiency of daratumumab might be improved by combining it with synergistic anti-MM agents.  We therefore investigated the potential of the histone deacetylase (HDAC) inhibitor ricolinostat to up-regulate CD38 on MM cells, thereby enhancing the performance of CD38-specific therapies.  Using quant. reverse transcription polymerase chain reaction and flow cytometry, we obsd. that ricolinostat significantly increases CD38 RNA levels and CD38 surface expression on MM cells.  Super-resoln. microscopy imaging of MM cells by direct stochastic optical reconstruction microscopy confirmed this rise with mol. resoln. and revealed homogeneous distribution of CD38 mols. on the cell membrane.  Particularly important is that combining ricolinostat with daratumumab induced enhanced lysis of MM cells.  We also evaluated next-generation HDAC6 inhibitors (ACY-241, WT-161) and obsd. similar increase of CD38 levels suggesting that the upregulation of CD38 expression on MM cells by HDAC6 inhibitors is a class effect.  This proof-of-concept illustrates the potential benefit of combining HDAC6 inhibitors and CD38-directed immunotherapy for MM treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTQ7Zn-kiub7Vg90H21EOLACvtfcHk0liZwRf7YFQ1Tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXotlSkurY%253D&md5=f226989703f664bf1d98b6ddc66b45e6</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fs41375-020-0840-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41375-020-0840-y%26sid%3Dliteratum%253Aachs%26aulast%3DGarcia-Guerrero%26aufirst%3DE.%26aulast%3DGotz%26aufirst%3DR.%26aulast%3DDoose%26aufirst%3DS.%26aulast%3DSauer%26aufirst%3DM.%26aulast%3DRodriguez-Gil%26aufirst%3DA.%26aulast%3DNerreter%26aufirst%3DT.%26aulast%3DKortum%26aufirst%3DK.%2BM.%26aulast%3DPerez-Simon%26aufirst%3DJ.%2BA.%26aulast%3DEinsele%26aufirst%3DH.%26aulast%3DHudecek%26aufirst%3DM.%26aulast%3DDanhof%26aufirst%3DS.%26atitle%3DUpregulation%2520of%2520CD38%2520expression%2520on%2520multiple%2520myeloma%2520cells%2520by%2520novel%2520HDAC6%2520inhibitors%2520is%2520a%2520class%2520effect%2520and%2520augments%2520the%2520efficacy%2520of%2520daratumumab%26jtitle%3DLeukemia%26date%3D2021%26volume%3D35%26spage%3D201%26epage%3D214%26doi%3D10.1038%2Fs41375-020-0840-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laino, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betts, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veerapathran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolgalev, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarnaik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woods, D. M.</span></span> <span> </span><span class="NLM_article-title">HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics</span>. <i>J. Immunother. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">33</span>, <span class="refDoi"> DOI: 10.1186/s40425-019-0517-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1186%2Fs40425-019-0517-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30728070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3cjpvVKmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2019&pages=33&author=A.+S.+Lainoauthor=B.+C.+Bettsauthor=A.+Veerapathranauthor=I.+Dolgalevauthor=A.+Sarnaikauthor=S.+N.+Quayleauthor=S.+S.+Jonesauthor=J.+S.+Weberauthor=D.+M.+Woods&title=HDAC6+selective+inhibition+of+melanoma+patient+T-cells+augments+anti-tumor+characteristics&doi=10.1186%2Fs40425-019-0517-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics</span></div><div class="casAuthors">Laino Andressa S; Dolgalev I; Weber J S; Woods David M; Betts B C; Veerapathran A; Sarnaik A; Quayle S N; Jones S S</div><div class="citationInfo"><span class="NLM_cas:title">Journal for immunotherapy of cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">33</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Therapies targeting anti-tumor T-cell responses have proven successful in the treatment of a variety of malignancies.  However, as most patients still fail to respond, approaches to augment immunotherapeutic efficacy are needed.  Here, we investigated the ability of histone deacetylase 6 (HDAC6)-selective inhibitors to decrease immunosuppression and enhance immune function of melanoma patient T-cells in ex vivo cultures.  METHODS:  T-cells were harvested from peripheral blood or tumor biopsies of metastatic melanoma patients and cultured in the presence of pan-, class-specific or class-selective histone deacetylase (HDAC) inhibitors.  Changes in cytokine production were evaluated by Luminex and intracellular flow cytometry staining.  Expression of surface markers, transcription factors, protein phosphorylation, and cell viability were assessed by flow cytometry.  Changes in chromatin structure were determined by ATAC-seq.  RESULTS:  T-cell viability was impaired with low doses of pan-HDAC inhibitors but not with specific or selective HDAC inhibitors.  The HDAC6-selective inhibitors ACY-1215 (ricolinostat) and ACY-241 (citarinostat) decreased Th2 cytokine production (i.e.  IL-4, IL-5, IL-6, IL-10 and IL-13).  Expansion of peripheral blood T-cells from melanoma patients in the presence of these inhibitors resulted in downregulation of the Th2 transcription factor GATA3, upregulation of the Th1 transcription factor T-BET, accumulation of central memory phenotype T-cells (CD45RA-CD45RO + CD62L + CCR7+), reduced exhaustion-associated phenotypes (i.e.  TIM3 + LAG3 + PD1+ and EOMES+PD1+), and enhanced killing in mixed lymphocyte reactions.  The frequency, FOXP3 expression, and suppressive function of T regulatory cells (Tregs) were decreased after exposure to ACY-1215 or ACY-241.  Higher frequencies of T-cells expressing CD107a + IFNγ+ and central memory markers were observed in melanoma tumor-infiltrating lymphocytes (TIL), which persisted after drug removal and further expansion.  After ACY-1215 treatment, increased chromatin accessibility was observed in regions associated with T-cell effector function and memory phenotypes, while condensed chromatin was found in regions encoding the mTOR downstream molecules AKT, SGK1 and S6K.  Decreased phosphorylation of these proteins was observed in ACY-1215 and ACY-241-treated T-cells.  AKT- and SGK1-specific inhibition recapitulated the increase in central memory frequency and decrease in IL-4 production, respectively, similar to the observed effects of HDAC6-selective inhibition.  CONCLUSIONS:  HDAC6-selective inhibitors augmented melanoma patient T-cell immune properties, providing a rationale for translational investigation assessing their potential clinical efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJrQDSufBIrJdYoSR9eyvsfW6udTcc2eYQUMGwU_dTsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjpvVKmtQ%253D%253D&md5=8499e2d6ce440a7b7110b4749a873595</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1186%2Fs40425-019-0517-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40425-019-0517-0%26sid%3Dliteratum%253Aachs%26aulast%3DLaino%26aufirst%3DA.%2BS.%26aulast%3DBetts%26aufirst%3DB.%2BC.%26aulast%3DVeerapathran%26aufirst%3DA.%26aulast%3DDolgalev%26aufirst%3DI.%26aulast%3DSarnaik%26aufirst%3DA.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DWeber%26aufirst%3DJ.%2BS.%26aulast%3DWoods%26aufirst%3DD.%2BM.%26atitle%3DHDAC6%2520selective%2520inhibition%2520of%2520melanoma%2520patient%2520T-cells%2520augments%2520anti-tumor%2520characteristics%26jtitle%3DJ.%2520Immunother.%2520Cancer%26date%3D2019%26volume%3D7%26spage%3D33%26doi%3D10.1186%2Fs40425-019-0517-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2786</span>– <span class="NLM_lpage">2796</span>, <span class="refDoi"> DOI: 10.1038/s41388-020-1172-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fs41388-020-1172-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32024967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXislSgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&pages=2786-2796&author=A.+Rayauthor=Y.+Songauthor=T.+Duauthor=D.+Chauhanauthor=K.+C.+Anderson&title=Preclinical+validation+of+Alpha-Enolase+%28ENO1%29+as+a+novel+immunometabolic+target+in+multiple+myeloma&doi=10.1038%2Fs41388-020-1172-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma</span></div><div class="casAuthors">Ray, Arghya; Song, Yan; Du, Ting; Chauhan, Dharminder; Anderson, Kenneth C.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2786-2796</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: Bone marrow plasmacytoid dendritic cells (pDCs) in patients with multiple myeloma (MM) promote tumor growth, survival, drug resistance, and immune suppression.  Understanding the mol. signaling crosstalk among the tumor cells, pDCs and immune cells will identify novel therapeutic approaches to enhance anti-MM immunity.  Using oligonucleotide arrays, we found that pDC-MM interactions induce metabolic enzyme Alpha-Enolase (ENO1) in both pDCs and MM cells.  Anal. of MM patient gene expression profiling database showed that ENO1 expression inversely correlates with overall survival.  Protein expression anal. showed that ENO1 is expressed in pDC and MM cells; and importantly, that pDC-MM coculture further increases ENO1 expression in both MM cells and pDCs.  Using our coculture models of patient autologous pDC-T-NK-MM cells, we examd. whether targeting ENO1 can enhance anti-MM immunity.  Biochem. inhibition of ENO1 with ENO1 inhibitor (ENO1i) activates pDCs, as well as increases pDC-induced MM-specific CD8+ CTL and NK cell activity against autologous tumor cells.  Combination of ENO1i and anti-PD-L1 Ab or HDAC6i ACY-241 enhances autologous MM-specific CD8+ CTL activity.  Our preclin. data therefore provide the basis for novel immune-based therapeutic approaches targeting ENO1, alone or in combination with anti-PD-L1 Ab or ACY241, to restore anti-MM immunity, enhance MM cytotoxicity, and improve patient outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZZmUPt3iML7Vg90H21EOLACvtfcHk0ljTPGEFBWqGXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXislSgt78%253D&md5=909625faf96ff50563fef1f00495df9b</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fs41388-020-1172-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-020-1172-0%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DA.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DT.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DPreclinical%2520validation%2520of%2520Alpha-Enolase%2520%2528ENO1%2529%2520as%2520a%2520novel%2520immunometabolic%2520target%2520in%2520multiple%2520myeloma%26jtitle%3DOncogene%26date%3D2020%26volume%3D39%26spage%3D2786%26epage%3D2796%26doi%3D10.1038%2Fs41388-020-1172-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">North, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeciga-Pinto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quayle, S. N.</span></span> <span> </span><span class="NLM_article-title">Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0173507</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0173507</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1371%2Fjournal.pone.0173507" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=28264055" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVGjtrfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=B.+J.+Northauthor=I.+Almeciga-Pintoauthor=D.+Tamangauthor=M.+Yangauthor=S.+S.+Jonesauthor=S.+N.+Quayle&title=Enhancement+of+pomalidomide+anti-tumor+response+with+ACY-241%2C+a+selective+HDAC6+inhibitor&doi=10.1371%2Fjournal.pone.0173507"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor</span></div><div class="casAuthors">North, Brian J.; Almeciga-Pinto, Ingrid; Tamang, David; Yang, Min; Jones, Simon S.; Quayle, Steven N.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e0173507/1-e0173507/16</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Thalidomide-based Immunomodulatory Drugs (IMiDs), including lenalidomide and pomalidomide, are effective therapeutics for multiple myeloma.  These agents have been approved with, or are under clin. development with, other targeted therapies including proteasome inhibitors, αCD38 monoclonal antibodies, as well as histone deacetylase (HDAC) inhibitors for combination therapy.  HDAC inhibitors broadly targeting Class I and IIb HDACs have shown potent preclin. efficacy but have frequently demonstrated an undesirable safety profile in combination therapy approaches in clin. studies.  Therefore, development of more selective HDAC inhibitors could provide enhanced efficacy with reduced side effects in combination with IMiDs for the treatment of B-cell malignancies, including multiple myeloma.  Here, the second generation selective HDAC6 inhibitor citarinostat (ACY-241), with a more favorable safety profile than non-selective pan-HDAC inhibitors, is shown to synergize with pomalidomide in in vitro assays through promoting greater apoptosis and cell cycle arrest.  Furthermore, utilizing a multiple myeloma in vivo murine xenograft model, combination treatment with pomalidomide and ACY-241 leads to increased tumor growth inhibition.  At the mol. level, combination treatment with ACY-241 and pomalidomide leads to greater suppression of the pro-survival factors survivin, Myc, and IRF4.  The results presented here demonstrate synergy between pomalidomide and ACY-241 in both in vitro and in vivo preclin. models, providing further impetus for clin. development of ACY-241 for use in combination with IMiDs for patients with multiple myeloma and potentially other B-cell malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaSAg6exJCNbVg90H21EOLACvtfcHk0ljTPGEFBWqGXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVGjtrfL&md5=175ef137cd119027f0462d07784375b5</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0173507&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0173507%26sid%3Dliteratum%253Aachs%26aulast%3DNorth%26aufirst%3DB.%2BJ.%26aulast%3DAlmeciga-Pinto%26aufirst%3DI.%26aulast%3DTamang%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DJones%26aufirst%3DS.%2BS.%26aulast%3DQuayle%26aufirst%3DS.%2BN.%26atitle%3DEnhancement%2520of%2520pomalidomide%2520anti-tumor%2520response%2520with%2520ACY-241%252C%2520a%2520selective%2520HDAC6%2520inhibitor%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0173507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chauhan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">843</span>– <span class="NLM_lpage">846</span>, <span class="refDoi"> DOI: 10.1038/leu.2017.322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fleu.2017.322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29104288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvFWrtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2018&pages=843-846&author=A.+Rayauthor=D.+S.+Dasauthor=Y.+Songauthor=T.+Hideshimaauthor=Y.+T.+Taiauthor=D.+Chauhanauthor=K.+C.+Anderson&title=Combination+of+a+novel+HDAC6+inhibitor+ACY-241+and+anti-PD-L1+antibody+enhances+anti-tumor+immunity+and+cytotoxicity+in+multiple+myeloma&doi=10.1038%2Fleu.2017.322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma</span></div><div class="casAuthors">Ray, A.; Das, D. S.; Song, Y.; Hideshima, T.; Tai, Y.-T.; Chauhan, D.; Anderson, K. C.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">843-846</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are attractive therapeutic targets, and selective HDAC inhibitors (HDACi), alone or in combination with other anti-cancer agents, are promising treatment strategies in multiple myeloma (MM).1234To date, however, the effect of HDACi on immune regulation in the MM bone marrow (BM) microenvironment, as well as the therapeutic potential of combining selective HDACi with immune-based therapies, is undefined.  Recent studies showed that besides histone modification, HDACs also modulate non-histone targets including immune regulatory mols.5, 6 For example, blockade of HDACs upregulates immunecheckpoints such as PD-1 ligand (PD-L1).6 Moreover, the combination of HDACi with PD-1/PD-L1 checkpoint blockade significantly improves immunotherapy in a murine B16F10 model.6 In MM, PD-L1 expression directly correlates with progression of disease, with highest levels in patients with relapsed/refractory MM.7, 8 Here, we utilized an orally bioavalable HDAC6 selective inhibitor ACY-241, currently in clin. trials,9 to examine whether the combination of ACY-241 with anti-PD-L1 antibody enhances anti-MM immunity in the MM BM microenvironment.  For our studies, we utilized a co-culture model of immune effector cells (plasmacytoid dendritic cells (pDCs), T cells, NK cells) and MM cells.7, 10 Specifically, we have identified that interactions of MM cells with innate and adaptive immune cells in the BM milieu confer immune suppression via PD-1/PD-L1 signaling axis (Figure 1a: Schema).7, 10 This is exemplified in our studies demonstrating a novel functional interaction between pDCs (Lin- MHC-II+ CD123+ CD4+ CD303/BDCA-2+ CD304/BDCA-4+) and MM cells, implicating pDCs in both MM pathogenesis and immune suppression.  We showed that increased nos. of pDCs are present in MM patient BM vs. normal BM.  Importantly, pDCs in MM BM are relatively resistant to current therapies; protect tumor cells from therapy-induced cytotoxicity; promote tumor growth and survival; and confer immune dysfunction.7, 10 Using our co-culture model, we further delineated the immunosuppressive mechanism(s) that have a role during pDC-T-NK cell interactions with tumor cells.  Specifically, we found that: (1) MM cells and pDCs expressed high surface levels of PD-L1, whereas T cells showed high PD-1 levels; and (2) PD-L1 on MM pDCs suppresses PD-1 expressing T-cell and NK cell immune function; and (3) blockade of PD-L1-PD-1 signaling axis by anti-PD-L1 Ab generates MM-specific CD8+ ctotoxic T lymphocyte (CTL) activity, as well as enhances NK cell-mediated MM cell cytolytic activity.  Importantly, our co-culture model allows for evaluation of the effect of anti-MM drugs on immune regulatory mols. expressed on immune cells and tumor cells, as well as provides a platform for validating all immune-based combination strategies, esp. in the context of immune cells within the MM BM microenvironment.  In the current study, we utilized these models to specifically examine whether the combination of ACY-241 with anti-PD-L1 Ab increases anti-tumor immunity and cytotoxicity in MM.  We first evaluated whether the combination of ACY-241 and anti-PD-L1 Ab enhances MM patient NK cell-mediated cytolytic activity.  For these studies, we utilized low concn. of ACY-241 that do not significantly affect the viability of pDCs, T cells or NK cells (Supplementary Figure 1 A-C).  Freshly isolated NK cells from MM patient BM (n=7) were co-cultured with autologous pDCs in the presence of anti-PD-L1 Ab (5 μg/mL), ACY-241 (0.2 μ) or ACY-241 plus anti-PD-L1 Ab for 5 days.  Cells were washed and resuspended in complete medium without drugs and cultured with autologous MM cells prestained with Celltrace violet for 24 h, followed by 7-AAD staining and quantification of MM cell lysis by flow cytometry.  The combination of ACY-241 and anti-PD-L1 Ab triggered a more robust NK cell-mediated cytotlytic activity against MM cells than either agent alone (Figure 1b and c).  No significant NK cell-mediated cytotoxicity was noted in the absence of pDCs in these expts. (Supplementary Figure 2B), confirming a key role of pDCs in NK cell functioning in response to treatment with ACY-241 and/or anti-PD-L1 Ab.  To further confirm our findings, we next performed anal. of CD107a as a marker of NK cell function.  MM patient pDCs and autologous NK cells were treated with ACY-241, anti-PD-L1 Ab or ACY-241 plus anti-PD-L1 Ab, followed by degranulation assay to assess surface CD107a expressing CD3-/CD56+ NK cells by multi-parameter flow cytometry.  In concert with our finding shown in Figures 1b and c, ACY-241 plus anti-PD-L1 Ab increases CD107a+ degranulated cytolytic NK cells (Supplementary Figure 3).  As in our prior study,7 anti-PD-L1 Ab alone restored NK cell-mediated anti-MM activity.  Interestingly, treatment of pDC-NK cells co-cultured with ACY-241 alone triggerred NK cell cytolytic activity against MM cells (Figures 1b and c).  In this context, a recent study showed a role of HDAC6 in the regulation of PD-L1 in melanoma.11 We hypothesized that ACY-241 may downregulate PD-L1/PD-1-mediated NK cell immune suppression during pDC-NK cell interactions.  Indeed, ACY-241 significantly decreases PD-L1 expression on pDCs (Supplementary Figure 5), which in turn attentuates PD-L1/PD-1-mediated NK suppression and thereby enhances NK cell-mediated MM cell cytotoxicity.  Although not examd. here, other possibilities may account for ACY-241 activity.  Similar to immunomodulatory agent Lenalidomide, ACY-241 may skew effector cytokine (IFN-γ; TNFα) prodn. toward enhancing NK cell anti-MM activity.  Alternatively, ACY-241 may act as reported for HDACi LBH589, which upregulates activation marker CD69 on NK cells.12 Finally, ACY-241 may enhance NK cell anti-MM activity by altering receptor-ligand (for example, NKG2D or KIR) expression-mediated tumor cell killing.  These issues remain to be examd.  Nonetheless, we here show that: (1) pDC-MM cell interactions modulate NK cell cytotoxic activity; (2) combined ACY-241 and anti-PD-L1 Ab enhances MM patient pDC-induced NK cell-mediated cytolytic activities against autologous MM cells; (3) ACY-241 or anti-PD-L1 alone have the ability to stimulate NK cell effector function, albiet to a lesser extent than in combination; and (4) ACY-241 is an immune-modulating agent as it triggers significant NK cell anti-MM activity.  A recent study showed that a HDAC6i ricolinostat triggers T-cell activation and APC function.13 We therefore next examd. whether ACY-241, anti-PD-L1 or their combination triggers the generation of MM-specific CTLs ex vivo.  MM patient BM CD8+T cells (n=7) were co-cultured with autologous pDCs (pDC:T; 1:10 ratio) in the presence of anti-PD-L1 Ab, ACY-241 or ACY-241 plus anti-PD-L1 Ab for 5 days.  Cells were washed and resuspended in complete medium without drugs and cultured with autologous MM cells that were prestained with CellTracker Green for 24 h, followed by 7-AAD staining and quantification of CTLs-mediated MM cell lysis by FACS.  The combination of ACY-241 and anti-PD-L1 Ab triggered a more robust autologous MM-specific CD8+ CTL activity than either agent alone, evidenced by decreased no. of viable CellTracker Green-pos. MM cells (Figure 2a and Supplementary Figure 4).  MM cells were also cultured alone without immune effector cells for the same time period, and data obtained from flow anal. were used for normalization to account for the spontaneous MM cells death.  We next performed CD107a degranulation assays to confirm the generation of CD8+ T-cell cytolytic activity.  MM patient pDCs were co-cultured with autologous T cells and treated with ACY-241, anti-PD-L1 Ab, or ACY-241 plus anti-PD-L1 Ab, followed by degranulation assay to measure CD107a on the cell surface of activated CD3+/CD8+ T cells using flow cytometry.  In agreement with our findings from CTL assays (Figure 2a and Supplementary Figure 4), a more robust increase in surface CD107a+ cytotoxic T cells was noted upon treatment with combined ACY-241 and anti-PD-L1 Ab vs. either ACY-241 or anti-PD-L1 Ab alone (Figure 2b).  No significant MM patient CTL activity was noticed in the absence of pDCs (Supplementary Figure 2C).  Collectively, our data show that combination of selective HDAC6 inhibitor ACY-241 with anti-PD-L1 Ab triggers both CTLs- and NK cells-mediated MM cell killing (Supplementary Figures 6 and 7; Schema).  Mechanistic studies show that combined activity of ACY-241 and anti-PD-L1 is due to downregulation of immunosuppressive PD-L1/PD-1 signaling during pDC-T cells and pDC-NK cells interactions.  It is likely that besides blockade of PD-L1/PD-1, this combination regimen also abrogates other immunosuppressive mechanisms and/or activates immune-activating pathways among pDCs, NK or T cells that together contribute in restoration of anti-MM immunity.  Ongoing studies are focused on investigating these immune mechanism(s).  Finally, recent data indicate potential toxicity assocd. with checkpoint inhibitors in MM.  However, in contrast to inhibitor of checkpoint PD-1 (pembrolizumab), clin. trials of anti-PD-L1 Abs to date show safety, without any significant adverse events in MM patients.14 Moreover, a recent study found a better response rate in patients with higher PD-L1 levels on MM cells, and PD-1 expression on lymphocytes correlated weakly with progression-free survival in a small subset of patients.15 These findings, coupled with our data, support translation of combined ACY-241 and anti-PD-L1 Ab into clin. trials to restore immune function, enhance MM cytotoxicity and improve patient outcome in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiLF586f3pxrVg90H21EOLACvtfcHk0lgE74wJDYK5Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvFWrtr0%253D&md5=b186fa9563c1e48519b4831dc3cebc3e</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1038%2Fleu.2017.322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2017.322%26sid%3Dliteratum%253Aachs%26aulast%3DRay%26aufirst%3DA.%26aulast%3DDas%26aufirst%3DD.%2BS.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DTai%26aufirst%3DY.%2BT.%26aulast%3DChauhan%26aufirst%3DD.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DCombination%2520of%2520a%2520novel%2520HDAC6%2520inhibitor%2520ACY-241%2520and%2520anti-PD-L1%2520antibody%2520enhances%2520anti-tumor%2520immunity%2520and%2520cytotoxicity%2520in%2520multiple%2520myeloma%26jtitle%3DLeukemia%26date%3D2018%26volume%3D32%26spage%3D843%26epage%3D846%26doi%3D10.1038%2Fleu.2017.322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cosenza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Civallero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcheselli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sacchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozzi, S.</span></span> <span> </span><span class="NLM_article-title">Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination</span>. <i>Apoptosis</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">370</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1007/s10495-020-01607-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs10495-020-01607-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32394008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpt1Kiurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=370-387&author=M.+Cosenzaauthor=M.+Civalleroauthor=L.+Marcheselliauthor=S.+Sacchiauthor=S.+Pozzi&title=Citarinostat+and+Momelotinib+co-target+HDAC6+and+JAK2%2FSTAT3+in+lymphoid+malignant+cell+lines%3A+a+potential+new+therapeutic+combination&doi=10.1007%2Fs10495-020-01607-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Citarinostat and Momelotinib co-target HDAC6 and JAK2/STAT3 in lymphoid malignant cell lines: a potential new therapeutic combination</span></div><div class="casAuthors">Cosenza, Maria; Civallero, Monica; Marcheselli, Luigi; Sacchi, Stefano; Pozzi, Samantha</div><div class="citationInfo"><span class="NLM_cas:title">Apoptosis</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">370-387</span>CODEN:
                <span class="NLM_cas:coden">APOPFN</span>;
        ISSN:<span class="NLM_cas:issn">1360-8185</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors represent an encouraging class of antitumor drugs.  HDAC inhibitors induce a series of mol. and biol. responses and minimal toxicity to normal cells.  Citarinostat is a second generation, orally administered, HDAC6-selective inhibitor.  Momelotinib is an orally administered inhibitor of JAK/STAT3 signaling.  Momelotinib showed efficacy in patients with myelofibrosis.  We hypothesized that both HDAC and JAK/STAT pathways were important in lymphoproliferative disorders, and that inhibiting JAK/STAT3 and HDAC simultaneously might enhance the efficacy of momelotinib and citarinostat without increasing toxicity.  Accordingly, we tested the citarinostat + momelotinib combination in lymphoid cell lines.  Citarinostat + momelotinib showed strong cytotoxicity; it significantly reduced mitochondrial membrane potential, down-regulated Bcl-2 and Bcl-xL, and activated caspases 9 and 3.  Caspase-8 was upregulated in only two lymphoid cell lines, which indicated activation of the extrinsic apoptotic pathway.  We identified a lymphoid cell line that was only slightly sensitive to the combination treatment.  We knocked down thioredoxin expression by transfecting with small interfering RNA that targeted thioredoxin.  This knockdown increased cell sensitivity to the combination-induced cell death.  The combination treatment reduced Bcl-2 expression, activated caspase 3, and significantly inhibited cell viability and clonogenic survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA9gyd6V5mR7Vg90H21EOLACvtfcHk0lgE74wJDYK5Vg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpt1Kiurw%253D&md5=fd17a3c8cb7bebdbe050c7d6622488df</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1007%2Fs10495-020-01607-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10495-020-01607-3%26sid%3Dliteratum%253Aachs%26aulast%3DCosenza%26aufirst%3DM.%26aulast%3DCivallero%26aufirst%3DM.%26aulast%3DMarcheselli%26aufirst%3DL.%26aulast%3DSacchi%26aufirst%3DS.%26aulast%3DPozzi%26aufirst%3DS.%26atitle%3DCitarinostat%2520and%2520Momelotinib%2520co-target%2520HDAC6%2520and%2520JAK2%252FSTAT3%2520in%2520lymphoid%2520malignant%2520cell%2520lines%253A%2520a%2520potential%2520new%2520therapeutic%2520combination%26jtitle%3DApoptosis%26date%3D2020%26volume%3D25%26spage%3D370%26epage%3D387%26doi%3D10.1007%2Fs10495-020-01607-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colling, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estiu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cottini, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorgun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tai, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiest, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>113</i></span>,  <span class="NLM_fpage">13162</span>– <span class="NLM_lpage">13167</span>, <span class="refDoi"> DOI: 10.1073/pnas.1608067113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1073%2Fpnas.1608067113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27799547" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslKnu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2016&pages=13162-13167&author=T.+Hideshimaauthor=J.+Qiauthor=R.+M.+Paranalauthor=W.+Tangauthor=E.+Greenbergauthor=N.+Westauthor=M.+E.+Collingauthor=G.+Estiuauthor=R.+Mazitschekauthor=J.+A.+Perryauthor=H.+Ohguchiauthor=F.+Cottiniauthor=N.+Mimuraauthor=G.+Gorgunauthor=Y.+T.+Taiauthor=P.+G.+Richardsonauthor=R.+D.+Carrascoauthor=O.+Wiestauthor=S.+L.+Schreiberauthor=K.+C.+Andersonauthor=J.+E.+Bradner&title=Discovery+of+selective+small-molecule+HDAC6+inhibitor+for+overcoming+proteasome+inhibitor+resistance+in+multiple+myeloma&doi=10.1073%2Fpnas.1608067113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma</span></div><div class="casAuthors">Hideshima, Teru; Qi, Jun; Paranal, Ronald M.; Tang, Weiping; Greenberg, Edward; West, Nathan; Colling, Meaghan E.; Estiu, Guillermina; Mazitschek, Ralph; Perry, Jennifer A.; Ohguchi, Hiroto; Cottini, Francesca; Mimura, Naoya; Gorgun, Gullu; Tai, Yu-Tzu; Richardson, Paul G.; Carrasco, Ruben D.; Wiest, Olaf; Schreiber, Stuart L.; Anderson, Kenneth C.; Bradner, James E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">13162-13167</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) has proven clin. susceptible to modulation of pathways of protein homeostasis.  Blockade of proteasomal degrdn. of polyubiquitinated misfolded proteins by the proteasome inhibitor bortezomib (BTZ) achieves responses and prolongs survival in MM, but long-term treatment with BTZ leads to drug-resistant relapse in most patients.  In a proof-of-concept study, the authors previously demonstrated that blocking aggresomal breakdown of polyubiquitinated misfolded proteins with the histone deacetylase 6 (HDAC6) inhibitor tubacin enhances BTZ-induced cytotoxicity in MM cells in vitro.  However, these foundational studies were limited by the pharmacol. liabilities of tubacin as a chem. probe with only in vitro utility.  Emerging from a focused library synthesis, a potent, selective, and bioavailable HDAC6 inhibitor, WT161, was created to study the mechanism of action of HDAC6 inhibition in MM alone and in combination with BTZ.  WT161 in combination with BTZ triggers significant accumulation of polyubiquitinated proteins and cell stress, followed by caspase activation and apoptosis.  More importantly, this combination treatment was effective in BTZ-resistant cells and in the presence of bone marrow stromal cells, which have been shown to mediate MM cell drug resistance.  The activity of WT161 was confirmed in the human MM cell xenograft mouse model and established the framework for clin. trials of the combination treatment to improve patient outcomes in MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxE_VYaPFUSbVg90H21EOLACvtfcHk0lg4VLa37vKG4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslKnu73M&md5=2515fcba03631917d0ca7656d1f62a7e</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1608067113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1608067113%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DTang%26aufirst%3DW.%26aulast%3DGreenberg%26aufirst%3DE.%26aulast%3DWest%26aufirst%3DN.%26aulast%3DColling%26aufirst%3DM.%2BE.%26aulast%3DEstiu%26aufirst%3DG.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DPerry%26aufirst%3DJ.%2BA.%26aulast%3DOhguchi%26aufirst%3DH.%26aulast%3DCottini%26aufirst%3DF.%26aulast%3DMimura%26aufirst%3DN.%26aulast%3DGorgun%26aufirst%3DG.%26aulast%3DTai%26aufirst%3DY.%2BT.%26aulast%3DRichardson%26aufirst%3DP.%2BG.%26aulast%3DCarrasco%26aufirst%3DR.%2BD.%26aulast%3DWiest%26aufirst%3DO.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26atitle%3DDiscovery%2520of%2520selective%2520small-molecule%2520HDAC6%2520inhibitor%2520for%2520overcoming%2520proteasome%2520inhibitor%2520resistance%2520in%2520multiple%2520myeloma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2016%26volume%3D113%26spage%3D13162%26epage%3D13167%26doi%3D10.1073%2Fpnas.1608067113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hideshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. C.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">80109</span>– <span class="NLM_lpage">80123</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.19019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.18632%2Foncotarget.19019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29113288" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BC1M7oslOksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=80109-80123&author=T.+Hideshimaauthor=R.+Mazitschekauthor=J.+Qiauthor=N.+Mimuraauthor=J.-C.+Tsengauthor=A.+L.+Kungauthor=J.+E.+Bradnerauthor=K.+C.+Anderson&title=HDAC6+inhibitor+WT161+downregulates+growth+factor+receptors+in+breast+cancer&doi=10.18632%2Foncotarget.19019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer</span></div><div class="casAuthors">Hideshima Teru; Qi Jun; Mimura Naoya; Bradner James E; Anderson Kenneth C; Mazitschek Ralph; Mimura Naoya; Tseng Jen-Chieh; Kung Andrew L; Tseng Jen-Chieh; Kung Andrew L; Kung Andrew L; Bradner James E</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">46</span>),
    <span class="NLM_cas:pages">80109-80123</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">We have shown that WT-161, a histone deacetylase 6 (HDAC6) inhibitor, shows remarkable anti-tumor activity in multiple myeloma (MM) in preclinical models.  However, its activity in other type of cancers has not yet been shown.  In this study, we further evaluated the biologic sequelae of WT161 in breast cancer cell lines.  WT161 triggers apoptotic cell death in MCF7, T47D, BT474, and MDA-MB231 cells, associated with decreased expression of EGFR, HER2, and ERα and downstream signaling.  However, HDAC6 knockdown shows that cytotoxicity and destabilization of these receptors triggered by WT161 are not dependent on HDAC6 inhibition.  Moreover WT161 analog MAZ1793, which lacks HDAC inhibitory effect, similarly triggers cell line growth inhibition and downregulation of these receptors.  We also confirm that WT161 significantly inhibits in vivo MCF7 cell growth, associated with downregulation of ERα, in a murine xenograft model.  Finally, WT161 synergistically enhances bortezomib-induced cytotoxicity, even in bortezomib-resistant breast cancer cells.  Our results therefore provide the rationale to develop a novel class of therapeutic agents targeting growth pathways central to the pathogenesis of breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWi2bvABUN7K2q3xNe7a7QfW6udTcc2eYoaUDzfqaIubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7oslOksg%253D%253D&md5=50fcf37b8db1e8acb520e650f6702bf5</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.19019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.19019%26sid%3Dliteratum%253Aachs%26aulast%3DHideshima%26aufirst%3DT.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DMimura%26aufirst%3DN.%26aulast%3DTseng%26aufirst%3DJ.-C.%26aulast%3DKung%26aufirst%3DA.%2BL.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAnderson%26aufirst%3DK.%2BC.%26atitle%3DHDAC6%2520inhibitor%2520WT161%2520downregulates%2520growth%2520factor%2520receptors%2520in%2520breast%2520cancer%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D80109%26epage%3D80123%26doi%3D10.18632%2Foncotarget.19019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapadar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luchini, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D. D.</span></span> <span> </span><span class="NLM_article-title">Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">4370</span>– <span class="NLM_lpage">4373</span>, <span class="refDoi"> DOI: 10.1021/jm8002894</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm8002894" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovVGmtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4370-4373&author=A.+P.+Kozikowskiauthor=S.+Tapadarauthor=D.+N.+Luchiniauthor=K.+H.+Kimauthor=D.+D.+Billadeau&title=Use+of+the+Nitrile+Oxide+Cycloaddition+%28NOC%29+Reaction+for+Molecular+Probe+Generation%3A+A+New+Class+of+Enzyme+Selective+Histone+Deacetylase+Inhibitors+%28HDACIs%29+Showing+Picomolar+Activity+at+HDAC6&doi=10.1021%2Fjm8002894"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Use of the Nitrile Oxide Cycloaddition (NOC) Reaction for Molecular Probe Generation: A New Class of Enzyme Selective Histone Deacetylase Inhibitors (HDACIs) Showing Picomolar Activity at HDAC6</span></div><div class="casAuthors">Kozikowski, Alan P.; Tapadar, Subhasish; Luchini, Doris N.; Kim, Ki Hwan; Billadeau, Daniel D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4370-4373</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of hydroxamate based HDAC inhibitors contg. a phenylisoxazole as the CAP group has been synthesized using nitrile oxide cycloaddn. chem.  An HDAC6 selective inhibitor having a potency of ∼2 picomolar was identified.  Some of the compds. were examd. for their ability to block pancreatic cancer cell growth and found to be about 10-fold more potent than SAHA (suberoylanilidehydroxamic acid).  This research provides valuable, new mol. probes for use in exploring HDAC biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJ7Ca9tXdBvbVg90H21EOLACvtfcHk0lg4VLa37vKG4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovVGmtbk%253D&md5=006c71fe6f2bb09c2c65196e134a695e</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1021%2Fjm8002894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm8002894%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DTapadar%26aufirst%3DS.%26aulast%3DLuchini%26aufirst%3DD.%2BN.%26aulast%3DKim%26aufirst%3DK.%2BH.%26aulast%3DBilladeau%26aufirst%3DD.%2BD.%26atitle%3DUse%2520of%2520the%2520Nitrile%2520Oxide%2520Cycloaddition%2520%2528NOC%2529%2520Reaction%2520for%2520Molecular%2520Probe%2520Generation%253A%2520A%2520New%2520Class%2520of%2520Enzyme%2520Selective%2520Histone%2520Deacetylase%2520Inhibitors%2520%2528HDACIs%2529%2520Showing%2520Picomolar%2520Activity%2520at%2520HDAC6%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4370%26epage%3D4373%26doi%3D10.1021%2Fjm8002894" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sixto-Lopez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Fonseca, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosales-Hernandez, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Archundia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Vidal, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa-Basurto, J.</span></span> <span> </span><span class="NLM_article-title">Searching the conformational complexity and binding properties of HDAC6 through docking and molecular dynamic simulations</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">2794</span>– <span class="NLM_lpage">2814</span>, <span class="refDoi"> DOI: 10.1080/07391102.2016.1231084</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1080%2F07391102.2016.1231084" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27589363" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGqs7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&pages=2794-2814&author=Y.+Sixto-Lopezauthor=M.+Belloauthor=R.+A.+Rodriguez-Fonsecaauthor=M.+C.+Rosales-Hernandezauthor=M.+Martinez-Archundiaauthor=J.+A.+Gomez-Vidalauthor=J.+Correa-Basurto&title=Searching+the+conformational+complexity+and+binding+properties+of+HDAC6+through+docking+and+molecular+dynamic+simulations&doi=10.1080%2F07391102.2016.1231084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Searching the conformational complexity and binding properties of HDAC6 through docking and molecular dynamic simulations</span></div><div class="casAuthors">Sixto-Lopez, Yudibeth; Bello, Martiniano; Rodriguez-Fonseca, Rolando Alberto; Rosales-Hernandez, Martha Cecilia; Martinez-Archundia, Marlet; Gomez-Vidal, Jose Antonio; Correa-Basurto, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2794-2814</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are a family of proteins involved in the deacetylation of histones and other non-histones substrates.  HDAC6 belongs to class II and shares similar biol. functions with others of its class.  Nevertheless, its three-dimensional structure that involves the catalytic site remains unknown for exploring the ligand recognition properties.  Therefore, in this contribution, homol. modeling, 100-ns-long Mol. Dynamics (MD) simulation and docking calcns. were combined to explore the conformational complexity and binding properties of the catalytic domain 2 from HDAC6 (DD2-HDAC6), for which activity and affinity toward five different ligands have been reported.  Clustering anal. allowed identifying the most populated conformers present during the MD simulation, which were used as starting models to perform docking calcns. with five DD2-HDAC6 inhibitors: Cay10603 (CAY), Rocilinostat (RCT), Tubastatin A (TBA), Tubacin (TBC), and Nexturastat (NXT), and then were also submitted to 100-ns-long MD simulations.  Docking calcns. revealed that the five inhibitors bind at the DD2-HDAC6 binding site with the lowest binding free energy, the same binding mode is maintained along the 100-ns-long MD simulations.  Overall, our results provide structural information about the mol. flexibility of apo and holo DD2-HDAC6 states as well as insight of the map of interactions between DD2-HDAC6 and five well-known DD2-HDAC6 inhibitors allowing structural details to guide the drug design.  Finally, we highlight the importance of combining different theor. approaches to provide suitable structural models for structure-based drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEjhU2jaMvbbVg90H21EOLACvtfcHk0lhIB-QtHeRMBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGqs7bI&md5=75556fa931fbc8dd3b1276216a309366</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1080%2F07391102.2016.1231084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2016.1231084%26sid%3Dliteratum%253Aachs%26aulast%3DSixto-Lopez%26aufirst%3DY.%26aulast%3DBello%26aufirst%3DM.%26aulast%3DRodriguez-Fonseca%26aufirst%3DR.%2BA.%26aulast%3DRosales-Hernandez%26aufirst%3DM.%2BC.%26aulast%3DMartinez-Archundia%26aufirst%3DM.%26aulast%3DGomez-Vidal%26aufirst%3DJ.%2BA.%26aulast%3DCorrea-Basurto%26aufirst%3DJ.%26atitle%3DSearching%2520the%2520conformational%2520complexity%2520and%2520binding%2520properties%2520of%2520HDAC6%2520through%2520docking%2520and%2520molecular%2520dynamic%2520simulations%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2017%26volume%3D35%26spage%3D2794%26epage%3D2814%26doi%3D10.1080%2F07391102.2016.1231084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sixto-Lopez, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Correa-Basurto, J.</span></span> <span> </span><span class="NLM_article-title">Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">4701</span>– <span class="NLM_lpage">4720</span>, <span class="refDoi"> DOI: 10.1080/07391102.2018.1557560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1080%2F07391102.2018.1557560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30558483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivVaisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=4701-4720&author=Y.+Sixto-Lopezauthor=M.+Belloauthor=J.+Correa-Basurto&title=Structural+and+energetic+basis+for+the+inhibitory+selectivity+of+both+catalytic+domains+of+dimeric+HDAC6&doi=10.1080%2F07391102.2018.1557560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and energetic basis for the inhibitory selectivity of both catalytic domains of dimeric HDAC6</span></div><div class="casAuthors">Sixto-Lopez, Yudibeth; Bello, Martiniano; Correa-Basurto, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4701-4720</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">HDAC6 is a protein involved in cancer, neurodegenerative disease and inflammatory disorders.  To date, the full three-dimensional (3D) structure of human HDAC6 has not been elucidated; however, there are some exptl. 3D structural homologs to HDAC6 that can be used as templates.  In this work, we utilized mol. modeling procedures to model both of the catalytic domains of HDAC6 connected by the linker region where DMB region is placed.  Once the 3D structure of human HDAC6 was obtained, it was structurally evaluated and submitted to docking and mol. dynamic (MD) simulations along with Mol. Mechanics/Generalized Born Surface Area (MM/GBSA) method to explore the stability and the binding free energy properties of the HDAC6-ligand complexes.  In addn., its structural and energetic behavior was explored with each one of the catalytic domains in the mol. recognition of six selective HDAC6 inhibitors, HPOB, CAY10603, Nexturastat, Rocilinostat, Tubacin and Tubastatin A for DD2, and with the so-called 9-peptide which is DD1-HDAC6 selective substrate.  The use of the whole system (DD1-DMB-DD2) showed a tendency toward the ligand affinity of DD2, CAY10603> Tubacin > Rocilinostat > Nexturastat > HPOB > Tubastatin > 9-peptide, which is in line with exptl. reports.  However, 9-peptide showed a higher affinity for DD1, which agrees with exptl. reports elsewhere.  Principal component anal. provided important information about the structural changes linked to the mol. recognition process, whereas per-residue decompn. anal. revealed the energetic contribution of the key residues in the mol. binding and structural characteristics that could assist in drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaDDSCE5cAdLVg90H21EOLACvtfcHk0lhIB-QtHeRMBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivVaisLg%253D&md5=7029672cda1c077774128f90422209d3</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1080%2F07391102.2018.1557560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2018.1557560%26sid%3Dliteratum%253Aachs%26aulast%3DSixto-Lopez%26aufirst%3DY.%26aulast%3DBello%26aufirst%3DM.%26aulast%3DCorrea-Basurto%26aufirst%3DJ.%26atitle%3DStructural%2520and%2520energetic%2520basis%2520for%2520the%2520inhibitory%2520selectivity%2520of%2520both%2520catalytic%2520domains%2520of%2520dimeric%2520HDAC6%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2019%26volume%3D37%26spage%3D4701%26epage%3D4720%26doi%3D10.1080%2F07391102.2018.1557560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, C.</span></span> <span> </span><span class="NLM_article-title">HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma</span>. <i>Oncol. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">589</span>– <span class="NLM_lpage">597</span>, <span class="refDoi"> DOI: 10.3892/or.2016.4811</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3892%2For.2016.4811" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27221381" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXmtl2mtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2016&pages=589-597&author=Z.+Wangauthor=F.+Tangauthor=P.+Huauthor=Y.+Wangauthor=J.+Gongauthor=S.+Sunauthor=C.+Xie&title=HDAC6+promotes+cell+proliferation+and+confers+resistance+to+gefitinib+in+lung+adenocarcinoma&doi=10.3892%2For.2016.4811"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma</span></div><div class="casAuthors">Wang, Zhihao; Tang, Fang; Hu, Pengchao; Wang, Ying; Gong, Jun; Sun, Shaoxing; Xie, Conghua</div><div class="citationInfo"><span class="NLM_cas:title">Oncology Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">589-597</span>CODEN:
                <span class="NLM_cas:coden">OCRPEW</span>;
        ISSN:<span class="NLM_cas:issn">1791-2431</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are promising targets for cancer therapy, and first-generation HDAC inhibitors are currently in clin. trials for the treatment of cancer patients.  HDAC6, which is a key regulator of many signaling pathways that are linked to cancer, has recently emerged as an attractive target for the treatment of cancer.  In the present study, HDAC6 was found to be overexpressed in lung adenocarcinoma cell lines and was neg. correlated with the prognosis of patients with lung adenocarcinoma.  Overexpression of HDAC6 promoted the proliferation of lung adenocarcinoma cells in a deacetylase activity-dependent manner.  HDAC6 overexpression conferred resistance to gefitinib via the stabilization of epidermal growth factor receptor (EGFR).  The inhibition of HDAC6 by CAY10603, a potent and selective inhibitor of HDAC6, inhibited the proliferation of lung adenocarcinoma cells and induced apoptosis.  CAY10603 downregulated the levels of EGFR protein, which in turn inhibited activation of the EGFR signaling pathway.  Moreover, CAY10603 synergized with gefitinib to induce apoptosis of the lung adenocarcinoma cell lines via the destabilization of EGFR.  Taken together, our results suggest that the inhibition of HDAC6 may be a promising strategy for the treatment of lung adenocarcinoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4lXuah65G6bVg90H21EOLACvtfcHk0lhIB-QtHeRMBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXmtl2mtLk%253D&md5=3a2778e81b86443b5e4fcc37bc11f11e</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.3892%2For.2016.4811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252For.2016.4811%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DS.%26aulast%3DXie%26aufirst%3DC.%26atitle%3DHDAC6%2520promotes%2520cell%2520proliferation%2520and%2520confers%2520resistance%2520to%2520gefitinib%2520in%2520lung%2520adenocarcinoma%26jtitle%3DOncol.%2520Rep.%26date%3D2016%26volume%3D36%26spage%3D589%26epage%3D597%26doi%3D10.3892%2For.2016.4811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shetty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, J.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury</span>. <i>Toxicol. Appl. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1016/j.taap.2019.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.taap.2019.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30910594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtVylsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2019&pages=178-183&author=L.+Liuauthor=X.+Zhouauthor=S.+Shettyauthor=G.+Houauthor=Q.+Wangauthor=J.+Fu&title=HDAC6+inhibition+blocks+inflammatory+signaling+and+caspase-1+activation+in+LPS-induced+acute+lung+injury&doi=10.1016%2Fj.taap.2019.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibition blocks inflammatory signaling and caspase-1 activation in LPS-induced acute lung injury</span></div><div class="casAuthors">Liu, Li; Zhou, Xiaoming; Shetty, Sreerama; Hou, Gang; Wang, Qiuyue; Fu, Jian</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology and Applied Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">178-183</span>CODEN:
                <span class="NLM_cas:coden">TXAPA9</span>;
        ISSN:<span class="NLM_cas:issn">0041-008X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">HDAC6 is a member of the class II histone deacetylase.  HDAC6 inhibition possesses anti-inflammatory effects.  However, the effects of HDAC6 inhibition in acute lung inflammation have not been studied.  Here, we investigated the effects of a highly selective and potent HDAC6 inhibitor CAY10603 in LPS-induced acute inflammatory lung injury.  We also conducted a series of expts. including immunoblotting, ELISA, and histol. assays to explore the inflammatory signaling pathways modulated by the selective HDAC6 inhibition.  We obsd. that HDAC6 activity was increased in the lung tissues after LPS challenge, which was assocd. with a decreased level of α-tubulin acetylation in the lung tissues.  HDAC6 inhibition by CAY10603 prevented LPS-induced α-tubulin deacetylation in the lung tissues.  HDAC6 inhibition also exhibited protective effects against LPS-induced acute lung inflammation, which was demonstrated by the reduced prodn. of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 and decreased leukocyte infiltration.  Furthermore, HDAC6 inhibition blocked the decrease of E-cadherin level and inhibited the increase of MMP9 expression in the lung tissues, which could prevent the destruction of the lung architecture in LPS-induced inflammatory injury.  Given the important roles of NFkB and inflammasome activation in inflammatory responses, we investigated their regulation by HDAC6 inhibition in LPS-induced lung injury.  Our results showed that HDAC6 inhibition blocked the activation of NFkB by inhibiting IkB phosphorylation in LPS-induced acute lung injury, and LPS-induced-inflammasome activity was reduced by HDAC6 inhibition as demonstrated by the decreased IL-1β and caspase-1 cleavage and activation.  Collectively, our data suggest that selective HDAC6 inhibition suppresses inflammatory signaling pathways and alleviates LPS-induced acute lung inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOnbD8x2_VybVg90H21EOLACvtfcHk0ljMyqEFsM72MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtVylsr8%253D&md5=c4c22ef2bbad18471b9464018f24a389</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.taap.2019.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.taap.2019.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DShetty%26aufirst%3DS.%26aulast%3DHou%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DFu%26aufirst%3DJ.%26atitle%3DHDAC6%2520inhibition%2520blocks%2520inflammatory%2520signaling%2520and%2520caspase-1%2520activation%2520in%2520LPS-induced%2520acute%2520lung%2520injury%26jtitle%3DToxicol.%2520Appl.%2520Pharmacol.%26date%3D2019%26volume%3D370%26spage%3D178%26epage%3D183%26doi%3D10.1016%2Fj.taap.2019.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibitor Cay10603 inhibits high glucose-induced oxidative stress, inflammation and apoptosis in retinal pigment epithelial cells via regulating NF-kappaB and NLRP3 inflammasome pathway</span>. <i>General physiology and biophysics</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.4149/gpb_2019058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.4149%2Fgpb_2019058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32329444" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1SqtrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&pages=169-177&author=Q.+Yangauthor=S.+Liauthor=Z.+Zhouauthor=M.+Fuauthor=X.+Yangauthor=K.+Haoauthor=Y.+Liu&title=HDAC6+inhibitor+Cay10603+inhibits+high+glucose-induced+oxidative+stress%2C+inflammation+and+apoptosis+in+retinal+pigment+epithelial+cells+via+regulating+NF-kappaB+and+NLRP3+inflammasome+pathway&doi=10.4149%2Fgpb_2019058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibitor Cay10603 inhibits high glucose-induced oxidative stress, inflammation and apoptosis in retinal pigment epithelial cells via regulating NF-kappaB and NLRP3 inflammasome pathway</span></div><div class="casAuthors">Yang, Qingsong; Li, Sizhen; Zhou, Zixiu; Fu, Min; Yang, Xiaodong; Hao, Kuanxiao; Liu, Yating</div><div class="citationInfo"><span class="NLM_cas:title">General Physiology and Biophysics</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">169-177</span>CODEN:
                <span class="NLM_cas:coden">GPBIE2</span>;
        ISSN:<span class="NLM_cas:issn">0231-5882</span>.
    
            (<span class="NLM_cas:orgname">Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences</span>)
        </div><div class="casAbstract">The present study aimed to investigate the effects of histone deacetylase 6 (HDAC6) inhibitor Cay10603 (Cay) on high glucose (HG)-stimulated human retinal pigment epithelium (RPE) cells and its underlying mechanisms.  ARPE-19 cells were cultured under normal glucose (NG) or high glucose (HG) conditions.  The results revealed that HDAC6 was upregulated in HG-stimulated ARPE-19 cells.  Cay treatment caused a decrease in intracellular reactive oxygen species (ROS).  The levels of malondialdehyde (MDA) and myeloperoxidase (MPO) were reduced accompanied by increase in the activities of superoxide dismutase (SOD) and catalase (CAT) after treatment with Cay.  Besides, Cay decreased the levels of tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-6 and monocyte chemoattractant protein-1 (MCP-1) in supernatant.  Meanwhile, the apoptotic rate in Cay-treated ARPE-19 cells notably reduced, coupled with an upregulation in Bcl-2 expression and a downregulation in cleaved caspase-3 and cleaved caspase-9 expression.  Cay decreased the expression of phospho (p)-NF-κB p65, p-IκB-α, NLRP3, cleaved caspase-1 and ASC while increased the expression of NF-κB p65 (cytoplasm).  Taken together, these findings demonstrated that Cay suppressed HG-induced oxidative stress, inflammation and apoptosis via regulating NF-κB and NLRP3 inflammasome pathway in HG-induced ARPE-19 cells, suggesting that Cay might be a therapeutic agent for the treatment of diabetic retinopathy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgDch-bOWQ2bVg90H21EOLACvtfcHk0ljMyqEFsM72MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1SqtrjN&md5=3ebdcf6ed1a56c032e14c3c565076b75</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.4149%2Fgpb_2019058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4149%252Fgpb_2019058%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DZ.%26aulast%3DFu%26aufirst%3DM.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DHao%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DY.%26atitle%3DHDAC6%2520inhibitor%2520Cay10603%2520inhibits%2520high%2520glucose-induced%2520oxidative%2520stress%252C%2520inflammation%2520and%2520apoptosis%2520in%2520retinal%2520pigment%2520epithelial%2520cells%2520via%2520regulating%2520NF-kappaB%2520and%2520NLRP3%2520inflammasome%2520pathway%26jtitle%3DGeneral%2520physiology%2520and%2520biophysics%26date%3D2020%26volume%3D39%26spage%3D169%26epage%3D177%26doi%3D10.4149%2Fgpb_2019058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span> <span> </span><span class="NLM_article-title">HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt’s Lymphoma Cells by Impeding the Cell Cycle</span>. <i>Current Medical Science</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.1007/s11596-019-2024-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs11596-019-2024-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31016515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FosFOitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=228-236&author=X.+J.+Maauthor=G.+Xuauthor=Z.+J.+Liauthor=F.+Chenauthor=D.+Wuauthor=J.+N.+Miaoauthor=Y.+Zhanauthor=Y.+Fan&title=HDAC-selective+Inhibitor+Cay10603+Has+Single+Anti-tumour+Effect+in+Burkitt%E2%80%99s+Lymphoma+Cells+by+Impeding+the+Cell+Cycle&doi=10.1007%2Fs11596-019-2024-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC-selective Inhibitor Cay10603 Has Single Anti-tumour Effect in Burkitt's Lymphoma Cells by Impeding the Cell Cycle</span></div><div class="casAuthors">Ma Xiu-Juan; Li Zhi-Jie; Wu Di; Miao Jia-Ning; Zhan Yue; Fan Yang; Xu Gang; Chen Fang</div><div class="citationInfo"><span class="NLM_cas:title">Current medical science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">228-236</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) inhibitors are novel in cancer therapy nowadays.  HDAC6-selective inhibitors exert advantageous effects due to higher selectivity and less toxicity.  We explored the anti-tumor effect and the molecular mechanism of cay10603, a potent HDAC6 inhibitor in Burkitt's lymphoma cells.  Our study revealed cay10603 inhibited the proliferation of Burkitt's lymphoma cell lines, and induced caspase-dependent apoptosis.  Cay10603 inhibited the expression of CDKs and cyclins to impede cell cycle progression in both Burkitt's lymphoma cell lines.  Cay10603 also showed the additive effect with vp16 notably.  Our data presented the promising anti-tumor effect of cay10603 in the Burkitt's lymphoma therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTYxaenw9OQZb7NkxioyDXTfW6udTcc2eayByXiCemFMbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FosFOitw%253D%253D&md5=beb0659f8068c10c84847566f487abe2</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1007%2Fs11596-019-2024-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11596-019-2024-4%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%2BJ.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DZ.%2BJ.%26aulast%3DChen%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DMiao%26aufirst%3DJ.%2BN.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DFan%26aufirst%3DY.%26atitle%3DHDAC-selective%2520Inhibitor%2520Cay10603%2520Has%2520Single%2520Anti-tumour%2520Effect%2520in%2520Burkitt%25E2%2580%2599s%2520Lymphoma%2520Cells%2520by%2520Impeding%2520the%2520Cell%2520Cycle%26jtitle%3DCurrent%2520Medical%2520Science%26date%3D2019%26volume%3D39%26spage%3D228%26epage%3D236%26doi%3D10.1007%2Fs11596-019-2024-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span> <span> </span><span class="NLM_article-title">Structure and property based design, synthesis and biological evaluation of gamma-lactam based HDAC inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1218</span>– <span class="NLM_lpage">1221</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.079</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmcl.2010.12.079" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=21256006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1amt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=1218-1221&author=E.+Choiauthor=C.+Leeauthor=J.+E.+Parkauthor=J.+J.+Seoauthor=M.+Choauthor=J.+S.+Kangauthor=H.+M.+Kimauthor=S.+K.+Parkauthor=K.+Leeauthor=G.+Han&title=Structure+and+property+based+design%2C+synthesis+and+biological+evaluation+of+gamma-lactam+based+HDAC+inhibitors&doi=10.1016%2Fj.bmcl.2010.12.079"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors</span></div><div class="casAuthors">Choi, Eunhyun; Lee, Chulho; Park, Jung Eun; Seo, Jeong Jea; Cho, Misun; Kang, Jong Soon; Kim, Hwan Mook; Park, Song-Kyu; Lee, Kiho; Han, Gyoonhee</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1218-1221</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are involved in post-translational modification and gene expression.  Cancer cells recruited amts. of HDACs for their survival by epi-genetic down regulation of tumor suppressor genes.  HDACs have been the promising targets for treatment of cancer, and many HDAC inhibitors have been investigated nowadays.  δ-Lactam core HDAC inhibitors which showed potent HDAC inhibitory activities as well as cancer cell growth inhibitory activities were previously synthesized.  Through QSAR study of the δ-lactam based inhibitors, the smaller core is suggested as more active than larger one because it fits better in narrow hydrophobic tunnel of the active pocket of HDAC enzyme.  The smaller γ-lactam core HDAC inhibitors were designed and synthesized for biol. and property optimization.  Ph, naphthyl and thiophenyl groups were introduced as the cap groups.  Hydrophobic and bulky cap groups increase potency of HDAC inhibition because of hydrophobic interaction between HDAC and inhibitors.  In overall, γ-lactam based HDAC inhibitors showed more potent than δ-lactam analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYjGdqmHi9ZrVg90H21EOLACvtfcHk0lixHeiitsOhFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1amt7w%253D&md5=30e06e53027b322aff25cf2e07dfb474</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.079&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.079%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DE.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DPark%26aufirst%3DJ.%2BE.%26aulast%3DSeo%26aufirst%3DJ.%2BJ.%26aulast%3DCho%26aufirst%3DM.%26aulast%3DKang%26aufirst%3DJ.%2BS.%26aulast%3DKim%26aufirst%3DH.%2BM.%26aulast%3DPark%26aufirst%3DS.%2BK.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DHan%26aufirst%3DG.%26atitle%3DStructure%2520and%2520property%2520based%2520design%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520gamma-lactam%2520based%2520HDAC%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D1218%26epage%3D1221%26doi%3D10.1016%2Fj.bmcl.2010.12.079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel delta-lactam-based histone deacetylase (HDAC) inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">4068</span>– <span class="NLM_lpage">4070</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2006.04.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmcl.2006.04.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=16723227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmt1GgtLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4068-4070&author=H.+M.+Kimauthor=K.+Leeauthor=B.+W.+Parkauthor=D.+K.+Ryuauthor=K.+Kimauthor=C.+W.+Leeauthor=S.+K.+Parkauthor=J.+W.+Hanauthor=H.+Y.+Leeauthor=H.+Y.+Leeauthor=G.+Han&title=Synthesis%2C+enzymatic+inhibition%2C+and+cancer+cell+growth+inhibition+of+novel+delta-lactam-based+histone+deacetylase+%28HDAC%29+inhibitors&doi=10.1016%2Fj.bmcl.2006.04.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel δ-lactam-based histone deacetylase (HDAC) inhibitors</span></div><div class="casAuthors">Kim, Hwan Mook; Lee, Kiho; Park, Bum Woo; Ryu, Dong Kyu; Kim, Kangjeon; Lee, Chang Woo; Park, Song-Kyu; Han, Jung Whan; Lee, Hee Yoon; Lee, Hyun Yong; Han, Gyoonhee</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4068-4070</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">δ-Lactam-based hydroxamic acids such as I (R = NHOH, II), inhibitors of histone deacetylase (HDAC), have been synthesized via ring closure metathesis of diene ester intermediates, e.g., III, followed by condensation with KONH2.  Three hydroxamic acids including II showed potent inhibitory activity in HDAC enzyme assay.  II also exhibited growth inhibitory activity on five human tumor cell lines, showing good sensitivity on the MDA-MB-231 breast tumor cell.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLnVqNNIEuvbVg90H21EOLACvtfcHk0lixHeiitsOhFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmt1GgtLY%253D&md5=4e24d35e0eed8be90818cd09298e9864</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.04.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.04.091%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DH.%2BM.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DPark%26aufirst%3DB.%2BW.%26aulast%3DRyu%26aufirst%3DD.%2BK.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLee%26aufirst%3DC.%2BW.%26aulast%3DPark%26aufirst%3DS.%2BK.%26aulast%3DHan%26aufirst%3DJ.%2BW.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DHan%26aufirst%3DG.%26atitle%3DSynthesis%252C%2520enzymatic%2520inhibition%252C%2520and%2520cancer%2520cell%2520growth%2520inhibition%2520of%2520novel%2520delta-lactam-based%2520histone%2520deacetylase%2520%2528HDAC%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4068%26epage%3D4070%26doi%3D10.1016%2Fj.bmcl.2006.04.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S. H.</span></span> <span> </span><span class="NLM_article-title">A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status</span>. <i>Carcinogenesis</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">72</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1093/carcin/bgx121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1093%2Fcarcin%2Fbgx121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29106445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlemu7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2018&pages=72-83&author=H.+W.+Ryuauthor=D.+H.+Shinauthor=D.+H.+Leeauthor=H.+R.+Wonauthor=S.+H.+Kwon&title=A+potent+hydroxamic+acid-based%2C+small-molecule+inhibitor+A452+preferentially+inhibits+HDAC6+activity+and+induces+cytotoxicity+toward+cancer+cells+irrespective+of+p53+status&doi=10.1093%2Fcarcin%2Fbgx121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status</span></div><div class="casAuthors">Ryu, Hyun-Wook; Shin, Dong-Hee; Lee, Dong Hoon; Won, Hye-Rim; Kwon, So Hee</div><div class="citationInfo"><span class="NLM_cas:title">Carcinogenesis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-83</span>CODEN:
                <span class="NLM_cas:coden">CRNGDP</span>;
        ISSN:<span class="NLM_cas:issn">1460-2180</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">HDAC6-selective inhibitors are novel epigenetic anticancer agents.  However, their precise mechanisms of action are incompletely understood.  We investigated the anticancer mechanisms of the novel potent and selective HDAC6 inhibitor A452 compared with current clin. tested HDAC6 inhibitor ACY-1215.  We demonstrate that A452 effectively inhibits the cell growth and viability of various cancer cell types, irresp. of p53 status.  A452-induced apoptosis as evidenced by activated caspase 3 and PARP, increased Bak and Bax and decreased Bcl-xL.  Moreover, A452 shifted cells away from antiapoptotic (AKT and ERK) pathways and toward proapoptotic (p38) pathways.  A452 triggered DNA damage via increased H2AX and activation of the checkpoint kinase Chk2.  A452 induced the suppression of cell migration and invasion.  Interestingly, A452 upregulated the expression of PD-L1, which regulates the PD-1 inhibitory pathway in T cells.  Overall, our results suggest that A452 is more effective as an anticancer agent than ACY-1215.  Therefore, therapeutically targeting HDAC6 may represent a novel strategy for cancer treatment irresp. of the p53 mutation status.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsO6pjmaUP9bVg90H21EOLACvtfcHk0lixHeiitsOhFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlemu7fI&md5=d933dce5755e119cac9a6d9ae6a6f4b2</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgx121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgx121%26sid%3Dliteratum%253Aachs%26aulast%3DRyu%26aufirst%3DH.%2BW.%26aulast%3DShin%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DWon%26aufirst%3DH.%2BR.%26aulast%3DKwon%26aufirst%3DS.%2BH.%26atitle%3DA%2520potent%2520hydroxamic%2520acid-based%252C%2520small-molecule%2520inhibitor%2520A452%2520preferentially%2520inhibits%2520HDAC6%2520activity%2520and%2520induces%2520cytotoxicity%2520toward%2520cancer%2520cells%2520irrespective%2520of%2520p53%2520status%26jtitle%3DCarcinogenesis%26date%3D2018%26volume%3D39%26spage%3D72%26epage%3D83%26doi%3D10.1093%2Fcarcin%2Fbgx121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Won, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryu, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shin, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeon, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S. H.</span></span> <span> </span><span class="NLM_article-title">A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells</span>. <i>Mol. Carcinog.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">1383</span>– <span class="NLM_lpage">1395</span>, <span class="refDoi"> DOI: 10.1002/mc.22852</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fmc.22852" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29917295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2jtL7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=1383-1395&author=H.+R.+Wonauthor=H.+W.+Ryuauthor=D.+H.+Shinauthor=S.+K.+Yeonauthor=D.+H.+Leeauthor=S.+H.+Kwon&title=A452%2C+an+HDAC6-selective+inhibitor%2C+synergistically+enhances+the+anticancer+activity+of+chemotherapeutic+agents+in+colorectal+cancer+cells&doi=10.1002%2Fmc.22852"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">A452, an HDAC6-selective inhibitor, synergistically enhances the anticancer activity of chemotherapeutic agents in colorectal cancer cells</span></div><div class="casAuthors">Won, Hye-Rim; Ryu, Hyun-Wook; Shin, Dong-Hee; Yeon, Soo-Keun; Lee, Dong Hoon; Kwon, So Hee</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Carcinogenesis</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1383-1395</span>CODEN:
                <span class="NLM_cas:coden">MOCAE8</span>;
        ISSN:<span class="NLM_cas:issn">0899-1987</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Although histone deacetylase inhibitors (HDACi) alone could be clin. useful, these are most recently used in combination with other anticancer agents in clin. trials for cancer treatment.  Recently, we reported the anticancer activity of an HDAC6-selective inhibitor A452 toward various cancer cell types.  This study aims to present a potent synergistic antiproliferative effect of A452/anticancer agent treatment in colorectal cancer cells (CRC) cells, independently of the p53 status.  A452 in combination with irinotecan, or SAHA is more potent than either drug alone in the apoptotic pathway as evidenced by activated caspase-3 and PARP, increased Bak and pp38, decreased Bcl-xL, pERK, and pAKT, and induced apoptotic cells.  Furthermore, A452 enhances DNA damage induced by anticancer agents as indicated by the increased accumulation of γH2AX and the activation of the checkpoint kinase Chk2.  The silencing of HDAC6 enhances the cell growth inhibition and cell death caused by anticancer agents.  In addn., A452 induces the synergistic suppression of cell migration and invasion.  This study suggests a mechanism by which HDAC6-selective inhibition can enhance the efficacy of specific anticancer agents in CRC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMCWkUJ3QG8bVg90H21EOLACvtfcHk0lhzleVlmyVfRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2jtL7L&md5=786e26a4d2755a4407ebf437b3eb97e0</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1002%2Fmc.22852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmc.22852%26sid%3Dliteratum%253Aachs%26aulast%3DWon%26aufirst%3DH.%2BR.%26aulast%3DRyu%26aufirst%3DH.%2BW.%26aulast%3DShin%26aufirst%3DD.%2BH.%26aulast%3DYeon%26aufirst%3DS.%2BK.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DKwon%26aufirst%3DS.%2BH.%26atitle%3DA452%252C%2520an%2520HDAC6-selective%2520inhibitor%252C%2520synergistically%2520enhances%2520the%2520anticancer%2520activity%2520of%2520chemotherapeutic%2520agents%2520in%2520colorectal%2520cancer%2520cells%26jtitle%3DMol.%2520Carcinog.%26date%3D2018%26volume%3D57%26spage%3D1383%26epage%3D1395%26doi%3D10.1002%2Fmc.22852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Won, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeon, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeon, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, S. H.</span></span> <span> </span><span class="NLM_article-title">A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma</span>. <i>Leuk. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">106398</span>, <span class="refDoi"> DOI: 10.1016/j.leukres.2020.106398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.leukres.2020.106398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32512378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFegtrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2020&pages=106398&author=G.+W.+Kimauthor=J.+Yooauthor=H.+R.+Wonauthor=S.+K.+Yeonauthor=S.+W.+Leeauthor=D.+H.+Leeauthor=Y.+H.+Jeonauthor=S.+H.+Kwon&title=A452%2C+HDAC6-selective+inhibitor+synergistically+enhances+the+anticancer+activity+of+immunomodulatory+drugs+in+IMiDs-resistant+multiple+myeloma&doi=10.1016%2Fj.leukres.2020.106398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">A452, HDAC6-selective inhibitor synergistically enhances the anticancer activity of immunomodulatory drugs in IMiDs-resistant multiple myeloma</span></div><div class="casAuthors">Kim, Go Woon; Yoo, Jung; Won, Hye-Rim; Yeon, Soo-Keun; Lee, Sang Woo; Lee, Dong Hoon; Jeon, Yu Hyun; Kwon, So Hee</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">106398</span>CODEN:
                <span class="NLM_cas:coden">LEREDD</span>;
        ISSN:<span class="NLM_cas:issn">0145-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Multiple Myeloma (MM) is a hematol. malignancy of plasma cells.  Although advanced therapies have elevated MM survival rate, MM eventually relapses.  Relapsed/refractory MM (R/R MM) cells gain resistance to previously used drugs, which reduces treatment options.  In this study, we propose a newly synthesized HDAC6-selective inhibitor, A452, as a strategy to overcome resistance to immunomodulatory drugs (IMiDs), the principal MM therapeutic drugs.  Here, we identified that A452 alone reduces the viability and growth of IMiDs-resistant cells as well as synergistically reduces viability when combined with IMiDs.  We confirmed that this anticancer activity occurrs by inducing apoptosis.  To det. if A452 overcomes IMiDs resistance, we checked the change in the protein level of IMiDs direct/indirect targets.  As a result, the combination of A452 and IMiDs slightly increased CRBN and decreased Aiolos and Ikaros, the targets of CRBN.  Moreover, A452 decreased c-Myc and IRF-4 when combined with IMiDs.  These data suggest that A452 helps to overcome the resistance of IMiDs.  Finally, significant synergy of anticancer activity was detected when using triple combinations of A452, IMiDs, and dexamethasone.  In conclusion, the novel HDAC6-selective inhibitor A452 would be beneficial to combination therapy, including IMiDs in R/R MM as a strategy for overcoming IMiDs resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHANzDF9SDg7Vg90H21EOLACvtfcHk0lh2pcad2CR53A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFegtrbL&md5=dc70a6cf2ae296455a53814991515bdf</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.leukres.2020.106398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.leukres.2020.106398%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DG.%2BW.%26aulast%3DYoo%26aufirst%3DJ.%26aulast%3DWon%26aufirst%3DH.%2BR.%26aulast%3DYeon%26aufirst%3DS.%2BK.%26aulast%3DLee%26aufirst%3DS.%2BW.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DJeon%26aufirst%3DY.%2BH.%26aulast%3DKwon%26aufirst%3DS.%2BH.%26atitle%3DA452%252C%2520HDAC6-selective%2520inhibitor%2520synergistically%2520enhances%2520the%2520anticancer%2520activity%2520of%2520immunomodulatory%2520drugs%2520in%2520IMiDs-resistant%2520multiple%2520myeloma%26jtitle%3DLeuk.%2520Res.%26date%3D2020%26volume%3D95%26spage%3D106398%26doi%3D10.1016%2Fj.leukres.2020.106398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Son, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maeng, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. J.</span></span> <span> </span><span class="NLM_article-title">Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">126</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.03.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2016.03.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27060764" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2htLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=126-135&author=J.+Yooauthor=S.+J.+Kimauthor=D.+Sonauthor=H.+Seoauthor=S.+Y.+Baekauthor=C.+Y.+Maengauthor=C.+Leeauthor=I.+S.+Kimauthor=Y.+H.+Jungauthor=S.+M.+Leeauthor=H.+J.+Park&title=Computer-aided+identification+of+new+histone+deacetylase+6+selective+inhibitor+with+anti-sepsis+activity&doi=10.1016%2Fj.ejmech.2016.03.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity</span></div><div class="casAuthors">Yoo, Jakyung; Kim, So-Jin; Son, Dohyun; Seo, Heewon; Baek, Seung Yeop; Maeng, Cheol-Young; Lee, Changsik; Kim, In Su; Jung, Young Hoon; Lee, Sun-Mee; Park, Hyun-Ju</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">126-135</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors have been recognized as promising approaches to the treatment of various human diseases including cancer, inflammation, neurodegenerative diseases, and metabolic disorders.  Several pan-HDAC inhibitors are currently approved only as anticancer drugs.  Interestingly, SAHA (vorinostat), one of clin. available pan-HDAC inhibitors, shows an anti-inflammatory effect at concns. lower than those required for inhibition of tumor cell growth.  It was also reported that HDAC6 selective inhibitor tubastatin A has anti-inflammatory and anti-rheumatic effect.  In our efforts to develop novel HDAC inhibitors, we rationally designed various HDAC inhibitors based on the structures of two hit compds. identified by virtual screening of chem. database.  Among them, 9a ((E)-N-hydroxy-4-(2-styrylthiazol-4-yl)butanamide) was identified as a HDAC6 selective inhibitor (IC50 values of 0.199 μM for HDAC6 vs. 13.8 μM for HDAC1), and it did not show significant cytotoxicity against HeLa cells.  In vivo biol. evaluation of 9a was conducted on a lipopolysaccharide (LPS)-induced mouse model of sepsis.  The compd. 9a significantly improved 40% survival rate (P = 0.0483), and suppressed the LPS-induced increase of TNF-α and IL-6 mRNA expression in the liver of mice.  Our study identified novel HDAC6 selective inhibitor 9a, which may serve as a potential lead for the development of anti-inflammatory or anti-sepsis agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqd0iuSLahJ6bVg90H21EOLACvtfcHk0lh2pcad2CR53A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2htLc%253D&md5=96bc037397ef5e1275c09085b6089d2e</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.03.046%26sid%3Dliteratum%253Aachs%26aulast%3DYoo%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DS.%2BJ.%26aulast%3DSon%26aufirst%3DD.%26aulast%3DSeo%26aufirst%3DH.%26aulast%3DBaek%26aufirst%3DS.%2BY.%26aulast%3DMaeng%26aufirst%3DC.%2BY.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DKim%26aufirst%3DI.%2BS.%26aulast%3DJung%26aufirst%3DY.%2BH.%26aulast%3DLee%26aufirst%3DS.%2BM.%26aulast%3DPark%26aufirst%3DH.%2BJ.%26atitle%3DComputer-aided%2520identification%2520of%2520new%2520histone%2520deacetylase%25206%2520selective%2520inhibitor%2520with%2520anti-sepsis%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D116%26spage%3D126%26epage%3D135%26doi%3D10.1016%2Fj.ejmech.2016.03.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nam, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baek, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mok, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, Y. H.</span></span> <span> </span><span class="NLM_article-title">Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">3408</span>– <span class="NLM_lpage">3420</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmc.2019.06.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31235266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1entbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=3408-3420&author=G.+Namauthor=J.+M.+Jungauthor=H.+J.+Parkauthor=S.+Y.+Baekauthor=K.+S.+Baekauthor=H.+Y.+Mokauthor=D.+E.+Kimauthor=Y.+H.+Jung&title=Structure-activity+relationship+study+of+thiazolyl-hydroxamate+derivatives+as+selective+histone+deacetylase+6+inhibitors&doi=10.1016%2Fj.bmc.2019.06.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationship study of thiazolyl-hydroxamate derivatives as selective histone deacetylase 6 inhibitors</span></div><div class="casAuthors">Nam, Gibeom; Jung, Jun Min; Park, Hyun-Ju; Baek, Seung Yeop; Baek, Ki Seon; Mok, Hui yeon; Kim, Da Eun; Jung, Young Hoon</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3408-3420</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Several human diseases are assocd. with aberrant epigenetic pathways mediated by histone deacetylases (HDACs), esp. HDAC6, a class IIb HDACs, which has emerged as an attractive target for neurodegenerative and autoimmune disease therapeutics.  In a previous study, we developed the novel HDAC6-selective inhibitor 9a ((E)-N-hydroxy-4-(2-styrylthiazol-4-yl)butanamide) and showed that it has anti-sepsis activity in vivo.  In this study, we conducted structure-activity relationship (SAR) studies to optimize the activity and selectivity of HDAC6, synthesizing its derivs. with various aliph. linker sizes and cap structures.  We identified 6u ((E)-N-hydroxy-3-(2-(4-fluorostyryl)thiazol-4-yl)propanamide), which has nanomolar inhibition activity and a 126-fold selectivity for HDAC6 over HDAC1.  Through the docking analyses of 6u against HDAC subtypes, we revealed the importance of the optimal aliph. linker size, as well as the electronic substituent effect and rigidity of the aryl cap group.  Thus, we suggest a new rationale for the design of HDAC6-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkTunBiRHSA7Vg90H21EOLACvtfcHk0lh2pcad2CR53A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1entbvI&md5=935aee709f4eb38e54fe2a5b28a7766d</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DG.%26aulast%3DJung%26aufirst%3DJ.%2BM.%26aulast%3DPark%26aufirst%3DH.%2BJ.%26aulast%3DBaek%26aufirst%3DS.%2BY.%26aulast%3DBaek%26aufirst%3DK.%2BS.%26aulast%3DMok%26aufirst%3DH.%2BY.%26aulast%3DKim%26aufirst%3DD.%2BE.%26aulast%3DJung%26aufirst%3DY.%2BH.%26atitle%3DStructure-activity%2520relationship%2520study%2520of%2520thiazolyl-hydroxamate%2520derivatives%2520as%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D3408%26epage%3D3420%26doi%3D10.1016%2Fj.bmc.2019.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedi, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhar, K. L.</span></span> <span> </span><span class="NLM_article-title">Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">422</span>– <span class="NLM_lpage">487</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.03.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2014.03.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=24685980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtVSjtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2014&pages=422-487&author=K.+Nepaliauthor=S.+Sharmaauthor=M.+Sharmaauthor=P.+M.+Bediauthor=K.+L.+Dhar&title=Rational+approaches%2C+design+strategies%2C+structure+activity+relationship+and+mechanistic+insights+for+anticancer+hybrids&doi=10.1016%2Fj.ejmech.2014.03.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids</span></div><div class="casAuthors">Nepali, Kunal; Sharma, Sahil; Sharma, Manmohan; Bedi, P. M. S.; Dhar, K. L.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">422-487</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  A Hybrid drug which comprises the incorporation of two drug pharmacophores in one single mol. are basically designed to interact with multiple targets or to amplify its effect through action on another bio target as one single mol. or to counterbalance the known side effects assocd. with the other hybrid part.  The present review article offers a detailed account of the design strategies employed for the synthesis of anticancer agents via mol. hybridization techniques.  Over the years, the researchers have employed this technique to discover some promising chem. architectures displaying significant anticancer profiles.  Mol. hybridization as a tool has been particularly utilized for targeting tubulin protein as exemplified through the no. of research papers.  The microtubule inhibitors such as taxol, colchicine, chalcones, combretastatin, phenstatins and vinca alkaloids have been utilized as one of the functionality of the hybrids and promising results have been obtained in most of the cases with some of the tubulin based hybrids exhibiting anticancer activity at nanomolar level.  Linkage with steroids as biol. carrier vector for anticancer drugs and the inclusion of pyrrolo [2,1-c] [1,4]benzodiazepines (PBDs), a family of DNA interactive antitumor antibiotics derived from Streptomyces species in hybrid structure based drug design has also emerged as a potential strategy.  Various heteroaryl based hybrids in particular isatin and coumarins have also been designed and reported to possess' remarkable inhibitory potential.  Apart from presenting the design strategies, the article also highlights the structure activity relationship along with mechanistic insights revealed during the biol. evaluation of the hybrids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWJz5umKzC17Vg90H21EOLACvtfcHk0lgz6X5P7X8RUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtVSjtb0%253D&md5=a85f1e69cf9db79f9b7ff18047a14395</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.03.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.03.018%26sid%3Dliteratum%253Aachs%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DM.%26aulast%3DBedi%26aufirst%3DP.%2BM.%26aulast%3DDhar%26aufirst%3DK.%2BL.%26atitle%3DRational%2520approaches%252C%2520design%2520strategies%252C%2520structure%2520activity%2520relationship%2520and%2520mechanistic%2520insights%2520for%2520anticancer%2520hybrids%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D77%26spage%3D422%26epage%3D487%26doi%3D10.1016%2Fj.ejmech.2014.03.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span> <span> </span><span class="NLM_article-title">Multi-Targeted Anticancer Agents</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3084</span>– <span class="NLM_lpage">3098</span>, <span class="refDoi"> DOI: 10.2174/1568026617666170707124126</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.2174%2F1568026617666170707124126" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=28685693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFens7fJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=3084-3098&author=W.+Zhengauthor=Y.+Zhaoauthor=Q.+Luoauthor=Y.+Zhangauthor=K.+Wuauthor=F.+Wang&title=Multi-Targeted+Anticancer+Agents&doi=10.2174%2F1568026617666170707124126"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-Targeted Anticancer Agents</span></div><div class="casAuthors">Zheng, Wei; Zhao, Yao; Luo, Qun; Zhang, Yang; Wu, Kui; Wang, Fuyi</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">28</span>),
    <span class="NLM_cas:pages">3084-3098</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">There is a great demand for the development of novel anticancer drugs, due to the increasing morbidity and high mortality of cancer.  To date, chemotherapy still plays a central role in the clin. treatment of cancer, but this role is being reduced by targeted therapies.  Since cancer is a complicated and multiple genes involved disease, drugs that act at multiple targets can enhance efficacy and lower drug resistance, and are thought to be the future of novel anticancer drug development.  In this paper, we discuss the recent development of "single mol., multi-target" anticancer agents that combine two or more pharmacophores in a single mol., including org. multitargeted anticancer agents and metal based complexes such as platinum, ruthenium, iridium and rhodium complexes.  These efforts will contribute to clin. cancer therapy and benefit patients in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj7unFBNhn3rVg90H21EOLACvtfcHk0lgz6X5P7X8RUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFens7fJ&md5=b9f6834bf2af9c3e9460badd9ca133c8</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.2174%2F1568026617666170707124126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026617666170707124126%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DLuo%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DF.%26atitle%3DMulti-Targeted%2520Anticancer%2520Agents%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2017%26volume%3D17%26spage%3D3084%26epage%3D3098%26doi%3D10.2174%2F1568026617666170707124126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindquist, S. L.</span></span> <span> </span><span class="NLM_article-title">HSP90 and the chaperoning of cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">761</span>– <span class="NLM_lpage">772</span>, <span class="refDoi"> DOI: 10.1038/nrc1716</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fnrc1716" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=16175177" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=761-772&author=L.+Whitesellauthor=S.+L.+Lindquist&title=HSP90+and+the+chaperoning+of+cancer&doi=10.1038%2Fnrc1716"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">HSP90 and the chaperoning of cancer</span></div><div class="casAuthors">Whitesell, Luke; Lindquist, Susan L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">761-772</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Standing watch over the proteome, mol. chaperones are an ancient and evolutionarily conserved class of proteins that guide the normal folding, intracellular disposition and proteolytic turnover of many of the key regulators of cell growth, differentiation and survival.  This essential guardian function is subverted during oncogenesis to allow malignant transformation and to facilitate rapid somatic evolution.  Pharmacol. 'bribing' the essential guard duty of the chaperone HSP90 (heat-shock protein of 90 kDa) seems to offer a unique anticancer strategy of considerable promise.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4Vmb5bGXgDLVg90H21EOLACvtfcHk0lgz6X5P7X8RUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVGjs7bF&md5=c418ec249a29c70047081cd241938931</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1038%2Fnrc1716&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc1716%26sid%3Dliteratum%253Aachs%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DLindquist%26aufirst%3DS.%2BL.%26atitle%3DHSP90%2520and%2520the%2520chaperoning%2520of%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2005%26volume%3D5%26spage%3D761%26epage%3D772%26doi%3D10.1038%2Fnrc1716" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nouri-Vaskeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alizadeh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajiasgharzadeh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mokhtarzadeh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halimi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baradaran, B.</span></span> <span> </span><span class="NLM_article-title">The role of HSP90 molecular chaperones in hepatocellular carcinoma</span>. <i>J. Cell. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>235</i></span>,  <span class="NLM_fpage">9110</span>– <span class="NLM_lpage">9120</span>, <span class="refDoi"> DOI: 10.1002/jcp.29776</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fjcp.29776" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32452023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFajur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=235&publication_year=2020&pages=9110-9120&author=M.+Nouri-Vaskehauthor=L.+Alizadehauthor=K.+Hajiasgharzadehauthor=A.+Mokhtarzadehauthor=M.+Halimiauthor=B.+Baradaran&title=The+role+of+HSP90+molecular+chaperones+in+hepatocellular+carcinoma&doi=10.1002%2Fjcp.29776"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">The role of HSP90 molecular chaperones in hepatocellular carcinoma</span></div><div class="casAuthors">Nouri-Vaskeh, Masoud; Alizadeh, Leila; Hajiasgharzadeh, Khalil; Mokhtarzadeh, Ahad; Halimi, Monireh; Baradaran, Behzad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">235</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">9110-9120</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Misfolded proteins have enhanced formation of toxic oligomers and nonfunctional protein copies lead to recruiting wild-type protein types.  Heat shock protein 90 (HSP90) is a mol. chaperone generated by cells that are involved in many cellular functions through regulation of folding and/or localization of large multi-protein complexes as well as client proteins.  HSP90 can regulate a no. of different cellular processes including cell proliferation, motility, angiogenesis, signal transduction, and adaptation to stress.  HSP90 makes the mutated oncoproteins able to avoid misfolding and degrdn. and permits the malignant transformation.  As a result, HSP90 is an important factor in several signaling pathways assocd. with tumorigenicity, therapy resistance, and inhibiting apoptosis.  Clin., the upregulation of HSP90 expression in hepatocellular carcinoma (HCC) is linked with advanced stages and inappropriate survival in cases suffering from this kind of cancer.  The present review comprehensively assesses HSP90 functions and its possible usefulness as a potential diagnostic biomarker and therapeutic option for HCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuf4B7xQE8vbVg90H21EOLACvtfcHk0lgZF1_r_3aOHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFajur%252FE&md5=f2357586d96e9b9d67a65cff5a5f5331</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1002%2Fjcp.29776&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.29776%26sid%3Dliteratum%253Aachs%26aulast%3DNouri-Vaskeh%26aufirst%3DM.%26aulast%3DAlizadeh%26aufirst%3DL.%26aulast%3DHajiasgharzadeh%26aufirst%3DK.%26aulast%3DMokhtarzadeh%26aufirst%3DA.%26aulast%3DHalimi%26aufirst%3DM.%26aulast%3DBaradaran%26aufirst%3DB.%26atitle%3DThe%2520role%2520of%2520HSP90%2520molecular%2520chaperones%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2020%26volume%3D235%26spage%3D9110%26epage%3D9120%26doi%3D10.1002%2Fjcp.29776" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">You, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X. L.</span></span> <span> </span><span class="NLM_article-title">Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1798</span>– <span class="NLM_lpage">1822</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00940</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00940" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKkurvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1798-1822&author=L.+Liauthor=L.+Wangauthor=Q.+D.+Youauthor=X.+L.+Xu&title=Heat+Shock+Protein+90+Inhibitors%3A+An+Update+on+Achievements%2C+Challenges%2C+and+Future+Directions&doi=10.1021%2Facs.jmedchem.9b00940"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions</span></div><div class="casAuthors">Li, Li; Wang, Lei; You, Qi-Dong; Xu, Xiao-Li</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1798-1822</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Hsp90 is one of the most important chaperones involved in regulating the maturation of more than 300 client proteins, many of which are closely assocd. with refractory diseases, including cancer, neurodegenerative diseases and viral infections.  Clin. Hsp90 inhibitors bind to the ATP pocket in the N-terminal domain of Hsp90 and subsequently suppress the ATPase activity of Hsp90.  Recently, with the increased understanding of the discrepancies in the isoforms of Hsp90 and the modes of Hsp90-cochaperone-client complex interactions, some new strategies for Hsp90 inhibition have emerged.  Novel Hsp90 inhibitors that offer selective suppression of Hsp90 isoforms or specific disruption of Hsp90-cochaperone protein-protein interactions are expected to breakthrough with satisfactory efficacy and safety profiles.  This review summarizes the recent progress in Hsp90 inhibitors.  Addnl., Hsp90 inhibitory strategies are emphasized in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkbKTcDYjrzrVg90H21EOLACvtfcHk0lgZF1_r_3aOHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKkurvO&md5=972a35d1b12f5e21a7fa27cbb6bfc0cd</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00940%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DYou%26aufirst%3DQ.%2BD.%26aulast%3DXu%26aufirst%3DX.%2BL.%26atitle%3DHeat%2520Shock%2520Protein%252090%2520Inhibitors%253A%2520An%2520Update%2520on%2520Achievements%252C%2520Challenges%252C%2520and%2520Future%2520Directions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1798%26epage%3D1822%26doi%3D10.1021%2Facs.jmedchem.9b00940" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dutta
Gupta, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, C. H.</span></span> <span> </span><span class="NLM_article-title">Recent update on discovery and development of Hsp90 inhibitors as senolytic agents</span>. <i>Int. J. Biol. Macromol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>161</i></span>,  <span class="NLM_fpage">1086</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1016/j.ijbiomac.2020.06.115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ijbiomac.2020.06.115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32561284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSiurzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=161&publication_year=2020&pages=1086-1098&author=S.+Dutta%0AGuptaauthor=C.+H.+Pan&title=Recent+update+on+discovery+and+development+of+Hsp90+inhibitors+as+senolytic+agents&doi=10.1016%2Fj.ijbiomac.2020.06.115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Recent update on discovery and development of Hsp90 inhibitors as senolytic agents</span></div><div class="casAuthors">Dutta Gupta, Sayan; Pan, Cheol Ho</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biological Macromolecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">161</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1086-1098</span>CODEN:
                <span class="NLM_cas:coden">IJBMDR</span>;
        ISSN:<span class="NLM_cas:issn">0141-8130</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Hsp90 chaperone is an encouraging target for the development of novel anticancer agents.  The failure of Hsp90 inhibitors to get regulatory approval for the treatment of cancer is hindered due to toxicity, cost involved in their development and formulation issues.  The inhibitors against this chaperone are also being evaluated in pre-clin. models for the treatment of diseases other than cancer (Alzheimer, malaria, AIDS, etc.).  Recently, Hsp90 inhibitors have shown promising senolytic effect that is helpful in increasing the health and life span of mice.  The senolytic property of Hsp90 inhibitors will make them less toxic for use in humans.  The review focuses on Hsp90 inhibitors discovered till date as senolytic agents along with their future prospects.  Further, the various models used for the evaluation of senolytic effect are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1uoonUYdu6rVg90H21EOLACvtfcHk0lgZF1_r_3aOHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSiurzP&md5=4a7639b075844edd1dca85da3ecc705d</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2Fj.ijbiomac.2020.06.115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ijbiomac.2020.06.115%26sid%3Dliteratum%253Aachs%26aulast%3DDutta%2BGupta%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DC.%2BH.%26atitle%3DRecent%2520update%2520on%2520discovery%2520and%2520development%2520of%2520Hsp90%2520inhibitors%2520as%2520senolytic%2520agents%26jtitle%3DInt.%2520J.%2520Biol.%2520Macromol.%26date%3D2020%26volume%3D161%26spage%3D1086%26epage%3D1098%26doi%3D10.1016%2Fj.ijbiomac.2020.06.115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ojha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">HuangFu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">667</span>– <span class="NLM_lpage">677</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2018.03.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29567459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXlt1OhtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=667-677&author=R.+Ojhaauthor=H.+L.+Huangauthor=W.+C.+HuangFuauthor=Y.+W.+Wuauthor=K.+Nepaliauthor=M.+J.+Laiauthor=C.+J.+Suauthor=T.+Y.+Sungauthor=Y.+L.+Chenauthor=S.+L.+Panauthor=J.+P.+Liou&title=1-Aroylindoline-hydroxamic+acids+as+anticancer+agents%2C+inhibitors+of+HSP90+and+HDAC&doi=10.1016%2Fj.ejmech.2018.03.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC</span></div><div class="casAuthors">Ojha, Ritu; Huang, Han-Li; Huang Fu, Wei-Chun; Wu, Yi-Wen; Nepali, Kunal; Lai, Mei-Jung; Su, Chih-Jou; Sung, Ting-Yi; Chen, Yi-Lin; Pan, Shiow-Lin; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">667-677</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of 1-aroylindoline-hydroxamic acids I [n = 2 - 8] and II were synthesized.  The results of the biol. evaluation led to the identification of compd. I [n = 6] as dual HDAC6/HSP90 inhibitor.  Compd. I [n = 6] displayed striking inhibitory effects towards the HDAC6 isoform and HSP90 protein with IC50 values of 1.15 nM (HDAC6) and 46.3 nM (HSP90).  Compd. I [n = 6] also exhibited 113, 139 and 246 fold higher selectivity for HDAC6 over HDAC 1, HDAC 3 and HDAC 8 isoforms and was endowed with significant cytotoxic effects with GI50 values ranging 1.04-1.61 μM against lung A549, colorectal HCT116, leukemia HL60 and EGFR T790M mutant lung H1975 cell lines.  Another interesting finding of the study was substantial cytotoxic effects of compd. I particularly against lung H1975 (NSCLC) cell lines with IC50 = 0.26 μM which was mediated through HSP90 inhibition.  Compd. I [n = 2] as such was devoid of HDAC inhibitory activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgF2Cb1sTQY7Vg90H21EOLACvtfcHk0li_-al-IEn5CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXlt1OhtLk%253D&md5=7c6b877c774d207150bf49c45f9a9303</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.006%26sid%3Dliteratum%253Aachs%26aulast%3DOjha%26aufirst%3DR.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DHuangFu%26aufirst%3DW.%2BC.%26aulast%3DWu%26aufirst%3DY.%2BW.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DSu%26aufirst%3DC.%2BJ.%26aulast%3DSung%26aufirst%3DT.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3D1-Aroylindoline-hydroxamic%2520acids%2520as%2520anticancer%2520agents%252C%2520inhibitors%2520of%2520HSP90%2520and%2520HDAC%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D150%26spage%3D667%26epage%3D677%26doi%3D10.1016%2Fj.ejmech.2018.03.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ojha, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>190</i></span>,  <span class="NLM_fpage">112086</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2020.112086" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32058238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtFSqs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=190&publication_year=2020&pages=112086&author=R.+Ojhaauthor=K.+Nepaliauthor=C.+H.+Chenauthor=K.+H.+Chuangauthor=T.+Y.+Wuauthor=T.+E.+Linauthor=K.+C.+Hsuauthor=M.+W.+Chaoauthor=M.+J.+Laiauthor=M.+H.+Linauthor=H.+L.+Huangauthor=C.+D.+Changauthor=S.+L.+Panauthor=M.+C.+Chenauthor=J.+P.+Liou&title=Isoindoline+scaffold-based+dual+inhibitors+of+HDAC6+and+HSP90+suppressing+the+growth+of+lung+cancer+in+vitro+and+in+vivo&doi=10.1016%2Fj.ejmech.2020.112086"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo</span></div><div class="casAuthors">Ojha, Ritu; Nepali, Kunal; Chen, Chun-Han; Chuang, Kuo-Hsiang; Wu, Tung-Yun; Lin, Tony Eight; Hsu, Kai-Cheng; Chao, Min-Wu; Lai, Mei-Jung; Lin, Mei-Hsiang; Huang, Han-Li; Chang, Chao-Di; Pan, Shiow-Lin; Chen, Mei-Chuan; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">190</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112086pp.</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">This study reported the synthesis of a series of 2-aroylisoindoline hydroxamic acids I [R = HOHNC(O)CH=CH, HOHNC(O)(CH2)2C(O)NH, HOHNC(O)C6H4CH2N, etc.] employing N-benzyl, long alkyl chain and acrylamide units as diverse linkers.  In-vitro studies led to the identification of N-benzyl linker-bearing compd. I [R = HOHNC(O)C6H4CH2N] and long chain linker-contg. compd. I [R = HOHNC(O)(CH2)8C(O)NH] as dual selective HDAC6/HSP90 inhibitors.  Compd. I [R = HOHNC(O)(CH2)8C(O)NH] displayed potent inhibition of HDAC6 isoform (IC50 = 4.3 nM) and HSP90a inhibition (IC50 = 46.8 nM) along with substantial cell growth inhibitory effects with GI50 = 0.76μM (lung A549) and GI50 = 0.52μM (lung EGFR resistant H1975).  Compd. I [R = HOHNC(O)C6H4CH2N] displayed potent antiproliferative activity against lung A549 (GI50 = 0.37μM) and lung H1975 cell lines (GI50 = 0.13μM) mediated through selective HDAC6 inhibition and HSP90 inhibition.  In the in vivo efficacy evaluation in human H1975 xenografts, compd. I [R = HOHNC(O)C6H4CH2N] induced slightly remarkable suppression of tumor growth both in monotherapy as well as the combination therapy with afatinib (20 mg/kg).  In addn., compd. I [R = HOHNC(O)(CH2)8C(O)NH] also modulated the expression of signatory biomarkers assocd. with HDAC6 and HSP90 inhibition.  Moreover, compd. I [R = HOHNC(O)C6H4CH2N] could effectively reduce programmed death-ligand 1 (PD-L1) expression in IFN-γ treated lung H1975 cells in a dose dependent manner suggesting that dual inhibition of HDAC6 and HSP90 can modulate immunosuppressive ability of tumor area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHtq06XN7-IrVg90H21EOLACvtfcHk0li_-al-IEn5CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtFSqs7w%253D&md5=eb9c93f039c112251848f9a4fb644955</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112086%26sid%3Dliteratum%253Aachs%26aulast%3DOjha%26aufirst%3DR.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DC.%2BH.%26aulast%3DChuang%26aufirst%3DK.%2BH.%26aulast%3DWu%26aufirst%3DT.%2BY.%26aulast%3DLin%26aufirst%3DT.%2BE.%26aulast%3DHsu%26aufirst%3DK.%2BC.%26aulast%3DChao%26aufirst%3DM.%2BW.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DChang%26aufirst%3DC.%2BD.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3DIsoindoline%2520scaffold-based%2520dual%2520inhibitors%2520of%2520HDAC6%2520and%2520HSP90%2520suppressing%2520the%2520growth%2520of%2520lung%2520cancer%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D190%26spage%3D112086%26doi%3D10.1016%2Fj.ejmech.2020.112086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rane, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, E. P.</span></span> <span> </span><span class="NLM_article-title">Janus kinases: components of multiple signaling pathways</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">5662</span>– <span class="NLM_lpage">5679</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1203925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fsj.onc.1203925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=11114747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosl2nurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=5662-5679&author=S.+G.+Raneauthor=E.+P.+Reddy&title=Janus+kinases%3A+components+of+multiple+signaling+pathways&doi=10.1038%2Fsj.onc.1203925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Janus kinases: components of multiple signaling pathways</span></div><div class="casAuthors">Rane, Sushil G.; Reddy, E. Premkumar</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">5662-5679</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with ∼200 refs.  Cytoplasmic Janus protein tyrosine kinases (JAKs) are crucial components of diverse signal transduction pathways that govern cellular survival, proliferation, differentiation, and apoptosis.  Evidence to date, indicates that JAK kinase function may integrate components of diverse signaling cascades.  While it is likely that activation of STAT proteins may be an important function attributed to the JAK kinases, it is certainly not the only function performed by this key family of cytoplasmic tyrosine kinases.  Emerging evidence indicates that phosphorylation of cytokine and growth factor receptors may be the primary functional attribute of JAK kinases.  The JAK-triggered receptor phosphorylation can potentially be a rate-limiting event for a successful culmination of downstream signaling events.  In support of this hypothesis, it has been found that JAK kinase function is required for optimal activation of the Src-kinase cascade, the Ras-MAP kinase pathway, the PI3K-AKT pathway and STAT signaling following the interaction of cytokine/interferon receptors with their ligands.  Aberrations in JAK kinase activity, that may lead to derailment of ≥1 of the above mentioned pathways could disrupt normal cellular responses and result in disease states.  Thus, over-activation of JAK kinases has been implicated in tumorigenesis.  In contrast, loss of JAK kinase function has been found to result in disease states such as severe-combined immunodeficiency.  In summary, optimal JAK kinase activity is a crit. determinant of normal transmission of cytokine and growth factor signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCdAspuPThPbVg90H21EOLACvtfcHk0li_-al-IEn5CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosl2nurY%253D&md5=e81c62f068d906d0b847c6a2ef4f22ee</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203925%26sid%3Dliteratum%253Aachs%26aulast%3DRane%26aufirst%3DS.%2BG.%26aulast%3DReddy%26aufirst%3DE.%2BP.%26atitle%3DJanus%2520kinases%253A%2520components%2520of%2520multiple%2520signaling%2520pathways%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D5662%26epage%3D5679%26doi%3D10.1038%2Fsj.onc.1203925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamaoka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saharinen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pesu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holt, V. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvennoinen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O'Shea, J. J</span></span> <span> </span><span class="NLM_article-title">The Janus kinases (Jaks)</span>. <i>Genome Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">253</span>, <span class="refDoi"> DOI: 10.1186/gb-2004-5-12-253</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1186%2Fgb-2004-5-12-253" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=15575979" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BD2cngtlKktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=253&author=K.+Yamaokaauthor=P.+Saharinenauthor=M.+Pesuauthor=V.+E.+Holtauthor=O.+Silvennoinenauthor=J.+J+O%27Shea&title=The+Janus+kinases+%28Jaks%29&doi=10.1186%2Fgb-2004-5-12-253"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">The Janus kinases (Jaks)</span></div><div class="casAuthors">Yamaoka Kunihiro; Saharinen Pipsa; Pesu Marko; Holt Vance E T 3rd; Silvennoinen Olli; O'Shea John J</div><div class="citationInfo"><span class="NLM_cas:title">Genome biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">253</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The Janus kinase (Jak) family is one of ten recognized families of non-receptor tyrosine kinases.  Mammals have four members of this family, Jak1, Jak2, Jak3 and Tyrosine kinase 2 (Tyk2).  Birds, fish and insects also have Jaks.  Each protein has a kinase domain and a catalytically inactive pseudo-kinase domain, and they each bind cytokine receptors through amino-terminal FERM (Band-4.1, ezrin, radixin, moesin) domains.  Upon binding of cytokines to their receptors, Jaks are activated and phosphorylate the receptors, creating docking sites for signaling molecules, especially members of the signal transducer and activator of transcription (Stat) family.  Mutations of the Drosophila Jak (Hopscotch) have revealed developmental defects, and constitutive activation of Jaks in flies and humans is associated with leukemia-like syndromes.  Through the generation of Jak-deficient cell lines and gene-targeted mice, the essential, nonredundant functions of Jaks in cytokine signaling have been established.  Importantly, deficiency of Jak3 is the basis of human autosomal recessive severe combined immunodeficiency (SCID); accordingly, a selective Jak3 inhibitor has been developed, forming a new class of immunosuppressive drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS0BwDh7EYTsV1C8OJBvdfbfW6udTcc2eZ5DjWotU-3k7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2cngtlKktg%253D%253D&md5=4f8335c37dc8c20245e771224c1d5b12</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1186%2Fgb-2004-5-12-253&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fgb-2004-5-12-253%26sid%3Dliteratum%253Aachs%26aulast%3DYamaoka%26aufirst%3DK.%26aulast%3DSaharinen%26aufirst%3DP.%26aulast%3DPesu%26aufirst%3DM.%26aulast%3DHolt%26aufirst%3DV.%2BE.%26aulast%3DSilvennoinen%26aufirst%3DO.%26aulast%3DO%2527Shea%26aufirst%3DJ.%2BJ%26atitle%3DThe%2520Janus%2520kinases%2520%2528Jaks%2529%26jtitle%3DGenome%2520Biol.%26date%3D2004%26volume%3D5%26spage%3D253%26doi%3D10.1186%2Fgb-2004-5-12-253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Musumeci, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacchello, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fallacara, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brullo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schenone, S.</span></span> <span> </span><span class="NLM_article-title">An Update on JAK Inhibitors</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1806</span>– <span class="NLM_lpage">1832</span>, <span class="refDoi"> DOI: 10.2174/0929867325666180327093502</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.2174%2F0929867325666180327093502" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29589523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1ensbbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=1806-1832&author=F.+Musumeciauthor=C.+Grecoauthor=I.+Giacchelloauthor=A.+L.+Fallacaraauthor=M.+M.+Ibrahimauthor=G.+Grossiauthor=C.+Brulloauthor=S.+Schenone&title=An+Update+on+JAK+Inhibitors&doi=10.2174%2F0929867325666180327093502"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">An Update on JAK Inhibitors</span></div><div class="casAuthors">Musumeci, Francesca; Greco, Chiara; Giacchello, Ilaria; Fallacara, Anna Lucia; Ibrahim, Munjed M.; Grossi, Giancarlo; Brullo, Chiara; Schenone, Silvia</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1806-1832</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Janus kinases (JAKs) are a family of non-receptor tyrosine kinases, composed by four members, JAK1, JAK2, JAK3 and TYK2.  JAKs are involved in different inflammatory and autoimmune diseases, as well as in malignancies, through the activation of the JAK/STAT signalling pathway.  Furthermore, the V617F mutation in JAK2 was identified in patients affected by myeloproliferative neoplasms.  This knowledge prompted researchers from academia and pharmaceutical companies to investigate this field in order to discover small mol. JAK inhibitors.  These efforts recently afforded to the market approval of four JAK inhibitors.  Despite the fact that all these drugs are pyrrolo[2,3-d]pyrimidine derivs., many compds. endowed with different heterocyclic scaffolds have been reported in the literature as selective or multi-JAK inhibitors, and a no. of them is currently being evaluated in clin. trials.  In this review we will report many representative compds. that have been published in articles or patents in the last five years (period 2013-2017).  The inhibitors will be classified on the basis of their chem. structure, focusing, when possible, on their structure activity relationships, selectivity and biol. activity.  For every class of derivs., compds. disclosed before 2013 that have entered clin. trials will also be briefly reported, to underline the importance of a particular chem. scaffold in the search for new inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkh7oMXXE96bVg90H21EOLACvtfcHk0lh7yfoMY1OPSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1ensbbN&md5=a453e5d90429f481c45a18257ea62b71</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.2174%2F0929867325666180327093502&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867325666180327093502%26sid%3Dliteratum%253Aachs%26aulast%3DMusumeci%26aufirst%3DF.%26aulast%3DGreco%26aufirst%3DC.%26aulast%3DGiacchello%26aufirst%3DI.%26aulast%3DFallacara%26aufirst%3DA.%2BL.%26aulast%3DIbrahim%26aufirst%3DM.%2BM.%26aulast%3DGrossi%26aufirst%3DG.%26aulast%3DBrullo%26aufirst%3DC.%26aulast%3DSchenone%26aufirst%3DS.%26atitle%3DAn%2520Update%2520on%2520JAK%2520Inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2019%26volume%3D26%26spage%3D1806%26epage%3D1832%26doi%3D10.2174%2F0929867325666180327093502" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8233</span>– <span class="NLM_lpage">8262</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00157</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00157" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8233-8262&author=E.+G.+Yangauthor=N.+Mustafaauthor=E.+C.+Tanauthor=A.+Poulsenauthor=P.+M.+Ramanujuluauthor=W.+J.+Chngauthor=J.+J.+Yenauthor=B.+W.+Dymock&title=Design+and+Synthesis+of+Janus+Kinase+2+%28JAK2%29+and+Histone+Deacetlyase+%28HDAC%29+Bispecific+Inhibitors+Based+on+Pacritinib+and+Evidence+of+Dual+Pathway+Inhibition+in+Hematological+Cell+Lines&doi=10.1021%2Facs.jmedchem.6b00157"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</span></div><div class="casAuthors">Yang, Eugene Guorong; Mustafa, Nurulhuda; Tan, Eng Chong; Poulsen, Anders; Ramanujulu, Pondy Murugappan; Chng, Wee Joo; Yen, Jeffrey J. Y.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8233-8262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Blockage of more than one oncoprotein or pathway is now a std. approach in modern cancer therapy.  Multiple inhibition is typically achieved with two or more drugs.  Herein the authors describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single mols. with both JAK and HDAC targeted inhibition.  A preferred ether hydroxamate, compd. 51 (11-(4-(N-hydroxyheptanamide)oxy)-[4,1,9]dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12-(27),16,21,23-decaene) inhibits JAK2 and HDAC6 with low nanomolar potency, is <100 nM potent against HDACs 2 and 10, sub-micromolar potent against HDACs 1, 8 and 11, and >50-fold selective for JAK2 in a panel of 97 kinases.  Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematol. cell lines, inhibition of colony formation in HEL cells, and anal. of apoptosis.  This study provides new tool compds. for further exploration of dual JAK-HDAC pathway inhibition achieved with a single mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeUHzB39AGWrVg90H21EOLACvtfcHk0lh7yfoMY1OPSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7rL&md5=aa9ae07a1ac1aa21d70ee0f24621fe82</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00157&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00157%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DE.%2BG.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Janus%2520Kinase%25202%2520%2528JAK2%2529%2520and%2520Histone%2520Deacetlyase%2520%2528HDAC%2529%2520Bispecific%2520Inhibitors%2520Based%2520on%2520Pacritinib%2520and%2520Evidence%2520of%2520Dual%2520Pathway%2520Inhibition%2520in%2520Hematological%2520Cell%2520Lines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8233%26epage%3D8262%26doi%3D10.1021%2Facs.jmedchem.6b00157" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujulu, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohlson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2636</span>– <span class="NLM_lpage">2640</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.06.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmcl.2018.06.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29945795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtF2qtb7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2636-2640&author=L.+Yaoauthor=P.+M.+Ramanujuluauthor=A.+Poulsenauthor=S.+Ohlsonauthor=B.+W.+Dymock&title=Merging+of+ruxolitinib+and+vorinostat+leads+to+highly+potent+inhibitors+of+JAK2+and+histone+deacetylase+6+%28HDAC6%29&doi=10.1016%2Fj.bmcl.2018.06.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Merging of ruxolitinib and vorinostat leads to highly potent inhibitors of JAK2 and histone deacetylase 6 (HDAC6)</span></div><div class="casAuthors">Yao, Lianbin; Ramanujulu, Pondy Murugappan; Poulsen, Anders; Ohlson, Sten; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">2636-2640</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Inhibition of more than one pathway in a cancer cell with a single mol. could result in better therapies with less complex dosing regimens.  In this work multi-component ligands have been prepd. by joining together key pharmacophores of two different enzyme inhibitors in a way which increases potency against the individual pathways.  Selective JAK1/2 inhibitor, ruxolitinib (3), and pan-HDAC inhibitor vorinostat (4) were linked together by a single nitrogen atom to create a new series of compds. with very potent JAK2 and HDAC6 inhibition with selectivity against HDAC1.  A preferred compd., I, had unprecedented sub-nanomolar JAK2 potency with an IC50 of 41 pM and a sub-nanomolar IC50 against HDAC6 of 200 pM.  Binding models show a good fit into both JAK2 and HDAC6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrF3j4Hop3jqrVg90H21EOLACvtfcHk0ljbm05ycozbTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtF2qtb7M&md5=78776f7cd6ac7384c701edd2fd4a6940</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.06.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.06.037%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DL.%26aulast%3DRamanujulu%26aufirst%3DP.%2BM.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DOhlson%26aufirst%3DS.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DMerging%2520of%2520ruxolitinib%2520and%2520vorinostat%2520leads%2520to%2520highly%2520potent%2520inhibitors%2520of%2520JAK2%2520and%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2636%26epage%3D2640%26doi%3D10.1016%2Fj.bmcl.2018.06.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu-Farseeva, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mustafa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, J. J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chng, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>158</i></span>,  <span class="NLM_fpage">593</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.09.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2018.09.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30243158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=158&publication_year=2018&pages=593-619&author=Y.+Y.+Chu-Farseevaauthor=N.+Mustafaauthor=A.+Poulsenauthor=E.+C.+Tanauthor=J.+J.+Y.+Yenauthor=W.+J.+Chngauthor=B.+W.+Dymock&title=Design+and+synthesis+of+potent+dual+inhibitors+of+JAK2+and+HDAC+based+on+fusing+the+pharmacophores+of+XL019+and+vorinostat&doi=10.1016%2Fj.ejmech.2018.09.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat</span></div><div class="casAuthors">Chu-Farseeva, Yu-yi; Mustafa, Nurulhuda; Poulsen, Anders; Tan, Eng Chong; Yen, Jeffrey J. Y.; Chng, Wee Joo; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">158</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">593-619</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Specifically blocking more than one oncogenic pathway simultaneously in a cancer cell with a combination of different drugs is the mainstay of the majority of cancer treatments.  Being able to do this via two targeted pathways without inducing side effects through a general mechanism, such as chemotherapy, could bring benefit to patients.  In this work we describe a new dual inhibitor of the JAK-STAT and HDAC pathways through designing and developing two types of mol. based on the JAK2 selective inhibitor XL019 and the pan-HDAC inhibitor, vorinostat.  Both series of compds. had examples with low nanomolar JAK2 and HDAC1/6 inhibition.  In some cases good HDAC1 selectivity was achieved while retaining HDAC6 activity.  The obsd. potency is explained through mol. docking studies of all three enzymes.  One example, 69c had 16-25 fold selectivity against the three other JAK-family proteins JAK1, JAK3 and TYK2.  A no. of compds. had sub-micromolar potencies against a panel of 4 solid tumor cell lines and 4 hematol. cell lines with the most potent compd., 45h, having a cellular IC50 of 70 nM against the multiple myeloma cell line KMS-12-BM.  Evidence of both JAK and HDAC pathway inhibition is presented in Hela cells showing that both pathways are modulated.  Evidence of apoptosis with two compds. in 4 sold tumor cell lines is also presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppP3twGjwSkLVg90H21EOLACvtfcHk0ljbm05ycozbTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslOltL%252FK&md5=a6a1456126270e44dfa2f28916f7b7c0</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.09.024%26sid%3Dliteratum%253Aachs%26aulast%3DChu-Farseeva%26aufirst%3DY.%2BY.%26aulast%3DMustafa%26aufirst%3DN.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DE.%2BC.%26aulast%3DYen%26aufirst%3DJ.%2BJ.%2BY.%26aulast%3DChng%26aufirst%3DW.%2BJ.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520potent%2520dual%2520inhibitors%2520of%2520JAK2%2520and%2520HDAC%2520based%2520on%2520fusing%2520the%2520pharmacophores%2520of%2520XL019%2520and%2520vorinostat%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D158%26spage%3D593%26epage%3D619%26doi%3D10.1016%2Fj.ejmech.2018.09.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">William, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teo, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraj, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goh, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasha, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span> <span> </span><span class="NLM_article-title">Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6). 1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">4638</span>– <span class="NLM_lpage">4658</span>, <span class="refDoi"> DOI: 10.1021/jm200326p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200326p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4638-4658&author=A.+D.+Williamauthor=A.+C.+Leeauthor=S.+Blanchardauthor=A.+Poulsenauthor=E.+L.+Teoauthor=H.+Nagarajauthor=E.+Tanauthor=D.+Chenauthor=M.+Williamsauthor=E.+T.+Sunauthor=K.+C.+Gohauthor=W.+C.+Ongauthor=S.+K.+Gohauthor=S.+Hartauthor=R.+Jayaramanauthor=M.+K.+Pashaauthor=K.+Ethirajuluauthor=J.+M.+Woodauthor=B.+W.+Dymock&title=Discovery+of+the+macrocycle+11-%282-pyrrolidin-1-yl-ethoxy%29-14%2C19-dioxa-5%2C7%2C26-triaza-tetracyclo%5B19.3.1.1%282%2C6%29.+1%288%2C12%29%5Dheptacosa-1%2825%29%2C2%2826%29%2C3%2C5%2C8%2C10%2C12%2827%29%2C16%2C21%2C23-decaene+%28SB1518%29%2C+a+potent+Janus+kinase+2%2Ffms-like+tyrosine+kinase-3+%28JAK2%2FFLT3%29+inhibitor+for+the+treatment+of+myelofibrosis+and+lymphoma&doi=10.1021%2Fjm200326p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma</span></div><div class="casAuthors">William, Anthony D.; Lee, Angeline C.-H.; Blanchard, Stephanie; Poulsen, Anders; Teo, Ee Ling; Nagaraj, Harish; Tan, Evelyn; Chen, Dizhong; Williams, Meredith; Sun, Eric T.; Goh, Kee Chuan; Ong, Wai Chung; Goh, Siok Kun; Hart, Stefan; Jayaraman, Ramesh; Pasha, Mohammed Khalid; Ethirajulu, Kantharaj; Wood, Jeanette M.; Dymock, Brian W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4638-4658</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2V617F), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (MF).  Herein, we describe the design and synthesis of a series of small mol. 4-aryl-2-aminopyrimidine macrocycles and their biol. evaluation against the JAK family of kinase enzymes and FLT3.  The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of I, a potent JAK2 (IC50 = 23 and 19 nM for JAK2WT and JAK2V617F, resp.) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, resp.).  Further profiling of I in preclin. species and mouse xenograft and allograft models is described.  Compd. I (SB1518) was selected as a development candidate and progressed into clin. trials where it is currently in phase 2 for MF and lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXtMiC4eaIMLVg90H21EOLACvtfcHk0ljuJC2J5qiA1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXns1ent7c%253D&md5=1fa1a5250cae6ec8c59db67e593fb1f6</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1021%2Fjm200326p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200326p%26sid%3Dliteratum%253Aachs%26aulast%3DWilliam%26aufirst%3DA.%2BD.%26aulast%3DLee%26aufirst%3DA.%2BC.%26aulast%3DBlanchard%26aufirst%3DS.%26aulast%3DPoulsen%26aufirst%3DA.%26aulast%3DTeo%26aufirst%3DE.%2BL.%26aulast%3DNagaraj%26aufirst%3DH.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DGoh%26aufirst%3DK.%2BC.%26aulast%3DOng%26aufirst%3DW.%2BC.%26aulast%3DGoh%26aufirst%3DS.%2BK.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DPasha%26aufirst%3DM.%2BK.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26atitle%3DDiscovery%2520of%2520the%2520macrocycle%252011-%25282-pyrrolidin-1-yl-ethoxy%2529-14%252C19-dioxa-5%252C7%252C26-triaza-tetracyclo%255B19.3.1.1%25282%252C6%2529.%25201%25288%252C12%2529%255Dheptacosa-1%252825%2529%252C2%252826%2529%252C3%252C5%252C8%252C10%252C12%252827%2529%252C16%252C21%252C23-decaene%2520%2528SB1518%2529%252C%2520a%2520potent%2520Janus%2520kinase%25202%252Ffms-like%2520tyrosine%2520kinase-3%2520%2528JAK2%252FFLT3%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520myelofibrosis%2520and%2520lymphoma%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4638%26epage%3D4658%26doi%3D10.1021%2Fjm200326p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quintás-Cardama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manshouri, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caulder, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waeltz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rupar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantarjian, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verstovsek, S.</span></span> <span> </span><span class="NLM_article-title">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">3109</span>– <span class="NLM_lpage">3117</span>, <span class="refDoi"> DOI: 10.1182/blood-2009-04-214957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1182%2Fblood-2009-04-214957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=20130243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2010&pages=3109-3117&author=A.+Quint%C3%A1s-Cardamaauthor=K.+Vaddiauthor=P.+Liuauthor=T.+Manshouriauthor=J.+Liauthor=P.+A.+Scherleauthor=E.+Caulderauthor=X.+Wenauthor=Y.+Liauthor=P.+Waeltzauthor=M.+Ruparauthor=T.+Burnauthor=Y.+Loauthor=J.+Kelleyauthor=M.+Covingtonauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=P.+Haleyauthor=H.+Kantarjianauthor=J.+S.+Fridmanauthor=S.+Verstovsek&title=Preclinical+characterization+of+the+selective+JAK1%2F2+inhibitor+INCB018424%3A+therapeutic+implications+for+the+treatment+of+myeloproliferative+neoplasms&doi=10.1182%2Fblood-2009-04-214957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms</span></div><div class="casAuthors">Quintas-Cardama, Alfonso; Vaddi, Kris; Liu, Phillip; Manshouri, Taghi; Li, Jun; Scherle, Peggy A.; Caulder, Eian; Wen, Xiaoming; Li, Yanlong; Waeltz, Paul; Rupar, Mark; Burn, Timothy; Lo, Yvonne; Kelley, Jennifer; Covington, Maryanne; Shepard, Stacey; Rodgers, James D.; Haley, Patrick; Kantarjian, Hagop; Fridman, Jordan S.; Verstovsek, Srdan</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3109-3117</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Constitutive JAK2 activation in hematopoietic cells by the JAK2V617F mutation recapitulates myeloproliferative neoplasm (MPN) phenotypes in mice, establishing JAK2 inhibition as a potential therapeutic strategy.  Although most polycythemia vera patients carry the JAK2V617F mutation, half of those with essential thrombocythemia or primary myelofibrosis do not, suggesting alternative mechanisms for constitutive JAK-STAT signaling in MPNs.  Most patients with primary myelofibrosis have elevated levels of JAK-dependent proinflammatory cytokines (eg, interleukin-6) consistent with our observation of JAK1 hyperactivation.  Accordingly, we evaluated the effectiveness of selective JAK1/2 inhibition in exptl. models relevant to MPNs and report on the effects of INCB018424, the first potent, selective, oral JAK1/JAK2 inhibitor to enter the clinic.  INCB018424 inhibited interleukin-6 signaling (50% inhibitory concn. [IC50] = 281nM), and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127nM).  In primary cultures, INCB018424 preferentially suppressed erythroid progenitor colony formation from JAK2V617F+ polycythemia vera patients (IC50 = 67nM) vs. healthy donors (IC50 > 400nM).  In a mouse model of JAK2V617F+ MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppressive effects.  Preliminary clin. results support these preclin. data and establish INCB018424 as a promising oral agent for the treatment of MPNs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvKGz1l6Y-CbVg90H21EOLACvtfcHk0ljuJC2J5qiA1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltlWqsr8%253D&md5=cd52b7013d76ed00ca2df22444c45160</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1182%2Fblood-2009-04-214957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2009-04-214957%26sid%3Dliteratum%253Aachs%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26aulast%3DVaddi%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DP.%26aulast%3DManshouri%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCaulder%26aufirst%3DE.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWaeltz%26aufirst%3DP.%26aulast%3DRupar%26aufirst%3DM.%26aulast%3DBurn%26aufirst%3DT.%26aulast%3DLo%26aufirst%3DY.%26aulast%3DKelley%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DHaley%26aufirst%3DP.%26aulast%3DKantarjian%26aufirst%3DH.%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DVerstovsek%26aufirst%3DS.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520selective%2520JAK1%252F2%2520inhibitor%2520INCB018424%253A%2520therapeutic%2520implications%2520for%2520the%2520treatment%2520of%2520myeloproliferative%2520neoplasms%26jtitle%3DBlood%26date%3D2010%26volume%3D115%26spage%3D3109%26epage%3D3117%26doi%3D10.1182%2Fblood-2009-04-214957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Forsyth, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kearney, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, B. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcalas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epshteyn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galan, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huynh, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koltun, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyr, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noguchi, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pack, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridgway, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeuchi, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aoyama, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engst, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gendreau, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassees, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stout, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolfrey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span> <span> </span><span class="NLM_article-title">SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">7653</span>– <span class="NLM_lpage">7658</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmcl.2012.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=23127890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1aqsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=7653-7658&author=T.+Forsythauthor=P.+C.+Kearneyauthor=B.+G.+Kimauthor=H.+W.+Johnsonauthor=N.+Aayauthor=A.+Arcalasauthor=D.+S.+Brownauthor=V.+Chanauthor=J.+Chenauthor=H.+Duauthor=S.+Epshteynauthor=A.+A.+Galanauthor=T.+P.+Huynhauthor=M.+A.+Ibrahimauthor=B.+Kaneauthor=E.+S.+Koltunauthor=G.+Mannauthor=L.+E.+Meyrauthor=M.+S.+Leeauthor=G.+L.+Lewisauthor=R.+T.+Noguchiauthor=M.+Packauthor=B.+H.+Ridgwayauthor=X.+Shiauthor=C.+S.+Takeuchiauthor=P.+Zuauthor=J.+W.+Leahyauthor=J.+M.+Nussauthor=R.+Aoyamaauthor=S.+Engstauthor=S.+B.+Gendreauauthor=R.+Kasseesauthor=J.+Liauthor=S.+H.+Linauthor=J.+F.+Martiniauthor=T.+Stoutauthor=P.+Tongauthor=J.+Woolfreyauthor=W.+Zhangauthor=P.+Yu&title=SAR+and+in+vivo+evaluation+of+4-aryl-2-aminoalkylpyrimidines+as+potent+and+selective+Janus+kinase+2+%28JAK2%29+inhibitors&doi=10.1016%2Fj.bmcl.2012.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors</span></div><div class="casAuthors">Forsyth, Timothy; Kearney, Patrick C.; Kim, Byung Gyu; Johnson, Henry W. B.; Aay, Naing; Arcalas, Arlyn; Brown, David S.; Chan, Vicky; Chen, Jeff; Du, Hongwang; Epshteyn, Sergey; Galan, Adam A.; Huynh, Tai P.; Ibrahim, Mohamed A.; Kane, Brian; Koltun, Elena S.; Mann, Grace; Meyr, Lisa E.; Lee, Matthew S.; Lewis, Gary L.; Noguchi, Robin T.; Pack, Michael; Ridgway, Brian H.; Shi, Xian; Takeuchi, Craig S.; Zu, Peiwen; Leahy, James W.; Nuss, John M.; Aoyama, Ron; Engst, Stefan; Gendreau, Steven B.; Kassees, Robert; Li, Jia; Lin, Shwu-Hwa; Martini, Jean-Francois; Stout, Thomas; Tong, Philip; Woolfrey, John; Zhang, Wentao; Yu, Peiwen</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7653-7658</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We report the discovery of a series of 4-aryl-2-aminoalkylpyrimidine derivs. as potent and selective JAK2 inhibitors.  High throughput screening of our inhouse compd. library led to the identification of hit 1 (I), from which optimization resulted in the discovery of highly potent and selective JAK2 inhibitors.  Advanced lead 10d demonstrated a significant dose-dependent pharmacodynamic and antitumor effect in a mouse xenograft model.  Based upon the desirable profile of 10d (XL019) it was advanced into clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNDaIhqnMysrVg90H21EOLACvtfcHk0lh_GcnhD2OJfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1aqsr%252FJ&md5=4c193c7978bc54a4999ccbc537b9f292</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DForsyth%26aufirst%3DT.%26aulast%3DKearney%26aufirst%3DP.%2BC.%26aulast%3DKim%26aufirst%3DB.%2BG.%26aulast%3DJohnson%26aufirst%3DH.%2BW.%26aulast%3DAay%26aufirst%3DN.%26aulast%3DArcalas%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DD.%2BS.%26aulast%3DChan%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DDu%26aufirst%3DH.%26aulast%3DEpshteyn%26aufirst%3DS.%26aulast%3DGalan%26aufirst%3DA.%2BA.%26aulast%3DHuynh%26aufirst%3DT.%2BP.%26aulast%3DIbrahim%26aufirst%3DM.%2BA.%26aulast%3DKane%26aufirst%3DB.%26aulast%3DKoltun%26aufirst%3DE.%2BS.%26aulast%3DMann%26aufirst%3DG.%26aulast%3DMeyr%26aufirst%3DL.%2BE.%26aulast%3DLee%26aufirst%3DM.%2BS.%26aulast%3DLewis%26aufirst%3DG.%2BL.%26aulast%3DNoguchi%26aufirst%3DR.%2BT.%26aulast%3DPack%26aufirst%3DM.%26aulast%3DRidgway%26aufirst%3DB.%2BH.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTakeuchi%26aufirst%3DC.%2BS.%26aulast%3DZu%26aufirst%3DP.%26aulast%3DLeahy%26aufirst%3DJ.%2BW.%26aulast%3DNuss%26aufirst%3DJ.%2BM.%26aulast%3DAoyama%26aufirst%3DR.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DGendreau%26aufirst%3DS.%2BB.%26aulast%3DKassees%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DS.%2BH.%26aulast%3DMartini%26aufirst%3DJ.%2BF.%26aulast%3DStout%26aufirst%3DT.%26aulast%3DTong%26aufirst%3DP.%26aulast%3DWoolfrey%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYu%26aufirst%3DP.%26atitle%3DSAR%2520and%2520in%2520vivo%2520evaluation%2520of%25204-aryl-2-aminoalkylpyrimidines%2520as%2520potent%2520and%2520selective%2520Janus%2520kinase%25202%2520%2528JAK2%2529%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D7653%26epage%3D7658%26doi%3D10.1016%2Fj.bmcl.2012.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Champoux, J. J.</span></span> <span> </span><span class="NLM_article-title">DNA topoisomerases: Structure, Function and Mechanism</span>. <i>Annu. Rev. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1146/annurev.biochem.70.1.369</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1146%2Fannurev.biochem.70.1.369" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=11395412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlsVeht7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2001&pages=369-413&author=J.+J.+Champoux&title=DNA+topoisomerases%3A+Structure%2C+Function+and+Mechanism&doi=10.1146%2Fannurev.biochem.70.1.369"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">DNA topoisomerases: structure, function, and mechanism</span></div><div class="casAuthors">Champoux, James J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">369-413</span>CODEN:
                <span class="NLM_cas:coden">ARBOAW</span>;
        ISSN:<span class="NLM_cas:issn">0066-4154</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with 196 refs.  DNA topoisomerases solve the topol. problems assocd. with DNA replication, transcription, recombination, and chromatin remodeling by introducing temporary single- or double-strand breaks in the DNA.  In addn., these enzymes fine-tune the steady-state level of DNA supercoiling both to facilitate protein interactions with the DNA and to prevent excessive supercoiling that is deleterious.  In recent years, the crystal structures of a no. of topoisomerase fragments, representing nearly all of the known classes of enzymes, have been solved.  These structures provide remarkable insights into the mechanisms of these enzymes and complement previous conclusions based on biochem. analyses.  Surprisingly, despite little or no sequence homol., both type IA and type IIA topoisomerases from prokaryotes and the type IIA enzymes from eukaryotes share structural folds that appear to reflect functional motifs within crit. regions of the enzymes.  The type IB enzymes are structurally distinct from all other known topoisomerases but are similar to a class of enzymes referred to as tyrosine recombinases.  The structural themes common to all topoisomerases include hinged clamps that open and close to bind DNA, the presence of DNA binding cavities for temporary storage of DNA segments, and the coupling of protein conformational changes to DNA rotation or DNA movement.  For the type II topoisomerases, the binding and hydrolysis of ATP further modulate conformational changes in the enzymes to effect changes in DNA topol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5Y4rDyIYy17Vg90H21EOLACvtfcHk0lh_GcnhD2OJfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlsVeht7Y%253D&md5=67c3e38eb4fcb85527b33d7077309482</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1146%2Fannurev.biochem.70.1.369&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.biochem.70.1.369%26sid%3Dliteratum%253Aachs%26aulast%3DChampoux%26aufirst%3DJ.%2BJ.%26atitle%3DDNA%2520topoisomerases%253A%2520Structure%252C%2520Function%2520and%2520Mechanism%26jtitle%3DAnnu.%2520Rev.%2520Biochem.%26date%3D2001%26volume%3D70%26spage%3D369%26epage%3D413%26doi%3D10.1146%2Fannurev.biochem.70.1.369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stiborova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckschlager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poljakova, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabeta, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kizek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frei, E.</span></span> <span> </span><span class="NLM_article-title">The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">4218</span>– <span class="NLM_lpage">4238</span>, <span class="refDoi"> DOI: 10.2174/092986712802884286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.2174%2F092986712802884286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=22680633" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtlensL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=4218-4238&author=M.+Stiborovaauthor=T.+Eckschlagerauthor=J.+Poljakovaauthor=J.+Hrabetaauthor=V.+Adamauthor=R.+Kizekauthor=E.+Frei&title=The+Synergistic+Effects+of+DNA-Targeted+Chemotherapeutics+and+Histone+Deacetylase+Inhibitors+As+Therapeutic+Strategies+for+Cancer+Treatment&doi=10.2174%2F092986712802884286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment</span></div><div class="casAuthors">Stiborova, M.; Eckschlager, T.; Poljakova, J.; Hrabeta, J.; Adam, V.; Kizek, R.; Frei, E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4218-4238</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors are a group of anticancer drugs which cause growth arrest and apoptosis of several tumor cells.  HDAC inhibitors have been also found to increase the anticancer efficacy of several treatment modalities i.e. chemotherapy or radiotherapy.  Here, we review the literature on combinations of HDAC inhibitors both with ionizing radiation and with other drugs, highlighting DNA-damaging compds.  The results of numerous studies with several types of cancer cells discussed in this review demonstrate that HDAC inhibitors enhance the effect of DNA damaging agents, such as inhibitors of topoisomerases, inhibitors of DNA synthesis, DNA-intercalators and agents covalently modifying DNA (i.e. doxorubicin, etoposid, 5-fluorouracil, cisplatin, melphalan, temozolomide and ellipticine) or of irradn.  Hence, the use of HDAC inhibitors combined with these antitumor drugs or ionizing radiation is a promising tool which may make treatment of patients suffering from many types of cancer more efficient.  Several mol. mechanisms are responsible for the obsd. higher sensitivity of tumor cells towards therapeutic agents elicited by HDAC inhibitors.  These mechanisms are discussed also in this review.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0aVL3K8P2R7Vg90H21EOLACvtfcHk0lh_GcnhD2OJfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtlensL8%253D&md5=a64b33f20e5a0880fd0a4f3dda6aec49</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.2174%2F092986712802884286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986712802884286%26sid%3Dliteratum%253Aachs%26aulast%3DStiborova%26aufirst%3DM.%26aulast%3DEckschlager%26aufirst%3DT.%26aulast%3DPoljakova%26aufirst%3DJ.%26aulast%3DHrabeta%26aufirst%3DJ.%26aulast%3DAdam%26aufirst%3DV.%26aulast%3DKizek%26aufirst%3DR.%26aulast%3DFrei%26aufirst%3DE.%26atitle%3DThe%2520Synergistic%2520Effects%2520of%2520DNA-Targeted%2520Chemotherapeutics%2520and%2520Histone%2520Deacetylase%2520Inhibitors%2520As%2520Therapeutic%2520Strategies%2520for%2520Cancer%2520Treatment%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2012%26volume%3D19%26spage%3D4218%26epage%3D4238%26doi%3D10.2174%2F092986712802884286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cincinelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guglielmi, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La Porta, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardile, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Signorino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fucci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frusciante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallavalle, S.</span></span> <span> </span><span class="NLM_article-title">Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e0205018</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0205018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1371%2Fjournal.pone.0205018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30300374" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtV2lt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&author=R.+Cincinelliauthor=L.+Mussoauthor=R.+Artaliauthor=M.+B.+Guglielmiauthor=I.+La+Portaauthor=C.+Melitoauthor=F.+Colelliauthor=F.+Cardileauthor=G.+Signorinoauthor=A.+Fucciauthor=M.+Fruscianteauthor=C.+Pisanoauthor=S.+Dallavalle&title=Hybrid+topoisomerase+I+and+HDAC+inhibitors+as+dual+action+anticancer+agents&doi=10.1371%2Fjournal.pone.0205018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Hybrid topoisomerase I and HDAC inhibitors as dual action anticancer agents</span></div><div class="casAuthors">Cincinelli, Raffaella; Musso, Loana; Artali, Roberto; Guglielmi, Mario B.; La Porta, Ilaria; Melito, Carmela; Colelli, Fabiana; Cardile, Francesco; Signorino, Giacomo; Fucci, Alessandra; Frusciante, Martina; Pisano, Claudio; Dallavalle, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e0205018/1-e0205018/22</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Recent studies have shown that HDAC inhibitors act synergistically with camptothecin derivs. in combination therapies.  To exploit this synergy, new hybrid mols. targeting simultaneously topoisomerase I and HDAC were designed.  In particular, a selected multivalent agent contg. a camptothecin and a SAHA-like template showed a broad spectrum of antiproliferative activity, with IC50 values in the nanomolar range.  Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzxTP2b69aALVg90H21EOLACvtfcHk0liRXpdogQGfuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtV2lt7g%253D&md5=8a96bd41321339c6ac43f108dd478cef</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0205018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0205018%26sid%3Dliteratum%253Aachs%26aulast%3DCincinelli%26aufirst%3DR.%26aulast%3DMusso%26aufirst%3DL.%26aulast%3DArtali%26aufirst%3DR.%26aulast%3DGuglielmi%26aufirst%3DM.%2BB.%26aulast%3DLa%2BPorta%26aufirst%3DI.%26aulast%3DMelito%26aufirst%3DC.%26aulast%3DColelli%26aufirst%3DF.%26aulast%3DCardile%26aufirst%3DF.%26aulast%3DSignorino%26aufirst%3DG.%26aulast%3DFucci%26aufirst%3DA.%26aulast%3DFrusciante%26aufirst%3DM.%26aulast%3DPisano%26aufirst%3DC.%26aulast%3DDallavalle%26aufirst%3DS.%26atitle%3DHybrid%2520topoisomerase%2520I%2520and%2520HDAC%2520inhibitors%2520as%2520dual%2520action%2520anticancer%2520agents%26jtitle%3DPLoS%2520One%26date%3D2018%26volume%3D13%26doi%3D10.1371%2Fjournal.pone.0205018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, A.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and evaluation of DNA topoisomerase II-targeted nucleosides</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">4133</span>– <span class="NLM_lpage">4144</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.06.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmc.2017.06.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=28619446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVWrtLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=4133-4144&author=H.+Matsumotoauthor=M.+Yamashitaauthor=T.+Taharaauthor=S.+Hayakawaauthor=S.+I.+Wadaauthor=K.+Tomiokaauthor=A.+Iida&title=Design%2C+synthesis%2C+and+evaluation+of+DNA+topoisomerase+II-targeted+nucleosides&doi=10.1016%2Fj.bmc.2017.06.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and evaluation of DNA topoisomerase II-targeted nucleosides</span></div><div class="casAuthors">Matsumoto, Hironobu; Yamashita, Mitsuaki; Tahara, Teruyuki; Hayakawa, Shinya; Wada, Shun-ichi; Tomioka, Kiyoshi; Iida, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4133-4144</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We developed novel nucleoside-based topoisomerase II selective inhibitors, e.g. I, and showed that small structural units, such as catechols, are essential for DNA topoisomerase II inhibitory activity.  Moreover, nucleoside analogs contg. TBS and 1,3-dithian moieties had potent and selective DNA topoisomerase II inhibitory activities.  In further expts., compd. I having aβconfiguration of the thymine moiety showed relatively strong growth inhibitory activity against cancer cell lines, and was more potent against all cancer cell lines than compd. II, which carries a thymine moiety in the α-configuration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_ceB57cuFXrVg90H21EOLACvtfcHk0liRXpdogQGfuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVWrtLjN&md5=acdd0e2f861441d80ee6eec4137bc611</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.06.001%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DH.%26aulast%3DYamashita%26aufirst%3DM.%26aulast%3DTahara%26aufirst%3DT.%26aulast%3DHayakawa%26aufirst%3DS.%26aulast%3DWada%26aufirst%3DS.%2BI.%26aulast%3DTomioka%26aufirst%3DK.%26aulast%3DIida%26aufirst%3DA.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520DNA%2520topoisomerase%2520II-targeted%2520nucleosides%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D4133%26epage%3D4144%26doi%3D10.1016%2Fj.bmc.2017.06.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yamashita, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tahara, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayakawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wada, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iida, A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1920</span>– <span class="NLM_lpage">1928</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.02.042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmc.2018.02.042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29519604" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjvVGhsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=1920-1928&author=M.+Yamashitaauthor=T.+Taharaauthor=S.+Hayakawaauthor=H.+Matsumotoauthor=S.+I.+Wadaauthor=K.+Tomiokaauthor=A.+Iida&title=Synthesis+and+biological+evaluation+of+histone+deacetylase+and+DNA+topoisomerase+II-Targeted+inhibitors&doi=10.1016%2Fj.bmc.2018.02.042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of histone deacetylase and DNA topoisomerase II-Targeted inhibitors</span></div><div class="casAuthors">Yamashita, Mitsuaki; Tahara, Teruyuki; Hayakawa, Shinya; Matsumoto, Hironobu; Wada, Shun-ichi; Tomioka, Kiyoshi; Iida, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1920-1928</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">HDAC inhibitors enable histones to maintain a high degree of acetylation.  The resulting looser state of chromatin DNA may increase the accessibility of DNA drug targets and consequently improve the efficiency of anticancer drugs targeting DNA, such as Topo II inhibitors.  A novel class of nucleoside-SAHA derivs. has been designed and synthesized based on the synergistic antitumor effects of topoisomerase II and histone deacetylase inhibitors.  Their inhibitory activities toward histone deacetylases and Topo II, and their cytotoxicities in cancer cell lines, were evaluated.  Among the synthesized hybrid compds., compd. 16b showed the potent HDAC inhibitory activity at a low nanomolar level and exhibited antiproliferative activity toward cancer cell lines including MCF-7 (breast), HCT-116 (colon), and DU-145 (prostate) cancer cells at a low micromolar level.  Moreover, compd. 16a showed HDAC6-selectivity 20-fold over HDAC1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0-RP6VIX6qLVg90H21EOLACvtfcHk0liRXpdogQGfuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjvVGhsro%253D&md5=99154f34a66242dc1a2501474a0bf091</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.02.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.02.042%26sid%3Dliteratum%253Aachs%26aulast%3DYamashita%26aufirst%3DM.%26aulast%3DTahara%26aufirst%3DT.%26aulast%3DHayakawa%26aufirst%3DS.%26aulast%3DMatsumoto%26aufirst%3DH.%26aulast%3DWada%26aufirst%3DS.%2BI.%26aulast%3DTomioka%26aufirst%3DK.%26aulast%3DIida%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520histone%2520deacetylase%2520and%2520DNA%2520topoisomerase%2520II-Targeted%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D1920%26epage%3D1928%26doi%3D10.1016%2Fj.bmc.2018.02.042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jordan, V. C.</span></span> <span> </span><span class="NLM_article-title">Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor Interactions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">883</span>– <span class="NLM_lpage">908</span>, <span class="refDoi"> DOI: 10.1021/jm020449y</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020449y" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtl2ku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=883-908&author=V.+C.+Jordan&title=Antiestrogens+and+Selective+Estrogen+Receptor+Modulators+as+Multifunctional+Medicines.+1.+Receptor+Interactions&doi=10.1021%2Fjm020449y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor Interactions</span></div><div class="casAuthors">Jordan, V. Craig</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">883-908</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Antiestrogens and selective Estrogen receptor modulators as multifunctional medicines are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYmuDHzDbu5LVg90H21EOLACvtfcHk0lj_A_4ZFNSOQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtl2ku78%253D&md5=b86cc4c3c4a4698a51eac9ab69ae9122</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm020449y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020449y%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DV.%2BC.%26atitle%3DAntiestrogens%2520and%2520Selective%2520Estrogen%2520Receptor%2520Modulators%2520as%2520Multifunctional%2520Medicines.%25201.%2520Receptor%2520Interactions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D883%26epage%3D908%26doi%3D10.1021%2Fjm020449y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. B.</span></span> <span> </span><span class="NLM_article-title">Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">4550</span>– <span class="NLM_lpage">4572</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00099</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00099" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovVShsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=4550-4572&author=C.+Tangauthor=C.+Liauthor=S.+Zhangauthor=Z.+Huauthor=J.+Wuauthor=C.+Dongauthor=J.+Huangauthor=H.+B.+Zhou&title=Novel+Bioactive+Hybrid+Compound+Dual+Targeting+Estrogen+Receptor+and+Histone+Deacetylase+for+the+Treatment+of+Breast+Cancer&doi=10.1021%2Facs.jmedchem.5b00099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer</span></div><div class="casAuthors">Tang, Chu; Li, Changhao; Zhang, Silong; Hu, Zhiye; Wu, Jun; Dong, Chune; Huang, Jian; Zhou, Hai-Bing</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4550-4572</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A strategy to develop chemotherapeutic agents by combining several active groups into a single mol. as a conjugate that can modulate multiple cellular pathways may produce compds. having higher efficacy compared to that of single-target drugs.  In this article, we describe the synthesis and evaluation of an array of dual-acting ER and histone deacetylase inhibitors.  These novel hybrid compds. combine an indirect antagonism structure motif of ER (OBHS, oxabicycloheptene sulfonate) with the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA).  These OBHS-HDACi conjugates I (R = OH, NHOH; Ar = Ph, 1-naphthyl, 2-naphthyl, 4-MeC6H5, 3-MeC6H5, 2-MeC6H5, 2-MeOC6H5, etc.) exhibited good ER binding affinity and excellent ERα antagonistic activity, and they also exhibited potent inhibitory activities against HDACs.  Compared with the approved drug tamoxifen, these conjugates exhibited higher antitumor potency in ERα-pos. breast cancer cells (MCF-7).  Moreover, these conjugates not only showed selective anticancer activity that was more potent against MCF-7 cells than DU 145 (prostate cancer), but they had no toxicity toward normal cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokzR9bn5jLU7Vg90H21EOLACvtfcHk0lj_A_4ZFNSOQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovVShsbk%253D&md5=223b9c3c43e1f8f012efcd1771547ee1</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00099%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DDong%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DH.%2BB.%26atitle%3DNovel%2520Bioactive%2520Hybrid%2520Compound%2520Dual%2520Targeting%2520Estrogen%2520Receptor%2520and%2520Histone%2520Deacetylase%2520for%2520the%2520Treatment%2520of%2520Breast%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D4550%26epage%3D4572%26doi%3D10.1021%2Facs.jmedchem.5b00099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span> <span> </span><span class="NLM_article-title">A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>828</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2018.03.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejphar.2018.03.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29563065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXms1Glu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=828&publication_year=2018&pages=67-79&author=J.+Dongauthor=N.+Zhengauthor=X.+Wangauthor=C.+Tangauthor=P.+Yanauthor=H.+B.+Zhouauthor=J.+Huang&title=A+novel+HDAC6+inhibitor+exerts+an+anti-cancer+effect+by+triggering+cell+cycle+arrest+and+apoptosis+in+gastric+cancer&doi=10.1016%2Fj.ejphar.2018.03.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">A novel HDAC6 inhibitor exerts an anti-cancer effect by triggering cell cycle arrest and apoptosis in gastric cancer</span></div><div class="casAuthors">Dong, Jing; Zheng, Nan; Wang, Xue; Tang, Chu; Yan, Ping; Zhou, Hai-bing; Huang, Jian</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">828</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">67-79</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Gastric cancer is the second leading cause of cancer-related deaths in the world.  SAHA, one of the emerging HDAC inhibitor widely used for cancer treatment, has unignorable side effects, as it is a multi-target HDAC inhibitor.  However, it is believed that specifically targeting against fewer HDACs might decrease this cytoxic effect.  In our previous work, we have designed and synthesized a series of new compds., which specifically targets to HDAC6, and TC24 was one of them.  In this study, we further demonstrated that TC24 selectively inhibited the activity of HDAC6 other than class I HDACs.  TC24 exhibited strong anti-proliferation and anti-motility ability toward gastric cancer cells but had no obvious cytoxic effect on gastric normal GES-1 cells.  The anti-cancer effect of TC24 was triggered by G2/M cell cycle arrest, apoptosis and the loss of mitochondrial membrane potential.  Bcl-2, cdc 2 and cyclin B1 were decreased while Bax and cleaved-PARP were increased.  Also, TC24 suppressed tumor angiogenesis via the redn. of HIF-1α and VEGF.  All the above data supported that TC24 was a selective inhibitor of HDAC6 and strongly suppressed the proliferation of gastric cancer cells via inducing cell cycle arrest and cell apoptosis and tumor angiogenesis inhibition, suggesting TC24 is potentially a novel therapeutic agent for gastric cancer and the research on chem. structure of TC24 would promote the understanding of the drug design of related compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp0eAYChmLArVg90H21EOLACvtfcHk0lj_A_4ZFNSOQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXms1Glu7w%253D&md5=884a1ad92720fe980f8829c6ff412f52</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2018.03.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2018.03.026%26sid%3Dliteratum%253Aachs%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DYan%26aufirst%3DP.%26aulast%3DZhou%26aufirst%3DH.%2BB.%26aulast%3DHuang%26aufirst%3DJ.%26atitle%3DA%2520novel%2520HDAC6%2520inhibitor%2520exerts%2520an%2520anti-cancer%2520effect%2520by%2520triggering%2520cell%2520cycle%2520arrest%2520and%2520apoptosis%2520in%2520gastric%2520cancer%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D828%26spage%3D67%26epage%3D79%26doi%3D10.1016%2Fj.ejphar.2018.03.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comninos, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stossi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katzenellenbogen, J. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Evaluation of Estrogen Receptor Ligands with Bridged Oxabicyclic Cores Containing a Diarylethylene Motif: Estrogen Antagonists of Unusual Structure</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">7261</span>– <span class="NLM_lpage">7274</span>, <span class="refDoi"> DOI: 10.1021/jm0506773</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0506773" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWku7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=7261-7274&author=H.+B.+Zhouauthor=J.+S.+Comninosauthor=F.+Stossiauthor=B.+S.+Katzenellenbogenauthor=J.+A.+Katzenellenbogen&title=Synthesis+and+Evaluation+of+Estrogen+Receptor+Ligands+with+Bridged+Oxabicyclic+Cores+Containing+a+Diarylethylene+Motif%3A+Estrogen+Antagonists+of+Unusual+Structure&doi=10.1021%2Fjm0506773"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of estrogen receptor ligands with bridged oxabicyclic cores containing a diarylethylene motif: estrogen antagonists of unusual structure</span></div><div class="casAuthors">Zhou, Hai-Bing; Comninos, John S.; Stossi, Fabio; Katzenellenbogen, Benita S.; Katzenellenbogen, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7261-7274</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of ligands for the estrogen receptor (ER), e.g., I, based on a three-dimensional structural motif consisting of a bridged oxabicyclic core (7-oxabicyclo[2.2.1]heptene or heptadiene) were synthesized and examd. for their receptor binding activity and as regulators of transcription through the two ER subtypes, ERα and ERβ.  The prototypical ligands also contain a 1,2-diarylethylene motif, common to many nonsteroidal estrogens, as an embellishment on the oxabicyclic core.  Thus, these ligands bear peripheral groups typically found in ER ligands, built here upon an overall three-dimensional core topol. that is unusual for these targets.  Most of these compds. were conveniently synthesized by a Diels-Alder reaction of various 3,4-diarylfurans with a variety of dienophiles, neat and under mild conditions in the absence of catalysts.  Some of the synthesized compds. display good binding affinity for the ER, and in transcription assays, the highest affinity compds. are antagonists on both ERs.  Mol. modeling studies suggest a structural basis for the antagonist activity of these compds.  These compds., based on the bicyclo[2.2.1]core system, expand the structural diversity of ligands that can be antagonists for the estrogen receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnZfRMyrwbwbVg90H21EOLACvtfcHk0lgIiY12x2e6_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWku7bN&md5=5e47c9d21b912183248dd66e22d0a5da</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm0506773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0506773%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DH.%2BB.%26aulast%3DComninos%26aufirst%3DJ.%2BS.%26aulast%3DStossi%26aufirst%3DF.%26aulast%3DKatzenellenbogen%26aufirst%3DB.%2BS.%26aulast%3DKatzenellenbogen%26aufirst%3DJ.%2BA.%26atitle%3DSynthesis%2520and%2520Evaluation%2520of%2520Estrogen%2520Receptor%2520Ligands%2520with%2520Bridged%2520Oxabicyclic%2520Cores%2520Containing%2520a%2520Diarylethylene%2520Motif%253A%2520Estrogen%2520Antagonists%2520of%2520Unusual%2520Structure%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D7261%26epage%3D7274%26doi%3D10.1021%2Fjm0506773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davids, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pagel, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kahl, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puvvada, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerecitano, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipps, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gressick, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunbar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerri, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heitner Enschede, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humerickhouse, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wierda, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seymour, J. F.</span></span> <span> </span><span class="NLM_article-title">Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">311</span>– <span class="NLM_lpage">322</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1513257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1056%2FNEJMoa1513257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=26639348" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtV2murrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2016&pages=311-322&author=A.+W.+Robertsauthor=M.+S.+Davidsauthor=J.+M.+Pagelauthor=B.+S.+Kahlauthor=S.+D.+Puvvadaauthor=J.+F.+Gerecitanoauthor=T.+J.+Kippsauthor=M.+A.+Andersonauthor=J.+R.+Brownauthor=L.+Gressickauthor=S.+Wongauthor=M.+Dunbarauthor=M.+Zhuauthor=M.+B.+Desaiauthor=E.+Cerriauthor=S.+Heitner+Enschedeauthor=R.+A.+Humerickhouseauthor=W.+G.+Wierdaauthor=J.+F.+Seymour&title=Targeting+BCL2+with+Venetoclax+in+Relapsed+Chronic+Lymphocytic+Leukemia&doi=10.1056%2FNEJMoa1513257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia</span></div><div class="casAuthors">Roberts, Andrew W.; Davids, Matthew S.; Pagel, John M.; Kahl, Brad S.; Puvvada, Soham D.; Gerecitano, John F.; Kipps, Thomas J.; Anderson, Mary Ann; Brown, Jennifer R.; Gressick, Lori; Wong, Shekman; Dunbar, Martin; Zhu, Ming; Desai, Monali B.; Cerri, Elisa; Enschede, Sari Heitner; Humerickhouse, Rod A.; Wierda, William G.; Seymour, John F.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">311-322</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND New treatments have improved outcomes for patients with relapsed chronic lymphocytic leukemia (CLL), but complete remissions remain uncommon.  Venetoclax has a distinct mechanism of action; it targets BCL2, a protein central to the survival of CLL cells.  METHODS We conducted a phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL or small lymphocytic lymphoma (SLL) to assess safety, pharmacokinetic profile, and efficacy.  In the dose-escalation phase, 56 patients received active treatment in one of eight dose groups that ranged from 150 to 1200 mg per day.  In an expansion cohort, 60 addnl. patients were treated with a weekly stepwise ramp-up in doses as high as 400 mg per day.  RESULTS The majority of the study patients had received multiple previous treatments, and 89% had poor prognostic clin. or genetic features.  Venetoclax was active at all dose levels.  Clin. tumor lysis syndrome occurred in 3 of 56 patients in the dose-escalation cohort, with one death.  After adjustments to the dose-escalation schedule, clin. tumor lysis syndrome did not occur in any of the 60 patients in the expansion cohort.  Other toxic effects included mild diarrhea (in 52% of the patients), upper respiratory tract infection (in 48%), nausea (in 47%), and grade 3 or 4 neutropenia (in 41%).  A max. tolerated dose was not identified.  Among the 116 patients who received venetoclax, 92 (79%) had a response.  Response rates ranged from 71 to 79% among patients in subgroups with an adverse prognosis, including those with resistance to fludarabine, those with chromosome 17p deletions (deletion 17p CLL), and those with unmutated IGHV.  Complete remissions occurred in 20% of the patients, including 5% who had no minimal residual disease on flow cytometry.  The 15-mo progression-free survival est. for the 400-mg dose groups was 69%.  CONCLUSIONS Selective targeting of BCL2 with venetoclax had a manageable safety profile and induced substantial responses in patients with relapsed CLL or SLL, including those with poor prognostic features.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHQgYgnKl88rVg90H21EOLACvtfcHk0lgIiY12x2e6_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtV2murrP&md5=b371a37b76ee88cfc6ac47ea0eeea0e6</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1513257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1513257%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DA.%2BW.%26aulast%3DDavids%26aufirst%3DM.%2BS.%26aulast%3DPagel%26aufirst%3DJ.%2BM.%26aulast%3DKahl%26aufirst%3DB.%2BS.%26aulast%3DPuvvada%26aufirst%3DS.%2BD.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DKipps%26aufirst%3DT.%2BJ.%26aulast%3DAnderson%26aufirst%3DM.%2BA.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DGressick%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DDunbar%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DDesai%26aufirst%3DM.%2BB.%26aulast%3DCerri%26aufirst%3DE.%26aulast%3DHeitner%2BEnschede%26aufirst%3DS.%26aulast%3DHumerickhouse%26aufirst%3DR.%2BA.%26aulast%3DWierda%26aufirst%3DW.%2BG.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26atitle%3DTargeting%2520BCL2%2520with%2520Venetoclax%2520in%2520Relapsed%2520Chronic%2520Lymphocytic%2520Leukemia%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2016%26volume%3D374%26spage%3D311%26epage%3D322%26doi%3D10.1056%2FNEJMoa1513257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, C.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">349</span>– <span class="NLM_lpage">352</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.12.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmcl.2018.12.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30594434" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1Whu7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=349-352&author=R.+Zhouauthor=S.+Fangauthor=M.+Zhangauthor=Q.+Zhangauthor=J.+Huauthor=M.+Wangauthor=C.+Wangauthor=J.+Zhuauthor=A.+Shenauthor=X.+Chenauthor=C.+Zheng&title=Design%2C+synthesis%2C+and+bioactivity+evaluation+of+novel+Bcl-2%2FHDAC+dual-target+inhibitors+for+the+treatment+of+multiple+myeloma&doi=10.1016%2Fj.bmcl.2018.12.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and bioactivity evaluation of novel Bcl-2/HDAC dual-target inhibitors for the treatment of multiple myeloma</span></div><div class="casAuthors">Zhou, Ruolan; Fang, Shaoyu; Zhang, Minmin; Zhang, Qingsen; Hu, Jian; Wang, Mingping; Wang, Chongqing; Zhu, Ju; Shen, Aijun; Chen, Xin; Zheng, Canhui</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">349-352</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Multiple myeloma (MM) is the second most common hematol. malignancy.  Almost all patients with MM eventually relapse, and most recommended treatment protocols for the patients with relapsed refractory MM comprise a combination of drugs with different mechanisms of action.  Therefore novel drugs are in urgent need in clinic.  Bcl-2 inhibitors and HDAC inhibitors were proved their anti-MM effect in clinic or under clin. trials, and they were further discovered to have synergistic interactions.  A series of Bcl-2/HDAC dual-target inhibitors were designed and synthesized.  Among them, compds. 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((6-(hydroxyamino)-6-oxohexyl)amino)-3-nitrophenyl)sulfonyl)benzamide, 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((6-(hydroxyamino)-6-oxohexyl)amino)-3-nitrophenyl)sulfonyl)benzamideoheptyl-amino-3-nitrophenyl-sulfonylbenzamide, 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((8-(hydroxyamino)-8-oxooctyl)amino)-3-nitrophenyl)sulfonyl)benzamide showed good inhibitory activities against HDAC6 and high binding affinities to Bcl-2 protein simultaneously.  They also displayed good growth inhibitory activities against human MM cell line RPMI-<8226≥, which proved their potential value for the treatment of multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqAqtNXkzMhbVg90H21EOLACvtfcHk0lgjfYROKoAo4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1Whu7bO&md5=b320094c8d301d20a7b45bfb6bf899c2</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.12.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.12.052%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DFang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZheng%26aufirst%3DC.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520bioactivity%2520evaluation%2520of%2520novel%2520Bcl-2%252FHDAC%2520dual-target%2520inhibitors%2520for%2520the%2520treatment%2520of%2520multiple%2520myeloma%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D349%26epage%3D352%26doi%3D10.1016%2Fj.bmcl.2018.12.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheppard, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fidanze, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hasvold, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pratt, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longenecker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrent, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kovar, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faivre, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magoc, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajaraman, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kati, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDaniel, K. F.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">5585</span>– <span class="NLM_lpage">5623</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00628</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00628" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvVeisrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=5585-5623&author=G.+S.+Sheppardauthor=L.+Wangauthor=S.+D.+Fidanzeauthor=L.+A.+Hasvoldauthor=D.+Liuauthor=J.+K.+Prattauthor=C.+H.+Parkauthor=K.+Longeneckerauthor=W.+Qiuauthor=M.+Torrentauthor=P.+J.+Kovarauthor=M.+Buiauthor=E.+Faivreauthor=X.+Huangauthor=X.+Linauthor=D.+Wilcoxauthor=L.+Zhangauthor=Y.+Shenauthor=D.+H.+Albertauthor=T.+J.+Magocauthor=G.+Rajaramanauthor=W.+M.+Katiauthor=K.+F.+McDaniel&title=Discovery+of+N-Ethyl-4-%5B2-%284-fluoro-2%2C6-dimethyl-phenoxy%29-5-%281-hydroxy-1-methyl-ethyl%29phenyl%5D-6-methyl-7-oxo-1H-pyrrolo%5B2%2C3-c%5Dpyridine-2-carboxamide+%28ABBV-744%29%2C+a+BET+Bromodomain+Inhibitor+with+Selectivity+for+the+Second+Bromodomain&doi=10.1021%2Facs.jmedchem.0c00628"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain</span></div><div class="casAuthors">Sheppard, George S.; Wang, Le; Fidanze, Steven D.; Hasvold, Lisa A.; Liu, Dachun; Pratt, John K.; Park, Chang H.; Longenecker, Kenton; Qiu, Wei; Torrent, Maricel; Kovar, Peter J.; Bui, Mai; Faivre, Emily; Huang, Xiaoli; Lin, Xiaoyu; Wilcox, Denise; Zhang, Lu; Shen, Yu; Albert, Daniel H.; Magoc, Terrance J.; Rajaraman, Ganesh; Kati, Warren M.; McDaniel, Keith F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5585-5623</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The BET family of proteins consists of BRD2, BRD3, BRD4, and BRDt.  Each protein contains two distinct bromodomains (BD1 and BD2).  BET family bromodomain inhibitors under clin. development for oncol. bind to each of the eight bromodomains with similar affinities.  We hypothesized that it may be possible to achieve an improved therapeutic index by selectively targeting subsets of the BET bromodomains.  Both BD1 and BD2 are highly conserved across family members (>70% identity), whereas BD1 and BD2 from the same protein exhibit a larger degree of divergence (~ 40% identity), suggesting selectivity between BD1 and BD2 of all family members would be more straightforward to achieve.  Exploiting the Asp144/His437 and Ile146/Val439 sequence differences (BRD4 BD1/BD2 numbering) allowed the identification of compd. 27 demonstrating greater than 100-fold selectivity for BRD4 BD2 over BRD4 BD1.  Further optimization to improve BD2 selectivity and oral bioavailability resulted in the clin. development compd. 46 (ABBV-744).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJtZIcWro0xLVg90H21EOLACvtfcHk0lhW2Ijvt3QADg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvVeisrk%253D&md5=675827659c3c7b6099ccd667f4c60f95</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00628%26sid%3Dliteratum%253Aachs%26aulast%3DSheppard%26aufirst%3DG.%2BS.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DFidanze%26aufirst%3DS.%2BD.%26aulast%3DHasvold%26aufirst%3DL.%2BA.%26aulast%3DLiu%26aufirst%3DD.%26aulast%3DPratt%26aufirst%3DJ.%2BK.%26aulast%3DPark%26aufirst%3DC.%2BH.%26aulast%3DLongenecker%26aufirst%3DK.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DTorrent%26aufirst%3DM.%26aulast%3DKovar%26aufirst%3DP.%2BJ.%26aulast%3DBui%26aufirst%3DM.%26aulast%3DFaivre%26aufirst%3DE.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DLin%26aufirst%3DX.%26aulast%3DWilcox%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DAlbert%26aufirst%3DD.%2BH.%26aulast%3DMagoc%26aufirst%3DT.%2BJ.%26aulast%3DRajaraman%26aufirst%3DG.%26aulast%3DKati%26aufirst%3DW.%2BM.%26aulast%3DMcDaniel%26aufirst%3DK.%2BF.%26atitle%3DDiscovery%2520of%2520N-Ethyl-4-%255B2-%25284-fluoro-2%252C6-dimethyl-phenoxy%2529-5-%25281-hydroxy-1-methyl-ethyl%2529phenyl%255D-6-methyl-7-oxo-1H-pyrrolo%255B2%252C3-c%255Dpyridine-2-carboxamide%2520%2528ABBV-744%2529%252C%2520a%2520BET%2520Bromodomain%2520Inhibitor%2520with%2520Selectivity%2520for%2520the%2520Second%2520Bromodomain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D5585%26epage%3D5623%26doi%3D10.1021%2Facs.jmedchem.0c00628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">112868</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2020.112868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=33077265" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFaht7nE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2021&pages=112868&author=J.+Chenauthor=Y.+Liauthor=J.+Zhangauthor=M.+Zhangauthor=A.+Weiauthor=H.+Liuauthor=Z.+Xieauthor=W.+Renauthor=W.+Duanauthor=Z.+Zhangauthor=A.+Shenauthor=Y.+Hu&title=Discovery+of+selective+HDAC%2FBRD4+dual+inhibitors+as+epigenetic+probes&doi=10.1016%2Fj.ejmech.2020.112868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes</span></div><div class="casAuthors">Chen, Jingjing; Li, Yalei; Zhang, Jie; Zhang, Minmin; Wei, Aihuan; Liu, Hongchun; Xie, Zhicheng; Ren, Wenming; Duan, Wenwen; Zhang, Zhuo; Shen, Aijun; Hu, Youhong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112868</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">According to the binding mode of ABBV-744 with bromodomains and the cape space of HDAC, the novel selective HDAC/BRD4 dual inhibitors were designed and synthesized by the pharmacophore fusion strategy.  Evaluating the biomol. activities through SARs exploration identified three kinds of selective dual inhibitors 41c (HDAC1/BRD4), 43a (pan-HDAC/BRD4) and 43d (HDAC6/BRD4(BD2)), whose target-related cellular activities in MV-4-11 cells were also confirmed.  Significantly, the selective dual inhibitor 41c (HDAC1/BRD4) exhibited synergistic effects against MV-4-11 cells, which strongly induced G0/G1 cell cycle arrest and apoptosis, and the first HDAC6/BRD4(BD2) dual inhibitor was found.  This study provides support for selective HDAC/BRD4 dual inhibitors as epigenetic probes based on pyrrolopyridone core for the future biol. evaluation in different cancer cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbMygNv9rC2bVg90H21EOLACvtfcHk0lhW2Ijvt3QADg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFaht7nE&md5=b39c2be6ed98f0f5ffee7bf8ac1f7cf4</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112868%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DW.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DA.%26aulast%3DHu%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520selective%2520HDAC%252FBRD4%2520dual%2520inhibitors%2520as%2520epigenetic%2520probes%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D209%26spage%3D112868%26doi%3D10.1016%2Fj.ejmech.2020.112868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venta-Perez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ham, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">Development of a histone deacetylase 6 inhibitor and its biological effects</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">15704</span>– <span class="NLM_lpage">15709</span>, <span class="refDoi"> DOI: 10.1073/pnas.1313893110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1073%2Fpnas.1313893110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=24023063" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1WlurjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=15704-15709&author=J.+H.+Leeauthor=A.+Mahendranauthor=Y.+S.+Yaoauthor=L.+Ngoauthor=G.+Venta-Perezauthor=M.+L.+Choyauthor=N.+Kimauthor=W.+S.+Hamauthor=R.+Breslowauthor=P.+A.+Marks&title=Development+of+a+histone+deacetylase+6+inhibitor+and+its+biological+effects&doi=10.1073%2Fpnas.1313893110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a histone deacetylase 6 inhibitor and its biological effects</span></div><div class="casAuthors">Lee, Ju-Hee; Mahendran, Adaickapillai; Yao, Yuanshan; Ngo, Lang; Venta-Perez, Gisela; Choy, Megan L.; Kim, Nathaniel; Ham, Won-Seok; Breslow, Ronald; Marks, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">15704-15709,S15704/1-S15704/2</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Development of isoform-selective histone deacetylase (HDAC) inhibitors is important in elucidating the function of individual HDAC enzymes and their potential as therapeutic agents.  Among the eleven zinc-dependent HDACs in humans, HDAC6 is structurally and functionally unique.  Here, we show that a hydroxamic acid-based small-mol. N-hydroxy-4-(2-[(2-hydroxyethyl)(phenyl)amino]-2-oxoethyl)benzamide (HPOB) selectively inhibits HDAC6 catalytic activity in vivo and in vitro.  HPOB causes growth inhibition of normal and transformed cells but does not induce cell death.  HPOB enhances the effectiveness of DNA-damaging anticancer drugs in transformed cells but not normal cells.  HPOB does not block the ubiquitin-binding activity of HDAC6.  The HDAC6-selective inhibitor HPOB has therapeutic potential in combination therapy to enhance the potency of anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvynfT8vxTmLVg90H21EOLACvtfcHk0lj6REcm2NiaYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1WlurjP&md5=e32e88dfc23a049ebe59b8d62beb8a8c</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313893110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313893110%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DMahendran%26aufirst%3DA.%26aulast%3DYao%26aufirst%3DY.%2BS.%26aulast%3DNgo%26aufirst%3DL.%26aulast%3DVenta-Perez%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DM.%2BL.%26aulast%3DKim%26aufirst%3DN.%26aulast%3DHam%26aufirst%3DW.%2BS.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DDevelopment%2520of%2520a%2520histone%2520deacetylase%25206%2520inhibitor%2520and%2520its%2520biological%2520effects%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D15704%26epage%3D15709%26doi%3D10.1073%2Fpnas.1313893110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W. P.</span></span> <span> </span><span class="NLM_article-title">HPOB, an HDAC6 inhibitor, attenuates corticosterone-induced injury in rat adrenal pheochromocytoma PC12 cells by inhibiting mitochondrial GR translocation and the intrinsic apoptosis pathway</span>. <i>Neurochem. Int.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>99</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1016/j.neuint.2016.08.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.neuint.2016.08.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27522966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVWmsbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=99&publication_year=2016&pages=239-251&author=Z.+Y.+Liauthor=Q.+Z.+Liauthor=L.+Chenauthor=B.+D.+Chenauthor=C.+Zhangauthor=X.+Wangauthor=W.+P.+Li&title=HPOB%2C+an+HDAC6+inhibitor%2C+attenuates+corticosterone-induced+injury+in+rat+adrenal+pheochromocytoma+PC12+cells+by+inhibiting+mitochondrial+GR+translocation+and+the+intrinsic+apoptosis+pathway&doi=10.1016%2Fj.neuint.2016.08.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">HPOB, an HDAC6 inhibitor, attenuates corticosterone-induced injury in rat adrenal pheochromocytoma PC12 cells by inhibiting mitochondrial GR translocation and the intrinsic apoptosis pathway</span></div><div class="casAuthors">Li, Zong-yang; Li, Qing-zhong; Chen, Lei; Chen, Bao-dong; Zhang, Ce; Wang, Xiang; Li, Wei-ping</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry International</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">99</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">239-251</span>CODEN:
                <span class="NLM_cas:coden">NEUIDS</span>;
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">High levels of glucocorticoids (GCs) have been reported to damage normal hippocampal neurons, and such damage has been pos. correlated with major depression (MD) and chronic stress.  Our previous study showed that HDAC6 might be a potential target to regulate GC-induced glucocorticoid receptor (GR) translocation to the mitochondria and subsequent apoptosis.  In the present study, we investigated the effect of HPOB, a selective HDAC6 inhibitor, on corticosterone (Cort)-induced apoptosis and explored the possible mechanism of action of HPOB in rat adrenal pheochromocytoma (PC12) cells, which possesses typical neuron features and expresses high levels of glucocorticoid receptors.  We demonstrated that pre-treatment with HPOB remarkably reduced Cort-induced cytotoxicity and confirmed the anti-apoptotic effect of HPOB via the caspase-3 activity assay and H33342/PI and TUNEL double staining.  Mechanistically, we demonstrated that HPOB reversed the Cort-induced elevation of GR levels in the mitochondria and blocked concomitant mitochondrial dysfunction and the intrinsic apoptosis pathway.  Furthermore, HPOB was shown to attenuate expression of the multi-chaperone machinery (Hsp90-Hop-Hsp70) and cooperate with mitochondrial translocase of the outer/inner membrane (TOM/TIM) complex recruitment by triggering hyperacetylation of Hsps through HDAC6 inhibition.  Considering all of these findings, the neuroprotective effect of HPOB demonstrated the crucial role of HDAC6 inhibition in reducing Cort-induced apoptosis in PC12 cells.  The data further suggested that the anti-apoptotic activity of HDAC6 inhibition against the mitochondria-mediated impairment pathway might be mechanistically linked to the hyperacetylation of Hsps and consequent suppression of GR translocation to the mitochondria.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0ofsFDJa8VbVg90H21EOLACvtfcHk0lj6REcm2NiaYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVWmsbzK&md5=75814b2bc8c066e8899b8cbd8be414e5</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.neuint.2016.08.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuint.2016.08.004%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DZ.%2BY.%26aulast%3DLi%26aufirst%3DQ.%2BZ.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DB.%2BD.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DW.%2BP.%26atitle%3DHPOB%252C%2520an%2520HDAC6%2520inhibitor%252C%2520attenuates%2520corticosterone-induced%2520injury%2520in%2520rat%2520adrenal%2520pheochromocytoma%2520PC12%2520cells%2520by%2520inhibiting%2520mitochondrial%2520GR%2520translocation%2520and%2520the%2520intrinsic%2520apoptosis%2520pathway%26jtitle%3DNeurochem.%2520Int.%26date%3D2016%26volume%3D99%26spage%3D239%26epage%3D251%26doi%3D10.1016%2Fj.neuint.2016.08.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boo, Y. C.</span></span> <span> </span><span class="NLM_article-title">Screening of an Epigenetic Drug Library Identifies 4-((hydroxyamino)carbonyl)-N-(2-hydroxyethyl)-N-Phenyl-Benzeneacetamide that Reduces Melanin Synthesis by Inhibiting Tyrosinase Activity Independently of Epigenetic Mechanisms</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4589</span>, <span class="refDoi"> DOI: 10.3390/ijms21134589</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3390%2Fijms21134589" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFymsbjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=4589&author=H.+Songauthor=Y.+J.+Hwangauthor=J.+W.+Haauthor=Y.+C.+Boo&title=Screening+of+an+Epigenetic+Drug+Library+Identifies+4-%28%28hydroxyamino%29carbonyl%29-N-%282-hydroxyethyl%29-N-Phenyl-Benzeneacetamide+that+Reduces+Melanin+Synthesis+by+Inhibiting+Tyrosinase+Activity+Independently+of+Epigenetic+Mechanisms&doi=10.3390%2Fijms21134589"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Screening of an epigenetic drug library identifies 4-((hydroxyamino)carbonyl)-N-(2-hydroxyethyl)-N-phenyl-benzeneacetamide that reduces melanin synthesis by inhibiting tyrosinase activity independently of epigenetic mechanisms</span></div><div class="casAuthors">Song, Hyerim; Hwang, Yun Jeong; Ha, Jae Won; Boo, Yong Chool</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4589</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The aim of this study was to identify novel antimelanogenic drugs from an epigenetic screening library contg. various modulators targeting DNA methyltransferases, histone deacetylases, and other related enzymes/proteins.  Of 141 drugs tested, K8 (4-((hydroxyamino)carbonyl)-N-(2-hydroxyethyl)-N-phenyl-benzeneacetamide; HPOB) was found to effectively inhibit the α-MSH (α-MSH)-induced melanin synthesis in B16-F10 murine melanoma cells without accompanying cytotoxicity.  Addnl. expts. showed that K8 did not significantly reduce the mRNA and protein level of tyrosinase (TYR) or microphthalmia-assocd. transcription factor (MITF) in cells, but it potently inhibited the catalytic activity TYR in vitro (IC50, 1.1-1.5μM) as compared to β-arbutin (IC50, 500-700μM) or kojic acid (IC50, 63μM).  K8 showed copper chelating activity similar to kojic acid.  Therefore, these data suggest that K8 inhibits cellular melanin synthesis not by downregulation of TYR protein expression through an epigenetic mechanism, but by direct inhibition of TYR catalytic activity through copper chelation.  Metal chelating activity of K8 is not surprising because it is known to inhibit histone deacetylase (HDAC) 6 through zinc chelation.  This study identified K8 as a potent inhibitor of cellular melanin synthesis, which may be useful for the treatment of hyperpigmentation disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovjTeOq5Eo8rVg90H21EOLACvtfcHk0lj6REcm2NiaYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFymsbjI&md5=5d4986f5dd34d3b8dc4ec031ab0e672f</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.3390%2Fijms21134589&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21134589%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DH.%26aulast%3DHwang%26aufirst%3DY.%2BJ.%26aulast%3DHa%26aufirst%3DJ.%2BW.%26aulast%3DBoo%26aufirst%3DY.%2BC.%26atitle%3DScreening%2520of%2520an%2520Epigenetic%2520Drug%2520Library%2520Identifies%25204-%2528%2528hydroxyamino%2529carbonyl%2529-N-%25282-hydroxyethyl%2529-N-Phenyl-Benzeneacetamide%2520that%2520Reduces%2520Melanin%2520Synthesis%2520by%2520Inhibiting%2520Tyrosinase%2520Activity%2520Independently%2520of%2520Epigenetic%2520Mechanisms%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D4589%26doi%3D10.3390%2Fijms21134589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Demyanenko, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzreyan, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uzdensky, A. B.</span></span> <span> </span><span class="NLM_article-title">Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of alpha-phenyl tropolone, HPOB, and sodium valproate</span>. <i>Brain Res. Bull.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1016/j.brainresbull.2020.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.brainresbull.2020.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32592806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlSku7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2020&pages=151-165&author=S.+V.+Demyanenkoauthor=V.+A.+Dzreyanauthor=A.+B.+Uzdensky&title=Overexpression+of+HDAC6%2C+but+not+HDAC3+and+HDAC4+in+the+penumbra+after+photothrombotic+stroke+in+the+rat+cerebral+cortex+and+the+neuroprotective+effects+of+alpha-phenyl+tropolone%2C+HPOB%2C+and+sodium+valproate&doi=10.1016%2Fj.brainresbull.2020.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of HDAC6, but not HDAC3 and HDAC4 in the penumbra after photothrombotic stroke in the rat cerebral cortex and the neuroprotective effects of α-phenyl tropolone, HPOB, and sodium valproate</span></div><div class="casAuthors">Demyanenko, S. V.; Dzreyan, V. A.; Uzdensky, A. B.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Bulletin</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">151-165</span>CODEN:
                <span class="NLM_cas:coden">BRBUDU</span>;
        ISSN:<span class="NLM_cas:issn">0361-9230</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">We studied effects of photothrombotic stroke on intracellular level and cellular localization of histone deacetylases HDAC3, HDAC4 and HDAC6 in rat brain cortex, and tested the potential neuroprotector ability of their inhibitors.  The background level of HDAC3, HDAC4 and HDAC6 in the rat cerebral cortex was relatively low.  HDAC3 localized in the nuclei of some neurons and few astrocytes.  HDAC4 was found in the neuronal cytoplasm.  After PTS, their levels in penumbra did not change, but HDAC4 appeared in the nuclei of some cells.  Its level in the cytoplasmic, but not nuclear fraction of penumbra decreased at 24, but not 4 h after PTS.  HDAC6 was upregulated in neurons and astrocytes in the PTS-induced penumbra, esp. in the nuclear fraction.  Unlike HDAC3 and HDAC4, HDAC6 co-localized with TUNEL-pos. apoptotic cells.  Inhibitory anal. confirmed the involvement of HDAC6, but not HDAC3 and HDAC4 in neurodegeneration.  HDAC6 inhibitor HPOB, HDAC2/8 inhibitor α-Ph tropolone, and non-specific histone deacetylase inhibitor sodium valproate, but not HDAC3 inhibitor BRD3308, or HDAC4 inhibitor LMK235, decreased PTS-induced infarction vol. in the mouse brain, reduced apoptosis, and recovered the motor behavior.  HPOB also restored PTS-impaired acetylation of α-tubulin. α-Ph tropolone restored acetylation of histone H4 in penumbra cells.  These results suggest that histone deacetylases HDAC6 and HDAC2 are the possible mol. targets for anti-ischemic therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdpe4-voSvY7Vg90H21EOLACvtfcHk0lgWnw5eXXWj3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlSku7zJ&md5=b40bc6d52f2899cb2c72c03e34099874</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresbull.2020.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresbull.2020.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DDemyanenko%26aufirst%3DS.%2BV.%26aulast%3DDzreyan%26aufirst%3DV.%2BA.%26aulast%3DUzdensky%26aufirst%3DA.%2BB.%26atitle%3DOverexpression%2520of%2520HDAC6%252C%2520but%2520not%2520HDAC3%2520and%2520HDAC4%2520in%2520the%2520penumbra%2520after%2520photothrombotic%2520stroke%2520in%2520the%2520rat%2520cerebral%2520cortex%2520and%2520the%2520neuroprotective%2520effects%2520of%2520alpha-phenyl%2520tropolone%252C%2520HPOB%252C%2520and%2520sodium%2520valproate%26jtitle%3DBrain%2520Res.%2520Bull.%26date%3D2020%26volume%3D162%26spage%3D151%26epage%3D165%26doi%3D10.1016%2Fj.brainresbull.2020.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahendran, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ngo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venta-Perez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breslow, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marks, P. A.</span></span> <span> </span><span class="NLM_article-title">Creation of a histone deacetylase 6 inhibitor and its biological effects</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>112</i></span>,  <span class="NLM_fpage">12005</span>– <span class="NLM_lpage">12010</span>, <span class="refDoi"> DOI: 10.1073/pnas.1515882112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1073%2Fpnas.1515882112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=26371309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsV2ntLjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=112&publication_year=2015&pages=12005-12010&author=J.+H.+Leeauthor=Y.+Yaoauthor=A.+Mahendranauthor=L.+Ngoauthor=G.+Venta-Perezauthor=M.+L.+Choyauthor=R.+Breslowauthor=P.+A.+Marks&title=Creation+of+a+histone+deacetylase+6+inhibitor+and+its+biological+effects&doi=10.1073%2Fpnas.1515882112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a histone deacetylase 6 inhibitor and its biological effects</span></div><div class="casAuthors">Lee, Ju-Hee; Yao, Yuanshan; Mahendran, Adaickapillai; Ngo, Lang; Venta-Perez, Gisela; Choy, Megan L.; Breslow, Ronald; Marks, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">112</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">12005-12010</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The authors report the development of a potent, selective histone deacetylase 6 (HDAC6) inhibitor, HPB (N-hydroxy-4-[(N-(((2-hydroxyethyl)-2-phenylacetamido)methyl)benzamide)]).  This HDAC6 inhibitor blocks growth of normal and transformed cells but does not induce death of normal cells.  The HDAC6 inhibitor alone is as effective as paclitaxel in anticancer activity in tumor-bearing mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonHNFE0-PzyLVg90H21EOLACvtfcHk0lgWnw5eXXWj3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsV2ntLjK&md5=d6dc50c8c83e0b03c5ecebc3da3a96c7</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1515882112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1515882112%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DMahendran%26aufirst%3DA.%26aulast%3DNgo%26aufirst%3DL.%26aulast%3DVenta-Perez%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DM.%2BL.%26aulast%3DBreslow%26aufirst%3DR.%26aulast%3DMarks%26aufirst%3DP.%2BA.%26atitle%3DCreation%2520of%2520a%2520histone%2520deacetylase%25206%2520inhibitor%2520and%2520its%2520biological%2520effects%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2015%26volume%3D112%26spage%3D12005%26epage%3D12010%26doi%3D10.1073%2Fpnas.1515882112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bergman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Villarroel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotomayor, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">9891</span>– <span class="NLM_lpage">9899</span>, <span class="refDoi"> DOI: 10.1021/jm301098e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301098e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=9891-9899&author=J.+A.+Bergmanauthor=K.+Woanauthor=P.+Perez-Villarroelauthor=A.+Villagraauthor=E.+M.+Sotomayorauthor=A.+P.+Kozikowski&title=Selective+histone+deacetylase+6+inhibitors+bearing+substituted+urea+linkers+inhibit+melanoma+cell+growth&doi=10.1021%2Fjm301098e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Histone Deacetylase 6 Inhibitors Bearing Substituted Urea Linkers Inhibit Melanoma Cell Growth</span></div><div class="casAuthors">Bergman, Joel A.; Woan, Karrune; Perez-Villarroel, Patricio; Villagra, Alejandro; Sotomayor, Eduardo M.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">9891-9899</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The incidence of malignant melanoma has dramatically increased in recent years thus requiring the need for improved therapeutic strategies.  In our efforts to design selective histone deactylase inhibitors (HDACI), we discovered that the aryl urea 1 is a modestly potent yet nonselective inhibitor.  Structure-activity relationship studies revealed that adding substituents to the nitrogen atom of the urea so as to generate compds. bearing a branched linker group results in increased potency and selectivity for HDAC6.  Compd. 5g shows low nanomolar inhibitory potency against HDAC6 and a selectivity of ∼600-fold relative to the inhibition of HDAC1.  These HDACIs were evaluated for their ability to inhibit the growth of B16 melanoma cells with the most potent and selective HDAC6I being found to decrease tumor cell growth.  To the best of our knowledge, this work constitutes the first report of HDAC6-selective inhibitors that possess antiproliferative effects against melanoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkTtPLqvwsrVg90H21EOLACvtfcHk0lgWnw5eXXWj3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lsrbJ&md5=d6be4c0efb3922fc35d814ba00ae9ed1</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1021%2Fjm301098e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301098e%26sid%3Dliteratum%253Aachs%26aulast%3DBergman%26aufirst%3DJ.%2BA.%26aulast%3DWoan%26aufirst%3DK.%26aulast%3DPerez-Villarroel%26aufirst%3DP.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DSotomayor%26aufirst%3DE.%2BM.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSelective%2520histone%2520deacetylase%25206%2520inhibitors%2520bearing%2520substituted%2520urea%2520linkers%2520inhibit%2520melanoma%2520cell%2520growth%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D9891%26epage%3D9899%26doi%3D10.1021%2Fjm301098e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ledezma, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cano-Mejia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweeney, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollard, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandes, R.</span></span> <span> </span><span class="NLM_article-title">Indocyanine Green-Nexturastat A-PLGA Nanoparticles Combine Photothermal and Epigenetic Therapy for Melanoma</span>. <i>Nanomaterials</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">161</span>, <span class="refDoi"> DOI: 10.3390/nano10010161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3390%2Fnano10010161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFWhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2020&pages=161&author=D.+K.+Ledezmaauthor=P.+B.+Balakrishnanauthor=J.+Cano-Mejiaauthor=E.+E.+Sweeneyauthor=M.+Hadleyauthor=C.+M.+Bollardauthor=A.+Villagraauthor=R.+Fernandes&title=Indocyanine+Green-Nexturastat+A-PLGA+Nanoparticles+Combine+Photothermal+and+Epigenetic+Therapy+for+Melanoma&doi=10.3390%2Fnano10010161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Indocyanine green-nexturastat A-PLGA nanoparticles combine photothermal and epigenetic therapy for melanoma</span></div><div class="casAuthors">Ledezma, Debbie K.; Balakrishnan, Preethi B.; Cano-Mejia, Juliana; Sweeney, Elizabeth E.; Hadley, Melissa; Bollard, Catherine M.; Villagra, Alejandro; Fernandes, Rohan</div><div class="citationInfo"><span class="NLM_cas:title">Nanomaterials</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">161</span>CODEN:
                <span class="NLM_cas:coden">NANOKO</span>;
        ISSN:<span class="NLM_cas:issn">2079-4991</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">In this study, we describe poly (lactic-co-glycolic) acid (PLGA)-based nanoparticles that combine photothermal therapy (PTT) with epigenetic therapy for melanoma.  Specifically, we co-encapsulated indocyanine green (ICG), a PTT agent, and Nexturastat A (NextA), an epigenetic drug within PLGA nanoparticles (ICG-NextA-PLGA; INAPs).  We hypothesized that combining PTT with epigenetic therapy elicits favorable cytotoxic and immunomodulatory responses that result in improved survival in melanoma-bearing mice.  We utilized a nanoemulsion synthesis scheme to co-encapsulate ICG and NextA within stable and monodispersed INAPs.  The INAPs exhibited concn.-dependent and near-IR (NIR) laser power-dependent photothermal heating characteristics, and functioned as effective single-use agents for PTT of melanoma cells in vitro.  The INAPs functioned as effective epigenetic therapy agents by inhibiting the expression of pan-histone deacetylase (HDAC) and HDAC6-specific activity in melanoma cells in vitro.  When used for both PTT and epigenetic therapy in vitro, the INAPs increased the expression of co-stimulatory mols. and major histocompatibility complex (MHC) Class I in melanoma cells relative to controls.  These advantages persisted in vivo in a syngeneic murine model of melanoma, where the combination therapy slowed tumor progression and improved median survival.  These findings demonstrate the potential of INAPs as agents of PTT and epigenetic therapy for melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpMLSZ-4Na_P7Vg90H21EOLACvtfcHk0lhrUdNhxSQ4lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFWhsbg%253D&md5=5422f34dcb9de9957dc53552c20393ee</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.3390%2Fnano10010161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fnano10010161%26sid%3Dliteratum%253Aachs%26aulast%3DLedezma%26aufirst%3DD.%2BK.%26aulast%3DBalakrishnan%26aufirst%3DP.%2BB.%26aulast%3DCano-Mejia%26aufirst%3DJ.%26aulast%3DSweeney%26aufirst%3DE.%2BE.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DBollard%26aufirst%3DC.%2BM.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DFernandes%26aufirst%3DR.%26atitle%3DIndocyanine%2520Green-Nexturastat%2520A-PLGA%2520Nanoparticles%2520Combine%2520Photothermal%2520and%2520Epigenetic%2520Therapy%2520for%2520Melanoma%26jtitle%3DNanomaterials%26date%3D2020%26volume%3D10%26spage%3D161%26doi%3D10.3390%2Fnano10010161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahakian, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noonepalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracia-Hernandez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinilla-Ibarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">6136</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-42237-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fs41598-019-42237-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30992475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3M%252FmtFOrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=6136&author=T.+Knoxauthor=E.+Sahakianauthor=D.+Banikauthor=M.+Hadleyauthor=E.+Palmerauthor=S.+Noonepalleauthor=J.+Kimauthor=J.+Powersauthor=M.+Gracia-Hernandezauthor=V.+Oliveiraauthor=F.+Chengauthor=J.+Chenauthor=C.+Barinkaauthor=J.+Pinilla-Ibarzauthor=N.+H.+Leeauthor=A.+Kozikowskiauthor=A.+Villagra&title=Selective+HDAC6+inhibitors+improve+anti-PD-1+immune+checkpoint+blockade+therapy+by+decreasing+the+anti-inflammatory+phenotype+of+macrophages+and+down-regulation+of+immunosuppressive+proteins+in+tumor+cells&doi=10.1038%2Fs41598-019-42237-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells</span></div><div class="casAuthors">Knox Tessa; Banik Debarati; Hadley Melissa; Palmer Erica; Noonepalle Satish; Kim Jennifer; Gracia-Hernandez Maria; Cheng Fengdong; Chen Jie; Lee Norman H; Villagra Alejandro; Sahakian Eva; Powers John; Pinilla-Ibarz Javier; Oliveira Vasco; Barinka Cyril; Kozikowski Alan</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">6136</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDACs) are involved in diverse cellular regulatory mechanisms including non-canonical functions outside the chromatin environment.  Several publications have demonstrated that selective HDAC inhibitors (HDACi) can influence tumor immunogenicity and the functional activity of specific immune cells.  In particular, the selective inhibition of HDAC6 has been reported to decrease tumor growth in several malignancies.  However, there is still no clarity about the cellular components mediating this effect.  In this study, we evaluated the HDAC6i Nexturastat A as a priming agent to facilitate the transition of the tumor microenvironment from "cold" to "hot", and potentially augment immune check-point blockade therapies.  This combination modality demonstrated to significantly reduce tumor growth in syngeneic melanoma tumor models.  Additionally, we observed a complete neutralization of the up-regulation of PD-L1 and other immunosuppressive pathways induced by the treatment with anti-PD-1 blockade.  This combination also showed profound changes in the tumor microenvironment such as enhanced infiltration of immune cells, increased central and effector T cell memory, and a significant reduction of pro-tumorigenic M2 macrophages.  The evaluation of individual components of the tumor microenvironment suggested that the in vivo anti-tumor activity of HDAC6i is mediated by its effect on tumor cells and tumor-associated macrophages, and not directly over T cells.  Overall, our results indicate that selective HDAC6i could be used as immunological priming agents to sensitize immunologically "cold" tumors and subsequently improve ongoing immune check-point blockade therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSl6RaBRQ4Kdw8IxFYvehhofW6udTcc2eY91N4RMiH_gLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M%252FmtFOrsg%253D%253D&md5=137a9261e021e60b002d9312608eba76</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-42237-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-42237-3%26sid%3Dliteratum%253Aachs%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DSahakian%26aufirst%3DE.%26aulast%3DBanik%26aufirst%3DD.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DPalmer%26aufirst%3DE.%26aulast%3DNoonepalle%26aufirst%3DS.%26aulast%3DKim%26aufirst%3DJ.%26aulast%3DPowers%26aufirst%3DJ.%26aulast%3DGracia-Hernandez%26aufirst%3DM.%26aulast%3DOliveira%26aufirst%3DV.%26aulast%3DCheng%26aufirst%3DF.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DPinilla-Ibarz%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DN.%2BH.%26aulast%3DKozikowski%26aufirst%3DA.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DSelective%2520HDAC6%2520inhibitors%2520improve%2520anti-PD-1%2520immune%2520checkpoint%2520blockade%2520therapy%2520by%2520decreasing%2520the%2520anti-inflammatory%2520phenotype%2520of%2520macrophages%2520and%2520down-regulation%2520of%2520immunosuppressive%2520proteins%2520in%2520tumor%2520cells%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26spage%3D6136%26doi%3D10.1038%2Fs41598-019-42237-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span> <span> </span><span class="NLM_article-title">The selective HDAC6 inhibitor Nexturastat A induces apoptosis, overcomes drug resistance and inhibits tumor growth in multiple myeloma</span>. <i>Biosci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">BSR20181916</span>, <span class="refDoi"> DOI: 10.1042/BSR20181916</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1042%2FBSR20181916" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30782785" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2019&pages=BSR20181916&author=X.+Sunauthor=Y.+Xieauthor=X.+Sunauthor=Y.+Yaoauthor=H.+Liauthor=Z.+Liauthor=R.+Yaoauthor=K.+Xu&title=The+selective+HDAC6+inhibitor+Nexturastat+A+induces+apoptosis%2C+overcomes+drug+resistance+and+inhibits+tumor+growth+in+multiple+myeloma&doi=10.1042%2FBSR20181916"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1042%2FBSR20181916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBSR20181916%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DYao%26aufirst%3DR.%26aulast%3DXu%26aufirst%3DK.%26atitle%3DThe%2520selective%2520HDAC6%2520inhibitor%2520Nexturastat%2520A%2520induces%2520apoptosis%252C%2520overcomes%2520drug%2520resistance%2520and%2520inhibits%2520tumor%2520growth%2520in%2520multiple%2520myeloma%26jtitle%3DBiosci.%2520Rep.%26date%3D2019%26volume%3D39%26spage%3DBSR20181916%26doi%3D10.1042%2FBSR20181916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1031</span>– <span class="NLM_lpage">1036</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00223</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00223" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7zL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1031-1036&author=M.+T.+Tavaresauthor=S.+Shenauthor=T.+Knoxauthor=M.+Hadleyauthor=Z.+Kutilauthor=C.+Barinkaauthor=A.+Villagraauthor=A.+P.+Kozikowski&title=Synthesis+and+Pharmacological+Evaluation+of+Selective+Histone+Deacetylase+6+Inhibitors+in+Melanoma+Models&doi=10.1021%2Facsmedchemlett.7b00223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Evaluation of Selective Histone Deacetylase 6 Inhibitors in Melanoma Models</span></div><div class="casAuthors">Tavares, Mauricio T.; Shen, Sida; Knox, Tessa; Hadley, Melissa; Kutil, Zsofia; Barinka, Cyril; Villagra, Alejandro; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1031-1036</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Only a handful of therapies offer significant improvement in the overall survival in cases of melanoma, a cancer whose incidence has continued to rise in the past 30 years.  In our effort to identify potent and isoform-selective histone deacetylase (HDAC) inhibitors as a therapeutic approach to melanoma, a series of new HDAC6 inhibitors based on the nexturastat A scaffold were prepd.  The new analogs bearing added hydrophilic substituents, so as to establish addnl. hydrogen bonding on the rim of the HDAC6 catalytic pocket, exhibit improved potency against HDAC6 and retain selectivity over HDAC1.  Compd. I exhibits antiproliferative effects on several types of melanoma and lymphoma cells.  Further studies indicates that I selectively increases acetylated tubulin levels in vitro and elicits an immune response through down-regulating cytokine IL-10.  A preliminary in vivo efficacy study indicates that I possesses improved capability to inhibit melanoma tumor growth and that this effect is based on the regulation of inflammatory and immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6cF7frE1ffLVg90H21EOLACvtfcHk0lgOygNic59hiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVejs7zL&md5=305123b6d7ecc3e4273d5fa02565367f</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00223%26sid%3Dliteratum%253Aachs%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DVillagra%26aufirst%3DA.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Evaluation%2520of%2520Selective%2520Histone%2520Deacetylase%25206%2520Inhibitors%2520in%2520Melanoma%2520Models%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D1031%26epage%3D1036%26doi%3D10.1021%2Facsmedchemlett.7b00223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Noonepalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ptáček, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stránský, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlíček, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferreira, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelaez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bařinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10246</span>– <span class="NLM_lpage">10262</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00567</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00567" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1ers7%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10246-10262&author=S.+Noonepalleauthor=S.+Shenauthor=J.+Pt%C3%A1%C4%8Dekauthor=M.+T.+Tavaresauthor=G.+Zhangauthor=J.+Str%C3%A1nsk%C3%BDauthor=J.+Pavl%C3%AD%C4%8Dekauthor=G.+M.+Ferreiraauthor=M.+Hadleyauthor=G.+Pelaezauthor=C.+Ba%C5%99inkaauthor=A.+P.+Kozikowskiauthor=A.+Villagra&title=Rational+Design+of+Suprastat%3A+A+Novel+Selective+Histone+Deacetylase+6+Inhibitor+with+the+Ability+to+Potentiate+Immunotherapy+in+Melanoma+Models&doi=10.1021%2Facs.jmedchem.0c00567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models</span></div><div class="casAuthors">Noonepalle, Satish; Shen, Sida; Ptacek, Jakub; Tavares, Mauricio T.; Zhang, Guiping; Stransky, Jan; Pavlicek, Jiri; Ferreira, Glaucio M.; Hadley, Melissa; Pelaez, Guido; Barinka, Cyril; Kozikowski, Alan P.; Villagra, Alejandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10246-10262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Selective inhibition of histone deacetylase 6 (HDAC6) is being recognized as a therapeutic approach for cancers.  In this study, we designed a new HDAC6 inhibitor, named Suprastat(I), using in silico simulations.  X-ray crystallog. and mol. dynamics simulations provide strong evidence to support the notion that the aminomethyl and hydroxyl groups in the capping group of Suprastat establish significant hydrogen bond interactions, either direct or water-mediated, with residues D460, N530, and S531, which play a vital role in regulating the deacetylase function of the enzyme and which are absent in other isoforms.  In vitro characterization of Suprastat demonstrates subnanomolar HDAC6 inhibitory potency and a hundred- to a thousand-fold HDAC6 selectivity over the other HDAC isoforms.  In vivo studies reveal that a combination of Suprastat and anti-PD1 immunotherapy enhances antitumor immune response, mediated by a decrease of protumoral M2 macrophages and increased infiltration of antitumor CD8+ effector and memory T-cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk6yLAJTV90rVg90H21EOLACvtfcHk0lgOygNic59hiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1ers7%252FP&md5=dfe4a0aed15153f03b49144392e746fe</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00567%26sid%3Dliteratum%253Aachs%26aulast%3DNoonepalle%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DPt%25C3%25A1%25C4%258Dek%26aufirst%3DJ.%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DStr%25C3%25A1nsk%25C3%25BD%26aufirst%3DJ.%26aulast%3DPavl%25C3%25AD%25C4%258Dek%26aufirst%3DJ.%26aulast%3DFerreira%26aufirst%3DG.%2BM.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DPelaez%26aufirst%3DG.%26aulast%3DBa%25C5%2599inka%26aufirst%3DC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DRational%2520Design%2520of%2520Suprastat%253A%2520A%2520Novel%2520Selective%2520Histone%2520Deacetylase%25206%2520Inhibitor%2520with%2520the%2520Ability%2520to%2520Potentiate%2520Immunotherapy%2520in%2520Melanoma%2520Models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10246%26epage%3D10262%26doi%3D10.1021%2Facs.jmedchem.0c00567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Butler, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brochier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vistoli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">10842</span>– <span class="NLM_lpage">10846</span>, <span class="refDoi"> DOI: 10.1021/ja102758v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja102758v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=10842-10846&author=K.+V.+Butlerauthor=J.+Kalinauthor=C.+Brochierauthor=G.+Vistoliauthor=B.+Langleyauthor=A.+P.+Kozikowski&title=Rational+Design+and+Simple+Chemistry+Yield+a+Superior%2C+Neuroprotective+HDAC6+Inhibitor%2C+Tubastatin+A&doi=10.1021%2Fja102758v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A</span></div><div class="casAuthors">Butler, Kyle V.; Kalin, Jay; Brochier, Camille; Vistoli, Guilio; Langley, Brett; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">10842-10846</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-based drug design combined with homol. modeling techniques were used to develop potent inhibitors of HDAC6 that display superior selectivity for the HDAC6 isoenzyme compared to other inhibitors.  These inhibitors can be assembled in a few synthetic steps, and thus are readily scaled up for in vivo studies.  An optimized compd. from this series, designated Tubastatin A, was tested in primary cortical neuron cultures in which it was found to induce elevated levels of acetylated α-tubulin, but not histone, consistent with its HDAC6 selectivity.  Tubastatin A also conferred dose-dependent protection in primary cortical neuron cultures against glutathione depletion-induced oxidative stress.  Importantly, when given alone at all concns. tested, this hydroxamate-contg. HDAC6-selective compd. displayed no neuronal toxicity, thus, forecasting the potential application of this agent and its analogs to neurodegenerative conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGruEaJPWQfjH7Vg90H21EOLACvtfcHk0lgD26Kf8jnWpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXos1ers7k%253D&md5=f0cc68bb68f94ad1ef48f88cc6b57129</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Fja102758v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja102758v%26sid%3Dliteratum%253Aachs%26aulast%3DButler%26aufirst%3DK.%2BV.%26aulast%3DKalin%26aufirst%3DJ.%26aulast%3DBrochier%26aufirst%3DC.%26aulast%3DVistoli%26aufirst%3DG.%26aulast%3DLangley%26aufirst%3DB.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DRational%2520Design%2520and%2520Simple%2520Chemistry%2520Yield%2520a%2520Superior%252C%2520Neuroprotective%2520HDAC6%2520Inhibitor%252C%2520Tubastatin%2520A%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D10842%26epage%3D10846%26doi%3D10.1021%2Fja102758v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svoboda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavasin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motlova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinsey, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">706</span>– <span class="NLM_lpage">712</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00560</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00560" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFarsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=706-712&author=S.+Shenauthor=M.+Svobodaauthor=G.+Zhangauthor=M.+A.+Cavasinauthor=L.+Motlovaauthor=T.+A.+McKinseyauthor=J.+H.+Eubanksauthor=C.+Barinkaauthor=A.+P.+Kozikowski&title=Structural+and+in+Vivo+Characterization+of+Tubastatin+A%2C+a+Widely+Used+Histone+Deacetylase+6+Inhibitor&doi=10.1021%2Facsmedchemlett.9b00560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor</span></div><div class="casAuthors">Shen, Sida; Svoboda, Michal; Zhang, Guangming; Cavasin, Maria A.; Motlova, Lucia; McKinsey, Timothy A.; Eubanks, James H.; Barinka, Cyril; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">706-712</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tubastatin A, a tetrahydro-γ-carboline-capped selective HDAC6 inhibitor (HDAC6i), was rationally designed 10 years ago, and has become the best investigated HDAC6i to date.  It shows efficacy in various neurol. disease animal models, as HDAC6 plays a crucial regulatory role in axonal transport deficits, protein aggregation, as well as oxidative stress.  In this work, we provide new insights into this HDAC6i by investigating the mol. basis of its interactions with HDAC6 through X-ray crystallog., detg. its functional capability to elevate the levels of acetylated α-tubulin in vitro and in vivo, correlating PK/PD profiles to det. EDs in plasma and brain, and finally assessing its therapeutic potential toward psychiatric diseases through use of the SmartCube screening platform.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi67K0VhCsP7Vg90H21EOLACvtfcHk0lgD26Kf8jnWpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFarsr8%253D&md5=431ff199537a679fc09f19f95e528219</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00560%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DSvoboda%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DCavasin%26aufirst%3DM.%2BA.%26aulast%3DMotlova%26aufirst%3DL.%26aulast%3DMcKinsey%26aufirst%3DT.%2BA.%26aulast%3DEubanks%26aufirst%3DJ.%2BH.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DStructural%2520and%2520in%2520Vivo%2520Characterization%2520of%2520Tubastatin%2520A%252C%2520a%2520Widely%2520Used%2520Histone%2520Deacetylase%25206%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D706%26epage%3D712%26doi%3D10.1021%2Facsmedchemlett.9b00560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kenechukwu, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HDAC6 alleviating lipopolysaccharide-induced p38MAPK phosphorylation and neuroinflammation in mice</span>. <i>Pharm. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">263</span>– <span class="NLM_lpage">268</span>, <span class="refDoi"> DOI: 10.1080/13880209.2018.1563620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1080%2F13880209.2018.1563620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31124385" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ptlWntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2019&pages=263-268&author=Y.+Songauthor=L.+Qinauthor=R.+Yangauthor=F.+Yangauthor=N.+A.+Kenechukwuauthor=X.+Zhaoauthor=X.+Zhouauthor=X.+Wenauthor=L.+Li&title=Inhibition+of+HDAC6+alleviating+lipopolysaccharide-induced+p38MAPK+phosphorylation+and+neuroinflammation+in+mice&doi=10.1080%2F13880209.2018.1563620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HDAC6 alleviating lipopolysaccharide-induced p38MAPK phosphorylation and neuroinflammation in mice</span></div><div class="casAuthors">Song Yuanjian; Yang Fan; Kenechukwu Nwobodo Alexander; Zhao Xiaofang; Li Lei; Song Yuanjian; Yang Fan; Kenechukwu Nwobodo Alexander; Wen Xiangru; Li Lei; Song Yuanjian; Qin Li; Yang Rongli; Li Lei; Zhou Xiaoyan</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">263-268</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Context: Researchers in a variety of fields have extensively focused on histone deacetylase 6 (HDAC6) due to its aggravation of inflammatory reaction.  However, relevant studies examining whether HDAC6 could exacerbate lipopolysaccharide (LPS)-induced inflammation are still lacking.  Objective: We assessed the role of HDAC6 in LPS-induced brain inflammation and used the HDAC6-selective inhibitor Tubastatin A (TBSA) to investigate the potential mechanisms further.  Materials and methods: Brain inflammation was induced in Kunming (KM) mice via intraperitoneal (I.P.), injection of Lipopolysaccharide (LPS) (1 mg/kg), the TBSA (0.5 mg/kg) was delivered via intraperitoneal.  The phosphorylated p38 (p-p38) Mitogen-activated protein kinases (MAPK) and expression of typical inflammatory mediators, including tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in both the hippocampus and cortex, were examined by immunoblotting.  Nissl staining was used to detect the neuronal damage in the hippocampus and the cortex.  Results: About 1 mg/kg LPS via daily intraperitoneal (I.P.) injections for 12 days significantly increased p38 MAPK phosphorylation, TNF-α and IL-6 expression, and neuronal loss.  However, 0.5 mg/kg TBSA (three days before LPS treatment) by I.P. injections for 15 days could reverse the above results.  Conclusions: This present study provided evidence that TBSA significantly suppressed LPS-induced neuroinflammation and the expression of p-p38.  Results derived from our study might help reveal the effective targeting strategies of LPS-induced brain inflammation through inhibiting HDAC6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTuCv_wHdytl5HZzFRCXxVKfW6udTcc2eYhWffRZZKcXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ptlWntg%253D%253D&md5=ce35a28b2a3843f2ca7cc306cee0e2bd</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1080%2F13880209.2018.1563620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13880209.2018.1563620%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DKenechukwu%26aufirst%3DN.%2BA.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DL.%26atitle%3DInhibition%2520of%2520HDAC6%2520alleviating%2520lipopolysaccharide-induced%2520p38MAPK%2520phosphorylation%2520and%2520neuroinflammation%2520in%2520mice%26jtitle%3DPharm.%2520Biol.%26date%3D2019%26volume%3D57%26spage%3D263%26epage%3D268%26doi%3D10.1080%2F13880209.2018.1563620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Song, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving alpha-tubulin acetylation</span>. <i>J. Mol. Cell. Cardiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">58</span>– <span class="NLM_lpage">69</span>, <span class="refDoi"> DOI: 10.1016/j.yjmcc.2018.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.yjmcc.2018.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30315806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFejtbfL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2018&pages=58-69&author=R.+Songauthor=Y.+Yangauthor=H.+Leiauthor=G.+Wangauthor=Y.+Huangauthor=W.+Xueauthor=Y.+Wangauthor=L.+Yaoauthor=Y.+Zhu&title=HDAC6+inhibition+protects+cardiomyocytes+against+doxorubicin-induced+acute+damage+by+improving+alpha-tubulin+acetylation&doi=10.1016%2Fj.yjmcc.2018.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibition protects cardiomyocytes against doxorubicin-induced acute damage by improving a-tubulin acetylation</span></div><div class="casAuthors">Song, Rui; Yang, Yurong; Lei, Han; Wang, Guangxue; Huang, Yong; Xue, Wenlong; Wang, Yinfang; Yao, Lingling; Zhu, Yichun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular and Cellular Cardiology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58-69</span>CODEN:
                <span class="NLM_cas:coden">JMCDAY</span>;
        ISSN:<span class="NLM_cas:issn">0022-2828</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Doxorubicin (Dox) is an efficacious antineoplastic drug but is limited used for its cardiotoxicity.  Histone Deacetylase 6 (HDAC6) has been indicated to participate in cardiomyopathies, however, its role in Dox-induced cardiac injury is largely unknown.  In this study, we firstly aimed to det. the role of HDAC6 in Dox-induced cardiomyopathy.  Immunoblotting revealed that Dox increased HDAC6 protein level and activity and decreased a-tubulin acetylation level in vitro and vivo.  HDAC6 knockout (HDAC6-/-) mice showed obvious anti-Dox cardiotoxicity by conserved cardiac function monitored by echocardiog. and the protection was reversed by Nocodazole, one drug lowering a-tubulin acetylation.  Further mechanism investigation showed that improvement of mitochondria function and autophagy flux was partially inhibited by Nocodazole and Colchicine which lowers a-tubulin acetylation in neonatal rat cardiac myocytes.  Aiming at transforming this research to clin. application, we then explored the effect of combined utilization of HDAC6 inhibitor and Dox on tumor and cardiac function.  Results showed that Tubastatin A, one HDAC6 selective inhibitor, protected against Dox-induced acute cardiomyopathy without influencing the effect of Dox on inhibiting MDA-MB-231 s.c. tumor growth.  These findings suggest a new treatment for cancer with Dox by combined utilization with HDAC6 selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGok6lfEJPZCOLVg90H21EOLACvtfcHk0lihWkAsgdXp-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFejtbfL&md5=bdef80de06b2be55f47036d8183d144a</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1016%2Fj.yjmcc.2018.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yjmcc.2018.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DSong%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DLei%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DY.%26atitle%3DHDAC6%2520inhibition%2520protects%2520cardiomyocytes%2520against%2520doxorubicin-induced%2520acute%2520damage%2520by%2520improving%2520alpha-tubulin%2520acetylation%26jtitle%3DJ.%2520Mol.%2520Cell.%2520Cardiol.%26date%3D2018%26volume%3D124%26spage%3D58%26epage%3D69%26doi%3D10.1016%2Fj.yjmcc.2018.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhuang, S.</span></span> <span> </span><span class="NLM_article-title">Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury</span>. <i>Clin. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">339</span>– <span class="NLM_lpage">359</span>, <span class="refDoi"> DOI: 10.1042/CS20171417</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1042%2FCS20171417" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1GktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2018&pages=339-359&author=J.+Tangauthor=Y.+Shiauthor=N.+Liuauthor=L.+Xuauthor=X.+Zangauthor=P.+Liauthor=J.+Zhangauthor=X.+Zhengauthor=A.+Qiuauthor=S.+Zhuang&title=Blockade+of+histone+deacetylase+6+protects+against+cisplatin-induced+acute+kidney+injury&doi=10.1042%2FCS20171417"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury</span></div><div class="casAuthors">Tang, Jinhua; Shi, Yingfeng; Liu, Na; Xu, Liuqing; Zang, Xiujuan; Li, Peibin; Zhang, Juanlian; Zheng, Xiaoqing; Qiu, Andong; Zhuang, Shougang</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">339-359</span>CODEN:
                <span class="NLM_cas:coden">CSCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1470-8736</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) has been shown to be involved in various pathol. conditions, including cancer, neurodegenerative disorders and inflammatory diseases.  Nonetheless, its specific role in drug-induced nephrotoxicity is poorly understood.  Cisplatin (dichlorodiamino platinum) belongs to an inorg. platinum - fundamental chemotherapeutic drug utilized in the therapy of various solid malignant tumors.  However, the use of cisplatin is extremely limited by obvious side effects, for instance bone marrow suppression and nephrotoxicity.  In the present study, we utilized a murine model of cisplatin-induced acute kidney injury (AKI) and a highly selective inhibitor of HDAC6, tubastatin A (TA), to assess the role of HDAC6 in nephrotoxicity and its assocd. mechanisms.  Cisplatin-induced AKI was accompanied by increased expression and activation of HDAC6; blocking HDAC6 with TA lessened renal dysfunction, attenuated renal pathol. changes, reduced expression of neutrophil gelatinase-assocd. lipocalin and kidney injury mol. 1, and decreased tubular cell apoptosis.  In cultured human epithelial cells, TA or HDAC6 siRNA treatment also inhibited cisplatin-induced apoptosis.  Mechanistic studies demonstrated that cisplatin treatment induced phosphorylation of AKT and loss of E-cadherin in the nephrotoxic kidney, and administration of TA enhanced AKT phosphorylation and preserved E-cadherin expression.  HDAC6 inhibition also potentiated autophagy as evidenced by increased expression of autophagy-related gene (Atg) 7 (Atg7), Beclin-1, and decreased renal oxidative stress as demonstrated by up-regulation of superoxide dismutase (SOD) activity and down-regulation of malondialdehyde levels.  Moreover, TA was effective in inhibiting nuclear factor-κ B (NF-κB) phosphorylation and suppressing the expression of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6).  Collectively, these data provide strong evidence that HDAC6 inhibition is protective against cisplatin-induced AKI and suggest that HDAC6 may be a potential therapeutic target for AKI treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoz2-zTf1M8F7Vg90H21EOLACvtfcHk0lihWkAsgdXp-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1GktLo%253D&md5=f3e12eabc8eaa36cd4db0d6af15e615e</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1042%2FCS20171417&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FCS20171417%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DZang%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DQiu%26aufirst%3DA.%26aulast%3DZhuang%26aufirst%3DS.%26atitle%3DBlockade%2520of%2520histone%2520deacetylase%25206%2520protects%2520against%2520cisplatin-induced%2520acute%2520kidney%2520injury%26jtitle%3DClin.%2520Sci.%26date%3D2018%26volume%3D132%26spage%3D339%26epage%3D359%26doi%3D10.1042%2FCS20171417" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennahy, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatti, U. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span> <span> </span><span class="NLM_article-title">Protective Effect of Tubastatin A in CLP-Induced Lethal Sepsis</span>. <i>Inflammation</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">2101</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1007/s10753-018-0853-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs10753-018-0853-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30047002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVCgsb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2018&pages=2101-2109&author=Q.+Dengauthor=T.+Zhaoauthor=B.+Panauthor=I.+S.+Dennahyauthor=X.+Duanauthor=A.+M.+Williamsauthor=B.+Liuauthor=N.+Linauthor=U.+F.+Bhattiauthor=E.+Chenauthor=H.+B.+Alamauthor=Y.+Li&title=Protective+Effect+of+Tubastatin+A+in+CLP-Induced+Lethal+Sepsis&doi=10.1007%2Fs10753-018-0853-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Protective Effect of Tubastatin A in CLP-Induced Lethal Sepsis</span></div><div class="casAuthors">Deng, Qiufang; Zhao, Ting; Pan, Baihong; Dennahy, Isabel S.; Duan, Xiuzhen; Williams, Aaron M.; Liu, Baoling; Lin, Nan; Bhatti, Umar F.; Chen, Eric; Alam, Hasan B.; Li, Yongqing</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2101-2109</span>CODEN:
                <span class="NLM_cas:coden">INFLD4</span>;
        ISSN:<span class="NLM_cas:issn">0360-3997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">We have found earlier that Tubastatin A (TubA), a selective inhibitor of histone deacetylase 6 (HDAC6), improves survival in a mouse model of lethal cecal ligation and puncture (CLP)-induced sepsis.  However, the underlying mechanisms have not been fully established.  This study sought to test the hypothesis that TubA could affect both lung and splenic functions.  C57BL/6J mice were subjected to CLP, and randomized to receive either TubA (70 mg/kg) dissolved in DMSO (DMSO), or DMSO alone, 1 h following CLP.  Sham animals acted as control.  Twenty-four hours later, lung tissue was harvested for pathol. examn., and splenic tissue was harvested for bacterial colonization.  In a parallel study, the spleen was collected 48 h following CLP, and single cell suspension was prepd.  Splenocytes then underwent flow cytometry to analyze the immune cell population.  RAW264.7 macrophages were treated with lipopolysaccharide (LPS) with or without the presence of TubA (10 μM) at 37 °C for 3 h to assess the effect on macrophage phagocytosis.  We found that acute lung injury secondary to lethal sepsis was attenuated by TubA.  Treatment with TubA restored the percentage of B lymphocytes, and significantly increased percentages of innate immune cells and macrophages compared to the vehicle-treated CLP group.  Moreover, TubA significantly decreased the bacterial load in the spleen, and improved the phagocytic ability of RAW264.7 murine macrophages in vitro.  Such findings may help to explain the beneficial effects of TubA treatment in a model of lethal sepsis, as previously reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWLxMIukM0ybVg90H21EOLACvtfcHk0lihWkAsgdXp-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVCgsb7E&md5=6cd0ff46eedd061059b3f29901acb706</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1007%2Fs10753-018-0853-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10753-018-0853-0%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DT.%26aulast%3DPan%26aufirst%3DB.%26aulast%3DDennahy%26aufirst%3DI.%2BS.%26aulast%3DDuan%26aufirst%3DX.%26aulast%3DWilliams%26aufirst%3DA.%2BM.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DN.%26aulast%3DBhatti%26aufirst%3DU.%2BF.%26aulast%3DChen%26aufirst%3DE.%26aulast%3DAlam%26aufirst%3DH.%2BB.%26aulast%3DLi%26aufirst%3DY.%26atitle%3DProtective%2520Effect%2520of%2520Tubastatin%2520A%2520in%2520CLP-Induced%2520Lethal%2520Sepsis%26jtitle%3DInflammation%26date%3D2018%26volume%3D41%26spage%3D2101%26epage%3D2109%26doi%3D10.1007%2Fs10753-018-0853-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jian, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Inhibition of HDAC6 Attenuates NLRP3 Inflammatory Response and Protects Dopaminergic Neurons in Experimental Models of Parkinson’s Disease</span>. <i>Front. Aging Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">78</span>, <span class="refDoi"> DOI: 10.3389/fnagi.2020.00078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3389%2Ffnagi.2020.00078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32296327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXit1Ols77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=78&author=S.+Yanauthor=X.+Weiauthor=W.+Jianauthor=Y.+Qinauthor=J.+Liuauthor=S.+Zhuauthor=F.+Jiangauthor=H.+Louauthor=B.+Zhang&title=Pharmacological+Inhibition+of+HDAC6+Attenuates+NLRP3+Inflammatory+Response+and+Protects+Dopaminergic+Neurons+in+Experimental+Models+of+Parkinson%E2%80%99s+Disease&doi=10.3389%2Ffnagi.2020.00078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological inhibition of HDAC6 attenuates NLRP3 inflammatory response and protects dopaminergic neurons in experimental models of Parkinson's disease</span></div><div class="casAuthors">Yan, Shaoqi; Wei, Xinbing; Jian, Wencheng; Qin, Yue; Liu, Jia; Zhu, Shaowei; Jiang, Fan; Lou, Haiyan; Zhang, Bin</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Aging Neuroscience</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">78</span>CODEN:
                <span class="NLM_cas:coden">FANRC5</span>;
        ISSN:<span class="NLM_cas:issn">1663-4365</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Aim: To investigate the role of histone deacetylase 6 (HDAC6) deacetylation activity in nucleotide-binding oligomerization domain and leucine-rich repeat pyrin 3 domain (NLRP3) inflammatory response and explore the effects of pharmacol. inhibition of HDAC6 with tubastatin A (TBA) on dopaminergic injury.  Methods: Using 6-OHDA-induced Parkinson's disease (PD) models, we examd. the effects of TBA on NLRP3 activation and cell injury in SH-SY5Y cells.  We also investigated the effects of TBA on NLRP3 inflammatory responses and dopaminergic injury in the nigrostriatal system in mice and analyzed the acetylation levels of peroxiredoxin2 (Prx2) and oxidative stress.  Results: TBA inhibited 6-OHDA-induced NLRP3 activation, as demonstrated by decreased expressions of NLRP3 and matured caspase-1 and IL-1β, and also alleviated glial proliferation and dopaminergic neuronal degeneration.  Notably, TBA recovered acetylation levels of Prx2 and reduced oxidative stress.  Conclusion: Our findings indicate that pharmacol. inhibition of HDAC6 with TBA attenuates NLRP3 inflammation and protects dopaminergic neurons, probably through Prx2 acetylation.  This study suggests that the deacetylase catalytic domain of HDAC6 is a potential target for PD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3pE2ZWtQtYrVg90H21EOLACvtfcHk0liawESBhF8puA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXit1Ols77F&md5=4622e8a74eb253f193e5d82b02491ed4</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.3389%2Ffnagi.2020.00078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnagi.2020.00078%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DX.%26aulast%3DJian%26aufirst%3DW.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DF.%26aulast%3DLou%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DB.%26atitle%3DPharmacological%2520Inhibition%2520of%2520HDAC6%2520Attenuates%2520NLRP3%2520Inflammatory%2520Response%2520and%2520Protects%2520Dopaminergic%2520Neurons%2520in%2520Experimental%2520Models%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DFront.%2520Aging%2520Neurosci.%26date%3D2020%26volume%3D12%26spage%3D78%26doi%3D10.3389%2Ffnagi.2020.00078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abouhish, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thounaojam, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jadeja, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutsaeva, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khriza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartoli, M.</span></span> <span> </span><span class="NLM_article-title">Inhibition of HDAC6 Attenuates Diabetes-Induced Retinal Redox Imbalance and Microangiopathy</span>. <i>Antioxidants</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">599</span>, <span class="refDoi"> DOI: 10.3390/antiox9070599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3390%2Fantiox9070599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Ciu73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2020&pages=599&author=H.+Abouhishauthor=M.+C.+Thounaojamauthor=R.+N.+Jadejaauthor=D.+R.+Gutsaevaauthor=F.+L.+Powellauthor=M.+Khrizaauthor=P.+M.+Martinauthor=M.+Bartoli&title=Inhibition+of+HDAC6+Attenuates+Diabetes-Induced+Retinal+Redox+Imbalance+and+Microangiopathy&doi=10.3390%2Fantiox9070599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of HDAC6 attenuates diabetes-induced retinal redox imbalance and microangiopathy</span></div><div class="casAuthors">Abouhish, Hossameldin; Thounaojam, Menaka C.; Jadeja, Ravirajsinh N.; Gutsaeva, Diana R.; Powell, Folami L.; Khriza, Mohamed; Martin, Pamela M.; Bartoli, Manuela</div><div class="citationInfo"><span class="NLM_cas:title">Antioxidants</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">599</span>CODEN:
                <span class="NLM_cas:coden">ANTIGE</span>;
        ISSN:<span class="NLM_cas:issn">2076-3921</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">We investigated the contributing role of the histone deacetylase 6 (HDAC6) to the early stages of diabetic retinopathy (DR).  Furthermore, we examd. the mechanism of action of HDAC6 in human retinal endothelial cells (HuREC) exposed to glucidic stress.  Streptozotocin-induced diabetic rats (STZ-rats), a rat model of type 1 diabetes, were used as model of DR.  HDAC6 expression and activity were increased in human diabetic postmortem donors and STZ-rat retinas and were augmented in HuREC exposed to glucidic stress (25 mM glucose).  Administration of the HDAC6 specific inhibitor Tubastatin A (TS) (10 mg/kg) prevented retinal microvascular hyperpermeability and up-regulation of inflammatory markers.  Furthermore, in STZ-rats, TS decreased the levels of senescence markers and rescued the expression and activity of the histone deacetylase sirtuin 1 (SIRT1), while downregulating the levels of free radicals and of the redox stress markers 4-hydroxynonenal (4-HNE) and nitrotyrosine (NT).  The antioxidant effects of TS, consequent to HDAC6 inhibition, were assocd. with preservation of Nrf2-dependent gene expression and up-regulation of thioredoxin-1 activity.  In summary, our data implicate HDAC6 activation in mediating hyperglycemia-induced retinal oxidative/nitrative stress leading to retinal microangiopathy and, potentially, DR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrB9dSjvoMARLVg90H21EOLACvtfcHk0liawESBhF8puA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Ciu73P&md5=471f95e0abc1eba63a5316b49117caf6</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.3390%2Fantiox9070599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fantiox9070599%26sid%3Dliteratum%253Aachs%26aulast%3DAbouhish%26aufirst%3DH.%26aulast%3DThounaojam%26aufirst%3DM.%2BC.%26aulast%3DJadeja%26aufirst%3DR.%2BN.%26aulast%3DGutsaeva%26aufirst%3DD.%2BR.%26aulast%3DPowell%26aufirst%3DF.%2BL.%26aulast%3DKhriza%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DP.%2BM.%26aulast%3DBartoli%26aufirst%3DM.%26atitle%3DInhibition%2520of%2520HDAC6%2520Attenuates%2520Diabetes-Induced%2520Retinal%2520Redox%2520Imbalance%2520and%2520Microangiopathy%26jtitle%3DAntioxidants%26date%3D2020%26volume%3D9%26spage%3D599%26doi%3D10.3390%2Fantiox9070599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byeon, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, Q. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandey, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkowitz, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. Y.</span></span> <span> </span><span class="NLM_article-title">Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine gamma-lyase protein degradation</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">104281</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2019.104281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.phrs.2019.104281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31125601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKisr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2019&pages=104281&author=Z.+Chiauthor=H.+E.+Byeonauthor=E.+Seoauthor=Q.+T.+Nguyenauthor=W.+Leeauthor=Y.+Jeongauthor=J.+Choiauthor=D.+Pandeyauthor=D.+E.+Berkowitzauthor=J.+H.+Kimauthor=S.+Y.+Lee&title=Histone+deacetylase+6+inhibitor+tubastatin+A+attenuates+angiotensin+II-induced+hypertension+by+preventing+cystathionine+gamma-lyase+protein+degradation&doi=10.1016%2Fj.phrs.2019.104281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation</span></div><div class="casAuthors">Chi, Zhexi; Byeon, Hye-Eun; Seo, Eunjeong; Nguyen, Quynh-Anh T.; Lee, Wonbeom; Jeong, Yunyong; Choi, Juyong; Pandey, Deepesh; Berkowitz, Dan E.; Kim, Jae Hyung; Lee, Sang Yoon</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">104281</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Cystathionine γ-lyase (CSEγ) is a hydrogen sulfide (H2S)-producing enzyme.  Endothelial H2S prodn. can mediate vasodilatory effects, contributing to the alleviation of hypertension (high blood pressure).  Recent studies have suggested a role of histone deacetylase 6 (HDAC6) in hypertension, although its underlying mechanisms are poorly understood.  Here, we addressed the potential regulation of CSEγ by HDAC6 in angiotensin II (AngII)-induced hypertension and its mol. details focusing on CSEγ posttranslational modification.  Treatment of mice with a selective HDAC6 inhibitor tubastatin A (TubA) alleviated high blood pressure and vasoconstriction induced by AngII.  Cotreatment of the aorta and human aortic endothelial cells with TubA recovered AngII-mediated decreased H2S levels.  AngII treatment upregulated HDAC6 mRNA and protein expression, but conversely downregulated CSEγ protein.  Notably, potent HDAC6 inhibitors and HDAC6 siRNA as well as a proteasomal inhibitor increased CSEγ protein levels and blocked the downregulatory effect of AngII on CSEγ.  In contrast, other HDAC isoforms-specific inhibitors and siRNAs did not show such blocking effects.  Transfected CSEγ protein levels were also reciprocally regulated by AngII and TubA, and were reduced by wild-type, but not by deacetylase-deficient, HDAC6.  Moreover, TubA significantly increased both protein stability and K73 acetylation level of CSEγ.  Consistent with these results, AngII induced CSEγ ubiquitination and degrdn., which was inhibited by TubA.  Our results indicate that AngII promoted HDAC6-dependent deacetylation of CSEγ at K73 residue, leading to its ubiquitin-mediated proteolysis, which underlies AngII-induced hypertension.  Overall, this study suggests that upregulation of CSEγ and H2S through HDAC6 inhibition may be considered as a valid strategy for preventing the progression of hypertension.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohIA6gZf-iXbVg90H21EOLACvtfcHk0liawESBhF8puA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKisr7P&md5=6945509e82de1423f901b2f36348526e</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2019.104281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2019.104281%26sid%3Dliteratum%253Aachs%26aulast%3DChi%26aufirst%3DZ.%26aulast%3DByeon%26aufirst%3DH.%2BE.%26aulast%3DSeo%26aufirst%3DE.%26aulast%3DNguyen%26aufirst%3DQ.%2BT.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DPandey%26aufirst%3DD.%26aulast%3DBerkowitz%26aufirst%3DD.%2BE.%26aulast%3DKim%26aufirst%3DJ.%2BH.%26aulast%3DLee%26aufirst%3DS.%2BY.%26atitle%3DHistone%2520deacetylase%25206%2520inhibitor%2520tubastatin%2520A%2520attenuates%2520angiotensin%2520II-induced%2520hypertension%2520by%2520preventing%2520cystathionine%2520gamma-lyase%2520protein%2520degradation%26jtitle%3DPharmacol.%2520Res.%26date%3D2019%26volume%3D146%26spage%3D104281%26doi%3D10.1016%2Fj.phrs.2019.104281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hour, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. W.</span></span> <span> </span><span class="NLM_article-title">Tubacin, an HDAC6 Selective Inhibitor, Reduces the Replication of the Japanese Encephalitis Virus via the Decrease of Viral RNA Synthesis</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">954</span>, <span class="refDoi"> DOI: 10.3390/ijms18050954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3390%2Fijms18050954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFGjsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=954&author=C.+Y.+Luauthor=Y.+C.+Changauthor=C.+H.+Huaauthor=C.+Chuangauthor=S.+H.+Huangauthor=S.+H.+Kungauthor=M.+J.+Hourauthor=C.+W.+Lin&title=Tubacin%2C+an+HDAC6+Selective+Inhibitor%2C+Reduces+the+Replication+of+the+Japanese+Encephalitis+Virus+via+the+Decrease+of+Viral+RNA+Synthesis&doi=10.3390%2Fijms18050954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Tubacin, an HDAC6 selective inhibitor, reduces the replication of the Japanese encephalitis virus via the decrease of viral RNA synthesis</span></div><div class="casAuthors">Lu, Chien-Yi; Chang, Yi-Chih; Hua, Chun-Hung; Chuang, Chieh; Huang, Su-Hua; Kung, Szu-Hao; Hour, Mann-Jen; Lin, Cheng-Wen</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">954/1-954/14</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Japanese encephalitis virus (JEV), a neurotropic flavivirus, annually causes over 30,000 Japanese Encephalitis (JE) cases in East and Southeast Asia.  Histone deacetylases (HDACs) modulate lysine acetylation of histones and non-histone proteins, regulating many processes including inflammation and antiviral immune response.  This study investigated antiviral activity of pan- and selective-HDAC inhibitors as host-targeting agents against JEV.  Among HDAC inhibitors, selective HDAC6 inhibitors (tubastatin-A (TBSA) and tubacin) concn.-dependently inhibited JEV-induced cytopathic effect and apoptosis, as well as reduced virus yield in human cerebellar medulloblastoma cells.  The 50% inhibitory concn. (IC50) values of virus yield was 0.26 μM for tubacin and 1.75 M for TBSA, resp.  Tubacin (IC50 of 1.52 μM), but not TBSA, meaningfully blocked the prodn. of intracellular infectious virus particles.  In time-of-addn. assays, the greatest potency of antiviral activity was obsd. in the mode of pre-treatment with tubacin (IC50 of 1.89 μM) compared to simultaneous (IC50 of 4.88 μM) and post-treatment (IC50 of 2.05 μM) modes.  Interestingly, tubacin induced the hyperacetylation of a HDAC6 substrate Hsp90 and reduced the interaction of Hsp90 with JEV NS5 protein.  Novobiocin, an Hsp90 inhibitor, diminished the NS5 protein amt. and virus replication in JEV-infected cells.  Meantime, tubacin suppressed the NS5 expression and antisense RNA genome synthesis in infected cells.  Tubacin-induced Hsp90 hyperacetylation was suggested to influence the NS5 activity in JEV replication.  Therefore, tubacin had a high potential of a host-targeting agent against JEV, exhibiting preventive and therapeutic activities against JEV infection.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxhk2RVCeLqrVg90H21EOLACvtfcHk0liDxE2Nl1yt0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFGjsrbP&md5=d3a7e0f226b6f8e157780664d0f8aecb</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.3390%2Fijms18050954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18050954%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DC.%2BY.%26aulast%3DChang%26aufirst%3DY.%2BC.%26aulast%3DHua%26aufirst%3DC.%2BH.%26aulast%3DChuang%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DS.%2BH.%26aulast%3DKung%26aufirst%3DS.%2BH.%26aulast%3DHour%26aufirst%3DM.%2BJ.%26aulast%3DLin%26aufirst%3DC.%2BW.%26atitle%3DTubacin%252C%2520an%2520HDAC6%2520Selective%2520Inhibitor%252C%2520Reduces%2520the%2520Replication%2520of%2520the%2520Japanese%2520Encephalitis%2520Virus%2520via%2520the%2520Decrease%2520of%2520Viral%2520RNA%2520Synthesis%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D954%26doi%3D10.3390%2Fijms18050954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span> <span> </span><span class="NLM_article-title">Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>119</i></span>,  <span class="NLM_fpage">6623</span>– <span class="NLM_lpage">6632</span>, <span class="refDoi"> DOI: 10.1002/jcb.26841</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fjcb.26841" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29665050" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnslSgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2018&pages=6623-6632&author=H.+Taoauthor=Y.+Y.+Chenauthor=Z.+W.+Sunauthor=H.+L.+Chenauthor=M.+Chen&title=Silence+of+HDAC6+suppressed+esophageal+squamous+cell+carcinoma+proliferation+and+migration+by+disrupting+chaperone+function+of+HSP90&doi=10.1002%2Fjcb.26841"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Silence of HDAC6 suppressed esophageal squamous cell carcinoma proliferation and migration by disrupting chaperone function of HSP90</span></div><div class="casAuthors">Tao, Hua; Chen, Yuan-Yuan; Sun, Zong-Wen; Chen, Hua-Lin; Chen, Ming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">6623-6632</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Esophageal carcinoma is aggressive in nature and its prognosis is largely dependent on the degree of invasion.  Histone deacetylase 6 (HDAC6), as the most unique member of HDACs family, has the pos. activity to promote initiation and progression of various cancers via targeting multiple non-histone proteins in cytoplasm.  In this study, we found that HDAC6 was over-expressed in three esophageal cancer cell lines (KYSE140, KYSE170, KYSE180) when compared to non-carcinoma esophageal epithelial cell HEEC-1.  Then two HDAC6 specific siRNAs and HDAC6 inhibitor tubastatin A greatly suppressed KYSE140 and KYSE180 cells proliferation and migration, and the inhibition of cell motility was accompanied by elevated acetylation of α-tubulin, a target of HDAC6.  Consistently, the microtubulin skeleton was stabilized after HDAC6 knockdown or inhibition.  In addn., acetylation status of HSP90, another HDAC6 target, was also increased towards HDAC6 knockdown or inhibition by co-immunopptn. assay.  Besides, co-treatment of HSP90 inhibitor (PU-H71) and HDAC6 inhibitor (tubastatin A) induced a stronger cell migration inhibition compared to administration of either drug alone.  Furthermore, cell proliferation of KYSE140 and KYSE180 were also compromised in response to combination of HDAC6 and HSP90 inhibitors.  Addnl., co-administration of HSP90 inhibitor and HDAC6 inhibitor strongly inhibited tumor growth in vivo.  Taken together, our results indicated that HDAC6 is a promising target by inhibiting HSP90 function in ESCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_6U1lcLK5w7Vg90H21EOLACvtfcHk0liDxE2Nl1yt0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnslSgtLo%253D&md5=d0e49518dd2059cc349ca0912a82f9c0</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1002%2Fjcb.26841&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.26841%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%2BY.%26aulast%3DSun%26aufirst%3DZ.%2BW.%26aulast%3DChen%26aufirst%3DH.%2BL.%26aulast%3DChen%26aufirst%3DM.%26atitle%3DSilence%2520of%2520HDAC6%2520suppressed%2520esophageal%2520squamous%2520cell%2520carcinoma%2520proliferation%2520and%2520migration%2520by%2520disrupting%2520chaperone%2520function%2520of%2520HSP90%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2018%26volume%3D119%26spage%3D6623%26epage%3D6632%26doi%3D10.1002%2Fjcb.26841" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urdiciain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erausquin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melendez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rey, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Idoate, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castresana, J. S.</span></span> <span> </span><span class="NLM_article-title">Tubastatin A, an inhibitor of HDAC6, enhances temozolomideinduced apoptosis and reverses the malignant phenotype of glioblastoma cells</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">1797</span>– <span class="NLM_lpage">1808</span>, <span class="refDoi"> DOI: 10.3892/ijo.2019.4739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3892%2Fijo.2019.4739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30864703" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlCgtbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2019&pages=1797-1808&author=A.+Urdiciainauthor=E.+Erausquinauthor=B.+Melendezauthor=J.+A.+Reyauthor=M.+A.+Idoateauthor=J.+S.+Castresana&title=Tubastatin+A%2C+an+inhibitor+of+HDAC6%2C+enhances+temozolomideinduced+apoptosis+and+reverses+the+malignant+phenotype+of+glioblastoma+cells&doi=10.3892%2Fijo.2019.4739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Tubastatin A, an inhibitor of HDAC6, enhances temozolomide-induced apoptosis and reverses the malignant phenotype of glioblastoma cells</span></div><div class="casAuthors">Urdiciain, Alejandro; Erausquin, Elena; Melendez, Barbara; Rey, Juan A.; Idoate, Miguel A.; Castresana, Javier S.</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1797-1808</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1791-2423</span>.
    
            (<span class="NLM_cas:orgname">Spandidos Publications Ltd.</span>)
        </div><div class="casAbstract">Glioblastoma or grade IV astrocytoma is the most common and lethal form of glioma.  Current glioblastoma treatment strategies use surgery followed by chemotherapy with temozolomide.  Despite this, numerous glioblastoma cases develop resistance to temozolomide treatments, resulting in a poor prognosis for the patients.  Novel approaches are being investigated, including the inhibition of histone deacetylase 6 (HDAC6), an enzyme that deacetylates α-tubulin, and whose overexpression in glioblastoma is assocd. with the loss of primary cilia.  The aim of the present study was to treat glioblastoma cells with a selective HDAC6 inhibitor, tubastatin A, to det. if the malignant phenotype may be reverted.  The results demonstrated a notable increase in acetylated α-tubulin levels in treated cells, which assocd. with downregulation of the sonic hedgehog pathway, and may hypothetically promote ciliogenesis in those cells.  Treatment with tubastatin A also reduced glioblastoma clonogenicity and migration capacities, and accelerated temozolomide-induced apoptosis.  Finally, HDAC6 inhibition decreased the expression of mesenchymal markers, contributing to reverse epithelial-mesenchymal transition in glioblastoma cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo35bGhqcuVxrVg90H21EOLACvtfcHk0liDxE2Nl1yt0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlCgtbvP&md5=d115db089f2048f2e360f99c738eec01</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.3892%2Fijo.2019.4739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.2019.4739%26sid%3Dliteratum%253Aachs%26aulast%3DUrdiciain%26aufirst%3DA.%26aulast%3DErausquin%26aufirst%3DE.%26aulast%3DMelendez%26aufirst%3DB.%26aulast%3DRey%26aufirst%3DJ.%2BA.%26aulast%3DIdoate%26aufirst%3DM.%2BA.%26aulast%3DCastresana%26aufirst%3DJ.%2BS.%26atitle%3DTubastatin%2520A%252C%2520an%2520inhibitor%2520of%2520HDAC6%252C%2520enhances%2520temozolomideinduced%2520apoptosis%2520and%2520reverses%2520the%2520malignant%2520phenotype%2520of%2520glioblastoma%2520cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2019%26volume%3D54%26spage%3D1797%26epage%3D1808%26doi%3D10.3892%2Fijo.2019.4739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geraldy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sehr, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steimbach, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ridinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nogueira, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunkel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. K.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">4426</span>– <span class="NLM_lpage">4443</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01936</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01936" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmvFSjsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=4426-4443&author=M.+Geraldyauthor=M.+Morgenauthor=P.+Sehrauthor=R.+R.+Steimbachauthor=D.+Moiauthor=J.+Ridingerauthor=I.+Oehmeauthor=O.+Wittauthor=M.+Malzauthor=M.+S.+Nogueiraauthor=O.+Kochauthor=N.+Gunkelauthor=A.+K.+Miller&title=Selective+Inhibition+of+Histone+Deacetylase+10%3A+Hydrogen+Bonding+to+the+Gatekeeper+Residue+is+Implicated&doi=10.1021%2Facs.jmedchem.8b01936"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated</span></div><div class="casAuthors">Geraldy, Magalie; Morgen, Michael; Sehr, Peter; Steimbach, Raphael R.; Moi, Davide; Ridinger, Johannes; Oehme, Ina; Witt, Olaf; Malz, Mona; Nogueira, Mauro S.; Koch, Oliver; Gunkel, Nikolas; Miller, Aubry K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4426-4443</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The discovery of isoenzyme-selective histone deacetylase (HDAC) inhibitors is crit. for understanding the biol. functions of individual HDACs and for validating HDACs as drug targets.  The isoenzyme HDAC10 contributes to chemotherapy resistance and has recently been described to be a polyamine deacetylase, but no studies toward selective HDAC10 inhibitors have been published.  Using two complementary assays, the authors found tubastatin A, an HDAC6 inhibitor, to potently bind HDAC10.  The authors synthesized tubastatin A derivs. and found that a basic amine in the cap group was required for strong HDAC10 binding.  HDAC10 inhibitors mimicked knockdown by causing dose-dependent accumulation of acidic vesicles in a neuroblastoma cell line.  Furthermore, docking into human HDAC10 homol. models indicated that a hydrogen-bond between a cap group nitrogen and the gatekeeper residue Glu272 was responsible for potent HDAC10 binding.  Taken together, the authors' data provide an optimal platform for the development of HDAC10-selective inhibitors, as exemplified with the tubastatin A scaffold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpl1kc8D1boarVg90H21EOLACvtfcHk0lg97SOKIFEaiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmvFSjsb8%253D&md5=9c8fbb8ac46ca0db29df3848cb5e9b50</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01936&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01936%26sid%3Dliteratum%253Aachs%26aulast%3DGeraldy%26aufirst%3DM.%26aulast%3DMorgen%26aufirst%3DM.%26aulast%3DSehr%26aufirst%3DP.%26aulast%3DSteimbach%26aufirst%3DR.%2BR.%26aulast%3DMoi%26aufirst%3DD.%26aulast%3DRidinger%26aufirst%3DJ.%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DMalz%26aufirst%3DM.%26aulast%3DNogueira%26aufirst%3DM.%2BS.%26aulast%3DKoch%26aufirst%3DO.%26aulast%3DGunkel%26aufirst%3DN.%26aulast%3DMiller%26aufirst%3DA.%2BK.%26atitle%3DSelective%2520Inhibition%2520of%2520Histone%2520Deacetylase%252010%253A%2520Hydrogen%2520Bonding%2520to%2520the%2520Gatekeeper%2520Residue%2520is%2520Implicated%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D4426%26epage%3D4443%26doi%3D10.1021%2Facs.jmedchem.8b01936" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stangl, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grunstein, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pongratz, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striegl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenei-Lanzl, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dove, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Straub, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span> <span> </span><span class="NLM_article-title">Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3454</span>– <span class="NLM_lpage">3477</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01593</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01593" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtFCnsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3454-3477&author=A.+Sellmerauthor=H.+Stanglauthor=M.+Beyerauthor=E.+Grunsteinauthor=M.+Leonhardtauthor=H.+Pongratzauthor=E.+Eichhornauthor=S.+Elzauthor=B.+Strieglauthor=Z.+Jenei-Lanzlauthor=S.+Doveauthor=R.+H.+Straubauthor=O.+H.+Kramerauthor=S.+Mahboobi&title=Marbostat-100+Defines+a+New+Class+of+Potent+and+Selective+Antiinflammatory+and+Antirheumatic+Histone+Deacetylase+6+Inhibitors&doi=10.1021%2Facs.jmedchem.7b01593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors</span></div><div class="casAuthors">Sellmer, Andreas; Stangl, Hubert; Beyer, Mandy; Gruenstein, Elisabeth; Leonhardt, Michel; Pongratz, Herwig; Eichhorn, Emerich; Elz, Sigurd; Striegl, Birgit; Jenei-Lanzl, Zsuzsa; Dove, Stefan; Straub, Rainer H.; Kraemer, Oliver H.; Mahboobi, Siavosh</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3454-3477</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epigenetic modifiers of the histone deacetylase (HDAC) family contribute to autoimmunity, cancer, HIV infection, inflammation, and neurodegeneration.  Hence, histone deacetylase inhibitors (HDACi), which alter protein acetylation, gene expression patterns, and cell fate decisions, represent promising new drugs for the therapy of these diseases.  Whereas pan-HDACi inhibit all 11 Zn2+-dependent histone deacetylases (HDACs) and cause a broad spectrum of side effects, specific inhibitors of histone deacetylase 6 (HDAC6i) are supposed to have less side effects.  The authors present the synthesis and biol. evaluation of Marbostats, novel HDAC6i that contain the hydroxamic acid moiety linked to tetrahydro-β-carboline derivs.  The lead compd. Marbostat-100 is a more potent and more selective HDAC6i than previously established well-characterized compds. in vitro as well as in cells.  Moreover, Marbostat-100 is well tolerated by mice and effective against collagen type II induced arthritis.  Thus, Marbostat-100 represents a most selective known HDAC6i and the possibility for clin. evaluation of a HDAC isoform-specific drug.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqqixUQJJP-7bVg90H21EOLACvtfcHk0lg97SOKIFEaiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtFCnsbg%253D&md5=0f6c62f03f50501728d43fef66d0d64b</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01593%26sid%3Dliteratum%253Aachs%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DStangl%26aufirst%3DH.%26aulast%3DBeyer%26aufirst%3DM.%26aulast%3DGrunstein%26aufirst%3DE.%26aulast%3DLeonhardt%26aufirst%3DM.%26aulast%3DPongratz%26aufirst%3DH.%26aulast%3DEichhorn%26aufirst%3DE.%26aulast%3DElz%26aufirst%3DS.%26aulast%3DStriegl%26aufirst%3DB.%26aulast%3DJenei-Lanzl%26aufirst%3DZ.%26aulast%3DDove%26aufirst%3DS.%26aulast%3DStraub%26aufirst%3DR.%2BH.%26aulast%3DKramer%26aufirst%3DO.%2BH.%26aulast%3DMahboobi%26aufirst%3DS.%26atitle%3DMarbostat-100%2520Defines%2520a%2520New%2520Class%2520of%2520Potent%2520and%2520Selective%2520Antiinflammatory%2520and%2520Antirheumatic%2520Histone%2520Deacetylase%25206%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3454%26epage%3D3477%26doi%3D10.1021%2Facs.jmedchem.7b01593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leonhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellmer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramer, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dove, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahboobi, S.</span></span> <span> </span><span class="NLM_article-title">Design and biological evaluation of tetrahydro-beta-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>152</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.04.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2018.04.046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29738953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpt1agtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=152&publication_year=2018&pages=329-357&author=M.+Leonhardtauthor=A.+Sellmerauthor=O.+H.+Kramerauthor=S.+Doveauthor=S.+Elzauthor=B.+Krausauthor=M.+Beyerauthor=S.+Mahboobi&title=Design+and+biological+evaluation+of+tetrahydro-beta-carboline+derivatives+as+highly+potent+histone+deacetylase+6+%28HDAC6%29+inhibitors&doi=10.1016%2Fj.ejmech.2018.04.046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Design and biological evaluation of tetrahydro-β-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors</span></div><div class="casAuthors">Leonhardt, Michel; Sellmer, Andreas; Kraemer, Oliver H.; Dove, Stefan; Elz, Sigurd; Kraus, Birgit; Beyer, Mandy; Mahboobi, Siavosh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">152</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">329-357</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Various diseases are related to epigenetic modifications.  Histone deacetylases (HDACs) and histone acetyltransferases (HATs) det. the pattern of histone acetylation, and thus are involved in the regulation of gene expression.  First generation histone deacetylase inhibitors (HDACi) are unselective, hinder all different kinds of zinc dependent HDACs and addnl. cause several side effects.  Subsequently, selective HDACi are gaining more and more interest.  Esp., selective histone deacetylase 6 inhibitors (HDAC6i) are supposed to be less toxic.  Here the authors present a successful optimization study of tubastatin A, the synthesis and biol. evaluation of new inhibitors based on hydroxamic acids linked to various tetrahydro-β-carboline derivs.  The potency of the authors' selective HDAC6 inhibitors, exhibiting IC50 values in a range of 1-10 nM towards HDAC6, was evaluated with the help of a recombinant human HDAC6 enzyme assay.  Selectivity was proofed in cellular assays by the hyperacetylation of surrogate parameter α-tubulin in the absence of acetylated histone H3 analyzed by Western Blot.  The authors show that all synthesized compds., with varies modifications of the rigid cap group, were selective and potent HDAC6 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO3jAwqO8N0LVg90H21EOLACvtfcHk0lgD5gWg5xnl_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpt1agtbY%253D&md5=668b7ae179e680a0ae7116589e315cb5</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.04.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.04.046%26sid%3Dliteratum%253Aachs%26aulast%3DLeonhardt%26aufirst%3DM.%26aulast%3DSellmer%26aufirst%3DA.%26aulast%3DKramer%26aufirst%3DO.%2BH.%26aulast%3DDove%26aufirst%3DS.%26aulast%3DElz%26aufirst%3DS.%26aulast%3DKraus%26aufirst%3DB.%26aulast%3DBeyer%26aufirst%3DM.%26aulast%3DMahboobi%26aufirst%3DS.%26atitle%3DDesign%2520and%2520biological%2520evaluation%2520of%2520tetrahydro-beta-carboline%2520derivatives%2520as%2520highly%2520potent%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529%2520inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D152%26spage%3D329%26epage%3D357%26doi%3D10.1016%2Fj.ejmech.2018.04.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krieger, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groll, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ressing, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahlert, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borkhardt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span> <span> </span><span class="NLM_article-title">Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">10299</span>– <span class="NLM_lpage">10309</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVWrur7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10299-10309&author=S.+Bhatiaauthor=V.+Kriegerauthor=M.+Grollauthor=J.+D.+Oskoauthor=N.+Ressingauthor=H.+Ahlertauthor=A.+Borkhardtauthor=T.+Kurzauthor=D.+W.+Christiansonauthor=J.+Hauerauthor=F.+K.+Hansen&title=Discovery+of+the+First-in-Class+Dual+Histone+Deacetylase-Proteasome+Inhibitor&doi=10.1021%2Facs.jmedchem.8b01487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of the First-in-Class Dual Histone Deacetylase-Proteasome Inhibitor</span></div><div class="casAuthors">Bhatia, Sanil; Krieger, Viktoria; Groll, Michael; Osko, Jeremy D.; Ressing, Nina; Ahlert, Heinz; Borkhardt, Arndt; Kurz, Thomas; Christianson, David W.; Hauer, Julia; Hansen, Finn K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10299-10309</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual- or multitarget drugs have emerged as a promising alternative to combination therapies.  Proteasome inhibitors (PIs) possess synergistic activity with histone deacetylase (HDAC) inhibitors due to the simultaneous blockage of the ubiquitin degrdn. and aggresome pathways.  Here, the authors present the design, synthesis, binding modes, and anticancer properties of RTS-V5 as the first-in-class dual HDAC-proteasome ligand.  The inhibition of both targets was confirmed by biochem. and cellular assays as well as x-ray crystal structures of the 20S proteasome and HDAC6 complexed with RTS-V5.  Cytotoxicity assays with leukemia and multiple myeloma cell lines as well as therapy refractory primary patient-derived leukemia cells demonstrated that RTS-V5 possesses potent and selective anticancer activity.  The results will thus guide the structure-based optimization of dual HDAC-proteasome inhibitors for the treatment of hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwJMqcDlzXA7Vg90H21EOLACvtfcHk0lgD5gWg5xnl_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVWrur7K&md5=7d47e664bd77ac1bc5ebd39ea6eed02a</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01487%26sid%3Dliteratum%253Aachs%26aulast%3DBhatia%26aufirst%3DS.%26aulast%3DKrieger%26aufirst%3DV.%26aulast%3DGroll%26aufirst%3DM.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DRessing%26aufirst%3DN.%26aulast%3DAhlert%26aufirst%3DH.%26aulast%3DBorkhardt%26aufirst%3DA.%26aulast%3DKurz%26aufirst%3DT.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DHauer%26aufirst%3DJ.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26atitle%3DDiscovery%2520of%2520the%2520First-in-Class%2520Dual%2520Histone%2520Deacetylase-Proteasome%2520Inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D10299%26epage%3D10309%26doi%3D10.1021%2Facs.jmedchem.8b01487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reßing, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonnichsen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schliehe-Diecks, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skerhut, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borkhardt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D.. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhatia, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span> <span> </span><span class="NLM_article-title">Multicomponent synthesis, binding mode and structure-activity relationships of selective histone deacetylase 6 (HDAC6) inhibitors with bifurcated capping groups</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">10339</span>– <span class="NLM_lpage">10351</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01888</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01888" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Srsr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=10339-10351&author=N.+Re%C3%9Fingauthor=M.+Sonnichsenauthor=J.+D.+Oskoauthor=A.+Scholerauthor=J.+Schliehe-Diecksauthor=A.+Skerhutauthor=A.+Borkhardtauthor=J.+Hauerauthor=M.+U.+Kassackauthor=D..+W.+Christiansonauthor=S.+Bhatiaauthor=F.+K.+Hansen&title=Multicomponent+synthesis%2C+binding+mode+and+structure-activity+relationships+of+selective+histone+deacetylase+6+%28HDAC6%29+inhibitors+with+bifurcated+capping+groups&doi=10.1021%2Facs.jmedchem.9b01888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Multicomponent synthesis, binding mode and structure-activity relationships of selective histone deacetylase 6 (HDAC6) inhibitors with bifurcated capping groups</span></div><div class="casAuthors">Ressing, Nina; Soennichsen, Melf; Osko, Jeremy D.; Schoeler, Andrea; Schliehe-Diecks, Julian; Skerhut, Alexander; Borkhardt, Arndt; Hauer, Julia; Kassack, Matthias U.; Christianson, David. W.; Bhatia, Sanil; Hansen, Finn K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">10339-10351</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multicomponent synthesis and structure-activity relationships of a series of tetrazole-based HDAC6 inhibitors was reported.  Hit compd. NR-160 was discovered by investigating the inhibition of recombinant HDAC enzymes and protein acetylation.  A co-crystal structure of HDAC6 complexed with NR-160 disclosed that the steric complementarity of the bifurcated capping group of NR-160 to the L1 and L2 loop pockets may be responsible for its HDAC6-selective inhibition.  NR-160 displayed only low cytotoxicity as single-agent against leukemia cell lines, it augmented the apoptosis induction of the proteasome inhibitor bortezomib in combination expts. significantly.  Furthermore, a combinatorial high throughput drug screen revealed significantly enhanced cytotoxicity when NR-160 was used in combination with epirubicin and daunorubicin.  The synergistic effect in combination with bortezomib and anthracyclines highlights NR-160's potential in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokiwDPM_2Xf7Vg90H21EOLACvtfcHk0lgD5gWg5xnl_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Srsr7P&md5=a8c3f9c5b70228e97bd147bc3e82a0f3</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01888%26sid%3Dliteratum%253Aachs%26aulast%3DRe%25C3%259Fing%26aufirst%3DN.%26aulast%3DSonnichsen%26aufirst%3DM.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DScholer%26aufirst%3DA.%26aulast%3DSchliehe-Diecks%26aufirst%3DJ.%26aulast%3DSkerhut%26aufirst%3DA.%26aulast%3DBorkhardt%26aufirst%3DA.%26aulast%3DHauer%26aufirst%3DJ.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DChristianson%26aufirst%3DD..%2BW.%26aulast%3DBhatia%26aufirst%3DS.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26atitle%3DMulticomponent%2520synthesis%252C%2520binding%2520mode%2520and%2520structure-activity%2520relationships%2520of%2520selective%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529%2520inhibitors%2520with%2520bifurcated%2520capping%2520groups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D10339%26epage%3D10351%26doi%3D10.1021%2Facs.jmedchem.9b01888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duane, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adejare, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span> <span> </span><span class="NLM_article-title">Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1369</span>– <span class="NLM_lpage">1382</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S124977</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.2147%2FDDDT.S124977" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=28496307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslKns7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=1369-1382&author=Y.+Wangauthor=J.+Wallachauthor=S.+Duaneauthor=Y.+Wangauthor=J.+Wuauthor=J.+Wangauthor=A.+Adejareauthor=H.+Ma&title=Developing+selective+histone+deacetylases+%28HDACs%29+inhibitors+through+ebselen+and+analogs&doi=10.2147%2FDDDT.S124977"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs</span></div><div class="casAuthors">Wang, Yuren; Wallach, Jason; Duane, Stephanie; Wang, Yuan; Wu, Jianghong; Wang, Jeffrey; Adejare, Adeboye; Ma, Haiching</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1369-1382</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are key regulators of gene expression in cells and have been investigated as important therapeutic targets for cancer and other diseases.  Different subtypes of HDACs appear to play disparate roles in the cells and are assocd. with specific diseases.  Therefore, substantial effort has been made to develop subtype-selective HDAC inhibitors.  In an effort to discover existing scaffolds with HDAC inhibitory activity, we screened a drug library approved by the US Food and Drug Administration and a National Institutes of Health Clin. Collection compd. library in HDAC enzymic assays.  Ebselen, a clin. safe compd., was identified as a weak inhibitor of several HDACs, including HDAC1, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, and HDAC9 with half maximal inhibitory concns. approx. single digit of μM.  Two ebselen analogs, ebselen oxide and ebsulfur (a diselenide analog of ebselen), also inhibited these HDACs, however with improved potencies on HDAC8.  Benzisothiazol, the core structure of ebsulfur, specifically inhibited HDAC6 at a single digit of μM but had no inhibition on other HDACs.  Further efforts on structure-activity relationship based on the core structure of ebsulfur led to the discovery of a novel class of potent and selective HDAC6 inhibitors with RBC-2008 as the lead compd. with single-digit nM potency.  This class of histone deacetylase inhibitor features a novel pharmacophore with an ebsulfur scaffold selectively targeting HDAC6.  Consistent with its inhibition on HDAC6, RBC-2008 significantly increased the acetylation levels of α-tubulin in PC-3 cells.  Furthermore, treatment with these compds. led to cell death of multiple tumor cell lines in a dose-dependent manner.  These results demonstrated that ebselen and ebsulfur analogs are inhibitors of HDACs, supporting further preclin. development of this class of compds. for potential therapeutic applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTSO9qayhR7rVg90H21EOLACvtfcHk0lijjsYuD1Ud1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslKns7rM&md5=7c71fca15cacf6026275682e886245b2</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S124977&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S124977%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWallach%26aufirst%3DJ.%26aulast%3DDuane%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DAdejare%26aufirst%3DA.%26aulast%3DMa%26aufirst%3DH.%26atitle%3DDeveloping%2520selective%2520histone%2520deacetylases%2520%2528HDACs%2529%2520inhibitors%2520through%2520ebselen%2520and%2520analogs%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2017%26volume%3D11%26spage%3D1369%26epage%3D1382%26doi%3D10.2147%2FDDDT.S124977" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer’s disease</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5718</span>– <span class="NLM_lpage">5729</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.10.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmc.2018.10.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30385227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVentL%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=5718-5729&author=J.+Huauthor=B.+Anauthor=T.+Panauthor=Z.+Liauthor=L.+Huangauthor=X.+Li&title=Design%2C+synthesis%2C+and+biological+evaluation+of+histone+deacetylase+inhibitors+possessing+glutathione+peroxidase-like+and+antioxidant+activities+against+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.bmc.2018.10.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease</span></div><div class="casAuthors">Hu, Jinhui; An, Baijiao; Pan, Tingting; Li, Zhengcunxiao; Huang, Ling; Li, Xingshu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5718-5729</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of hybrids contg. the pharmacophores of the histone deacetylase (HDAC) inhibitor, SAHA, and the antioxidant ebselen were designed and synthesized as multi-target-directed ligands against Alzheimer's disease.  An in vitro assay indicated that some of these mols. exhibit potent HDAC inhibitory activity and ebselen-related pharmacol. effects.  Specifically, the optimal compd. 7f was found to be a potent HDAC inhibitor (IC50 = 0.037 μM), possessing rapid hydrogen peroxide scavenging activity and glutathione peroxidase-like activity (ν0 = 150.0 μM min-1) and good free oxygen radical absorbance capacity (value of ORAC: 2.2).  Furthermore, compd. 7f showed significant protective effects against damage induced by H2O2 and the ability to prevent ROS accumulation in PC12 cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv2EKWVVijlLVg90H21EOLACvtfcHk0lijjsYuD1Ud1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVentL%252FK&md5=b9a5f6059db2b4c611f9a050e2b54d6f</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.10.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.10.022%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DAn%26aufirst%3DB.%26aulast%3DPan%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DHuang%26aufirst%3DL.%26aulast%3DLi%26aufirst%3DX.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520histone%2520deacetylase%2520inhibitors%2520possessing%2520glutathione%2520peroxidase-like%2520and%2520antioxidant%2520activities%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D5718%26epage%3D5729%26doi%3D10.1016%2Fj.bmc.2018.10.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oh, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeong, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seo, Y. H.</span></span> <span> </span><span class="NLM_article-title">Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">6213</span>, <span class="refDoi"> DOI: 10.3390/ijms20246213</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3390%2Fijms20246213" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslChtb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=6213&author=C.+Sharmaauthor=Y.+J.+Ohauthor=B.+Parkauthor=S.+Leeauthor=C.+H.+Jeongauthor=S.+Leeauthor=J.+H.+Seoauthor=Y.+H.+Seo&title=Development+of+Thiazolidinedione-Based+HDAC6+Inhibitors+to+Overcome+Methamphetamine+Addiction&doi=10.3390%2Fijms20246213"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">Development of thiazolidinedione-based HDAC6 inhibitors to overcome methamphetamine addiction</span></div><div class="casAuthors">Sharma, Chiranjeev; Oh, Yong Jin; Park, Byoungduck; Lee, Sooyeun; Jeong, Chul-Ho; Lee, Sangkil; Seo, Ji Hae; Seo, Young Ho</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6213</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Thiazolidinedione is a five-membered heterocycle that is widely used in drug discovery endeavors.  In this study, we report the design, synthesis, and biol. evaluation of a series of thiazolidinedione-based HDAC6 inhibitors.  In particular, compd. 6b exerts an excellent inhibitory activity against HDAC6 with an IC50 value of 21 nM, displaying a good HDAC6 selectivity over HDAC1.  Compd. 6b dose-dependently induces the acetylation level of alpha-tubulin via inhibition of HDAC6 in human neuroblastoma SH-SY5Y cell line.  Moreover, compd. 6b efficiently reverses methamphetamine-induced morphol. changes of SH-SY5Y cells via regulating acetylation landscape of α-tubulin.  Collectively, compd. 6b represents a novel HDAC6-isoform selective inhibitor and demonstrates promising therapeutic potential for the treatment of methamphetamine addiction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM-EVD1Rc2abVg90H21EOLACvtfcHk0lijjsYuD1Ud1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslChtb7I&md5=372dcca52fe0cb3946e1b40c899f968a</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.3390%2Fijms20246213&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20246213%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DC.%26aulast%3DOh%26aufirst%3DY.%2BJ.%26aulast%3DPark%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DJeong%26aufirst%3DC.%2BH.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DSeo%26aufirst%3DJ.%2BH.%26aulast%3DSeo%26aufirst%3DY.%2BH.%26atitle%3DDevelopment%2520of%2520Thiazolidinedione-Based%2520HDAC6%2520Inhibitors%2520to%2520Overcome%2520Methamphetamine%2520Addiction%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D6213%26doi%3D10.3390%2Fijms20246213" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1122</span>– <span class="NLM_lpage">1127</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00084</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00084" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlamsLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1122-1127&author=T.+Liangauthor=X.+Houauthor=Y.+Zhouauthor=X.+Yangauthor=H.+Fang&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+2%2C4-Imidazolinedione+Derivatives+as+HDAC6+Isoform-Selective+Inhibitors&doi=10.1021%2Facsmedchemlett.9b00084"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors</span></div><div class="casAuthors">Liang, Tao; Hou, Xuben; Zhou, Yi; Yang, Xinying; Fang, Hao</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1122-1127</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) has emerged as a promising drug target for various human diseases, including diverse neurodegenerative diseases and cancer.  Herein, a series of 2,4-imidazolinedione derivs. as HDAC6 isoform-selective inhibitors based on structure-based drug design, is reported.  Most target compds. exhibit good profiles in a preliminary screening concerning HDAC6 inhibitory activities.  Moreover, the most active compd. I increases the acetylation level of α-tubulin with little effect on the acetylation of histone H3.  Further biol. evaluation suggested that potent compd. I, which possesses good antiproliferative activity, could induce apoptosis in HL-60 cell by activating caspase 3.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbKZDLzBq-JLVg90H21EOLACvtfcHk0lh_EDoYUi2NpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlamsLzL&md5=e97c451e0cb8a770ef36775c4c00f14b</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00084%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DT.%26aulast%3DHou%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DFang%26aufirst%3DH.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%25202%252C4-Imidazolinedione%2520Derivatives%2520as%2520HDAC6%2520Isoform-Selective%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1122%26epage%3D1127%26doi%3D10.1021%2Facsmedchemlett.9b00084" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Arias, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miguel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Gonzalez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estella-Hermoso de Mendoza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espelosin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pineda-Lucena, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span> <span> </span><span class="NLM_article-title">Multitarget Approach for the Treatment of Alzheimer’s Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">4076</span>– <span class="NLM_lpage">4101</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.9b00303</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.9b00303" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1egu7rF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=4076-4101&author=O.+Rabalauthor=J.+A.+Sanchez-Ariasauthor=M.+Cuadrado-Tejedorauthor=I.+de+Miguelauthor=M.+Perez-Gonzalezauthor=C.+Garcia-Barrosoauthor=A.+Ugarteauthor=A.+Estella-Hermoso+de+Mendozaauthor=E.+Saezauthor=M.+Espelosinauthor=S.+Ursuaauthor=H.+Tanauthor=W.+Wuauthor=M.+Xuauthor=A.+Pineda-Lucenaauthor=A.+Garcia-Ostaauthor=J.+Oyarzabal&title=Multitarget+Approach+for+the+Treatment+of+Alzheimer%E2%80%99s+Disease%3A+Inhibition+of+Phosphodiesterase+9+%28PDE9%29+and+Histone+Deacetylases+%28HDACs%29+Covering+Diverse+Selectivity+Profiles&doi=10.1021%2Facschemneuro.9b00303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget Approach for the Treatment of Alzheimer's Disease: Inhibition of Phosphodiesterase 9 (PDE9) and Histone Deacetylases (HDACs) Covering Diverse Selectivity Profiles</span></div><div class="casAuthors">Rabal, Obdulia; Sanchez-Arias, Juan A.; Cuadrado-Tejedor, Mar; de Miguel, Irene; Perez-Gonzalez, Marta; Garcia-Barroso, Carolina; Ugarte, Ana; Estella-Hermoso de Mendoza, Ander; Saez, Elena; Espelosin, Maria; Ursua, Susana; Tan, Haizhong; Wu, Wei; Xu, Musheng; Pineda-Lucena, Antonio; Garcia-Osta, Ana; Oyarzabal, Julen</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4076-4101</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Here, we present a series of dual-target phosphodiesterase 9 (PDE9) and histone deacetylase (HDAC) inhibitors devised as pharmacol. tool compds. for assessing the implications of these two targets in Alzheimer's disease (AD).  These novel inhibitors were designed taking into account the key pharmacophoric features of known selective PDE9 inhibitors as well as privileged chem. structures, bearing zinc binding groups (hydroxamic acids and ortho-amino anilides) that hit HDAC targets.  These substituents were selected according to rational criteria and previous knowledge from our group to explore diverse HDAC selectivity profiles (pan-HDAC, HDAC6 selective, and class I selective) that were confirmed in biochem. screens.  Their functional response in inducing acetylation of histone and tubulin and phosphorylation of cAMP response element binding (CREB) was measured as a requisite for further progression into complete in vitro absorption, distribution, metab. and excretion (ADME) and in vivo brain penetration profiling.  Compd. 31b, a selective HDAC6 inhibitor with acceptable brain permeability, was chosen for assessing in vivo efficacy of these first-in-class inhibitors, as well as studying their mode of action (MoA).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9GkgLW75qELVg90H21EOLACvtfcHk0lh_EDoYUi2NpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1egu7rF&md5=be57148d4b99a7e517c51142a1908fb8</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.9b00303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.9b00303%26sid%3Dliteratum%253Aachs%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DSanchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3Dde%2BMiguel%26aufirst%3DI.%26aulast%3DPerez-Gonzalez%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DEstella-Hermoso%2Bde%2BMendoza%26aufirst%3DA.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DEspelosin%26aufirst%3DM.%26aulast%3DUrsua%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DPineda-Lucena%26aufirst%3DA.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26aulast%3DOyarzabal%26aufirst%3DJ.%26atitle%3DMultitarget%2520Approach%2520for%2520the%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Inhibition%2520of%2520Phosphodiesterase%25209%2520%2528PDE9%2529%2520and%2520Histone%2520Deacetylases%2520%2528HDACs%2529%2520Covering%2520Diverse%2520Selectivity%2520Profiles%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D4076%26epage%3D4101%26doi%3D10.1021%2Facschemneuro.9b00303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thakur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tawa, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henderson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Danchik, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padilha, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simeonov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kharbanda, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grewal, G.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">4256</span>– <span class="NLM_lpage">4292</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c00193</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c00193" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlslCgsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=4256-4292&author=A.+Thakurauthor=G.+J.+Tawaauthor=M.+J.+Hendersonauthor=C.+Danchikauthor=S.+Liuauthor=P.+Shahauthor=A.+Q.+Wangauthor=G.+Dunnauthor=M.+Kabirauthor=E.+C.+Padilhaauthor=X.+Xuauthor=A.+Simeonovauthor=S.+Kharbandaauthor=R.+Stoneauthor=G.+Grewal&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Quinazolin-4-one-Based+Hydroxamic+Acids+as+Dual+PI3K%2FHDAC+Inhibitors&doi=10.1021%2Facs.jmedchem.0c00193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors</span></div><div class="casAuthors">Thakur, Ashish; Tawa, Gregory J.; Henderson, Mark J.; Danchik, Carina; Liu, Suiyang; Shah, Pranav; Wang, Amy Q.; Dunn, Garrett; Kabir, Md.; Padilha, Elias C.; Xu, Xin; Simeonov, Anton; Kharbanda, Surender; Stone, Richard; Grewal, Gurmit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">4256-4292</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of quinazolin-4-one based hydroxamic acids was rationally designed and synthesized as novel dual PI3K/HDAC inhibitors by incorporating an HDAC pharmacophore into a PI3K inhibitor (Idelalisib) via an optimized linker.  Several of these dual inhibitors were highly potent (IC50 < 10 nM) and selective against PI3Kγ, δ and HDAC6 enzymes and exhibited good antiproliferative activity against multiple cancer cell lines.  The lead compd. 48c, induced necrosis in several mutant and FLT3-resistant AML cell lines and primary blasts from AML patients, while showing no cytotoxicity against normal PBMCs, NIH3T3, and HEK293 cells.  Target engagement of PI3Kδ and HDAC6 by 48c was demonstrated in MV411 cells using the cellular thermal shift assay (CETSA).  Compd. 48c showed good pharmacokinetics properties in mice via i.p. administration and provides a means to examine the biol. effects of inhibiting these two important enzymes with a single mol., either in vitro or in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWWMm2AttIWLVg90H21EOLACvtfcHk0lh_EDoYUi2NpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlslCgsrg%253D&md5=75f1696a5d5826a46380a85e2a115b59</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c00193%26sid%3Dliteratum%253Aachs%26aulast%3DThakur%26aufirst%3DA.%26aulast%3DTawa%26aufirst%3DG.%2BJ.%26aulast%3DHenderson%26aufirst%3DM.%2BJ.%26aulast%3DDanchik%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DShah%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DA.%2BQ.%26aulast%3DDunn%26aufirst%3DG.%26aulast%3DKabir%26aufirst%3DM.%26aulast%3DPadilha%26aufirst%3DE.%2BC.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DSimeonov%26aufirst%3DA.%26aulast%3DKharbanda%26aufirst%3DS.%26aulast%3DStone%26aufirst%3DR.%26aulast%3DGrewal%26aufirst%3DG.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Quinazolin-4-one-Based%2520Hydroxamic%2520Acids%2520as%2520Dual%2520PI3K%252FHDAC%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D4256%26epage%3D4292%26doi%3D10.1021%2Facs.jmedchem.0c00193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Relitti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saraswati, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtkunz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccoccia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruberti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulivieri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamponi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span> <span> </span><span class="NLM_article-title">Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_fpage">112998</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112998</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2020.112998" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=33199154" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3s3ls1ygsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&pages=112998&author=N.+Relittiauthor=A.+P.+Saraswatiauthor=G.+Chemiauthor=M.+Brindisiauthor=S.+Brogiauthor=D.+Herpauthor=K.+Schmidtkunzauthor=F.+Saccocciaauthor=G.+Rubertiauthor=C.+Ulivieriauthor=F.+Vanniauthor=F.+Sarnoauthor=L.+Altucciauthor=S.+Lamponiauthor=M.+Jungauthor=S.+Gemmaauthor=S.+Butiniauthor=G.+Campiani&title=Novel+quinolone-based+potent+and+selective+HDAC6+inhibitors%3A+Synthesis%2C+molecular+modeling+studies+and+biological+investigation&doi=10.1016%2Fj.ejmech.2020.112998"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation</span></div><div class="casAuthors">Relitti Nicola; Saraswati A Prasanth; Chemi Giulia; Brindisi Margherita; Lamponi Stefania; Gemma Sandra; Butini Stefania; Brogi Simone; Herp Daniel; Schmidtkunz Karin; Jung Manfred; Saccoccia Fulvio; Ruberti Giovina; Ulivieri Cristina; Vanni Francesca; Sarno Federica; Altucci Lucia; Campiani Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">European journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112998</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In this work we describe the synthesis of potent and selective quinolone-based histone deacetylase 6 (HDAC6) inhibitors.  The quinolone moiety has been exploited as an innovative bioactive cap-group for HDAC6 inhibition; its synthesis was achieved by applying a multicomponent reaction.  The optimization of potency and selectivity of these products was performed by employing computational studies which led to the discovery of the diethylaminomethyl derivatives 7g and 7k as the most promising hit molecules.  These compounds were investigated in cellular studies to evaluate their anticancer effect against colon (HCT-116) and histiocytic lymphoma (U9347) cancer cells, showing good to excellent potency, leading to tumor cell death by apoptosis induction.  The small molecules 7a, 7g and 7k were able to strongly inhibit the cytoplasmic and slightly the nuclear HDAC enzymes, increasing the acetylation of tubulin and of the lysine 9 and 14 of histone 3, respectively.  Compound 7g was also able to increase Hsp90 acetylation levels in HCT-116 cells, thus further supporting its HDAC6 inhibitory profile.  Cytotoxicity and mutagenicity assays of these molecules showed a safe profile; moreover, the HPLC analysis of compound 7k revealed good solubility and stability profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwT9brH_VNAP_I8Jvzw4xCfW6udTcc2eZ0zczhGn_1yLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3s3ls1ygsg%253D%253D&md5=e96c6ae6db6fd3f724e8bd24c031a250</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112998%26sid%3Dliteratum%253Aachs%26aulast%3DRelitti%26aufirst%3DN.%26aulast%3DSaraswati%26aufirst%3DA.%2BP.%26aulast%3DChemi%26aufirst%3DG.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DHerp%26aufirst%3DD.%26aulast%3DSchmidtkunz%26aufirst%3DK.%26aulast%3DSaccoccia%26aufirst%3DF.%26aulast%3DRuberti%26aufirst%3DG.%26aulast%3DUlivieri%26aufirst%3DC.%26aulast%3DVanni%26aufirst%3DF.%26aulast%3DSarno%26aufirst%3DF.%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DLamponi%26aufirst%3DS.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26atitle%3DNovel%2520quinolone-based%2520potent%2520and%2520selective%2520HDAC6%2520inhibitors%253A%2520Synthesis%252C%2520molecular%2520modeling%2520studies%2520and%2520biological%2520investigation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26spage%3D112998%26doi%3D10.1016%2Fj.ejmech.2020.112998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors--What Some May Have Forgotten or Would Rather Forget?</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">15</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500486</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fcmdc.201500486" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=26603496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvV2jsrbL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=15-21&author=S.+Shenauthor=A.+P.+Kozikowski&title=Why+Hydroxamates+May+Not+Be+the+Best+Histone+Deacetylase+Inhibitors%2D%2DWhat+Some+May+Have+Forgotten+or+Would+Rather+Forget%3F&doi=10.1002%2Fcmdc.201500486"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Why Hydroxamates May Not Be the Best Histone Deacetylase Inhibitors-What Some May Have Forgotten or Would Rather Forget?</span></div><div class="casAuthors">Shen, Sida; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-21</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Hydroxamate-based histone deacetylase inhibitors (HDACIs) have been approved as therapeutic agents by the US Food and Drug Administration for use in oncol. applications.  While the potential utility of such HDACIs in other areas of medicinal chem. is tremendous, there are significant concerns that "pan-HDAC inhibitors" may be too broadly acting and/or toxic for clin. use beyond oncol.  In addn. to the isoenzyme selectivity challenge, the potential mutagenicity of hydroxamate-contg. HDAC inhibitors represents a major hindrance in their application to other therapeutic areas.  Herein the authors report on the mutagenicity of known hydroxamates, discuss the mechanisms responsible for their genotoxicity, and review some of the current alternatives to hydroxamates.  The authors conclude that the hydroxamate group, while providing high-potency HDACIs, is not necessarily the best zinc-binding group for HDACI drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplftHMFVoN6rVg90H21EOLACvtfcHk0liNU4ROEsg01A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvV2jsrbL&md5=5183d2c0a4c86fe67bea480a66bc5dc6</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500486&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500486%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DWhy%2520Hydroxamates%2520May%2520Not%2520Be%2520the%2520Best%2520Histone%2520Deacetylase%2520Inhibitors--What%2520Some%2520May%2520Have%2520Forgotten%2520or%2520Would%2520Rather%2520Forget%253F%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D15%26epage%3D21%26doi%3D10.1002%2Fcmdc.201500486" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steimbach, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Y.</span></span> <span> </span><span class="NLM_article-title">Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>187</i></span>,  <span class="NLM_fpage">111950</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111950</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2019.111950" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31865013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVeqtLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=187&publication_year=2020&pages=111950&author=X.+Chenauthor=X.+Chenauthor=R.+R.+Steimbachauthor=T.+Wuauthor=H.+Liauthor=W.+Danauthor=P.+Shiauthor=C.+Caoauthor=D.+Liauthor=A.+K.+Millerauthor=Z.+Qiuauthor=J.+Gaoauthor=Y.+Zhu&title=Novel+2%2C+5-diketopiperazine+derivatives+as+potent+selective+histone+deacetylase+6+inhibitors%3A+Rational+design%2C+synthesis+and+antiproliferative+activity&doi=10.1016%2Fj.ejmech.2019.111950"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity</span></div><div class="casAuthors">Chen, Xin; Chen, Xinyang; Steimbach, Raphael R.; Wu, Tong; Li, Hongmei; Dan, Wenjia; Shi, Peidong; Cao, Chenyu; Li, Ding; Miller, Aubry K.; Qiu, Zhixia; Gao, Jinming; Zhu, Yong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">187</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111950</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) has gained popular attention for its wide participation in various patNovel 2, 5-diketopiperazine derivs. as potent selective histone deacetylase 6 inhibitors: Rational desighol. process recently.  In this paper, a series of novel derivs. contg. 2, 5-diketopiperazine (DKP) skeleton were developed as potent selective HDAC6 inhibitors (sHDAC6is).  Most of these compds. exhibited low nanomolar IC50 values toward HDAC6, and the best compd. was 21b (IC50 = 0.73 nM) which had 144-10941-fold selectivity over other HDAC isoforms.  Western blot assay further validated these compds. to be sHDAC6is.  Mol. simulation of 21b was conducted to rationalize the high binding affinity for HDAC6.  In the cytotoxicity expt., 18a, 18b and 18d gave superior or comparable influence on the growth of two multiple myeloma cells U266 and RPMI-8226 compared to ACY-1215.  Moreover, the combination of 18a and adriamycin showed synergistic effect against non-small cell lung cancer cell A549. 18a and 18b also demonstrated appropriate drug metab. in human liver microsome (HLM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxkduBDp5v4bVg90H21EOLACvtfcHk0ljpASQrBJGH1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVeqtLfJ&md5=d662060f4aee956b065d0e24a534fe1e</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111950&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111950%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DSteimbach%26aufirst%3DR.%2BR.%26aulast%3DWu%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DDan%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DP.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DMiller%26aufirst%3DA.%2BK.%26aulast%3DQiu%26aufirst%3DZ.%26aulast%3DGao%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DY.%26atitle%3DNovel%25202%252C%25205-diketopiperazine%2520derivatives%2520as%2520potent%2520selective%2520histone%2520deacetylase%25206%2520inhibitors%253A%2520Rational%2520design%252C%2520synthesis%2520and%2520antiproliferative%2520activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D187%26spage%3D111950%26doi%3D10.1016%2Fj.ejmech.2019.111950" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, J. W.</span></span> <span> </span><span class="NLM_article-title">Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">857</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01590</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01590" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKrtr%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=857-874&author=C.+W.+Yuauthor=P.+Y.+Hungauthor=H.+T.+Yangauthor=Y.+H.+Hoauthor=H.+Y.+Laiauthor=Y.+S.+Chengauthor=J.+W.+Chern&title=Quinazolin-2%2C4-dione-Based+Hydroxamic+Acids+as+Selective+Histone+Deacetylase-6+Inhibitors+for+Treatment+of+Non-Small+Cell+Lung+Cancer&doi=10.1021%2Facs.jmedchem.8b01590"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">Quinazolin-2,4-dione-Based Hydroxamic Acids as Selective Histone Deacetylase-6 Inhibitors for Treatment of Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Yu, Chao-Wu; Hung, Pei-Yun; Yang, Hui-Ting; Ho, Yi-Hsun; Lai, Hsing-Yi; Cheng, Yi-Sheng; Chern, Ji-Wang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">857-874</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We designed and synthesized quinazolin-2,4-dione-based hydroxamic acids to serve as selective competitive inhibitors of histone deacetylase-6 (HDAC6).  The most potent and selective compd., I (IC50, 4 nM, HDAC6; IC50 > 10 μM, HDAC1), substantially increased acetylation of α-tubulin instead of histones in the lung cancer cell line, LL2.  Paclitaxel in combination with I had a synergistic anticancer effect on redn. of programmed death-ligand 1 expression in LL/2 cells.  When given orally, I was mainly found to locate in the liver and lungs, at a concn. 18- to 70-fold greater, resp., than in plasma.  As an orally active HDAC6 inhibitor, I (20 mg/kg), potentiated paclitaxel antitumor activity (percentage tumor growth inhibition, 67.5%) in a xenograft syngeneic non-small cell lung cancer mouse model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIz_AQ5jytrrVg90H21EOLACvtfcHk0ljpASQrBJGH1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKrtr%252FF&md5=eaee2fc7b612a60eac2469eeb8afdc49</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01590%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DC.%2BW.%26aulast%3DHung%26aufirst%3DP.%2BY.%26aulast%3DYang%26aufirst%3DH.%2BT.%26aulast%3DHo%26aufirst%3DY.%2BH.%26aulast%3DLai%26aufirst%3DH.%2BY.%26aulast%3DCheng%26aufirst%3DY.%2BS.%26aulast%3DChern%26aufirst%3DJ.%2BW.%26atitle%3DQuinazolin-2%252C4-dione-Based%2520Hydroxamic%2520Acids%2520as%2520Selective%2520Histone%2520Deacetylase-6%2520Inhibitors%2520for%2520Treatment%2520of%2520Non-Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D857%26epage%3D874%26doi%3D10.1021%2Facs.jmedchem.8b01590" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsin, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, J. W.</span></span> <span> </span><span class="NLM_article-title">High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">458</span>– <span class="NLM_lpage">471</span>, <span class="refDoi"> DOI: 10.1016/j.bcp.2019.03.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bcp.2019.03.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30885763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1eitbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2019&pages=458-471&author=J.+R.+Liuauthor=C.+W.+Yuauthor=P.+Y.+Hungauthor=L.+W.+Hsinauthor=J.+W.+Chern&title=High-selective+HDAC6+inhibitor+promotes+HDAC6+degradation+following+autophagy+modulation+and+enhanced+antitumor+immunity+in+glioblastoma&doi=10.1016%2Fj.bcp.2019.03.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">High-selective HDAC6 inhibitor promotes HDAC6 degradation following autophagy modulation and enhanced antitumor immunity in glioblastoma</span></div><div class="casAuthors">Liu, Jia-Rong; Yu, Chao-Wu; Hung, Pei-Yun; Hsin, Ling-Wei; Chern, Ji-Wang</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">458-471</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Glioblastoma is the most fatal type of primary brain cancer, and current treatments for glioblastoma are insufficient.  HDAC6 is overexpressed in glioblastoma, and siRNA-mediated knockdown of HDAC6 inhibits glioma cell proliferation.  Herein, we report a high-selective HDAC6 inhibitor, J22352, which has PROTAC (proteolysis-targeting chimeras)-like property resulted in both p62 accumulation and proteasomal degrdn., leading to proteolysis of aberrantly overexpressed HDAC6 in glioblastoma.  The consequences of decreased HDAC6 expression in response to J22352 decreased cell migration, increased autophagic cancer cell death and significant tumor growth inhibition.  Notably, J22352 reduced the immunosuppressive activity of PD-L1, leading to the restoration of host anti-tumor activity.  These results demonstrate that J22352 promotes HDAC6 degrdn. and induces anticancer effects by inhibiting autophagy and eliciting the antitumor immune response in glioblastoma.  Therefore, this highly selective HDAC6 inhibitor can be considered a potential therapeutic for the treatment of glioblastoma and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4CvL8Dho7i7Vg90H21EOLACvtfcHk0ljpASQrBJGH1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1eitbg%253D&md5=5fcf3fe4d0236e802e93a8043af27213</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2019.03.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2019.03.023%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%2BR.%26aulast%3DYu%26aufirst%3DC.%2BW.%26aulast%3DHung%26aufirst%3DP.%2BY.%26aulast%3DHsin%26aufirst%3DL.%2BW.%26aulast%3DChern%26aufirst%3DJ.%2BW.%26atitle%3DHigh-selective%2520HDAC6%2520inhibitor%2520promotes%2520HDAC6%2520degradation%2520following%2520autophagy%2520modulation%2520and%2520enhanced%2520antitumor%2520immunity%2520in%2520glioblastoma%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2019%26volume%3D163%26spage%3D458%26epage%3D471%26doi%3D10.1016%2Fj.bcp.2019.03.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ho, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fung, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chern, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. W.</span></span> <span> </span><span class="NLM_article-title">A highly HDAC6-selective inhibitor acts as a fluorescent probe</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">7820</span>– <span class="NLM_lpage">7832</span>, <span class="refDoi"> DOI: 10.1039/C8OB00966J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1039%2FC8OB00966J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30168823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFOqtrrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=7820-7832&author=Y.+H.+Hoauthor=K.+J.+Wangauthor=P.+Y.+Hungauthor=Y.+S.+Chengauthor=J.+R.+Liuauthor=S.+T.+Fungauthor=P.+H.+Liangauthor=J.+W.+Chernauthor=C.+W.+Yu&title=A+highly+HDAC6-selective+inhibitor+acts+as+a+fluorescent+probe&doi=10.1039%2FC8OB00966J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">A highly HDAC6-selective inhibitor acts as a fluorescent probe</span></div><div class="casAuthors">Ho, Yi-Hsun; Wang, Kuang-Jui; Hung, Pei-Yun; Cheng, Yi-Sheng; Liu, Jia-Rong; Fung, Sheang-Tze; Liang, Pi-Hui; Chern, Ji-Wang; Yu, Chao-Wu</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">7820-7832</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">HDAC6 receives great attention because of its therapeutic potential for the treatment of various diseases.  Selective fluorescence imaging for HDAC6 is important for its pathol. and biol. studies.  However, specific detection of HDAC6 by using a fluorescent small mol. probe remains a great challenge.  Herein, a series of fluorescent HDAC6-selective inhibitors incorporating a naphthalimide skeleton were designed and synthesized.  A structure-activity relationship study identified that compd. JW-1 had the greatest inhibitory activity and superior specificity against HDAC6.  JW-1 could substantially increase α-tubulin acetylation and was active against a panel of six cancer cell lines.  Photophys. characterization and cellular imaging of MDA-MB-231 cells demonstrated that JW-1 is a highly fluorescent, cell penetrable, small-mol. inhibitor of HDAC6 that can be used for the detection of HDAC6 in complex cellular environments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOU3VXU8SZybVg90H21EOLACvtfcHk0lh0nTN88BpqqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFOqtrrM&md5=212d645f0245b2f092b3d75f4a10f38a</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1039%2FC8OB00966J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC8OB00966J%26sid%3Dliteratum%253Aachs%26aulast%3DHo%26aufirst%3DY.%2BH.%26aulast%3DWang%26aufirst%3DK.%2BJ.%26aulast%3DHung%26aufirst%3DP.%2BY.%26aulast%3DCheng%26aufirst%3DY.%2BS.%26aulast%3DLiu%26aufirst%3DJ.%2BR.%26aulast%3DFung%26aufirst%3DS.%2BT.%26aulast%3DLiang%26aufirst%3DP.%2BH.%26aulast%3DChern%26aufirst%3DJ.%2BW.%26aulast%3DYu%26aufirst%3DC.%2BW.%26atitle%3DA%2520highly%2520HDAC6-selective%2520inhibitor%2520acts%2520as%2520a%2520fluorescent%2520probe%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2018%26volume%3D16%26spage%3D7820%26epage%3D7832%26doi%3D10.1039%2FC8OB00966J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pardo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szarics, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benoy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutil, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Den
Bosch, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jope, R. S.</span></span> <span> </span><span class="NLM_article-title">Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1679</span>– <span class="NLM_lpage">1695</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.8b00600</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.8b00600" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitl2jtb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1679-1695&author=A.+P.+Kozikowskiauthor=S.+Shenauthor=M.+Pardoauthor=M.+T.+Tavaresauthor=D.+Szaricsauthor=V.+Benoyauthor=C.+A.+Zimprichauthor=Z.+Kutilauthor=G.+Zhangauthor=C.+Barinkaauthor=M.+B.+Robersauthor=L.+Van+Den%0ABoschauthor=J.+H.+Eubanksauthor=R.+S.+Jope&title=Brain+Penetrable+Histone+Deacetylase+6+Inhibitor+SW-100+Ameliorates+Memory+and+Learning+Impairments+in+a+Mouse+Model+of+Fragile+X+Syndrome&doi=10.1021%2Facschemneuro.8b00600"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome</span></div><div class="casAuthors">Kozikowski, Alan P.; Shen, Sida; Pardo, Marta; Tavares, Mauricio T.; Szarics, Dora; Benoy, Veronick; Zimprich, Chad A.; Kutil, Zsofia; Zhang, Guiping; Barinka, Cyril; Robers, Matthew B.; Van Den Bosch, Ludo; Eubanks, James H.; Jope, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1679-1695</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Disease-modifying therapies are needed for Fragile X Syndrome (FXS), as at present there are no effective treatments or cures.  Herein, we report on a tetrahydroquinoline-based selective histone deacetylase 6 (HDAC6) inhibitor SW-100, its pharmacol. and ADMET properties, and its ability to improve upon memory performance in a mouse model of FXS, Fmr1-/- mice.  This small mol. demonstrates good brain penetrance, low-nanomolar potency for the inhibition of HDAC6 (IC50 = 2.3 nM), with at least a thousand-fold selectivity over all other class I, II, and IV HDAC isoforms.  Moreover, through its inhibition of the α-tubulin deacetylase domain of HDAC6 (CD2), in cells SW-100 upregulates α-tubulin acetylation with no effect on histone acetylation and selectively restores the impaired acetylated α-tubulin levels in the hippocampus of Fmr1-/- mice.  Lastly, SW-100 ameliorates several memory and learning impairments in Fmr1-/- mice, thus modeling the intellectual deficiencies assocd. with FXS, and hence providing a strong rationale for pursuing HDAC6-based therapies for the treatment of this rare disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphc-8bfGiZh7Vg90H21EOLACvtfcHk0lh0nTN88BpqqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitl2jtb3E&md5=b1e70a1a45522720d481985b3a4339f3</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.8b00600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.8b00600%26sid%3Dliteratum%253Aachs%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DPardo%26aufirst%3DM.%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DSzarics%26aufirst%3DD.%26aulast%3DBenoy%26aufirst%3DV.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DKutil%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DVan%2BDen%2BBosch%26aufirst%3DL.%26aulast%3DEubanks%26aufirst%3DJ.%2BH.%26aulast%3DJope%26aufirst%3DR.%2BS.%26atitle%3DBrain%2520Penetrable%2520Histone%2520Deacetylase%25206%2520Inhibitor%2520SW-100%2520Ameliorates%2520Memory%2520and%2520Learning%2520Impairments%2520in%2520a%2520Mouse%2520Model%2520of%2520Fragile%2520X%2520Syndrome%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2019%26volume%3D10%26spage%3D1679%26epage%3D1695%26doi%3D10.1021%2Facschemneuro.8b00600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Picci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, V. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKinnon, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swift, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alam, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prusky, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langley, B.</span></span> <span> </span><span class="NLM_article-title">HDAC6 inhibition promotes alpha-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice</span>. <i>Exp. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>328</i></span>,  <span class="NLM_fpage">113281</span>, <span class="refDoi"> DOI: 10.1016/j.expneurol.2020.113281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.expneurol.2020.113281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32147437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXkvF2juro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=2020&pages=113281&author=C.+Picciauthor=V.+S.+C.+Wongauthor=C.+J.+Costaauthor=M.+C.+McKinnonauthor=D.+C.+Goldbergauthor=M.+Swiftauthor=N.+M.+Alamauthor=G.+T.+Pruskyauthor=S.+Shenauthor=A.+P.+Kozikowskiauthor=D.+E.+Willisauthor=B.+Langley&title=HDAC6+inhibition+promotes+alpha-tubulin+acetylation+and+ameliorates+CMT2A+peripheral+neuropathy+in+mice&doi=10.1016%2Fj.expneurol.2020.113281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice</span></div><div class="casAuthors">Picci, Cristina; Wong, Victor S. C.; Costa, Christopher J.; McKinnon, Marion C.; Goldberg, David C.; Swift, Michelle; Alam, Nazia M.; Prusky, Glen T.; Shen, Sida; Kozikowski, Alan P.; Willis, Dianna E.; Langley, Brett</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113281</span>CODEN:
                <span class="NLM_cas:coden">EXNEAC</span>;
        ISSN:<span class="NLM_cas:issn">0014-4886</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Charcot-Marie-Tooth type 2A (CMT2A) peripheral neuropathy, the most common axonal form of CMT, is caused by dominantly inherited point mutations in the Mitofusin 2 (Mfn2) gene.  It is characterized by progressive length-dependent degeneration of motor and sensory nerves with corresponding clin. features of motor and sensory impairment.  There is no cure for CMT, and therapeutic approaches are limited to phys. therapy, orthopedic devices, surgery, and analgesics.  In this study we focus on histone deacetylase 6 (HDAC6) as a therapeutic target in a mouse model of mutant MFN2 (MFN2R94Q)-induced CMT2A.  We report that these mice display progressive motor and sensory dysfunction as well as a significant decrease in α-tubulin acetylation in distal segments of long peripheral nerves.  Treatment with a new, highly selective HDAC6 inhibitor, SW-100, was able to restore α-tubulin acetylation and ameliorate motor and sensory dysfunction when given either prior to or after the onset of symptoms.  To confirm HDAC6 is the target for ameliorating the CMT2A phenotype, we show that genetic deletion of Hdac6 in CMT2A mice prevents the development of motor and sensory dysfunction.  Our findings suggest α-tubulin acetylation defects in distal parts of nerves as a pathogenic mechanism and HDAC6 as a therapeutic target for CMT2A.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLIL7Cazwz7rVg90H21EOLACvtfcHk0lh0nTN88BpqqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXkvF2juro%253D&md5=c8b6b6c12c5b341a6ab773ff7ecbd300</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.1016%2Fj.expneurol.2020.113281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.expneurol.2020.113281%26sid%3Dliteratum%253Aachs%26aulast%3DPicci%26aufirst%3DC.%26aulast%3DWong%26aufirst%3DV.%2BS.%2BC.%26aulast%3DCosta%26aufirst%3DC.%2BJ.%26aulast%3DMcKinnon%26aufirst%3DM.%2BC.%26aulast%3DGoldberg%26aufirst%3DD.%2BC.%26aulast%3DSwift%26aufirst%3DM.%26aulast%3DAlam%26aufirst%3DN.%2BM.%26aulast%3DPrusky%26aufirst%3DG.%2BT.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DWillis%26aufirst%3DD.%2BE.%26aulast%3DLangley%26aufirst%3DB.%26atitle%3DHDAC6%2520inhibition%2520promotes%2520alpha-tubulin%2520acetylation%2520and%2520ameliorates%2520CMT2A%2520peripheral%2520neuropathy%2520in%2520mice%26jtitle%3DExp.%2520Neurol.%26date%3D2020%26volume%3D328%26spage%3D113281%26doi%3D10.1016%2Fj.expneurol.2020.113281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepali, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span> <span> </span><span class="NLM_article-title">(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">905</span>– <span class="NLM_lpage">917</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01404</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01404" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXksVKiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=905-917&author=H.+Y.+Leeauthor=K.+Nepaliauthor=F.+I.+Huangauthor=C.+Y.+Changauthor=M.+J.+Laiauthor=Y.+H.+Liauthor=H.+L.+Huangauthor=C.+R.+Yangauthor=J.+P.+Liou&title=%28N-Hydroxycarbonylbenylamino%29quinolines+as+Selective+Histone+Deacetylase+6+Inhibitors+Suppress+Growth+of+Multiple+Myeloma+in+Vitro+and+in+Vivo&doi=10.1021%2Facs.jmedchem.7b01404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">(N-Hydroxycarbonylbenzylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo</span></div><div class="casAuthors">Lee, Hsueh-Yun; Nepali, Kunal; Huang, Fang-I.; Chang, Chih-Yi; Lai, Mei-Jung; Li, Yu-Hsuan; Huang, Hsiang-Ling; Yang, Chia-Ron; Liou, Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">905-917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of bicyclic arylamino/heteroarylamino hydroxamic acids (7-31) have been examd. as novel histone deacetylase 6 (HDAC6) inhibitors.  One compd. (13, N-hydroxy-4-((quinolin-8-ylamino)methyl)benzamide) exhibits remarkable inhibitory activity of HDAC6 with an IC50 value of 0.29 nM, which is 4000-43,000 times more selective over other HDAC isoforms.  Compd. 13 was shown to have antiproliferative activity against human multiple myeloma RPMI 8226, U266, and NCI-H929 cells with no effect on normal bone marrow cells.  Compd. 13, as a single drug, suppresses the growth of tumors by a %TGI factor of 60.4% in human multiple myeloma RPMI 8226 xenograft models and, in combination with bortezomib, shows significant in vivo antitumor activity (%TGI = 86.2%).  Compd. 13 also demonstrates good human hepatocytic stability and high permeability, without any effect on mutagenicity and cytotoxicity.  Thus, compd. 13 is a potent HDAC6 inhibitor that could be developed for the treatment of multiple myeloma in the future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRGAacR3ID_LVg90H21EOLACvtfcHk0lhrhjknb0nhDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXksVKiuw%253D%253D&md5=4e76a60f13c7414ba7cf871aa0193b14</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01404%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BY.%26aulast%3DNepali%26aufirst%3DK.%26aulast%3DHuang%26aufirst%3DF.%2BI.%26aulast%3DChang%26aufirst%3DC.%2BY.%26aulast%3DLai%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DY.%2BH.%26aulast%3DHuang%26aufirst%3DH.%2BL.%26aulast%3DYang%26aufirst%3DC.%2BR.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26atitle%3D%2528N-Hydroxycarbonylbenylamino%2529quinolines%2520as%2520Selective%2520Histone%2520Deacetylase%25206%2520Inhibitors%2520Suppress%2520Growth%2520of%2520Multiple%2520Myeloma%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D905%26epage%3D917%26doi%3D10.1021%2Facs.jmedchem.7b01404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. R.</span></span> <span> </span><span class="NLM_article-title">The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">655</span>, <span class="refDoi"> DOI: 10.1038/s41419-018-0688-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fs41419-018-0688-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29844403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BC1MbhsFejtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=655&author=S.+J.+Fanauthor=F.+I.+Huangauthor=J.+P.+Liouauthor=C.+R.+Yang&title=The+novel+histone+de+acetylase+6+inhibitor%2C+MPT0G211%2C+ameliorates+tau+phosphorylation+and+cognitive+deficits+in+an+Alzheimer%E2%80%99s+disease+model&doi=10.1038%2Fs41419-018-0688-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model</span></div><div class="casAuthors">Fan Sheng-Jun; Huang Fang-I; Yang Chia-Ron; Liou Jing-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Cell death & disease</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">655</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Alzheimer's disease (AD) is a dreadful neurodegenerative disease that leads to severe impairment of cognitive function, leading to a drastic decline in the quality of life.  The primary pathological features of AD include senile plaques (SPs) and intracellular neurofibrillary tangles (NFTs), comprising aggregated amyloid β (Aβ) and hyperphosphorylated tau protein, respectively, in the hippocampus of AD patients.  Histone deacetylase 6 (HDAC6) is a key enzyme in this neurodegenerative disease, in particular, as it relates to tau hyperphosphorylation.  This study aimed to investigate the protective effects and mechanism of the novel HDAC6 inhibitor, MPT0G211, using an AD model.  Our results indicated that MPT0G211 significantly reduced tau phosphorylation and aggregation, the processes highly correlated with the formation of NFTs.  This HDAC6 inhibitory activity resulted in an increase in acetylated Hsp90, which decreased Hsp90 and HDAC6 binding, causing ubiquitination of phosphorylated tau proteins.  In addition, a significant increase of phospho-glycogen synthase kinase-3β (phospho-GSK3β) on Ser9 (the inactive form) through Akt phosphorylation was associated with the inhibition of phospho-tau Ser396 in response to MPT0G211 treatment.  In AD in vivo models, MPT0G211 appeared to ameliorate learning and memory impairment in animals.  Furthermore, MPT0G211 treatment reduced the amount of phosphorylated tau in the hippocampal CA1 region.  In summary, MPT0G211 treatment appears to be a promising strategy for improving the AD phenotypes, including tau hyperphosphorylation and aggregation, neurodegeneration, and learning and memory impairment, making it a valuable agent for further investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcThODJPxWFHy0EgZCMqtRBifW6udTcc2eYSgc8Rw6HkA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbhsFejtQ%253D%253D&md5=5b9b227e4df99bd8150004e7342c214c</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1038%2Fs41419-018-0688-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-018-0688-5%26sid%3Dliteratum%253Aachs%26aulast%3DFan%26aufirst%3DS.%2BJ.%26aulast%3DHuang%26aufirst%3DF.%2BI.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DYang%26aufirst%3DC.%2BR.%26atitle%3DThe%2520novel%2520histone%2520de%2520acetylase%25206%2520inhibitor%252C%2520MPT0G211%252C%2520ameliorates%2520tau%2520phosphorylation%2520and%2520cognitive%2520deficits%2520in%2520an%2520Alzheimer%25E2%2580%2599s%2520disease%2520model%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2018%26volume%3D9%26spage%3D655%26doi%3D10.1038%2Fs41419-018-0688-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C. R.</span></span> <span> </span><span class="NLM_article-title">Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo</span>. <i>Biochim. Biophys. Acta, Mol. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>1866</i></span>,  <span class="NLM_fpage">992</span>– <span class="NLM_lpage">1003</span>, <span class="refDoi"> DOI: 10.1016/j.bbamcr.2019.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bbamcr.2019.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30867138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVWgsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1866&publication_year=2019&pages=992-1003&author=Y.+L.+Hsiehauthor=H.+J.+Tuauthor=S.+L.+Panauthor=J.+P.+Liouauthor=C.+R.+Yang&title=Anti-metastatic+activity+of+MPT0G211%2C+a+novel+HDAC6+inhibitor%2C+in+human+breast+cancer+cells+in+vitro+and+in+vivo&doi=10.1016%2Fj.bbamcr.2019.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo</span></div><div class="casAuthors">Hsieh, Yi-Ling; Tu, Huang-Ju; Pan, Shiow-Lin; Liou, Jing-Ping; Yang, Chia-Ron</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">1866</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">992-1003</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is assocd. with an increased risk of metastasis and a poor prognosis.  The invasive ability of TNBC relies on actin reorganization and is regulated by histone deacetylase 6 (HDAC6).  The present study aimed to examine the effect of MPT0G211, a novel HDAC6 inhibitor, on cell migration and microtubule assocn. in both in vitro and in vivo models of TNBC.  Here MPT0G211 more selectively and potently targeted and inhibited HDAC6, compared with tubastatin A, another selective HDAC6 inhibitor.  In vitro, MPT0G211 decreased the migration of the TNBC cell line MDA-MB-231, particularly when administered together with paclitaxel, and increased heat shock protein 90 (Hsp90) acetylation, leading to the dissocn. of Hsp90 from aurora-A and proteasomal degrdn.  Furthermore, MPT0G211 significantly disrupted F-actin polymn. by increasing cortactin acetylation and downregulating slingshot protein phosphatase 1 (SSH1) and active cofilin expression.  In vivo, MPT0G211 treatment significantly ameliorated TNBC metastasis.  In conclusion, our results demonstrate that MPT0G211 reduces TNBC cell motility by promoting cortactin acetylation and aurora-A degrdn., and inhibiting the cofilin-F-actin pathway via HDAC6 activity attenuation.  MPT0G211 therefore demonstrates therapeutic potential for invasive TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW5PmBHL4-8LVg90H21EOLACvtfcHk0lhrhjknb0nhDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVWgsrc%253D&md5=9bb277696b5badb7e95c09754cf3306c</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2019.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2019.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DHsieh%26aufirst%3DY.%2BL.%26aulast%3DTu%26aufirst%3DH.%2BJ.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DYang%26aufirst%3DC.%2BR.%26atitle%3DAnti-metastatic%2520activity%2520of%2520MPT0G211%252C%2520a%2520novel%2520HDAC6%2520inhibitor%252C%2520in%2520human%2520breast%2520cancer%2520cells%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2019%26volume%3D1866%26spage%3D992%26epage%3D1003%26doi%3D10.1016%2Fj.bbamcr.2019.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W. J.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>192</i></span>,  <span class="NLM_fpage">112193</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2020.112193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32151835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFels70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=192&publication_year=2020&pages=112193&author=H.+J.+Tsengauthor=M.+H.+Linauthor=Y.+J.+Shiaoauthor=Y.+C.+Yangauthor=J.+C.+Chuauthor=C.+Y.+Chenauthor=Y.+Y.+Chenauthor=T.+E.+Linauthor=C.+J.+Suauthor=S.+L.+Panauthor=L.+C.+Chenauthor=C.+Y.+Wangauthor=K.+C.+Hsuauthor=W.+J.+Huang&title=Synthesis+and+biological+evaluation+of+acridine-based+histone+deacetylase+inhibitors+as+multitarget+agents+against+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2020.112193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of acridine-based histone deacetylase inhibitors as multitarget agents against Alzheimer's disease</span></div><div class="casAuthors">Tseng, Hui-Ju; Lin, Mei-Hsiang; Shiao, Young-Ji; Yang, Ying-Chen; Chu, Jung-Chun; Chen, Chun-Yung; Chen, Yi-Ying; Lin, Tony Eight; Su, Chih-Jou; Pan, Shiow-Lin; Chen, Liang-Chieh; Wang, Chen-Yu; Hsu, Kai-Cheng; Huang, Wei-Jan</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">192</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112193</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Multitarget agents simultaneously trigger mols. in functionally complementary pathways, and are therefore considered to have potential in effectively treating Alzheimer's disease (AD), which has a complex pathogenetic mechanism.  In this study, the HDAC inhibitor core is incorporated into the acetylcholine esterase (ACE) inhibitor acridine-derived moiety and resulted in compds. that exhibited higher class IIa HDAC (4, 5, 7, and 9)- and class IIb HDAC6-inhibiting activity when compared to the pan-HDAC inhibitor SAHA in clin. practice.  One of these compds., I, displayed greater selectivity toward HDAC6 than other isoform enzymes.  In contrast, the activity of compd. II was selective toward class IIa HDAC and HDAC6.  These two compds. exhibited strong activity against Aβ-aggregation as well as significantly disrupted Aβ-oligomer.  Addnl., I and II strongly inhibited AChE.  These exptl. findings demonstrate that the above two are HDAC-Aβ-aggregation-AChE inhibitors.  Notably, they can enhance neurite outgrowth, but with no significant neurotoxicity.  Further biol. evaluation revealed the various cellular effects of multitarget compds. I and II, which have the potential to treat AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqexIdMql7N8bVg90H21EOLACvtfcHk0lh_nqGhpmX7KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFels70%253D&md5=f4dd58408b6092ade3b9183065014f33</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112193%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DH.%2BJ.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DShiao%26aufirst%3DY.%2BJ.%26aulast%3DYang%26aufirst%3DY.%2BC.%26aulast%3DChu%26aufirst%3DJ.%2BC.%26aulast%3DChen%26aufirst%3DC.%2BY.%26aulast%3DChen%26aufirst%3DY.%2BY.%26aulast%3DLin%26aufirst%3DT.%2BE.%26aulast%3DSu%26aufirst%3DC.%2BJ.%26aulast%3DPan%26aufirst%3DS.%2BL.%26aulast%3DChen%26aufirst%3DL.%2BC.%26aulast%3DWang%26aufirst%3DC.%2BY.%26aulast%3DHsu%26aufirst%3DK.%2BC.%26aulast%3DHuang%26aufirst%3DW.%2BJ.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520acridine-based%2520histone%2520deacetylase%2520inhibitors%2520as%2520multitarget%2520agents%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D192%26spage%3D112193%26doi%3D10.1016%2Fj.ejmech.2020.112193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vögerl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtkunz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robaa, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracher, F.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">1138</span>– <span class="NLM_lpage">1166</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01090</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01090" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3cjhs1Sltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=1138-1166&author=K.+V%C3%B6gerlauthor=N.+Ongauthor=J.+Sengerauthor=D.+Herpauthor=K.+Schmidtkunzauthor=M.+Marekauthor=M.+M%C3%BCllerauthor=K.+Bartelauthor=T.+B.+Shaikauthor=N.+J.+Porterauthor=D.+Robaaauthor=D.+W.+Christiansonauthor=C.+Romierauthor=W.+Sipplauthor=M.+Jungauthor=F.+Bracher&title=Synthesis+and+Biological+Investigation+of+Phenothiazine-Based+Benzhydroxamic+Acids+as+Selective+Histone+Deacetylase+6+Inhibitors&doi=10.1021%2Facs.jmedchem.8b01090"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors</span></div><div class="casAuthors">Vogerl Katharina; Ong Nghia; Muller Martin; Bartel Karin; Bracher Franz; Senger Johanna; Herp Daniel; Schmidtkunz Karin; Jung Manfred; Marek Martin; Shaik Tajith B; Romier Christophe; Porter Nicholas J; Christianson David W; Robaa Dina; Sippl Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of medicinal chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1138-1166</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The phenothiazine system was identified as a favorable cap group for potent and selective histone deacetylase 6 (HDAC6) inhibitors.  Here, we report the preparation and systematic variation of phenothiazines and their analogues containing a benzhydroxamic acid moiety as the zinc-binding group.  We evaluated their ability to selectively inhibit HDAC6 by a recombinant HDAC enzyme assay, by determining the protein acetylation levels in cells by western blotting (tubulin vs histone acetylation), and by assessing their effects on various cancer cell lines.  Structure-activity relationship studies revealed that incorporation of a nitrogen atom into the phenothiazine framework results in increased potency and selectivity for HDAC6 (more than 500-fold selectivity relative to the inhibition of HDAC1, HDAC4, and HDAC8), as rationalized by molecular modeling and docking studies.  The binding mode was confirmed by co-crystallization of the potent azaphenothiazine inhibitor with catalytic domain 2 from Danio rerio HDAC6.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSkSJzGKNxKWK69lAbTj9rGfW6udTcc2eb-mlGosFgTOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjhs1Sltw%253D%253D&md5=9d72da7b8f4bb63cd05ccc5f907d2dca</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01090&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01090%26sid%3Dliteratum%253Aachs%26aulast%3DV%25C3%25B6gerl%26aufirst%3DK.%26aulast%3DOng%26aufirst%3DN.%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DHerp%26aufirst%3DD.%26aulast%3DSchmidtkunz%26aufirst%3DK.%26aulast%3DMarek%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%26aulast%3DBartel%26aufirst%3DK.%26aulast%3DShaik%26aufirst%3DT.%2BB.%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DRobaa%26aufirst%3DD.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DBracher%26aufirst%3DF.%26atitle%3DSynthesis%2520and%2520Biological%2520Investigation%2520of%2520Phenothiazine-Based%2520Benzhydroxamic%2520Acids%2520as%2520Selective%2520Histone%2520Deacetylase%25206%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D1138%26epage%3D1166%26doi%3D10.1021%2Facs.jmedchem.8b01090" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mackwitz, M. K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamacher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Held, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassack, M. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, F. K.</span></span> <span> </span><span class="NLM_article-title">Multicomponent Synthesis and Binding Mode of Imidazo[1,2- a]pyridine-Capped Selective HDAC6 Inhibitors</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3255</span>– <span class="NLM_lpage">3258</span>, <span class="refDoi"> DOI: 10.1021/acs.orglett.8b01118</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.orglett.8b01118" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvVCnsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2018&pages=3255-3258&author=M.+K.+W.+Mackwitzauthor=A.+Hamacherauthor=J.+D.+Oskoauthor=J.+Heldauthor=A.+Scholerauthor=D.+W.+Christiansonauthor=M.+U.+Kassackauthor=F.+K.+Hansen&title=Multicomponent+Synthesis+and+Binding+Mode+of+Imidazo%5B1%2C2-+a%5Dpyridine-Capped+Selective+HDAC6+Inhibitors&doi=10.1021%2Facs.orglett.8b01118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Multicomponent Synthesis and Binding Mode of Imidazo[1,2-a]pyridine-Capped Selective HDAC6 Inhibitors</span></div><div class="casAuthors">Mackwitz, Marcel K. W.; Hamacher, Alexandra; Osko, Jeremy D.; Held, Jana; Schoeler, Andrea; Christianson, David W.; Kassack, Matthias U.; Hansen, Finn K.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3255-3258</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7052</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The multicomponent synthesis of a mini-library of histone deacetylase inhibitors with imidazo[1,2-a]pyridine-based cap groups is presented.  The biol. evaluation led to the discovery of the hit compd. MAIP-032 as a selective HDAC6 inhibitor with promising anticancer activity.  The X-ray structure of catalytic domain 2 from Danio rerio HDAC6 complexed with MAIP-032 revealed a monodentate zinc-binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4rI48LyncTrVg90H21EOLACvtfcHk0ljIPYGw2K12rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvVCnsbw%253D&md5=0c53331fabd83781717e0678a56dab7e</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1021%2Facs.orglett.8b01118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.orglett.8b01118%26sid%3Dliteratum%253Aachs%26aulast%3DMackwitz%26aufirst%3DM.%2BK.%2BW.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DHeld%26aufirst%3DJ.%26aulast%3DScholer%26aufirst%3DA.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DHansen%26aufirst%3DF.%2BK.%26atitle%3DMulticomponent%2520Synthesis%2520and%2520Binding%2520Mode%2520of%2520Imidazo%255B1%252C2-%2520a%255Dpyridine-Capped%2520Selective%2520HDAC6%2520Inhibitors%26jtitle%3DOrg.%2520Lett.%26date%3D2018%26volume%3D20%26spage%3D3255%26epage%3D3258%26doi%3D10.1021%2Facs.orglett.8b01118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavella, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cucinella, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamponi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iside, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebbioso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaik, T. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span> <span> </span><span class="NLM_article-title">Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>157</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.07.069</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2018.07.069" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30092367" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVOntbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=157&publication_year=2018&pages=127-138&author=M.+Brindisiauthor=J.+Sengerauthor=C.+Cavellaauthor=A.+Grilloauthor=G.+Chemiauthor=S.+Gemmaauthor=D.+M.+Cucinellaauthor=S.+Lamponiauthor=F.+Sarnoauthor=C.+Isideauthor=A.+Nebbiosoauthor=E.+Novellinoauthor=T.+B.+Shaikauthor=C.+Romierauthor=D.+Herpauthor=M.+Jungauthor=S.+Butiniauthor=G.+Campianiauthor=L.+Altucciauthor=S.+Brogi&title=Novel+spiroindoline+HDAC+inhibitors%3A+Synthesis%2C+molecular+modelling+and+biological+studies&doi=10.1016%2Fj.ejmech.2018.07.069"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies</span></div><div class="casAuthors">Brindisi, Margherita; Senger, Johanna; Cavella, Caterina; Grillo, Alessandro; Chemi, Giulia; Gemma, Sandra; Cucinella, Dora Mariagrazia; Lamponi, Stefania; Sarno, Federica; Iside, Concetta; Nebbioso, Angela; Novellino, Ettore; Shaik, Tajith Baba; Romier, Christophe; Herp, Daniel; Jung, Manfred; Butini, Stefania; Campiani, Giuseppe; Altucci, Lucia; Brogi, Simone</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">157</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">127-138</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Spiroindolinylmethyl arylhydroxamates such as I (R = t-BuOCO, Me, MeCO, t-BuCO) were prepd. as selective inhibitors of histone deacetylase 6 (HDAC6) for potential use as antitumor agents.  The spiroindolinylmethyl arylhydroxamates were prepd. using a one-pot Fischer indole synthesis of cyclohexane- or piperidinecarboxaldehydes and phenylhydrazine followed by indolenine redn. and reductive amination with formylarylcarboxylates as the key step.  The inhibition of HDAC1 and HDAC6 by the spiroindolinylmethyl arylhydroxamates was detd. and mol. docking calcns. of their binding to HDAC1 and HDAC6 performed; in addn., their calcd. lipophilicities, biol. permeabilities, polar mol. surface areas, and hERG inhibition were detd.  The inhibition of HDAC8 by I (R = t-BuOCO), its effect on metastasis and its toxicity to mouse fibroblasts, and the effect of I (R = t-BuOCO, t-BuCO) on HDAC acetylation in cells were detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBNiJdoIAsrVg90H21EOLACvtfcHk0ljIPYGw2K12rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVOntbnJ&md5=e12eadf2c73e321b1a733c1cbfdfc822</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.07.069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.07.069%26sid%3Dliteratum%253Aachs%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DCavella%26aufirst%3DC.%26aulast%3DGrillo%26aufirst%3DA.%26aulast%3DChemi%26aufirst%3DG.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DCucinella%26aufirst%3DD.%2BM.%26aulast%3DLamponi%26aufirst%3DS.%26aulast%3DSarno%26aufirst%3DF.%26aulast%3DIside%26aufirst%3DC.%26aulast%3DNebbioso%26aufirst%3DA.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DShaik%26aufirst%3DT.%2BB.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DHerp%26aufirst%3DD.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DCampiani%26aufirst%3DG.%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DBrogi%26aufirst%3DS.%26atitle%3DNovel%2520spiroindoline%2520HDAC%2520inhibitors%253A%2520Synthesis%252C%2520molecular%2520modelling%2520and%2520biological%2520studies%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D157%26spage%3D127%26epage%3D138%26doi%3D10.1016%2Fj.ejmech.2018.07.069" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saraswati, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Relitti, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brindisi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osko, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chemi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Federico, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCabe, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turkington, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Sullivan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamponi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghanim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, V. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zisterer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amet, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannon Barroeta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ulivieri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Costanzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccoccia, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruberti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campiani, G.</span></span> <span> </span><span class="NLM_article-title">Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2268</span>– <span class="NLM_lpage">2276</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00395</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00395" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFGrurrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=2268-2276&author=A.+P.+Saraswatiauthor=N.+Relittiauthor=M.+Brindisiauthor=J.+D.+Oskoauthor=G.+Chemiauthor=S.+Federicoauthor=A.+Grilloauthor=S.+Brogiauthor=N.+H.+McCabeauthor=R.+C.+Turkingtonauthor=O.+Ibrahimauthor=J.+O%E2%80%99Sullivanauthor=S.+Lamponiauthor=M.+Ghanimauthor=V.+P.+Kellyauthor=D.+Zistererauthor=R.+Ametauthor=P.+Hannon+Barroetaauthor=F.+Vanniauthor=C.+Ulivieriauthor=D.+Herpauthor=F.+Sarnoauthor=A.+Di+Costanzoauthor=F.+Saccocciaauthor=G.+Rubertiauthor=M.+Jungauthor=L.+Altucciauthor=S.+Gemmaauthor=S.+Butiniauthor=D.+W.+Christiansonauthor=G.+Campiani&title=Spiroindoline-Capped+Selective+HDAC6+Inhibitors%3A+Design%2C+Synthesis%2C+Structural+Analysis%2C+and+Biological+Evaluation&doi=10.1021%2Facsmedchemlett.0c00395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation</span></div><div class="casAuthors">Saraswati, A. Prasanth; Relitti, Nicola; Brindisi, Margherita; Osko, Jeremy D.; Chemi, Giulia; Federico, Stefano; Grillo, Alessandro; Brogi, Simone; McCabe, Niamh H.; Turkington, Richard C.; Ibrahim, Ola; O'Sullivan, Jeffrey; Lamponi, Stefania; Ghanim, Magda; Kelly, Vincent P.; Zisterer, Daniela; Amet, Rebecca; Hannon Barroeta, Patricia; Vanni, Francesca; Ulivieri, Cristina; Herp, Daniel; Sarno, Federica; Di Costanzo, Antonella; Saccoccia, Fulvio; Ruberti, Giovina; Jung, Manfred; Altucci, Lucia; Gemma, Sandra; Butini, Stefania; Christianson, David W.; Campiani, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2268-2276</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase inhibitors (HDACi) have emerged as promising therapeutics for the treatment of neurodegeneration, cancer, and rare disorders.  Herein, we report the development of a series of spiroindoline-based HDAC6 isoform-selective inhibitors based on the X-ray crystal studies of the hit 6a.  We identified compd. 6j as the most potent and selective hHDAC6 inhibitor of the series.  Biol. investigation of compds. 6b, 6h, and 6j demonstrated their antiproliferative activity against several cancer cell lines.  Western blotting studies indicated that they were able to increase tubulin acetylation, without significant variation in histone acetylation state, and induced PARP cleavage indicating their apoptotic potential at the mol. level. 6j induced HDAC6-dependent pSTAT3 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDjoa_t6NxLbVg90H21EOLACvtfcHk0lgHi0yAIAsziQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFGrurrJ&md5=eb2bb9788f4a646180dce78cce7d8957</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00395%26sid%3Dliteratum%253Aachs%26aulast%3DSaraswati%26aufirst%3DA.%2BP.%26aulast%3DRelitti%26aufirst%3DN.%26aulast%3DBrindisi%26aufirst%3DM.%26aulast%3DOsko%26aufirst%3DJ.%2BD.%26aulast%3DChemi%26aufirst%3DG.%26aulast%3DFederico%26aufirst%3DS.%26aulast%3DGrillo%26aufirst%3DA.%26aulast%3DBrogi%26aufirst%3DS.%26aulast%3DMcCabe%26aufirst%3DN.%2BH.%26aulast%3DTurkington%26aufirst%3DR.%2BC.%26aulast%3DIbrahim%26aufirst%3DO.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DJ.%26aulast%3DLamponi%26aufirst%3DS.%26aulast%3DGhanim%26aufirst%3DM.%26aulast%3DKelly%26aufirst%3DV.%2BP.%26aulast%3DZisterer%26aufirst%3DD.%26aulast%3DAmet%26aufirst%3DR.%26aulast%3DHannon%2BBarroeta%26aufirst%3DP.%26aulast%3DVanni%26aufirst%3DF.%26aulast%3DUlivieri%26aufirst%3DC.%26aulast%3DHerp%26aufirst%3DD.%26aulast%3DSarno%26aufirst%3DF.%26aulast%3DDi%2BCostanzo%26aufirst%3DA.%26aulast%3DSaccoccia%26aufirst%3DF.%26aulast%3DRuberti%26aufirst%3DG.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DGemma%26aufirst%3DS.%26aulast%3DButini%26aufirst%3DS.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26aulast%3DCampiani%26aufirst%3DG.%26atitle%3DSpiroindoline-Capped%2520Selective%2520HDAC6%2520Inhibitors%253A%2520Design%252C%2520Synthesis%252C%2520Structural%2520Analysis%252C%2520and%2520Biological%2520Evaluation%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D2268%26epage%3D2276%26doi%3D10.1021%2Facsmedchemlett.0c00395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bansal, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deep, A.</span></span> <span> </span><span class="NLM_article-title">Thiazole-containing compounds as therapeutic targets for cancer therapy</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">112016</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.112016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2019.112016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31926469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCjtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2020&pages=112016&author=P.+C.+Sharmaauthor=K.+K.+Bansalauthor=A.+Sharmaauthor=D.+Sharmaauthor=A.+Deep&title=Thiazole-containing+compounds+as+therapeutic+targets+for+cancer+therapy&doi=10.1016%2Fj.ejmech.2019.112016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">Thiazole-containing compounds as therapeutic targets for cancer therapy</span></div><div class="casAuthors">Sharma, Prabodh Chander; Bansal, Kushal Kumar; Sharma, Archana; Sharma, Diksha; Deep, Aakash</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112016</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  In the last few decades, considerable progress has been made in anticancer agents development, and several new anticancer agents of natural and synthetic origin have been produced.  Among heterocyclic compds., thiazole, a 5-membered unique heterocyclic motif contg. sulfur and nitrogen atoms, serves as an essential core scaffold in several medicinally important compds.  Thiazole nucleus is a fundamental part of some clin. applied anticancer drugs, such as dasatinib, dabrafenib, ixabepilone, patellamide A, and epothilone.  Recently, thiazole-contg. compds. have been successfully developed as possible inhibitors of several biol. targets, including enzyme-linked receptor(s) located on the cell membrane, (i.e., polymerase inhibitors) and the cell cycle (i.e., microtubular inhibitors).  Moreover, these compds. have been proven to exhibit high effectiveness, potent anticancer activity, and less toxicity.  This review presents current research on thiazoles and elucidates their biol. importance in anticancer drug discovery.  The findings may aid researchers in the rational design of more potent and bio-target specific anticancer drug mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopwqMNI9zt1rVg90H21EOLACvtfcHk0lgHi0yAIAsziQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCjtb4%253D&md5=100a7bbfe827f34164ab989e86699aa0</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.112016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.112016%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DP.%2BC.%26aulast%3DBansal%26aufirst%3DK.%2BK.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DD.%26aulast%3DDeep%26aufirst%3DA.%26atitle%3DThiazole-containing%2520compounds%2520as%2520therapeutic%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D188%26spage%3D112016%26doi%3D10.1016%2Fj.ejmech.2019.112016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palta, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhargava, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahiya, L.</span></span> <span> </span><span class="NLM_article-title">Therapeutic potential of oxazole scaffold: a patent review (2006–2017)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">812</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1526280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1080%2F13543776.2018.1526280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30239247" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslymurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=783-812&author=R.+Kaurauthor=K.+Paltaauthor=M.+Kumarauthor=M.+Bhargavaauthor=L.+Dahiya&title=Therapeutic+potential+of+oxazole+scaffold%3A+a+patent+review+%282006%E2%80%932017%29&doi=10.1080%2F13543776.2018.1526280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic potential of oxazole scaffold: a patent review (2006-2017)</span></div><div class="casAuthors">Kaur, Ramandeep; Palta, Kezia; Kumar, Manoj; Bhargava, Meha; Dahiya, Lalita</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">783-812</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Oxazoles are oxygen and nitrogen contg. five membered heterocyclic ring systems that are present in various anticancer, antimicrobial, antihyperglycemic, anti-inflammatory agents etc. of natural origin.  These pharmacol. active oxazole derivs. have attracted numerous researchers to explore this scaffold for the design and development of newer potential therapeutic agents.  A large no. of synthetic oxazole contg. mols. have been reported over the period that exhibited wide spectrum of pharmacol. profiles.  Some of them have shown promising therapeutic potential and have qualified for both preclin. and clin. evaluations.  In this review, the patents (published during 2006-2017) focusing on the biol. potential of oxazoles have been covered.  Therapeutic applications and various techniques/assays employed for the in vitro/in vivo evaluation of patented derivs. have been discussed majorly.  Chem. oxazole offers three positions for substitution.  These substituted oxazole derivs. of natural as well as synthetic origin have numerous pharmacol. applications including anticancer, anti-Alzheimers, anti-hyperglycemic, anti-inflammatory, antibacterial etc.  Their pharmacol. actions are mainly mediated through enzyme/receptor involved in the particular disease.  The flexible nature of this ligand for various mol. level targets (enzyme/receptor) make this heterocylce an attractive scaffold for development of effective and clin. relevant oxazole contg. therapeutic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQjVtEFDptT7Vg90H21EOLACvtfcHk0lgHi0yAIAsziQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslymurnM&md5=eecd45cbc407acda93c90ad666025515</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1526280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1526280%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DR.%26aulast%3DPalta%26aufirst%3DK.%26aulast%3DKumar%26aufirst%3DM.%26aulast%3DBhargava%26aufirst%3DM.%26aulast%3DDahiya%26aufirst%3DL.%26atitle%3DTherapeutic%2520potential%2520of%2520oxazole%2520scaffold%253A%2520a%2520patent%2520review%2520%25282006%25E2%2580%25932017%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26spage%3D783%26epage%3D812%26doi%3D10.1080%2F13543776.2018.1526280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schultheisz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwarzbich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidtkunz, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalek, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goskowitz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borchert, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praetorius, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sewald, N.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationship of Propargylamine-Based HDAC Inhibitors</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2044</span>– <span class="NLM_lpage">2053</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700550</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fcmdc.201700550" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29120081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BC1M7psVGnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=2044-2053&author=M.+Wunschauthor=J.+Sengerauthor=P.+Schultheiszauthor=S.+Schwarzbichauthor=K.+Schmidtkunzauthor=C.+Michalekauthor=M.+Klassauthor=S.+Goskowitzauthor=P.+Borchertauthor=L.+Praetoriusauthor=W.+Sipplauthor=M.+Jungauthor=N.+Sewald&title=Structure-Activity+Relationship+of+Propargylamine-Based+HDAC+Inhibitors&doi=10.1002%2Fcmdc.201700550"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationship of Propargylamine-Based HDAC Inhibitors</span></div><div class="casAuthors">Wunsch Matthias; Schultheisz Philipp; Schwarzbich Sabrina; Michalek Carmela; Klass Michaela; Goskowitz Stefanie; Borchert Philipp; Sewald Norbert; Senger Johanna; Schmidtkunz Karin; Jung Manfred; Praetorius Lucas; Sippl Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2044-2053</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">As histone deacetylases (HDACs) play an important role in the treatment of cancer, their selective inhibition has been the subject of various studies.  These continuous investigations have given rise to a large collection of pan- and selective HDAC inhibitors, containing diverse US Food and Drug Administration (FDA)-approved representatives.  In previous studies, a class of alkyne-based HDAC inhibitors was presented.  We modified this scaffold in two previously neglected regions and compared their cytotoxicity and affinity toward HDAC1, HDAC6, and HDAC8.  We were able to show that R-configured propargylamines contribute to increased selectivity for HDAC6.  Docking studies on available HDAC crystal structures were carried out to rationalize the observed selectivity of the compounds.  Substitution of the aromatic portion by a thiophene derivative results in high affinity and low cytotoxicity, indicating an improved drug tolerance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQpjuKsoe-S4v9pSBfyDvp7fW6udTcc2eavzEnmBKYqyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7psVGnsA%253D%253D&md5=71967e607dac8d4a467f7da6bddf634d</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700550&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700550%26sid%3Dliteratum%253Aachs%26aulast%3DWunsch%26aufirst%3DM.%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DSchultheisz%26aufirst%3DP.%26aulast%3DSchwarzbich%26aufirst%3DS.%26aulast%3DSchmidtkunz%26aufirst%3DK.%26aulast%3DMichalek%26aufirst%3DC.%26aulast%3DKlass%26aufirst%3DM.%26aulast%3DGoskowitz%26aufirst%3DS.%26aulast%3DBorchert%26aufirst%3DP.%26aulast%3DPraetorius%26aufirst%3DL.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26aulast%3DSewald%26aufirst%3DN.%26atitle%3DStructure-Activity%2520Relationship%2520of%2520Propargylamine-Based%2520HDAC%2520Inhibitors%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D2044%26epage%3D2053%26doi%3D10.1002%2Fcmdc.201700550" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Senger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melesina, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marek, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romier, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oehme, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witt, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sippl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jung, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1545</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01493</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01493" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1545-1555&author=J.+Sengerauthor=J.+Melesinaauthor=M.+Marekauthor=C.+Romierauthor=I.+Oehmeauthor=O.+Wittauthor=W.+Sipplauthor=M.+Jung&title=Synthesis+and+Biological+Investigation+of+Oxazole+Hydroxamates+as+Highly+Selective+Histone+Deacetylase+6+%28HDAC6%29+Inhibitors&doi=10.1021%2Facs.jmedchem.5b01493"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors</span></div><div class="casAuthors">Senger, Johanna; Melesina, Jelena; Marek, Martin; Romier, Christophe; Oehme, Ina; Witt, Olaf; Sippl, Wolfgang; Jung, Manfred</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1545-1555</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) catalyzes the removal of an acetyl group from lysine residues of several non-histone proteins.  Herein, the prepn. of thiazole-, oxazole-, and oxadiazole-contg. biarylhydroxamic acids by a short synthetic procedure is reported.  They were identified as selective HDAC6 inhibitors by investigating the inhibition of recombinant HDAC enzymes and the protein acetylation in cells by Western blotting (tubulin vs histone acetylation).  The most active compds. exhibited nanomolar potency and high selectivity for HDAC6.  For example, an oxazole hydroxamate inhibits HDAC6 with an IC50 of 59 nM and has a selectivity index of >200 against HDAC1 and HDAC8.  This is the first report showing that the nature of a heterocycle directly connected to a zinc binding group (ZBG) can be used to modulate subtype selectivity and potency for HDAC6 inhibitors to such an extent.  Compds. I (R = Br or Ph) were found to have the bect activity/HDAC6 selectivity.  The high potency and selectivity of the oxazoles was rationalized by mol. modeling and docking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH3cCvoW67w7Vg90H21EOLACvtfcHk0lipo5G5-AmdSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7rO&md5=19436b79e523ac3ad5a2a3fcec7c5493</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01493%26sid%3Dliteratum%253Aachs%26aulast%3DSenger%26aufirst%3DJ.%26aulast%3DMelesina%26aufirst%3DJ.%26aulast%3DMarek%26aufirst%3DM.%26aulast%3DRomier%26aufirst%3DC.%26aulast%3DOehme%26aufirst%3DI.%26aulast%3DWitt%26aufirst%3DO.%26aulast%3DSippl%26aufirst%3DW.%26aulast%3DJung%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520Biological%2520Investigation%2520of%2520Oxazole%2520Hydroxamates%2520as%2520Highly%2520Selective%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1545%26epage%3D1555%26doi%3D10.1021%2Facs.jmedchem.5b01493" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabal, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Arias, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado-Tejedor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Miguel, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Gonzalez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Barroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugarte, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estella-Hermoso
de Mendoza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espelosin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ursua, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haizhong, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musheng, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Osta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyarzabal, J.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer’s disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">506</span>– <span class="NLM_lpage">524</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2018.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29549837" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslaiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=506-524&author=O.+Rabalauthor=J.+A.+Sanchez-Ariasauthor=M.+Cuadrado-Tejedorauthor=I.+de+Miguelauthor=M.+Perez-Gonzalezauthor=C.+Garcia-Barrosoauthor=A.+Ugarteauthor=A.+Estella-Hermoso%0Ade+Mendozaauthor=E.+Saezauthor=M.+Espelosinauthor=S.+Ursuaauthor=T.+Haizhongauthor=W.+Weiauthor=X.+Mushengauthor=A.+Garcia-Ostaauthor=J.+Oyarzabal&title=Design%2C+synthesis%2C+biological+evaluation+and+in+vivo+testing+of+dual+phosphodiesterase+5+%28PDE5%29+and+histone+deacetylase+6+%28HDAC6%29-selective+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejmech.2018.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease</span></div><div class="casAuthors">Rabal, Obdulia; Sanchez-Arias, Juan A.; Cuadrado-Tejedor, Mar; de Miguel, Irene; Perez-Gonzalez, Marta; Garcia-Barroso, Carolina; Ugarte, Ana; Estella-Hermoso de Mendoza, Ander; Saez, Elena; Espelosin, Maria; Ursua, Susana; Tan, Haizhong; Wu, Wei; Xu, Musheng; Garcia-Osta, Ana; Oyarzabal, Julen</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">506-524</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The authors have identified chem. probes that act as dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors (>1 log unit difference vs. class I HDACs) to decipher the contribution of HDAC isoforms to the pos. impact of dual-acting PDE5 and HDAC inhibitors on mouse models of Alzheimer's disease (AD) and fine-tune this systems therapeutics approach.  Structure- and knowledge-based approaches led to the design of first-in-class mols. with the desired target compd. profile: dual PDE5 and HDAC6-selective inhibitors.  Compd. 44b (5-[[4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl]methyl]thiophene-2-carbohydroxamic acid), which fulfilled the biochem., functional and ADME-Tox profiling requirements and exhibited adequate pharmacokinetic properties, was selected as pharmacol. tool compd. and tested in a mouse model of AD (Tg2576) in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFqq9VoRla3bVg90H21EOLACvtfcHk0ljZfd7Ab1DHZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslaiur4%253D&md5=1ced6634343dd8c0913ea3e6be07ff91</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DRabal%26aufirst%3DO.%26aulast%3DSanchez-Arias%26aufirst%3DJ.%2BA.%26aulast%3DCuadrado-Tejedor%26aufirst%3DM.%26aulast%3Dde%2BMiguel%26aufirst%3DI.%26aulast%3DPerez-Gonzalez%26aufirst%3DM.%26aulast%3DGarcia-Barroso%26aufirst%3DC.%26aulast%3DUgarte%26aufirst%3DA.%26aulast%3DEstella-Hermoso%2Bde%2BMendoza%26aufirst%3DA.%26aulast%3DSaez%26aufirst%3DE.%26aulast%3DEspelosin%26aufirst%3DM.%26aulast%3DUrsua%26aufirst%3DS.%26aulast%3DHaizhong%26aufirst%3DT.%26aulast%3DWei%26aufirst%3DW.%26aulast%3DMusheng%26aufirst%3DX.%26aulast%3DGarcia-Osta%26aufirst%3DA.%26aulast%3DOyarzabal%26aufirst%3DJ.%26atitle%3DDesign%252C%2520synthesis%252C%2520biological%2520evaluation%2520and%2520in%2520vivo%2520testing%2520of%2520dual%2520phosphodiesterase%25205%2520%2528PDE5%2529%2520and%2520histone%2520deacetylase%25206%2520%2528HDAC6%2529-selective%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D150%26spage%3D506%26epage%3D524%26doi%3D10.1016%2Fj.ejmech.2018.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H. P.</span></span> <span> </span><span class="NLM_article-title">The recent progress of isoxazole in medicinal chemistry</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">3065</span>– <span class="NLM_lpage">3075</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmc.2018.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=29853341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVamtLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=3065-3075&author=J.+Zhuauthor=J.+Moauthor=H.+Z.+Linauthor=Y.+Chenauthor=H.+P.+Sun&title=The+recent+progress+of+isoxazole+in+medicinal+chemistry&doi=10.1016%2Fj.bmc.2018.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">The recent progress of isoxazole in medicinal chemistry</span></div><div class="casAuthors">Zhu, Jie; Mo, Jun; Lin, Hong-zhi; Chen, Yao; Sun, Hao-peng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3065-3075</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Isoxazole compds. exhibit a wide spectrum of targets and broad biol. activities.  Developing compds. with heterocycle rings has been one of the trends.  The integration of isoxazole ring can offer improved phys.-chem. properties.  Because of the unique profiles, isoxazole ring becomes a popular moiety in compds. design.  In this review article, the major focus has been paid to the applications of isoxazole compds. in treating multiple diseases, including anticancer, antimicrobial, anti-inflammatory, etc.  Strategies for compds. design for preclin., clin., and FDA approved drugs were discussed.  Also, the emphasis has been addressed to the future perspectives and trend for the application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_Igl9jCgG1rVg90H21EOLACvtfcHk0ljZfd7Ab1DHZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVamtLnL&md5=f2cf06eed32e8655baa76d35b41ef6a1</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DMo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DH.%2BZ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.%2BP.%26atitle%3DThe%2520recent%2520progress%2520of%2520isoxazole%2520in%2520medicinal%2520chemistry%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D3065%26epage%3D3075%26doi%3D10.1016%2Fj.bmc.2018.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaisina, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tueckmantel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugolkov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskyi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schoon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billadeau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">92</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500456</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1002%2Fcmdc.201500456" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=26592932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVyhtLnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=81-92&author=I.+N.+Gaisinaauthor=W.+Tueckmantelauthor=A.+Ugolkovauthor=S.+Shenauthor=J.+Hoffenauthor=O.+Dubrovskyiauthor=A.+Mazarauthor=R.+A.+Schoonauthor=D.+Billadeauauthor=A.+P.+Kozikowski&title=Identification+of+HDAC6-Selective+Inhibitors+of+Low+Cancer+Cell+Cytotoxicity&doi=10.1002%2Fcmdc.201500456"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of HDAC6-Selective Inhibitors of Low Cancer Cell Cytotoxicity</span></div><div class="casAuthors">Gaisina, Irina N.; Tueckmantel, Werner; Ugolkov, Andrey; Shen, Sida; Hoffen, Jessica; Dubrovskyi, Oleksii; Mazar, Andrew; Schoon, Renee A.; Billadeau, Daniel; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-92</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The histone deacetylases (HDACs) occur in 11 different isoforms, and these enzymes regulate the activity of a large no. of proteins involved in cancer initiation and progression.  The discovery of isoform-selective HDAC inhibitors (HDACIs) is desirable, as it is likely that such compds. would avoid some of the undesirable side effects found with the first-generation inhibitors.  A series of HDACIs previously reported by the authors were found to display some selectivity for HDAC6 and to induce cell-cycle arrest and apoptosis in pancreatic cancer cells.  In the present work, the authors show that structural modification of these isoxazole-based inhibitors leads to high potency and selectivity for HDAC6 over HDAC1-3 and HDAC10, while unexpectedly abolishing their ability to block cell growth.  Three inhibitors with lower HDAC6 selectivity inhibit the growth of cell lines BxPC3 and L3.6pl, and they only induce apoptosis in L3.6pl cells.  The authors conclude that HDAC6 inhibition alone is insufficient for disruption of cell growth, and that some degree of class 1 HDAC inhibition is required.  Moreover, the highly selective HDAC6Is reported herein that are weakly cytotoxic may find use in cancer immune system reactivation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8NrQruF5oObVg90H21EOLACvtfcHk0ljZfd7Ab1DHZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVyhtLnI&md5=2c241c869dfcdd2863cee7aec9c2e898</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500456&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500456%26sid%3Dliteratum%253Aachs%26aulast%3DGaisina%26aufirst%3DI.%2BN.%26aulast%3DTueckmantel%26aufirst%3DW.%26aulast%3DUgolkov%26aufirst%3DA.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DHoffen%26aufirst%3DJ.%26aulast%3DDubrovskyi%26aufirst%3DO.%26aulast%3DMazar%26aufirst%3DA.%26aulast%3DSchoon%26aufirst%3DR.%2BA.%26aulast%3DBilladeau%26aufirst%3DD.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DIdentification%2520of%2520HDAC6-Selective%2520Inhibitors%2520of%2520Low%2520Cancer%2520Cell%2520Cytotoxicity%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D81%26epage%3D92%26doi%3D10.1002%2Fcmdc.201500456" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadley, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ustinova, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavlicek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knox, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noonepalle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimprich, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robers, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villagra, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8557</span>– <span class="NLM_lpage">8577</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00946</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00946" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbzI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8557-8577&author=S.+Shenauthor=M.+Hadleyauthor=K.+Ustinovaauthor=J.+Pavlicekauthor=T.+Knoxauthor=S.+Noonepalleauthor=M.+T.+Tavaresauthor=C.+A.+Zimprichauthor=G.+Zhangauthor=M.+B.+Robersauthor=C.+Barinkaauthor=A.+P.+Kozikowskiauthor=A.+Villagra&title=Discovery+of+a+New+Isoxazole-3-hydroxamate-Based+Histone+Deacetylase+6+Inhibitor+SS-208+with+Antitumor+Activity+in+Syngeneic+Melanoma+Mouse+Models&doi=10.1021%2Facs.jmedchem.9b00946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models</span></div><div class="casAuthors">Shen, Sida; Hadley, Melissa; Ustinova, Kseniya; Pavlicek, Jiri; Knox, Tessa; Noonepalle, Satish; Tavares, Mauricio T.; Zimprich, Chad A.; Zhang, Guiping; Robers, Matthew B.; Barinka, Cyril; Kozikowski, Alan P.; Villagra, Alejandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8557-8577</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Isoxazole is a five-membered heterocycle that is widely used in drug discovery endeavors.  Here, the authors report the design, synthesis, and structural and biol. characterization of SS-208, a novel HDAC6-selective inhibitor contg. the isoxazole-3-hydroxamate moiety as a zinc-binding group as well as a hydrophobic linker.  A crystal structure of the Danio rerio HDAC6/SS-208 complex reveals a bidentate coordination of the active-site zinc ion that differs from the preferred monodentate coordination obsd. for HDAC6 complexes with phenylhydroxamate-based inhibitors.  While SS-208 has minimal effects on the viability of murine SM1 melanoma cells in vitro, it significantly reduced in vivo tumor growth in a murine SM1 syngeneic melanoma mouse model.  These findings suggest that the antitumor activity of SS-208 is mainly mediated by immune-related antitumor activity as evidenced by the increased infiltration of CD8+ and NK+ T cells and the enhanced ratio of M1 and M2 macrophages in the tumor microenvironment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUagVGHIiRHbVg90H21EOLACvtfcHk0lhX65fYmBUvCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFymtbzI&md5=53b4c45ce582d8752869430407d44649</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00946%26sid%3Dliteratum%253Aachs%26aulast%3DShen%26aufirst%3DS.%26aulast%3DHadley%26aufirst%3DM.%26aulast%3DUstinova%26aufirst%3DK.%26aulast%3DPavlicek%26aufirst%3DJ.%26aulast%3DKnox%26aufirst%3DT.%26aulast%3DNoonepalle%26aufirst%3DS.%26aulast%3DTavares%26aufirst%3DM.%2BT.%26aulast%3DZimprich%26aufirst%3DC.%2BA.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DRobers%26aufirst%3DM.%2BB.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DVillagra%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520New%2520Isoxazole-3-hydroxamate-Based%2520Histone%2520Deacetylase%25206%2520Inhibitor%2520SS-208%2520with%2520Antitumor%2520Activity%2520in%2520Syngeneic%2520Melanoma%2520Mouse%2520Models%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8557%26epage%3D8577%26doi%3D10.1021%2Facs.jmedchem.9b00946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, C.</span></span> <span> </span><span class="NLM_article-title">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">6056</span>– <span class="NLM_lpage">6074</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00393</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00393" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=6056-6074&author=Y.+Huangauthor=G.+Dongauthor=H.+Liauthor=N.+Liuauthor=W.+Zhangauthor=C.+Sheng&title=Discovery+of+Janus+Kinase+2+%28JAK2%29+and+Histone+Deacetylase+%28HDAC%29+Dual+Inhibitors+as+a+Novel+Strategy+for+the+Combinational+Treatment+of+Leukemia+and+Invasive+Fungal+Infections&doi=10.1021%2Facs.jmedchem.8b00393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections</span></div><div class="casAuthors">Huang, Yahui; Dong, Guoqiang; Li, Huanqiu; Liu, Na; Zhang, Wannian; Sheng, Chunquan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6056-6074</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Clin., leukemia patients often suffer from the limited efficacy of chemotherapy and high risks of infection by invasive fungal pathogens.  Herein, a novel therapeutic strategy was developed in which a small mol. can simultaneously treat leukemia and invasive fungal infections (IFIs).  Novel Janus kinase 2 (JAK2) and histone deacetylase (HDAC) dual inhibitors were identified to possess potent anti-proliferative activity toward hematol. cell lines and excellent synergistic effects with fluconazole to treat resistant Candida albicans infections.  In particular, compd. I, a highly active and selective JAK2/HDAC6 dual inhibitor, showed excellent in vivo antitumor efficacy in several acute myeloid leukemia (AML) models and synergized with fluconazole for the treatment of resistant C. albicans infections.  This study highlights the therapeutic potential of JAK2/HDAC dual inhibitors in treating AML and IFIs and provides an efficient strategy for multitargeting drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3_ii7EQG1qLVg90H21EOLACvtfcHk0lhX65fYmBUvCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1Snu7rN&md5=ba7cf74761120f0526ab520196e3dded</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00393%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DDong%26aufirst%3DG.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DSheng%26aufirst%3DC.%26atitle%3DDiscovery%2520of%2520Janus%2520Kinase%25202%2520%2528JAK2%2529%2520and%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Dual%2520Inhibitors%2520as%2520a%2520Novel%2520Strategy%2520for%2520the%2520Combinational%2520Treatment%2520of%2520Leukemia%2520and%2520Invasive%2520Fungal%2520Infections%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D6056%26epage%3D6074%26doi%3D10.1021%2Facs.jmedchem.8b00393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, F. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. Y.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of 2-quinolineacrylamides</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">115250</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.115250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.bmc.2019.115250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=31924504" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A280%3ADC%252BB3MbovVSnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2020&pages=115250&author=S.+W.+Wangauthor=M.+H.+Linauthor=F.+C.+Hsuauthor=M.+C.+Chenauthor=J.+P.+Liouauthor=Y.+T.+Liuauthor=S.+S.+Chenauthor=H.+Y.+Lee&title=Synthesis+and+biological+evaluation+of+2-quinolineacrylamides&doi=10.1016%2Fj.bmc.2019.115250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of 2-quinolineacrylamides</span></div><div class="casAuthors">Wang Shih-Wei; Lin Mei-Hsiang; Hsu Fu-Chun; Liou Jing-Ping; Liu Yi-Ting; Chen Mei-Chuan; Chen Shiou-Sheng; Lee Hsueh-Yun</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & medicinal chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">115250</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">A series of C6-substituted N-hydroxy-2-quinolineacrylamides (3-15), with four types of bridging groups have been synthesized.  Most of these compounds exhibit antiproliferative activity against A549 and HCT116 cells and Western blot analysis revealed that they are able to inhibit HDAC.  Measurement of the HDAC isoform activity of ether-containing compounds showed that compound 9 has distinct HDAC6 selectivity, more than 300-fold over other isoforms.  This paper describes the development of 6-aryloxy-N-hydroxy-2-quinolineacrylamides as potential HDAC6 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgYp6bSmGsmWLFM_lbR1VmfW6udTcc2ebJF3dDpE_vZbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbovVSnsQ%253D%253D&md5=b74f14db94cc7db32ee7c8c80d3b863f</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.115250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.115250%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DS.%2BW.%26aulast%3DLin%26aufirst%3DM.%2BH.%26aulast%3DHsu%26aufirst%3DF.%2BC.%26aulast%3DChen%26aufirst%3DM.%2BC.%26aulast%3DLiou%26aufirst%3DJ.%2BP.%26aulast%3DLiu%26aufirst%3DY.%2BT.%26aulast%3DChen%26aufirst%3DS.%2BS.%26aulast%3DLee%26aufirst%3DH.%2BY.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%25202-quinolineacrylamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2020%26volume%3D28%26spage%3D115250%26doi%3D10.1016%2Fj.bmc.2019.115250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Porter, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1301</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.8b00487</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.8b00487" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1yjtLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1301-1305&author=N.+J.+Porterauthor=S.+Shenauthor=C.+Barinkaauthor=A.+P.+Kozikowskiauthor=D.+W.+Christianson&title=Molecular+Basis+for+the+Selective+Inhibition+of+Histone+Deacetylase+6+by+a+Mercaptoacetamide+Inhibitor&doi=10.1021%2Facsmedchemlett.8b00487"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Basis for the Selective Inhibition of Histone Deacetylase 6 by a Mercaptoacetamide Inhibitor</span></div><div class="casAuthors">Porter, Nicholas J.; Shen, Sida; Barinka, Cyril; Kozikowski, Alan P.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1301-1305</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mercaptoacetamide histone deacetylase inhibitors are neuroprotective agents that do not exhibit the genotoxicity assocd. with more commonly used hydroxamate inhibitors.  Here, the authors present the crystal structure of a selective mercaptoacetamide complexed with the C-terminal catalytic domain of HDAC6.  When compared with the structure of a mercaptoacetamide bound to the class I isoenzyme HDAC8, different interactions are obsd. with the conserved tandem histidine pair in the active site.  These differences likely contribute to the selectivity for inhibition of HDAC6, an important target for cancer chemotherapy and the treatment of neurodegenerative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMteS3uqOlwrVg90H21EOLACvtfcHk0lhGaCoFUkVqEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1yjtLfP&md5=aa88b205bd6c1ddfa084be1772a06f89</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.8b00487&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.8b00487%26sid%3Dliteratum%253Aachs%26aulast%3DPorter%26aufirst%3DN.%2BJ.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DMolecular%2520Basis%2520for%2520the%2520Selective%2520Inhibition%2520of%2520Histone%2520Deacetylase%25206%2520by%2520a%2520Mercaptoacetamide%2520Inhibitor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D9%26spage%3D1301%26epage%3D1305%26doi%3D10.1021%2Facsmedchemlett.8b00487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barinka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">515</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.7b00012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.7b00012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVaqtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=510-515&author=W.+Lvauthor=G.+Zhangauthor=C.+Barinkaauthor=J.+H.+Eubanksauthor=A.+P.+Kozikowski&title=Design+and+Synthesis+of+Mercaptoacetamides+as+Potent%2C+Selective%2C+and+Brain+Permeable+Histone+Deacetylase+6+Inhibitors&doi=10.1021%2Facsmedchemlett.7b00012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Mercaptoacetamides as Potent, Selective, and Brain Permeable Histone Deacetylase 6 Inhibitors</span></div><div class="casAuthors">Lv, Wei; Zhang, Guangming; Barinka, Cyril; Eubanks, James H.; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">510-515</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of non-hydroxamate HDAC6 inhibitors were prepd. in our effort to develop potent and selective compds. for possible use in Central Nervous System (CNS) disorders, thus obviating the genotoxicity often assocd. with the hydroxamates.  Halogens are incorporated in the cap groups of the designed mercaptoacetamides in order to increase brain accessibility.  The indole analog and quinoline analog displayed potent HDAC6 inhibitory activity (IC50 11 nM and 2.8 nM) and excellent selectivity against HDAC1.  Both compds., together with their ester prodrug and disulfide prodrugs were found to be effective in promoting tubulin acetylation in HEK cells.  The disulfide prodrugs also released a stable concn. of the indole and quinoline analogs upon microsomal incubation.  Administration of disulfide prodrugs in vivo was found to trigger an increase of tubulin acetylation in mouse cortex.  These results suggest that further exploration of these com-pounds for the treatment of CNS disorders is warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4LBQBS-jHCrVg90H21EOLACvtfcHk0lhGaCoFUkVqEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVaqtb8%253D&md5=f7709c8f4c339737da3201149afe0f82</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.7b00012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.7b00012%26sid%3Dliteratum%253Aachs%26aulast%3DLv%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DG.%26aulast%3DBarinka%26aufirst%3DC.%26aulast%3DEubanks%26aufirst%3DJ.%2BH.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Mercaptoacetamides%2520as%2520Potent%252C%2520Selective%252C%2520and%2520Brain%2520Permeable%2520Histone%2520Deacetylase%25206%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D8%26spage%3D510%26epage%3D515%26doi%3D10.1021%2Facsmedchemlett.7b00012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pinzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Design of Dual Inhibitors of Histone Deacetylase 6 and Heat Shock Protein 90</span>. <i>ACS omega</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">11473</span>– <span class="NLM_lpage">11480</span>, <span class="refDoi"> DOI: 10.1021/acsomega.0c00559</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsomega.0c00559" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovVyntbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2020&pages=11473-11480&author=L.+Pinziauthor=R.+Benedettiauthor=L.+Altucciauthor=G.+Rastelli&title=Design+of+Dual+Inhibitors+of+Histone+Deacetylase+6+and+Heat+Shock+Protein+90&doi=10.1021%2Facsomega.0c00559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Design of Dual Inhibitors of Histone Deacetylase 6 and Heat Shock Protein 90</span></div><div class="casAuthors">Pinzi, Luca; Benedetti, Rosaria; Altucci, Lucia; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">ACS Omega</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">11473-11480</span>CODEN:
                <span class="NLM_cas:coden">ACSODF</span>;
        ISSN:<span class="NLM_cas:issn">2470-1343</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) and heat shock protein 90 (Hsp90) are widely investigated anticancer drug targets.  Importantly, several lines of evidence indicate that their regulation and activity are intimately linked, and that their combined inhibition may lead to impressive therapeutic benefits.  In this study, we developed and applied an integrated computational strategy to design dual inhibitors of HDAC6 and Hsp90.  Although the two targets share very little homol., an integrated ligand-based and structure-based virtual screening approach indicated a subset of compds. possessing the key structural requirements for binding at both targets.  In vitro tests demonstrated that some of the selected candidates are able to selectively inhibit HDAC6 over HDAC1, to increase the acetylation levels of tubulin on cell assays and to reduce cell proliferation.  The discovered compds. represent valuable starting points for further hit optimization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaKvpHIkSRTbVg90H21EOLACvtfcHk0ljCzlhVGDGr9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovVyntbY%253D&md5=a615fa649778b667d748b5905045bf19</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1021%2Facsomega.0c00559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsomega.0c00559%26sid%3Dliteratum%253Aachs%26aulast%3DPinzi%26aufirst%3DL.%26aulast%3DBenedetti%26aufirst%3DR.%26aulast%3DAltucci%26aufirst%3DL.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DDesign%2520of%2520Dual%2520Inhibitors%2520of%2520Histone%2520Deacetylase%25206%2520and%2520Heat%2520Shock%2520Protein%252090%26jtitle%3DACS%2520omega%26date%3D2020%26volume%3D5%26spage%3D11473%26epage%3D11480%26doi%3D10.1021%2Facsomega.0c00559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madauss, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlhaus, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, Q. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trocha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baloglu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trump, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray-Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravorty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mander, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruidenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turunen, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, M. A.</span></span> <span> </span><span class="NLM_article-title">Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fnchembio.1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=23524983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=319-325&author=M.+Loberaauthor=K.+P.+Madaussauthor=D.+T.+Pohlhausauthor=Q.+G.+Wrightauthor=M.+Trochaauthor=D.+R.+Schmidtauthor=E.+Balogluauthor=R.+P.+Trumpauthor=M.+S.+Headauthor=G.+A.+Hofmannauthor=M.+Murray-Thompsonauthor=B.+Schwartzauthor=S.+Chakravortyauthor=Z.+Wuauthor=P.+K.+Manderauthor=L.+Kruidenierauthor=R.+A.+Reidauthor=W.+Burkhartauthor=B.+J.+Turunenauthor=J.+X.+Rongauthor=C.+Wagnerauthor=M.+B.+Moyerauthor=C.+Wellsauthor=X.+Hongauthor=J.+T.+Mooreauthor=J.+D.+Williamsauthor=D.+Solerauthor=S.+Ghoshauthor=M.+A.+Nolan&title=Selective+class+IIa+histone+deacetylase+inhibition+via+a+nonchelating+zinc-binding+group&doi=10.1038%2Fnchembio.1223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group</span></div><div class="casAuthors">Lobera, Mercedes; Madauss, Kevin P.; Pohlhaus, Denise T.; Wright, Quentin G.; Trocha, Mark; Schmidt, Darby R.; Baloglu, Erkan; Trump, Ryan P.; Head, Martha S.; Hofmann, Glenn A.; Murray-Thompson, Monique; Schwartz, Benjamin; Chakravorty, Subhas; Wu, Zining; Mander, Palwinder K.; Kruidenier, Laurens; Reid, Robert A.; Burkhart, William; Turunen, Brandon J.; Rong, James X.; Wagner, Craig; Moyer, Mary B.; Wells, Carrow; Hong, Xuan; Moore, John T.; Williams, Jon D.; Soler, Dulce; Ghosh, Shomir; Nolan, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">319-325</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In contrast to studies on class I histone deacetylase (HDAC) inhibitors, the elucidation of the mol. mechanisms and therapeutic potential of class IIa HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) is impaired by the lack of potent and selective chem. probes.  Here we report the discovery of inhibitors that fill this void with an unprecedented metal-binding group, trifluoromethyloxadiazole (TFMO), which circumvents the selectivity and pharmacol. liabilities of hydroxamates.  We confirm direct metal binding of the TFMO through crystallog. approaches and use chemoproteomics to demonstrate the superior selectivity of the TFMO series relative to a hydroxamate-substituted analog.  We further apply these tool compds. to reveal gene regulation dependent on the catalytic active site of class IIa HDACs.  The discovery of these inhibitors challenges the design process for targeting metalloenzymes through a chelating metal-binding group and suggests therapeutic potential for class IIa HDAC enzyme blockers distinct in mechanism and application compared to current HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpglr3JvlNjhbVg90H21EOLACvtfcHk0ljCzlhVGDGr9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D&md5=f15a4565213d7a0ec5dc0a0b6032b9ab</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1223%26sid%3Dliteratum%253Aachs%26aulast%3DLobera%26aufirst%3DM.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DPohlhaus%26aufirst%3DD.%2BT.%26aulast%3DWright%26aufirst%3DQ.%2BG.%26aulast%3DTrocha%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DD.%2BR.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DTrump%26aufirst%3DR.%2BP.%26aulast%3DHead%26aufirst%3DM.%2BS.%26aulast%3DHofmann%26aufirst%3DG.%2BA.%26aulast%3DMurray-Thompson%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DChakravorty%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DMander%26aufirst%3DP.%2BK.%26aulast%3DKruidenier%26aufirst%3DL.%26aulast%3DReid%26aufirst%3DR.%2BA.%26aulast%3DBurkhart%26aufirst%3DW.%26aulast%3DTurunen%26aufirst%3DB.%2BJ.%26aulast%3DRong%26aufirst%3DJ.%2BX.%26aulast%3DWagner%26aufirst%3DC.%26aulast%3DMoyer%26aufirst%3DM.%2BB.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DHong%26aufirst%3DX.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26aulast%3DWilliams%26aufirst%3DJ.%2BD.%26aulast%3DSoler%26aufirst%3DD.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DNolan%26aufirst%3DM.%2BA.%26atitle%3DSelective%2520class%2520IIa%2520histone%2520deacetylase%2520inhibition%2520via%2520a%2520nonchelating%2520zinc-binding%2520group%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D319%26epage%3D325%26doi%3D10.1038%2Fnchembio.1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. P.</span></span> <span> </span><span class="NLM_article-title">Evaluation of WO2017018805:1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1080/13543776.2018.1508451</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1080%2F13543776.2018.1508451" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30073889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGrtr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=647-651&author=Y.+Y.+Liangauthor=C.+M.+Zhangauthor=Z.+P.+Liu&title=Evaluation+of+WO2017018805%3A1%2C3%2C4-oxadiazole+sulfamide+derivatives+as+selective+HDAC6+inhibitors&doi=10.1080%2F13543776.2018.1508451"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors</span></div><div class="casAuthors">Liang, Yuan-Yuan; Zhang, Cheng-Mei; Liu, Zhao-Peng</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">647-651</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">There are great potential in the development of selective HDAC6 inhibitors for the treatment of infectious diseases, neoplasms, endocrine diseases, and other diseases assocd. with HDAC6 activity.  The application claims 1,3,4-oxadiazole sulfamide derivs. as selective HDAC6 inhibitors for the treatment of infectious diseases, neoplasms, endocrine, nutritional, and metabolic diseases; mental and behavioral disorders; neurol. diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and s.c. tissue; disease of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.  Many of the exemplified compds. showed nanomole potency against HDAC6 and were more than 5000-fold selectivity for HDAC6 over HDAC1.  These 1,3,4-oxadiazole sulfamide derivs. have a unique zinc-binding group (ZBG) that provide good leads for the discovery of potent selective HDAC6 inhibitors for the treatment of a variety of diseases assocd. with HDAC6 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprQFwE60NVurVg90H21EOLACvtfcHk0li8cE3FuCYNlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGrtr3M&md5=846dc4375f614a5b1fca386c74c21d37</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1080%2F13543776.2018.1508451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2018.1508451%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DY.%2BY.%26aulast%3DZhang%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DZ.%2BP.%26atitle%3DEvaluation%2520of%2520WO2017018805%253A1%252C3%252C4-oxadiazole%2520sulfamide%2520derivatives%2520as%2520selective%2520HDAC6%2520inhibitors%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2018%26volume%3D28%26spage%3D647%26epage%3D651%26doi%3D10.1080%2F13543776.2018.1508451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Induced protein degradation: an emerging drug discovery paradigm</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">114</span>, <span class="refDoi"> DOI: 10.1038/nrd.2016.211</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1038%2Fnrd.2016.211" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27885283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2017&pages=101-114&author=A.+C.+Laiauthor=C.+M.+Crews&title=Induced+protein+degradation%3A+an+emerging+drug+discovery+paradigm&doi=10.1038%2Fnrd.2016.211"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Induced protein degradation: an emerging drug discovery paradigm</span></div><div class="casAuthors">Lai, Ashton C.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">101-114</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Small-mol. drug discovery has traditionally focused on occupancy of a binding site that directly affects protein function, and this approach typically precludes targeting proteins that lack such amenable sites.  Furthermore, high systemic drug exposures may be needed to maintain sufficient target inhibition in vivo, increasing the risk of undesirable off-target effects.  Induced protein degrdn. is an alternative approach that is event-driven: upon drug binding, the target protein is tagged for elimination.  Emerging technologies based on proteolysis-targeting chimaeras (PROTACs) that exploit cellular quality control machinery to selectively degrade target proteins are attracting considerable attention in the pharmaceutical industry owing to the advantages they could offer over traditional small-mol. strategies.  These advantages include the potential to reduce systemic drug exposure, the ability to counteract increased target protein expression that often accompanies inhibition of protein function and the potential ability to target proteins that are not currently therapeutically tractable, such as transcription factors, scaffolding and regulatory proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj-O7zXGOpXLVg90H21EOLACvtfcHk0li8cE3FuCYNlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFCit7rP&md5=a01ff43e9b696fe4dc03f0815158a98f</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1038%2Fnrd.2016.211&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd.2016.211%26sid%3Dliteratum%253Aachs%26aulast%3DLai%26aufirst%3DA.%2BC.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DInduced%2520protein%2520degradation%253A%2520an%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2017%26volume%3D16%26spage%3D101%26epage%3D114%26doi%3D10.1038%2Fnrd.2016.211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, W.</span></span> <span> </span><span class="NLM_article-title">PROTACs: A novel strategy for cancer therapy</span>. <i>Semin. Cancer Biol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">171</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1016/j.semcancer.2020.02.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.semcancer.2020.02.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32058059" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjvFynur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2020&pages=171-179&author=J.+Liuauthor=J.+Maauthor=Y.+Liuauthor=J.+Xiaauthor=Y.+Liauthor=Z.+P.+Wangauthor=W.+Wei&title=PROTACs%3A+A+novel+strategy+for+cancer+therapy&doi=10.1016%2Fj.semcancer.2020.02.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">PROTACs: A novel strategy for cancer therapy</span></div><div class="casAuthors">Liu, Jing; Ma, Jia; Liu, Yi; Xia, Jun; Li, Yuyun; Wang, Z. Peter; Wei, Wenyi</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">Part_2</span>),
    <span class="NLM_cas:pages">171-179</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  However, most intracellular proteins lack of active sites or antigens where SMIs or mAbs bind with, and are called as non-druggable targets for a long time.  From the first year of this century, PROteolysis-TArgeting Chimeras (PROTACs) has emerged to be a promising approach for proteins, including those non-druggable ones, such as transcriptional factors and scaffold proteins.  The first generation of peptide-based PROTACs adopts β-TrCP and VHL as E3 ligases, but the cellular permeability and chem. stability issues restrict their clin. application.  The second generation of small mol.-based PROTACs adopts MDM2, VHL, IAPs and Cereblon as E3 ligases have been tensely studied.  To date, the targets of PROTACs including those overexpressed oncogenic proteins such as ER, AR and BRDs, disease-relevant fusion proteins such as NPM/EML4-ALK and BCR-ABL, cancer-driven mutant proteins such as EGFR, kinases such as CDKs and RTKs.  The major disadvantage of PROTACs is the noncancer specificity and relative higher toxicity, due to its catalytic role.  To overcome this, we and other have recently developed several similar light-controllable PROTACs, termed as the third generation controllable PROTACs.  The degrdn. of targets by those PROTACs can be triggered by UVA or visible light, providing a tool box for further PROTACs design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYKjhYqcuOobVg90H21EOLACvtfcHk0li8cE3FuCYNlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjvFynur8%253D&md5=857bf22e06e986d57ad70fdd4a518953</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2020.02.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2020.02.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DZ.%2BP.%26aulast%3DWei%26aufirst%3DW.%26atitle%3DPROTACs%253A%2520A%2520novel%2520strategy%2520for%2520cancer%2520therapy%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2020%26volume%3D67%26spage%3D171%26epage%3D179%26doi%3D10.1016%2Fj.semcancer.2020.02.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neklesa, T. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winkler, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crews, C. M.</span></span> <span> </span><span class="NLM_article-title">Targeted protein degradation by PROTACs</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">138</span>– <span class="NLM_lpage">144</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.pharmthera.2017.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=28223226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=138-144&author=T.+K.+Neklesaauthor=J.+D.+Winklerauthor=C.+M.+Crews&title=Targeted+protein+degradation+by+PROTACs&doi=10.1016%2Fj.pharmthera.2017.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted protein degradation by PROTACs</span></div><div class="casAuthors">Neklesa, Taavi K.; Winkler, James D.; Crews, Craig M.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">138-144</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Targeted protein degrdn. using the PROTAC technol. is emerging as a novel therapeutic method to address diseases driven by the aberrant expression of a disease-causing protein.  PROTAC mols. are bifunctional small mols. that simultaneously bind a target protein and an E3-ubiquitin ligase, thus causing ubiquitination and degrdn. of the target protein by the proteasome.  Like small mols., PROTAC mols. possess good tissue distribution and the ability to target intracellular proteins.  Herein, we highlight the advantages of protein degrdn. using PROTACs, and provide specific examples where degrdn. offers therapeutic benefit over classical enzyme inhibition.  Foremost, PROTACs can degrade proteins regardless of their function.  This includes the currently "undruggable" proteome, which comprises approx. 85% of all human proteins.  Other beneficial aspects of protein degrdn. include the ability to target overexpressed and mutated proteins, as well as the potential to demonstrate prolonged pharmacodynamics effect beyond drug exposure.  Lastly, due to their catalytic nature and the pre-requisite ubiquitination step, an exquisitely potent mols. with a high degree of degrdn. selectivity can be designed.  Impressive preclin. in vitro and in vivo PROTAC data have been published, and these data have propelled the development of clin. viable PROTACs.  With the mol. wt. falling in the 700-1000 Da range, the delivery and bioavailability of PROTACs remain the largest hurdles on the way to the clinic.  Solving these issues and demonstrating proof of concept clin. data will be the focus of many labs over the next few years.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4RSLWYqqBMrVg90H21EOLACvtfcHk0liFS_AW7phpEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjtVemsbg%253D&md5=08a74402a274a13c8c484cd68167a5a1</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DNeklesa%26aufirst%3DT.%2BK.%26aulast%3DWinkler%26aufirst%3DJ.%2BD.%26aulast%3DCrews%26aufirst%3DC.%2BM.%26atitle%3DTargeted%2520protein%2520degradation%2520by%2520PROTACs%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D174%26spage%3D138%26epage%3D144%26doi%3D10.1016%2Fj.pharmthera.2017.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, W.</span></span> <span> </span><span class="NLM_article-title">Development of Selective Histone Deacetylase 6 (HDAC6) Degraders Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00046</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXltValtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=575-581&author=K.+Yangauthor=H.+Wuauthor=Z.+Zhangauthor=E.+D.+Leistenauthor=X.+Nieauthor=B.+Liuauthor=Z.+Wenauthor=J.+Zhangauthor=M.+D.+Cunninghamauthor=W.+Tang&title=Development+of+Selective+Histone+Deacetylase+6+%28HDAC6%29+Degraders+Recruiting+Von+Hippel-Lindau+%28VHL%29+E3+Ubiquitin+Ligase&doi=10.1021%2Facsmedchemlett.0c00046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Development of selective histone deacetylase 6 (HDAC6) degraders recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase</span></div><div class="casAuthors">Yang, Ka; Wu, Hao; Zhang, Zhongrui; Leisten, Eric D.; Nie, Xueqing; Liu, Binkai; Wen, Zhi; Zhang, Jing; Cunningham, Michael D.; Tang, Weiping</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">575-581</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Histone deacetylase 6 (HDAC6) is involved in multiple cellular processes such as aggresome formation, protein stability, and cell motility.  Numerous HDAC6-selective inhibitors have been developed as cellular chem. tools to elucidate the function of HDAC6.  Since HDAC6 has multiple domains that cannot be studied by HDAC6-selective inhibitors, CRISPR-CAS9 and siRNA/shRNA have been employed to elucidate the nonenzymic functions of HDAC6.  However, these genetic methods have many limitations.  Proteolysis targeting chimera (PROTAC) is an emerging technol. for the development of small mols. that can quickly remove the entire protein in cells.  We previously developed multifunctional HDAC6 degraders that can recruit cereblon (CRBN) E3 ubiquitin ligase.  These HDAC6 degraders can degrade not only HDAC6 but also neo-substrates of CRBN.  They are excellent candidates for the development of anticancer therapeutics, but the multifunctional nature of the CRBN-based HDAC6 degraders has limited their utility as specific chem. probes for the study of HDAC6-related cellular pathways.  Herein we report the development of the first cell-permeable HDAC6-selective degraders employing Von Hippel-Lindau (VHL) E3 ubiquitin ligase, which does not have any known neo-substrates.  The DC50's of the most potent compd. 3j are 7.1 nM and 4.3 nM in human MM1S and mouse 4935 cell lines, resp.  The Dmax's of 3j in these two cell lines are 90% and 57%, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5wocEPQJIsLVg90H21EOLACvtfcHk0liFS_AW7phpEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXltValtr8%253D&md5=262e34a4a9376e31fed2d031cc04cb92</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00046%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLeisten%26aufirst%3DE.%2BD.%26aulast%3DNie%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DWen%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DCunningham%26aufirst%3DM.%2BD.%26aulast%3DTang%26aufirst%3DW.%26atitle%3DDevelopment%2520of%2520Selective%2520Histone%2520Deacetylase%25206%2520%2528HDAC6%2529%2520Degraders%2520Recruiting%2520Von%2520Hippel-Lindau%2520%2528VHL%2529%2520E3%2520Ubiquitin%2520Ligase%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D575%26epage%3D581%26doi%3D10.1021%2Facsmedchemlett.0c00046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Si, X.</span></span> <span> </span><span class="NLM_article-title">Hydroxamic acid hybrids as the potential anticancer agents: An Overview</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>205</i></span>,  <span class="NLM_fpage">112679</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2Fj.ejmech.2020.112679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=32791404" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsF2qtL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=205&publication_year=2020&pages=112679&author=W.+Liuauthor=Y.+Liangauthor=X.+Si&title=Hydroxamic+acid+hybrids+as+the+potential+anticancer+agents%3A+An+Overview&doi=10.1016%2Fj.ejmech.2020.112679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Hydroxamic acid hybrids as the potential anticancer agents: An Overview</span></div><div class="casAuthors">Liu, Wenhua; Liang, Yuchen; Si, Xiaoyong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">205</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112679</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Hydroxamic acid derivs. are potential histone deacetylase inhibitors, and several hydroxamic acid-based histone deacetylase inhibitors have already been used clin. as potent anticancer agents, so hydroxamic acid derivs. are useful scaffolds for the development of novel anticancer agents.  Hybridization of hydroxamic acid moiety with other anticancer pharmacophores can overcome drug resistance and improve the specificity, so rational design of hydroxamic acid hybrids may provide valuable therapeutic interventions for the treatment of cancers.  The purpose of the present review article is to update the current developments in hydroxamic acid hybrids with an emphasis on anticancer activity, structure-activity relationships, and mechanisms of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrE_wMu67SxuLVg90H21EOLACvtfcHk0lgZqg9nYhSDAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsF2qtL%252FE&md5=68cf1d971d0762edd53e1a549c9ad308</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112679%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DSi%26aufirst%3DX.%26atitle%3DHydroxamic%2520acid%2520hybrids%2520as%2520the%2520potential%2520anticancer%2520agents%253A%2520An%2520Overview%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D205%26spage%3D112679%26doi%3D10.1016%2Fj.ejmech.2020.112679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galloway, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wirth, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colevas, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saba, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raben, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atoyan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burtness, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimeno, A.</span></span> <span> </span><span class="NLM_article-title">A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1566</span>– <span class="NLM_lpage">1573</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-2820</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1158%2F1078-0432.CCR-14-2820" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=25573383" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmtVahs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=1566-1573&author=T.+J.+Gallowayauthor=L.+J.+Wirthauthor=A.+D.+Colevasauthor=J.+Gilbertauthor=J.+E.+Baumanauthor=N.+F.+Sabaauthor=D.+Rabenauthor=R.+Mehraauthor=A.+W.+Maauthor=R.+Atoyanauthor=J.+Wangauthor=B.+Burtnessauthor=A.+Jimeno&title=A+Phase+I+Study+of+CUDC-101%2C+a+Multitarget+Inhibitor+of+HDACs%2C+EGFR%2C+and+HER2%2C+in+Combination+with+Chemoradiation+in+Patients+with+Head+and+Neck+Squamous+Cell+Carcinoma&doi=10.1158%2F1078-0432.CCR-14-2820"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma</span></div><div class="casAuthors">Galloway, Thomas J.; Wirth, Lori J.; Colevas, Alexander D.; Gilbert, Jill; Bauman, Julie E.; Saba, Nabil F.; Raben, David; Mehra, Ranee; Ma, Anna W.; Atoyan, Ruzanna; Wang, Jing; Burtness, Barbara; Jimeno, Antonio</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1566-1573</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CUDC-101 is a small mol. that simultaneously inhibits the epidermal growth factor receptor (EGFR), human growth factor receptor 2 (HER2), and histone deacetylase (HDAC) with preclin. activity in head and neck squamous cell cancer (HNSCC).  The primary objective of this investigation is to det. the max. tolerated dose (MTD) of CUDC-101 with cisplatin-radiotherapy in the treatment of HNSCC.  CUDC-101 monotherapy was administered i.v. three times weekly (Monday, Wednesday, Friday) for a one-week run-in, then continued with concurrent cisplatin (100 mg/m2 every 3 wk) and external beam radiation (70 Gy to gross disease) over 7 wk.  Twelve patients with intermediate or high-risk HNSCC enrolled.  Eleven were p16INKa (p16)-neg.  The MTD of CUDC-101-based combination therapy was established at 275 mg/m2/dose.  Five patients discontinued CUDC-101 due to an adverse event (AE); only one was considered a dose-limiting toxicity (DLT), at the MTD.  Pharmacokinetic evaluation suggested low accumulation with this dosing regimen.  HDAC inhibition was demonstrated by pharmacodynamic analyses in peripheral blood mononuclear cells (PBMC), tumor biopsies, and paired skin biopsies.  Paired tumor biopsies demonstrated a trend of EGFR inhibition.  At 1.5 years of median follow-up, there has been one recurrence and two patient deaths (neither attributed to CUDC-101).  The remaining nine patients are free of progression.  CUDC-101, cisplatin, and radiation were feasible in intermediate-/high-risk patients with HNSCC, with no unexpected patterns of AE.  Although the MTD was identified, a high rate of DLT-independent discontinuation of CUDC-101 suggests a need for alternate schedules or routes of administration.  Clin Cancer Res; 21(7); 1566-73. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRDbfIvcyF87Vg90H21EOLACvtfcHk0lgZqg9nYhSDAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmtVahs7o%253D&md5=dd6b5663ffbf995b5def843a8b8b7556</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-2820&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-2820%26sid%3Dliteratum%253Aachs%26aulast%3DGalloway%26aufirst%3DT.%2BJ.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DColevas%26aufirst%3DA.%2BD.%26aulast%3DGilbert%26aufirst%3DJ.%26aulast%3DBauman%26aufirst%3DJ.%2BE.%26aulast%3DSaba%26aufirst%3DN.%2BF.%26aulast%3DRaben%26aufirst%3DD.%26aulast%3DMehra%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DA.%2BW.%26aulast%3DAtoyan%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DBurtness%26aufirst%3DB.%26aulast%3DJimeno%26aufirst%3DA.%26atitle%3DA%2520Phase%2520I%2520Study%2520of%2520CUDC-101%252C%2520a%2520Multitarget%2520Inhibitor%2520of%2520HDACs%252C%2520EGFR%252C%2520and%2520HER2%252C%2520in%2520Combination%2520with%2520Chemoradiation%2520in%2520Patients%2520with%2520Head%2520and%2520Neck%2520Squamous%2520Cell%2520Carcinoma%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D1566%26epage%3D1573%26doi%3D10.1158%2F1078-0432.CCR-14-2820" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Younes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berdeja, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinn, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerecitano, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neelapu, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akins, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clancy, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viner, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oki, Y.</span></span> <span> </span><span class="NLM_article-title">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">622</span>– <span class="NLM_lpage">631</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(15)00584-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1016%2FS1470-2045%2815%2900584-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=27049457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=622-631&author=A.+Younesauthor=J.+G.+Berdejaauthor=M.+R.+Patelauthor=I.+Flinnauthor=J.+F.+Gerecitanoauthor=S.+S.+Neelapuauthor=K.+R.+Kellyauthor=A.+R.+Copelandauthor=A.+Akinsauthor=M.+S.+Clancyauthor=L.+Gongauthor=J.+Wangauthor=A.+Maauthor=J.+L.+Vinerauthor=Y.+Oki&title=Safety%2C+tolerability%2C+and+preliminary+activity+of+CUDC-907%2C+a+first-in-class%2C+oral%2C+dual+inhibitor+of+HDAC+and+PI3K%2C+in+patients+with+relapsed+or+refractory+lymphoma+or+multiple+myeloma%3A+an+open-label%2C+dose-escalation%2C+phase+1+trial&doi=10.1016%2FS1470-2045%2815%2900584-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial</span></div><div class="casAuthors">Younes, Anas; Berdeja, Jesus G.; Patel, Manish R.; Flinn, Ian; Gerecitano, John F.; Neelapu, Sattva S.; Kelly, Kevin R.; Copeland, Amanda R.; Akins, Amy; Clancy, Myles S.; Gong, Lucy; Wang, Jing; Ma, Anna; Viner, Jaye L.; Oki, Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">622-631</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited.  CUDC-907 is an oral, first-in-class, small mol. that is designed to inhibit both histone deacetylase (HDAC) and PI3K enzymes, which are members of common oncogenic pathways in haematol. malignancies.  We aimed to assess overall safety and preliminary activity in this dose-escalation study of CUDC-907 monotherapy in patients with relapsed or refractory lymphoma and multiple myeloma.  This open-label, first-in-man, phase 1 trial recruited adult patients (aged ≥18 years) with lymphoma or multiple myeloma who were refractory to or had relapsed after two or more previous regimens, from four US cancer centers.  CUDC-907 was orally administered in a std. 3 + 3 dose-escalation design at four different dosing schedules, to which participants were sequentially assigned as follows: once daily, intermittently (twice or three times weekly; simultaneous enrolment), and daily for 5 days followed by a 2-day break (5/2), in 21-day cycles.  Dosing started at 30 mg for the once-daily schedule and 60 mg for other schedules, escalating in 30 mg increments.  Patients continued to receive CUDC-907 until disease progression or until other treatment discontinuation criteria were met.  The primary objective was to det. the max. tolerated dose (MTD) and recommended phase 2 dose, assessed in patients who received at least 66% of cycle 1 doses without modification and those who had a dose-limiting toxicity (DLT) in cycle 1 irresp. of dose modification.  We assessed safety in all patients who received at least one dose of study drug.  This ongoing trial is registered at ClinicalTrials.gov, no. NCT01742988.  Between Jan 23, 2013, and July 27, 2015, we enrolled 44 patients, of whom ten were sequentially assigned to CUDC-907 once-daily (MTD 60 mg), 12 to twice-weekly (MTD 150 mg), 15 to three-times-weekly (MTD 150 mg), and seven to the 5/2 dosing schedule (MTD 60 mg). 37 (84%) patients had discontinued study drug as a result of progressive disease or clin. signs of progressive disease at the data cutoff.  Four DLTs occurred in three of 40 DLT-evaluable patients (diarrhoea and hyperglycemia in one patient on 60 mg once daily, hyperglycemia in one patient on 150 mg twice weekly, and diarrhoea in one patient on 150 mg three times weekly); no DLTs were reported in patients on the 5/2 schedule.  Grade 3 or worse adverse events occurred in 19 (43%) of 44 patients, the most common of which were thrombocytopenia (in nine [20%] of 44 patients), neutropenia (three [7%]), and hyperglycemia (three [7%]). 11 (25%) of 44 patients had serious adverse events, three of which were regarded as treatment related (epistaxis and the DLTs of diarrhoea and hyperglycemia).  Adverse events led to dose redns. in six (14%) patients and treatment discontinuation in seven (16%).  Five (14%) of 37 response-evaluable patients achieved an objective response (two complete responses and three partial responses).  All five responses occurred in the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; n=9), and three occurred in those with transformed follicular lymphoma DLBCL (n=5). 21 (57%) of 37 response-evaluable patients had stable disease, including those with DLBCL, Hodgkin's lymphoma, and multiple myeloma.  On the basis of these findings, we selected CUDC-907 60 mg on the 5/2 dosing schedule as the recommended phase 2 dose.  The safety and tolerability profile of CUDC-907 and the promising preliminary evidence of response support continued development of CUDC-907 at the 60 mg 5/2 dosing schedule, alone and in combination with other therapies.  A dose-expansion trial of this dose in patients with refractory and relapsed DLBCL in particular, is ongoing.  Curis, Inc, and the Leukemia and Lymphoma Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAFEt7vSuwM7Vg90H21EOLACvtfcHk0lgZqg9nYhSDAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlsFOhs78%253D&md5=b759c77ac239b6ae0052d30c9bea3221</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2815%2900584-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252815%252900584-7%26sid%3Dliteratum%253Aachs%26aulast%3DYounes%26aufirst%3DA.%26aulast%3DBerdeja%26aufirst%3DJ.%2BG.%26aulast%3DPatel%26aufirst%3DM.%2BR.%26aulast%3DFlinn%26aufirst%3DI.%26aulast%3DGerecitano%26aufirst%3DJ.%2BF.%26aulast%3DNeelapu%26aufirst%3DS.%2BS.%26aulast%3DKelly%26aufirst%3DK.%2BR.%26aulast%3DCopeland%26aufirst%3DA.%2BR.%26aulast%3DAkins%26aufirst%3DA.%26aulast%3DClancy%26aufirst%3DM.%2BS.%26aulast%3DGong%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DA.%26aulast%3DViner%26aufirst%3DJ.%2BL.%26aulast%3DOki%26aufirst%3DY.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520preliminary%2520activity%2520of%2520CUDC-907%252C%2520a%2520first-in-class%252C%2520oral%252C%2520dual%2520inhibitor%2520of%2520HDAC%2520and%2520PI3K%252C%2520in%2520patients%2520with%2520relapsed%2520or%2520refractory%2520lymphoma%2520or%2520multiple%2520myeloma%253A%2520an%2520open-label%252C%2520dose-escalation%252C%2520phase%25201%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2016%26volume%3D17%26spage%3D622%26epage%3D631%26doi%3D10.1016%2FS1470-2045%2815%2900584-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hoffman, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zylla, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhattacharya, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calar, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhardwaj, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miskimins, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de la Puente, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnimpieba, E. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messerli, S. M.</span></span> <span> </span><span class="NLM_article-title">Analysis of Dual Class I Histone Deacetylase and Lysine Demethylase Inhibitor Domatinostat (4SC-202) on Growth and Cellular and Genomic Landscape of Atypical Teratoid/Rhabdoid</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">756</span>, <span class="refDoi"> DOI: 10.3390/cancers12030756</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.3390%2Fcancers12030756" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVShtr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=756&author=M.+M.+Hoffmanauthor=J.+S.+Zyllaauthor=S.+Bhattacharyaauthor=K.+Calarauthor=T.+W.+Hartmanauthor=R.+D.+Bhardwajauthor=W.+K.+Miskiminsauthor=P.+de+la+Puenteauthor=E.+Z.+Gnimpiebaauthor=S.+M.+Messerli&title=Analysis+of+Dual+Class+I+Histone+Deacetylase+and+Lysine+Demethylase+Inhibitor+Domatinostat+%284SC-202%29+on+Growth+and+Cellular+and+Genomic+Landscape+of+Atypical+Teratoid%2FRhabdoid&doi=10.3390%2Fcancers12030756"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of dual class I histone deacetylase and lysine demethylase inhibitor domatinostat (4SC-202) on growth and cellular and genomic landscape of atypical teratoid/rhabdoid</span></div><div class="casAuthors">Hoffman, Mariah M.; Zylla, Jessica S.; Bhattacharya, Somshuvra; Calar, Kristin; Hartman, Timothy W.; Bhardwaj, Ratan D.; Miskimins, W. Keith; de la Puente, Pilar; Gnimpieba, Etienne Z.; Messerli, Shanta M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">756</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Central nervous system atypical teratoid/rhabdoid tumors (ATRTs) are rare and aggressive tumors with a very poor prognosis.  Current treatments for ATRT include resection of the tumor, followed by systemic chemotherapy and radiation therapy, which have toxic side effects for young children.  Gene expression analyses of human ATRTs and normal brain samples indicate that ATRTs have aberrant expression of epigenetic markers including class I histone deacetylases (HDAC's) and lysine demethylase (LSD1).  Here, we investigate the effect of a small mol. epigenetic modulator known as Domatinostat (4SC-202), which inhibits both class I HDAC's and Lysine Demethylase (LSD1), on ATRT cell survival and single cell heterogeneity.  Our findings suggest that 4SC-202 is both cytotoxic and cytostatic to ATRT in 2D and 3D scaffold cell culture models and may target cancer stem cells.  Single-cell RNA sequencing data from ATRT-06 spheroids treated with 4SC-202 have a reduced population of cells overexpressing stem cell-related genes, including SOX2.  Flow cytometry and immunofluorescence on 3D ATRT-06 scaffold models support these results suggesting that 4SC-202 reduces expression of cancer stem cell markers SOX2, CD133, and FOXM1.  Drug-induced changes to the systems biol. landscape are also explored by multi-omics enrichment analyses.  In summary, our data indicate that 4SC-202 has both cytotoxic and cytostatic effects on ATRT, targets specific cell sub-populations, including those with cancer stem-like features, and is an important potential cancer therapeutic to be investigated in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ0LyYtW0QabVg90H21EOLACvtfcHk0liKDiNaoa8YAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVShtr3M&md5=26d4293a3e4025eda9745e8099460f26</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.3390%2Fcancers12030756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12030756%26sid%3Dliteratum%253Aachs%26aulast%3DHoffman%26aufirst%3DM.%2BM.%26aulast%3DZylla%26aufirst%3DJ.%2BS.%26aulast%3DBhattacharya%26aufirst%3DS.%26aulast%3DCalar%26aufirst%3DK.%26aulast%3DHartman%26aufirst%3DT.%2BW.%26aulast%3DBhardwaj%26aufirst%3DR.%2BD.%26aulast%3DMiskimins%26aufirst%3DW.%2BK.%26aulast%3Dde%2Bla%2BPuente%26aufirst%3DP.%26aulast%3DGnimpieba%26aufirst%3DE.%2BZ.%26aulast%3DMesserli%26aufirst%3DS.%2BM.%26atitle%3DAnalysis%2520of%2520Dual%2520Class%2520I%2520Histone%2520Deacetylase%2520and%2520Lysine%2520Demethylase%2520Inhibitor%2520Domatinostat%2520%25284SC-202%2529%2520on%2520Growth%2520and%2520Cellular%2520and%2520Genomic%2520Landscape%2520of%2520Atypical%2520Teratoid%252FRhabdoid%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D756%26doi%3D10.3390%2Fcancers12030756" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">An, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, Y.</span></span> <span> </span><span class="NLM_article-title">Developing potent PROTACs tools for selective degradation of HDAC6 protein</span>. <i>Protein Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">606</span>– <span class="NLM_lpage">609</span>, <span class="refDoi"> DOI: 10.1007/s13238-018-0602-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=10.1007%2Fs13238-018-0602-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=30603959" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVCktLjL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=606-609&author=Z.+Anauthor=W.+Lvauthor=S.+Suauthor=W.+Wuauthor=Y.+Rao&title=Developing+potent+PROTACs+tools+for+selective+degradation+of+HDAC6+protein&doi=10.1007%2Fs13238-018-0602-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Developing potent PROTACs tools for selective degradation of HDAC6 protein</span></div><div class="casAuthors">An, Zixuan; Lv, Wenxing; Su, Shang; Wu, Wei; Rao, Yu</div><div class="citationInfo"><span class="NLM_cas:title">Protein & Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">606-609</span>CODEN:
                <span class="NLM_cas:coden">PCREFB</span>;
        ISSN:<span class="NLM_cas:issn">1674-800X</span>.
    
            (<span class="NLM_cas:orgname">Higher Education Press</span>)
        </div><div class="casAbstract">The present article describes about developing potent PROTACs tools for selective degrdn. of HDAC6 protein.  To evaluate the degrdn. capability of our PROTACs for HDAC6 protein, analyzed the cellular levels of HDAC6 in HeLa cells by Western blot after incubation with four different PROTACs.  It was found that all PROTACs can effectively induce HDAC6 degrdn. after 24 h.  Among them, NP8 was the most potent degrader which can significantly reduce the HDAC6 protein level at 100 nmol/L.  Then went on to evaluate the degrdn. potential of NP8 in a panel of cell lines from different origin.  NP8 consistently induced significant degrdn. of HDAC6 in all the cell lines we tested, while the multiple myeloma cell line MM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0CReXjWgVRbVg90H21EOLACvtfcHk0liKDiNaoa8YAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVCktLjL&md5=f3c3a4afb585f9d09b753b005d5b6428</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1007%2Fs13238-018-0602-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13238-018-0602-z%26sid%3Dliteratum%253Aachs%26aulast%3DAn%26aufirst%3DZ.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DSu%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DRao%26aufirst%3DY.%26atitle%3DDeveloping%2520potent%2520PROTACs%2520tools%2520for%2520selective%2520degradation%2520of%2520HDAC6%2520protein%26jtitle%3DProtein%2520Cell%26date%3D2019%26volume%3D10%26spage%3D606%26epage%3D609%26doi%3D10.1007%2Fs13238-018-0602-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G0J" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G0J','PDB','5G0J'); return false;">PDB: 5G0J</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGL" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGL','PDB','5WGL'); return false;">PDB: 5WGL</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EDU','PDB','5EDU'); return false;">PDB: 5EDU</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ICN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ICN','PDB','5ICN'); return false;">PDB: 5ICN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4A69','PDB','4A69'); return false;">PDB: 4A69</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQW','PDB','2VQW'); return false;">PDB: 2VQW</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4BKX','PDB','4BKX'); return false;">PDB: 4BKX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2B7A" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2B7A','PDB','2B7A'); return false;">PDB: 2B7A</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EF7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EF7','PDB','5EF7'); return false;">PDB: 5EF7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5EEM','PDB','5EEM'); return false;">PDB: 5EEM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G0I" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5G0I','PDB','5G0I'); return false;">PDB: 5G0I</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TCY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6TCY','PDB','6TCY'); return false;">PDB: 6TCY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6THV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6THV','PDB','6THV'); return false;">PDB: 6THV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WGK','PDB','5WGK'); return false;">PDB: 5WGK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WEK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5WEK','PDB','5WEK'); return false;">PDB: 5WEK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CW8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CW8','PDB','6CW8'); return false;">PDB: 6CW8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PYE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PYE','PDB','6PYE'); return false;">PDB: 6PYE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CGP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6CGP','PDB','6CGP'); return false;">PDB: 6CGP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V7A" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6V7A','PDB','6V7A'); return false;">PDB: 6V7A</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q0Z" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6Q0Z','PDB','6Q0Z'); return false;">PDB: 6Q0Z</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UOB" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6UOB','PDB','6UOB'); return false;">PDB: 6UOB</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PZR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6PZR','PDB','6PZR'); return false;">PDB: 6PZR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MR5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6MR5','PDB','6MR5'); return false;">PDB: 6MR5</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01782&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01782%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-3%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01782" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ad44aa8e924bf","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
